PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Grobet, L; Martin, LJR; Poncelet, D; Pirottin, D; Brouwers, B; Riquet, J; Schoeberlein, A; Dunner, S; Menissier, F; Massabanda, J; Fries, R; Hanset, R; Georges, M				Grobet, L; Martin, LJR; Poncelet, D; Pirottin, D; Brouwers, B; Riquet, J; Schoeberlein, A; Dunner, S; Menissier, F; Massabanda, J; Fries, R; Hanset, R; Georges, M			A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle	NATURE GENETICS			English	Letter							MUSCULAR HYPERTROPHY; BELGIAN WHITE; GENOME; MAPS; LOCI; CONSTRUCTION; DETERMINISM; BREED	An exceptional muscle development commonly referred to as 'double-muscled' (Fig. 1) has been seen in several cattle breeds and has attracted considerable attention from beef producers. Double-muscled animals are characterized by an increase in muscle mass of about 20%, due to general skeletal-muscle hyperplasia-that is, an increase in the number of muscle fibers rather than in their individual diameter(1). Although the hereditary nature of the double-muscled condition was recognized early on, the precise mode of inheritance has remained controversial; monogenic (dominant and recessive), oligogenic and polygenic models have been proposed(2). In the Belgian Blue cattle breed (BBCB)(4), segregation analysis performed both in experimental crosses(3) and in the outbred population suggested an autosomal recessive inheritance. This was confirmed when the muscular hypertrophy (mh) locus was mapped 3.1 cM from microsatellite TCLA44 on the centromeric end of bovine chromosome 2 (ref. 5). We used a positional candidate approach to demonstrate that a mutation in bovine MSTN, which encodes myostatin, a member of the TGF beta superfamily, is responsible for the double-muscled phenotype. We report an 11-bp deletion in the coding sequence for the bioactive carboxy-terminal domain of the protein causing the muscular hypertrophy observed in Belgian Blue cattle.	UNIV LIEGE,FAC VET MED,DEPT GENET,B-4000 LIEGE,BELGIUM; UNIV COMPLUTENSE MADRID,DPTO PROD ANIM,GENET LAB,E-28040 MADRID,SPAIN; INRA,GENET QUANTITAT & APPL STN,F-78352 JOUY EN JOSAS,FRANCE; TECH UNIV MUNICH,D-85350 FREISING,GERMANY	University of Liege; Complutense University of Madrid; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Technical University of Munich			Schoeberlein, Andreina/H-8413-2019; Dunner, Susana/H-3124-2015; Schoeberlein, Andreina/C-8688-2009; Royo, Luis/B-4024-2012	Schoeberlein, Andreina/0000-0002-6716-9551; Schoeberlein, Andreina/0000-0002-6716-9551; Royo, Luis/0000-0002-5939-3000; grobet, Luc/0000-0003-0724-4369; Fries, Ruedi/0000-0002-4657-1787; Georges, Michel/0000-0003-4124-2375				CHARLIER C, 1995, MAMM GENOME, V6, P788, DOI 10.1007/BF00539005; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORNELIS F, 1992, GENOMICS, V13, P820, DOI 10.1016/0888-7543(92)90159-P; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dunner S, 1997, MAMM GENOME, V8, P430, DOI 10.1007/s003359900462; GEORGES M, 1995, GENETICS, V139, P907; HANSET R, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P467; HANSET R, 1985, GENET SEL EVOL, V17, P369, DOI 10.1186/1297-9686-17-3-369; HANSET R, 1985, GENET SEL EVOL, V17, P359, DOI 10.1186/1297-9686-17-3-359; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Hunter KW, 1996, GENOME RES, V6, P290, DOI 10.1101/gr.6.4.290; Kappes SM, 1997, GENOME RES, V7, P235, DOI 10.1101/gr.7.3.235; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LENSTRA JA, 1993, ANIM GENET, V24, P33, DOI 10.1111/j.1365-2052.1993.tb00916.x; LIBERT F, 1993, GENOMICS, V18, P270, DOI 10.1006/geno.1993.1465; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC., 1996, GROWTH FACTORS CYTOK, P357, DOI [10.1016/s1874-5687(96)80016-4, DOI 10.1016/S1874-5687(96)80016-4]; MENISSIER F, 1982, CURR TOP VET ANIM SC, V16, P387; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; SOLINASTOLDO S, 1995, GENOMICS, V27, P489, DOI 10.1006/geno.1995.1081; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; [No title captured]; [No title captured]	23	1136	1333	6	160	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1997	17	1					71	74		10.1038/ng0997-71	http://dx.doi.org/10.1038/ng0997-71			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288100				2022-12-25	WOS:A1997XU72400020
J	Malins, DC; Polissar, NL; Sy, YZ; Gardner, HS; Gunselman, SJ				Malins, DC; Polissar, NL; Sy, YZ; Gardner, HS; Gunselman, SJ			A new structural analysis of DNA using statistical models of infrared spectra	NATURE MEDICINE			English	Article							AGENTS		MT WHISPER LIGHT STAT CONSULTING,SEATTLE,WA 98112; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; USA,CTR ENVIRONM HLTH RES,FT COLLINS,CO 80523; COLORADO STATE UNIV,CTR ENVIRONM TOXICOL & TECHNOL,GEOCENTERS INC,FT COLLINS,CO 80523	University of Washington; University of Washington Seattle; Colorado State University	Malins, DC (corresponding author), PACIFIC NW RES FDN,MOL EPIDEMIOL PROGRAM,720 BROADWAY,SEATTLE,WA 98122, USA.							Algan O, 1996, RADIAT RES, V146, P267, DOI 10.2307/3579456; Camplejohn RS, 1996, CANCER SURV, V26, P193; Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140-6736(96)90013-6; Dees C, 1996, RADIAT RES, V146, P444, DOI 10.2307/3579306; Ferrari R, 1996, J CARDIOVASC PHARM, V28, pS1; Jenner P, 1996, PATHOL BIOL, V44, P57; KIRBY RS, 1996, PROSTATE CANC; Malins DC, 1996, P NATL ACAD SCI USA, V93, P14047, DOI 10.1073/pnas.93.24.14047; Malins DC, 1997, P NATL ACAD SCI USA, V94, P259, DOI 10.1073/pnas.94.1.259; MALINS DC, 1995, CANCER, V75, P503, DOI 10.1002/1097-0142(19950115)75:2<503::AID-CNCR2820750213>3.0.CO;2-0; Malins DC, 1996, P NATL ACAD SCI USA, V93, P2557, DOI 10.1073/pnas.93.6.2557; Mandavilli BS, 1996, J NEUROCHEM, V67, P1559; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Monforte JA, 1997, NAT MED, V3, P360, DOI 10.1038/nm0397-360; OKAMOTO A, 1993, JPN J CANCER RES, V84, P93, DOI 10.1111/j.1349-7006.1993.tb02789.x; Sikka SC, 1995, J ANDROL, V16, P464; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; WENDER PA, 1991, P NATL ACAD SCI USA, V88, P8835, DOI 10.1073/pnas.88.19.8835	18	19	19	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					927	930		10.1038/nm0897-927	http://dx.doi.org/10.1038/nm0897-927			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256288				2022-12-25	WOS:A1997XP01400039
J	Sykes, M; Szot, GL; Swenson, KA; Pearson, DA				Sykes, M; Szot, GL; Swenson, KA; Pearson, DA			Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; T-CELLS; MARROW TRANSPLANTATION; CLONAL DELETION; HOST DISEASE; ENGRAFTMENT; MICE; ANTIGENS; EXPRESSION; LEUKEMIA	Donor-specific tolerance induced by bone marrow transplantation (BMT) would allow organ allografting without chronic immunosuppressive therapy. However, the toxicity(1) of conditioning regimens used to achieve marrow engraftment has precluded the clinical use of BMT for tolerance induction. We have developed a BMT strategy that achieves alloengraftment without toxic or myelosuppressive host conditioning. B6 mice received depleting anti-CD4 and anti-CD8 monoclonal antibodies, local thymic irradiation, and a high-dose (174 x 10(6)) of major histocompatibility (MHC)-mismatched B10.A bone marrow cells (BMCs) divided over days 0 through 4. High levels of donor cells were observed among white blood cells (WBCs) of all lineages. Permanent, multilineage mixed chimerism; donor-specific skin-graft tolerance; and in vitro tolerance were observed in most animals. Large numbers of donor class IIhigh cells were detected in thymuses of long-term chimeras, and their presence was associated with intrathymic deletion of donor-reactive host thymocytes. The treatment was not associated with significant myelosuppression, toxicity, or graft-versus-host disease (GVHD). Thus, high levels of allogeneic stem-cell engraftment can be achieved without myelosuppressive host conditioning. As stem-cell mobilization(2) and in vitro culture techniques' have increased the feasibility of administering high doses of hematopoietic cells to humans, this approach brings hematopoietic cell transplantation closer to clinical use for the induction of central deletional T-cell tolerance.			Sykes, M (corresponding author), HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,TRANSPLANTAT BIOL RES CTR,SURG SERV,MGH E,BOSTON,MA 02129, USA.			Szot, Gregory/0000-0002-3921-049X	NHLBI NIH HHS [R01-HL-49915, R01-HL-18646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; AVERSA F, 1994, BLOOD, V84, P3948, DOI 10.1182/blood.V84.11.3948.bloodjournal84113948; BACHARLUSTIG E, 1995, NAT MED, V1, P1268, DOI 10.1038/nm1295-1268; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; Emerson SG, 1996, BLOOD, V87, P3082, DOI 10.1182/blood.V87.8.3082.bloodjournal8783082; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; Hayashi H, 1996, BONE MARROW TRANSPL, V18, P285; KAUFMAN CL, 1994, BLOOD, V84, P2436; Lee LA, 1996, TRANSPLANTATION, V61, P125, DOI 10.1097/00007890-199601150-00024; MARTIN PJ, 1993, J EXP MED, V178, P703, DOI 10.1084/jem.178.2.703; OREILLY RJ, 1985, TRANSPLANT P, V17, P455; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCOLLAY R, 1980, J IMMUNOL, V124, P2845; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SHERMAN LA, 1981, IMMUNOGENETICS, V12, P183, DOI 10.1007/BF01561661; Shizuru J A, 1996, Biol Blood Marrow Transplant, V2, P3; STEWART FM, 1993, BLOOD, V81, P2566; SYKES M, 1988, J IMMUNOL, V140, P2903; SYKES M, 1990, J EXP MED, V171, P645, DOI 10.1084/jem.171.3.645; Tomita Y, 1996, TRANSPLANTATION, V61, P477, DOI 10.1097/00007890-199602150-00028; TOMITA Y, 1994, J IMMUNOL, V153, P1087; Tomita Y, 1996, TRANSPLANTATION, V61, P469, DOI 10.1097/00007890-199602150-00027; TOMONARI K, 1991, IMMUNOGENETICS, V33, P157, DOI 10.1007/BF01719234; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WATANABE M, 1983, TRANSPLANTATION, V36, P712, DOI 10.1097/00007890-198336060-00025	30	261	269	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					783	787		10.1038/nm0797-783	http://dx.doi.org/10.1038/nm0797-783			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212108				2022-12-25	WOS:A1997XG76700041
J	Breslow, JL				Breslow, JL			Cardiovascular disease burden increases, NIH funding decreases	NATURE MEDICINE			English	Editorial Material											Breslow, JL (corresponding author), ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.		Breslow, Jan L/B-7544-2008						0	91	102	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					600	601		10.1038/nm0697-600	http://dx.doi.org/10.1038/nm0697-600			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176478				2022-12-25	WOS:A1997XB97400021
J	Kalchman, MA; Koide, HB; McCutcheon, K; Graham, RK; Nichol, K; Nishiyama, K; KazemiEsfarjani, P; Lynn, FC; Wellington, C; Metzler, M; Goldberg, YP; Kanazawa, I; Gietz, RD; Hayden, MR				Kalchman, MA; Koide, HB; McCutcheon, K; Graham, RK; Nichol, K; Nishiyama, K; KazemiEsfarjani, P; Lynn, FC; Wellington, C; Metzler, M; Goldberg, YP; Kanazawa, I; Gietz, RD; Hayden, MR			HIP1, a human homologue of S-cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; REPEAT LENGTH; LEUCINE-ZIPPER; DISEASE; PROTEIN; GENE; EXPRESSION; CYTOSKELETON; EXPANSION; IDENTIFY	Huntington disease (HD) is associated with the expansion of a polyglutamine tract, greater than 35 repeats, in the HD gene product, huntingtin. Here we describe a novel huntingtin interacting protein, HIP1, which co-localizes with huntingtin and shares sequence homology and biochemical characteristics with Sla2p, a protein essential for function of the cytoskeleton in Saccharomyces cerevisiae. The huntingtin-HIP1 interaction is restricted to the brain and is inversely correlated to the polyglutamine length in huntingtin. This provides the first molecular link between huntingtin and the neuronal cytoskeleton and suggests that, in HD, loss of normal huntingtin-HIP1 interaction may contribute to a defect in membrane-cytoskeletal integrity in the brain.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z4,CANADA; UNIV TOKYO,FAC MED,DEPT CLIN NEUROL & NEUROSCI,TOKYO 113,JAPAN; UNIV MANITOBA,FAC MED,DEPT HUMAN GENET,WINNIPEG,MB R3E 0W3,CANADA	University of British Columbia; University of Tokyo; University of Manitoba			Hayden, Michael R/D-8581-2011; Metzler, Markus/AAS-2066-2021; Graham, Rona K/R-7358-2018	Hayden, Michael R/0000-0001-5159-1419; Metzler, Markus/0000-0002-4523-1676; Graham, Rona K/0000-0003-3722-6241; Lynn, Francis/0000-0001-9318-1063				ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ARAI M, 1994, J NEUROSCI RES, V38, P348, DOI 10.1002/jnr.490380313; ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; Bhide PG, 1996, J NEUROSCI, V16, P5523; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1996, IN PRESS CELL BIOL L; Goldberg YP, 1996, HUM MOL GENET, V5, P177, DOI 10.1093/hmg/5.2.177; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; HARPER PS, 1991, HUNTINGTONS DIS, P31; Hayden MR, 1981, HUNTINGTONS CHOREA, P59, DOI [10.1007/978-1-4471-1308-9_5, DOI 10.1007/978-1-4471-1308-9_5]; Hodgson JG, 1996, HUM MOL GENET, V5, P1875, DOI 10.1093/hmg/5.12.1875; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; *HUNT DIS COLL RES, 1993, CELL, V72, P971; JOHN M, 1994, J BIOL CHEM, V269, P16247; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; KREMER HPH, 1994, NEW ENGL J MED, V330, P1401; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; MacLennan D H, 1987, Soc Gen Physiol Ser, V41, P287; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NA S, 1995, J BIOL CHEM, V270, P375; Nasir J, 1996, HUM MOL GENET, V5, P1431, DOI 10.1093/hmg/5.Supplement_1.1431; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; PEARLMAN JA, 1994, FEBS LETT, V354, P183, DOI 10.1016/0014-5793(94)01119-2; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; REES DJ, 1990, NATURE, V347, P18; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; SCHILLING G, 1995, HUM MOL GENET, V4, P1365, DOI 10.1093/hmg/4.8.1365; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SHULL GE, 1985, NATURE, V316, P33; Sirover MA, 1996, LIFE SCI, V58, P2271, DOI 10.1016/0024-3205(96)00123-3; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Suzuki T, 1996, BIOCHEM BIOPH RES CO, V219, P708, DOI 10.1006/bbrc.1996.0299; TELENIUS H, 1993, HUM MOL GENET, V2, P1535, DOI 10.1093/hmg/2.10.1535; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P100; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wood J. D., 1996, American Journal of Human Genetics, V59, pA295; WOOD JD, 1996, HUM MOL GENET, V5, P418; Zoghbi HY, 1996, NAT GENET, V14, P237, DOI 10.1038/ng1196-237	49	310	319	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	MAY	1997	16	1					44	53		10.1038/ng0597-44	http://dx.doi.org/10.1038/ng0597-44			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140394				2022-12-25	WOS:A1997WX02400021
J	DeSanctis, GT; Itoh, A; Green, FHY; Qin, SX; Kimura, T; Grobholz, JK; Martin, TR; Maki, T; Drazen, JM				DeSanctis, GT; Itoh, A; Green, FHY; Qin, SX; Kimura, T; Grobholz, JK; Martin, TR; Maki, T; Drazen, JM			T-lymphocytes regulate genetically determined airway hyperresponsiveness in mice	NATURE MEDICINE			English	Article							MAST-CELLS; ASTHMA; EOSINOPHILS; HYPERSENSITIVITY; RESPONSES; ALLERGEN; MEDIATE	Airway hyperresponsiveness (AHR) is a hallmark of asthma(1) and a heritable polygenic trait in the mouse(2). In the mouse, candidate gene products of hematopoietic origin implicated in asthma mapped to the regions of the previously defined quantitative trait loci(2). Since hematopoietic cells(3-5) have been implicated in the pathogenesis of asthma, we evaluated the role of hematopoietic cells in general and T cells specifically in the genetic modulation of native airway responsiveness in mice. Here, with the use of bone marrow transplantation, anti-T-cell monoclonal antibody treatment and T-cell transfer, we demonstrate that intrinsic non-atopic AHR is mediated by T lymphocytes. Our data support the novel concept that, in the absence of identified environmental influences, T cells enhance genetically determined airway responsiveness.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,COMBINED PROGRAM PULMONARY & CRIT CARE MED,BOSTON,MA 02115; UNIV CALGARY,RESP RES GRP,CALGARY,AB T2N 4N1,CANADA; LEUKOSITE INC,CAMBRIDGE,MA 02142; CHILDRENS HOSP,DEPT PEDIAT,BOSTON,MA 02115; BETH ISRAEL DEACONESS MED CTR,DEPT SURG,DIV ORGAN TRANSPLANTAT,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Calgary; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center			Drazen, Jeffrey M/E-5841-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36110] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGOSTI JM, 1988, NEW ENGL J MED, V319, P1623, DOI 10.1056/NEJM198812223192502; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BUSSE WW, 1992, ANN ALLERGY, V68, P286; CALVO M, 1994, J INVEST ALLERG CLIN, V4, P126; CHANG TL, 1990, J IMMUNOL, V145, P2803; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; MOORE MW, 1995, SCIENCE, V269, P1590; MOSSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; National Heart Lung and Blood Institute National Asthma Education Program, 1991, J ALLERGY CLIN IMMUN, V88, P425, DOI DOI 10.1016/0091-6749(91)92135-N; RENZ H, 1993, J IMMUNOL, V151, P1907; SUSTIEL A, 1989, CLIN EXP ALLERGY, V19, P11, DOI 10.1111/j.1365-2222.1989.tb02337.x; WALKER C, 1991, INT ARCH ALLER A IMM, V94, P241, DOI 10.1159/000235370	18	97	97	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					460	462		10.1038/nm0497-460	http://dx.doi.org/10.1038/nm0497-460			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095183				2022-12-25	WOS:A1997WQ82500039
J	Guo, Z; Liu, QH; Smith, LM				Guo, Z; Liu, QH; Smith, LM			Enhanced discrimination of single nucleotide polymorphisms by artificial mismatch hybridization	NATURE BIOTECHNOLOGY			English	Article						PCR; specificity; fluorescence; 3-nitropyrrole	REFRACTORY MUTATION SYSTEM; BASE-PAIR MISMATCHES; SYNTHETIC OLIGONUCLEOTIDES; UNIVERSAL NUCLEOSIDE; PCR-AMPLIFICATION; DUPLEX STABILITY; DNA DUPLEXES; SEQUENCE; TRANSPLANTATION; PRIMERS	In order to increase the discrimination of single nucleotide polymorphisms in DNA hybridization, artificial mismatches are inserted into probe oligonucleotides using the base analog 3-nitropyrrole. Differences in thermal stability (Delta T-m) between hybrids formed with normal and single-nucleotide-variant DNA targets are increased by as much as 200% over conventional hybridization, and are strongly dependent upon the spacing between mismatches. The increased specificity is demonstrated by hybridization analysis and allele-specific amplification within the HLA-DRB locus.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BAXTERLOWE LA, 1989, J CLIN INVEST, V84, P613, DOI 10.1172/JCI114206; BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; BERGSTROM DE, 1995, J AM CHEM SOC, V117, P1201, DOI 10.1021/ja00109a003; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; DOKTYCZ MJ, 1995, J BIOL CHEM, V270, P8439, DOI 10.1074/jbc.270.15.8439; *DYN INC, 1989, DYN M 280 TECHN HDB, V6; EBEL S, 1992, BIOCHEMISTRY-US, V31, P12083, DOI 10.1021/bi00163a017; GUO Z, 1994, NUCLEIC ACIDS RES, V22, P5456, DOI 10.1093/nar/22.24.5456; IKUTA S, 1987, NUCLEIC ACIDS RES, V15, P797, DOI 10.1093/nar/15.2.797; ISHIKAWA Y, 1995, HUM IMMUNOL, V42, P315, DOI 10.1016/0198-8859(94)00119-B; JACOBS JW, 1994, TRENDS BIOTECHNOL, V12, P19, DOI 10.1016/0167-7799(94)90007-8; KE SH, 1993, NUCLEIC ACIDS RES, V21, P5137, DOI 10.1093/nar/21.22.5137; LEONARD GA, 1990, NUCLEIC ACIDS RES, V18, P5617, DOI 10.1093/nar/18.19.5617; MCGRAW RA, 1990, BIOTECHNIQUES, V8, P674; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; NICHOLS R, 1994, NATURE, V369, P492, DOI 10.1038/369492a0; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SMITH LM, 1987, METHOD ENZYMOL, V155, P260; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; TIBANYENDA N, 1984, EUR J BIOCHEM, V139, P19, DOI 10.1111/j.1432-1033.1984.tb07970.x; WALLACE RB, 1981, NUCLEIC ACIDS RES, V9, P879, DOI 10.1093/nar/9.4.879; WENHAM PR, 1991, CLIN CHEM, V37, P241; WERNTGES H, 1986, NUCLEIC ACIDS RES, V14, P3773, DOI 10.1093/nar/14.9.3773	26	112	193	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					331	335		10.1038/nbt0497-331	http://dx.doi.org/10.1038/nbt0497-331			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094133				2022-12-25	WOS:A1997WQ55400032
J	Vage, DI; Lu, DS; Klungland, H; Lien, S; Adalsteinsson, S; Cone, RD				Vage, DI; Lu, DS; Klungland, H; Lien, S; Adalsteinsson, S; Cone, RD			A non-epistatic interaction of agouti and extension in the fox, Vulpes vulpes	NATURE GENETICS			English	Article							STIMULATING-HORMONE-RECEPTOR; MSH RECEPTOR; MOUSE; GENE; MICE; CLONING; PROTEIN; LOCUS; CELLS	Agouti and extension are two genes that control the production of yellow-red (phaeomelanin) and brown-black (eumelanin) pigments in the mammalian coat(1). Extension encodes the melanocyte-stimulating hormone receptor (MC1R)(2,3) while agouti encodes a peptide antagonist of the receptor(4-6). In the mouse, extension is epistatic to agouti(7,8), hence dominant mutants of the MC1R encoding constitutively active receptors are not inhibited by the agouti antagonist, and animals with dominant alleles of both loci remain darkly pigmented, In the fox the proposed extension locus is not epistatic to the agouti locus(9,10). We have cloned and characterized the MC1R and the agouti gene in coat colour variants of the fox (Vulpes vulpes). A constitutively activating C125R mutation in the MC1R was found specifically in darkly pigmented animals carrying the Alaska Silver allele (E(A)). A deletion in the first coding exon of the agouti gene was found associated with the proposed recessive allele of agouti in the darkly pigmented Standard Silver fox (aa). Thus, as in the mouse, dark pigmentation can be caused by a constitutively active MC1R, or homozygous recessive status at the agouti locus. Our results, demonstrating the presence of dominant extension alleles in foxes with significant red coat colouration, suggest the ability of the fox agouti protein to counteract the signalling activity of a constitutively active fox MC1R.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA; AGR UNIV NORWAY, DEPT ANIM SCI, N-1432 AS, NORWAY; AGR UNIV NORWAY, NORDIC GENE BANK FARM ANIM, N-1432 AS, NORWAY	Oregon Health & Science University; Norwegian University of Life Sciences; Norwegian University of Life Sciences			Våge, Dag Inge/AAD-5178-2020	Våge, Dag Inge/0000-0003-2568-1554	NIAMS NIH HHS [AR42415] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042415] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADALSTEINSSON S, 1987, J HERED, V78, P235, DOI 10.1093/oxfordjournals.jhered.a110373; Ashbrook FG., 1937, YRB AGR, P1379; BATEMAN N, 1961, J HERED, V52, P186, DOI 10.1093/oxfordjournals.jhered.a107062; BLANCHARD SG, 1995, BIOCHEMISTRY-US, V34, P10406, DOI 10.1021/bi00033a012; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; KLUNGLAND H, 1995, MAMM GENOME, V6, P636, DOI 10.1007/BF00352371; Koppula SV, 1997, HUM MUTAT, V9, P30, DOI 10.1002/(SICI)1098-1004(1997)9:1<30::AID-HUMU5>3.3.CO;2-5; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SEARLE AG, COMP GENETICS COAT C, P67; SOLCA F, 1989, J BIOL CHEM, V264, P14277; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; WOLFF GL, 1978, J HERED, V69, P295, DOI 10.1093/oxfordjournals.jhered.a108953; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733	24	175	187	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					311	315		10.1038/ng0397-311	http://dx.doi.org/10.1038/ng0397-311			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054949				2022-12-25	WOS:A1997WK38600026
J	Koyama, S; Haruyama, T; Kobatake, E; Aizawa, M				Koyama, S; Haruyama, T; Kobatake, E; Aizawa, M			Electrically induced NGF production by astroglial cells	NATURE BIOTECHNOLOGY			English	Article						astroglial cells; nerve growth factor; electric stimulation; protein kinase C	NERVE GROWTH-FACTOR; FACTOR SECRETION; GENE-EXPRESSION; ASTROCYTES; ELECTRODE; CULTURES; SURFACE	A controlled culture system has been developed to induce nerve growth factor (NGF) production in astroglial cells that are cultured on an electrode surface. The electrode potential is alternatively modulated at an amplitude of 300 mV and a frequency of 10 Hz. The electric stimulation triggers NGF production and secretion. The mechanism of the electrically induced NGF production is discussed in association with protein kinase C (PKC) activation.			Koyama, S (corresponding author), TOKYO INST TECHNOL,DEPT BIOENGN,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN.							BOWMAN CL, 1992, BRAIN RES, V584, P272, DOI 10.1016/0006-8993(92)90906-P; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; FURUKAWA Y, 1993, J NEUROSCI RES, V35, P522, DOI 10.1002/jnr.490350508; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; KOJIMA J, 1992, BIOTECHNOL BIOENG, V39, P27, DOI 10.1002/bit.260390106; KOJIMA J, 1991, J BIOTECHNOL, V18, P129, DOI 10.1016/0168-1656(91)90241-M; Lindholm D, 1990, Neuroreport, V1, P9; LU B, 1991, J NEUROSCI, V11, P318; PSHENICHKIN SP, 1995, J BIOL CHEM, V270, P5994, DOI 10.1074/jbc.270.11.5994; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9	15	42	47	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					164	166		10.1038/nbt0297-164	http://dx.doi.org/10.1038/nbt0297-164			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035143				2022-12-25	WOS:A1997WE99800024
J	Miller, HI				Miller, HI			The end of big government?	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					111	111		10.1038/nbt0297-111	http://dx.doi.org/10.1038/nbt0297-111			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035118				2022-12-25	WOS:A1997WE99800004
J	Shi, ZZ; Habib, GM; Rhead, WJ; Gahl, WA; He, XW; Sazer, S; Lieberman, MW				Shi, ZZ; Habib, GM; Rhead, WJ; Gahl, WA; He, XW; Sazer, S; Lieberman, MW			Mutations in the glutathione synthetase gene cause 5-oxoprolinuria	NATURE GENETICS			English	Article							SCHIZOSACCHAROMYCES-POMBE; INBORN ERROR; FIBROBLASTS; DEFICIENCY; EXPRESSION; PATIENT		BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242; NICHHD,HERITABLE DISORDERS BRANCH,NIH,BETHESDA,MD 20892	Baylor College of Medicine; Baylor College of Medicine; University of Iowa; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049119] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07827] Funding Source: Medline; NIGMS NIH HHS [GM49119] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTOR MB, 1984, BRIT J RADIOL, V57, P717, DOI 10.1259/0007-1285-57-680-717; BEUTLER E, 1976, NEW ENGL J MED, V295, P441, DOI 10.1056/NEJM197608192950809; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; GALI RR, 1995, BIOCHEM J, V310, P353, DOI 10.1042/bj3100353; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JAIN A, 1994, J PEDIATR-US, V124, P229, DOI 10.1016/S0022-3476(94)70309-4; JELLUM E, 1970, SCAND J CLIN LAB INV, V26, P327, DOI 10.3109/00365517009046241; KAVANAGH TJ, 1994, EXP CELL RES, V212, P69, DOI 10.1006/excr.1994.1119; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LARSSON A, 1981, ACTA PAEDIATR SCAND, V70, P301, DOI 10.1111/j.1651-2227.1981.tb16556.x; LARSSON A, 1983, CLIN CHIM ACTA, V135, P57, DOI 10.1016/0009-8981(83)90388-1; LARSSON A, 1990, GLUTATHIONE METABOLI, P359; MAJERUS PW, 1971, J CLIN INVEST, V50, P1637, DOI 10.1172/JCI106652; MEISTER A, 1985, METHOD ENZYMOL, V113, P393; Meister A., 1995, METABOLIC BASIS INHE, P1461; MOHLER DN, 1970, NEW ENGL J MED, V283, P1253, DOI 10.1056/NEJM197012032832304; MUTOH N, 1988, BIOCHEM BIOPH RES CO, V151, P32, DOI 10.1016/0006-291X(88)90555-4; MUTOH N, 1991, BIOCHEM BIOPH RES CO, V181, P430, DOI 10.1016/S0006-291X(05)81437-8; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Shi ZZ, 1996, ARCH BIOCHEM BIOPHYS, V331, P215, DOI 10.1006/abbi.1996.0301; SPIELBERG SP, 1977, J PEDIATR-US, V91, P237, DOI 10.1016/S0022-3476(77)80819-6; SPIELBERG SP, 1978, J CLIN INVEST, V61, P1417, DOI 10.1172/JCI109060	22	67	68	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					361	365		10.1038/ng1196-361	http://dx.doi.org/10.1038/ng1196-361			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896573				2022-12-25	WOS:A1996VQ14600038
J	Whitcomb, DC; Gorry, MC; Preston, RA; Furey, W; Sossenheimer, MJ; Ulrich, CD; Martin, SP; Gates, LK; Amann, ST; Toskes, PP; Liddle, R; McGrath, K; Uomo, G; Post, JC; Ehrlich, GD				Whitcomb, DC; Gorry, MC; Preston, RA; Furey, W; Sossenheimer, MJ; Ulrich, CD; Martin, SP; Gates, LK; Amann, ST; Toskes, PP; Liddle, R; McGrath, K; Uomo, G; Post, JC; Ehrlich, GD			Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene	NATURE GENETICS			English	Article							CYSTIC-FIBROSIS GENE; NUCLEOTIDE-SEQUENCE; IDENTIFICATION; CLONING; PROTEINASES; RESOLUTION; COMPLEX; CDNA	Hereditary pancreatitis (HP) is a rare, early-onset genetic disorder characterized by epigastric pain and often more serious complications, We now report that an Arg-His substitution at residue 117 of the cationic trypsinogen gene is associated with the HP phenotype. This mutation was observed in all HP affected individuals and obligate carriers from five kindreds, but not in individuals who married into the families nor in 140 unrelated individuals. X-ray crystal structure analysis, molecular modelling, and protein digest data indicate that the Arg 117 residue is a trypsin-sensitive site. Cleavage at this site is probably part of a fail-safe mechanism by which trypsin, which is activated within the pancreas, may be inactivated; loss of this cleavage site would permit autodigestion resulting in pancreatitis.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,CTR GENOME SCI,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA 15261; VET ADM MED CTR,DEPT MED,PITTSBURGH,PA 15240; VET ADM MED CTR,DEPT CRYSTALLOG,PITTSBURGH,PA 15240; UNIV CINCINNATI,DIV DIGEST DIS,CINCINNATI,OH 45267; UNIV KENTUCKY,MED CTR,LEXINGTON,KY 40536; UNIV FLORIDA,SCH MED,DEPT GASTROENTEROL HEPATOL,GAINESVILLE,FL 32610; UNIV FLORIDA,SCH MED,DEPT NUTR,GAINESVILLE,FL 32610; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; OSPED ANTONIO CARDARELLI,INTERNAL MED UNIT 31,NAPLES,ITALY; CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT OTOLARYNGOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Ohio; University of Cincinnati; University of Kentucky; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Duke University; Antonio Cardarelli Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Amann, Stephen/0000-0002-1487-6965; Ehrlich, Garth/0000-0003-1140-6594	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002148] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC02148] Funding Source: Medline; NIDDK NIH HHS [R01 DK50236, R29 DK45781] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIEGER W, 1980, ANAL BIOCHEM, V109, P222, DOI 10.1016/0003-2697(80)90640-5; BODIC LL, 1996, HUM MOL GENET, V5, P549; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; Chiari H., 1896, ZEITSCHRIFTFURHEILKU, V17, P69; COMFORT MW, 1952, GASTROENTEROLOGY, V21, P54; CUCCHIARA S, 1990, J PEDIATR GASTR NUTR, V3, P422; DASSELL B, 1973, SCIENCE, V180, P1022; EMI M, 1986, GENE, V41, P305; FIGARELLA C, 1984, BIOCHEM BIOPH RES CO, V118, P154, DOI 10.1016/0006-291X(84)91080-5; GORRY MC, 1995, HUM MOL GENET, V4, P1387, DOI 10.1093/hmg/4.8.1387; HIGAKI JN, 1986, J BIOL CHEM, V261, P606; HIGAKI JN, 1985, ANAL BIOCHEM, V148, P111, DOI 10.1016/0003-2697(85)90635-9; HUBER R, TRYPSINOGEN COMPLEX; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MADRAZODELAGARZ.JA, 1993, PANCREAS BIOL PATHOB, P1095; MARTISE TC, 1994, NAT GENET, V6, P384; MCELROY R, 1972, AM J MED, V52, P228, DOI 10.1016/0002-9343(72)90072-1; PERRAULT J, 1994, GASTROENTEROL CLIN N, V23, P743; RINDERKNECHT H, 1988, INT J PANCREATOL, V3, P33; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124; Rinderknecht Heinrich, 1993, P219; ROMMENS JM, 1988, AM J HUM GENET, V43, P645; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROVERY M, 1988, BIOCHIMIE, V70, P1131, DOI 10.1016/0300-9084(88)90177-0; ROWEN L, IN PRESS SCIENCE; STEER ML, 1987, NEW ENGL J MED, V316, P144; STEWART EA, 1990, AM J HUM GENET, V46, P795; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; TANI T, 1990, NUCLEIC ACIDS RES, V18, P1631, DOI 10.1093/nar/18.6.1631; WEINGAND U, 1993, GENE, V136, P167; Whitcomb DC, 1996, GASTROENTEROLOGY, V110, P1975, DOI 10.1053/gast.1996.v110.pm8964426; YAMAMOTO T, 1985, BIOCHEM BIOPH RES CO, V132, P605, DOI 10.1016/0006-291X(85)91176-3	34	1130	1163	0	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					141	145		10.1038/ng1096-141	http://dx.doi.org/10.1038/ng1096-141			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841182				2022-12-25	WOS:A1996VL44600016
J	Morrison, SJ; Wandycz, AM; Akashi, K; Globerson, A; Weissman, IL				Morrison, SJ; Wandycz, AM; Akashi, K; Globerson, A; Weissman, IL			The aging of hematopoietic stem cells	NATURE MEDICINE			English	Article							BONE-MARROW CELLS; PROLIFERATIVE CAPACITY; REPOPULATING ABILITY; IRRADIATED MICE; MITOTIC CLOCK; FETAL LIVER; B-CELLS; AGE; PROGENITORS; INVITRO	We have purified hematopoietic stem cells (HSCs) from the bone marrow of old mice and compared their properties to HSCs in young and middle-aged mice. Single, reconstituting HSCs (by limit dilution) from old and young mice exhibited indistinguishable progenitor activities in vivo. HSCs were five times as frequent in the bone marrow of old mice; however, HSCs from old mice were only one-quarter as efficient at homing to and engrafting the bone marrow of irradiated recipients. HSCs in young and middle-aged mice rarely were in the S/C-2/M phases of the cell cycle, but HSCs in old mice were frequently in cycle. We speculate that the unexpected proliferation of HSCs in old mice might be related to the increased incidence of leukemia in old mice. HSCs change with age, but it is unknown whether these changes are determined intrinsically or caused by the aging of their environment.	STANFORD UNIV,DEPT PATHOL,STANFORD,CA 94305; STANFORD UNIV,DEPT DEV BIOL,STANFORD,CA 94305; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL	Stanford University; Stanford University; Weizmann Institute of Science			Morrison, Sean/ABD-5326-2021	Morrison, Sean/0000-0003-1587-8329	NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; FARRAR JJ, 1974, J IMMUNOL, V112, P1244; FRANCUS T, 1986, J IMMUNOL, V137, P2411; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARRISON DE, 1983, J EXP MED, V157, P1496, DOI 10.1084/jem.157.5.1496; HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526; HARRISON DE, 1982, J EXP MED, V156, P1767, DOI 10.1084/jem.156.6.1767; HARRISON DE, 1979, MECH AGEING DEV, V9, P409, DOI 10.1016/0047-6374(79)90082-4; HARRISON DE, 1987, J NUTR, V117, P376, DOI 10.1093/jn/117.2.376; HARRISON DE, 1989, J IMMUNOL, V142, P3833; HARRISON DE, 1984, J EXP MED, V160, P759, DOI 10.1084/jem.160.3.759; HARRISON DE, 1973, P NATL ACAD SCI USA, V70, P4184; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HEIMFELD S, 1991, P NATL ACAD SCI USA, V88, P9902, DOI 10.1073/pnas.88.21.9902; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; OGDEN DA, 1976, TRANSPLANTATION, V22, P287, DOI 10.1097/00007890-197609000-00010; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; Peters SO, 1996, BLOOD, V87, P30; REINCKE U, 1982, SCIENCE, V215, P1619, DOI 10.1126/science.7071580; ROLINK A, 1993, BLOOD, V81, P2290; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; SHARP A, 1989, MECH AGEING DEV, V48, P91, DOI 10.1016/0047-6374(89)90029-8; SIMINOVITCH L, 1964, J CELL COMPAR PHYSL, V64, P23, DOI 10.1002/jcp.1030640104; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; TSUJI K, 1992, BLOOD, V79, P2855; UCHIDA N, 1994, BLOOD, V83, P3758; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857	35	602	616	2	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1011	1016		10.1038/nm0996-1011	http://dx.doi.org/10.1038/nm0996-1011			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782459				2022-12-25	WOS:A1996VF49700036
J	Nord, K; Gunneriusson, E; Ringdahl, J; Stahl, S; Uhlen, M; Nygren, PA				Nord, K; Gunneriusson, E; Ringdahl, J; Stahl, S; Uhlen, M; Nygren, PA			Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain	NATURE BIOTECHNOLOGY			English	Article						combinatorial chemistry; phage display,; staphylococcal protein A	AFFINITY HUMAN-ANTIBODIES; PEPTIDE LIBRARIES; ESCHERICHIA-COLI; IGG; FRAGMENT; COMPLEX	Small protein domains, capable of specific binding to different target proteins have been selected using combinatorial approaches. These binding proteins, Galled affibodies, were designed by randomization of 13 solvent-accessible surface residues of a stable alpha-helical bacterial receptor domain Z, derived from staphylococcal protein A. Repertoires of mutant Z domain genes were assembled and inserted into a phagemid vector adapted for monovalent phage display. Two libraries, each comprising approximately 4x10(7) transformants, were constructed using either an NN(G/T) or an alternative (C/A/G)NN degeneracy Biopanning against: the target proteins Tag DNA polymerase, human insulin, and a human apolipoprotein A-1 variant, showed that in all cases significant enrichments were obtained by file selection procedures. Selected clones were subsequently expressed in Escherichia coli and analyzed by SDS-PAGE, circular dichroism spectroscopy, and binding studies to their respective targets by biospecific interaction analysis. The affibodies have a secondary structure similar to the native Z domain and have micromolar dissociation constants (K-D) for their respective targets.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,KTH,S-10044 STOCKHOLM,SWEDEN	Royal Institute of Technology			Uhlen, Mathias/B-3262-2016; Nygren, Per-Åke/AAM-7888-2020; Uhlen, Mathias/AAV-8746-2021	Uhlen, Mathias/0000-0002-4858-8056; Nygren, Per-Åke/0000-0003-4214-6991; 				ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; Berkower I, 1996, CURR OPIN BIOTECH, V7, P622, DOI 10.1016/S0958-1669(96)80073-5; BIANCHI E, 1995, J MOL BIOL, V247, P154, DOI 10.1006/jmbi.1994.0129; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; CALABRESI L, 1994, J BIOL CHEM, V269, P32168; CEDERGREN L, 1993, PROTEIN ENG, V6, P441, DOI 10.1093/protein/6.4.441; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DJOJONEGORO BM, 1994, BIO-TECHNOL, V12, P169, DOI 10.1038/nbt0294-169; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Dunn IS, 1996, CURR OPIN BIOTECH, V7, P547, DOI 10.1016/S0958-1669(96)80060-7; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; Graslund T, 1997, PROTEIN EXPRES PURIF, V9, P125, DOI 10.1006/prep.1996.0674; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; JENDEBERG L, 1995, J MOL RECOGNIT, V8, P270, DOI 10.1002/jmr.300080405; JENDEBERG L, 1996, J MOL RECOGNIT, V35, P22; Kraulis PJ, 1996, FEBS LETT, V378, P190, DOI 10.1016/0014-5793(95)01452-7; KU J, 1995, P NATL ACAD SCI USA, V92, P6552, DOI 10.1073/pnas.92.14.6552; KUSHWAHA A, 1994, GENE, V151, P45, DOI 10.1016/0378-1119(94)90631-9; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; LYONS BA, 1993, BIOCHEMISTRY-US, V32, P7839, DOI 10.1021/bi00082a001; Makrides SC, 1996, J PHARMACOL EXP THER, V277, P534; Markland W, 1996, BIOCHEMISTRY-US, V35, P8058, DOI 10.1021/bi952629y; Markland W, 1996, BIOCHEMISTRY-US, V35, P8045, DOI 10.1021/bi9526286; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MARTIN F, 1994, EMBO J, V13, P5303, DOI 10.1002/j.1460-2075.1994.tb06864.x; Martin F, 1996, J MOL BIOL, V255, P86, DOI 10.1006/jmbi.1996.0008; MAURER R, 1980, J MOL BIOL, V139, P147, DOI 10.1016/0022-2836(80)90302-2; MCCONNELL SJ, 1995, J MOL BIOL, V250, P460, DOI 10.1006/jmbi.1995.0390; MOKS T, 1986, EUR J BIOCHEM, V156, P637, DOI 10.1111/j.1432-1033.1986.tb09625.x; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Nilsson J, 1997, BIOTECHNIQUES, V22, P744, DOI 10.2144/97224rr04; Nilsson J, 1996, J MOL RECOGNIT, V9, P585, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<585::AID-JMR306>3.0.CO;2-Z; NILSSON J, 1994, EUR J BIOCHEM, V224, P103, DOI 10.1111/j.1432-1033.1994.tb20000.x; NORD K, 1995, PROTEIN ENG, V8, P601, DOI 10.1093/protein/8.6.601; NYGREN PA, 1991, VACCINES, V91, P363; OLSSON A, 1987, EUR J BIOCHEM, V168, P319, DOI 10.1111/j.1432-1033.1987.tb13423.x; PINILLA C, 1995, BIOPOLYMERS, V37, P221, DOI 10.1002/bip.360370306; RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2; RUTHER U, 1982, NUCLEIC ACIDS RES, V10, P5765, DOI 10.1093/nar/10.19.5765; Samuelsson E, 1996, NAT BIOTECHNOL, V14, P751, DOI 10.1038/nbt0696-751; SAMUELSSON E, 1994, BIOCHEMISTRY-US, V33, P4207, DOI 10.1021/bi00180a013; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; Stahl S, 1997, PATHOL BIOL, V45, P66; STAHL S, 1993, CURR OPIN IMMUNOL, V5, P272, DOI 10.1016/0952-7915(93)90017-M; TASHIRO M, 1995, CURR OPIN STRUC BIOL, V5, P471, DOI 10.1016/0959-440X(95)80031-X; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309	51	495	639	1	67	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					772	777		10.1038/nbt0897-772	http://dx.doi.org/10.1038/nbt0897-772			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255793				2022-12-25	WOS:A1997XM70700030
J	Tsurumi, Y; Murohara, T; Krasinski, K; Chen, DF; Witzenbichler, B; Kearney, M; Couffinhal, T; Isner, JM				Tsurumi, Y; Murohara, T; Krasinski, K; Chen, DF; Witzenbichler, B; Kearney, M; Couffinhal, T; Isner, JM			Reciprocal relation between VEGF and NO in the regulation of endothelial integrity	NATURE MEDICINE			English	Article							VASCULAR-PERMEABILITY FACTOR; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR VEGF; HYPOXIC INDUCTION; PROTEIN-KINASE; ANGIOGENESIS; EXPRESSION; BINDING; ARTERIES; RECEPTOR	Balloon angioplasty disrupts the protective endothelial lining of the arterial wall, rendering arteries susceptible to thrombosis and intimal thickening. We show here that Vascular endothelial growth factor (VEGF), an endothelial cell mitogen, is upregulated in medial smooth muscle cells of the arterial wall in response to balloon injury. Both protein kinase C (PKC) and tyrosine kinase pp60(src) mediate augmented VEGF expression. In contrast, nitric oxide (NO) donors inhibit PKC-induced VEGF upregulation by interfering with binding of the transcription factor activator protein-1 (AP-1) to the VEGF promoter. Inhibition of VEGF promoter activation suggests that NO secreted by a restored endothelium functions as the negative feedback mechanism that downregulates VEGF expression to basal levels. Administration of a neutralizing VEGF antibody impaired reendothelialization following balloon injury performed in vivo. These findings establish a reciprocal relation between VEGF and NO in the endogenous regulation of endothelial integrity following arterial injury.	TUFTS UNIV,ST ELIZABETHS MED CTR BOSTON,SCH MED,DEPT MED CARDIOL,BOSTON,MA 02135; TUFTS UNIV,ST ELIZABETHS MED CTR BOSTON,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University			Witzenbichler, Bernhard/ABC-2525-2021; Couffinhal, Thierry/M-6857-2014; Murohara, Toyoaki/M-4958-2014	Couffinhal, Thierry/0000-0002-9217-2533; 	NHLBI NIH HHS [HL 02824, HL 40518, HL 57516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057516, R01HL040518, K07HL002824] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; Asahara T, 1996, CIRCULATION, V94, P3291, DOI 10.1161/01.CIR.94.12.3291; ASAHARA T, 1997, SCIENCE, V275, P965; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BAUTERS C, 1995, CIRCULATION, V91, P2802, DOI 10.1161/01.CIR.91.11.2802; BROCK TA, 1991, AM J PATHOL, V138, P213; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Couffinhal T, 1997, AM J PATHOL, V150, P1673; COUFFINHAL T, 1996, CIRCULATION, V94; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLUGELMAN MY, 1993, CIRCULATION, V88, P2493, DOI 10.1161/01.CIR.88.6.2493; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Hewett PW, 1996, BIOCHEM BIOPH RES CO, V221, P697, DOI 10.1006/bbrc.1996.0659; HISHIKAWA K, 1994, J CLIN INVEST, V93, P1975, DOI 10.1172/JCI117189; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; KATOH O, 1995, CANCER RES, V55, P5687; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOCH AE, 1994, J IMMUNOL, V152, P4149; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; Lee SL, 1996, AM J PHYSIOL-LUNG C, V270, pL362, DOI 10.1152/ajplung.1996.270.3.L362; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; LIU MY, 1995, AM J PHYSIOL-LUNG C, V268, pL729, DOI 10.1152/ajplung.1995.268.5.L729; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; LUSCHER TF, 1993, ANNU REV MED, V44, P395, DOI 10.1146/annurev.med.44.1.395; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; PARK JE, 1994, J BIOL CHEM, V269, P25646; PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SAFFITZ JE, 1996, CIRCULATION, V94, P1; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Senger DR, 1996, AM J PATHOL, V149, P293; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; Takeshita S, 1996, LAB INVEST, V75, P487; TAKESHITA S, 1995, AM J PATHOL, V147, P1649; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VanBelle E, 1997, CIRCULATION, V95, P438; VANBELLE E, IN PRESS J AM COLL C; vanderZee R, 1997, CIRCULATION, V95, P1030; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741	62	307	319	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					879	886		10.1038/nm0897-879	http://dx.doi.org/10.1038/nm0897-879			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256279				2022-12-25	WOS:A1997XP01400030
J	Chesi, M; Nardini, E; Brents, LA; Schrock, E; Ried, T; Kuehl, WM; Bergsagel, PL				Chesi, M; Nardini, E; Brents, LA; Schrock, E; Ried, T; Kuehl, WM; Bergsagel, PL			Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3	NATURE GENETICS			English	Article							BREAKPOINTS; REARRANGEMENTS; LYMPHOMA; FGFR-3; GENE		NCI, MED BRANCH, DEPT GENET, BETHESDA, MD 20889 USA; CORNELL UNIV, COLL MED, DIV HEMATOL & ONCOL, DEPT MED, NEW YORK, NY 10021 USA; NIH, NATL CTR HUMAN GENOME RES, DIAGNOST DEV BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Bergsagel, Peter Leif/A-7842-2011	Bergsagel, Peter Leif/0000-0003-1523-7388	NATIONAL CANCER INSTITUTE [K01CA074265] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA074265-03, K01 CA074265-04, K01 CA074265-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLOUCHE M, 1995, LEUKEMIA, V9, P937; BAXENDALE S, 1993, NAT GENET, V4, P181, DOI 10.1038/ng0693-181; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Davis LG, 1994, BASIC METHODS MOL BI; DEBOER CJ, 1993, CANCER RES, V53, P4148; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Francomano C. A., 1996, American Journal of Human Genetics, V59, pA25; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KEEGAN K, 1991, ONCOGENE, V6, P2229; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kuehl WM, 1996, CANCER RES, V56, P4370; LAI JL, 1995, BLOOD, V85, P2490, DOI 10.1182/blood.V85.9.2490.bloodjournal8592490; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; SAWYER JR, 1995, CANCER GENET CYTOGEN, V82, P41, DOI 10.1016/0165-4608(94)00284-I; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TANIWAKI M, 1994, BLOOD, V84, P2283, DOI 10.1182/blood.V84.7.2283.bloodjournal8472283; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WILLIAMS ME, 1993, LEUKEMIA, V7, P1437	31	553	613	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1997	16	3					260	264		10.1038/ng0797-260	http://dx.doi.org/10.1038/ng0797-260			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207791	Green Accepted			2022-12-25	WOS:A1997XG60900021
J	Ma, SW; Zhao, DL; Yin, ZQ; Mukherjee, R; Singh, B; Qin, HY; Stiller, CR; Jevnikar, AM				Ma, SW; Zhao, DL; Yin, ZQ; Mukherjee, R; Singh, B; Qin, HY; Stiller, CR; Jevnikar, AM			Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance	NATURE MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; NONOBESE DIABETIC MICE; INSULIN; IMMUNIZATION; SUPPRESSION; ISOFORM; CLONING; MOUSE	Oral administration of protein can induce antigen-specific immune hyporesponsiveness(1). However, the utility of oral tolerance to autoantigens in the treatment of autoimmune diseases may be limited when candidate autoantigens cannot be produced by conventional systems in quantities sufficient for clinical studies. Plants may be ideally suited for this purpose, as they can synthesize, glycosylate and assemble mammalian proteins to provide huge quantities of relatively low cost soluble proteins(2). Furthermore, edible transgenic plants could provide a simple and direct method of autoantigen delivery for oral tolerance. Therefore, the aim of this study was to determine whether a transgenic plant expression system was capable of synthesizing the diabetes-associated autoantigen, glutamic acid decarboxylase (GAD)(3,4) in an immunogenic form and whether the oral administration of an autoantigen expressed by a plant could directly induce protective immune responses in a mouse model of diabetes. We show that a GAD-expressing transgenic plant, given as a dietary supplement, inhibits the development of diabetes in the non-obese diabetic (NOD) mouse.	UNIV WESTERN ONTARIO,SIEBENS DRAKE RES INST,LONDON,ON N6G 2V4,CANADA; UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,JOHN P ROBARTS RES INST,TRANSPLANTAT IMMUNOBIOL GRP,LONDON,ON N6G 2V4,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Jevnikar, Anthony M./G-3309-2011; Singh, Bhagirath/C-4010-2013	Singh, Bhagirath/0000-0002-9792-8694				Blanas E, 1996, SCIENCE, V274, P1707, DOI 10.1126/science.274.5293.1707; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; DEAIZPURUA HJ, 1992, P NATL ACAD SCI USA, V89, P9841, DOI 10.1073/pnas.89.20.9841; DEBLOCK M, 1988, THEOR APPL GENET, V76, P767, DOI 10.1007/BF00303524; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; ELLIOTT JF, 1994, DIABETES, V43, P1494, DOI 10.2337/diabetes.43.12.1494; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; KARLSEN AE, 1991, P NATL ACAD SCI USA, V88, P8337, DOI 10.1073/pnas.88.19.8337; KATAROVA Z, 1990, EUR J NEUROSCI, V2, P190, DOI 10.1111/j.1460-9568.1990.tb00412.x; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; QIN HY, 1995, AUTOIMMUNITY, V21, P50; SIJMONS PC, 1990, BIO-TECHNOL, V8, P217, DOI 10.1038/nbt0390-217; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; Tian JD, 1996, NAT MED, V2, P1348, DOI 10.1038/nm1296-1348; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	24	154	173	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					793	796		10.1038/nm0797-793	http://dx.doi.org/10.1038/nm0797-793			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212110				2022-12-25	WOS:A1997XG76700043
J	Woldbye, DPD; Larsen, PJ; Mikkelsen, JD; Klemp, K; Madsen, TM; Bolwig, TG				Woldbye, DPD; Larsen, PJ; Mikkelsen, JD; Klemp, K; Madsen, TM; Bolwig, TG			Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors	NATURE MEDICINE			English	Article							FUNCTIONAL EXPRESSION; PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; CLONING; BRAIN; RAT; NEURONS	Neuropeptide Y (NPY) is widely distributed in interneurons of the central nervous system (CNS), including the hippocampus and cerebral cortex, in concentrations exceeding those of any other known neuropeptides(1,2). Sequence data comparing different species show that NPY is highly conserved(3). This suggests a critical role in regulation of regional neuronal excitability. Kainic acid, a glutamate agonist at kainic acid receptors, causes severe limbic motor seizures culminating in status epilepticus(4). We here report that NPY administered into the lateral ventricle is a powerful inhibitor of motor as well as electroencephalographic (EEC) seizures induced by kainic acid. This effect was mediated via receptors with a pharmacological profile similar to the recently cloned rat Y5 receptor(5). The present study is the first to demonstrate that NPY possesses anticonvulsant activity. This is consistent with the concept that NPY is an endogenous anticonvulsant and suggests that agonists acting at Y5-like receptors may constitute a novel group of drugs in antiepileptic therapy.	UNIV COPENHAGEN,INST MED ANAT,DK-2200 COPENHAGEN N,DENMARK; COPENHAGEN UNIV HOSP,RIGSHOSP O6234,LAB EXPT NEUROPSYCHIAT,DK-2100 COPENHAGEN,DENMARK; H LUNDBECK & CO AS,DEPT NEUROBIOL,DK-2500 COPENHAGEN,DENMARK	University of Copenhagen; Rigshospitalet; University of Copenhagen; Lundbeck Corporation	Woldbye, DPD (corresponding author), UNIV COPENHAGEN,DEPT PHARMACOL,NEUROPHARMACOL LAB,3 BLEGDAMSVEJ,DK-2200 COPENHAGEN N,DENMARK.			Woldbye, David/0000-0002-6321-3850				BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; CHRONWALL BM, 1985, NEUROSCIENCE, V15, P1159, DOI 10.1016/0306-4522(85)90260-X; COLMERS WF, 1994, TRENDS NEUROSCI, V17, P373, DOI 10.1016/0166-2236(94)90046-9; DREIFUSS FE, 1985, EPILEPSIA, V26, P268; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; GEHLERT DR, 1994, LIFE SCI, V55, P551, DOI 10.1016/0024-3205(94)00481-1; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GREBER S, 1994, BRIT J PHARMACOL, V113, P737, DOI 10.1111/j.1476-5381.1994.tb17055.x; Hendry S. H. C., 1993, BIOL NEUROPEPTIDE Y, P65; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LIU Z, 1993, BRAIN RES, V631, P51, DOI 10.1016/0006-8993(93)91185-U; McQuiston AR, 1996, J NEUROSCI, V16, P1422; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SZREDER Z, 1994, GEN PHARMACOL-VASC S, V25, P85, DOI 10.1016/0306-3623(94)90014-0; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; Weinberg DH, 1996, J BIOL CHEM, V271, P16435, DOI 10.1074/jbc.271.28.16435; Woldbye DPD, 1996, BRAIN RES, V737, P162, DOI 10.1016/0006-8993(96)00730-5; Woldbye DPD, 1996, BRAIN RES, V720, P111, DOI 10.1016/0006-8993(96)00158-8	21	223	229	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					761	764		10.1038/nm0797-761	http://dx.doi.org/10.1038/nm0797-761			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212103				2022-12-25	WOS:A1997XG76700036
J	Pantaleo, G				Pantaleo, G			How immune-based interventions can change HIV therapy	NATURE MEDICINE			English	Editorial Material							INFECTION; DISEASE				Pantaleo, G (corresponding author), CHU VAUDOIS,DIV INFECT DIS,DEPT MED,LAB AIDS IMMUNOPATHOGENESIS,CH-1011 LAUSANNE,SWITZERLAND.		Pantaleo, Giuseppe/K-6163-2016					CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COREY L, 1995, J INFECT DIS, V171, P521, DOI 10.1093/infdis/171.3.521; EBERL G, EUR J IMMUNOL, V26, P2709; Emery S, 1996, AIDS, V10 Suppl A, pS159, DOI 10.1097/00002030-199601001-00022; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251	13	82	82	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					483	486		10.1038/nm0597-483	http://dx.doi.org/10.1038/nm0597-483			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142107				2022-12-25	WOS:A1997WX54300018
J	Schmidt, L; Duh, FM; Chen, F; Kishida, T; Glenn, G; Choyke, P; Scherer, SW; Zhuang, ZP; Lubensky, I; Dean, M; Allikmets, R; Chidambaram, A; Bergerheim, UR; Feltis, JT; Casadevall, C; Zamarron, A; Bernues, M; Richard, S; Lips, CJM; Walther, MM; Tsui, LC; Geil, L; Orcutt, ML; Stackhouse, T; Lipan, J; Slife, L; Brauch, H; Decker, J; Niehans, G; Hughson, MD; Moch, H; Storkel, S; Lerman, MI; Linehan, WM; Zbar, B				Schmidt, L; Duh, FM; Chen, F; Kishida, T; Glenn, G; Choyke, P; Scherer, SW; Zhuang, ZP; Lubensky, I; Dean, M; Allikmets, R; Chidambaram, A; Bergerheim, UR; Feltis, JT; Casadevall, C; Zamarron, A; Bernues, M; Richard, S; Lips, CJM; Walther, MM; Tsui, LC; Geil, L; Orcutt, ML; Stackhouse, T; Lipan, J; Slife, L; Brauch, H; Decker, J; Niehans, G; Hughson, MD; Moch, H; Storkel, S; Lerman, MI; Linehan, WM; Zbar, B			Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR GENE; MEDULLARY-THYROID CARCINOMA; RET PROTOONCOGENE; CELL CARCINOMA; C-MET; TRANSFORMING GENE; POINT MUTATION; GROWTH-FACTOR; SEQUENCE; RECEPTOR	Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumours(1-4). The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance. HPRC is histologically and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8)(5-6). Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome(7), Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of both copies of the VHL gene by mutation, and/or by hypermethylation(8-11). We found that the HPRC gene was located at chromosome 7q31.1-34 in a 27-centimorgan (cM) interval between D7S496 and D7S1837. We identified missense mutations located in the tyrosine kinase domain of the MET gene in the germline of affected members of HPRC families and in a subset of sporadic Family: papillary renal carcinomas. Three mutations in the MET gene are located in codons that are homologous to those in c-kit and RET, proto-oncogenes that are targets of naturally-occurring mutations. The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas.	NCI, IMMUNOBIOL LAB, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; NIH, GENET EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; NIH, DEPT DIAGNOST RADIOL, BETHESDA, MD 20892 USA; HOSP SICK CHILDREN, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA; NCI, LAB GEN DIVERS, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; KAROLINSKA HOSP, DEPT SURG, S-10401 STOCKHOLM, SWEDEN; CREDIT VALLEY HOSP, DEPT LAB MED, MISSISSAUGA, ON, CANADA; UNIV AUTONOMA BARCELONA, INST BIOL FONAMENTAL, E-08193 BARCELONA, SPAIN; HOSP COMARCAL SANTIAGO APOSTOL, BURGOS, SPAIN; HOP NECKER ENFANTS MALAD, LAB NEUROONCOL, PARIS, FRANCE; UNIV UTRECHT HOSP, UTRECHT, NETHERLANDS; NIH, SURG BRANCH, BETHESDA, MD 20892 USA; UNIV HAMBURG, KRANKENHAUS EPPENDORF, D-2000 HAMBURG, GERMANY; UNIV MAINZ, DEPT HEMATOL & ONCOL, D-6500 MAINZ, GERMANY; INST PATHOL, WUPPERTAL, GERMANY; VET AFFAIRS, MINNEAPOLIS, MN 55362 USA; VET AFFAIRS, NORTHPORT, NY 11768 USA; UNIV BASEL, INST PATHOL, BASEL, SWITZERLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Karolinska Institutet; Karolinska University Hospital; University of Toronto; Trillium Health Partners; Credit Valley Hospital; Autonomous University of Barcelona; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Utrecht University; Utrecht University Medical Center; National Institutes of Health (NIH) - USA; University of Hamburg; Johannes Gutenberg University of Mainz; University of Basel	Schmidt, L (corresponding author), SAIC FREDERICK, INTRAMURAL RES SUPPORT PROGRAM, FREDERICK, MD 21702 USA.		Dean, Michael C/G-8172-2012; Scherer, Stephen W./B-3785-2013; Dean, Michael/R-7501-2019; Tsui, Lap-chee/A-1081-2010; RICHARD, Stéphane/O-1005-2017; Allikmets, Rando/ABD-4533-2021	Dean, Michael C/0000-0003-2234-0631; Scherer, Stephen W./0000-0002-8326-1999; RICHARD, Stéphane/0000-0002-9859-9773; Brauch, Hiltrud/0000-0001-7531-2736; Casadevall, Carme/0000-0001-6458-8972				Bergerheim Ulf S. R., 1996, Journal of Urology, V155, p543A; BERNADES P, 1972, SEM HOP PARIS, V48, P2813; Bernues M, 1995, CANCER GENET CYTOGEN, V84, P123, DOI 10.1016/0165-4608(95)00044-5; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOLINO A, 1995, ONCOGENE, V10, P2415; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CHOYKE PL, IN PRESS J COMPUTER; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1995, ONCOGENE, V10, P509; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PONZETTO C, 1991, ONCOGENE, V6, P553; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schmidt L, 1995, Cancer J Sci Am, V1, P191; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Stuart ET, 1996, CELL GROWTH DIFFER, V7, P405; TAKAHASHI M, 1989, ONCOGENE, V4, P805; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIER HUG, 1991, HUM GENET, V87, P489; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; WIRSCHUBSKY Z, 1984, INT J CANCER, V33, P477, DOI 10.1002/ijc.2910330410; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; ZBAR B, 1995, J UROLOGY, V153, P907, DOI 10.1016/S0022-5347(01)67601-8	41	1101	1164	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1997	16	1					68	73		10.1038/ng0597-68	http://dx.doi.org/10.1038/ng0597-68			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140397				2022-12-25	WOS:A1997WX02400024
J	Borrow, P; Lewicki, H; Wei, XP; Horwitz, MS; Peffer, N; Meyers, H; Nelson, JA; Gairin, JE; Hahn, BH; Oldstone, MBA; Shaw, GM				Borrow, P; Lewicki, H; Wei, XP; Horwitz, MS; Peffer, N; Meyers, H; Nelson, JA; Gairin, JE; Hahn, BH; Oldstone, MBA; Shaw, GM			Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus	NATURE MEDICINE			English	Article							HIV-1 INFECTION; CHORIOMENINGITIS VIRUS; RESPONSES; TYPE-1; RECOGNITION; VARIANTS; MEMORY; PLASMA; SEQUENCES; VIREMIA	The HIV-1-specific cytotoxic T lymphocyte (CTL) response is temporally associated with the decline in viremia during primary HIV-1 infection, but definitive evidence that it is of importance in virus containment has been lacking. Here we show that in a patient whose early CTL response was focused on a highly immunodominant epitope in gp160, there was rapid elimination of the transmitted virus strain and selection for a virus population bearing amino acid changes at a single residue within this epitope, which conferred escape from recognition by epitope-specific CTL. The magnitude (>100-fold), kinetics (30-72 days from onset of symptoms) and genetic pathways of virus escape from CTL pressure were comparable to virus escape from antiretroviral therapy, indicating the biological significance of the CTL response in vivo. One aim of HIV-1 vaccines should thus be to elicit strong CTL responses against multiple codominant viral epitopes.	OREGON HLTH SCI UNIV, DEPT MOL MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA; CNRS, UPR 9021, INST PHARMACOL & BIOL STRUCT, F-31077 TOULOUSE, FRANCE; UNIV ALABAMA, DEPT MED, DIV HEMATOL ONCOL, BIRMINGHAM, AL 35294 USA	Oregon Health & Science University; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Alabama System; University of Alabama Birmingham	Borrow, P (corresponding author), Scripps Res Inst, DEPT NEUROPHARMACOL, DIV VIROL, 10550 N TORREY PINES RD IMM-6, LA JOLLA, CA 92037 USA.			Borrow, Persephone/0000-0002-3877-9780; Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037430, R01AI009484, R37AI009484, R01AI035467, R29AI037430, R37AI035467] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37430, AI 35467, AI 09484] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, P11; Flynn JN, 1996, J IMMUNOL, V157, P3658; GAIRIN JE, 1995, J VIROL, V69, P2297, DOI 10.1128/JVI.69.4.2297-2305.1995; GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167; Harrer T, 1996, J IMMUNOL, V156, P2616; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KORBER B, 1995, HIV MOL IMMUNOLOGY D; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; MYERS G, 1995, HUMAN RETROVIRUSES A; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; Selin LK, 1996, J EXP MED, V183, P2489, DOI 10.1084/jem.183.6.2489; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WHITTON JL, 1988, VIROLOGY, V162, P321, DOI 10.1016/0042-6822(88)90471-0	39	919	944	0	29	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					205	211		10.1038/nm0297-205	http://dx.doi.org/10.1038/nm0297-205			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018240				2022-12-25	WOS:A1997WF08800040
J	Porter, PL; Malone, KE; Heagerty, PJ; Alexander, GM; Gatti, LA; Firpo, EJ; Daling, JR; Roberts, JM				Porter, PL; Malone, KE; Heagerty, PJ; Alexander, GM; Gatti, LA; Firpo, EJ; Daling, JR; Roberts, JM			Expression of cell-cycle regulators p27(Kip1) and cyclin E, alone and in combination, correlate with survival in young breast cancer patients	NATURE MEDICINE			English	Article							KINASE; GENE	Mutations in certain genes that regulate the cell cycle, such as p16 and p53, are frequently found in human cancers(1). However, tumor-specific mutations are uncommon in genes encoding cyclin E and the CDK inhibitor p27(Kip1), two cell-cycle regulators that are also thought to contribute to tumor progression(2-8). It is now known that levels of both cyclin E and p27 can be controlled by posttranscriptional mechanisms, indicating that expression of these proteins can be altered by means other than simply mutation of their respective genes(9,10). Thus, changes in p27 and cyclin E protein levels in tumors might be more common than previously anticipated and may be indicators of tumor behavior.	UNIV WASHINGTON,DIV PUBL HLTH SCI,PROGRAM EPIDEMIOL,SEATTLE,WA 98109; UNIV WASHINGTON,DIV PUBL HLTH SCI,PROGRAM BIOSTAT,SEATTLE,WA 98109; UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98109; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT BIOSTAT,SEATTLE,WA 98109; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT PATHOL,SEATTLE,WA 98109; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98109	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Porter, PL (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM CANC BIOL,C1-105,1100 FAIRVIEW AVE N,SEATTLE,WA 98109, USA.				NCI NIH HHS [N01-CN-05230, R01-CA 59736, R21-CA 66186] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA059736, R21CA066186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLUMAN B, 1996, GENE DEV, V10, P1979; CLURMAN BE, 1995, J NATL CANCER I, V87, P1499, DOI 10.1093/jnci/87.20.1499; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GERDES J, 1992, J PATHOL, V168, P85, DOI 10.1002/path.1711680114; KEYOMARSI K, 1994, CANCER RES, V54, P380; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KONSTANTIN S, 1996, CANCER RES, V56, P2400; LEACH FS, 1993, CANCER RES, V53, P1986; LIN DY, 1993, J AM STAT ASSOC, V88, P1341, DOI 10.2307/2291275; MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823	20	805	825	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					222	225		10.1038/nm0297-222	http://dx.doi.org/10.1038/nm0297-222			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018243				2022-12-25	WOS:A1997WF08800043
J	Riley, DJ; Nikitin, AY; Lee, WH				Riley, DJ; Nikitin, AY; Lee, WH			Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb-+/- mice	NATURE MEDICINE			English	Article							CARCINOMA-CELLS; PROTEIN; EXPRESSION; MOUSE; P53; PRODUCT; CANCER; APOPTOSIS; PHASE; LUNG	The retinoblastoma gene (RB) is the prototypic tumor suppressor. Studies to date have demonstrated cancer suppression with tumor cells reconstituted with RB ex vivo and implanted into immunodeficient mice, as well as with germline transmission of a human RB transgene into tumor-prone Rb-+/- mice. To mimic the therapy of cancer more closely, spontaneous pituitary melanotroph tumors arising in immunocompetent Rb-+/- mice were treated with a recombinant adenovirus carrying RB cDNA. Intratumoral RB gene transfer decreased tumor cell proliferation, reestablished innervation by growth-regulatory dopaminergic neurons, inhibited the growth of tumors, and prolonged the life spans of treated animals.	UNIV TEXAS,HLTH SCI CTR,CTR MOL MED,SAN ANTONIO,TX 78245; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio					NCI NIH HHS [CA 58318] Funding Source: Medline; NEI NIH HHS [EY 05758] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Berry DE, 1996, ONCOGENE, V12, P1809; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FALCONI G, 1964, ENDOCRINOLOGY, V74, P301, DOI 10.1210/endo-74-2-301; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HASSKOGAN DA, 1995, EMBO J, V14, P461; HENSEL CH, 1990, CANCER RES, V50, P3067; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HU NP, 1994, ONCOGENE, V9, P1021; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; MADREPERLA SA, 1990, CANCER RES, V61, P6381; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OOKAWA K, 1993, ONCOGENE, V8, P2175; PACK RJ, 1984, EUR J RESPIR DIS, V65, P559; RICH DP, 1993, HUM GENE THER, V4, P461, DOI 10.1089/hum.1993.4.4-461; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; RUSSELL ELIZABETH S., 1966, P511; SHIZMU E, 1994, ONCOGENE, V9, P2441; SLARK RS, 1995, J CELL BIOL, V129, P779; SOUSA R, 1990, NEUROSCIENCE, V34, P403, DOI 10.1016/0306-4522(90)90149-X; SOUSA R, 1992, J NEUROSCI, V12, P2130; WANG NP, 1993, ONCOGENE, V8, P279; Weidenman B., 1985, CELL, V41, P1017; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zabner J, 1996, J CLIN INVEST, V97, P1504, DOI 10.1172/JCI118573	49	66	69	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1316	1321		10.1038/nm1296-1316	http://dx.doi.org/10.1038/nm1296-1316			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946829				2022-12-25	WOS:A1996VW51500036
J	Shoemaker, DD; Lashkari, DA; Morris, D; Mittmann, M; Davis, RW				Shoemaker, DD; Lashkari, DA; Morris, D; Mittmann, M; Davis, RW			Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSFORMATION; DISRUPTION; SEQUENCE; ARRAYS; GENES; PCR	A quantitative and highly parallel method for analysing deletion mutants has been developed to aid in determining the biological function of thousands of newly identified open reading frames (ORFs) in Saccharomyces cerevisiae. This approach uses a PCR targeting strategy to generate large numbers of deletion strains. Each deletion strain is labelled with a unique 20-base tag sequence that can be detected by hybridization to a high-density oligonucleotide array. The tags serve as unique identifiers (molecular bar codes) that allow analysis of large numbers of deletion strains simultaneously through selective growth conditions. Hybridization experiments show that the arrays are specific, sensitive and quantitative. A pilot study with 11 known yeast genes suggests that the method can be extended to include all of the ORFs in the yeast genome, allowing whole genome analysis with a single selective growth condition and a single hybridization.	STANFORD UNIV, BECKMAN CTR, DEPT BIOCHEM, MED CTR, STANFORD, CA 94305 USA; AFFYMETRIX, SANTA CLARA, CA 95051 USA	Stanford University; Affymetrix								BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; JIMENEZ A, 1980, NATURE, V287, P869, DOI 10.1038/287869a0; LASHKARI DA, 1995, P NATL ACAD SCI USA, V92, P7912, DOI 10.1073/pnas.92.17.7912; LIPSHUTZ RJ, 1995, BIOTECHNIQUES, V19, P442; LOCKHART D, IN PRESS NATURE BIOT; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sherman F., 1986, METHODS YEAST GENETI; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	17	428	705	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1996	14	4					450	456		10.1038/ng1296-450	http://dx.doi.org/10.1038/ng1296-450			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944025				2022-12-25	WOS:A1996VV73000021
J	Gear, RW; Miaskowski, C; Gordon, NC; Paul, SM; Heller, PH; Levine, JD				Gear, RW; Miaskowski, C; Gordon, NC; Paul, SM; Heller, PH; Levine, JD			Kappa-opioids produce significantly greater analgesia in women than in men	NATURE MEDICINE			English	Article							SEX-DIFFERENCES; SWIM ANALGESIA; PAIN; GENDER; PHARMACOKINETICS; PREGNANCY; MORPHINE; RECEPTOR; RATS; GONADECTOMY	Sex differences in human responses to nociceptive stimuli and painful pathological conditions have generally indicated that women report higher pain levels or exhibit less tolerance than men for given stimulus intensities (reviewed in ref. 1 and 2). However, studies have not evaluated sex differences in analgesic responses. We recently reported the opioid agonist-antagonist that pentazocine, which acts predominantly at kappa-receptors, produced significantly better postoperative analgesia in females than in males(3,4) in patients who underwent surgery for the removal of their third molars (wisdom teeth). In the current study, we evaluated the hypothesis that this sex difference is a characteristic of kappa-opioid agonism. In order to determine whether there are sex differences associated with kappa-opioid agonism, the analgesic efficacy of two other predominantly kappa-opioid analgesics, nalbuphine and butorphanol, was compared in males and females who underwent surgery for the removal of third molar teeth. We found that both nalbuphine and butorphanol produced significantly greater analgesia in females as compared with males. Considering our earlier findings, we conclude that kappa-opioid analgesia is greater in females than in males, probably reflecting a difference in kappa-opioid-activated endogenous pain modulating circuits.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV RHEUMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RESTORAT DENT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL NURSING,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ORAL & MAXILLOFACIAL SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOSTAT & EPIDEMIOL,SAN FRANCISCO,CA 94143; KAISER FDN HOSP,HAYWARD,CA 94545	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente			Paul, Steve/ABE-5400-2020		NINR NIH HHS [NR 03923 T32-DE07204] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR003923] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ALOISI AM, 1994, NEUROSCI LETT, V179, P79, DOI 10.1016/0304-3940(94)90939-3; BAAMONDE AI, 1989, NEUROPHARMACOLOGY, V28, P967, DOI 10.1016/0028-3908(89)90197-4; BEATTY WW, 1970, J COMP PHYSIOL PSYCH, V73, P446, DOI 10.1037/h0030216; CANDIDO J, 1992, PHARMACOL BIOCHEM BE, V42, P685, DOI 10.1016/0091-3057(92)90015-8; COGAN R, 1986, PAIN, V27, P63, DOI 10.1016/0304-3959(86)90223-X; COYLE DE, 1995, NEUROSCI LETT, V186, P135, DOI 10.1016/0304-3940(95)11304-F; DAWSONBASOA MB, 1993, BRAIN RES, V601, P241, DOI 10.1016/0006-8993(93)91716-6; DYRENFURTH I, 1974, BIORHYTHMS HUMAN REP, P171; FAUCETT J, 1994, J PAIN SYMPTOM MANAG, V9, P383, DOI 10.1016/0885-3924(94)90175-9; Fillingim RB, 1995, PAIN FORUM, V4, P209, DOI 10.1016/S1082-3174(11)80022-X; Gear RW, 1996, NEUROSCI LETT, V205, P207, DOI 10.1016/0304-3940(96)12402-2; GINTZLER AR, 1980, SCIENCE, V210, P193, DOI 10.1126/science.7414330; GORDON NC, 1995, NEUROSCIENCE, V69, P345, DOI 10.1016/0306-4522(95)00335-G; HALPERN SH, 1996, ANESTH ANALG, V82, pS159; JAILLON P, 1989, CLIN PHARMACOL THER, V46, P226, DOI 10.1038/clpt.1989.130; KEPLER KL, 1989, PHARMACOL BIOCHEM BE, V34, P119, DOI 10.1016/0091-3057(89)90363-8; KEPLER KL, 1991, PAIN, V45, P87, DOI 10.1016/0304-3959(91)90168-W; KEPLER KL, 1988, PHARMACOL BIOCHEM BE, V29, P83, DOI 10.1016/0091-3057(88)90278-X; LEVINE JD, 1988, J CLIN INVEST, V82, P1574, DOI 10.1172/JCI113768; LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0; MARKS HE, 1972, PHYSIOL BEHAV, V8, P1113, DOI 10.1016/0031-9384(72)90206-5; MUSACCHIO JM, 1990, NEUROPSYCHOPHARMACOL, V3, P191; Pande AC, 1996, CLIN NEUROPHARMACOL, V19, P92, DOI 10.1097/00002826-199619010-00009; PARE WP, 1969, J COMP PHYSIOL PSYCH, V69, P214, DOI 10.1037/h0028196; Reisine T, 1996, GOODMAN GILMANS PHAR, P521; ROMERO MT, 1986, PHYSIOL BEHAV, V37, P893, DOI 10.1016/S0031-9384(86)80009-9; ROMERO MT, 1988, PHYSIOL BEHAV, V44, P257, DOI 10.1016/0031-9384(88)90147-3; SANDER HW, 1988, BRAIN RES, V474, P343, DOI 10.1016/0006-8993(88)90448-9; SHYU WC, 1994, EUR J CLIN PHARMACOL, V47, P57; UNRUH AM, 1993, PAIN, V65, P123; WILSON SJ, 1986, AM J OBSTET GYNECOL, V155, P340, DOI 10.1016/0002-9378(86)90822-7	31	341	351	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1248	1250		10.1038/nm1196-1248	http://dx.doi.org/10.1038/nm1196-1248			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898754				2022-12-25	WOS:A1996VQ10100042
J	Pulst, SM; Nechiporuk, A; Nechiporuk, T; Gispert, S; Chen, XN; LopesCendes, I; Pearlman, S; Starkman, S; OrozcoDiaz, G; Lunkes, A; DeJong, P; Rouleau, GA; Auburger, G; Korenberg, JR; Figueroa, C; Sahba, S				Pulst, SM; Nechiporuk, A; Nechiporuk, T; Gispert, S; Chen, XN; LopesCendes, I; Pearlman, S; Starkman, S; OrozcoDiaz, G; Lunkes, A; DeJong, P; Rouleau, GA; Auburger, G; Korenberg, JR; Figueroa, C; Sahba, S			Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2	NATURE GENETICS			English	Article							HUNTINGTONS-DISEASE; MOLECULAR ANALYSIS; CAG REPEAT; GENE; MUTATIONS; ATROPHY; FAMILY; DYSTROPHY; ALLELES; SCA2	The gene for spinocerebellar ataxia type 2 (SCA2) has been mapped to 12q24.1. A 1.1-megabase contig in the candidate region was assembled in P1 artificial chromosome and bacterial artificial chromosome clones. Using this contig, we identified a CAG trinucleotide repeat with CAA interruptions that was expanded in patients with SCA2. In contrast to other unstable trinucleotide repeats, this CAG repeat was not highly polymorphic in normal individuals. In SCA2 patients, the repeat was perfect and expanded to 36-52 repeats. The most common disease allele contained (CAG)(37), one of the shortest expansions seen in a CAG expansion syndrome. The repeat occurs in the 5'-coding region of SCA2 which is a member of a novel gene family.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV NEUROL,LOS ANGELES,CA 90048; UNIV DUSSELDORF,DEPT NEUROL,D-4000 DUSSELDORF 1,GERMANY; ROSWELL PK CANC INST,DEPT HUMAN GENET,BUFFALO,NY 14263; UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90069; LENIN HOSP,NEUROL SERV,HOLGUIN,CUBA; MCGILL UNIV,MONTREAL GEN HOSP,CTR RES NEUROSCI,MONTREAL,PQ H3G 1A4,CANADA; UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV MED GENET,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Heinrich Heine University Dusseldorf; Roswell Park Cancer Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; McGill University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pulst, SM (corresponding author), UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,BURNS & ALLEN RES INST,LOS ANGELES,CA 90048, USA.		Lopes-Cendes, Iscia/B-9416-2013	Lopes-Cendes, Iscia/0000-0002-6221-6822				BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CHUNG MY, 1993, NAT GENET, V5, P252; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DURR A, 1995, CLIN NEUROSCI, V3, P12; FILLA A, 1995, NEUROLOGY, V45, P793, DOI 10.1212/WNL.45.4.793; Flanigan K, 1996, AM J HUM GENET, V59, P392; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GACY AM, 1995, CELL, V81, P533; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; Gispert S, 1995, Am J Hum Genet, V57, P972; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; GOUW LG, 1995, NAT GENET, V10, P89, DOI 10.1038/ng0595-89; GUDMUNDSSON KR, 1969, ACTA NEUROL SCAND, V45, P114; HUYNH DP, 1994, HUM MOL GENET, V3, P1075, DOI 10.1093/hmg/3.7.1075; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KORENBERG JR, 1995, CYTOGENET CELL GENET, V69, P196, DOI 10.1159/000133962; KRAUTER K, 1995, NATURE, V377, P321; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LARIN Z, 1990, GENET RES, V56, P203, DOI 10.1017/S0016672300035308; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; MCMURRAY CT, 1995, CHROMOSOMA, V104, P2; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; Nechiporuk A, 1996, NEUROLOGY, V46, P1731, DOI 10.1212/WNL.46.6.1731; Nechiporuk T, 1996, HUM GENET, V97, P462; NELSON DL, 1995, SEMIN CELL BIOL, V6, P5, DOI 10.1016/1043-4682(95)90009-8; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PULST SM, 1993, NAT GENET, V5, P8, DOI 10.1038/ng0993-8c; RALSTON ML, 1978, TECHNOMETRICS, V20, P7, DOI 10.2307/1268154; RANUM LPW, 1994, NAT GENET, V8, P280, DOI 10.1038/ng1194-280; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; YAMAKAWA K, 1995, HUM MOL GENET, V4, P709, DOI 10.1093/hmg/4.4.709; 1993, CELL, V72, P971	40	908	938	1	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					269	276		10.1038/ng1196-269	http://dx.doi.org/10.1038/ng1196-269			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896555				2022-12-25	WOS:A1996VQ14600020
J	Scrocchi, LA; Brown, TJ; MacLusky, N; Brubaker, PL; Auerbach, AB; Joyner, AL; Drucker, DJ				Scrocchi, LA; Brown, TJ; MacLusky, N; Brubaker, PL; Auerbach, AB; Joyner, AL; Drucker, DJ			Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene	NATURE MEDICINE			English	Article							FUNCTIONAL EXPRESSION; 7-36 AMIDE; DIABETES-MELLITUS; INSULIN RELEASE; RAT-BRAIN; INCRETIN; CELL; POLYPEPTIDE; CLONING; HORMONE	Glucagon-like peptide 1 (GLP1) is postulated to regulate blood glucose and satiety, but the biological importance of GLP1 as an incretin and neuropeptide remains controversial. The regulation of nutrient-induced insulin secretion is dependent on the secretion of incretins, gut-derived peptides that potentiate insulin secretion from the pancreatic islets'. To ascertain the relative physiological importance of GLP1 as a regulator of feeding behavior and insulin secretion, we have generated mice with a targeted disruption of the GLP1 receptor gene (GLP1R). These GLP1R(-/-) mice are viable, develop normally but exhibit circulating insulin. It is surprising that they also exhibit abnormal levels of blood glucose following intraperitoneal glucose challenge. Intracerebroventricular administration of GLP1 inhibited-feeding in wild-type mice but not in GLP1R(-/-) mice; however, no evidence for abnormal body weight or feeding behavior was observed in GLP1R(-/-) mice. These observations demonstrate that GLP1 plays a central role in the regulation of glycemia; however, disruption of GLP1/GLP1R signaling in the central nervous system is not associated with perturbation of feeding behavior or obesity in vivo.	UNIV TORONTO,DEPT MED,TORONTO,ON M5G 2C4,CANADA; TORONTO HOSP,BANTING & BEST DIABET CTR,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,TORONTO HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 1A8,CANADA; NYU,MED CTR,SKIRBALL INST BIOMOL MED,DEPT CELL BIOL PHYSIOL & NEUROSCI,NEW YORK,NY 10016	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; New York University			Brown, Theodore J./E-2192-2013; Drucker, Daniel J/A-4092-2010	Brown, Theodore J./0000-0002-3074-4516; MacLusky, Neil/0000-0002-9202-0564				AKESSON TR, 1987, NEUROENDOCRINOLOGY, V45, P257, DOI 10.1159/000124737; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; CAMPOS RV, 1994, ENDOCRINOLOGY, V134, P2156, DOI 10.1210/en.134.5.2156; CREUTZFELDT W, 1985, DIABETOLOGIA, V28, P565, DOI 10.1007/BF00281990; DALESSIO DA, 1994, J CLIN INVEST, V93, P2263, DOI 10.1172/JCI117225; DAlessio DA, 1996, J CLIN INVEST, V97, P133, DOI 10.1172/JCI118380; DALESSIO DA, 1995, DIABETES, V44, P1433, DOI 10.2337/diabetes.44.12.1433; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; DUPRE J, 1995, DIABETES, V44, P626, DOI 10.2337/diabetes.44.6.626; EGAN JM, 1994, ENDOCRINOLOGY, V135, P2070, DOI 10.1210/en.135.5.2070; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GREMLICH S, 1995, DIABETES, V44, P1202, DOI 10.2337/diabetes.44.10.1202; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HEINRICHS SC, 1992, PEPTIDES, V13, P879, DOI 10.1016/0196-9781(92)90044-4; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOOSEIN NM, 1984, FEBS LETT, V178, P83, DOI 10.1016/0014-5793(84)81245-4; HVIDBERG A, 1994, METABOLISM, V43, P104, DOI 10.1016/0026-0495(94)90164-3; KANSE SM, 1988, FEBS LETT, V241, P209, DOI 10.1016/0014-5793(88)81063-9; KREYMANN B, 1987, LANCET, V2, P1300; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; RITZEL R, 1995, DIABETOLOGIA, V38, P720, DOI 10.1007/s001250050344; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; ToftNielsen MB, 1996, DIABETES, V45, P552, DOI 10.2337/diabetes.45.5.552; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VILLANUEVAPENACARRILLO ML, 1994, DIABETOLOGIA, V37, P1163, DOI 10.1007/BF00418382; WEI Y, 1995, FEBS LETT, V358, P219, DOI 10.1016/0014-5793(94)01430-9; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; Willms B, 1996, J CLIN ENDOCR METAB, V81, P327, DOI 10.1210/jc.81.1.327; Wurst W., 1993, Gene targeting: a practical approach., P33	36	615	675	0	35	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1254	1258		10.1038/nm1196-1254	http://dx.doi.org/10.1038/nm1196-1254			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898756				2022-12-25	WOS:A1996VQ10100044
J	Southgate, CD; Chishti, AH; Mitchell, B; Yi, SJ; Palek, J				Southgate, CD; Chishti, AH; Mitchell, B; Yi, SJ; Palek, J			Targeted disruption of the murine erythroid band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal membrane skeleton	NATURE GENETICS			English	Letter							ANION-EXCHANGER; BINDING; CELL; EXPRESSION; PROTEINS; SITE				Southgate, CD (corresponding author), TUFTS UNIV,SCH MED,ST ELIZABETHS MED CTR,DEPT BIOMED RES,BOSTON,MA 02135, USA.				NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037462, R01HL051445] Funding Source: NIH RePORTER; NCI NIH HHS [CA66263] Funding Source: Medline; NHLBI NIH HHS [HL37462, HL51445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; HANSPAL M, 1992, EUR J CELL BIOL, V58, P313; Hogan B, 1994, MANIPULATING MOUSE E; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1987, CELL, V51, P345, DOI 10.1016/0092-8674(87)90631-3; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LIU SC, 1981, J CLIN INVEST, V68, P597, DOI 10.1172/JCI110293; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LU SE, 1995, BLOOD PRINCIPLES PRA; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; OKOYE VCN, 1985, SCIENCE, V227, P169, DOI 10.1126/science.3880920; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; WOODS CM, 1986, J CELL BIOL, V103, P1789, DOI 10.1083/jcb.103.5.1789	20	120	120	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					227	230		10.1038/ng1096-227	http://dx.doi.org/10.1038/ng1096-227			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841202				2022-12-25	WOS:A1996VL44600036
J	Crabbe, JC; Phillips, TJ; Feller, DJ; Hen, R; Wenger, CD; Lessov, CN; Schafer, GL				Crabbe, JC; Phillips, TJ; Feller, DJ; Hen, R; Wenger, CD; Lessov, CN; Schafer, GL			Elevated alcohol consumption in null mutant mice lacking 5-HT1B serotonin receptors	NATURE GENETICS			English	Letter							ETHANOL; DEPENDENCE; TOLERANCE; ABUSE; LOCALIZATION; SENSITIVITY; AGGRESSION; DRUGS; WITHDRAWAL; BEHAVIOR		OREGON HLTH SCI UNIV,RES SERV 151W,PORTLAND,OR 97201; COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Oregon Health & Science University; Columbia University	Crabbe, JC (corresponding author), DEPT VET AFFAIRS MED CTR,PORTLAND,OR 97201, USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA005828, P01AA008621, P60AA010760, P50AA010760] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA08621, P60 AA010760, AA05828, AA10760] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BELKNAP JK, 1993, PSYCHOPHARMACOLOGY, V112, P503, DOI 10.1007/BF02244901; BOSCHERT U, 1994, NEUROSCIENCE, V58, P167, DOI 10.1016/0306-4522(94)90164-3; BRUINVELS AT, 1994, NEUROPHARMACOLOGY, V33, P367, DOI 10.1016/0028-3908(94)90067-1; CRABBE JC, 1979, J PHARMACOL EXP THER, V208, P128; CRABBE JC, 1994, BEHAV NEUROSCI, V108, P186, DOI 10.1037/0735-7044.108.1.186; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; CRABBE JC, 1991, J PHARMACOL EXP THER, V257, P663; CRABBE JC, 1983, PHARMACOL BIOCHEM BE, V18, P541, DOI 10.1016/0091-3057(83)90233-2; Goldman D, 1996, NAT GENET, V13, P137, DOI 10.1038/ng0696-137; KALANT H, 1971, PHARMACOL REV, V23, P135; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LAGERSPE.KY, 1968, SCAND J PSYCHOL, V9, P157, DOI 10.1111/j.1467-9450.1968.tb00530.x; LE AD, 1980, PSYCHOPHARMACOLOGY, V67, P143, DOI 10.1007/BF00431969; LEMARQUAND D, 1994, BIOL PSYCHIAT, V36, P326, DOI 10.1016/0006-3223(94)90630-0; LEMARQUAND D, 1994, BIOL PSYCHIAT, V36, P395, DOI 10.1016/0006-3223(94)91215-7; LINNOILA M, 1983, LIFE SCI, V33, P2609, DOI 10.1016/0024-3205(83)90344-2; MAROTEAUX L, 1992, P NATL ACAD SCI USA, V89, P3020, DOI 10.1073/pnas.89.7.3020; MEHLMAN PT, 1994, AM J PSYCHIAT, V151, P1485; Melo JA, 1996, NAT GENET, V13, P147, DOI 10.1038/ng0696-147; MICZEK KA, 1995, PSYCHOPHARMACOLOGY, V121, P38, DOI 10.1007/BF02245590; Phillips TJ, 1996, J PHARMACOL EXP THER, V277, P613; PHILLIPS TJ, 1994, ALCOHOL CLIN EXP RES, V18, P931, DOI 10.1111/j.1530-0277.1994.tb00062.x; Pineyro G, 1995, NEUROREPORT, V7, P353; Ramboz Sylvie, 1995, Behavioural Brain Research, V73, P305, DOI 10.1016/0166-4328(96)00119-2; RATEY JJ, 1995, CNS DRUGS, V4, P256, DOI 10.2165/00023210-199504040-00003; RODRIGUEZ LA, 1995, ALCOHOL CLIN EXP RES, V19, P367, DOI 10.1111/j.1530-0277.1995.tb01517.x; SANMARINA A, 1989, PSYCHOPHARMACOLOGY, V99, P450, DOI 10.1007/BF00589891; SAUDOU F, 1994, NEUROCHEM INT, V25, P503, DOI 10.1016/0197-0186(94)90150-3; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; TERDAL ES, 1994, ALCOHOL CLIN EXP RES, V18, P542, DOI 10.1111/j.1530-0277.1994.tb00907.x	30	282	288	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					98	101		10.1038/ng0996-98	http://dx.doi.org/10.1038/ng0996-98			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782828				2022-12-25	WOS:A1996VF61100029
J	Mahtani, MM; Widen, E; Lehto, M; Thomas, J; McCarthy, M; Brayer, J; Bryant, B; Chan, GY; Daly, M; Forsblom, C; Kanninen, T; Kirby, A; Kruglyak, L; Munnelly, K; Parkkonen, M; ReeveDaly, MP; Weaver, A; Brettin, T; Duyk, G; Lander, ES; Groop, LC				Mahtani, MM; Widen, E; Lehto, M; Thomas, J; McCarthy, M; Brayer, J; Bryant, B; Chan, GY; Daly, M; Forsblom, C; Kanninen, T; Kirby, A; Kruglyak, L; Munnelly, K; Parkkonen, M; ReeveDaly, MP; Weaver, A; Brettin, T; Duyk, G; Lander, ES; Groop, LC			Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families	NATURE GENETICS			English	Letter							IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL; CHROMOSOME 12Q; COMPLEX TRAITS; BREAST-CANCER; PIMA-INDIANS; LINKAGE; ONSET; MELLITUS; NIDDM		WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; LUND UNIV,DEPT ENDOCRINOL,WALLENBERG LAB,MALMO,SWEDEN; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MILLENIUM PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV HELSINKI HOSP,DEPT MED,HELSINKI,FINLAND	Massachusetts Institute of Technology (MIT); Whitehead Institute; Lund University; Massachusetts Institute of Technology (MIT); Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; University of Helsinki; Helsinki University Central Hospital			McCarthy, Mark/M-3763-2015	McCarthy, Mark/0000-0002-4393-0510				BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CERASI E, 1973, LANCET, V1, P794; CHARLES MA, 1991, DIABETES, V40, P796, DOI 10.2337/diabetes.40.7.796; COOK JTE, 1994, DIABETOLOGIA, V37, P1231, DOI 10.1007/s001250050240; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ERIKSSON J, 1992, DIABETIC MED, V9, P654, DOI 10.1111/j.1464-5491.1992.tb01862.x; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; Galli J, 1996, NAT GENET, V12, P31, DOI 10.1038/ng0196-31; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAFFNER SM, 1990, METABOLISM, V39, P842, DOI 10.1016/0026-0495(90)90130-5; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; KAHN SE, 1993, DIABETES, V42, P1663, DOI 10.2337/diabetes.42.11.1663; KING H, 1988, World Health Statistics Quarterly, V41, P190; KOBBERLING J, 1971, DIABETOLOGIA, V7, P46, DOI 10.1007/BF02346253; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LESAGE S, 1995, DIABETES, V44, P1243, DOI 10.2337/diabetes.44.10.1243; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; MENZEL S, 1995, DIABETES, V44, P1408, DOI 10.2337/diabetes.44.12.1408; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; ORAHILLY SP, 1986, LANCET, V2, P360; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SARTOR G, 1980, DIABETES, V29, P41, DOI 10.2337/diabetes.29.1.41; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; VIRTARANTAKNOWLES K, 1991, HUM HERED, V41, P248, DOI 10.1159/000154009; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; *WHO, 1985, DIABETES MELLITUS RE; YKIJARVINEN H, 1990, DIABETOLOGIA, V33, P579, DOI 10.1007/BF00400200	39	297	304	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					90	94		10.1038/ng0996-90	http://dx.doi.org/10.1038/ng0996-90			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782826				2022-12-25	WOS:A1996VF61100027
J	Sakamuro, D; Elliott, KJ; WechslerReya, R; Prendergast, GC				Sakamuro, D; Elliott, KJ; WechslerReya, R; Prendergast, GC			BIN1 is a novel MYC-interacting protein with features of a tumour suppressor	NATURE GENETICS			English	Article							TRANSCRIPTIONAL ACTIVATION DOMAIN; STIFF-MAN SYNDROME; C-MYC; BREAST-CANCER; TRANSACTIVATION DOMAIN; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; TRANSGENIC MICE; ADENOVIRUS E1A; DNA-BINDING	BIN1 is a novel protein that interacts with the functionally critical Myc box regions at the N terminus of the MYC oncoprotein. BIN1 is structurally related to amphiphysin, a breast cancer-associated autoimmune antigen, and RVS167, a negative regulator of the yeast cell cycle, suggesting roles in malignancy and cell cycle control. Consistent with this likelihood, BIN1 inhibited malignant cell transformation by MYC. Although BIN1 is expressed in many normal cells, its levels were greatly reduced or undetectable in 14/27 carcinoma cell lines and 3/6 primary breast tumours. Deficits were functionally significant because ectopic expression of BIN1 inhibited the growth of tumour cells tacking endogenous message. We conclude that BIN1 is an MYC-interacting protein with features of a tumour suppressor.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute					NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA10815, CA66179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BIANCHI MW, 1993, GENE, V134, P51, DOI 10.1016/0378-1119(93)90173-Z; BORN T, 1994, MOL CELL BIOL, V14, P5741; BROWN RH, 1994, PRINCIPLES INTERNAL, P1878; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cher ML, 1996, CANCER RES, V56, P3091; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYATA I, 1983, CANCER RES, V43, P367; HEHIR DJ, 1993, J SURG ONCOL, V54, P207, DOI 10.1002/jso.2930540402; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KREIPE H, 1993, CANCER RES, V53, P1956; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PULVERER BJ, 1994, ONCOGENE, V9, P59; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sakamuro D, 1995, ONCOGENE, V11, P2411; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHIOZAWA M, 1990, GENE, V87, P299, DOI 10.1016/0378-1119(90)90317-K; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATSON PH, 1993, J NATL CANCER I, V85, P902, DOI 10.1093/jnci/85.11.902; YAMAMOTO R, 1995, HUM MOL GENET, V4, P265, DOI 10.1093/hmg/4.2.265; YANO T, 1993, ONCOGENE, V8, P2741	63	302	312	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					69	77		10.1038/ng0996-69	http://dx.doi.org/10.1038/ng0996-69			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782822				2022-12-25	WOS:A1996VF61100023
J	Shirasawa, S; Yunker, AMR; Roth, KA; Brown, GA; Horning, S; Korsmeyer, SJ				Shirasawa, S; Yunker, AMR; Roth, KA; Brown, GA; Horning, S; Korsmeyer, SJ			Enx (Hox11L1)-deficient mice develop myenteric neuronal hyperplasia and megacolon	NATURE MEDICINE			English	Article							ENTERIC NERVOUS-SYSTEM; ENDOTHELIN-B RECEPTOR; NITRIC-OXIDE SYNTHASE; HIRSCHSPRUNGS-DISEASE; INTESTINAL DYSPLASIA; NADPH DIAPHORASE; TRANSGENIC MICE; HOX11 GENE; GUINEA-PIG; EXPRESSION	The isolated homeobox gene Enx (Hox11L1) is expressed in enteric neurons Innervating distal ileum, and proximal and distal colon. Enx-deficient mice develop megacolon with massive distension of the proximal colon. The number of myenteric ganglia, total neurons per ganglion, and NADPH diaphorase presumptive inhibitory neurons per ganglion are increased in the proximal and distal colon, but decreased in the distal ileum of all Enx(-/-) mice. Enx(-/-) mice provide a model for human neuronal intestinal dysplasia (NID), in which myenteric neuronal hyperplasia and megacolon are seen. These results suggest that Enx is required for the proper positional specification and differentiative cell fate of enteric neurons.	WASHINGTON UNIV,SCH MED,DEPT MED,HOWARD HUGHES MED INST,DIV MOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)				Roth, Kevin/0000-0002-0643-995X	NINDS NIH HHS [NS 35107] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035107] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barone V, 1996, AM J MED GENET, V62, P195, DOI 10.1002/(SICI)1096-8628(19960315)62:2<195::AID-AJMG15>3.0.CO;2-J; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; EDERY P, 1994, J MED GENET, V31, P602, DOI 10.1136/jmg.31.8.602; GABELLA G, 1984, J NEUROCYTOL, V13, P73, DOI 10.1007/BF01148319; GERSHON MD, 1993, J NEUROBIOL, V24, P199, DOI 10.1002/neu.480240207; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HEINICKE EA, 1987, J NEUROSCI METH, V21, P45, DOI 10.1016/0165-0270(87)90101-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Hug BA, 1996, MOL CELL BIOL, V16, P2906; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MUNAKATA K, 1985, J PEDIATR SURG, V20, P231, DOI 10.1016/S0022-3468(85)80109-3; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; REIFFERSCHEID P, 1982, HIRSCHSPRUNGS DISEAS, P133; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROBERTS CWM, 1995, AM J PATHOL, V146, P1089; ROTHMAN TP, 1982, J NEUROSCI, V2, P381; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHARLI AF, 1981, J PEDIATR SURG, V16, P164, DOI 10.1016/S0022-3468(81)80344-2; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TENNYSON VM, 1993, DEV DYNAM, V198, P28, DOI 10.1002/aja.1001980105; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; YOUNG HM, 1992, HISTOCHEMISTRY, V97, P375, DOI 10.1007/BF00270041; YUNKER AM, 1997, AM J PHYSL, V271	30	100	105	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					646	650		10.1038/nm0697-646	http://dx.doi.org/10.1038/nm0697-646			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176491				2022-12-25	WOS:A1997XB97400034
J	Haase, G; Kennel, P; Vigne, E; Akli, S; Revah, F; Schmalbruch, H; Kahn, A				Haase, G; Kennel, P; Vigne, E; Akli, S; Revah, F; Schmalbruch, H; Kahn, A			Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTONEURON SURVIVAL; MEDIATED TRANSFER; SKELETAL-MUSCLE; GROWTH-FACTOR; MOUSE MUTANT; CELL-DEATH; INVIVO; BDNF; DEGENERATION	Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy cause progressive paralysis, often leading to premature death. Neurotrophic factors have been suggested as therapeutic agents for motor neuron diseases, but their clinical use as injected recombinant protein was limited by toxicity and/or poor bioavailability. We demonstrate here that adenovirus-mediated gene transfer of neurotrophin-3 (NT-3) can produce substantial therapeutic effects in the mouse mutant pmn (progressive motor neuronopathy). After intramuscular injection of the NT-3 adenoviral vector, pmn mice showed a 50% increase in life span, reduced loss of motor axons and improved neuromuscular function as assessed by electromyography. These results were further improved by coinjecting an adenoviral vector coding for ciliary neurotrophic factor. Therefore, adenovirus-mediated gene transfer of neurotrophic factors offers new prospects for the treatment of motor neuron diseases.	INST COCHIN GENET MOL,INSERM,U129,F-75014 PARIS,FRANCE; INST DEV BIOL,INSERM,U382,F-13288 MARSEILLE,FRANCE; INST GUSTAVE ROUSSY,CNRS,PR2 URA 1301,F-94805 VILLEJUIF,FRANCE; UNIV COPENHAGEN,PANUM INST,INST MED PHYSIOL,DK-2200 COPENHAGEN N,DENMARK; RHONE POULENC RORER GENCELL,F-94403 VITRY SUR SEINE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Copenhagen; Sanofi-Aventis								AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; BISCHOFF C, 1994, MUSCLE NERVE, V17, P842, DOI 10.1002/mus.880170803; BOTTENSTEIN JE, 1980, EXP CELL RES, V125, P183, DOI 10.1016/0014-4827(80)90202-5; Braun S, 1996, J NEUROL SCI, V136, P17, DOI 10.1016/0022-510X(95)00315-S; BRUNIALTI ALB, 1995, GENOMICS, V29, P131, DOI 10.1006/geno.1995.1223; CEDARBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P515; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; Finiels F, 1995, NEUROREPORT, V7, P373, DOI 10.1097/00001756-199512000-00088; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; GHADGE GD, 1995, GENE THER, V2, P132; GRIESBECK O, 1995, J NEUROSCI RES, V42, P21, DOI 10.1002/jnr.490420104; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HANSEN S, 1978, J NEUROL NEUROSUR PS, V41, P773, DOI 10.1136/jnnp.41.9.773; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1995, ADV NEUROL, V68, P235; HITT M, 1994, CELL BIOL LAB HDB, V1, P479; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; JOHNSON DR, 1967, J EMBRYOL EXP MORPH, V17, P543; Kennel PF, 1996, NEUROBIOL DIS, V3, P137, DOI 10.1006/nbdi.1996.0014; LANGFORD LA, 1983, ANAT REC, V205, P207, DOI 10.1002/ar.1092050211; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1986, DEV BRAIN RES, V25, P195; Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; NAMBA T, 1967, AM J CLIN PATHOL, V47, P74; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; OZCELIK T, 1991, GENOMICS, V10, P569, DOI 10.1016/0888-7543(91)90437-J; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; Sagot Y, 1996, J NEUROSCI, V16, P2335; SAGOT Y, 1995, J NEUROSCI, V15, P7727; SCHMALBRUCH H, 1991, J NEUROPATH EXP NEUR, V50, P192, DOI 10.1097/00005072-199105000-00002; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; THOENEN H, 1993, EXP NEUROL, V124, P47, DOI 10.1006/exnr.1993.1173; VINCENT N, 1993, NAT GENET, V5, P130, DOI 10.1038/ng1093-130; WILLISON RG, 1964, J NEUROL NEUROSUR PS, V27, P386, DOI 10.1136/jnnp.27.5.386	46	206	217	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					429	436		10.1038/nm0497-429	http://dx.doi.org/10.1038/nm0497-429			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095177				2022-12-25	WOS:A1997WQ82500033
J	Sezonov, G; Blanc, V; BamasJacques, N; Friedmann, A; Pernodet, JL; Guerineau, M				Sezonov, G; Blanc, V; BamasJacques, N; Friedmann, A; Pernodet, JL; Guerineau, M			Complete conversion of antibiotic precursor to pristinamycin IIA by overexpression of Streptomyces pristinaespiralis biosynthetic genes	NATURE BIOTECHNOLOGY			English	Article						pristinamycin; pSAM2; Streptomyces pristinaespiralis	SITE-SPECIFIC INTEGRATION; PLASMID PSAM2; ELEMENT PSAM2; RP 59500; HYBRID ANTIBIOTICS; COELICOLOR A3(2); AMBOFACIENS; CLONING; REPLICATION; MECHANISM	A Streptomyces pristinaespiralis strain, which produces a streptogramin antibiotic pristinamycin II (PII) as a mixture of two biologically active molecules PIIB and Pll(A) was genetically engineered to produce exclusively PIIA. The snaA,B genes, which encode a PIIA synthase that performs oxidation of the precursor (PIIB) to the final product (PIIA), were integrated in the chromosome of S. pristinaespiralis using an integrative derivative of the pSAM2 genetic element from Streptomyces ambofaciens. Integration was due to site-specific recombination at the attB site of S. pristinaespiralis, and no homologous recombination at the snaA,B locus was observed. The attB site of S. pristinaespiralis was sequenced and found to overlap the 3' end of a pro-tRNA gene. The integrants were stable in industrial conditions of pristinamycin production and showed no decrease in PII biosynthesis. Western blot analysis showed a constant production of the PIIA synthase in the overall fermentation process due to expression of the cloned snaA,B genes from the constitutive ermE* promoter. This allows the complete conversion of the PIIB form into PIIA.	RHONE POULENC RORER SA,CTR RECH VITRY ALFORTVILLE,MOL BIOL UNIT,F-94403 VITRY SUR SEINE,FRANCE	Sanofi-Aventis; Sanofi France	Sezonov, G (corresponding author), UNIV PARIS 11,LAB BIOL & GENET MOL,INST MICROBIOL & GENET,CNRS,URA 2225,BATIMENT 400,F-91405 ORSAY,FRANCE.		Sezonov, Guennadi/ABB-5734-2020; Pernodet, Jean-Luc/A-4074-2015	Sezonov, Guennadi/0000-0002-2016-6126; Pernodet, Jean-Luc/0000-0002-6129-7093				ALEGRE MT, 1994, APPL ENVIRON MICROB, V60, P4279, DOI 10.1128/AEM.60.12.4279-4283.1994; Alvarez MA, 1996, NAT BIOTECHNOL, V14, P335, DOI 10.1038/nbt0396-335; AUMERCIER M, 1992, J ANTIMICROB CHEMOTH, V30, P9, DOI 10.1093/jac/30.suppl_A.9; BARRIERE JC, 1992, J ANTIMICROB CHEMOTH, V30, P1; BIBB MJ, 1986, GENE, V41, pE357, DOI 10.1016/0378-1119(86)90122-8; BIBB MJ, 1994, MOL MICROBIOL, V14, P533, DOI 10.1111/j.1365-2958.1994.tb02187.x; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BLANC V, 1995, MOL MICROBIOL, V17, P989, DOI 10.1111/j.1365-2958.1995.mmi_17050989.x; BOCCARD F, 1989, EMBO J, V8, P973, DOI 10.1002/j.1460-2075.1989.tb03460.x; BOCCARD F, 1989, PLASMID, V21, P59, DOI 10.1016/0147-619X(89)90087-5; BOCCARD F, 1988, MOL GEN GENET, V212, P432, DOI 10.1007/BF00330847; COCITO C, 1985, J ANTIMICROB CHEMOTH, V16, P35, DOI 10.1093/jac/16.suppl_A.35; COCITO C, 1979, MICROBIOL REV, V43, P145, DOI 10.1128/MMBR.43.2.145-192.1979; COX KL, 1990, J CELL BIOCH A S, V14; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; HAGEGE J, 1993, J BACTERIOL, V175, P5529; HAGEGE J, 1993, MOL MICROBIOL, V10, P799, DOI 10.1111/j.1365-2958.1993.tb00950.x; HAGEGE J, 1994, PLASMID, V31, P166, DOI 10.1006/plas.1994.1018; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KUHSTOSS S, 1989, J BACTERIOL, V171, P16, DOI 10.1128/jb.171.1.16-23.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAZODIER P, 1990, MOL GEN GENET, V222, P431, DOI 10.1007/BF00633850; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; PERNODET JL, 1984, MOL GEN GENET, V198, P35, DOI 10.1007/BF00328697; Preud'homme J, 1968, Bull Soc Chim Fr, V2, P585; PREUDHOM.J, 1965, CR HEBD ACAD SCI, V260, P1309; SALAHBEY K, 1995, MOL MICROBIOL, V17, P1001, DOI 10.1111/j.1365-2958.1995.mmi_17051001.x; Sambrook J., 2002, MOL CLONING LAB MANU; SEZONOV G, 1995, MOL MICROBIOL, V17, P533, DOI 10.1111/j.1365-2958.1995.mmi_17030533.x; SEZONOV G, 1995, BIOTECHNOLOGIA, V7, P80; SMOKVINA T, 1990, GENE, V94, P53, DOI 10.1016/0378-1119(90)90467-6; SMOKVINA T, 1991, PLASMID, V25, P40, DOI 10.1016/0147-619X(91)90005-H; SMOKVINA T, 1990, THESIS U PARIS SUD; SOUSSY CJ, 1992, J ANTIMICROB CHEMOTH, V30, P53, DOI 10.1093/jac/30.suppl_A.53; TAKANO E, 1992, MOL MICROBIOL, V6, P2797, DOI 10.1111/j.1365-2958.1992.tb01459.x; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; THOMAS DI, 1991, J GEN MICROBIOL, V137, P2331, DOI 10.1099/00221287-137-10-2331; THOMPSON CJ, 1980, NATURE, V286, P525, DOI 10.1038/286525a0; VALLINS WJS, 1985, J GEN MICROBIOL, V131, P1657; VAZQUEZ D, 1975, ANTIBIOTICS, V3, P521	43	33	38	1	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					349	353		10.1038/nbt0497-349	http://dx.doi.org/10.1038/nbt0497-349			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094136				2022-12-25	WOS:A1997WQ55400035
J	Steck, PA; Pershouse, MA; Jasser, SA; Yung, WKA; Lin, H; Ligon, AH; Langford, LA; Baumgard, ML; Hattier, T; Davis, T; Frye, C; Hu, R; Swedlund, B; Teng, DHF; Tavtigian, SV				Steck, PA; Pershouse, MA; Jasser, SA; Yung, WKA; Lin, H; Ligon, AH; Langford, LA; Baumgard, ML; Hattier, T; Davis, T; Frye, C; Hu, R; Swedlund, B; Teng, DHF; Tavtigian, SV			Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers	NATURE GENETICS			English	Article							HUMAN GLIOBLASTOMAS; PROSTATE-CANCER; MXI1 GENE; LONG ARM; HETEROZYGOSITY; AMPLIFICATION; PROGRESSION; SEQUENCES; REGIONS; LOCI	Deletions involving regions of chromosome 10 occur in the vast majority (>90%) of human glioblastoma multiformes. A region at chromosome 10q23-24 was implicated to contain a tumour suppressor gene and the identification of homozygous deletions in four glioma cell lines further refined the location. We have identified a gene, designated MMAC1, that spans these deletions and encodes a widely expressed 5.5-kb mRNA. The predicted MMAC1 protein contains sequence motifs with significant homology to the catalytic domain of protein phosphatases and to the cytoskeletal proteins, tensin and auxilin. MMAC1 coding-region mutations were observed in a number of glioma, prostate, kidney and breast carcinoma cell lines or tumour specimens. Our results identify a strong candidate tumour suppressor gene at chromosome 10q23.3, whose loss of function appears to be associated with the oncogenesis of multiple human cancers.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,BRAIN TUMOUR CTR,HOUSTON,TX 77030; MYRIAD GENET INC,SALT LAKE CITY,UT 84108	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Myriad Genetics, Inc	Steck, PA (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT NEUROONCOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P01CA055261, R55CA056041, R01CA056041] Funding Source: NIH RePORTER; NCI NIH HHS [CA56041, CA55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAROSA R, 1995, HUM GENET, V95, P709; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; FULTS D, 1990, CANCER RES, V50, P5784; GRAY IC, 1995, CANCER RES, V55, P4800; HERBST RA, 1994, CANCER RES, V54, P3111; HERMAN JG, 1995, CANCER RES, V55, P4520; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MORITA R, 1991, CANCER RES, V51, P5817; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; PEIFFER SL, 1995, CANCER RES, V55, P1922; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RAHSEED BK, 1992, GENE CHROMOSOME CANC, V5, P75; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; REMPEL SA, 1993, CANCER RES, V53, P2386; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; TOKIYOSHI K, 1996, J CLIN PATHOL MOL PA, V49, P218; Trybus TM, 1996, CANCER RES, V56, P2263; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295	30	2340	2584	2	94	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	APR	1997	15	4					356	362		10.1038/ng0497-356	http://dx.doi.org/10.1038/ng0497-356			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WQ389	9090379				2022-12-25	WOS:A1997WQ38900012
J	Hafezi, F; Steinbach, JP; Marti, A; Munz, K; Wang, ZQ; Wagner, EF; Aguzzi, A; Reme, CE				Hafezi, F; Steinbach, JP; Marti, A; Munz, K; Wang, ZQ; Wagner, EF; Aguzzi, A; Reme, CE			The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo	NATURE MEDICINE			English	Article							RAT RETINA; MESSENGER-RNA; EXPRESSION; MOUSE; MICE; JUN; DIFFERENTIATION; IDENTIFICATION; PROTOONCOGENES; TRANSCRIPTION	Apoptotic cell death in the retina was recently demonstrated in animal models of the hereditary human retinal dystrophy known as retinitis pigmentosa(1,2). Although recent evidence indicates that the proto-oncogene c-fos is a mediator of apoptosis(3-7), its precise role is unclear. In fact, under some conditions, c-fos may even protect against apoptotic cell death(8). In the retina, c-fos is physiologically expressed in a diurnal manner and is inducible by light(9,10). We previously observed a light-elicited, dose-dependent apoptotic response in rat photoreceptors(11). To determine whether c-fos is involved in the light-induced apoptotic pathway we have used control mice and mice lacking c-fos. We found that following dark adaptation and two hours of light exposure both groups of animals exhibited only a few apoptotic cells. However, at 12 and 24 additional hours after light exposure, apoptosis increased dramatically in controls but was virtually absent in those mice lacking c-fos. Therefore, c-fos is essential for light-induced apoptosis of photoreceptors. Notably, c-fos is continuously upregulated concomitant with apoptotic photoreceptor death in our system and in animal models of retinitis pigmentosa (Agarwal, N. et al., Invest. Ophthalmol. Vis. Sci. Suppl. 36, S638 and Rich, K.A, et al., Invest. Ophthalmol. Vis. Sci. Suppl. 35, 1833). Inhibition of c-fos expression might therefore represent a novel therapeutic strategy to retard the time course of retinal dystrophies and light-induced retinal degeneration.	UNIV CLIN ZURICH,DEPT OPHTHALMOL,CH-8091 ZURICH,SWITZERLAND; UNIV CLIN ZURICH,DEPT NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Hafezi, Farhad/A-1446-2010; Aguzzi, Adriano/A-3351-2008	Hafezi, Farhad/0000-0001-8935-4558; Wagner, Erwin F/0000-0001-7872-0196; Aguzzi, Adriano/0000-0002-0344-6708				CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUDEHITHLU KP, 1993, BRAIN RES, V631, P77, DOI 10.1016/0006-8993(93)91189-Y; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MARINO S, 1995, LAB INVEST, V73, P103; MARTI A, 1994, ONCOGENE, V9, P1213; NIR I, 1993, MOL BRAIN RES, V19, P47, DOI 10.1016/0169-328X(93)90147-H; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Preston GA, 1996, MOL CELL BIOL, V16, P211; REINBOTH JJ, 1995, CURR EYE RES, V14, P1001, DOI 10.3109/02713689508998521; REME CE, 1991, J BIOL RHYTHM, V6, P5, DOI 10.1177/074873049100600104; REME CE, 1994, INVEST OPHTH VIS SCI, V35, P78; REME CE, 1995, RETINAL DEGENERATION, P19; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRANGE R, 1992, DEVELOPMENT, V115, P49; SZCZESNY PJ, 1995, CELL TISSUE PROTECTI, P163; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307	26	214	225	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					346	349		10.1038/nm0397-346	http://dx.doi.org/10.1038/nm0397-346			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055866				2022-12-25	WOS:A1997WL30500040
J	Catzavelos, C; Bhatacharya, N; Ung, YC; Wilson, JA; Roncari, L; Sandhu, C; Shaw, P; Yeger, H; MoravaProtzner, I; Kapusta, L; Franssen, E; Pritchard, KI; Slingerland, JM				Catzavelos, C; Bhatacharya, N; Ung, YC; Wilson, JA; Roncari, L; Sandhu, C; Shaw, P; Yeger, H; MoravaProtzner, I; Kapusta, L; Franssen, E; Pritchard, KI; Slingerland, JM			Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; DEPENDENT KINASE; P27; G1	Breast cancer is the second leading cause of cancer death in North American women. There is considerable need for reliable prognostic markers to assist clinicians in making management decisions. Although a variety of factors have been tested, only tumor stage, grade, size, hormone receptor status, and S-phase fraction are used on a routine basis(1). The cell cycle is governed by a family of cyclin-dependent kinases (cdks), which are regulated by associated cyclins and by phosphorylation(2). p27(Kip1), a cyclin-dependent kinase inhibitor, regulates progression from G(1) into S phase by binding and inhibiting cyclin/cdks(3,4). p27(Kip1) protein levels and/or activity are upregulated by growth inhibitory cytokines including transforming growth factor-beta (TGF-beta) and, thus, provide an important link between extracellular regulators and the cell cycle(5-7). Loss of p27(Kip1), a negative cell-cycle regulator, may contribute to oncogenesis and tumor progression. However, p27(Kip1) mutations in human tumors are extremely rare(8,9). We have demonstrated by immunohistochemistry that p27(Kip1) protein levels are reduced in primary breast cancers and that this is associated with tumor progression in both in situ and invasive lesions. This was confirmed by western analysis, reflected in increased G(1)/S-phase cyclin-dependent kinase activities and shown to be regulated posttranscriptionally by in situ hybridization. Furthermore, on multivariate analysis, low p27(KiP1) is a predictor of reduced disease-free survival. This simple and reliable immunohistochemical assay may become a routine part of breast cancer evaluation and may influence patient management.	SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL RES, TORONTO, ON M4N 3M5, CANADA; SUNNYBROOK HLTH SCI CTR, DEPT PATHOL, TORONTO, ON M4N 3M5, CANADA; HOSP SICK CHILDREN, DEPT PAEDIAT LAB MED, TORONTO, ON M5G 1X8, CANADA; TORONTO SUMMYBROOK REG CANC CLIN, DIV RADIAT ONCOL, TORONTO, ON M4N 3M5, CANADA; TORONTO SUMMYBROOK REG CANC CLIN, DIV CLIN TRIALS & EPIDEMIOL, TORONTO, ON M4N 3M5, CANADA; TORONTO SUMMYBROOK REG CANC CLIN, DIV MED ONCOL, TORONTO, ON M4N 3M5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Sunnybrook Research Institute; University of Toronto; Sunnybrook Research Institute; University of Toronto; Sunnybrook Research Institute								Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Ferrando AA, 1996, HUM GENET, V97, P91; HARRIS JR, 1987, BREAST DIS, P327; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LODA M, 1996, NAT MED, V3, P230; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REED SI, 1994, J CELL SCI, P69; *SAS I, 1990, SAS STAT US GUID, V2, P1027; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; StCroix B, 1996, NAT MED, V2, P1204; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang DS, 1996, AM J RESP CELL MOL, V14, P409, DOI 10.1165/ajrcmb.14.5.8624245; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	20	753	776	6	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1997	3	2					227	230		10.1038/nm0297-227	http://dx.doi.org/10.1038/nm0297-227			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018244				2022-12-25	WOS:A1997WF08800044
J	Hemminki, A; Tomlinson, I; Markie, D; Jarvinen, H; Sistonen, P; Bjorkqvist, AM; Knuutila, S; Salovaara, R; Bodmer, W; Shibata, D; delaChapelle, A; Aaltonen, LA				Hemminki, A; Tomlinson, I; Markie, D; Jarvinen, H; Sistonen, P; Bjorkqvist, AM; Knuutila, S; Salovaara, R; Bodmer, W; Shibata, D; delaChapelle, A; Aaltonen, LA			Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis	NATURE GENETICS			English	Article							SOLID TUMORS; CANCER	Many human cancer susceptibility genes have been successfully mapped by genetic linkage studies(1). One that has so far eluded researchers is that for Peutz-Jeghers (P-J) syndrome, a condition characterized by intestinal hamartomatous polyposis and melanin spots of the lips, buccal mucosa and digits(2,3). A dramatically elevated risk of malignancy has also been documented(4). Gastrointestinal tumours as well as cancers of the breast, ovary, testis and uterine cervix appear to be overrepresented in families with this syndrome(4,5). The nature of hamartomatous polyps is equivicol. Hamartomas are usually considered histologically benign(6), but in the case of Peutz-Jeghers patients, there are reports of adenomatous and malignant changes in the polyps, and the possibility of a hamartoma-carcinoma sequence has been discussed(5,7,8). A search for a putative tumour suppressor locus was made using comparative genomic hybridization (CGH) of Peutz-Jeghers polyps, combined with loss of heterozygosity (LOH) study. Genetic linkage analysis in 12 families using markers from a deletion site demonstrated the presence of a high-penetrance locus in distal 19p with a multipoint lod score of 7.00 at marker D19S886 without evidence of genetic heterogeneity. The study demonstrates the power of CCH combined with LOH analysis in identifying putative tumour suppressor loci, and provides molecular evidence of malignant potential in hamartomas.	UNIV HELSINKI,DEPT MED GENET,HAARTMAN INST,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT PATHOL,HAARTMAN INST,FIN-00014 HELSINKI,FINLAND; IMPERIAL CANC RES FUND,CANC GENET LAB,LONDON WC2A 3PX,ENGLAND; DUNEDIN SCH MED,DEPT PATHOL,DUNEDIN,NEW ZEALAND; UNIV HELSINKI,CENT HOSP,DEPT SURG 2,FIN-00290 HELSINKI,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,SF-00310 HELSINKI,FINLAND; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033	University of Helsinki; University of Helsinki; Cancer Research UK; University of Otago; University of Helsinki; Helsinki University Central Hospital; University of Southern California			Aaltonen, Lauri/A-5375-2010; Markie, David/I-7893-2019	Aaltonen, Lauri/0000-0001-6839-4286; Bodmer, Walter/0000-0001-6244-9792; Markie, David/0000-0001-5452-9194				COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Defago MR, 1996, ENDOSCOPY, V28, P267, DOI 10.1055/s-2007-1005447; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; HIZAWA K, 1993, DIS COLON RECTUM, V36, P953, DOI 10.1007/BF02050632; JEGHERS H, 1949, NEW ENGL J MED, V241, P992; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Ott J., 1991, ANAL HUMAN GENETIC L; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; PHILLIPS RK, 1994, FAMILIAL ADENOMATOUS; ROSAI J, 1996, ACKERMANS SURGICAL P; SHIBATA D, 1992, AM J PATHOL, V141, P539; Shibata D, 1996, NAT MED, V2, P676, DOI 10.1038/nm0696-676	15	342	364	1	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					87	90		10.1038/ng0197-87	http://dx.doi.org/10.1038/ng0197-87			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988175				2022-12-25	WOS:A1997WA37300027
J	vanWezel, T; Stassen, APM; Moen, CJA; Hart, AAM; vanderValk, MA; Demant, P				vanWezel, T; Stassen, APM; Moen, CJA; Hart, AAM; vanderValk, MA; Demant, P			Gene interaction and single gene effects in colon tumour susceptibility in mice	NATURE GENETICS			English	Article							RECOMBINANT CONGENIC STRAINS; INTESTINAL NEOPLASIA; MAJOR MODIFIER; MOUSE; LOCUS; TRAITS; LINKAGE; CANCER; TOOL; TIME	To dissect the multigenic control of colon tumour susceptibility in the mouse(1) we used the set of 20 CcS/Dem (CcS) recombinant congenic (RC) strains(2). Each CcS strain carries a unique, random subset of approximately 12.5% of the genome of strain STS/A (STS) on the genetic background of BALB/cHeA (BALB/c)(3). Previously, applying a protocol of 26 injections of 1,2-dimethylhydrazine (DMH), we detected two susceptibility loci, Scc1 and Scc2, on chromosome 2 (refs 4, 5). Using a shorter tumour-induction procedure, combining DMH and N-ethyl-N-nitrosourea (ENU) treatment, we demonstrate that BALB/c, STS and most CcS strains are relatively resistant. The strain CcS-19, however, is susceptible, probably due to a combination of BALB/c and STS alleles at several loci. Analysis of 192 (BALB/c x CcS-19) F2 mice revealed, in addition to the Scc1/Scc2 region, three new susceptibility loci: Scc3 on chromosome 1, Scc4 on chromosome 17 and Scc5 on chromosome 18. Scc4 and Scc5 have no apparent individual effect, but show a strong reciprocal interaction. Their BALB/c and STS alleles are not a priori susceptible or resistant but the genotype at one locus determines the effect of the allele at the second locus and vice versa. These findings and the accompanying paper on lung tumour susceptibility(6) show that interlocus interactions are likely to be an important component of tumour susceptibility.	NETHERLANDS CANC INST,DIV MOL GENET,NL-1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DIV RADIOTHERAPY,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute			van Wezel, Tom/A-9599-2008; van Wezel, Tom/AAL-5626-2021; van Wezel, Tom/Z-3092-2019	van Wezel, Tom/0000-0001-5773-7730; van Wezel, Tom/0000-0001-5773-7730				AVNER P, 1994, NAT GENET, V7, P3, DOI 10.1038/ng0594-3; CHEVERUD JM, 1995, GENETICS, V139, P1455; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; Demant P, 1992, Semin Cancer Biol, V3, P159; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; DESCHNER EE, 1979, CANCER LETT, V8, P23, DOI 10.1016/0304-3835(79)90018-1; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; FIJNEMAN RJA, 1995, CANCER RES, V55, P3179; FRENKEL WN, 1995, MAMM GENOME, V6, P830; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LARK KG, 1995, P NATL ACAD SCI USA, V92, P4656, DOI 10.1073/pnas.92.10.4656; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MOEN CJA, 1992, ONCOGENE, V7, P563; Moen CJA, 1996, P NATL ACAD SCI USA, V93, P1082, DOI 10.1073/pnas.93.3.1082; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; NEUMAN RJ, 1992, GENET EPIDEMIOL, V9, P347, DOI 10.1002/gepi.1370090506; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; RISCH N, 1993, AM J HUM GENET, V53, P702; SCHORK NJ, 1993, AM J HUM GENET, V53, P1127; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; WU S, 1992, J CELL BIOL, V115, P187	27	121	121	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					468	470		10.1038/ng1296-468	http://dx.doi.org/10.1038/ng1296-468			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944029				2022-12-25	WOS:A1996VV73000025
J	LoTenFoe, JR; Rooimans, MA; BosnoyanCollins, L; Alon, N; Wijker, M; Parker, L; Lightfoot, J; Carreau, M; Callen, DF; Savoia, A; Cheng, NC; vanBerkel, CGM; Strunk, MHP; Gille, JJP; Pals, G; Kruyt, FAE; Pronk, JC; Arwert, F; Buchwald, M; Joenje, H				LoTenFoe, JR; Rooimans, MA; BosnoyanCollins, L; Alon, N; Wijker, M; Parker, L; Lightfoot, J; Carreau, M; Callen, DF; Savoia, A; Cheng, NC; vanBerkel, CGM; Strunk, MHP; Gille, JJP; Pals, G; Kruyt, FAE; Pronk, JC; Arwert, F; Buchwald, M; Joenje, H			Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA	NATURE GENETICS			English	Article							COMPLEMENTATION GROUPS; ANEMIA-REGISTRY; PROTEIN; LOCALIZATION; DIAGNOSIS; CYTOPLASM; FACC		FREE UNIV AMSTERDAM, DEPT HUMAN GENET, NL-1081 BT AMSTERDAM, NETHERLANDS; HOSP SICK CHILDREN, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A1, CANADA; WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOL GENET, ADELAIDE, SA 5006, AUSTRALIA; IRCCS OSPED CSS, SERV GENET MED, I-71013 SAN GIOVANNI ROTONDO, ITALY	Vrije Universiteit Amsterdam; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Womens & Childrens Hospital Australia			Strunk, Mark HP/K-3597-2014; Savoia, Anna/B-6463-2014; Pals, Gerard/A-5198-2011; Savoia, Anna/AIC-4560-2022; Callen, David F/G-1975-2012; Strunk, Mark/I-2423-2017	Strunk, Mark HP/0000-0002-8619-3979; Savoia, Anna/0000-0002-2407-2696; Savoia, Anna/0000-0002-2407-2696; Strunk, Mark/0000-0002-8619-3979; Kruyt, Frank/0000-0002-2445-9380; Callen, David/0000-0002-6189-9991; Carreau, Madeleine/0000-0002-0582-6114; Pals, Gerard/0000-0003-4091-7115; Gille, Johan/0000-0003-4526-298X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL032987, R01HL032987, R01HL050131] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50131, HL32987] Funding Source: Medline; Telethon [E.0364] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUERBACH AD, 1993, EXP HEMATOL, V21, P731; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BUCHWALD M, 1995, NAT GENET, V11, P228, DOI 10.1038/ng1195-228; BUCHWALD M, 1989, FANCONI ANEMIA CLIN, P226; BUTTURINI A, 1994, BLOOD, V84, P1650, DOI 10.1182/blood.V84.5.1650.bloodjournal8451650; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUCKWORTHRYSIECKI G, 1985, SOMAT CELL MOLEC GEN, V11, P35, DOI 10.1007/BF01534732; FANTES JA, 1992, AM J HUM GENET, V51, P1286; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P633; GIAMPIETRO PF, 1993, PEDIATRICS, V91, P1116; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; HURST HC, 1994, PROTEIN PROFILE, V1, P123; ISHIDA R, 1982, CANCER RES, V42, P4000; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; Joenje H, 1996, HUM GENET, V97, P280, DOI 10.1007/BF02185753; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kruyt FAE, 1996, BLOOD, V87, P938, DOI 10.1182/blood.V87.3.938.bloodjournal873938; LIU JM, 1994, BLOOD, V84, P3995, DOI 10.1182/blood.V84.12.3995.bloodjournal84123995; PRONK JC, 1995, NAT GENET, V11, P338, DOI 10.1038/ng1195-338; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; STRATHDEE CA, 1992, NATURE, V358, P434, DOI 10.1038/358434a0; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; Young NS., 1994, APLASTIC ANEMIA ACQU, P275; YOUSSOUFIAN H, 1994, P NATL ACAD SCI USA, V91, P7975, DOI 10.1073/pnas.91.17.7975	27	291	294	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					320	323		10.1038/ng1196-320	http://dx.doi.org/10.1038/ng1196-320			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896563				2022-12-25	WOS:A1996VQ14600028
J	Eicher, EM; Washburn, LL; Schork, NJ; Lee, BK; Shown, EP; Xu, XL; Dredge, RD; Pringle, MJ; Page, DC				Eicher, EM; Washburn, LL; Schork, NJ; Lee, BK; Shown, EP; Xu, XL; Dredge, RD; Pringle, MJ; Page, DC			Sex-determining genes on mouse autosomes identified by linkage analysis of C57BL/6J-Y-POS sex reversal	NATURE GENETICS			English	Letter							Y-CHROMOSOME; MICE; TESTIS; SRY; PROTEIN		CASE WESTERN RESERVE UNIV, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT GENET, CLEVELAND, OH 44106 USA; MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02142 USA; MIT, WHITEHEAD INST, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Case Western Reserve University; Case Western Reserve University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Eicher, EM (corresponding author), JACKSON LAB, 600 MAIN ST, BAR HARBOR, ME 04609 USA.			Schork, Nicholas/0000-0003-0920-5013	NICHD NIH HHS [HD22532] Funding Source: Medline; NIGMS NIH HHS [GM20919] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020919, R01GM020919] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beamer W G, 1978, Basic Life Sci, V12, P195; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BOGAN JS, 1994, CELL, V76, P603, DOI 10.1016/0092-8674(94)90501-0; Burgoyne PS, 1993, GONADAL DEV FUNCTION, P17; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; EICHER EM, 1994, NAT GENET, V6, P221, DOI 10.1038/ng0394-221; EICHER EM, 1988, PHILOS T R SOC B, V322, P109, DOI 10.1098/rstb.1988.0118; EICHER EM, 1986, ANNU REV GENET, V20, P327, DOI 10.1146/annurev.ge.20.120186.001551; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; EICHER EM, 1980, CYTOGENET CELL GENET, V28, P104, DOI 10.1159/000131518; EICHER EM, 1995, T B ROY SOC, V350, P2623; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GOODFELLOW PN, 1992, SERONO SYM, V94, P5; HACKER A, 1995, DEVELOPMENT, V121, P1603; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Nadeau J H, 1991, Mamm Genome, V1 Spec No, pS461, DOI 10.1007/BF00656504; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; PALMER SJ, 1991, DEVELOPMENT, V113, P709; PRINGLE MJ, 1996, INFERTILITY MALE; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOKAL RR, 1981, BIOMERY; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; WASHBURN LL, 1983, NATURE, V303, P338, DOI 10.1038/303338a0; WASHBURN LL, 1989, GENETICS, V123, P173; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	29	95	95	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1996	14	2					206	209		10.1038/ng1096-206	http://dx.doi.org/10.1038/ng1096-206			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841197				2022-12-25	WOS:A1996VL44600031
J	Grant, SFA; Reid, DM; Blake, G; Herd, R; Fogelman, I; Ralston, SH				Grant, SFA; Reid, DM; Blake, G; Herd, R; Fogelman, I; Ralston, SH			Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene	NATURE GENETICS			English	Letter							MINERAL DENSITY; ALLELES; MASS; TRANSCRIPTION; PROCOLLAGEN; ACTIVATION; SEQUENCES; WOMEN; CELLS; TWIN		UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND; GUYS HOSP,DEPT NUCL MED,LONDON SE1 2RT,ENGLAND	University of Aberdeen; Guy's & St Thomas' NHS Foundation Trust				Grant, Struan/0000-0003-2025-5302				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CHODOSH LA, 1992, SHORT PROTOCOLS MOL, V2; CHU ML, 1985, J BIOL CHEM, V260, P2315; COOPER C, 1992, BRIT MED J, V304, P793, DOI 10.1136/bmj.304.6830.793; EISMAN JA, 1995, J BONE MINER RES, V10, P1289; GARTON M, 1995, CLIN ENDOCRINOL, V41, P747; GUEGUEN R, 1995, J BONE MINER RES, V12, P2017; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Keen RW, 1996, OSTEOPOROSIS INT S1, V6, P102, DOI 10.1007/BF02499946; Kobayashi S, 1996, J BONE MINER RES, V11, P306; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MUNDY GR, 1994, NATURE, V367, P216, DOI 10.1038/367216a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PEACOCK M, 1995, J BONE MINER RES, V10, P1294; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; PROCKOP DJ, 1989, AM J MED GENET, V34, P60, DOI 10.1002/ajmg.1320340112; QI JC, 1995, J BONE MINER RES  S1, V10, pS170; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; Rowe DW, 1991, BONE MINERAL RES, P209; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; SOROKO SB, 1994, J BONE MINER RES, V9, P761; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; SPOTILA LD, 1994, J BONE MINER RES, V9, P923; SPOTILA LD, 1991, P NATL ACAD SCI USA, V88, P5243; SYKES B, 1990, NATURE, V348, P18, DOI 10.1038/348018a0; UITTERLINDEN AG, 1996, OSTEOPOROS INT S1, V6, P124	29	526	579	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					203	205		10.1038/ng1096-203	http://dx.doi.org/10.1038/ng1096-203			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841196				2022-12-25	WOS:A1996VL44600030
J	Marx, PA; Spira, AI; Gettie, A; Dailey, PJ; Veazey, RS; Lackner, AA; Mahoney, CJ; Miller, CJ; Claypool, LE; Ho, DD; Alexander, NJ				Marx, PA; Spira, AI; Gettie, A; Dailey, PJ; Veazey, RS; Lackner, AA; Mahoney, CJ; Miller, CJ; Claypool, LE; Ho, DD; Alexander, NJ			Progesterone implants enhance SIV vaginal transmission and early virus load	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; INTRAVAGINAL INOCULATION; RHESUS MACAQUES; INFECTION; TYPE-2; MODEL; CYCLE; HIV	Simian immunodeficiency virus (SIV) can cross the intact vaginal epithelium to establish a systemic infection in macaques (mac). Using this SIVmac model, we found that subcutaneous progesterone implants, which could mimic hormonally based contraceptives, thinned the vaginal epithelium and enhanced SIV vaginal transmission 7.7-fold over that observed in macaques treated with placebo implants and exposed to SIV in the follicular phase of the menstrual cycle. Progesterone treatment also increased the number of SIV DNA-positive cells in the vaginal lamina propria as detected by in situ polymerase chain reaction analysis. Moreover, plasma viral RNA was elevated for the first three months in macaques with progesterone implants, and three of the progesterone-treated macaques developed relatively rapid disease courses. This study shows that SIV genital infection and disease course are enhanced by subcutaneous implants containing progesterone when compared with the rate of vaginal transmission in the follicular phase.	NYU,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10016; CHIRON CORP,NUCLE ACID SYST,EMERYVILLE,CA 94608; HARVARD UNIV,NEW ENGLAND REG PRIMATE RES CTR,SCH MED,SOUTHBOROUGH,MA 01772; NYU,MED CTR,LAB EXPT MED & SURG PRIMATES,TUXEDO PK,NY 10987; UNIV CALIF DAVIS,CALIF REG PRIMATE RES CTR,DAVIS,CA 95616; EASTERN VIRGINIA MED SCH,CONRAD PROGRAM,ARLINGTON,VA 22209; NICHHD,CONTRACEPT DEV BRANCH,NIH,BETHESDA,MD 20892	New York University; Novartis; Harvard University; New York University; University of California System; University of California Davis; Eastern Virginia Medical School; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Marx, PA (corresponding author), ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,455 1ST AVE,7TH FLOOR,NEW YORK,NY 10016, USA.				NCRR NIH HHS [RR 00168] Funding Source: Medline; NIAID NIH HHS [AI 28147, AI 38573-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI028147, R01AI038573, U01AI028147] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLLINS ML, 1995, ANAL BIOCHEM, V226, P120, DOI 10.1006/abio.1995.1199; DALY CC, 1994, GENITOURIN MED, V70, P110; ELLINWOOD WE, 1984, BIOL REPROD, V31, P714, DOI 10.1095/biolreprod31.4.714; FAWCETT DW, 1994, TXB HISTOLOGY, P857; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; KELL PD, 1992, J ROY SOC MED, V85, P706; KULLER L, 1994, J MED PRIMATOL, V23, P397, DOI 10.1111/j.1600-0684.1994.tb00127.x; MARX PA, 1993, SCIENCE, V260, P1363; MILLER CJ, 1994, J VIROL, V68, P6391, DOI 10.1128/JVI.68.10.6391-6400.1994; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; OVERPECK JG, 1978, J TOXICOL ENV HEALTH, V4, P785, DOI 10.1080/15287397809529700; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PARAKKAL PF, 1972, BIOL REPROD, V6, P117, DOI 10.1093/biolreprod/6.1.117; PARR MB, 1994, LAB INVEST, V70, P369; PLOURDE PJ, 1994, HIV EPIDEMIOLOGY, P107; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RASHEED S, 1995, J REPROD MED, V40, P747; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; STRATTON P, 1994, REPROD MED REV, V3, P113; TEEPE AG, 1990, ANTIVIR RES, V14, P227, DOI 10.1016/0166-3542(90)90004-Q	21	390	397	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1084	1089		10.1038/nm1096-1084	http://dx.doi.org/10.1038/nm1096-1084			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837605	Bronze			2022-12-25	WOS:A1996VK99500027
J	Borrow, J; Stanton, VP; Andresen, JM; Becher, R; Behm, FG; Chaganti, RSK; Civin, CI; Disteche, C; Dube, I; Frischauf, AM; Horsman, D; Mitelman, F; Volinia, S; Watmore, AE; Housman, DE				Borrow, J; Stanton, VP; Andresen, JM; Becher, R; Behm, FG; Chaganti, RSK; Civin, CI; Disteche, C; Dube, I; Frischauf, AM; Horsman, D; Mitelman, F; Volinia, S; Watmore, AE; Housman, DE			The translocation t(8;l6)(p11, p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB binding protein	NATURE GENETICS			English	Article							TRANSCRIPTIONAL COACTIVATOR CBP; RUBINSTEIN-TAYBI SYNDROME; T(8 16)(P11 P13); SACCHAROMYCES-CEREVISIAE; SHORT ARM; GENE; LEUKEMIA; YEAST; FINGER; ACETYLATION	The recurrent translocation t(8;16)(p11;p13) is a cytogenetic hallmark for the M4/M5 subtype of acute myeloid leukaemia. Here we identify the breakpoint-associated genes. Positional cloning on chromosome 16 implicates the CREB-binding protein (CBP), a transcriptional adaptor/coactivator protein. At the chromosome 8 breakpoint we identify a novel gene, MOZ, which encodes a 2,004-amino-acid protein characterized by two C4HC3 zinc fingers and a single C2HC zinc finger in conjunction with a putative acetyltransferase signature. In-frame MOZ-CBP fusion transcripts combine the MOZ finger motifs and putative acetyltransferase domain with a largely intact CBP. We suggest that MOZ may represent a chromatin-associated acetyltransferase, and raise the possibility that a dominant MOZ-CBP fusion protein could mediate leukaemogenesis via aberrant chromatin acetylation.	W GERMAN CANC CTR, D-45122 ESSEN 1, GERMANY; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21287 USA; UNIV WASHINGTON, MED CTR, SEATTLE, WA 98195 USA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, TORONTO, ON M4N 3M5, CANADA; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; BRITISH COLUMBIA CANC AGCY, VANCOUVER, BC V5Z 4E6, CANADA; UNIV LUND HOSP, DEPT CLIN GENET, S-22185 LUND, SWEDEN; UNIV FERRARA, I-44100 FERRARA, ITALY; CTR HUMAN GENET, SHEFFIELD S10 5DN, S YORKSHIRE, ENGLAND	St Jude Children's Research Hospital; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; University of Washington; University of Washington Seattle; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Cancer Research UK; British Columbia Cancer Agency; Lund University; Skane University Hospital; University of Ferrara	Borrow, J (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.		Volinia, Stefano/A-3029-2010; Volinia, Stefano/AAA-9264-2019	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Mitelman, Felix/0000-0002-3757-7212; Andresen, J. Michael/0000-0002-8791-1266; Stanton, Vincent/0000-0002-2205-6000	NCI NIH HHS [5U01 CA31566, 5U01 CA28476, CA 34775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA031566, R01CA034775, U10CA028476] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ALTABA AR, 1987, EMBO J, V6, P3065, DOI 10.1002/j.1460-2075.1987.tb02613.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1988, CANCER GENET CYTOGEN, V30, P1; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BALDARELLI RM, 1988, DEV BIOL, V125, P85, DOI 10.1016/0012-1606(88)90061-9; BELLOMO MJ, 1992, BRIT J HAEMATOL, V81, P307, DOI 10.1111/j.1365-2141.1992.tb08225.x; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BUCHMAN VL, 1992, NUCLEIC ACIDS RES, V20, P5579, DOI 10.1093/nar/20.21.5579; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DIB A, 1995, ONCOGENE, V10, P995; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; HANSLIP JJ, 1992, LEUKEMIA LYMPHOMA, V6, P479, DOI 10.3109/10428199209053586; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P325; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; INHORN RC, 1995, BLOOD, V85, P1881, DOI 10.1182/blood.V85.7.1881.bloodjournal8571881; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAI JL, 1992, CANCER GENET CYTOGEN, V60, P180, DOI 10.1016/0165-4608(92)90013-X; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIU J, 1995, GENOMICS, V26, P178, DOI 10.1016/0888-7543(95)80199-V; LOIDL P, 1994, CHROMOSOMA, V103, P441; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; QUESNEL B, 1993, J CLIN ONCOL, V11, P2370, DOI 10.1200/JCO.1993.11.12.2370; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; RINE J, 1987, GENETICS, V116, P9; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUBINSTEIN JH, 1963, AM J DIS CHILD, V105, P588, DOI 10.1001/archpedi.1963.02080040590010; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; STARK B, 1995, LEUKEMIA RES, V19, P367, DOI 10.1016/0145-2126(94)00150-9; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TANAKA S, 1989, MOL GEN GENET, V217, P289, DOI 10.1007/BF02464895; TANZER J, 1988, NOUV REV FR HEMATOL, V30, P63; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; WESSELS JW, 1991, BLOOD, V77, P1555; WYDNER KL, 1995, GENOMICS, V30, P395	59	629	652	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					33	41		10.1038/ng0996-33	http://dx.doi.org/10.1038/ng0996-33			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782817				2022-12-25	WOS:A1996VF61100018
J	Melder, RJ; Koenig, GC; Witwer, BP; Safabakhsh, N; Munn, LL; Jain, RK				Melder, RJ; Koenig, GC; Witwer, BP; Safabakhsh, N; Munn, LL; Jain, RK			During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium	NATURE MEDICINE			English	Article							INDUCED LEUKOCYTE ADHESION; CRANIAL WINDOWS; NECROSIS-FACTOR; E-SELECTIN; EXPRESSION; VESSELS; PERMEABILITY; METASTASIS; KINETICS; INVIVO	Localization of activated natural killer (A-NK) cells in the microvasculature of growing tumors is the result of recognition of the intracellular and vascular cell-adhesion molecules ICAM-1 and VCAM-1 on the tumor endothelium, mediated by lymphocyte function-associated protein LFA-1 and vascular lymphocyte function-associated protein VLA-4. In vitro and in vivo studies of A-NK cell adhesion to endothelial cells showed that vascular endothelial growth factor (VEGF) promotes adhesion, whereas basic fibroblast growth factor (bFGF) inhibits adhesion through the regulation of these molecules on tumor vasculature. Thus, some angiogenic factors may facilitate lymphocyte recognition of angiogenic vessels, whereas others may provide such vessels with a mechanism that protects them from cytotoxic lymphocytes.	HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	Melder, RJ (corresponding author), MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,EDWIN L STEELE LAB,100 FRUIT ST,BOSTON,MA 02114, USA.		Munn, Lance L/L-3950-2016; Jain, Rakesh K/I-1384-2017	Munn, Lance L/0000-0003-0698-7232; Jain, Rakesh K/0000-0001-7571-3548	NCI NIH HHS [R35-CA 56591, F32-CA 61631] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA056591, F32CA061631] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAVENA P, 1991, J EXP MED, V173, P39; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2893; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; Dellian M, 1996, AM J PATHOL, V149, P59; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1995, NATURE, V376, P467, DOI 10.1038/376467a0; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Folkman J, 1995, MOL BASIS CANC, P206; FREEMAN MR, 1995, CANCER RES, V55, P4140; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FUKUMURA D, 1995, CANCER RES, V55, P4824; GAMBLE JR, 1993, J IMMUNOL, V150, P4494; GOTO F, 1993, LAB INVEST, V69, P508; GULLINO PM, 1970, METHOD CANCER RES, P45; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; JAIN RK, 1988, CANCER RES, V48, P2641; JALLAL B, 1995, CANCER RES, V55, P3223; KITAYAMA J, 1994, CANCER IMMUNOL IMMUN, V38, P317, DOI 10.1007/s002620050072; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Melder R J, 1992, Cell Biophys, V20, P161; MELDER RJ, 1990, AIDS RES HUM RETROV, V6, P1011, DOI 10.1089/aid.1990.6.1011; MELDER RJ, 1995, MICROVASC RES, V50, P35, DOI 10.1006/mvre.1995.1036; MELDER RJ, 1988, CANCER RES, V48, P3461; Melder RJ, 1995, BIOPHYS J, V69, P2131, DOI 10.1016/S0006-3495(95)80087-1; MELDER RJ, 1993, CANCER RES, V53, P5867; MELDER RJ, 1991, CELL IMMUNOL, V132, P177, DOI 10.1016/0008-8749(91)90017-6; MUNN LL, 1994, BIOPHYS J, V67, P889, DOI 10.1016/S0006-3495(94)80550-8; MUNN LL, 1995, BIOTECHNIQUES, V19, P622; OHKUBO C, 1991, CANCER RES, V51, P1561; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; REED JA, 1994, AM J PATHOL, V144, P329; SANTAMBROGIO L, 1993, J IMMUNOL, V151, P1116; SASAKI A, 1991, JNCI-J NATL CANCER I, V83, P433, DOI 10.1093/jnci/83.6.433; SASAKI A, 1989, CANCER RES, V49, P3742; WATSON CA, 1995, SCIENCE, V268, P447, DOI 10.1126/science.7716553; WHITESIDE TL, 1994, IMMUNOL SER, V61, P159; WU NZ, 1992, CANCER RES, V52, P4265; YUAN F, 1994, CANCER RES, V54, P4564	39	378	393	1	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					992	997		10.1038/nm0996-992	http://dx.doi.org/10.1038/nm0996-992			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782456				2022-12-25	WOS:A1996VF49700033
J	Cohen, B; Bashirullah, A; Dagnino, L; Campbell, C; Fisher, WW; Leow, CC; Whiting, E; Ryan, D; Zinyk, D; Boulianne, G; Hui, CC; Gallie, B; Phillips, RA; Lipshitz, HD; Egan, SE				Cohen, B; Bashirullah, A; Dagnino, L; Campbell, C; Fisher, WW; Leow, CC; Whiting, E; Ryan, D; Zinyk, D; Boulianne, G; Hui, CC; Gallie, B; Phillips, RA; Lipshitz, HD; Egan, SE			Fringe boundaries coincide with Notch-dependent patterning centres in mammals and alter Notch-dependent development in Drosophila	NATURE GENETICS			English	Article							GENE SERRATE ENCODES; TRANSMEMBRANE PROTEIN; VERTEBRATE DEVELOPMENT; NEUROGENIC GENE; CELL FATE; DELTA; EXPRESSION; MELANOGASTER; MORPHOGENESIS; COMPLEX		HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DIV ENDOCRINOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,PROGRAM DEV BIOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DIV NEUROL,TORONTO,ON M5G 1X8,CANADA; CALTECH,DIV BIOL,PASADENA,CA 91125; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); California Institute of Technology; University of Toronto; University of Toronto				Lipshitz, Howard/0000-0002-7372-4419; Gallie, Brenda/0000-0002-9697-9211; Dagnino, Lina/0000-0003-1483-5159				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BRAND AH, 1993, DEVELOPMENT, V118, P401; CONLON RA, 1995, DEVELOPMENT, V121, P1533; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Lardelli M, 1995, INT J DEV BIOL, V39, P769; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Lawrence P.A., 1986, P229; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; Myat A, 1996, DEV BIOL, V174, P233, DOI 10.1006/dbio.1996.0069; PARKS AL, 1993, DEV BIOL, V157, P484, DOI 10.1006/dbio.1993.1151; PARODY TR, 1993, GENETICS, V135, P527; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; THOMAS U, 1991, DEVELOPMENT, V111, P749; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8	36	128	135	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					283	288		10.1038/ng0797-283	http://dx.doi.org/10.1038/ng0797-283			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207795				2022-12-25	WOS:A1997XG60900025
J	Selivanova, G; Iotsova, V; Okan, I; Fritsche, M; Strom, M; Groner, B; Grafstrom, RC; Wiman, KG				Selivanova, G; Iotsova, V; Okan, I; Fritsche, M; Strom, M; Groner, B; Grafstrom, RC; Wiman, KG			Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain	NATURE MEDICINE			English	Article							DNA-BINDING FUNCTION; GENE-EXPRESSION; CELL-GROWTH; IN-VIVO; ACTIVATION; MUTATIONS; APOPTOSIS; CANCER; SEQUENCE; FORMS	We demonstrate here that synthetic 22-mer peptide 46, corresponding to the carboxy-terminal amino acid residues 361-382 of p53, can activate specific DNA binding of wild-type p53 in vitro and can restore the transcriptional transactivating function of at least some mutant p53 proteins in living cells. Introduction of peptide 46 in Saos-2 cells carrying a Tet-regulatable His-273 mutant p53 construct caused growth inhibition and apoptosis in the presence of mutant p53 but not in its absence, confirming that the effect of the peptide is mediated by reactivation of mutant p53. Moreover, peptide 46 caused apoptosis in mutant as well as wild-type p53-carrying human tumor cell lines of different origin, whereas p53 null tumor cells were not affected. These findings raise possibilities for developing drugs that restore the tumor suppressor function of mutant p53 proteins, thus selectively eliminating tumor cells.	KAROLINSKA INST,DEPT ENVIRONM MED,S-17177 STOCKHOLM,SWEDEN; INST EXPT CANC RES,TUMOR BIOL CTR,D-79106 FREIBURG,GERMANY	Karolinska Institutet	Selivanova, G (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN.		Grafström, Roland C/N-7217-2016; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332				ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; CHO Y, 1994, SCIENCE, V265, P356; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OKAN I, 1995, ONCOGENE, V11, P1027; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	23	297	311	0	20	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					632	638		10.1038/nm0697-632	http://dx.doi.org/10.1038/nm0697-632			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176489				2022-12-25	WOS:A1997XB97400032
J	Dachs, GU; Patterson, AV; Firth, JD; Ratcliffe, PJ; Townsend, KMS; Stratford, IJ; Harris, AL				Dachs, GU; Patterson, AV; Firth, JD; Ratcliffe, PJ; Townsend, KMS; Stratford, IJ; Harris, AL			Targeting gene expression to hypoxic tumor cells	NATURE MEDICINE			English	Article							ERYTHROPOIETIN 3' ENHANCER; CYTOSINE DEAMINASE; BIOREDUCTIVE DRUGS; CANCER-THERAPY; SENSITIVITY; INVOLVEMENT; RADIATION; RSU-1069; INVITRO	Solid tumors with areas of low oxygen tension (hypoxia) have a poor prognosis, as cells in this environment often survive radiation and chemotherapy. In this report we describe how this hypoxic environment can be used to activate heterologous gene expression driven by a hypoxia-responsive element (HRE), which interacts with the transcriptional complex hypoxia-inducible factor-1 (HIF-1). Our results demonstrate that the HIF-1/HRE system of gene regulation is active in hypoxic tumor cells and show the potential of exploiting tumor-specific conditions for the targeted expression of diagnostic or therapeutic genes in cancer therapy.	UNIV MANCHESTER,SCH PHARM & PHARMACEUT SCI,MANCHESTER M13 9PL,LANCS,ENGLAND; MRC,EXPT ONCOL DIV,HARWELL OX11 0RD,BERKS,ENGLAND; MT VERNON HOSP,GRAY LAB,NORTHWOOD HA6 2JR,MIDDX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,ONCOL MOL LAB,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOL MED,ERYTHROPOIETIN GRP,OXFORD OX3 9DU,ENGLAND; ADDENBROOKES HOSP,CAMBRIDGE CB2 2QG,ENGLAND	University of Manchester; University of Oxford; University of Oxford; University of Oxford; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Ratcliffe, Peter/0000-0002-2853-806X; Patterson, Adam/0000-0001-5138-1227; stratford, ian/0000-0002-5222-4765	NATIONAL CANCER INSTITUTE [P01CA055165] Funding Source: NIH RePORTER; Medical Research Council [G0500366] Funding Source: Medline; NCI NIH HHS [P01-CA-55165] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome Trust)		ADAMS GE, 1984, BRIT J CANCER, V49, P571, DOI 10.1038/bjc.1984.91; ANDERSEN L, 1989, ARCH MICROBIOL, V152, P115, DOI 10.1007/BF00456087; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHAPLIN DJ, 1995, BRIT J CANCER, V71, P1210, DOI 10.1038/bjc.1995.235; Connors TA, 1995, GENE THER, V2, P702; Dachs GU, 1996, BRIT J CANCER, V74, pS126; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; HOECKEL M, 1996, SEMIN RADIAT ONCOL, V6, P1; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MANOME Y, 1994, CANCER RES, V54, P5408; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MOULDER JE, 1988, INT J RADIAT ONCOL, V14, P913, DOI 10.1016/0360-3016(88)90014-4; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; OLIVE PL, 1995, BRIT J CANCER, V71, P537, DOI 10.1038/bjc.1995.106; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; STRATFORD IJ, 1989, INT J RADIAT ONCOL, V16, P973, DOI 10.1016/0360-3016(89)90898-5; Vaupel Peter W., 1993, P53; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WORKMAN P, 1993, CANCER METAST REV, V12, P73, DOI 10.1007/BF00689802; [No title captured]	27	330	360	1	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					515	520		10.1038/nm0597-515	http://dx.doi.org/10.1038/nm0597-515			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142119				2022-12-25	WOS:A1997WX54300030
J	MacQuitty, JJ				MacQuitty, JJ			Embryo research - The real implications of Dolly	NATURE BIOTECHNOLOGY			English	Editorial Material											MacQuitty, JJ (corresponding author), GENPHARM INT,855 CALIFORNIA AVE,SUITE C,PALO ALTO,CA 94304, USA.								0	2	2	2	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					294	294		10.1038/nbt0497-294	http://dx.doi.org/10.1038/nbt0497-294			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094106	Bronze			2022-12-25	WOS:A1997WQ55400004
J	Donnelly, SC; Haslett, C; Reid, PT; Grant, IS; Wallace, WAH; Metz, CN; Bruce, LJ; Bucala, R				Donnelly, SC; Haslett, C; Reid, PT; Grant, IS; Wallace, WAH; Metz, CN; Bruce, LJ; Bucala, R			Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome	NATURE MEDICINE			English	Article							LUNG INJURY; FACTOR MIF; ARDS; INTERLEUKIN-8; MECHANISMS; CYTOKINE; ELASTASE; RABBITS; SHOCK	Migration inhibitory factor (MIF) is known to exert significant pro-inflammatory effects and has the potential to override the anti-inflammatory action of glucocorticoids. In this study we have identified significant quantities of MIF in the alveolar airspaces of patients with acute respiratory distress syndrome (ARDS). We show in alveolar cells from patients with ARDS that MIF augments pro-inflammatory cytokine secretion (TNF alpha and IL-8), anti-MIF significantly attenuates TNF alpha and IL-8 secretion and MIF overrides, in a concentration-related fashion, the anti-inflammatory effects of glucocorticoids. These findings suggest that MIF may act as a mediator sustaining the pulmonary inflammatory response in ARDS and that an anti-MIF strategy may represent a novel therapeutic approach in inflammatory diseases such as ARDS.	UNIV EDINBURGH,RAYNE LAB,RESP MED UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,DEPT INTENS CARE,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; PICOWER INST MED RES,MANHASSET,NY 11030	University of Edinburgh; University of Edinburgh; University of Edinburgh; Northwell Health				Christine, Metz/0000-0002-1013-1691; Donnelly, Seamas/0000-0001-7145-1843	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035931] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35931] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHBAUGH DG, 1985, ARCH SURG-CHICAGO, V120, P530; BALDWIN SR, 1986, LANCET, V1, P11; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, pS125, DOI 10.1164/ajrccm/152.6_Pt_2.S125; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERNARD GR, 1987, NEW ENGL J MED, V317, P1365; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; DONNELLY SC, 1995, AM J RESP CRIT CARE, V151, P1428, DOI 10.1164/ajrccm.151.5.7735596; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009; HOOPER RG, 1990, CHEST, V97, P138, DOI 10.1378/chest.97.1.138; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; MEDURI GU, 1994, CHEST, V105, P1516, DOI 10.1378/chest.105.5.1516; NISHINO T, 1995, MOL MED, V1, P781, DOI 10.1007/BF03401892; ROCKER GM, 1989, LANCET, V1, P120; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; WARSHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797	23	356	387	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					320	323		10.1038/nm0397-320	http://dx.doi.org/10.1038/nm0397-320			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055860				2022-12-25	WOS:A1997WL30500034
J	Flint, J; Thomas, K; Micklem, G; Raynham, H; Clark, K; Doggett, NA; King, A; Higgs, DR				Flint, J; Thomas, K; Micklem, G; Raynham, H; Clark, K; Doggett, NA; King, A; Higgs, DR			The relationship between chromosome structure and function at a human telomeric region	NATURE GENETICS			English	Article							GLOBIN GENE-CLUSTER; HUMAN ZETA-GLOBIN; ALPHA-THALASSEMIA; LENGTH POLYMORPHISM; REGULATORY ELEMENT; HUMAN GENOME; DNA; SEQUENCE; EXPRESSION; CHROMATIN	We have sequenced a contiguous 284,495-bp segment of DNA extending from the terminal (TTAGGC)(n) repeats of the short arm of chromosome 16, providing a full description of the transition from telomeric through subtelomeric DNA to sequences that are unique to the chromosome. To complement and extend analysis of the primary sequence, we have characterized mRNA transcripts, patterns of DNA methylation and DNase I sensitivity. Together with previous data these studies describe in detail the structural and functional organization of a human telomeric region.	JOHN RADCLIFFE HOSP, INST MOL MED, MRC, MOL HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND; SANGER CTR, CAMBRIDGE CB10 1RQ, ENGLAND; LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA	University of Oxford; Wellcome Trust Sanger Institute; United States Department of Energy (DOE); Los Alamos National Laboratory				Micklem, Gos/0000-0002-6883-6168; Flint, Jonathan/0000-0002-9427-4429	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS MD, 1995, NATURE, V377, P3; BICKMORE WA, 1989, TRENDS GENET, V5, P144, DOI 10.1016/0168-9525(89)90055-3; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chen EY, 1996, HUM MOL GENET, V5, P659, DOI 10.1093/hmg/5.5.659; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHENSOLAL MM, 1982, DNA-J MOLEC CELL BIO, V1, P355, DOI 10.1089/dna.1982.1.355; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; FLINT J, 1994, AM J HUM GENET, V55, P505; FOUGEROUSSE F, 1992, NUCLEIC ACIDS RES, V20, P1165, DOI 10.1093/nar/20.5.1165; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GOODBOURN SEY, 1983, P NATL ACAD SCI-BIOL, V80, P5022, DOI 10.1073/pnas.80.16.5022; GOURDON G, 1994, NUCLEIC ACIDS RES, V22, P4139, DOI 10.1093/nar/22.20.4139; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HARDISON RC, 1986, NUCLEIC ACIDS RES, V14, P1903, DOI 10.1093/nar/14.4.1903; Harris Peter C., 1993, V5, P107; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; Higgs DR, 1993, CHROMOSOMES TODAY, V11, P35; HILL AVS, 1985, CELL, V42, P809, DOI 10.1016/0092-8674(85)90277-6; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; HSU SL, 1988, NATURE, V331, P94, DOI 10.1038/331094a0; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; JARMAN AP, 1988, AM J HUM GENET, V42, P8; JURKA J, 1988, NUCLEIC ACIDS RES, V16, P766, DOI 10.1093/nar/16.2.766; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KERMOUNI A, 1995, GENOMICS, V29, P371, DOI 10.1006/geno.1995.9992; Kitsberg D, 1991, CURR OPIN GENET DEV, V1, P534, DOI 10.1016/S0959-437X(05)80204-7; LAMB J, 1993, AM J HUM GENET, V52, P668; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; LAUER J, 1980, CELL, V20, P119, DOI 10.1016/0092-8674(80)90240-8; LEDBETTER DH, 1992, AM J HUM GENET, V51, P451; LEUNG S, 1987, NATURE, V329, P551, DOI 10.1038/329551a0; NELLIST M, 1993, CELL, V75, P1305; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; PROUDFOOT NJ, 1980, CELL, V21, P537, DOI 10.1016/0092-8674(80)90491-2; Raynham H, 1996, QJM-MON J ASSOC PHYS, V89, P169; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEDL P, CHROMATIN STRUCTURE; Solovyev V V, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P367; SONNHAMMER E, 1994, P INT SOC MOL BIOL, V94, P363; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; VYAS P, 1995, GENOMICS, V29, P679, DOI 10.1006/geno.1995.9951; VYAS P, 1992, CELL, V69, P781, DOI 10.1016/0092-8674(92)90290-S; WARD CJ, 1994, CELL, V77, P881; WILKIE AOM, 1992, GENOMICS, V13, P81, DOI 10.1016/0888-7543(92)90205-7; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILKIE AOM, 1990, AM J HUM GENET, V46, P1112; WILSON JT, 1978, NUCLEIC ACIDS RES, V5, P563, DOI 10.1093/nar/5.2.563; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	56	129	133	0	4	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					252	257		10.1038/ng0397-252	http://dx.doi.org/10.1038/ng0397-252			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054936				2022-12-25	WOS:A1997WK38600013
J	Schon, MP; Detmar, M; Parker, CM				Schon, MP; Detmar, M; Parker, CM			Murine psoriasis-like disorder induced by naive CD4(+) T cells	NATURE MEDICINE			English	Article							VASCULAR-PERMEABILITY FACTOR; ENDOTHELIAL GROWTH-FACTOR; VERSUS-HOST DISEASE; MINOR HISTOCOMPATIBILITY BARRIERS; EXPRESS HIGH-LEVELS; TRANSGENIC MICE; SKIN-DISEASE; ANIMAL-MODEL; MAST-CELLS; EPIDERMIS	Psoriasis is a complex disorder involving alterations of many cell types. Although evidence suggests a T-cell pathogenesis for psoriasis, a primary role of T cells has not been directly demonstrated. Here, we show that reconstitution of scid/scid mice with minor histocompatibility mismatched naive CD4(+) T lymphocytes resulted in skin alterations that strikingly resembled human psoriasis clinically, histopathologically and in cytokine expression. This skin disorder was diminished when memory T cells were coinjected. Thus, a subset of dysregulated CD4(+) T cells can cause tissue alterations seen in psoriasis without the presence of CD8(+) cells or a primary epithelial abnormality.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT PATHOL, BETH ISRAEL DEACONESS MED CTR, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT DERMATOL, BETH ISRAEL DEACONESS MED CTR, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Schon, MP (corresponding author), BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, 250 LONGWOOD AVE, BOSTON, MA 02115 USA.							ARNAOUT MA, 1986, J CLIN INVEST, V78, P597, DOI 10.1172/JCI112615; BARKER JNWN, 1994, BAILLIERE CLIN RHEUM, V8, P429, DOI 10.1016/S0950-3579(94)80027-8; BERNARD BA, 1986, BRIT J DERMATOL, V114, P279, DOI 10.1111/j.1365-2133.1986.tb02818.x; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974; Bullard DC, 1996, P NATL ACAD SCI USA, V93, P2116, DOI 10.1073/pnas.93.5.2116; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; CHANG JCC, 1994, P NATL ACAD SCI USA, V91, P9282, DOI 10.1073/pnas.91.20.9282; Christophers E, 1996, INT ARCH ALLERGY IMM, V110, P199, DOI 10.1159/000237288; Christophers E, 1993, DERMATOLOGY GEN MED, P489; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; ELLIS CN, 1986, JAMA-J AM MED ASSOC, V256, P3110, DOI 10.1001/jama.256.22.3110; FEDY DJ, 1990, BRIT MED J, V300, P908; FINNERTY H, 1993, ONCOGENE, V8, P2293; FORMAN J, 1984, J EXP MED, V159, P1724, DOI 10.1084/jem.159.6.1724; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Gilliam A. C., 1996, GRAFT VS HOST DIS, P291; Gilliam AC, 1996, J INVEST DERMATOL, V107, P377, DOI 10.1111/1523-1747.ep12363361; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; GRAMMER SF, 1994, HDB MOUSE MUTATIONS, P143; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; GROVES RW, 1995, P NATL ACAD SCI USA, V92, P11874, DOI 10.1073/pnas.92.25.11874; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KORNGOLD R, 1987, J EXP MED, V165, P1552, DOI 10.1084/jem.165.6.1552; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCGUIRE J, 1984, BRIT J DERMATOL, V111, P27, DOI 10.1111/j.1365-2133.1984.tb15579.x; MENSSEN A, 1995, J IMMUNOL, V155, P4078; MORRISSEY PJ, 1993, J EXP MED, V178, P237, DOI 10.1084/jem.178.1.237; MUELLER W, 1979, NEW ENGL J MED, V301, P555; MURPHY GF, 1994, J INVEST DERMATOL, V102, P451, DOI 10.1111/1523-1747.ep12373016; Nanney LB, 1996, J INVEST DERMATOL, V106, P1169, DOI 10.1111/1523-1747.ep12347791; NICKOLOFF BJ, 1990, J INVEST DERMATOL, V94, pS151, DOI 10.1111/1523-1747.ep12876134; NICKOLOFF BJ, 1995, AM J PATHOL, V146, P580; NICOLAS JF, 1991, LANCET, V338, P321, DOI 10.1016/0140-6736(91)90465-2; ONUMA A, 1994, J DERMATOL, V21, P223; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; PRINZ J, 1991, LANCET, V338, P320, DOI 10.1016/0140-6736(91)90464-Z; SCHLEGEL PG, 1995, J IMMUNOL, V155, P3856; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; SUNDBERG JP, 1990, J INVEST DERMATOL, V95, pS62, DOI 10.1111/1523-1747.ep12505816; Sundberg JP, 1994, HDB MOUSE MUTATIONS, P253; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; Townsend RM, 1996, BLOOD, V88, P3038, DOI 10.1182/blood.V88.8.3038.bloodjournal8883038; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	51	133	143	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1997	3	2					183	188		10.1038/nm0297-183	http://dx.doi.org/10.1038/nm0297-183			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018237				2022-12-25	WOS:A1997WF08800037
J	Basson, CT; Bachinsky, DR; Lin, RC; Levi, T; Elkins, JA; Soults, J; Grayzel, D; Kroumpouzou, E; Traill, TA; LeblancStraceski, J; Renault, B; Kucherlapati, R; Seidman, JG; Seidman, CE				Basson, CT; Bachinsky, DR; Lin, RC; Levi, T; Elkins, JA; Soults, J; Grayzel, D; Kroumpouzou, E; Traill, TA; LeblancStraceski, J; Renault, B; Kucherlapati, R; Seidman, JG; Seidman, CE			Mutations in human cause limb and cardiac malformation in Holt-Oram syndrome	NATURE GENETICS			English	Article							CONSERVED PROTEIN MOTIF; GRAM SYNDROME; GENES; EMBRYOGENESIS; BRACHYURY; DISEASE; HOMOLOG; FAMILY; LOCUS; MAPS	Holt-Gram syndrome is characterized by upper limb malformations and cardiac septation defects, Here, we demonstrate that mutations in the human TBX5 gene underlie this disorder. TBX5 was cloned from the disease locus on human chromosome 12q24.1 and identified as a member of the T-box transcription factor family, A nonsense mutation in TBX5 causes Holt-Gram syndrome in affected members of one family; a TBX5 missense mutation was identified in affected members of another, We conclude that TBX5 is critical for limb and heart development and suggest that haploinsufficiency of TBX5 causes Holt-Gram syndrome.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115; JOHNS HOPKINS UNIV HOSP,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205; ALBERT EINSTEIN COLL MED,DEPT MOL GENET,BRONX,NY 10461; BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute	Basson, CT (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.		Kucherlapati, Raju/ABC-8807-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003468] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000965] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00965] Funding Source: Medline; NHLBI NIH HHS [HL03468-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agulnik SI, 1996, GENETICS, V144, P249; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BASSON CT, 1995, CIRCULATION, V91, P1326, DOI 10.1161/01.CIR.91.5.1326; BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; BONNET D, 1994, NAT GENET, V6, P405, DOI 10.1038/ng0494-405; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; CAMPBELL C, 1995, GENOMICS, V28, P255, DOI 10.1006/geno.1995.1139; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; DALTON ME, 1993, NEW ENGL J MED, V328, P114; Edwards YH, 1996, GENOME RES, V6, P226, DOI 10.1101/gr.6.3.226; FOOTE S, 1996, CURRENT PROTOCOLS HU; GALL JC, 1966, AM J HUM GENET, V18, P187; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HOLT M, 1960, BRIT HEART J, V22, P236; HUANG JX, 1995, ANN NY ACAD SCI, V752, P217; HURST JA, 1991, J MED GENET, V28, P406, DOI 10.1136/jmg.28.6.406; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KULLMANN F, 1993, DEUT MED WOCHENSCHR, V118, P1455, DOI 10.1055/s-2008-1059473; LAW DJ, 1995, MAMM GENOME, V6, P793, DOI 10.1007/BF00539006; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LEBLANCSTRACESKI JM, 1994, GENOMICS, V19, P341, DOI 10.1006/geno.1994.1067; LETTS RM, 1976, CLIN ORTHOPAEDICS, V116, P149; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; OTT J, 1976, AM J HUM GENET, V28, P528; Park MY, 1996, DEV BIOL, V177, P104, DOI 10.1006/dbio.1996.0149; PRUZNANSKI W, 1964, CARDIOLOGIA, V45, P1; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; RUZIC B, 1981, RADIOLOGE, V21, P296; SAHN DJ, 1981, CHEST, V79, P113, DOI 10.1378/chest.79.1.113; SATOH N, 1995, TRENDS GENET, V11, P354, DOI 10.1016/S0168-9525(00)89106-4; SMITH AT, 1979, J PEDIATR-US, V95, P538, DOI 10.1016/S0022-3476(79)80758-1; STARKE H, 1967, AM J CARDIOL, V19, P588, DOI 10.1016/0002-9149(67)90436-5; STERNBERG NL, 1996, CURRENT PROTOCOLS HU; TERRETT JA, 1994, NAT GENET, V6, P401, DOI 10.1038/ng0494-401; Terrett JA, 1996, AM J HUM GENET, V59, P1337; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WESLEY CS, 1993, NUCLEIC ACIDS RES, V22, P538; ZHANG KZ, 1986, AM HEART J, V111, P572, DOI 10.1016/0002-8703(86)90066-9	45	797	816	0	366	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					30	35		10.1038/ng0197-30	http://dx.doi.org/10.1038/ng0197-30			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988165				2022-12-25	WOS:A1997WA37300017
J	Gunsalus, JR; Brady, DA; Coulter, SM; Gray, M; Edge, ASB				Gunsalus, JR; Brady, DA; Coulter, SM; Gray, M; Edge, ASB			Reduction of serum cholesterol in Watanabe rabbits by xenogeneic hepatocellular transplantation	NATURE MEDICINE			English	Article							RECEPTOR-DEFICIENT RABBITS; GENE-THERAPY; HEPATOCYTE TRANSPLANTATION; FAMILIAL HYPERCHOLESTEROLEMIA; RECOMBINANT ADENOVIRUSES; PARTIAL-HEPATECTOMY; WHHL RABBIT; LIVER; PIG; DELIVERY	Transplantation of xenogeneic hepatocytes would provide a novel therapy for liver disease and would help to solve the problem of an insufficient supply of donor organs. We have tested whether xenogeneic cells infused into the liver could correct the metabolic defect in the Watanabe heritable hyperlipidemic (WHHL) rabbit, an animal model for homozygous familial hypercholesterolemia, rand we have investigated whether the infused cells traverse the lining of the portal vasculature. We find that porcine hepatocytes are localized in the hepatic sinusoids after surgery and subsequently migrate out of the vessels and integrate into the hepatic parenchyma. The integrated porcine hepatocytes provide functional LDL receptors that lower serum cholesterol in the WHHL rabbit by 30-60% for at least 100 days.	DIACRIN INC,DEPT MOL & CELLULAR BIOL,CHARLESTOWN,MA 02129				Edge, Albert/Q-5448-2019	Nicoloro, Sarah/0000-0002-8638-4556	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK048596] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48596] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBISCHER P, 1991, DIABETES, V40, P482, DOI 10.2337/diabetes.40.4.482; ARBER N, 1988, LIVER, V8, P80; AUCHINCLOSS H, 1990, TRANSPLANT REV, V4, P14; BACHORIK PS, 1982, BIOCHEMISTRY-US, V21, P5675, DOI 10.1021/bi00265a044; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; BLIKKENDAALLIEFTINCK LF, 1977, EXP MOL PATHOL, V26, P184, DOI 10.1016/0014-4800(77)90048-X; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUJA LM, 1990, EUR HEART J, V11, P41, DOI 10.1093/eurheartj/11.suppl_E.41; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; FLEIG WE, 1986, J HEPATOL, V3, P19, DOI 10.1016/S0168-8278(86)80141-6; GERLACH JC, 1994, TRANSPLANTATION, V57, P1318, DOI 10.1097/00007890-199405150-00005; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Gumucio Jorge J., 1994, P1143; GUPTA S, 1995, P NATL ACAD SCI USA, V92, P5860, DOI 10.1073/pnas.92.13.5860; HAVEL RJ, 1989, ARTERIOSCLER, V9, P33; HOLMQUIST L, 1978, ANAL BIOCHEM, V88, P457, DOI 10.1016/0003-2697(78)90444-X; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAY MA, 1993, CELL TRANSPLANT, V2, P405, DOI 10.1177/096368979300200506; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LAGROST L, 1989, J LIPID RES, V30, P701; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LI J, 1995, J CLIN INVEST, V95, P768, DOI 10.1172/JCI117725; MAGANTO P, 1992, TRANSPLANT P, V24, P2826; MOSCIONI AD, 1993, SURGERY, V113, P304; OETTINGER HF, 1995, CELL TRANSPLANT, V4, P253, DOI 10.1016/0963-6897(95)90037-3; PANGBURN SH, 1981, J BIOL CHEM, V256, P3340; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; SIMEONOVIC CJ, 1990, TRANSPLANTATION, V49, P849, DOI 10.1097/00007890-199005000-00002; SPADY DK, 1987, J LIPID RES, V28, P32; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; TEJERA ML, 1992, TRANSPLANT P, V24, P160; VEMURU RP, 1992, FASEB J, V6, P2836, DOI 10.1096/fasebj.6.10.1634046; WANG J, 1991, TRANSPLANT P, V23, P894; WIEDERKEHR JC, 1990, TRANSPLANTATION, V50, P466, DOI 10.1097/00007890-199009000-00021; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1992, J BIOL CHEM, V267, P963; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	41	76	77	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					48	53		10.1038/nm0197-48	http://dx.doi.org/10.1038/nm0197-48			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986740				2022-12-25	WOS:A1997WA73300036
J	Murphy, M; Stinnakre, MG; SenamaudBeaufort, C; Winston, NJ; Sweeney, C; Kubelka, M; Carrington, M; Brechot, C; SobczakThepot, J				Murphy, M; Stinnakre, MG; SenamaudBeaufort, C; Winston, NJ; Sweeney, C; Kubelka, M; Carrington, M; Brechot, C; SobczakThepot, J			Delayed early embryonic lethality following disruption of the murine cyclin A2 gene	NATURE GENETICS			English	Article							S-PHASE; MOUSE EMBRYO; CELL-CYCLE; MICE; OVEREXPRESSION; LINK; D1	In higher eukaryotes, cell cycle progression is controlled by cyclin dependent kinases (Cdks) complexed with cyclins. A-type cyclins are involved at both G1/S and G2/M transitions of the cell cycle. Cyclin A2 activates cdc2 (Cdk1) on passage into mitosis and Cdk2 at the G1/S transition(1). Antisense constructs, or antibodies directed against cyclin AZ block cultured mammalian cells at both of these transitions(2-4). In contrast, overexpression of cyclin A2 appears to advance S phase entry(5,6) and confer anchorage-independent growth(7), and can lead to apoptosis(8). A second A-type cyclin, cyclin A1 has been described recently which, in the mouse, is expressed in germ cells but not somatic tissues(9,10). To address the possible redundancy between different cyclins in vivo and also the control of early embryonic cell cycles, we undertook the targeted deletion of the murine cyclin A2 gene. The homozygous null mutant is embryonically lethal, demonstrating that the cyclin A2 gene is essential. Surprisingly, homozygous null mutant embryos develop normally until postimplantation, around day 5.5 p.c. This observation may be explained by the persistence of a maternal pool of cyclin AZ protein until at least the blastocyst stage, or an unexpected role for cyclin Al during early embryo development.	FAC MED NECKER ENFANTS MALAD,INSERM U370,F-75730 PARIS 15,FRANCE; INRA,BIOCHIM GENET LAB,JOUY EN JOSAS,FRANCE; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; BABRAHAM INST,CAMBRIDGE CB2 4AT,ENGLAND; ACAD SCI CZECH REPUBL,INST ANIM PHYSIOL & GENET,DEPT GENET,CR-27721 LIBECHOV,CZECH REPUBLIC	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Czech Academy of Sciences; Institute of Animal Physiology & Genetics of the Czech Academy of Sciences			Sobczak, Joelle/HHZ-5610-2022; Carrington, Mark/N-3653-2019; Carrington, Mark/N-4892-2018; Kubelka, Michal/G-7127-2014	Carrington, Mark/0000-0002-6435-7266; Carrington, Mark/0000-0002-6435-7266; Sobczak, Joelle/0000-0001-7180-2789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1989, SCIENCE; BACHVAROVA R, 1980, DEV BIOL, V74, P1, DOI 10.1016/0012-1606(80)90048-2; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FLACH G, 1982, EMBO J, V1, P681, DOI 10.1002/j.1460-2075.1982.tb01230.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Hogan B, 1994, MANIPULATING MOUSE E; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Strausfeld UP, 1996, J CELL SCI, V109, P1555; Sweeney C, 1996, DEVELOPMENT, V122, P53; THEILER K, 1989, HOUSE MOUSE; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	20	198	205	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					83	86		10.1038/ng0197-83	http://dx.doi.org/10.1038/ng0197-83			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988174				2022-12-25	WOS:A1997WA37300026
J	Gimmi, CD; Morrison, BW; Mainprice, BA; Gribben, JG; Boussiotis, VA; Freeman, GJ; Park, SYL; Watanabe, M; Gong, JL; Hayes, DF; Kufe, DW; Nadler, LM				Gimmi, CD; Morrison, BW; Mainprice, BA; Gribben, JG; Boussiotis, VA; Freeman, GJ; Park, SYL; Watanabe, M; Gong, JL; Hayes, DF; Kufe, DW; Nadler, LM			Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells	NATURE MEDICINE			English	Article							LYMPHOCYTES-T; MUCIN; IMMUNITY; PROTEIN; EPITOPE; DF3; CARCINOMAS; EPISIALIN; ADHESION; CORE	Given the plethora of well-documented breast carcinoma-associated antigens in humans including MAGE-1, -2 and -3, mutated p53, p21ras, HER-2/neu and DF3/MUC-1, coupled with evidence that humoral and cytotoxic T-cell responses against these antigens exist(1-6), the central dilemma facing tumor immunologists is why the host immune response is so inefficient. One possibility is that tumor cells themselves are either inefficient or ineffective antigen-presenting cells (APCs). The failure of tumor cells to function as APCs may be due to their inability to process and present the antigen, the absence or insufficient numbers of adhesion and costimulatory molecules or, potentially, the secretion of inhibitory cytokines. Therefore, we sought to determine whether human breast cancer cell lines could function as APCs and, if not, to identify mechanism(s) responsible for this defect. Here, we show that human breast cancer cell lines fail to present alloantigen. This defect does not reside in their inherent capacity to present antigen but rather is due to apoptosis of activated T cells induced by exposure to the breast carcinoma-associated mucin antigen, DF3/MUC1. These results support the hypothesis that DF3/MUC1 may contribute to the paucity of clinically significant anticarcinoma-specific immune responses.	DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Gimmi, CD (corresponding author), DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,44 BINNEY ST,BOSTON,MA 02115, USA.		Freeman, Gordon/AAC-5380-2019; Hayes, Daniel/ABE-1129-2020	Freeman, Gordon/0000-0002-7210-5616; 	NCI NIH HHS [CA 38493, UO1-CA 64057] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA038493, U01CA064057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; DISIS ML, 1994, CANCER RES, V54, P16; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; HAYES DF, 1990, J IMMUNOL, V145, P962; Hull S R, 1989, Cancer Commun, V1, P261; JEROME KR, 1991, CANCER RES, V51, P2908; JUNG V, 1990, J BIOL CHEM, V265, P1827; KOTERA Y, 1994, CANCER RES, V54, P2856; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; MCKOLANIS J, 1996, P AM ASSOC CANC RES, V87, P3144; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565	20	155	162	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1367	1370		10.1038/nm1296-1367	http://dx.doi.org/10.1038/nm1296-1367			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946837				2022-12-25	WOS:A1996VW51500044
J	Larochelle, A; Vormoor, J; Hanenberg, H; Wang, JCY; Bhatia, M; Lapidot, T; Moritz, T; Murdoch, B; Xiang, LX; Kato, I; Williams, DA; Dick, JE				Larochelle, A; Vormoor, J; Hanenberg, H; Wang, JCY; Bhatia, M; Lapidot, T; Moritz, T; Murdoch, B; Xiang, LX; Kato, I; Williams, DA; Dick, JE			Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy	NATURE MEDICINE			English	Article							CORD-BLOOD-CELLS; STEM-CELLS; PROGENITOR CELLS; SCID MICE; ADENOSINE-DEAMINASE; IMMUNODEFICIENT MICE; EXPRESSION; ENGRAFTMENT; LEUKEMIA; INVITRO	The development of stem-cell gene therapy is hindered by the absence of repopulation assays for primitive human hematopoietic cells. Current methods of gene transfer rely on in vitro colony-forming cell (CFC) and long-term culture-initiating cell (LTC-IC) assays, as well as inference from other mammalian species. We have identified a novel human hematopoietic cell, the SCID-repopulating cell (SRC), a cell more primitive than most LTC-ICs and CFCs. The SRC, exclusively present in the CD4(+)CD8(-) fraction, is capable of multilineage repopulation of the bone marrow of nonobese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice). SRCs were rarely transduced with retroviruses, distinguishing them from most CFCs and LTC-ICs. This observation is consistent with the low level of gene marking seen in human gene therapy trials. An SRC assay may aid in the characterization of hematopoiesis, as well as the improvement of transduction methods.	UNIV TORONTO, HOSP SICK CHILDREN, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5G 1X8, CANADA; INDIANA UNIV, SCH MED, JAMES WHITCOMB RILEY HOSP CHILDREN, HERMAN WELLS CTR PEDIAT RES, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, HOWARD HUGHES MED INST, INDIANAPOLIS, IN 46202 USA; TAKARA SHUZO CO LTD, BIOTECHNOL RES LABS, OTSU, SHIGA 52021, JAPAN	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Howard Hughes Medical Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Takara Holdings Inc.			Lapidot, Tsvee/A-1812-2010; Vormoor, Josef/GPS-7248-2022; Larochelle, Andre/P-1342-2016	Vormoor, Josef/0000-0002-1825-1890; Larochelle, Andre/0000-0003-0685-2186; Wang, Jean/0000-0001-7543-3917; Dick, John/0000-0002-9527-8317	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049218] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 53586] Funding Source: Medline; NIDDK NIH HHS [P50 DK 49218] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BODINE DM, 1991, EXP HEMATOL, V19, P206; BODINE DM, 1993, BLOOD, V82, P1975; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; CASHMAN J, 1994, BLOOD, V84, pA368; CIVIN CI, 1984, J IMMUNOL, V133, P157; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DICK JE, 1991, BLOOD, V78, P624, DOI 10.1182/blood.V78.3.624.bloodjournal783624; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; EAVES CJ, 1992, BLOOD CELLS, V18, P301; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; HAO QL, 1995, BLOOD, V86, P3745, DOI 10.1182/blood.V86.10.3745.bloodjournal86103745; HARRISON DE, 1987, BLOOD, V69, P1021; HOCK RA, 1986, NATURE, V320, P275, DOI 10.1038/320275a0; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; HUGHES PFD, 1989, BLOOD, V74, P1915; Jonsson JI, 1996, BLOOD, V87, P1771; KIMIZUKA F, 1991, J BIOCHEM-TOKYO, V110, P284, DOI 10.1093/oxfordjournals.jbchem.a123572; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LAROCHELLE A, 1995, HUM MOL GENET, V4, P163, DOI 10.1093/hmg/4.2.163; LIM B, 1989, P NATL ACAD SCI USA, V86, P8892, DOI 10.1073/pnas.86.22.8892; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MORITZ T, 1994, J CLIN INVEST, V93, P1451, DOI 10.1172/JCI117122; MORITZ T, 1993, J EXP MED, V178, P529, DOI 10.1084/jem.178.2.529; Moritz T, 1996, BLOOD, V88, P855, DOI 10.1182/blood.V88.3.855.bloodjournal883855; NOLTA JA, 1994, BLOOD, V83, P3041, DOI 10.1182/blood.V83.10.3041.3041; Nolta JA, 1996, P NATL ACAD SCI USA, V93, P2414, DOI 10.1073/pnas.93.6.2414; OCHMAN H, 1988, GENETICS, V120, P621; Roath S, 1994, Prog Clin Biol Res, V389, P155; RUSTEN LS, 1994, BLOOD, V84, P1473; SCHUENING FG, 1991, BLOOD, V78, P2568; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Sirard C, 1996, BLOOD, V87, P1539, DOI 10.1182/blood.V87.4.1539.bloodjournal8741539; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; VORMOOR J, 1994, BLOOD, V83, P2489; VORMOOR J, 1995, HUMAN HEMATOPOIESIS, P197; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0	43	617	654	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1996	2	12					1329	1337		10.1038/nm1296-1329	http://dx.doi.org/10.1038/nm1296-1329			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946831				2022-12-25	WOS:A1996VW51500038
J	WhittumHudson, JA; An, LL; Saltzman, WM; Prendergast, RA; MacDonald, AB				WhittumHudson, JA; An, LL; Saltzman, WM; Prendergast, RA; MacDonald, AB			Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection	NATURE MEDICINE			English	Article							OUTER-MEMBRANE PROTEIN; T-CELLS; ANTIIDIOTYPIC ANTIBODIES; GENITAL-TRACT; MURINE MODEL; VACCINE; NEUTRALIZATION; PATHOGENESIS; IGG; MICROSPHERES	Chlamydia trachomatis is the leading cause worldwide of preventable infectious blindness (trachoma) and sexually transmitted disease, including nongonoccocal urethritis and pelvic inflammatory disease. To date, no effective vaccine against C. trachomatis infection has been identified. A monoclonal anti-idiotypic antibody (anti-Id) to the chlamydial exoglycolipid antigen (GLXA) was tested in a murine model of ocular chlamydial infection for its ability to induce systemic immunity, which reduces microbiologic and clinical disease. The anti-Id to GLXA, delivered either systemically in soluble form or orally after encapsulation in poly(lactide) microspheres, induced significant protective immunity against ocular challenge of mice with a human biovar of C. trachomatis. Protection was associated with induction of anti-GLXA antibody and anti-chlamydial neutralizing antibody.	UNIV MASSACHUSETTS, DEPT MICROBIOL, AMHERST, MA 01003 USA; JOHNS HOPKINS UNIV, DEPT CHEM ENGN, BALTIMORE, MD 21218 USA	University of Massachusetts System; University of Massachusetts Amherst; Johns Hopkins University	WhittumHudson, JA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, WILMER OPHTHALMOL INST, BALTIMORE, MD 21287 USA.		MacDonald, Alan Bruce/AAX-9220-2020		NEI NIH HHS [EY 03324] Funding Source: Medline; NIAID NIH HHS [AI 24760] Funding Source: Medline; NIGMS NIH HHS [GM 43873] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043873] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN LL, 1993, THESIS U MASSACHUSET; BATTEIGER BE, 1993, J GEN MICROBIOL, V139, P2965, DOI 10.1099/00221287-139-12-2965; BLANCHARD TG, 1990, CHLAMYDIAL INFECT, P205; BROSSAY L, 1994, INFECT IMMUN, V62, P341, DOI 10.1128/IAI.62.2.341-347.1994; BRUNHAM RC, 1987, J INFECT DIS, V155, P749, DOI 10.1093/infdis/155.4.749; BYRNE GI, 1993, J INFECT DIS, V168, P415, DOI 10.1093/infdis/168.2.415; CAIN TK, 1995, INFECT IMMUN, V63, P1784, DOI 10.1128/IAI.63.5.1784-1789.1995; CAMPOS M, 1995, INVEST OPHTH VIS SCI, V36, P1477; CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; HARLOW E, 1994, ANTIBODIES, P139; HAWKINS RE, 1993, J IMMUNOTHER, V14, P273, DOI 10.1097/00002371-199311000-00004; Igietseme Joseph U., 1993, Regional Immunology, V5, P317; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KENNEDY R C, 1985, Biotechniques, V3, P404; KIYONO H, 1994, HDB MUCOSAL IMMUNOLO, P263; MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576; MICHALEK SM, 1983, ANN NY ACAD SCI, V409, P48, DOI 10.1111/j.1749-6632.1983.tb26859.x; MURDIN AD, 1995, INFECT IMMUN, V63, P1116, DOI 10.1128/IAI.63.3.1116-1121.1995; NEWHALL WJ, 1982, INFECT IMMUN, V38, P1181, DOI 10.1128/IAI.38.3.1181-1189.1982; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; PAL S, 1990, Regional Immunology, V3, P171; PIOT P, 1994, CHLAMYDIAL INFECTION, P7; RANK RG, 1992, AM J PATHOL, V140, P927; REACHER MH, 1991, OPHTHALMOLOGY, V98, P334; REES ADM, 1987, EUR J IMMUNOL, V17, P197, DOI 10.1002/eji.1830170208; ROLF JM, 1989, P NATL ACAD SCI USA, V86, P2036, DOI 10.1073/pnas.86.6.2036; SALEHIHAD S, 1994, ACS SYM SER, P278; SCHACHTER J, 1990, SCAND J INFECT DIS, P55; SCHACHTER J, 1985, REV INFECT DIS, V7, P713; SCIEUX C, 1992, SEX TRANSM DIS, V19, P161, DOI 10.1097/00007435-199205000-00010; STEIN KE, 1985, CURR TOP MICROBIOL, V119, P57; STEPHENS RS, 1988, J EXP MED, V167, P817, DOI 10.1084/jem.167.3.817; STUART ES, 1991, IMMUNOLOGY, V74, P740; STUART ES, 1994, CURR MICROBIOL, V28, P85, DOI 10.1007/BF01569052; STUART ES, 1984, CURR MICROBIOL, V11, P123, DOI 10.1007/BF01567715; STUART ES, 1989, IMMUNOLOGY, V68, P469; STUART ES, 1987, IMMUNOLOGY, V61, P527; SU H, 1995, VACCINE, V13, P1023, DOI 10.1016/0264-410X(95)00017-U; SU H, 1995, INFECT IMMUN, V63, P3302, DOI 10.1128/IAI.63.9.3302-3308.1995; SU S, 1992, J IMMUNOL, V148, P234; TAYLOR HR, 1982, INVEST OPHTH VIS SCI, V23, P507; TAYLOR HR, 1987, J IMMUNOL, V138, P3023; TAYLOR HR, 1984, J CLIN MICROBIOL, V20, P391, DOI 10.1128/JCM.20.3.391-395.1984; TING LM, 1995, INFECT IMMUN, V63, P3600, DOI 10.1128/IAI.63.9.3600-3608.1995; TROIDLE KM, 1992, THESIS U MASSACHUSET; WAGAR EA, 1990, J INFECT DIS, V162, P922, DOI 10.1093/infdis/162.4.922; WESTERINK MAJ, 1993, SPRINGER SEMIN IMMUN, V15, P227; WESTROM L, 1993, GENITOURIN MED, V69, P9; WHITTUMHUDSON JA, 1995, INVEST OPHTH VIS SCI, V36, P1976; Wyrick Priscilla B., 1994, Immunology and Infectious Diseases (Oxford), V4, P131	54	61	66	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1996	2	10					1116	1121		10.1038/nm1096-1116	http://dx.doi.org/10.1038/nm1096-1116			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837610				2022-12-25	WOS:A1996VK99500032
J	Zavazava, N; Kronke, M				Zavazava, N; Kronke, M			Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes	NATURE MEDICINE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN FAS LIGAND; BIOCHEMICAL-CHARACTERIZATION; MONOCLONAL ANTIBODY; HUMAN SERUM; CELL-LINE; ANTIGENS; TRANSPLANTATION; PEPTIDES; LIVER	Soluble HLA class I molecules (sHLAs) have been identified in the serum of patients with inflammatory diseases, allografts and autoimmune diseases and in serum of healthy individuals. The biological significance of these molecules, particularly after allogeneic organ transplantation, has been enigmatic. Here we show that primary alloreactive CD8(+) T cells interact with sHLA and undergo apoptosis in the absence of a second signal. Ligation of CD28 rescued T cells from death, implying that sHLAs induce apoptosis through selective stimulation of the T-cell receptor. CD95-L was upregulated after cytotoxic T lymphocytes were incubated with sHLAs, and cell death was blocked by a neutralizing anti-CD95-L antibody, suggesting that sHLAs induce endogenous mutual killing of activated T cells. These results provide a molecular basis for the capacity of sHLAs to downregulate T-cell responses, which may be especially relevant to organ transplantation.			Zavazava, N (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,INST IMMUNOL,MICHAELISTR 5,D-24105 KIEL,GERMANY.							ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; ALTMAN J, 1992, TRANSPLANT P, V224, P967; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CALNE R, 1994, LANCET, V343, P67, DOI 10.1016/S0140-6736(94)90809-5; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; CHARLTON RK, 1970, SCIENCE, V170, P636, DOI 10.1126/science.170.3958.636; CLAYBERGER C, 1987, NATURE, V330, P763, DOI 10.1038/330763a0; DOBBE LME, 1988, IMMUNOGENETICS, V27, P203, DOI 10.1007/BF00346587; DUKE R, 1989, J EXP MED, V169, P765; EMERSON SG, 1981, J IMMUNOL, V127, P482; EMERSON SG, 1980, J EXP MED, V152, P783, DOI 10.1084/jem.152.4.783; GONWA TA, 1988, TRANSPLANTATION, V46, P690, DOI 10.1097/00007890-198811000-00013; HAGA JA, 1991, J BIOL CHEM, V266, P3695; HAUSMANN R, 1993, CLIN EXP IMMUNOL, V91, P183; JU ST, 1990, J IMMUNOL, V144, P23; KANE K, 1989, J IMMUNOL, V142, P4253; KANE KP, 1989, NATURE, V340, P157, DOI 10.1038/340157a0; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KRANGEL MS, 1984, J IMMUNOL, V132, P2984; KRANGEL MS, 1986, J EXP MED, V163, P1173, DOI 10.1084/jem.163.5.1173; KRESS M, 1983, CELL, V34, P189, DOI 10.1016/0092-8674(83)90149-6; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OSTERGAARD HL, 1989, J IMMUNOL, V143, P2120; PARHAM P, 1983, IMMUNOGENETICS, V18, P1, DOI 10.1007/BF00401351; PARHAM P, 1987, NATURE, V325, P625, DOI 10.1038/325625a0; PARHAM P, 1979, J IMMUNOL, V123, P342; PARHAM P, 1978, NATURE, V276, P397, DOI 10.1038/276397a0; PUPPO F, 1995, IMMUNOL TODAY, V16, P124, DOI 10.1016/0167-5699(95)80127-8; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STARZL T, 1989, NEW ENGL J MED, V10, P1092; STARZL T, 1993, IMMUNOL TODAY, V326, P326; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; VANROOD JJ, 1970, NATURE, V226, P366, DOI 10.1038/226366a0; ZAVAZAVA N, 1993, TISSUE ANTIGENS, V42, P20, DOI 10.1111/j.1399-0039.1993.tb02161.x; ZAVAZAVA N, 1994, HUM IMMUNOL, V40, P174, DOI 10.1016/0198-8859(94)90065-5; ZAVAZAVA N, 1991, TRANSPLANTATION, V51, P838, DOI 10.1097/00007890-199104000-00019; ZAVAZAVA N, 1991, J IMMUNOGENET, V17, P387	41	244	255	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1005	1010		10.1038/nm0996-1005	http://dx.doi.org/10.1038/nm0996-1005			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782458				2022-12-25	WOS:A1996VF49700035
J	Gao, SJ; Kingsley, L; Li, M; Zheng, W; Parravicini, C; Ziegler, J; Newton, R; Rinaldo, CR; Saah, A; Phair, J; Detels, R; Chang, Y; Moore, PS				Gao, SJ; Kingsley, L; Li, M; Zheng, W; Parravicini, C; Ziegler, J; Newton, R; Rinaldo, CR; Saah, A; Phair, J; Detels, R; Chang, Y; Moore, PS			KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma	NATURE MEDICINE			English	Article							HERPESVIRUS	A major controversy regarding Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8)(1,2) is whether or not it is a ubiquitous infection of humans(3,4). Immunoassays based on KSHV- and Epstein-Barr virus (EBV)-coinfected cell lines show that most US AIDS-KS patients have specific antibodies to KSHV-related antigens(2,5,6). We have developed a sensitive indirect immunofluorescence assay (IFA) based on an EBV-negative, KSHV-infected cell line, BCP-1. When we used this IFA assay, KSHV-related antibodies were found in 71-88% of serum samples from US, Italian and Ugandan AIDS-KS patients, as well as all serum samples examined from HIV-seronegative KS patients. Although none of the US blood donors examined were KSHV seropositive by IFA, intermediate and high seroprevalence rates were found in Italian and Ugandan control populations. Antibody kinetics showed that more than half of the AIDS-KS patients who were examined IgG-seroconverted before KS development, and antibody levels did not decline after seroconversion. For these patients, seropositivity rates increased linearly with time, suggesting that the rate of infection was constant and that the risk of developing KS once infected with KSHV is not highly dependent on the duration of infection. These data strongly suggest that KSHV is not ubiquitous in most populations and that the virus may be under strict immunologic control in healthy KSHV-infected persons.	COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; UNIV PITTSBURGH, DEPT INFECT DIS & MICROBIOL, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15213 USA; LUIGI SACCO HOSP, DEPT PATHOL, I-20157 MILAN, ITALY; WHO, INT AGCY RES CANC, F-69372 LYON, FRANCE; UNIV OXFORD, RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, OXFORD OX2 6HE, ENGLAND; JOHNS HOPKINS UNIV, DIV EPIDEMIOL, SCH PUBL HLTH, BALTIMORE, MD 21205 USA; NW UNIV MED, COMPREHENS AIDS CTR, CHICAGO, IL 60611 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA 90095 USA	Columbia University; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Milan; Luigi Sacco Hospital; World Health Organization; International Agency for Research on Cancer (IARC); Radcliffe Infirmary; University of Oxford; Johns Hopkins University; University of California System; University of California Los Angeles			Moore, Patrick S./F-3960-2011; Gao, Shou-Jiang/B-8641-2012; Chang, Yuan/F-4146-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041; Kingsley, Lawrence/0000-0002-7000-8556; Gao, Shou-Jiang/0000-0001-6194-1742	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035040, U01AI035039] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI 35039, U01-AI 35040] Funding Source: Medline; PHS HHS [U64CCU210852-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; GAIDANO G, IN PRESS LEUKEMIA; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GEDDES M, 1994, BRIT J CANCER, V69, P333, DOI 10.1038/bjc.1994.60; LEVY JA, 1995, LANCET, V346, P786, DOI 10.1016/S0140-6736(95)91611-3; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; WABINGA HR, 1993, INT J CANCER, V54, P5; Weiss RA, 1996, NAT MED, V2, P277, DOI 10.1038/nm0396-277	14	681	713	1	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					925	928		10.1038/nm0896-925	http://dx.doi.org/10.1038/nm0896-925			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705864				2022-12-25	WOS:A1996UZ80400041
J	Jansen, G; Hazendonk, E; Thijssen, KL; Plasterk, RHA				Jansen, G; Hazendonk, E; Thijssen, KL; Plasterk, RHA			Reverse genetics by chemical mutagenesis in Caenorhabditis elegans	NATURE GENETICS			English	Letter							SEQUENCE; GENES	Traditional reverse genetics on yeast, mice and other organisms a uses homologous recombination with transgenic DNA to interrupt a target gene. Here we report that target-selected gene inactivation can be achieved in Caenorhabditis elegans with the use of chemical mutagens, We use PCR to selectively visualize deletions in genes of interest; the method is sensitive enough to permit detection of a single mutant among more than 15,000 wild types. A permanent frozen mutant collection of more than a million mutagenized animals has been established, and deletion mutants of several G-protein genes were isolated from it. The approach is suitable to be scaled up for systematic inactivation of all 17,000 C. elegans genes. Because it requires no transgenesis or cell culturing, it may also be applicable to small organisms usually considered to be outside the realm of reverse genetics (for example, other nematodes and insects), Any sequenced gene in any organism that can be handled in Very large numbers can possibly be targeted in this way.	NETHERLANDS CANC INST,DIV MOL BIOL,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			Jansen, Gert/HCI-8852-2022	Jansen, Gert/0000-0002-7524-171X	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR010082] Funding Source: NIH RePORTER; NCRR NIH HHS [5R01 RR10082] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson P, 1995, METHOD CELL BIOL, V48, P31; Plasterk RHA, 1995, METHOD CELL BIOL, V48, P59; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Sulston J., 1988, NEMATODE CAENORHABDI, P587; VANLUENEN HGAM, 1994, NUCLEIC ACIDS RES, V22, P262, DOI 10.1093/nar/22.3.262; WATERSTON R, 1995, P NATL ACAD SCI USA, V92, P10836, DOI 10.1073/pnas.92.24.10836; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	10	230	252	2	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1997	17	1					119	121		10.1038/ng0997-119	http://dx.doi.org/10.1038/ng0997-119			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288111				2022-12-25	WOS:A1997XU72400031
J	Kimura, A; Harada, H; Park, JE; Nishi, H; Satoh, M; Takahashi, M; Hiroi, S; Sasaoka, T; Ohbuchi, N; Nakamura, T; Koyanagi, T; Hwang, TH; Choo, TA; Chung, KS; Hasegawa, A; Nagai, R; Okazaki, O; Nakamura, H; Matsuzaki, M; Sakamoto, T; Toshima, H; Koga, Y; Imaizumi, T; Sasazuki, T				Kimura, A; Harada, H; Park, JE; Nishi, H; Satoh, M; Takahashi, M; Hiroi, S; Sasaoka, T; Ohbuchi, N; Nakamura, T; Koyanagi, T; Hwang, TH; Choo, TA; Chung, KS; Hasegawa, A; Nagai, R; Okazaki, O; Nakamura, H; Matsuzaki, M; Sakamoto, T; Toshima, H; Koga, Y; Imaizumi, T; Sasazuki, T			Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy	NATURE GENETICS			English	Article							HEAVY-CHAIN GENE; PROTEIN-C GENE; SKELETAL-MUSCLE; BIOLOGICAL-ACTIVITY; MISSENSE MUTATION; ALPHA-TROPOMYOSIN; MOLECULAR-BASIS; SEQUENCE; LOCUS; MAPS	Hypertrophic cardiomyopathy (HCM), the most common cause of sudden death in the young, is an autosomal dominant disease characterized by ventricular hypertrophy accompanied by myofibrillar disarrays(1). Linkage studies and candidate-gene approaches have demonstrated that about half of the patients have mutations in one of six disease genes: cardiac beta-myosin heavy chain (c beta MHC)(2,3), cardiac troponin T (cTnT)(4,5), alpha-tropomyosin (alpha TM)(5,6), cardiac myosin binding protein C (cMBP-C)(7-9), ventricular myosin essential light chain (vMLC1)(10) and ventricular myosin regulatory light chain (vMLC2)(10) genes. Other disease genes remain unknown. Because all the known disease genes encode major contractile elements in cardiac muscle(11), we have systematically characterized the cardiac sarcomere genes, including cardiac troponin I (cTnI), cardiac actin (cACT) and cardiac troponin C (cTnC)(12) in 184 unrelated patients with HCM and found mutations in the cTnI gene in several patients(13).	KURUME UNIV,SCH MED,DEPT INTERNAL MED 3,KURUME,FUKUOKA 830,JAPAN; SAMSUNG MED CTR,DIV CARDIOL,SEOUL 135230,SOUTH KOREA; KURUME UNIV,INST CARDIOVASC RES,KURUME,FUKUOKA 830,JAPAN; GUNMA UNIV,SCH MED,DEPT INTERNAL MED 2,MAEBASHI,GUMMA 371,JAPAN; INT MED CTR,DEPT CARDIOL,TOKYO 162,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 2,YAMAGUCHI 755,JAPAN; HANZOMON HOSP,TOKYO 102,JAPAN; KURUME UNIV,KURUME MED CTR,DEPT CARDIOL,KURUME,FUKUOKA 835,JAPAN; KYUSHU UNIV,MED INST BIOREGULAT,DEPT GENET,FUKUOKA 812,JAPAN	Kurume University; Sungkyunkwan University (SKKU); Samsung Medical Center; Kurume University; Gunma University; Yamaguchi University; Kurume University; Kyushu University	Kimura, A (corresponding author), TOKYO MED & DENT UNIV,MED RES INST,DEPT TISSUE PSYCHOL,DIV ADULT DIS,TOKYO 101,JAPAN.		nishi, Hiroaki/X-7736-2019; Kimura, Akinori/I-5989-2018	nishi, Hiroaki/0000-0002-6331-2947; Kimura, Akinori/0000-0002-4933-2132				BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; Bermingham N, 1995, GENOMICS, V30, P620, DOI 10.1006/geno.1995.1288; Bhavsar PK, 1996, GENOMICS, V35, P11, DOI 10.1006/geno.1996.0317; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; CARRIER L, 1993, NAT GENET, V4, P311, DOI 10.1038/ng0793-311; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FODOR WL, 1989, J BIOL CHEM, V264, P2143; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P5901, DOI 10.1073/pnas.79.19.5901; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; Ko YL, 1996, HUM GENET, V97, P457; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; MACRAE CA, 1995, J CLIN INVEST, V96, P1216, DOI 10.1172/JCI118154; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; NISHI H, 1995, CIRCULATION, V91, P2911, DOI 10.1161/01.CIR.91.12.2911; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; SCHREIER T, 1990, J BIOL CHEM, V265, P21247; SCHWARTZ K, 1995, CIRCULATION, V91, P532, DOI 10.1161/01.CIR.91.2.532; SOLARO RJ, 1995, ADV EXP MED BIOL, V382, P109; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1989, BIOCHEMISTRY-US, V28, P5902, DOI 10.1021/bi00440a029; THIERFELDER L, 1993, P NATL ACAD SCI USA, V90, P6270, DOI 10.1073/pnas.90.13.6270; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WATKINS H, 1993, NAT GENET, V3, P333, DOI 10.1038/ng0493-333; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434	29	431	450	1	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					379	382		10.1038/ng0897-379	http://dx.doi.org/10.1038/ng0897-379			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241277				2022-12-25	WOS:A1997XM90900022
J	Parikh, A; Gillam, EMJ; Guengerich, FP				Parikh, A; Gillam, EMJ; Guengerich, FP			Drug metabolism by Escherichia coli expressing human cytochromes P450	NATURE BIOTECHNOLOGY			English	Article						drug metabolism; cytochrome P450; NADPH-cytochrome P450; bicistronic constructs	REDUCTASE; PURIFICATION; RAT; 4-HYDROXYLATION; OXIDOREDUCTASE; HYDROXYLATION; DEBRISOQUINE; PROTEINS; P-450	The broad substrate specificity of the cytochrome P450 (P450) enzyme superfamily of heme-thiolate proteins lends itself to diverse environmental and pharmaceutical applications. Until recently, the primary drawback in using living bacteria to catalyze mammalian P450-mediated reactions has been the paucity of electron transport from NADPH to P450 via endogenous flavoproteins. We report the functional expression in Escherichia coli of bicistronic constructs consisting of a human microsomal P450 enzyme encoded by the first cistron and the auxiliary protein NADPH-P450 reductase by the second. Expression levels of P450s ranged from 35 nmol per liter culture to 350 nmol per liter culture, with expression of NADPH-P450 reductase typically ranging from 50% to 100% of that of P450. Transformed bacteria metabolized a number of typical P450 substrates at levels comparable to isolated bacterial membranes fortified with an NADPH-generating system. These rates compare favorably with those obtained using human liver microsomes as well as those of reconstituted in vitro systems composed of purified proteins, lipids, and cofactors.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA; VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; University of Queensland; Vanderbilt University			GILLAM, ELIZABETH/D-1011-2016	GILLAM, ELIZABETH/0000-0003-0378-793X	NCI NIH HHS [R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Blake JAR, 1996, FEBS LETT, V397, P210, DOI 10.1016/S0014-5793(96)01196-9; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243; BURKE MD, 1975, DRUG METAB DISPOS, V3, P245; CHOC MG, 1982, J BIOL CHEM, V257, P865; Chun YJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P48, DOI 10.1006/abbi.1996.0224; DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057; Dong JS, 1996, ARCH BIOCHEM BIOPHYS, V327, P254, DOI 10.1006/abbi.1996.0118; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P540, DOI 10.1006/abbi.1995.1329; GOLD L, 1990, METHOD ENZYMOL, V185, P11; Guengerich F. Peter, 1995, P473; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1981, BIOCHEMISTRY-US, V20, P2379, DOI 10.1021/bi00512a003; Guengerich FP, 1996, METHOD ENZYMOL, V272, P35, DOI 10.1016/S0076-6879(96)72006-2; Guengerich FP, 1996, CRIT REV TOXICOL, V26, P551, DOI 10.3109/10408449609037477; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; JOSEPHY PD, 1995, CANCER RES, V55, P799; KNODELL RG, 1987, J PHARMACOL EXP THER, V241, P1112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARREY D, 1984, BIOCHEMISTRY-US, V23, P2787, DOI 10.1021/bi00307a039; LARSON JR, 1991, J BIOL CHEM, V266, P7321; Lieschke GJ, 1997, NAT BIOTECHNOL, V15, P35, DOI 10.1038/nbt0197-35; Metz MZ, 1996, VIROLOGY, V217, P230, DOI 10.1006/viro.1996.0110; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; OMURA T, 1964, J BIOL CHEM, V239, P2370; Parikh A, 1997, PROTEIN EXPRES PURIF, V9, P346, DOI 10.1006/prep.1997.0721; PORTER TD, 1987, ARCH BIOCHEM BIOPHYS, V254, P353, DOI 10.1016/0003-9861(87)90111-1; Riley M., 1996, ESCHERICHIA COLI SAL, P2118; Sambrook J., 2002, MOL CLONING LAB MANU; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; SCHONER BE, 1990, METHOD ENZYMOL, V185, P94; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; Shet MS, 1997, ARCH BIOCHEM BIOPHYS, V339, P218, DOI 10.1006/abbi.1996.9868; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; TARRAGONAFIOL A, 1992, GENE, V118, P239, DOI 10.1016/0378-1119(92)90194-T; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	41	267	276	3	28	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					784	788		10.1038/nbt0897-784	http://dx.doi.org/10.1038/nbt0897-784			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255795				2022-12-25	WOS:A1997XM70700032
J	Ross, GM; Shamovsky, IL; Lawrance, G; Solc, M; Dostaler, SM; Jimmo, SL; Weaver, DF; Riopelle, RJ				Ross, GM; Shamovsky, IL; Lawrance, G; Solc, M; Dostaler, SM; Jimmo, SL; Weaver, DF; Riopelle, RJ			Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins	NATURE MEDICINE			English	Article							TRK PROTOONCOGENE PRODUCT; HUMAN CARBONIC-ANHYDRASE; METAL-BINDING SITES; CELL-DEATH; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; SYMPATHETIC NEURONS; RECEPTOR-BINDING; ION CHANNELS; ENZYMES	A role for Zn2+ in a variety of neurological conditions such as stroke, epilepsy and Alzheimer's disease has been postulated. In many instances, susceptible neurons are located in regions rich In Zn2+ where nerve growth factor (NGF) levels rise as a result of insult. Although the interaction of Zn2+ with this neurotrophin has previously been suggested, the direct actions of the ion on NGF function have not been explored. Molecular modeling studies predict that Zn2+ binding to NGF will Induce structural changes within domains of this neurotrophin that participate in the recognition of TrkA and p75(NTR). We demonstrate here that Zn2+ alters the conformation of NGF, rendering it unable to bind to p75(NTR) or TrkA receptors or to activate signal transduction pathways and biological outcomes normally induced by this protein. Similar actions of Zn2+ are also observed with other members of the NGF family, suggesting a modulatory role for this metal ion in neurotrophin function.	QUEENS UNIV, DEPT MED, KGH, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PHARMACOL & TOXICOL, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT CHEM, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada				Weaver, Donald/0000-0003-2042-6220				ARGOS P, 1978, J MOL BIOL, V126, P141, DOI 10.1016/0022-2836(78)90356-X; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BERTINI I, 1982, STRUCT BOND, V48, P45; BRADSHAW RA, 1994, PROTEIN SCI, V3, P1901, DOI 10.1002/pro.5560031102; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; DENT AJ, 1989, PHYSICA B, V158, P95, DOI 10.1016/0921-4526(89)90211-1; Dostaler SM, 1996, EUR J NEUROSCI, V8, P870, DOI 10.1111/j.1460-9568.1996.tb01574.x; Frade JM, 1996, NATURE, V383, P166; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREGORY DS, 1993, PROTEIN ENG, V6, P29, DOI 10.1093/protein/6.1.29; HANCOCK RD, 1989, CHEM REV, V89, P1875, DOI 10.1021/cr00098a011; HARRISON NL, 1994, NEUROPHARMACOLOGY, V33, P935, DOI 10.1016/0028-3908(94)90152-X; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P9396, DOI 10.1021/bi00103a002; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Matthews DJ, 1994, CHEM BIOL, V1, P25, DOI 10.1016/1074-5521(94)90037-X; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; RASHID K, 1995, P NATL ACAD SCI USA, V92, P9495, DOI 10.1073/pnas.92.21.9495; ROBINSON RC, 1995, BIOCHEMISTRY-US, V34, P4139, DOI 10.1021/bi00013a001; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYLETT RJ, 1994, TRENDS NEUROSCI, V17, P486, DOI 10.1016/0166-2236(94)90138-4; SARKAR B, 1982, J INDIAN CHEM SOC, V59, P1403; Shamovsky IL, 1996, J AM CHEM SOC, V118, P9743, DOI 10.1021/ja9611194; SHERIDAN RP, 1981, J AM CHEM SOC, V103, P1544, DOI 10.1021/ja00396a042; SHIH A, 1994, J BIOL CHEM, V269, P27679; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; UEDA Y, 1994, NEUROSCI LETT, V165, P203, DOI 10.1016/0304-3940(94)90745-5; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VANDERZEE CEE, 1996, JSCIENCE, V274, P1729; VEDANI A, 1989, J AM CHEM SOC, V111, P4075, DOI 10.1021/ja00193a045; Woo SB, 1996, J BIOL CHEM, V271, P24433, DOI 10.1074/jbc.271.40.24433; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0; ZHANG D, PROTEIN DATA BANK	54	68	70	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1997	3	8					872	878		10.1038/nm0897-872	http://dx.doi.org/10.1038/nm0897-872			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256278				2022-12-25	WOS:A1997XP01400029
J	Drucker, DJ; Shi, Q; Crivici, A; SumnerSmith, M; Tavares, W; Hill, M; DeForest, L; Cooper, S; Brubaker, PL				Drucker, DJ; Shi, Q; Crivici, A; SumnerSmith, M; Tavares, W; Hill, M; DeForest, L; Cooper, S; Brubaker, PL			Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV	NATURE BIOTECHNOLOGY			English	Article						protein modeling; protease inactivation; growth factor; intestine; therapeutic	HORMONE RELEASING HORMONE; INTESTINAL ADAPTATION; ENZYMATIC DEGRADATION; RAT STRAIN; IN-VITRO; EXPRESSION; PLASMA; POLYPEPTIDE; ANALOGS	Species-specific differences in the enzymatic inactivation of peptides is an important consideration in the evaluation of therapeutic efficacy. We demonstrate that glucagon-like peptide 2 (GLP-2), shown to be highly intestinotrophic in mice, promotes an increase in intestinal villus height but has no trophic effect on small bowel weight in rats. The reduced intestinotrophic activity of GLP-5 in rats is attributable to inactivation by the enzyme dipeptidyl peptidase IV (DPP-IV), GLP-2(1-33) was degraded to GLP-2(3-33) following incubation with human placental DPP-IV or rat serum but not by serum from DPP-IV-deficient rats, Administration of rat GLP-2 to DPP-IV-deficient rats was associated with markedly increased bioactivity of rat GLP-2 resulting in a significant increase in small bowel weight. A synthetic GLP-2 analog, r[Gly(2)]GLP-2, with an alanine to glycine substitution at position 2, was resistant to cleavage by both DPP-IV and rat serum in vitro. Treatment of wild-type rats with r[Gly(2)]GLP-2 produced a statistically significant increase in small bowel mass. DPP-IV-mediated inactivation of GLP-5 is a critical determinant of the growth factor-like properties of GLP-2.	UNIV TORONTO,TORONTO HOSP,DEPT PHYSIOL,BANTING & BEST DIABET CTR,TORONTO,ON,CANADA; ALLELIX BIOPHARMACEUT INC,MISSISSAUGA,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Drucker, DJ (corresponding author), UNIV TORONTO,TORONTO HOSP,DEPT MED,BANTING & BEST DIABET CTR,100 COLL ST,TORONTO,ON,CANADA.		Drucker, Daniel J/A-4092-2010					BAI JPF, 1994, PHARMACEUT RES, V11, P897, DOI 10.1023/A:1018946228432; BESTERMAN HS, 1982, GUT, V23, P854, DOI 10.1136/gut.23.10.854; BLOOM SR, 1982, SCAND J GASTROENTERO, V17, P93; BONGERS J, 1992, BIOCHIM BIOPHYS ACTA, V1122, P147, DOI 10.1016/0167-4838(92)90317-7; DARMOUL D, 1994, BIOCHEM BIOPH RES CO, V203, P1224, DOI 10.1006/bbrc.1994.2313; DARMOUL D, 1991, AM J PHYSIOL, V261, pG763, DOI 10.1152/ajpgi.1991.261.5.G763; DEACON CF, 1995, J CLIN ENDOCR METAB, V80, P952, DOI 10.1210/jc.80.3.952; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; EHRLICH P, 1994, AM J PHYSIOL-ENDOC M, V267, pE662, DOI 10.1152/ajpendo.1994.267.5.E662; ERICKSON RH, 1992, J BIOL CHEM, V267, P21623; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; FROHMAN LA, 1986, J CLIN INVEST, V78, P906, DOI 10.1172/JCI112679; FULLER PJ, 1993, GASTROENTEROLOGY, V104, P459, DOI 10.1016/0016-5085(93)90414-8; GLEESON MH, 1971, GUT, V12, P773, DOI 10.1136/gut.12.10.773; HILDEBRANDT M, 1991, BIOCHEM J, V277, P331, DOI 10.1042/bj2770331; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Knudsen LB, 1996, EUR J PHARMACOL, V318, P429, DOI 10.1016/S0014-2999(96)00795-9; LANCE VA, 1984, BIOCHEM BIOPH RES CO, V119, P265, DOI 10.1016/0006-291X(84)91647-4; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; ORSKOV C, 1987, SCAND J CLIN LAB INV, V47, P165; STEVENS FM, 1984, GUT, V25, P784, DOI 10.1136/gut.25.7.784; TAYLOR RG, 1994, BAILLIERE CLIN ENDOC, V8, P165, DOI 10.1016/S0950-351X(05)80230-7; THOMPSON NL, 1991, BIOCHEM J, V273, P497, DOI 10.1042/bj2730497; Tsai CH, 1997, AM J PHYSIOL-GASTR L, V272, pG662, DOI 10.1152/ajpgi.1997.272.3.G662; WATANABE Y, 1987, EXPERIENTIA, V43, P400, DOI 10.1007/BF01940426	25	220	235	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					673	677		10.1038/nbt0797-673	http://dx.doi.org/10.1038/nbt0797-673			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219272				2022-12-25	WOS:A1997XH58300033
J	Lee, MK; Borchelt, DR; Kim, G; Thinakaran, G; Slunt, HH; Ratovitski, T; Martin, LJ; Kittur, A; Gandy, S; Levey, AI; Jenkins, N; Copeland, N; Price, DL; Sisodia, SS				Lee, MK; Borchelt, DR; Kim, G; Thinakaran, G; Slunt, HH; Ratovitski, T; Martin, LJ; Kittur, A; Gandy, S; Levey, AI; Jenkins, N; Copeland, N; Price, DL; Sisodia, SS			Hyperaccumulation of FAD-linked presenilin 1 variants in vivo	NATURE MEDICINE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; GENE; CHROMOSOME-1; LOCUS	Mutations in the presenilin 1 (PS1) and presenilin 2 (PS2) genes can cause Alzheimer's disease in affected members of the majority of early-onset familiar Alzheimer's disease (FAD) pedigrees(1-7). PS1 encodes an ubiquitously expressed, eight transmembrane protein(1,8-11). PS1 is endoproteolytically processed to an aminoterminal derivative (similar to 27-28 kDa) and a carboxy-terminal derivative (similar to 17-18 kDa). These polypeptides accumulate to saturable levels in the brains of transgenic mice, independent of the expression of PS1 holoprotein(12). We now document that, in the brains of transgenic mice, the absolute amounts of accumulated N- and C-terminal derivatives generated from the FAD-linked PS1 variants in which Glu replaces Ala at codon 246 (A246E) or Leu replaces Met at codon 146 (M146L) accumulate to a significantly higher degree (similar to 40-50%) than the fragments derived from wild-type PS1. Moreover, the FAD-linked Delta E9 PS1 variant, a polypeptide that is not subject to endoproteolytic cleavage in vivo, also accumulates in greater amounts than the fragments generated from wild-type human PS1. Thus, the metabolism of PS1 variants linked to FAD is fundamentally different from that of wild-type PS1 in vivo.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; CORNELL UNIV,COLL MED,NEW YORK,NY 10021; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30322; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	Johns Hopkins University; Johns Hopkins University; Cornell University; Emory University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Lee, MK (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,558 ROSS BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.		Lee, Michael K/D-9491-2013; Levey, Allan/F-2104-2011	Lee, Michael K/0000-0001-5865-9682; Levey, Allan/0000-0002-3153-502X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS020471, P01NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER; NIA NIH HHS [AG 05146, 1 P01-AG 14248] Funding Source: Medline; NINDS NIH HHS [NS 20471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		*ALZH DIS COLL GRO, 1995, NAT GENET, V11, P219; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; PerezTur J, 1995, NEUROREPORT, V7, P297; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3	20	130	133	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					756	760		10.1038/nm0797-756	http://dx.doi.org/10.1038/nm0797-756			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212102				2022-12-25	WOS:A1997XG76700035
J	Oda, T; Elkahloun, AG; Pike, BL; Okajima, K; Krantz, ID; Genin, A; Piccoli, DA; Meltzer, PS; Spinner, NB; Collins, FS; Chandrasekharappa, SC				Oda, T; Elkahloun, AG; Pike, BL; Okajima, K; Krantz, ID; Genin, A; Piccoli, DA; Meltzer, PS; Spinner, NB; Collins, FS; Chandrasekharappa, SC			Mutations in the human Jagged1 gene are responsible for Alagille syndrome	NATURE GENETICS			English	Article							ARTERIOHEPATIC DYSPLASIA; DELETION; FAMILY; NOTCH; MICRODELETIONS; CHROMOSOME-20; DROSOPHILA; REGION; 20P	Alagille syndrome (AGS) is an autosomal-dominant disorder characterized by intrahepatic cholestasis and abnormalities of heart, eye and vertebrae, as well as a characteristic facial appearance. Identification of rare AGS patients with cytogenetic deletions has allowed mapping of the gene to 20p12. We have generated a cloned contig of the critical region and used fluorescent in situ hybridization on cells from patients with submicroscopic deletions to narrow the candidate region to only 250 kb. Within this region we identified JAG1, the human homologue of rat Jagged1, which encodes a ligand for the Notch receptor. Cell-cell Jagged/Notch interactions are known to be critical for determination of cell fates in early development, making this an attractive candidate gene for a developmental disorder in humans. Determining the complete exon-intron structure of JAG1 allowed detailed mutational analysis of DNA samples from non-deletion ACS patients, revealing three frame-shift mutations, two splice donor mutations and one mutation abolishing RNA expression from the altered allele. We conclude that AGS is caused by haploinsufficiency of JAG1.	NATL HUMAN GENOME RES INST,LAB GENE TRANSFER,NIH,BETHESDA,MD 20892; NATL HUMAN GENOME RES INST,CANC GENET LAB,NIH,BETHESDA,MD 20892; NAGOYA CITY UNIV,SCH MED,DEPT PEDIAT,NAGOYA,AICHI 467,JAPAN; CHILDRENS HOSP,PHILADELPHIA,PA 19104; RES GENET INC,HUNTSVILLE,AL 35801	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Nagoya City University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia								ALAGILLE D, 1987, J PEDIATR-US, V110, P195, DOI 10.1016/S0022-3476(87)80153-1; ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2; ANAD F, 1990, J MED GENET, V27, P729, DOI 10.1136/jmg.27.12.729; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bao ZZ, 1997, J NEUROSCI, V17, P1425; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BYRNE JLB, 1986, AM J MED GENET, V24, P673, DOI 10.1002/ajmg.1320240411; DANKS DM, 1977, ARCH DIS CHILD, V52, P360, DOI 10.1136/adc.52.5.360; Deleuze Jean-Francois, 1994, European Journal of Human Genetics, V2, P185; DELEUZE JF, 1994, MAMM GENOME, V5, P663, DOI 10.1007/BF00426072; DESMAZE C, 1992, J MED GENET, V29, P233, DOI 10.1136/jmg.29.4.233; DHOMEPOLLET S, 1994, J MED GENET, V31, P453; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ELMSLIE FV, 1995, J MED GENET, V32, P264, DOI 10.1136/jmg.32.4.264; Garrod A, 1928, LANCET, V1, P1055; HATTORI M, 1995, NIPPON SHONIKA GAKKA, V99, P1984; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOL FA, 1995, HUM GENET, V95, P687; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Krantz I. D., 1996, American Journal of Human Genetics, V59, pA224; Krantz ID, 1996, CYTOGENET CELL GENET, V74, P304; LEGIUS E, 1990, AM J MED GENET, V35, P532, DOI 10.1002/ajmg.1320350419; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; ODA T, IN PRESS GENOMCIS; POLLET N, 1995, GENOMICS, V27, P467, DOI 10.1006/geno.1995.1078; RAND EB, 1995, AM J HUM GENET, V57, P1068; SCHNITTGER S, 1989, HUM GENET, V83, P239, DOI 10.1007/BF00285164; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; Spinner N. B., 1995, American Journal of Human Genetics, V57, pA35; SPINNER NB, 1994, AM J HUM GENET, V55, P238; SPINNER NB, IN PRESS CYTOGENET C; TEEBI AS, 1992, AM J MED GENET, V42, P35, DOI 10.1002/ajmg.1320420109	37	783	825	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					235	242		10.1038/ng0797-235	http://dx.doi.org/10.1038/ng0797-235			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207787	Green Published			2022-12-25	WOS:A1997XG60900017
J	Boder, ET; Wittrup, KD				Boder, ET; Wittrup, KD			Yeast surface display for screening combinatorial polypeptide libraries	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; combinatorial library; surface display; affinity maturation; scFv	SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CELL-WALL; HETEROLOGOUS PROTEIN; PHAGE ANTIBODIES; ALPHA-AGGLUTININ; A-AGGLUTININ; AFFINITY; SELECTION; BINDING	Display on the yeast cell wall is well suited for engineering mammalian cell-surface and secreted proteins (e.g., antibodies, receptors, cytokines) that require endoplasmic reticulum-specific post-translational processing for efficient folding and activity. C-terminal fusion to the Aga2p mating adhesion receptor of Saccharomyces cerevisiae has been used for the selection of scFv antibody fragments with threefold decreased antigen dissociation rate from a randomly mutated library. A eukaryotic host should alleviate expression biases present in bacterially propagated combinatorial libraries. Quantitative flow cytometric analysis enables fine discrimination of kinetic parameters for protein binding to soluble ligands.	UNIV ILLINOIS,DEPT CHEM ENGN,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign			Boder, Eric T./E-9635-2015	Boder, Eric T./0000-0003-4095-5680				BARBAS SM, 1994, FIBRINOLYSIS, V8, P245, DOI 10.1016/0268-9499(94)90722-6; BURTON DR, 1993, ACCOUNTS CHEM RES, V26, P405, DOI 10.1021/ar00032a003; CAPPELLARO C, 1994, EMBO J, V13, P4737, DOI 10.1002/j.1460-2075.1994.tb06799.x; DENG SJ, 1995, P NATL ACAD SCI USA, V92, P4992, DOI 10.1073/pnas.92.11.4992; FRANCISCO JA, 1993, P NATL ACAD SCI USA, V90, P10444, DOI 10.1073/pnas.90.22.10444; Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; HOCKNEY RC, 1994, TRENDS BIOTECHNOL, V12, P456, DOI 10.1016/0167-7799(94)90021-3; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KRETZSCHMAR T, 1995, ANAL BIOCHEM, V224, P413, DOI 10.1006/abio.1995.1059; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; PAREKH R, 1995, PROTEIN EXPRES PURIF, V6, P537, DOI 10.1006/prep.1995.1071; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; ROY A, 1991, MOL CELL BIOL, V11, P4196, DOI 10.1128/MCB.11.8.4196; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; SCHLOM J, 1992, CANCER RES, V52, P1067; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; Schreuder MP, 1996, TRENDS BIOTECHNOL, V14, P115, DOI 10.1016/0167-7799(96)10017-2; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	28	1149	1524	5	249	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					553	557		10.1038/nbt0697-553	http://dx.doi.org/10.1038/nbt0697-553			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181578				2022-12-25	WOS:A1997XC77200031
J	Srivastava, D; Thomas, T; Lin, Q; Kirby, ML; Brown, D; Olson, EN				Srivastava, D; Thomas, T; Lin, Q; Kirby, ML; Brown, D; Olson, EN			Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND	NATURE GENETICS			English	Article							MORPHOGENESIS; EXPRESSION; PROTEINS; LINEAGES; HEART; EMBRYOGENESIS; LACKING; EMBRYO; MICE	dHAND and eHAND are related basic helix-loop-helix (bHLH) transcription factors that are expressed in mesodermal and neural crest-derived structures of the developing heart. In contrast to their homogeneous expression during avian cardiogenesis, during mouse heart development we show that dHAND and eHAND are expressed in a complementary fashion and are restricted to segments of the heart tube fated to form the right and left ventricles, respectively. dHAND and eHAND represent the earliest cardiac chamber-specific transcription factors yet identified. Targeted gene deletion of dHAND in mouse embryos resulted in embryonic lethality at embryonic day 10.5 from heart failure. Our description of the cardiac phenotype of dHAND mutant embryos is the first demonstration of a single gene controlling the formation of the mesodermally derived right ventricle and the neural crest-derived aortic arches and reveals a novel cardiogenic subprogramme for right ventricular development.	UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235; MED COLL GEORGIA,DEPT ANAT & CELLULAR BIOL,AUGUSTA,GA 30912	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Georgia; Augusta University	Srivastava, D (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DIV CARDIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057181] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL57181-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; DEHAAN RL, 1964, ORGANOGENESIS, P377; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LIN Q, 1997, IN PRESS SCIENCE; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIKAWA T, 1992, DEV DYNAM, V193, P11, DOI 10.1002/aja.1001930104; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PEXIEDER T, 1984, CONGENITAL HEART DIS, P423; Ross RS, 1996, DEVELOPMENT, V122, P1799; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STANIER DYR, 1992, DEV BIOL, V153, P91; YUTZEY KE, 1995, CIRC RES, V77, P216, DOI 10.1161/01.RES.77.2.216	32	537	552	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					154	160		10.1038/ng0697-154	http://dx.doi.org/10.1038/ng0697-154			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171826				2022-12-25	WOS:A1997XB54300015
J	Cook, CJ				Cook, CJ			Real-time measurements of corticosteroids in conscious animals using an antibody-based electrode	NATURE BIOTECHNOLOGY			English	Article						immunosensor; cortisol; antibody; electrochemical; hormone	MICRODIALYSIS; RELEASE; ACID	An electrochemical immunosensor for real-time determination of corticosteroids, a group of steroidal hormones, is reported. The sensor measures competitive binding of endogenous corticosteroid and a corticosteroid-peroxidase conjugate with antibodies, immobilized on a platinum electrode, by monitoring of peroxidase activity. The electrode is encased within a dialysate membrane, which separates the electrode environment from the sampled fluid, allowing corticosteroid to equilibrate across the membrane. This permits measurements to be made in vivo. The small size of the probe (350 mu m D) allows implantation into tissue or circulatory systems. The electrode was viable for 200 to 400 sequential measurements and at least 48 h in vivo. Detection sensitivity is 0.2 to 0.6 mu g/100 ml of cortisol or corticosterone. The results suggest the possibility of monitoring hormones in real-time within the blood or organ systems of conscious animals.	HORTRES,ENGN DEV GRP,HAMILTON,NEW ZEALAND	New Zealand Institute for Plant & Food Research Ltd	Cook, CJ (corresponding author), MEAT IND RES INST NEW ZEALAND INC,ANIM STRESS & WELFARE PROGRAMME,PRIVATE BAG 3123,HAMILTON,NEW ZEALAND.			Cook, Christian/0000-0001-9677-0306				ALBERY WJ, 1992, J CHEM SOC CHEM COMM, V12, P900; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BROOKE SM, 1994, NEUROENDOCRINOLOGY, V60, P134, DOI 10.1159/000126743; COOK CJ, 1995, MEAT SCI, V40, P137, DOI 10.1016/0309-1740(94)00043-7; COOK CJ, 1995, NEW ZEAL VET J, V43, P248, DOI 10.1080/00480169.1995.35902; Cook CJ, 1996, RES VET SCI, V60, P255, DOI 10.1016/S0034-5288(96)90050-8; Cook CJ, 1996, PHYSIOL BEHAV, V60, P741; COOK CJ, 1997, IN PRESS J NEUROSCIE; Dzantiev BB, 1996, BIOSENS BIOELECTRON, V11, P179, DOI 10.1016/0956-5663(96)83725-0; FRANEK M, 1994, J AGR FOOD CHEM, V42, P1369, DOI 10.1021/jf00042a024; GOODROW M, 1990, J AGR FOOD CHEM, V35, P990; GREEN MJ, 1987, BIOSENSORS FUNDAMENT, P57; KENDRICK KM, 1990, J NEUROSCI METH, V34, P35, DOI 10.1016/0165-0270(90)90040-M; KENDRICK KM, 1989, METHOD ENZYMOL, V168, P182; OBRENOVITCH TP, 1995, J NEUROCHEM, V64, P1884; Petrie NJ, 1996, NEW ZEAL VET J, V44, P4, DOI 10.1080/00480169.1996.35923; Sapolsky RM, 1992, STRESS AGING BRAIN M; WILLS MR, 1983, LAB INVESTIGATIONS E; ZILKHA E, 1995, J NEUROSCI METH, V60, P1, DOI 10.1016/0165-0270(94)00214-2	19	46	49	3	29	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					467	471		10.1038/nbt0597-467	http://dx.doi.org/10.1038/nbt0597-467			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131628				2022-12-25	WOS:A1997WX23700033
J	Kondo, K; Miura, Y; Sone, H; Kobayashi, K; Iijima, H				Kondo, K; Miura, Y; Sone, H; Kobayashi, K; Iijima, H			High-level expression of a sweet protein, monellin, in the food yeast Candida utilis	NATURE BIOTECHNOLOGY			English	Article						Candida utilis; heterologous gene expression; monellin; food yeast	COPY-NUMBER INTEGRATION; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL DNA; GENE; TRANSFORMATION; VECTOR	We describe the heterologous expression of monellin in the yeast Candida utilis. A single-chain monellin gene was expressed under the control of the glyceraldehyde-3-phosphate decarboxylase gene promoter from C. utilis. A promoter-deficient marker gene allowed high-copy-number integration of vectors into either the rDNA locus or the URA3 gene locus. Monellin was produced at a high level, accounting for >50% of the soluble protein. No significant decrease in the production level of monellin was detected in transformants after 50 generations of nonselective growth.	KIRIN BREWERY CO LTD,APPL BIORES CTR,TAKASAKI,GUMMA 37012,JAPAN; KIRIN BREWERY CO LTD,PHARMACEUT RES LABS,TAKASAKI,GUMMA 37012,JAPAN	Kirin Brewery Company Limited; Kirin Brewery Company Limited	Kondo, K (corresponding author), KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,1-13-5 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.							BOHAK Z, 1976, BIOCHIM BIOPHYS ACTA, V427, P153, DOI 10.1016/0005-2795(76)90293-2; BOZE H, 1992, CRIT REV BIOTECHNOL, V12, P65, DOI 10.3109/07388559209069188; BUCKHOLZ RG, 1991, BIO-TECHNOL, V9, P1067, DOI 10.1038/nbt1191-1067; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; ICHII T, 1993, J FERMENT BIOENG, V75, P375, DOI 10.1016/0922-338X(93)90137-W; KIM SH, 1989, PROTEIN ENG, V2, P571, DOI 10.1093/protein/2.8.571; KOHMURA M, 1990, AGR BIOL CHEM TOKYO, V54, P2219, DOI 10.1080/00021369.1990.10870299; KONDO K, 1995, J BACTERIOL, V177, P7171, DOI 10.1128/jb.177.24.7171-7177.1995; KONDO K, 1991, J BIOL CHEM, V266, P17537; LEE JH, 1988, BIOCHEMISTRY-US, V27, P5101, DOI 10.1021/bi00414a023; Lopes TS, 1996, YEAST, V12, P467, DOI 10.1002/(SICI)1097-0061(199604)12:5<467::AID-YEA933>3.0.CO;2-3; LOPES TS, 1991, GENE, V105, P83, DOI 10.1016/0378-1119(91)90516-E; LOPES TS, 1989, GENE, V79, P199, DOI 10.1016/0378-1119(89)90202-3; MORRIS JA, 1972, BIOCHIM BIOPHYS ACTA, V261, P114, DOI 10.1016/0304-4165(72)90320-0; PENARRUBIA L, 1992, BIO-TECHNOL, V10, P561, DOI 10.1038/nbt0592-561; Sambrook J., 2002, MOL CLONING LAB MANU; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; YAMANO S, 1994, J BIOTECHNOL, V32, P165, DOI 10.1016/0168-1656(94)90179-1; ZEMANEK EC, 1995, CRIT REV FOOD SCI, V35, P455, DOI 10.1080/10408399509527709	20	61	82	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					453	457		10.1038/nbt0597-453	http://dx.doi.org/10.1038/nbt0597-453			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131625				2022-12-25	WOS:A1997WX23700030
J	Sassaman, DM; Dombroski, BA; Moran, JV; Kimberland, ML; Naas, TP; DeBerardinis, RJ; Gabriel, A; Swergold, GD; Kazazian, HH				Sassaman, DM; Dombroski, BA; Moran, JV; Kimberland, ML; Naas, TP; DeBerardinis, RJ; Gabriel, A; Swergold, GD; Kazazian, HH			Many human L1 elements are capable of retrotransposition	NATURE GENETICS			English	Article							HUMAN TRANSPOSABLE ELEMENT; REVERSE-TRANSCRIPTASE; SACCHAROMYCES-CEREVISIAE; DNA-SEQUENCES; INSERTION; LINE-1; MUTAGENESIS; GENE; IDENTIFICATION; FAMILY	Using a selective screening strategy to enrich for active L1 elements, we isolated 13 full-length elements from a human genomic library. We tested these and two previously-isolated L1s (L1.3 and L1.4) for reverse transcriptase (RT) activity and the ability to retrotranspose in HeLa cells, Of the 13 newly-isolated L1s, eight had RT activity and three were able to retrotranspose. L1.3 and L1.4 possessed RT activity and retrotransposed at remarkably high frequencies. These studies bring the number of characterized active human L1 elements to seven. Based on these and other data, we estimate that 30-60 active L1 elements reside in the average diploid genome.	UNIV PENN, SCH MED, DEPT GENET, PHILADELPHIA, PA 19104 USA; RUTGERS STATE UNIV, DEPT MOL BIOL & BIOCHEM, PISCATAWAY, NJ 08855 USA; US FDA, BETHESDA, MD 20892 USA	University of Pennsylvania; Rutgers State University New Brunswick; US Food & Drug Administration (FDA)			Naas, Thierry/O-3999-2018	Naas, Thierry/0000-0001-9937-9572				ADAMS JW, 1980, NUCLEIC ACIDS RES, V8, P6113, DOI 10.1093/nar/8.24.6113; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BRAITERMAN LT, 1994, GENE, V139, P19, DOI 10.1016/0378-1119(94)90518-5; BURTON FH, 1986, J MOL BIOL, V187, P291, DOI 10.1016/0022-2836(86)90235-4; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOMBROSKI BA, 1993, P NATL ACAD SCI USA, V90, P6513, DOI 10.1073/pnas.90.14.6513; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FREEMAN JD, 1994, BIOTECHNIQUES, V17, P47; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GRIMALDI G, 1984, EMBO J, V3, P1753, DOI 10.1002/j.1460-2075.1984.tb02042.x; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; HOLMES SE, 1992, J BIOL CHEM, V267, P19765; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; HWU HR, 1986, P NATL ACAD SCI USA, V83, P3875, DOI 10.1073/pnas.83.11.3875; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MIKI Y, 1992, CANCER RES, V52, P643; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASSAMAN DM, 1996, THESIS J HOPKINS U B; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; TEMIN HM, 1985, MOL BIOL EVOL, V2, P455; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; [No title captured]	39	361	368	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1997	16	1					37	43		10.1038/ng0597-37	http://dx.doi.org/10.1038/ng0597-37			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140393				2022-12-25	WOS:A1997WX02400020
J	Smith, DJ; Stevens, ME; Sudanagunta, SP; Bronson, RT; Makhinson, M; Watabe, AM; ODell, TJ; Fung, J; Weier, HUG; Cheng, JF; Rubin, EM				Smith, DJ; Stevens, ME; Sudanagunta, SP; Bronson, RT; Makhinson, M; Watabe, AM; ODell, TJ; Fung, J; Weier, HUG; Cheng, JF; Rubin, EM			Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down's syndrome	NATURE GENETICS			English	Article							LONG-TERM POTENTIATION; GAMMA-MUTANT MICE; CGMP-PHOSPHODIESTERASE; BETA-SUBUNIT; RD MOUSE; HIPPOCAMPAL; GENE; GENERATION; DISRUPTION; DEFICITS	Using Down syndrome as a model for complex trait analysis, we sought to identify loci from chromosome 21q22.2 which, when present in an extra dose, contribute to learning abnormalities. We generated low-copy-number transgenic mice, containing four different yeast artificial chromosomes (YACs) that together cover approximately 2 megabases (Mb) of contiguous DNA from 21q22.2. We subjected independent lines derived from each of these YAC transgenes to a series of behavioural and learning assays. Two of the four YACs caused defects in learning and memory in the transgenic animals, while the other two YACs had no effect. The most severe defects were caused by a 570-kb YAC; the interval responsible for these defects was narrowed to a 180-kb critical region as a consequence of YAC fragmentation, This region contains the human homologue of a Drosophila gene, minibrain, and strongly implicates it in learning defects associated with Down syndrome.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CTR HUMAN GENOME,BERKELEY,CA 94720; TUFTS UNIV,SCH MED,USDA,HUMAN NUTR RES CTR AGING,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111; JACKSON LAB,BAR HARBOR,ME 04609; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tufts University; United States Department of Agriculture (USDA); Tufts University; Jackson Laboratory; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Cheng, Jan-Fang/0000-0001-7315-7613	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BAUMAN ML, 1995, NEUROLOGY, V45, P1581, DOI 10.1212/WNL.45.8.1581; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CHENG JF, 1994, GENOMICS, V23, P75, DOI 10.1006/geno.1994.1461; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Epstein C J, 1993, Prog Clin Biol Res, V384, P1; FILIPPI M, 1990, GENOMICS, V7, P453, DOI 10.1016/0888-7543(90)90184-V; GUIREMA J, 1996, HUM MOL GENET, V5, P1305; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; JOHNSTON MV, 1995, NEUROPEDIATRICS, V26, P119, DOI 10.1055/s-2007-979740; Kentrup H, 1996, J BIOL CHEM, V271, P3488; KORENBERG JR, 1994, P NATL ACAD SCI USA, V91, P4997, DOI 10.1073/pnas.91.11.4997; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lupski JR, 1996, AM J HUM GENET, V58, P21; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Ohira M, 1997, GENOME RES, V7, P47, DOI 10.1101/gr.7.1.47; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; PETERSON A, 1994, HUM MOL GENET, V3, P1735, DOI 10.1093/hmg/3.10.1735; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; RAHMANI Z, 1989, P NATL ACAD SCI USA, V86, P5958, DOI 10.1073/pnas.86.15.5958; REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095-177; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SELEMON LD, 1995, ARCH GEN PSYCHIAT, V52, P805; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SIDMAN RL, 1965, J HERED, V56, P23, DOI 10.1093/oxfordjournals.jhered.a107364; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SMITH DJ, 1995, GENOMICS, V27, P425, DOI 10.1006/geno.1995.1073; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; TONIOLO D, 1988, P NATL ACAD SCI USA, V85, P851, DOI 10.1073/pnas.85.3.851; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; WEIER HU, 1994, METHOD MOL CELL BIOL, V4, P231; WEIER HUG, 1995, HUM MOL GENET, V4, P1903	46	248	254	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	MAY	1997	16	1					28	36		10.1038/ng0597-28	http://dx.doi.org/10.1038/ng0597-28			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140392				2022-12-25	WOS:A1997WX02400019
J	Chang, CC; Lee, WH; Moser, H; Valle, D; Gould, SJ				Chang, CC; Lee, WH; Moser, H; Valle, D; Gould, SJ			Isolation of the human PEX12 gene, mutated in group 3 of the peroxisome biogenesis disorders	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; TARGETING SIGNAL; PROTEIN; MUTATIONS; THIOLASE; MEMBER; IMPORT	The peroxisome biogenesis disorders (PBDs) are a group of genetically heterogeneous diseases lethal in early infancy(1). Although the clinical features of PBD patients may vary, cells from all PBD patients exhibit a defect in the import of one or more classes of peroxisomal matrix proteins. This cellular phenotype is shared by yeast per mutants, and human orthologues of yeast PEX genes have been shown to be defective in some groups of PBD patients(2,3). We identified a putative human orthologue of ScPEX12 by screening the database of expressed sequence tags for cDNAs capable of encoding a protein similar to yeast Pex12p(4). Although its sequence similarity to yeast Pex12 proteins was limited. PEX12 shared the same subcellular distribution as yeast Pex12p and localized to the peroxisome membrane. PEX12 expression restored peroxisomal protein import in fibroblasts from PBD patients of complement group 3 (CG3) and frameshift mutations in PEX12 were detected in two unrelated CG3 patients. These data demonstrate that mutations in PEX12 are responsible for CG3 of the PBD and that PEX12 plays an essential role in peroxisomal matrix protein import.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,KENNEDY KRIEGER INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ANAT & CELL BIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Chang, Chia-Che/0000-0003-3509-3713	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10981] Funding Source: Medline; NIDDK NIH HHS [DK45787] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MICHAUD J, 1992, GENOMICS, V13, P389, DOI 10.1016/0888-7543(92)90258-T; MOTLEY A, 1994, J CELL BIOL, V125, P735; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x	19	121	123	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	APR	1997	15	4					385	388		10.1038/ng0497-385	http://dx.doi.org/10.1038/ng0497-385			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WQ389	9090384				2022-12-25	WOS:A1997WQ38900017
J	Bohl, D; Naffakh, N; Heard, JM				Bohl, D; Naffakh, N; Heard, JM			Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts	NATURE MEDICINE			English	Article							INDUCIBLE GENE-EXPRESSION; TRANSGENIC MICE; RETROVIRUS VECTORS; MAMMALIAN-CELLS; RECOMBINANT RETROVIRUSES; REGULATED EXPRESSION; CHROMOSOMAL POSITION; PROMOTERS; ENHANCER; HYPOXIA	We investigated tetracycline regulation of gene expression in an experimental model relevant to gene therapy. Mouse primary myogenic cells were engineered for doxycycline-inducible and skeletal muscle-specific expression of the mouse erythropoietin (Epo) cDNA by using two retrovirus vectors. Gene expression increased 200 fold in response to both myogenic cell differentiation and doxycycline stimulation. After transplantation of transduced cells into mouse skeletal muscles, Epo secretion could be iteratively switched on and off over a five-month period, depending on the presence or the absence of doxycycline in the drinking water. We conclude that tetracycline regulation provides a suitable control system for adjusting the delivery of therapeutic proteins from engineered tissues over long periods of time.			Bohl, D (corresponding author), INST PASTEUR,LAB RETROVIRUS & TRANSFERT GENET,CNRS,URA 1157,28 RUE DR ROUX,F-75724 PARIS,FRANCE.		Bohl, Delphine/L-8709-2016	Bohl, Delphine/0000-0001-8262-5642; Naffakh, Nadia/0000-0002-0424-0277				BAUER TR, 1994, HUM GENE THER, V5, P709, DOI 10.1089/hum.1994.5.6-709; BECK I, 1993, BLOOD, V82, P704; CONE RD, 1987, MOL CELL BIOL, V7, P887, DOI 10.1128/MCB.7.2.887; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; EMERMAN M, 1986, MOL CELL BIOL, V6, P792, DOI 10.1128/MCB.6.3.792; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; GUILD BC, 1988, J VIROL, V62, P3795, DOI 10.1128/JVI.62.10.3795-3801.1988; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; Hwang JJ, 1996, J VIROL, V70, P8138, DOI 10.1128/JVI.70.11.8138-8141.1996; Iida A, 1996, J VIROL, V70, P6054, DOI 10.1128/JVI.70.9.6054-6059.1996; Jacque JM, 1996, J VIROL, V70, P2930; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; JENSEN JD, 1994, EUR J CLIN PHARMACOL, V46, P333; KLEIN J, 1975, BIOL MOUSE HISTOCOMP, P329; LI ZL, 1991, J BIOL CHEM, V266, P6562; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MADAN A, 1995, BLOOD, V85, P2735; Metcalf D, 1988, MOL CONTROL BLOOD CE; NAFFAKH N, 1995, P NATL ACAD SCI USA, V92, P3194, DOI 10.1073/pnas.92.8.3194; Naffakh N, 1996, HUM GENE THER, V7, P11, DOI 10.1089/hum.1996.7.1-11; PASSMAN RS, 1994, J CLIN INVEST, V94, P2421, DOI 10.1172/JCI117609; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; SAKAGUCHI M, 1987, BIOCHEM BIOPH RES CO, V146, P7, DOI 10.1016/0006-291X(87)90682-6; SALMONSON T, 1990, BRIT J PHARMACOL, V29, P703; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SORIANO P, 1986, SCIENCE, V234, P1409, DOI 10.1126/science.3024318; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; VILE R, 1994, GENE THER, V1, P307; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YEE JK, 1987, P NATL ACAD SCI USA, V84, P5199; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194	42	148	157	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					299	305		10.1038/nm0397-299	http://dx.doi.org/10.1038/nm0397-299			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055857				2022-12-25	WOS:A1997WL30500031
J	Michael, NL; Chang, G; Louie, LG; Mascola, JR; Dondero, D; Birx, DL; Sheppard, HW				Michael, NL; Chang, G; Louie, LG; Mascola, JR; Dondero, D; Birx, DL; Sheppard, HW			The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION	Delta ellular entry of human immunodeficiency virus type 1 (HIV-1) requires binding to both CD4 (ref. 1, 2) and to one of the chemokine receptors recently discovered to act as coreceptors(3-11). Viruses that infect T-cell lines to form syncytia (syncytium-inducing, SI) are frequently found in late-stage HIV disease and utilize the chemokine receptor CXCR-4; macrophage-tropic viruses are non-syncytium-inducing (NSI), found throughout disease and utilize CCR-5 (ref. 3-11). We postulated that CCR-5 gene defects might reduce infection risk in seronegative subjects and prolong AIDS-free survival in seropositive subjects with NSI but not SI virus. Homozygous (Delta ccr5/Delta ccr5) and heterozygous (CCR5/Delta ccr5) CCR-5 deletions (Delta ccr5)(12,13) were found in 7 (2.7%) and 51 (19.5%), respectively, of 261 seronegative subjects from the San Francisco Men's Health Study. CCR-5/Delta ccr5 genotype was identified in 33 of 172 (19.2%) nonprogressors and 25 of 234 (10.7%) progressors from the seropositive arm of this cohort. The Delta ccr5 allele conferred a significant protective effect against HIV-1 infection (P = 0.001) and a survival advantage against disease progression (P = 0.02). Although both progressing and nonprogressing CCR5/Delta ccr5 subjects were identified, a distinct survival advantage was shown for those with NSI virus (P < 0.0001). Thus, the protective effect of Delta ccr5 against disease progression is lost when the infecting virus uses CXCR-4 as a coreceptor.	HENRY M JAKCSON FDN,ROCKVILLE,MD 20850; UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720; USN,MED RES INST,DEPT INFECT DIS,BETHESDA,MD 20889; CALIF DEPT HLTH SERV,BERKELEY,CA 94704	University of California System; University of California Berkeley; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; California Department of Health Care Services	Michael, NL (corresponding author), WALTER REED ARMY INST RES,DIV RETROVIROL,ROCKVILLE,MD 20850, USA.		Mascola, John/AAI-7193-2021		NIAID NIH HHS [R01-AI-36661, R01-AI-34783, N01-AI-82515] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036661, R01AI034783, N01AI082515] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; SAMPSON M, 1996, NATURE, V382, P722; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0	22	416	434	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					338	340		10.1038/nm0397-338	http://dx.doi.org/10.1038/nm0397-338			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055864				2022-12-25	WOS:A1997WL30500038
J	Goel, A; Kumar, G; Payne, GF; Dube, SK				Goel, A; Kumar, G; Payne, GF; Dube, SK			Plant cell biodegradation of a xenobiotic nitrate ester, nitroglycerin	NATURE BIOTECHNOLOGY			English	Article						phytoremediation; nitroglycerin; xenobiotic; nitrate ester; Beta vulgaris	GLUTATHIONE-S-TRANSFERASE; NITRIC-OXIDE FORMATION; GLYCERYL TRINITRATE; PHANEROCHAETE-CHRYSOSPORIUM; ORGANIC-CHEMICALS; NITROAROMATIC COMPOUNDS; METABOLIC-FATE; INVOLVEMENT; SYSTEMS; DEGRADATION	The ability of plants to metabolize the xenobiotic nitrate ester, glycerol trinitrate (GTN, nitroglycerin), was examined using cultured plant cells and plant cell extracts. Intact cells rapidly degrade GTN with the initial formation of glycerol dinitrate (GDN) and the later formation of glycerol mononitrate (GMN). A material balance analysis of these intermediates indicates little, if any, formation of reduced, conjugated or cell-bound carbonaceous metabolites. Cell extracts were shown to be capable of degrading GTN with the simultaneous formation of GDN in stoichiometric amounts. The intermediates observed, and the timing of their appearance, are consistent with a sequential denitration pathway that has been reported for the microbial degradation of nitrate esters. The degradative activities of plant cells are only tenfold less than those reported for bacterial GTN degradation. These results suggest that plants may serve a direct degradative function for the phytoremediation of sites contaminated by organic nitrate esters.	UNIV MARYLAND BALTIMORE CTY,DEPT CHEM & BIOCHEM ENGN,BALTIMORE,MD 21228; UNIV MARYLAND,CTR AGR BIOTECHNOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland College Park								ANDERSON TA, 1993, ENVIRON SCI TECHNOL, V27, P2630, DOI 10.1021/es00049a001; BELLIN CA, 1990, J ENVIRON QUAL, V19, P598, DOI 10.2134/jeq1990.00472425001900030040x; Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Bokern M, 1996, J AGR FOOD CHEM, V44, P1123, DOI 10.1021/jf950376+; BRIGGS GG, 1982, PESTIC SCI, V13, P495, DOI 10.1002/ps.2780130506; Cunningham SD, 1996, PLANT PHYSIOL, V110, P715, DOI 10.1104/pp.110.3.715; CUNNINGHAM SD, 1993, IN VITRO CELL DEV-PL, V29P, P207, DOI 10.1007/BF02632036; DUCROCQ C, 1989, FEMS MICROBIOL LETT, V65, P219, DOI 10.1111/j.1574-6968.1989.tb03625.x; DUCROCQ C, 1990, BIOTECHNOL APPL BIOC, V12, P325; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; HABIG WH, 1975, BIOCHEM BIOPH RES CO, V64, P501, DOI 10.1016/0006-291X(75)90349-6; HALL DR, 1992, TETRAHEDRON LETT, V33, P4811, DOI 10.1016/S0040-4039(00)61292-3; HARMS H, 1977, Z NATURFORSCH C, V32, P321; HARMS H, 1986, PLANT SCI, V45, P157, DOI 10.1016/0168-9452(86)90135-4; HARMS HH, 1992, PESTIC SCI, V35, P277, DOI 10.1002/ps.2780350313; Hegde RS, 1996, CHEMOSPHERE, V32, P2471, DOI 10.1016/0045-6535(96)00144-0; HILL KE, 1992, BIOCHEM PHARMACOL, V43, P561, DOI 10.1016/0006-2952(92)90579-8; HUGHES JB, IN PRESS ENV SCI TEC; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; INGERSOL LJC, 1996, PLANT CELL REP, V15, P836; KAPLAN DL, 1982, APPL ENVIRON MICROB, V43, P144, DOI 10.1128/AEM.43.1.144-150.1982; KOMOSSA D, 1992, PESTIC BIOCHEM PHYS, V43, P85, DOI 10.1016/0048-3575(92)90022-R; LANGEBARTELS C, 1985, ECOTOX ENVIRON SAFE, V10, P268, DOI 10.1016/0147-6513(85)90073-9; LAU DTW, 1990, DRUG METAB DISPOS, V18, P292; LEE I, 1992, PLANT CELL REP, V11, P97, DOI 10.1007/BF00235262; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; MARVINSIKKEMA FD, 1994, APPL MICROBIOL BIOT, V42, P499; MENG M, 1995, APPL ENVIRON MICROB, V61, P2548, DOI 10.1128/AEM.61.7.2548-2553.1995; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAIR DR, 1993, J ENVIRON ENG, V119, P842, DOI 10.1061/(ASCE)0733-9372(1993)119:5(842); OCONNOR GA, 1990, J ENVIRON QUAL, V19, P113, DOI 10.2134/jeq1990.00472425001900010016x; PATERSON S, 1990, CHEMOSPHERE, V21, P297, DOI 10.1016/0045-6535(90)90002-B; PESARI H, 1993, BIOTECHNOL BIOENG, V41, P79, DOI 10.1002/bit.260410111; Ramos JL, 1996, NAT BIOTECHNOL, V14, P320, DOI 10.1038/nbt0396-320; RYAN JA, 1988, CHEMOSPHERE, V17, P2299, DOI 10.1016/0045-6535(88)90142-7; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; SCHMIDT B, 1994, PESTIC SCI, V40, P231, DOI 10.1002/ps.2780400310; Schnoor J.L., 1995, ENV SCI TECH, V29, P318; SERVENT D, 1992, BIOTECHNOL APPL BIOC, V15, P257; SERVENT D, 1989, BIOCHEM BIOPH RES CO, V163, P1210, DOI 10.1016/0006-291X(89)91106-6; SERVENT D, 1991, BIOCHIM BIOPHYS ACTA, V1074, P320, DOI 10.1016/0304-4165(91)90170-L; SHIMP JF, 1993, CRIT REV ENV SCI TEC, V23, P41, DOI 10.1080/10643389309388441; SMETS BF, 1995, J ENERG MATS, V13, P385; SPAIN JC, 1995, ANNU REV MICROBIOL, V49, P523, DOI 10.1146/annurev.mi.49.100195.002515; Sun WQ, 1996, APPL MICROBIOL BIOT, V45, P525; TOPP E, 1986, ECOTOX ENVIRON SAFE, V11, P219, DOI 10.1016/0147-6513(86)90066-7; WALTON B T, 1992, Current Opinion in Biotechnology, V3, P267, DOI 10.1016/0958-1669(92)90102-O; WENDT TM, 1978, APPL ENVIRON MICROB, V36, P693, DOI 10.1128/AEM.36.5.693-699.1978; WETZEL A, 1994, ARCH BIOCHEM BIOPHYS, V314, P323, DOI 10.1006/abbi.1994.1449; White GF, 1996, APPL ENVIRON MICROB, V62, P637, DOI 10.1128/AEM.62.2.637-642.1996; WHITE GF, 1993, J GEN MICROBIOL, V139, P1947, DOI 10.1099/00221287-139-9-1947; WILKEN A, 1995, ENVIRON TOXICOL CHEM, V14, P2017, DOI [10.1897/1552-8618(1995)14[2017:MODPCI]2.0.CO;2, 10.1002/etc.5620141203]; YEATES RA, 1989, BIOCHEM PHARMACOL, V38, P1749, DOI 10.1016/0006-2952(89)90408-5	53	45	52	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					174	177		10.1038/nbt0297-174	http://dx.doi.org/10.1038/nbt0297-174			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035145				2022-12-25	WOS:A1997WE99800026
J	Brooks, AI; Muhkerjee, B; Panahian, N; CorySlechta, D; Federoff, HJ				Brooks, AI; Muhkerjee, B; Panahian, N; CorySlechta, D; Federoff, HJ			Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of cre recombinase	NATURE BIOTECHNOLOGY			English	Article						NGF; cre/loxP; gene transfer; herpes virus	GENE-TRANSFER; BETA-GALACTOSIDASE; VECTOR; PROMOTER; NEURONS; REGION; RECEPTOR; PROTEIN; TYPE-1; BRAIN	Focal molecular genetic alteration of the intact mammalian brain will be required to elucidate gene product function in cells comprising synaptic networks. To this end, a somatic mosaic approach has been developed for the mouse whereby a dormant germline transgene is activated by the somatic delivery and expression of cre recombinase. Transgenic mice harboring a recombinational substrate, the germline-transmitted nerve growth factor excision activation transgene (NGF-XAT) were generated. Somatic delivery of virus vectors expressing cre recombinase into the brain of NGF-XAT mice resulted in regional recombination and activation of the transgene as demonstrated at the DNA level by PCR and at the protein level by both immunocytochemistry and ELISA. This approach has been used to evaluate a behavioral correlate of unilateral NGF mosaicism within the dorsal hippocampal formation. NGF-XAT mice activated by expression of cre recombinase manifest increased locomotor activity compared with NGF-XAT mice transduced by a control virus expressing Escherichia coli beta-galactosidase. These data indicate that focally increased expression of NGF in one part of a synaptic network can elicit changes in behavior presumably by altering the overall function of NGF-responsive neural circuitry. This approach should have broad application to other gene products and promises to provide the unprecedented ability to create and study discrete genetic modifications in the context of an intact adult mammal.	UNIV ROCHESTER, MED CTR, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT NEUROL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT MED, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester			Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031300] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31300] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ashburner M., 1989, DROSOPHILA LAB HDB; BATTLEMAN DS, 1993, J NEUROSCI, V13, P941; BERGOLD PJ, 1993, P NATL ACAD SCI USA, V90, P6165, DOI 10.1073/pnas.90.13.6165; BYRNES AP, 1995, NEUROSCIENCE, V66, P1015, DOI 10.1016/0306-4522(95)00068-T; CONNER JM, 1992, J COMP NEUROL, V319, P454, DOI 10.1002/cne.903190310; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; FEDEROFF HJ, 1992, P NATL ACAD SCI USA, V89, P1636, DOI 10.1073/pnas.89.5.1636; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GESCHWIND M, 1994, PROVIDING PHARM ACCE, P462; Geschwind MD, 1996, HUM GENE THER, V7, P173, DOI 10.1089/hum.1996.7.2-173; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Jin BK, 1996, HUM GENE THER, V7, P2015, DOI 10.1089/hum.1996.7.16-2015; JOHNSON PA, 1992, J VIROL, V66, P2952, DOI 10.1128/JVI.66.5.2952-2965.1992; KAPLITT MG, 1994, P NATL ACAD SCI USA, V91, P8979, DOI 10.1073/pnas.91.19.8979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PALMER TD, 1993, NUCLEIC ACIDS RES, V21, P3451, DOI 10.1093/nar/21.15.3451; PATERSON T, 1990, J GEN VIROL, V71, P1775, DOI 10.1099/0022-1317-71-8-1775; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; TANTRAVAHI J, 1993, MOL CELL BIOL, V13, P578, DOI 10.1128/MCB.13.1.578; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; XU H, 1994, DEV BIOL, V163, P152, DOI 10.1006/dbio.1994.1131; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995	23	31	31	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					57	62		10.1038/nbt0197-57	http://dx.doi.org/10.1038/nbt0197-57			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035107				2022-12-25	WOS:A1997WA72900024
J	Lieschke, GJ; Rao, PK; Gately, MK; Mulligan, RC				Lieschke, GJ; Rao, PK; Gately, MK; Mulligan, RC			Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo	NATURE BIOTECHNOLOGY			English	Article						interleukin; cytokine; fusion protein; retrovirus; tumor immunotherapy	IL-12 P40 HOMODIMER; MOUSE INTERLEUKIN-12; CELL-SURFACE; IN-VIVO; T-CELLS; FIBROBLASTS; TUMORS; GENES; RETROVIRUSES; COEXPRESSION	Interleukin-12 (IL-12) is unique amongst cytokines in being a disulfide-linked heterodimer of two separately encoded subunits (p35 and p40). We expressed single chain IL-12 proteins from retroviral constructs in which the two IL-12 subunits were linked by a 6-15 amino acid polypeptide linker, with deletion of the 22 amino acid leader sequence of the,trailing subunit. The murine fusion protein IL-12.p40.L.Delta p35 containing a (Gly(4)Ser)(3) linker was stably expressed, bioactive in vitro, and had an apparent specific activity comparable to that of native and recombinant IL-12. Western blotting confirmed that murine IL-12.p40.L.Delta p35 retained the linking polypeptide sequences. The analogous human IL-12.p40.L.Delta p35 fusion protein containing a Gly(6)Ser linker was bioactive with an apparent specific activity comparable to recombinant human IL-12. In a preexisting CMS-5 tumor model, CMS-5 cells secreting either native or fusion protein forms of IL-12 prolonged survival and led to complete tumor regression.	HOFFMANN LA ROCHE INC,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Roche Holding; Massachusetts Institute of Technology (MIT); Whitehead Institute				Lieschke, Graham/0000-0003-0325-798X	NCI NIH HHS [CA-63399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bramson J, 1996, HUM GENE THER, V7, P333, DOI 10.1089/hum.1996.7.3-333; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; Bueler H, 1996, MOL MED, V2, P545, DOI 10.1007/BF03401639; CHEN TT, 1995, J IMMUNOL, V154, P3105; Colombo MP, 1996, CANCER RES, V56, P2531; CURTIS BM, 1991, P NATL ACAD SCI USA, V88, P5809, DOI 10.1073/pnas.88.13.5809; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FIDLER IJ, 1975, CANCER RES, V35, P218; FREBOURG T, 1994, CANCER RES, V54, P878; GATELY MK, 1995, CURRENT PROTOCOLS IM, V1; GATELY MK, 1994, INT IMMUNOL, V6, P1257; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GILLESSEN S, 1995, EUR J IMMUNOL, V25, P200, DOI 10.1002/eji.1830250133; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JENKS S, 1966, J NATL CANCER I, V88, P576; KAI K, 1986, VIROLOGY, V150, P509, DOI 10.1016/0042-6822(86)90315-6; LING P, 1995, J IMMUNOL, V154, P116; MARTINOTTI A, 1995, EUR J IMMUNOL, V25, P137, DOI 10.1002/eji.1830250124; MATTNER F, 1993, EUR J IMMUNOL, V23, P2202, DOI 10.1002/eji.1830230923; MILLER LL, 1996, P AM SOC CLIN ONCOL, V14, P1718; NASTALA CL, 1994, J IMMUNOL, V153, P1679; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rakhmilevich AL, 1996, P NATL ACAD SCI USA, V93, P6291, DOI 10.1073/pnas.93.13.6291; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P7633; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; TAHARA H, 1995, J IMMUNOL, V154, P6466; TAHARA H, 1994, CANCER RES, V54, P182; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; Wigginton JM, 1996, JNCI-J NATL CANCER I, V88, P38, DOI 10.1093/jnci/88.1.38; Wilkinson VL, 1996, J IMMUNOL METHODS, V189, P15, DOI 10.1016/0022-1759(95)00223-5; WOLF SF, 1991, J IMMUNOL, V146, P3074; WU CY, 1994, J IMMUNOL, V152, P1141; ZITVOGEL L, 1995, J IMMUNOL, V155, P1393; ZITVOGEL L, 1994, HUM GENE THER, V5, P1493, DOI 10.1089/hum.1994.5.12-1493; ZOU JJ, 1995, J BIOL CHEM, V270, P5864, DOI 10.1074/jbc.270.11.5864	40	109	142	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					35	40		10.1038/nbt0197-35	http://dx.doi.org/10.1038/nbt0197-35			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035103				2022-12-25	WOS:A1997WA72900020
J	Simon, MP; Pedeutour, F; Sirvent, N; Grosgeorge, J; Minoletti, F; Coindre, JM; TerrierLacombe, MJ; Mandahl, N; Craver, RD; Blin, N; Sozzi, G; TurcCarel, C; OBrien, KP; Kedra, D; Fransson, I; Guilbaud, C; Dumanski, JP				Simon, MP; Pedeutour, F; Sirvent, N; Grosgeorge, J; Minoletti, F; Coindre, JM; TerrierLacombe, MJ; Mandahl, N; Craver, RD; Blin, N; Sozzi, G; TurcCarel, C; OBrien, KP; Kedra, D; Fransson, I; Guilbaud, C; Dumanski, JP			Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma	NATURE GENETICS			English	Article							SIMIAN SARCOMA-VIRUS; SIS; CHROMOSOME-17; TRANSLOCATION; EXPRESSION; SEQUENCES; CONTIG; REGION; LOCUS; RANGE	Dermatofibrosarcoma protuberans (DP), an infiltrative skin tumour of intermediate malignancy(1). presents specific features such as reciprocal translocations t(17;22)(q22;q13) and supernumerary ring chromosomes derived from the t(17;22)(2,3). In this report, the breakpoints from translocations and rings in DP and its juvenile form. giant cell fibroblastoma (GCF)(4.5), were characterised on the genomic and RNA level. These rearrangements fuse the platelet-derived growth factor B-chain (PDGFB, c-sis proto-oncogene) and the collagen type I alpha 1 (COL1A1) genes. PDGFB has transforming activity and is a potent mitogen for a number of cell types. but its role in oncogenic processes is not fully understood(6,7). COL1A1 is a major constituent of the connective tissue matrix(8). Neither PDGFB nor COL1A1 have so far been implicated in any tumour translocations. These gene fusions delete exon 1 of PDGFB, and release this growth factor from its normal regulation.	FAC MED NICE,CNRS URA 1462,LAB GENET CHROMOSOM TUMEURS,F-06107 NICE 02,FRANCE; IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,I-20133 MILAN,ITALY; INST BERGONIE,ANAT PATHOL LAB,F-33076 BORDEAUX,FRANCE; INST GUSTAVE ROUSSY,LAB HISTOPATHOL A,F-94905 VILLEJUIF,FRANCE; UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN; NEW ORLEANS CHILDRENS HOSP,DEPT PATHOL,NEW ORLEANS,LA 70118; UNIV TUBINGEN,ABT MOL GENET,D-72074 TUBINGEN,GERMANY; KAROLINSKA HOSP,CLIN GENET UNIT,DEPT MOL MED,S-17176 STOCKHOLM,SWEDEN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Fondazione IRCCS Istituto Nazionale Tumori Milan; UNICANCER; Institut Bergonie; UNICANCER; Gustave Roussy; Lund University; Skane University Hospital; Children's Hospital of New Orleans; Eberhard Karls University of Tubingen; Karolinska Institutet; Karolinska University Hospital			Kedra, Darek/H-7641-2012; SIMON, Marie-Pierre/B-8017-2012; sozzi, gabriella/G-8259-2011	Kedra, Darek/0000-0002-9723-4465; sozzi, gabriella/0000-0001-9360-6914; Dumanski, Jan Piotr/0000-0002-1489-1452				BLIN N, 1993, CANCER GENET CYTOGEN, V70, P108, DOI 10.1016/0165-4608(93)90177-N; CHU ML, 1993, CONNECTIVE TISSUE IT; COLLINS JE, 1995, NATURE, V377, P367; CRAVER RD, 1995, CANCER GENET CYTOGEN, V80, P20, DOI 10.1016/0165-4608(94)00152-2; DalCin P, 1996, GENE CHROMOSOME CANC, V15, P73; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; JEFFREYS AJ, 1984, NUCLEIC ACIDS RES, V12, P3235, DOI 10.1093/nar/12.7.3235; Kedra D, 1996, HUM MOL GENET, V5, P625, DOI 10.1093/hmg/5.5.625; KIKUCHI K, 1993, BIOCHEM BIOPH RES CO, V196, P409, DOI 10.1006/bbrc.1993.2264; MINOLETTI F, 1995, GENE CHROMOSOME CANC, V13, P62, DOI 10.1002/gcc.2870130110; PDEUTOUR F, 1996, CELL GENET, V72, P171; PEDEUTOUR F, 1995, CANCER RES, V55, P2400; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P5007, DOI 10.1093/nar/13.14.5007; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROYCE PM, 1993, CONNECTIVE TISSUE IT, P1; Sambrook J., 2002, MOL CLONING LAB MANU; SMITS A, 1992, AM J PATHOL, V140, P639; Soenen V, 1996, GENE CHROMOSOME CANC, V15, P191, DOI 10.1002/(SICI)1098-2264(199603)15:3<191::AID-GCC9>3.0.CO;2-Y; Staden R, 1994, Methods Mol Biol, V25, P9; VANDENOUWELAND AMW, 1985, BIOCHIM BIOPHYS ACTA, V825, P140, DOI 10.1016/0167-4781(85)90097-1; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Westermark B, 1993, CYTOKINES, V5, P1; XIE YG, 1993, HUM MOL GENET, V2, P1361; YAN XQ, 1994, ONCOGENE, V9, P163	30	367	387	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					95	98		10.1038/ng0197-95	http://dx.doi.org/10.1038/ng0197-95			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988177				2022-12-25	WOS:A1997WA37300029
J	Albini, A; Soldi, R; Giunciuglio, D; Giraudo, E; Benelli, R; Primo, L; Noonan, D; Salio, M; Camussi, G; Rockl, W; Bussolino, F				Albini, A; Soldi, R; Giunciuglio, D; Giraudo, E; Benelli, R; Primo, L; Noonan, D; Salio, M; Camussi, G; Rockl, W; Bussolino, F			The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells	NATURE MEDICINE			English	Article							FIBROBLAST GROWTH-FACTOR; KAPOSIS-SARCOMA; TRANSGENIC MICE; VIRUS TYPE-1; IN-VIVO; GENE; EXPRESSION; LESIONS	The HIV-1 Tat protein transactivates HIV, viral and some host cell genes(1). Tat can be released by infected cells(2) and acts extracellularly in the microenvironment, regulating functions of immunocompetent and mesenchymal cells(3,4). One of the most striking effects of Tat is the induction of a functional program in vascular cells related to angiogenesis and inflammation (migration, proliferation and expression of plasminogen activator inhibitor-1 and E selectin(5-7)). Tat induces growth of Kaposi's sarcoma (KS) spindle cells(8) and is angiogenic in vivo(7,9) and in transgenic mice(10-12). We previously reported that Tat is a direct angiogenic factor(7) and noted the Tat arginine- and lysine-rich sequence is similar to that of other potent angiogenic growth factors, such as vascular endothelial growth factor-A (VEGF-A). It is possible that Tat mimics one of these factors by interacting with its growth factor tyrosine kinase receptor. Here we demonstrate that Tat specifically binds and activates the Flk-1/kinase insert domain receptor (Flk-1/KDR), a VEGF-A tyrosine kinase receptor (for review see ref. 13), and that Tat-induced angiogenesis is blocked by agents blocking the Flk-1/KDR receptor. Endothelial cell stimulation by Tat occurs in the absence of activation of FLT-1, another VEGF-A tyrosine kinase receptor.	UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,I-10126 TURIN,ITALY; IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV PAVIA,FAC MED 2,CATTEDRA NEFROL,I-21100 VARESE,ITALY; GESELL BIOTECHNOL FORSCH MBH,D-38124 BRAUNSCHWEIG,GERMANY	University of Turin; University of Genoa; IRCCS AOU San Martino IST; University of Pavia; Gesellschaft fur Biotechnologische Forschung mbH			Bussolino, Federico/AES-3951-2022; Giraudo, Enrico/K-3192-2016; Camussi, Giovanni/J-7624-2016; Giraudo, Enrico/K-6441-2019; Benelli, Roberto/AAF-3143-2019; Noonan, Douglas M/A-8620-2010; Bussolino, Federico/K-2500-2016	Giraudo, Enrico/0000-0003-4128-4786; Camussi, Giovanni/0000-0003-2795-232X; Giraudo, Enrico/0000-0003-4128-4786; Benelli, Roberto/0000-0002-9769-0954; Noonan, Douglas M/0000-0001-8058-0719; Salio, Mariolina/0000-0002-4821-3801; Bussolino, Federico/0000-0002-5348-1341; Albini, Adriana/0000-0002-9624-5103; PRIMO, Luca/0000-0002-1294-0441				ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; Albini A, 1996, ONCOGENE, V12, P289; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARNETT SW, 1994, SCIENCE, V266, P642, DOI 10.1126/science.7939718; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7; KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0	23	325	332	0	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1371	1375		10.1038/nm1296-1371	http://dx.doi.org/10.1038/nm1296-1371			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946838				2022-12-25	WOS:A1996VW51500045
J	Angrist, M; Bolk, S; Halushka, M; Lapchak, PA; Chakravarti, A				Angrist, M; Bolk, S; Halushka, M; Lapchak, PA; Chakravarti, A			Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a hirschsprung disease patient	NATURE GENETICS			English	Article							TYROSINE KINASE; SURVIVAL FACTOR; RECEPTOR GENE; MOTOR-NEURONS; PROTOONCOGENE; MAPS; CHROMOSOME-10; MOTONEURONS		CASE WESTERN RESERVE UNIV,DEPT GENET,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CTR HUMAN GENET,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106; AMGEN INC,DEPT NEUROSCI,THOUSAND OAKS,CA 91320	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Amgen			Lapchak, Paul/P-1845-2019	Lapchak, Paul/0000-0003-4413-7554; Halushka, Marc/0000-0002-7112-7389	NICHD NIH HHS [HD28088] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028088] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028088] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BADNER JA, 1990, AM J HUM GENET, V46, P568; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; BERMINGHAM N, 1995, HUM GENET, V96, P671, DOI 10.1007/BF00210297; BODIAN M, 1963, ANN HUM GENET, V26, P261, DOI 10.1111/j.1469-1809.1963.tb01983.x; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DRESSLER GR, 1994, CURR BIOL, V4, P354, DOI 10.1016/S0960-9822(00)00078-6; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; EZOE K, 1995, AM J HUM GENET, V56, P58; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; HOLSCHNEIDER AM, 1982, HIRSCHSPRUNGS DIS; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAPCHAK PA, IN PRESS REV NEUROSC; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHINDELHAUER D, 1995, GENOMICS, V28, P605, DOI 10.1006/geno.1995.1202; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; Yin Luo, 1994, European Journal of Human Genetics, V2, P272; ZURN AD, 1994, NEUROREPORT, V6, P113, DOI 10.1097/00001756-199412300-00030	43	213	219	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					341	344		10.1038/ng1196-341	http://dx.doi.org/10.1038/ng1196-341			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896568				2022-12-25	WOS:A1996VQ14600033
J	Apostolou, S; Whitmore, SA; Crawford, J; Lennon, G; Sutherland, GR; Callen, DF; Ianzano, L; Savino, M; DApolito, M; Notarangelo, A; Memeo, E; Piemontese, MR; Zelante, L; Savoia, A; Gibson, RA; Tipping, AJ; Morgan, NV; Hassock, S; Jansen, S; deRavel, TJ; VanBerkel, C; Pronk, JC; Easton, DF; Mathew, CG; Levran, O; Verlander, PC; Batish, SD; Erlich, T; Auerbach, AD; CletonJansen, AM; Moerland, EW; Cornelisse, CJ; Doggett, NA; Deaven, LL; Moyzis, RK				Apostolou, S; Whitmore, SA; Crawford, J; Lennon, G; Sutherland, GR; Callen, DF; Ianzano, L; Savino, M; DApolito, M; Notarangelo, A; Memeo, E; Piemontese, MR; Zelante, L; Savoia, A; Gibson, RA; Tipping, AJ; Morgan, NV; Hassock, S; Jansen, S; deRavel, TJ; VanBerkel, C; Pronk, JC; Easton, DF; Mathew, CG; Levran, O; Verlander, PC; Batish, SD; Erlich, T; Auerbach, AD; CletonJansen, AM; Moerland, EW; Cornelisse, CJ; Doggett, NA; Deaven, LL; Moyzis, RK			Positional cloning of the Fanconi anaemia group A gene	NATURE GENETICS			English	Article							EXON AMPLIFICATION; PHYSICAL MAP; ANEMIA; COMPLEMENTATION; LOCALIZATION; STRATEGIES; MUTATION; FACC		UMDS, GUYS HOSP, DIV MED & MOL GENET, LONDON SE1 9RT, ENGLAND; ADELAIDE WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOL GENET, ADELAIDE, SA 5006, AUSTRALIA; LAWRENCE LIVERMORE NATL LAB, CTR HUMAN GENOME, LIVERMORE, CA 94550 USA; UNIV ORANGE FREE STATE, DEPT HUMAN GENET, ZA-9301 BLOEMFONTEIN, SOUTH AFRICA; UNIV WITWATERSRAND, S AFRICAN INST MED RES, DEPT HUMAN GENET, ZA-2050 WITWATERSRAND, SOUTH AFRICA; FREE UNIV AMSTERDAM, DEPT HUMAN GENET, AMSTERDAM, NETHERLANDS; UNIV CAMBRIDGE, INST PUBL HLTH, GENET EPIDEMIOL UNIT, CAMBRIDGE CB2 1TN, ENGLAND; ROCKEFELLER UNIV, LAB HUMAN GENET & HEMATOL, NEW YORK, NY 10021 USA; LEIDEN UNIV, DEPT PATHOL, LEIDEN, NETHERLANDS; LOS ALAMOS NATL LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA; OSPED CASA SOLLIEVO SOFFERENZA, I-71013 SAN GIOVANNI ROTONDO, FOGGIA, ITALY	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Womens & Childrens Hospital Australia; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of the Free State; University of Witwatersrand; Vrije Universiteit Amsterdam; University of Cambridge; Rockefeller University; Leiden University; Leiden University - Excl LUMC; United States Department of Energy (DOE); Los Alamos National Laboratory; IRCCS Casa Sollievo Della Sofferenza			Savoia, Anna/B-6463-2014; Sutherland, Grant Robert/D-2606-2012; Savoia, Anna/AIC-4560-2022; Crawford, Joanna/F-9135-2013; Callen, David F/G-1975-2012; d'Apolito, Maria/G-5793-2012; d'Apolito, Maria/AAQ-9290-2021; Levran, Orna/H-2772-2019; Lennon, Greg/T-4717-2019; Morgan, Neil V/A-5475-2009	Savoia, Anna/0000-0002-2407-2696; Savoia, Anna/0000-0002-2407-2696; Crawford, Joanna/0000-0003-0786-6889; Morgan, Neil V/0000-0001-6433-5692; Gibson, Rachel/0000-0002-1338-1290; Notarangelo, Angelantonio/0000-0002-1540-8530	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032987, R37HL032987] Funding Source: NIH RePORTER; Fondazione Telethon Funding Source: Custom; NHLBI NIH HHS [HL32987] Funding Source: Medline; Telethon [E.0364] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Fondazione Telethon(Fondazione Telethon); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon)		Altherr MR, 1996, CYTOGENET CELL GENET, V72, P271; AUERBACH AD, 1993, EXP HEMATOL, V21, P731; BUCHWALD M, 1995, NAT GENET, V11, P228, DOI 10.1038/ng1195-228; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BUTTURINI A, 1994, BLOOD, V84, P1650, DOI 10.1182/blood.V84.5.1650.bloodjournal8451650; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOGGETT NA, 1995, NATURE, V377, P335; Gibson RA, 1996, HUM MUTAT, V8, P140, DOI 10.1002/(SICI)1098-1004(1996)8:2<140::AID-HUMU6>3.0.CO;2-F; GIBSON RA, 1993, HUM MOL GENET, V2, P797, DOI 10.1093/hmg/2.6.797; Gschwend M, 1996, AM J HUM GENET, V59, P377; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIU JM, 1994, BLOOD, V84, P3995, DOI 10.1182/blood.V84.12.3995.bloodjournal84123995; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PRONK JC, 1995, NAT GENET, V11, P338, DOI 10.1038/ng1195-338; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Savoia A, 1996, HUM GENET, V97, P599; SIDERAS P, 1992, J IMMUNOL, V149, P244; STALLINGS RL, 1992, GENOMICS, V13, P1031, DOI 10.1016/0888-7543(92)90016-L; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; VERLANDER PC, 1994, AM J HUM GENET, V54, P595	29	245	246	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1996	14	3					324	328		10.1038/ng1196-324	http://dx.doi.org/10.1038/ng1196-324			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896564				2022-12-25	WOS:A1996VQ14600029
J	Liyanage, M; Coleman, A; duManoir, S; Veldman, T; McCormack, S; Dickson, RB; Barlow, C; WynshawBoris, A; Janz, S; Wienberg, J; FergusonSmith, MA; Schrock, E; Ried, T				Liyanage, M; Coleman, A; duManoir, S; Veldman, T; McCormack, S; Dickson, RB; Barlow, C; WynshawBoris, A; Janz, S; Wienberg, J; FergusonSmith, MA; Schrock, E; Ried, T			Multicolour spectral karyotyping of mouse chromosomes	NATURE GENETICS			English	Article							TUMORIGENESIS; MODELS; MICE		NIH,DIAGNOST DEV BRANCH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; NIH,LAB GENET DIS RES,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; NCI,GENET LAB,NIH,BETHESDA,MD 20892; GEORGETOWN UNIV,LOMBARDI CANC CTR,WASHINGTON,DC 20057; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1TN,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University; University of Cambridge			du manoir, stan p/O-8677-2017	du manoir, stan p/0000-0002-2200-2651	NCI NIH HHS [1P50CA58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundadottir LT, 1996, ONCOGENE, V13, P757; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARDIFF RD, 1993, CANCER SURV, V16, P97; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; KASTAN MB, 1993, NAT GENET, V5, P207, DOI 10.1038/ng1193-207; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Malik Z, 1996, J MICROSC-OXFORD, V182, P133, DOI 10.1046/j.1365-2818.1996.131411.x; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; RABBITTS P, 1995, NAT GENET, V9, P369, DOI 10.1038/ng0495-369; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Telenius H, 1992, GENE CHROMOSOME CANC, V4, P267	15	236	245	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					312	315		10.1038/ng1196-312	http://dx.doi.org/10.1038/ng1196-312			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896561				2022-12-25	WOS:A1996VQ14600026
J	Zhao, Y; Swenson, K; Sergio, JJ; Arn, JS; Sachs, DH; Sykes, M				Zhao, Y; Swenson, K; Sergio, JJ; Arn, JS; Sachs, DH; Sykes, M			Skin graft tolerance across a discordant xenogeneic barrier	NATURE MEDICINE			English	Article							T-CELL TOLERANCE; TRANSPLANTATION TOLERANCE; THYMIC EPITHELIUM; CLONAL DELETION; MONOCLONAL-ANTIBODIES; NEGATIVE SELECTION; CLASS-I; ANTIGENS; ANERGY; MICE	Specific T-cell tolerance may be essential for successful xenotransplantation in humans. Grafting of thymectomized, T cell-depleted normal mice with xenogeneic fetal pig thymus and liver (FP THY/LIV) tissue results in the recovery of functional CD4 antigen-positive cells. We have tested T-cell tolerance by skin grafting. Donor-matched pig skin survived permanently (>200 days), whereas allogeneic mouse skin was rapidly rejected. Nontolerant control mice rejected pig skin within 26 days. Both porcine and murine histocompatibility class IIhigh cells were detected in long-term thymus grafts, and T-cell repertoire analyses suggested that tolerance to both donors and recipients developed, at least in part, by intragraft clonal deletion. This study demonstrates the principle that tolerance, measured by the stringent criterion of skin grafting, can be induced across a widely disparate species barrier.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,SURG SERV,TRANSPLANTAT BIOL RES CTR,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039755] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI 39755] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUCHINCLOSS H, 1995, XENO, V3, P19; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; Davies JD, 1996, J IMMUNOL, V156, P3602; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; GRUSBY MJ, 1995, ANNU REV IMMUNOL, V13, P417, DOI 10.1146/annurev.iy.13.040195.002221; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; GUERY JC, 1995, J IMMUNOL, V154, P536; HOUSSAINT E, 1990, IMMUNOL TODAY, V11, P357, DOI 10.1016/0167-5699(90)90141-U; ILDSTAD ST, 1985, J EXP MED, V162, P231, DOI 10.1084/jem.162.1.231; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KYEWSKI BA, 1984, NATURE, V308, P196, DOI 10.1038/308196a0; LAFFERTY KJ, 1994, CLIN TRANSPLANT, V8, P181; LEE LA, 1994, P NATL ACAD SCI USA, V91, P10864, DOI 10.1073/pnas.91.23.10864; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LORENZ RG, 1989, NATURE, V340, P557, DOI 10.1038/340557a0; LUNNEY JK, 1993, IMMUNOL TODAY, V14, P147, DOI 10.1016/0167-5699(93)90227-C; Martin C, 1991, Dev Immunol, V1, P265, DOI 10.1155/1991/57259; MILLER JFAP, 1960, BRIT J CANCER, V14, P93, DOI 10.1038/bjc.1960.11; MODIGLIANI Y, 1995, P NATL ACAD SCI USA, V92, P7555, DOI 10.1073/pnas.92.16.7555; MOSES RD, 1992, TRANSPLANTATION, V53, P203, DOI 10.1097/00007890-199201000-00039; OHKI H, 1987, SCIENCE, V237, P1032, DOI 10.1126/science.3616623; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V124, P533; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SACHS DH, 1995, NAT MED, V1, P969, DOI 10.1038/nm0995-969; SACHS DH, 1981, MONOCLONAL ANTIBODIE, P95; SALAUN J, 1992, P NATL ACAD SCI USA, V89, P10420, DOI 10.1073/pnas.89.21.10420; SALAUN J, 1990, SCIENCE, V247, P1471, DOI 10.1126/science.2321009; SHARABI Y, 1990, J EXP MED, V172, P195, DOI 10.1084/jem.172.1.195; SPEISER DE, 1992, J EXP MED, V175, P1277, DOI 10.1084/jem.175.5.1277; SYKES M, 1993, J EXP MED, V178, P223, DOI 10.1084/jem.178.1.223; SYKES M, 1994, IMMUNOL REV, V141, P245, DOI 10.1111/j.1600-065X.1994.tb00880.x; SYKES M, 1994, XENO, V2, P65; SYKES M, IN PRESS CURR OPIN I; TOMITA Y, 1994, J IMMUNOL, V153, P1087; Tomita Yukihiro, 1994, Xenotransplantation, V1, P109, DOI 10.1111/j.1399-3089.1994.tb00056.x; TOMONARI K, 1991, IMMUNOGENETICS, V33, P157, DOI 10.1007/BF01719234; TOMONARI K, 1993, IMMUNOL REV, V131, P131, DOI 10.1111/j.1600-065X.1993.tb01534.x; WATANABE M, 1983, TRANSPLANTATION, V36, P712, DOI 10.1097/00007890-198336060-00025; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEIENS PW, 1994, TRANSPLANTATION, V57, P1795; YAMADA K, 1995, J IMMUNOL, V155, P5249; YANG YG, 1995, J IMMUNOL, V155, P1981; YIN DP, 1995, J IMMUNOL, V154, P6339	46	155	157	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1211	1216		10.1038/nm1196-1211	http://dx.doi.org/10.1038/nm1196-1211			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898747				2022-12-25	WOS:A1996VQ10100035
J	Zubieta, JK; Gorelick, DA; Stauffer, R; Ravert, HT; Dannals, RF; Frost, JJ				Zubieta, JK; Gorelick, DA; Stauffer, R; Ravert, HT; Dannals, RF; Frost, JJ			Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving	NATURE MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; MESSENGER-RNA; EXPOSURE INCREASES; OPIATE RECEPTORS; BRAIN; BUPRENORPHINE; EXPRESSION; METABOLISM; STRIATUM; HUMANS	The endogenous opioid system has been recently implicated in the reinforcing actions of cocaine and other addictive drugs. In this study we examined mu opioid receptor binding in ten cocaine-dependent men and seven nonaddicted controls using positron emission tomography and [C-11]carfentanil. Mu opioid binding was increased in several brain regions of the cocaine addicts studied 1-4 days after their last use of cocaine. Binding was positively correlated with the severity of cocaine craving experienced at the time. The upregulation of mu opioid receptor binding persisted after 4 weeks of monitored cocaine abstinence. These findings demonstrate for the first time the involvement of the endogenous opioid system in cocaine dependence and cocaine craving in living human subjects.	JOHNS HOPKINS MED INST,DEPT RADIOL,DIV NUCL MED,BALTIMORE,MD 21287; NIDA,INTRAMURAL RES PROGRAM,TREATMENT BRANCH,BALTIMORE,MD 21224; JOHNS HOPKINS MED INST,DEPT NEUROSCI,DIV NUCL MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins Medicine			Gorelick, David/ABF-4941-2021; Zubieta, Jon-Kar/AAB-5565-2022		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009479] Funding Source: NIH RePORTER; NIDA NIH HHS [IR01-DA 09479] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		APA, 1987, DIAGN STAT MAN MENT, V3rd; BAIN GT, 1987, LIFE SCI, V40, P1119, DOI 10.1016/0024-3205(87)90575-3; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; CARROLL ME, 1992, PSYCHOPHARMACOLOGY, V106, P439, DOI 10.1007/BF02244812; CHEN JF, 1993, NEUROSCIENCE, V54, P669, DOI 10.1016/0306-4522(93)90238-B; CLOW DW, 1991, DEV BRAIN RES, V59, P179, DOI 10.1016/0165-3806(91)90098-4; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; GOODWIN GA, 1993, NEUROTOXICOL TERATOL, V15, P425, DOI 10.1016/0892-0362(93)90060-2; HALIKAS JA, 1991, COMPR PSYCHIAT, V32, P22, DOI 10.1016/0010-440X(91)90066-L; HAMMER RP, 1989, SYNAPSE, V3, P55, DOI 10.1002/syn.890030108; HURD YL, 1989, BRAIN RES, V498, P199, DOI 10.1016/0006-8993(89)90422-8; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; HURD YL, 1992, MOL BRAIN RES, V16, P97, DOI 10.1016/0169-328X(92)90198-K; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; KALIVAS PW, 1983, J PHARMACOL EXP THER, V227, P229; LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P567; MANNELLI P, 1993, BRIT J PSYCHIAT, V163, P39, DOI 10.1192/S0007125000292489; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MELLO NK, 1989, SCIENCE, V245, P859, DOI 10.1126/science.2772637; MELTZER CC, 1990, J COMPUT ASSIST TOMO, V14, P418, DOI 10.1097/00004728-199005000-00019; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SCHOTTENFELD RS, 1993, BIOL PSYCHIAT, V34, P66, DOI 10.1016/0006-3223(93)90258-F; SCHULZ R, 1980, PSYCHOPHARMACOLOGY, V68, P221, DOI 10.1007/BF00428107; STEINER H, 1993, J NEUROSCI, V13, P5066, DOI 10.1523/JNEUROSCI.13-12-05066.1993; TECH SK, 1994, J CLIN PHARMACOL, V14, P15; UNTERWALD EM, 1992, BRAIN RES, V584, P314, DOI 10.1016/0006-8993(92)90912-S; VOLKOW ND, 1988, BRIT J PSYCHIAT, V152, P641, DOI 10.1192/bjp.152.5.641; VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210; VOLKOW ND, 1991, AM J PSYCHIAT, V148, P621	32	207	216	1	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1225	1229		10.1038/nm1196-1225	http://dx.doi.org/10.1038/nm1196-1225			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898749				2022-12-25	WOS:A1996VQ10100037
J	Condon, C; Watkins, SC; Celluzzi, CM; Thompson, K; Falo, LD				Condon, C; Watkins, SC; Celluzzi, CM; Thompson, K; Falo, LD			DNA-based immunization by in vivo transfection of dendritic cells	NATURE MEDICINE			English	Article							GENETIC IMMUNIZATION; SOLUBLE-PROTEIN; T-LYMPHOCYTES; ANTIGEN; VACCINES; PATHWAY; IMMUNITY; PEPTIDES; INVIVO; MICE	Delivery of antigen in a manner that induces effective, antigen-specific immunity is a critical challenge in vaccine design. Optimal antigen presentation is mediated by professional antigen-presenting cells (APCs) capable of taking up, processing and presenting antigen to T cells in the context of costimulatory signals required for T-cell activation. Developing immunization strategies to optimize antigen presentation by dendritic cells, the most potent APCs, is a rational approach to vaccine design. Here we show that cutaneous genetic immunization with naked DNA results in potent, antigen-specific, cytotoxic T lymphocyte-mediated protective tumor immunity. This method of immunization results in the transfection of skin-derived dendritic cells, which localize in the draining lymph nodes. These observations provide a basis for further development of DNA-based vaccines and demonstrate the feasibility of genetically engineering dendritic cells in vivo.	UNIV PITTSBURGH,SCH MED,DEPT CELL BIOL & PHYSIOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Condon, C (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT DERMATOL,190 LOTHROP ST,PITTSBURGH,PA 15213, USA.		Watkins, Simon/ABG-2590-2021; Falo, Louis/ABD-1499-2020	Watkins, Simon/0000-0003-4092-1552; Celluzzi, Christina/0000-0002-2886-5597	NIAMS NIH HHS [AR01 1884] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALIJAGIC S, 1995, EUR J IMMUNOL, V25, P3100, DOI 10.1002/eji.1830251117; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; CIERNIK F, 1996, J IMMUNOL, V156, P2369; Conry RM, 1996, GENE THER, V3, P67; CONRY RM, 1995, GENE THER, V2, P59; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583; EISENBRAUN MD, 1993, DNA CELL BIOL, V12, P791, DOI 10.1089/dna.1993.12.791; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; FIDLER IJ, 1976, CANCER RES, V36, P3160; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HUANG YCA, 1996, IMMUNITY, V4, P349; Irvine KR, 1996, J IMMUNOL, V156, P238; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; KRISHNAN S, 1995, NAT MED, V1, P521, DOI 10.1038/nm0695-521; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; Matsuno K, 1996, J EXP MED, V183, P1865, DOI 10.1084/jem.183.4.1865; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; Porgador A, 1996, J IMMUNOL, V156, P2918; PORGADOR A, 1995, J EXP MED, V182, P255, DOI 10.1084/jem.182.1.255; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VANWILSEM EJG, 1994, J INVEST DERMATOL, V103, P217, DOI 10.1111/1523-1747.ep12393088; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; YANG NS, 1995, NAT MED, V1, P481, DOI 10.1038/nm0595-481; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZHOU F, 1992, CANCER RES, V52, P6287	34	714	788	1	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1122	1128		10.1038/nm1096-1122	http://dx.doi.org/10.1038/nm1096-1122			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837611				2022-12-25	WOS:A1996VK99500033
J	Robertson, MM				Robertson, MM			D2 be or not to be?	NATURE MEDICINE			English	Editorial Material							TOURETTES-SYNDROME; BASAL GANGLIA; BINDING		NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Robertson, MM (corresponding author), UCL, DEPT PSYCHIAT & BEHAV SCI, MIDDLESEX HOSP SITE, LONDON W1N 8AA, ENGLAND.							BEUTINK P, 1993, HDB TOURETTES SYNDRO, P517; GEORGE MS, 1994, PSYCHIAT RES-NEUROIM, V55, P193, DOI 10.1016/0165-1781(95)91245-9; GERLERNTER J, 1994, ARCH NEUROL-CHICAGO, V51, P397; HYDE TM, 1995, NEUROLOGY, V45, P1176, DOI 10.1212/WNL.45.6.1176; LECKMAN JF, 1987, ARCH GEN PSYCHIAT, V44, P100; MALISON RT, 1995, AM J PSYCHIAT, V152, P1359; MOARIARTY J, 1995, BRIT J PSYCHIAT, V167, P249; NOTHEN MM, 1994, AM J MED GENET, V54, P249, DOI 10.1002/ajmg.1320540311; PETERSON B, 1993, NEUROLOGY, V43, P941, DOI 10.1212/WNL.43.5.941; PILOWSKY LS, 1994, BRIT J PSYCHIAT, V164, P16, DOI 10.1192/bjp.164.1.16; ROBERTSON MM, 1994, J CHILD PSYCHOL PSYC, V35, P597, DOI 10.1111/j.1469-7610.1994.tb01209.x; SINGER HS, 1992, ADV NEUROL, V58, P135; TURJANSKI N, 1994, J NEUROL NEUROSUR PS, V57, P688, DOI 10.1136/jnnp.57.6.688; WOLF SS, 1996, SCIENCE, V273, P1255; WONG DF, 1994, J NUCL MED P, V130	15	4	4	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1076	1077		10.1038/nm1096-1076	http://dx.doi.org/10.1038/nm1096-1076			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837600				2022-12-25	WOS:A1996VK99500022
J	Fauci, AS				Fauci, AS			Resistance to HIV-1 infection: It's in the genes	NATURE MEDICINE			English	Editorial Material											Fauci, AS (corresponding author), NIAID,NIH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0	11	28	28	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					966	967		10.1038/nm0996-966	http://dx.doi.org/10.1038/nm0996-966			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782446				2022-12-25	WOS:A1996VF49700023
J	FernandezCanon, JM; Granadino, B; deBernabe, DBV; Renedo, M; FernandezRuiz, E; Penalva, MA; deCordoba, SR				FernandezCanon, JM; Granadino, B; deBernabe, DBV; Renedo, M; FernandezRuiz, E; Penalva, MA; deCordoba, SR			The molecular basis of alkaptonuria	NATURE GENETICS			English	Article							ASCORBIC-ACID; GENE; MAPS; AKU	Alkaptonuria (AKU) occupies a unique place in the history of human genetics because it was the first disease to be interpreted as a mendelian recessive trait by Garrod in 1902. Alkaptonuria is a rare metabolic disorder resulting from loss of homogentisate 1,2 dioxygenase (HGO) activity. Affected individuals accumulate large quantities of homogentisic acid, an intermediary product of the catabolism of tyrosine and phenylalanine, which darkens the urine and deposits in connective tissues causing a debilitating arthritis. Here we report the cloning of the human HGO gene and establish that it is the AKU gene. We show that HGO maps to the same location described for AKU, illustrate that HGO harbours missense mutations that cosegregate with the disease, and provide biochemical evidence that at least one of these missense mutations is a loss-of-function mutation.	CSIC,DEPT MOL MICROBIOL,E-28006 MADRID,SPAIN; CSIC,CTR INVEST BIOL,DEPT INMUNOL,E-28006 MADRID,SPAIN; UNIV AUTONOMA MADRID,HOSP PRINCESA,UNIDAD BIOL MOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Autonomous University of Madrid; Hospital de La Princesa			Fernández-Cañón, José Manuel/AAO-5607-2020; goenechea, begoña granadino/Y-4694-2019; Penalva, Miguel A/G-2295-2015; Fernandez-canon, Jose/ADI-4196-2022; Fernández-Ruiz, Elena/A-7971-2019; Fernández-Cañón, José Manuel/AAO-6088-2020; de Cordoba, Santiago Rodriguez/K-6727-2014	Penalva, Miguel A/0000-0002-3102-2806; Fernández-Ruiz, Elena/0000-0001-5380-1686; Fernández-Cañón, José Manuel/0000-0002-8092-2181; de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; granadino, begona/0000-0002-0144-8638				FERNANDEZCANON JM, 1995, J BIOL CHEM, V270, P21199, DOI 10.1074/jbc.270.36.21199; FERNANDEZCANON JM, 1995, P NATL ACAD SCI USA, V92, P9132, DOI 10.1073/pnas.92.20.9132; FERNANDEZRUIZ E, 1992, EUR J IMMUNOL, V22, P587, DOI 10.1002/eji.1830220243; Garrod AE, 1908, LANCET, V2, P73; Garrod AE, 1902, LANCET, V2, P1616; JANOCHA S, 1994, GENOMICS, V19, P5, DOI 10.1006/geno.1994.1003; KAMOUN P, 1992, EUR J PEDIATR, V151, P149, DOI 10.1007/BF01958966; LADU BN, 1958, J BIOL CHEM, V230, P251; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; MONTAGUTELLI X, 1994, GENOMICS, V19, P9, DOI 10.1006/geno.1994.1004; OBRIEN WM, 1963, AM J MED, V34, P813, DOI 10.1016/0002-9343(63)90089-5; POLLAK MR, 1993, NAT GENET, V5, P201, DOI 10.1038/ng1093-201; ROTH M, 1968, ENZYMOL BIOL CLIN, V9, P53, DOI 10.1159/000458234; SCHMIDT SR, 1995, EUR J BIOCHEM, V228, P425, DOI 10.1111/j.1432-1033.1995.00425.x; Srsen S, 1985, Cas Lek Cesk, V124, P1288; Srsen S, 1982, Bratisl Lek Listy, V77, P662; SRSEN S, 1984, ALKAPTONURIA; WOLFF JA, 1989, PEDIATR RES, V26, P140, DOI 10.1203/00006450-198908000-00015; ZANNONI VG, 1962, NATURE, V193, P952, DOI 10.1038/193952a0; ZANNONI VG, 1969, BIOCHIM BIOPHYS ACTA, V177, P94, DOI 10.1016/0304-4165(69)90068-3	20	188	197	0	24	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					19	24		10.1038/ng0996-19	http://dx.doi.org/10.1038/ng0996-19			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782815				2022-12-25	WOS:A1996VF61100016
J	Gailani, MR; StahleBackdahl, M; Leffell, DJ; Glynn, M; Zaphiropoulos, PG; Pressman, C; Unden, AB; Dean, M; Brash, DE; Bale, AE; Toftgard, R				Gailani, MR; StahleBackdahl, M; Leffell, DJ; Glynn, M; Zaphiropoulos, PG; Pressman, C; Unden, AB; Dean, M; Brash, DE; Bale, AE; Toftgard, R			The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas	NATURE GENETICS			English	Letter							TUMOR-SUPPRESSOR; GORLIN SYNDROME; GENE; PROTEIN; LOCALIZATION; CHROMOSOME-9; ASSOCIATION; MUTATIONS; HEDGEHOG; RNA		YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT PAEDIAT,NEW HAVEN,CT 06520; KAROLINSKA HOSP,DEPT DERMATOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA INST,NOVUM,DEPT BIOSCI,S-14157 HUDDINGE,SWEDEN; KAROLINSKA INST,NOVUM,CTR NUTR & TOXICOL,S-14157 HUDDINGE,SWEDEN; FREDERICK NATL CANC INST,HUMAN GENET SECT,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702	Yale University; Yale University; Yale University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; Zaphiropoulos, Peter/0000-0003-4298-3861	NCI NIH HHS [K11CA60199, R01CA57605] Funding Source: Medline; NICHD NIH HHS [1-P30-HD27757-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027757] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA057605, K11CA060199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASKARAN N, IN PRESS GENOME RES; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHENEVIXTRENCH G, 1993, AM J HUM GENET, V53, P760; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HOLMBERG E, IN PRESS BR J CANC; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; REIS A, 1992, LANCET, V339, P617, DOI 10.1016/0140-6736(92)90903-G; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; SHANLEY SM, 1995, HUM MOL GENET, V4, P129; STAHLEBACKDAHL M, 1992, J INVEST DERMATOL, V99, P497, DOI 10.1111/1523-1747.ep12616171; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x	30	594	625	0	20	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					78	81		10.1038/ng0996-78	http://dx.doi.org/10.1038/ng0996-78			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782823				2022-12-25	WOS:A1996VF61100024
J	Morse, RP; Evans, EF				Morse, RP; Evans, EF			Enhancement of vowel coding for cochlear implants by addition of noise	NATURE MEDICINE			English	Article							STOCHASTIC RESONANCE; AUDITORY-NERVE; ELECTRICAL-STIMULATION; POTASSIUM CHANNELS; FIBERS; CRAYFISH; PARALLEL; MEMBRANE; NEURONS; RANVIER	Profoundly deaf people, who gain no benefit from conventional hearing aids, can receive speech cues by direct electrical stimulation of the cochlear nerve(1,2). This is achieved by an electronic device, a cochlear implant, which is surgically inserted into the ear. Here we show physiological results from the isolated sciatic nerve of the toad Xenopus laevis, used to predict the response of the human cochlear nerve to vowels coded by a cochlear implant. These results suggest that standard analogue cochlear implants do not evoke the patterns of neural excitation that are normally associated with acoustic stimulation. Adding noise to the stimulus, however, enhanced distinguishing features of the vowel encoded by the fine time structure of neural discharges. On the basis of these results, and those concerning stochastic resonance(3-5), we advocate a cochlear implant coding strategy in which noise is deliberately added to cochlear implant signals.			Morse, RP (corresponding author), UNIV KEELE, DEPT COMMUN & NEUROSCI, KEELE ST5 5BG, STAFFS, ENGLAND.			Morse, Robert/0000-0002-5656-6009				BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; Bilger RC, 1977, ANN OTOL RHINOL  S38, V86, P1, DOI 10.1177/00034894770860S303; BRETAG AH, 1975, PFLUG ARCH EUR J PHY, V354, P257, DOI 10.1007/BF00584649; CLOPTON BM, 1984, HEARING RES, V14, P1, DOI 10.1016/0378-5955(84)90063-7; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; DELGUTTE B, 1984, J ACOUST SOC AM, V75, P866, DOI 10.1121/1.390596; DODGE FA, 1958, J PHYSIOL-LONDON, V143, P76, DOI 10.1113/jphysiol.1958.sp006045; DUBOIS JM, 1981, J PHYSIOL-LONDON, V318, P297; ERLANGER J, 1937, ELECTRICAL SIGNS NER; EVANS EF, 1978, AUDIOLOGY, V17, P369; EVANS EF, 1972, J PHYSIOL-LONDON, V226, P263, DOI 10.1113/jphysiol.1972.sp009984; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; FRANKENHAEUSER B, 1964, J PHYSIOL-LONDON, V171, P302, DOI 10.1113/jphysiol.1964.sp007378; GINGL Z, 1995, EUROPHYS LETT, V29, P191, DOI 10.1209/0295-5075/29/3/001; GOLDBERG JM, 1973, BRAIN RES, V64, P35, DOI 10.1016/0006-8993(73)90169-8; Hill AV, 1936, PROC R SOC SER B-BIO, V121, P74, DOI 10.1098/rspb.1936.0053; Kiang NY, 1970, SENSORINEURAL HEARIN, P241, DOI DOI 10.1002/9780470719756.CH15; KIANG NYS, 1972, ANN OTO RHINOL LARYN, V81, P714, DOI 10.1177/000348947208100513; Kiang NYS, 1965, DISCHARGE PATTERNS S; KLATT DH, 1980, J ACOUST SOC AM, V67, P971, DOI 10.1121/1.383940; KNAUTH M, 1994, HEARING RES, V74, P247, DOI 10.1016/0378-5955(94)90193-7; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; MOSS F, 1995, NATURE, V376, P211, DOI 10.1038/376211a0; PARKIN JL, 1988, LARYNGOSCOPE, V98, P262; ROPER J, 1989, J PHYSIOL-LONDON, V416, P93; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; SCHWARZ JR, 1995, PFLUG ARCH EUR J PHY, V430, P283, DOI 10.1007/BF00374660; SHANNON RV, 1983, HEARING RES, V11, P157, DOI 10.1016/0378-5955(83)90077-1; SIMMONS FB, 1966, ARCHIV OTOLARYNGOL, V84, P2; SPOENDLIN H, 1989, HEARING RES, V43, P25, DOI 10.1016/0378-5955(89)90056-7; TYLER RS, 1989, J SPEECH HEAR RES, V32, P887, DOI 10.1044/jshr.3204.887; WLSON BS, 1988, COCHLEAR IMPLANT CUR, P395; YOUNG ED, 1979, J ACOUST SOC AM, V66, P1381, DOI 10.1121/1.383532	36	170	174	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1996	2	8					928	932		10.1038/nm0896-928	http://dx.doi.org/10.1038/nm0896-928			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705865				2022-12-25	WOS:A1996UZ80400042
J	Sigalas, I; Calvert, AH; Anderson, JJ; Neal, DE; Lunec, J				Sigalas, I; Calvert, AH; Anderson, JJ; Neal, DE; Lunec, J			Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer	NATURE MEDICINE			English	Article							ONCOPROTEIN MDM2; GENE; EXPRESSION; PROTEIN; AMPLIFICATION; CELLS; CARCINOMAS; MUTATIONS; SARCOMAS; ONCOGENE	The mdm2 oncogene encodes a 90-kilodalton nuclear phosphoprotein that binds and inactivates the p53 tumor suppressor protein. Here we report the observation of five alternatively spliced mdm2 gene transcripts in a range of human cancers and their absence in normal tissues. Transfection of NIH 3T3 cells with each of these forms gave foci of morphologically transformed cells. A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding, consistent with partial deletion of sequences encoding the p53 binding domain, but retain carboxyterminal zinc-finger domains. These observations suggest a reassessment of the transforming mechanisms of mdm2 and its relation to p53.	UNIV NEWCASTLE UPON TYNE,SCH MED,CANC RES UNIT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PATHOL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK				Neal, David/0000-0002-6033-5086				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P188; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLIFFORD SC, 1994, BRIT J CANCER, V69, P680, DOI 10.1038/bjc.1994.130; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; GUDAS JM, 1995, CLIN CANCER RES, V1, P71; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; LEACH FS, 1993, CANCER RES, V53, P2231; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; QUESNEL B, 1994, EUR J CANCER, V30A, P982, DOI 10.1016/0959-8049(94)90128-7; REIFENBERGER G, 1993, CANCER RES, V53, P2736; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; WABER PG, 1993, CANCER RES, V53, P6028; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	25	254	262	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					912	917		10.1038/nm0896-912	http://dx.doi.org/10.1038/nm0896-912			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705862				2022-12-25	WOS:A1996UZ80400039
J	Brennan, TJ; Seeley, WW; Kilgard, M; Schreiner, CE; Tecott, LH				Brennan, TJ; Seeley, WW; Kilgard, M; Schreiner, CE; Tecott, LH			Sound-induced seizures in serotonin 5-HT2C receptor mutant mice	NATURE GENETICS			English	Article							INFERIOR COLLICULUS NEURONS; CENTRAL-NERVOUS-SYSTEM; EPILEPSY-PRONE RATS; AUDIOGENIC-SEIZURES; C-FOS; HEARING-LOSS; SUSCEPTIBILITY; MOUSE; 5-HYDROXYTRYPTAMINE; RESOLUTION	The epilepsies are a heterogeneous collection of seizure disorders with a lifetime expectancy risk rate of 2-4%(1). A convergence of evidence indicates that heritable factors contribute significantly to seizure susceptibility(2,3). Genetically epilepsy-prone rodent strains have been frequently used to examine the effect of genetic factors on seizure susceptibility. The most extensively studied of these have been strains that are susceptible to sound-induced convulsions (audiogenic seizures, or AGSs). Early observations of the ACS phenomenon were made in the laboratory of Dr. Ivan Pavlov; in the course of appetite-conditioning experiments in mice, the loud bell used to signal food presentation unexpectedly produced seizures in some animals(4). In 1947, DBA/2 (D2) mice were found to exhibit a genetic susceptibility to AGSs stimulated by a doorbell mounted in an iron tub(5). Since this discovery, AGSs have been among the most intensively studied phenotypes in behavioural genetics(6,7). Although several genetic loci confer susceptibility to AGSs, the corresponding genes have not been cloned. We report that null mutant mice lacking serotonin 5-HT2C receptors are extremely susceptible to AGSs. The onset of susceptibility is between two and three months of age, with complete penetrance in adult animals. ACS-induced immediate early gene expression indicates that AGSs are subcortical phenomena in auditory circuits. This AGS syndrome is the first produced by a known genetic defect; it provides a robust model for the examination of serotoninergic mechanisms in epilepsy.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR NEUROBIOL & PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OTOLARYNGOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Schreiner, Christoph/0000-0002-4571-4328; Kilgard, Michael/0000-0002-6699-1818	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002260] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC002260] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ANDERMANN E, 1982, GENETIC BASIS EPILEP, P355; ANDERSON VE, 1982, GENETIC BASIS EPILEP, P103; BEVAN W, 1955, PSYCHOL BULL, V52, P473, DOI 10.1037/h0044568; Browning R A, 1978, Ann N Y Acad Sci, V305, P437, DOI 10.1111/j.1749-6632.1978.tb31540.x; BUTERBAUGH GG, 1978, LIFE SCI, V23, P2393, DOI 10.1016/0024-3205(78)90297-7; COLLINS RL, 1968, SCIENCE, V162, P1137, DOI 10.1126/science.162.3858.1137; COLLINS RL, 1972, EXPT MODELS EPILEPSY, P347; DAILEY JW, 1992, LIFE SCI, V50, P319, DOI 10.1016/0024-3205(92)90340-U; DAILEY JW, 1992, J PHARMACOL EXP THER, V260, P533; DECKARD BS, 1976, DEV PSYCHOBIOL, V9, P17, DOI 10.1002/dev.420090104; DELGADOESCUETA AV, 1986, ADV NEUROL, P3; FULLER JL, 1967, J HERED, V58, P135, DOI 10.1093/oxfordjournals.jhered.a107565; Hall Calvin S., 1947, JOUR HEREDITY, V38, P3; HENRY KR, 1980, AUDIOLOGY, V19, P369; HENRY KR, 1967, SCIENCE, V158, P938, DOI 10.1126/science.158.3803.938-a; HIRAMATSU M, 1987, EPILEPSY RES, V1, P40, DOI 10.1016/0920-1211(87)90049-0; JOBE PC, 1973, LIFE SCI, V13, P1, DOI 10.1016/0024-3205(73)90271-3; Krushinsky L., 1970, PHYSIOLOGICAL EFFECT, P159; LANGNER G, 1987, HEARING RES, V31, P197, DOI 10.1016/0378-5955(87)90127-4; LASALLE GL, 1990, BRAIN RES, V518, P308, DOI 10.1016/0006-8993(90)90988-N; LAZAROVA M, 1983, N-S ARCH PHARMACOL, V322, P147, DOI 10.1007/BF00512388; Milatovich Athena, 1992, Human Molecular Genetics, V1, P681, DOI 10.1093/hmg/1.9.681; MORGAN JI, 1991, TRENDS PHARMACOL SCI, V12, P343, DOI 10.1016/0165-6147(91)90594-I; NEUMANN PE, 1991, P NATL ACAD SCI USA, V88, P5408, DOI 10.1073/pnas.88.12.5408; PIERSON M, 1992, EPILEPSY RES, V13, P35, DOI 10.1016/0920-1211(92)90005-E; RIGEL CE, 1989, EPILEPSY RES, V4, P63; SCHLESINGER K, 1968, LIFE SCI PT 1 PHYSI, V7, P437, DOI 10.1016/0024-3205(68)90015-5; SCHREIBER RA, 1971, PHYSIOL BEHAV, V6, P635, DOI 10.1016/0031-9384(71)90247-2; SCHREINER CE, 1990, J NEUROPHYSIOL, V64, P1442, DOI 10.1152/jn.1990.64.5.1442; SEYFRIED TN, 1983, BRAIN RES, V271, P325, DOI 10.1016/0006-8993(83)90294-9; SEYFRIED TN, 1981, GENETICS, V99, P117; SHARP FR, 1993, CRIT REV NEUROBIOL, V7, P205; SNYDERKELLER AM, 1992, NEUROSCI LETT, V135, P108, DOI 10.1016/0304-3940(92)90147-Y; SPARKS DL, 1985, PHARMACOL BIOCHEM BE, V23, P753, DOI 10.1016/0091-3057(85)90067-X; SPROTT RL, 1975, BEHV STUDIES USING G, P27; Statnick M. A., 1992, Society for Neuroscience Abstracts, V18, P907; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Vicari EM, 1951, J PSYCHOL, V32, P79, DOI 10.1080/00223980.1951.9916086; WADA JA, 1972, ELECTROEN CLIN NEURO, V33, P520, DOI 10.1016/0013-4694(72)90216-7; WILLOTT JF, 1981, J NEUROPHYSIOL, V45, P35, DOI 10.1152/jn.1981.45.1.35; WILLOTT JF, 1986, J NEUROPHYSIOL, V56, P391, DOI 10.1152/jn.1986.56.2.391	41	123	125	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					387	390		10.1038/ng0897-387	http://dx.doi.org/10.1038/ng0897-387			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241279				2022-12-25	WOS:A1997XM90900024
J	Xie, MH; Yuan, J; Adams, C; Gurney, A				Xie, MH; Yuan, J; Adams, C; Gurney, A			Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv	NATURE BIOTECHNOLOGY			English	Article						tyrosine kinase; MuSK; agonist; ScFv; receptor	TORPEDO ELECTRIC ORGAN; AGRIN; EXPRESSION; ANTIBODY; MUSCLE; DOMAIN	MuSK is a tyrosine kinase localized to the postsynaptic surface of the neuromuscular junction. We have searched for modulators of MuSK function using a library of human single chain variable region antibodies (scFv) that can be displayed on M13 phage or expressed as soluble protein, A panel of 21 independent MuSK-specific scFv, identified in a screen for binding to MuSK-Fe immunoadhesin, were examined for ability to induce proliferation in a factor dependent cell line (Ba/F3) through a chimeric receptor, MuSK-MpI, Four of the scFv induced a proliferative response, suggesting an ability to induce dimerization of MuSK, These scFv were also able to induce tyrosine phosphorylation of full-length MuSK and retained this ability when re-engineered to be expressed as authentic (and dimeric) human IgG molecules., Addition of agonist scFv to a cultured myo tube cell line induced AChR clustering and tyrosine phosphorylation. These results provide direct evidence that MuSK activation is capable of triggering a key event in neuromuscular junction formation and further demonstrate that large libraries of phage-displayed scFv provide a robust method for generating highly specific agonist agents.	GENENTECH INC,DEPT MOL BIOL,SAN FRANCISCO,CA 94080	Roche Holding; Genentech								ALFTHAN K, 1995, PROTEIN ENG, V8, P725, DOI 10.1093/protein/8.7.725; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; CARTER SC, 1996, ANNU REV PHYSIOL, V58, P187; CLACKSON T, 1991, NATURE, V352, P642; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; KLEIMAN J, 1996, CELL, V85, P461; KORTT AA, 1994, EUR J BIOCHEM, V221, P151, DOI 10.1111/j.1432-1033.1994.tb18724.x; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OTTOLE JJ, 1996, P NATL ACAD SCI USA, V93, P7369; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9	21	48	79	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					768	771		10.1038/nbt0897-768	http://dx.doi.org/10.1038/nbt0897-768			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255792				2022-12-25	WOS:A1997XM70700029
J	Xia, YF; Haws, CM; Wine, JJ				Xia, YF; Haws, CM; Wine, JJ			Disruption of monolayer integrity enables activation of a cystic fibrosis ''bypass'' channel in human airway epithelia	NATURE MEDICINE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RECTIFYING CHLORIDE CHANNELS; HUMAN TRACHEAL EPITHELIUM; APICAL-MEMBRANE; CL CHANNELS; CELLS; CFTR; CAMP; JUNCTIONS; SECRETION	Cystic fibrosis (CF) is a genetic disease characterized by marked reduction in Cl- conductance across many epithelia. Two kinds of Cl- channels have been associated with CF. One channel, termed the cystic fibrosis transmembrane conductance regulator (CFTR), is directly coded by the CF gene(1-3). The other channel is an outwardly rectifying depolarization induced Cl- channel (ORDIC) that is distinguished from other outwardly rectifying chloride channels (ORCCs) because its activity is induced most reliably by patch excision and depolarization(4-7). An issue in current CF research is whether ORDIC channels are indirectly activated by CFTR to contribute a significant portion of apical membrane Cl- conductance in airway cells(6). We now show that ORDIC channels are readily activated in patches excised and depolarized from isolated cells, but are rarer or refractory to activation in patches from the apical membranes of confluent human airway epithelia. These findings have important implications for proposed therapies that would bypass the CFTR conductance by activating ORDIC channels.	STANFORD UNIV, CYST FIBROSIS RES LAB, STANFORD, CA 94305 USA	Stanford University					NHLBI NIH HHS [HL 42368] Funding Source: Medline; NIDDK NIH HHS [DK/HL51817] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051817] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; ARMITAGE WJ, 1994, CRYOBIOLOGY, V31, P453, DOI 10.1006/cryo.1994.1055; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BIJMAN J, 1987, PFLUG ARCH EUR J PHY, V408, P511, DOI 10.1007/BF00585077; BRAYDEN DJ, 1993, AM J PHYSIOL, V264, pG325, DOI 10.1152/ajpgi.1993.264.2.G325; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GRAHAM A, 1992, J PHYSIOL-LONDON, V453, P475, DOI 10.1113/jphysiol.1992.sp019240; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; PISAM M, 1976, J CELL BIOL, V71, P907, DOI 10.1083/jcb.71.3.907; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEN BQ, 1995, AM J PHYSIOL-LUNG C, V269, pL561, DOI 10.1152/ajplung.1995.269.5.L561; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; SHOEMAKER RL, 1986, BIOCHIM BIOPHYS ACTA, V858, P235, DOI 10.1016/0005-2736(86)90328-7; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; TABCHARANI JA, 1991, AM J PHYSIOL, V261, pG992, DOI 10.1152/ajpgi.1991.261.6.G992; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085	33	12	12	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					802	805		10.1038/nm0797-802	http://dx.doi.org/10.1038/nm0797-802			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212112				2022-12-25	WOS:A1997XG76700045
J	Li, M				Li, M			Use of a modified bacteriophage to probe the interactions between peptides and ion channel receptors in mammalian cells	NATURE BIOTECHNOLOGY			English	Article						NMDA receptors; random peptide display; receptor detection	LIBRARY; EXPRESSION; LIGANDS; PHAGE; IDENTIFICATION; AFFINITY; SURFACE	Besides natural peptide ligands, screening of random peptide libraries has yielded novel bioactive peptides for cell surface receptors. A method is described that uses a modified bacteriophage as a detection reagent to monitor the expression of receptor channels in mammalian cells and to probe the molecular interaction between phage-tethered peptides (Phi T-peptides) and specific receptor targets. By taking advantage of a specific multivalent interaction between Phi T-peptides and the receptor target, assays have been developed that use Phi T-peptides specific for the N-methyl-D-aspartate glutamate receptor, an important ligand-gated ion channel in the nervous system, to monitor the receptor expression in cultured mammalian cells. Combining these Phi T-peptide binding assays with fluorescence-activated cell sorting, 10(4) random glutamate receptor mutants were screened and candidate interaction residues were identified. This dual heterologous expression system offers a powerful approach to the molecular studies of protein-protein interactions.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University	Li, M (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							Barry MA, 1996, NAT MED, V2, P299, DOI 10.1038/nm0396-299; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEDMAN JR, 1993, J BIOL CHEM, V268, P23025; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; Leung DW, 1989, TECHNIQUE, V1, P11; Li M, 1996, NAT BIOTECHNOL, V14, P986, DOI 10.1038/nbt0896-986; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; RICE GC, 1992, P NATL ACAD SCI USA, V89, P5467, DOI 10.1073/pnas.89.12.5467; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; WHITEHORN EA, 1995, BIO-TECHNOL, V13, P1215, DOI 10.1038/nbt1195-1215; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	18	8	9	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					559	563		10.1038/nbt0697-559	http://dx.doi.org/10.1038/nbt0697-559			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181579				2022-12-25	WOS:A1997XC77200032
J	Kondo, T; Suda, T; Fukuyama, H; Adachi, M; Nagata, S				Kondo, T; Suda, T; Fukuyama, H; Adachi, M; Nagata, S			Essential roles of the Fas ligand in the development of hepatitis	NATURE MEDICINE			English	Article							CELL-MEDIATED CYTOTOXICITY; FULMINANT-HEPATITIS; MICE; APOPTOSIS; PERFORIN; PATHWAYS; PATHOGENESIS; INVOLVEMENT; MACROPHAGES; EXPRESSION	The Fas ligand (FasL) is expressed in activated T cells and induces apoptosis in Fas-bearing cells. A cytotoxic T lymphocyte (CTL) clone specific for hepatitis B surface antigen (HBsAg) causes an acute liver disease in HBsAg transgenic mice. Here we observed that the CTL clone killed hepatocytes expressing HBsAg in a Fas-dependent manner. Administration of the soluble form of Fas into HBsAg transgenic mice prevented the CTL-induced liver disease. In the second model, mice were primed with Propionibacterium acnes. A subsequent challenge with lipopolysaccharide (LPS) killed the mice by inducing liver injury. Neutralization of FasL rescued the mice from LPS-induced mortality, and Fas-null mice were resistant to LPS-induced mortality. These results suggest that FasL has an essential role in the development of hepatitis.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN	Osaka University			Kondo, Toru/F-9420-2012; Fukuyama, Hidehiro/N-5276-2018; Fukuyama, Hidehiro/AAY-6256-2021; Nagata, Shigekazu/AAG-3203-2019	Fukuyama, Hidehiro/0000-0002-6457-0630; Fukuyama, Hidehiro/0000-0002-6457-0630; Nagata, Shigekazu/0000-0001-9758-8426				ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ADACHI M, 1996, P NATL ACAD SCI USA, V93, P2137; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; BERKE G, 1994, CELL, V81, P9; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; DING AH, 1988, J IMMUNOL, V141, P2407; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERLUGA J, 1978, LANCET, V2, P610; FUJIOKA N, 1995, J LEUKOCYTE BIOL, V58, P90, DOI 10.1002/jlb.58.1.90; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KATAOKA T, 1994, J IMMUNOL, V153, P3938; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SATO T, 1993, J LEUKOCYTE BIOL, V53, P144, DOI 10.1002/jlb.53.2.144; SELGEN PO, 1976, METHOD CELL BIOL, V13, P29; STUEHR DJ, 1987, J IMMUNOL, V139, P518; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TORRES RM, 1992, J IMMUNOL, V148, P620; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; Vilanova M, 1996, SCAND J IMMUNOL, V43, P155, DOI 10.1046/j.1365-3083.1996.d01-25.x; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274	38	437	452	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					409	413		10.1038/nm0497-409	http://dx.doi.org/10.1038/nm0497-409			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095174				2022-12-25	WOS:A1997WQ82500030
J	Nicholas, J; Ruvolo, VR; Burns, WH; Sandford, G; Wan, XY; Ciufo, D; Hendrickson, SB; Guo, HG; Hayward, GS; Reitz, MS				Nicholas, J; Ruvolo, VR; Burns, WH; Sandford, G; Wan, XY; Ciufo, D; Hendrickson, SB; Guo, HG; Hayward, GS; Reitz, MS			Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6	NATURE MEDICINE			English	Article							MULTICENTRIC CASTLEMANS DISEASE; IL-6 SIGNAL TRANSDUCER; STIMULATORY FACTOR-II; DNA-SEQUENCES; GROWTH-FACTOR; ONCOSTATIN-M; CELL-GROWTH; IN-VITRO; IDENTIFICATION; EXPRESSION	Human herpesvirus-8 (HHV-8) has been detected in Kaposi's sarcoma (KS) lesions of all types (AIDS-related, classical and endemic), in body-cavity-based B-cell lymphomas (BCBLs) and in lesions of multicentric Castleman's disease (MCD). We have identified a major gamma-herpesvirus-divergent locus (DL-B) in HHV-8 DNA encoding several HHV-8 unique open reading frames (ORFs), including a homologue of interleukin-6 (IL-6) and two homologues of macrophage inflammatory protein MIP-1. We show that the HHV-8-encoded IL-6 homologue (vIL-6) shares functional properties with endogenous IL-6 proteins and that both vIL-6 and vMIP-1 transcripts are present at high levels following butyrate induction of an HHV-8(+) BCBL cell line. Low amounts of constitutive vIL-6, but not vMIP-1, mRNA were also detected. The presence of a functional IL-6 homologue encoded by HHV-8 may provide a mechanistic model for the hypothesized role of HHV-8 in KS, MCD and BCBL that involves the mitogenic effects of vIL-6 on surrounding cells. MIP-1 proteins may enhance these effects through the chemotactic recruitment of endogenous cytokine-producing cells into affected tissues and could potentially influence HIV disease progression in coinfected individuals through interactions with the HIV co-receptor CCR-5.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; UNIV MARYLAND,INST HUMAN VIROL,BALTIMORE,MD 21201; MED COLL WISCONSIN,DEPT HEMATOL ONCOL,MILWAUKEE,WI 53226	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Medical College of Wisconsin	Nicholas, J (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035483] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BOSHOFF C, 1995, LANCET, V345, P1043; CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GERRARD C, 1994, ANNU REV IMMUNOL, V12, P775; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; ISHIYAMA T, 1994, BRIT J HAEMATOL, V86, P483, DOI 10.1111/j.1365-2141.1994.tb04777.x; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MURAKAMIMORI K, 1995, J CLIN INVEST, V96, P1319, DOI 10.1172/JCI118167; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NICHOLAS J, IN PRESS J VIROL; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; SMITH CA, 1995, TRENDS CELL BIOL, V5, P344, DOI 10.1016/S0962-8924(00)89061-3; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; STURZL M, 1995, ONCOGENE, V10, P2007; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; YAMAMURA Y, 1989, J CLIN INVEST, V84, P1707, DOI 10.1172/JCI114353; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; ZHANG XG, 1989, BLOOD, V74, P11	45	318	330	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					287	292		10.1038/nm0397-287	http://dx.doi.org/10.1038/nm0397-287			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055855				2022-12-25	WOS:A1997WL30500029
J	Coloma, MJ; Morrison, SL				Coloma, MJ; Morrison, SL			Design and production of novel tetravalent bispecific antibodies	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; single chain Fvs; bispecific	GENETICALLY-ENGINEERED ANTIBODIES; SITE-DIRECTED MUTAGENESIS; MURINE IGG1 MOLECULE; F(AB'-GAMMA)2 ANTIBODY; OVERLAP EXTENSION; ESCHERICHIA-COLI; HINGE REGION; BINDING-SITE; CH2 DOMAIN; FRAGMENTS	We have produced novel bispecific antibodies by fusing the DNA encoding a single chain antibody (ScFv) after the C terminus (C(H)3-ScFv) or after the hinge (Hinge-ScFv) with an antibody of a different specificity, The fusion protein is expressed by gene transfection in the context of a murine variable region, Transfectomas secrete a homogeneous population of the recombinant antibody with two different specificities, one at the N terminus (anti-dextran) and one at the C terminus (anti-dansyl). The C(H)3-ScFv antibody, which maintains the constant region of human IgG3, has some of the associated effector functions such as long half-life and Fc receptor binding, The Hinge-ScFv antibody which lacks the C(H)2 and C(H)3 domains has no known effector functions.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOL GENET, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								AYALA M, 1995, BIOTECHNIQUES, V18, P832; AYALA M, 1992, BIOTECHNIQUES, V13, P790; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P1066, DOI 10.1073/pnas.87.3.1066; DANGL JL, 1982, CYTOMETRY, V2, P395; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1994, J EXP MED, V180, P1087; FLAVELL DJ, 1991, BRIT J CANCER, V64, P274, DOI 10.1038/bjc.1991.291; GEORGE AJT, 1994, J IMMUNOL, V152, P1802; GLENNIE MJ, 1988, J IMMUNOL, V141, P3662; GLENNIE MJ, 1987, J IMMUNOL, V139, P2367; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLTON TA, 1991, NUCL ACIDS RES, V19; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HUSTON JS, 1989, GENE, V77, P51; KIM JK, 1994, SCAND J IMMUNOL, V40, P457, DOI 10.1111/j.1365-3083.1994.tb03488.x; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; KIM JK, 1995, MOL IMMUNOL, V32, P467, DOI 10.1016/0161-5890(95)00019-B; KONTSEKOVA E, 1992, HYBRIDOMA, V11, P461, DOI 10.1089/hyb.1992.11.461; LLOYD F, 1991, J NATL MED ASSOC, V83, P901; MARTINIS J, 1982, PROTIDES BIOL FLUIDS, P311; MILSTEIN C, 1983, NATURE, V305, P537, DOI 10.1038/305537a0; NIETO A, 1984, MOL IMMUNOL, V21, P537, DOI 10.1016/0161-5890(84)90070-1; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; RASO V, 1981, CANCER RES, V41, P2073; READING CL, 1983, HYBRIDOMAS CELLULAR, P235; Runge MS, 1990, BIOCONJUGATE CHEM, V1, P274, DOI 10.1021/bc00004a008; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SHIN SU, 1992, IMMUNOL REV, V130, P87, DOI 10.1111/j.1600-065X.1992.tb01522.x; SMITH RIF, 1994, BIO-TECHNOL, V12, P683, DOI 10.1038/nbt0794-683; TADA H, 1994, J BIOTECHNOL, V33, P157, DOI 10.1016/0168-1656(94)90108-2; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; TAO MH, 1989, J IMMUNOL, V143, P2595; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; WALLICK SC, 1988, J IMMUNOL, V141, P3516; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087; WRIGHT A, 1992, CRIT REV IMMUNOL, V12, P125	38	173	360	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					159	163		10.1038/nbt0297-159	http://dx.doi.org/10.1038/nbt0297-159			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035142				2022-12-25	WOS:A1997WE99800023
J	Loda, M; Cukor, B; Tam, SW; Lavin, P; Fiorentino, M; Draetta, GF; Jessup, JM; Pagano, M				Loda, M; Cukor, B; Tam, SW; Lavin, P; Fiorentino, M; Draetta, GF; Jessup, JM; Pagano, M			Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas	NATURE MEDICINE			English	Article							P27(KIP1); PATHWAY; GENE	The cell-cycle inhibitor p27 is a potential tumor suppressor, but its gene has never been found inactivated in human tumors(1-4). Because cell-cycle regulation of p27 cellular abundance occurs at the post-transcriptional level(5-7), we analyzed p27 protein expression and degradation in human colorectal carcinomas. Proteasome-mediated degradation activity of p27 was compared with its protein levels in a subset of tumor samples. We found that carcinomas with low or absent p27 protein displayed enhanced proteolytic activity specific for p27, suggesting that low p27 expression can result from increased proteasome-mediated degradation rather than altered gene expression. Patients whose tumors expressed p27 had a median survival of 151 months, whereas patients who lacked p27 (10%) had a median survival of 69 months. By multivariate analysis, p27 was found to be an independent prognostic marker. Lack of p27 was associated with poor prognosis (2.9 risk ratio for death; P = 0.003). The absence of p27 protein expression is thus a powerful negative prognostic marker in colorectal carcinomas, particularly in stage II tumors, and thereby may help in the selection of patients who will benefit from adjuvant therapy. These data suggest that aggressive tumors may result from the selection of a clone or clones that lack p27 due to increased proteasome-mediated degradation.	HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,DEPT SURG,BOSTON,MA 02215; MITOTIX INC,CAMBRIDGE,MA 02139; BOSTON BIOSTAT RES FDN INC,FRAMINGHAM,MA 01702; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY; HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; IRCCS European Institute of Oncology (IEO); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAHRS OH, 1992, MANUAL STAGING CANCE; BROWN JP, IN PRESS BIOCH BIOPH; COX DR, 1972, J R STAT SOC B, V34, P187; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.1093/biomet/41.1-2.133; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAWAMATA N, 1995, CANCER RES, V55, P2266; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; Loda M, 1996, AM J PATHOL, V149, P1553; Maki CG, 1996, CANCER RES, V56, P2649; MANTEL N, 1959, J NATL CANCER I, V22, P719; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P761; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; RISLO M, 1988, GASTROENTEROLOGY, V94, P899; SAHIN AA, 1994, MODERN PATHOL, V7, P17; Stegmaier K, 1996, CANCER RES, V56, P1413; YAN J, IN PRESS J BIOL CHEM	21	948	1001	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					231	234		10.1038/nm0297-231	http://dx.doi.org/10.1038/nm0297-231			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018245				2022-12-25	WOS:A1997WF08800045
J	Mortlock, DP; Innis, JW				Mortlock, DP; Innis, JW			Mutation of HOXA13 in hand-foot-genital syndrome	NATURE GENETICS			English	Article							URINARY-TRACT ABNORMALITIES; HOMEO DOMAIN; ANOMALIES; PROTEIN; FAMILY; UPDATE; DNA	There are several human syndromes which involve defects of the limbs and the Mullerian ducts or its derivatives. The hand-foot-genital (HFG) syndrome is an autosomal dominant, fully penetrant disorder that was originally described by Stern et al. Additional reports describing other affected families have also been published. Limb anomalies include short first metacarpals of normal thickness, small distal phalanges of the thumbs, short middle phalanges of the fifth fingers, and fusion or delayed ossification of wrist bones. In the feet, the great toe is shorter due to a short first metatarsal and a small, pointed distal phalanx. Uterine anomalies are common in females with HFG, and typically involve a partially divided (bicornuate) or completely divided (didelphic) uterus, representing defects of Mullerian duct fusion. Urinary tract malformations in affected HFG females include a displaced urethral opening and malposition of ureteral orifices in the bladder wall; affected males may have hypospadias (ventrally misplaced urethral opening) of variable severity. We report the identification of a HOXA13 nonsense mutation in a family with hand-foot-genital syndrome. The mutation converts a highly conserved tryptophan residue in the homeodomain to a stop codon, which truncates 20 amino acids from the protein and likely eliminates or greatly reduces the ability of the protein to bind to DNA.	UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PEDIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Mortlock, Douglas P/C-9981-2010; Morlock, Doug/C-3482-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD034059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NIAMS NIH HHS [5 P60 AR20557] Funding Source: Medline; NICHD NIH HHS [HD34059] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACIEN P, 1992, HUM REPROD, V7, P437, DOI 10.1093/oxfordjournals.humrep.a137666; Blum V, 1986, VERTEBRATE REPRODUCT; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; CLEVELAND RH, 1990, PEDIATR RADIOL, V20, P339, DOI 10.1007/BF02013170; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; DONNENFELD AE, 1992, AM J MED GENET, V44, P482, DOI 10.1002/ajmg.1320440419; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FRYNS JP, 1993, CLIN GENET, V43, P232; Giedion A, 1976, Pediatr Radiol, V4, P96, DOI 10.1007/BF00973951; Gruenwald P, 1941, ANAT REC, V81, P1, DOI 10.1002/ar.1090810102; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALAL F, 1988, AM J MED GENET, V30, P793, DOI 10.1002/ajmg.1320300312; HALAL F, 1986, AM J MED GENET, V24, P119, DOI 10.1002/ajmg.1320240114; HUMMEL KP, 1970, J HERED, V61, P219, DOI 10.1093/oxfordjournals.jhered.a108088; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; PINSKY L, 1973, TERATOLOGY, V9, P65; POZNANSKI AK, 1970, RADIOLOGY, V95, P129, DOI 10.1148/95.1.129; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; SHARMAN G B, 1970, Science (Washington D C), V167, P1221, DOI 10.1126/science.167.3922.1221; STERN AM, 1970, J PEDIATR-US, V77, P109, DOI 10.1016/S0022-3476(70)80052-X; VERP MS, 1983, FERTIL STERIL, V40, P80; VERP MS, 1989, AM J MED GENET, V32, P555, DOI 10.1002/ajmg.1320320429; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	25	397	420	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					179	180		10.1038/ng0297-179	http://dx.doi.org/10.1038/ng0297-179			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020844				2022-12-25	WOS:A1997WF08700018
J	Kishino, T; Lalande, M; Wagstaff, J				Kishino, T; Lalande, M; Wagstaff, J			UBE3A/E6-AP mutations cause Angelman syndrome	NATURE GENETICS			English	Article							PRADER-WILLI-SYNDROME; FACTOR-II GENE; LINKAGE ANALYSIS; PROTEIN; REGION; MOUSE; SNRPN; IDENTIFICATION; EXPRESSION; DEFINE	Angelman syndrome (AS), characterized by mental retardation, seizures, frequent smiling and laughter, and abnormal gait, is one of the best examples of human disease in which genetic imprinting plays a role(1). In about 70% of cases, AS is caused by de novo maternal deletions at 15q11-q13 (ref, 2), Approximately 2% of AS cases are caused by paternal uniparental disomy (UPD) of chromosome 15 (ref, 3) and 2-3% are caused by imprinting mutations'(4). In the remaining 25% of AS cases, no deletion, uniparental disomy (UPD), or methylation abnormality is detectable, and these cases, unlike deletions or UPD, can be familial(5-7). These cases are likely to result from mutations in a gene that is expressed either exclusively or preferentially from the maternal chromosome 15. We have found that a 15q inversion inherited by an AS child from her normal mother disrupts the 5' end of the UBE3A (E6-AP) gene, the product of which functions in protein ubiquitination(15). We have looked for novel UBE2A mutations in nondeletion/non-UPD/non-imprinting mutation (NDUI) AS patients and have found one patient who is heterozygous for a 5-bp de novo tandem duplication, We have also found in two brothers a heterozygous mutation, an A to G transition that creates a new 3' splice junction 7 bp upstream from the normal splice junction. Both mutations are predicted to cause a frameshift and premature termination of translation. Our results demonstrate that UBE3A mutations are one cause of AS and indicate a possible abnormality in ubiquitin-mediated protein degradation during brain development in this disease.	CHILDRENS HOSP,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030628] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS30628] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; Burke LW, 1996, AM J HUM GENET, V58, P777; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CLAYTONSMITH J, 1992, AM J MED GENET, V44, P256, DOI 10.1002/ajmg.1320440236; COOPER DN, 1991, HUM GENET, V87, P409; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DELTOUR L, 1995, DEV BIOL, V168, P686, DOI 10.1006/dbio.1995.1114; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GREGER V, 1994, AM J MED GENET, V53, P396, DOI 10.1002/ajmg.1320530425; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KNOLL JHM, 1991, AM J HUM GENET, V48, P16; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; MALCOLMM S, 1992, LANCET, V337, P694; MEIJERSHEIJBOER EJ, 1992, J MED GENET, V29, P853, DOI 10.1136/jmg.29.12.853; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; NAKAO M, 1994, HUM MOL GENET, V3, P309, DOI 10.1093/hmg/3.2.309; NING Y, 1996, GENOME RES, V6, P735; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pearsall RS, 1996, BIOCHEM BIOPH RES CO, V222, P171, DOI 10.1006/bbrc.1996.0716; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; Riesewijk AM, 1996, GENOMICS, V35, P380, DOI 10.1006/geno.1996.0372; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WAGSTAFF J, 1993, AM J HUM GENET, V53, P105; WAGSTAFF J, 1992, NAT GENET, V1, P291, DOI 10.1038/ng0792-291; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; Williams C A, 1995, Curr Probl Pediatr, V25, P216, DOI 10.1016/S0045-9380(06)80036-8; WOODAGE T, 1994, GENOMICS, V19, P170, DOI 10.1006/geno.1994.1031	33	942	979	3	86	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					70	73		10.1038/ng0197-70	http://dx.doi.org/10.1038/ng0197-70			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988171				2022-12-25	WOS:A1997WA37300023
J	Jenuth, JP; Peterson, AC; Fu, K; Shoubridge, EA				Jenuth, JP; Peterson, AC; Fu, K; Shoubridge, EA			Random genetic drift in the female germline explains the rapid segregation of mammalian mitochondrial DNA	NATURE GENETICS			English	Article							HEREDITARY OPTIC NEUROPATHY; RED FIBERS MERRF; MOUSE EMBRYOS; D-LOOP; MUTATION; CELLS; EVOLUTION; TRANSCRIPTS; SEQUENCES; EPILEPSY	Mitochondrial DNA (mtDNA) is maternally inherited in mammals. Despite the high genome copy number in mature oocytes (10(5)) and the relatively small number of cell divisions in the female germline, mtDNA sequence variants segregate rapidly between generations. To investigate the molecular basis for this apparent paradox we created lines of heteroplasmic mice carrying two mtDNA genotypes. We show that the pattern of segregation can be explained by random genetic drift ocurring in early oogenesis, and that the effective number of segregating units for mtDNA is similar to 200 in mice. These results provide the basis for estimating recurrence risks for mitochondrial disease due to pathogenic mtDNA mutations and for predicting the rate of fixation of neutral mtDNA mutations in maternal lineages.	MONTREAL NEUROL HOSP & INST, MONTREAL, PQ H3A 2B4, CANADA; MCGILL UNIV, DEPT HUMAN GENET, MONTREAL, PQ H3A 1B1, CANADA; MCGILL UNIV, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA	McGill University; McGill University; McGill University								ASHLEY MV, 1989, NUCLEIC ACIDS RES, V17, P7325, DOI 10.1093/nar/17.18.7325; BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; BIRKY CW, 1994, J HERED, V85, P355, DOI 10.1093/oxfordjournals.jhered.a111480; BIRKY CW, 1983, GENETICS, V103, P513; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BOULET L, 1992, AM J HUM GENET, V51, P1187; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Ghosh SS, 1996, AM J HUM GENET, V58, P325; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GONDOS B, 1987, INT J GYNECOL PATHOL, V6, P114, DOI 10.1097/00004347-198706000-00003; HANDYSIDE AH, 1984, J EXP ZOOL, V231, P429, DOI 10.1002/jez.1402310317; HAUSWIRTH WW, 1984, CELL, V37, P1001, DOI 10.1016/0092-8674(84)90434-3; HAUSWIRTH WW, 1982, P NATL ACAD SCI-BIOL, V79, P4686, DOI 10.1073/pnas.79.15.4686; HOWELL N, 1992, HUM GENET, V90, P117; HOWELL N, 1994, AM J HUM GENET, V55, P203; HOWELL N, 1991, AM J HUM GENET, V49, P939; KOEHLER CM, 1991, GENETICS, V129, P247; LAIPIS PJ, 1988, P NATL ACAD SCI USA, V85, P8107, DOI 10.1073/pnas.85.21.8107; Larsson N G, 1995, Muscle Nerve Suppl, V3, pS102; LARSSON NG, 1992, AM J HUM GENET, V51, P1201; LI H, 1991, Methods (Orlando), V2, P49, DOI 10.1016/S1046-2023(05)80125-2; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MANGIA F, 1975, DEV BIOL, V45, P211, DOI 10.1016/0012-1606(75)90061-5; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; NASS MMK, 1969, J MOL BIOL, V42, P521, DOI 10.1016/0022-2836(69)90240-X; NOGAWA T, 1988, J MORPHOL, V195, P225, DOI 10.1002/jmor.1051950208; OLIVO PD, 1983, NATURE, V306, P400, DOI 10.1038/306400a0; PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2; REIS RJS, 1983, J BIOL CHEM, V258, P9078; SANTORELLI FM, 1994, NEUROLOGY, V44, P972, DOI 10.1212/WNL.44.5.972; SOLIGNAC M, 1984, MOL GEN GENET, V197, P183, DOI 10.1007/BF00330961; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096; ZHU DP, 1992, AM J MED GENET, V42, P173, DOI 10.1002/ajmg.1320420208	38	425	439	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1996	14	2					146	151		10.1038/ng1096-146	http://dx.doi.org/10.1038/ng1096-146			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841183				2022-12-25	WOS:A1996VL44600017
J	Miyata, M; Smith, JD				Miyata, M; Smith, JD			Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides	NATURE GENETICS			English	Article							ISOFORM-SPECIFIC BINDING; ONSET ALZHEIMER-DISEASE; E-DEFICIENT MICE; PLASMA-LIPOPROTEINS; DENSITY-LIPOPROTEIN; LIPID-PEROXIDATION; PROTEIN TOXICITY; EPSILON-4; CELLS; GENE	The apolipoprotein E (APOE) E4 allele is associated with Alzheimer's disease, cardiovascular disease, and decreased longevity. To probe the mechanism of these associations, cell lines were created which secrete each apoE isoform. ApoE conditioned media, purified apoE, and commercially obtained apoE protected B12 cells from hydrogen peroxide cytotoxicity with E2 > E3 > E4. Physiological levels of apoE protected cells from P-amyloid peptides, while higher doses of apoE led to increased cytotoxicity. E2 > E3 > E4 possessed antioxidant activity, and apoE bound certain metal ions. The decreased antioxidant activity of E4 could contribute to its association with Alzheimer's disease, cardiovascular disease and decreased longevity.	ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Rockefeller University			Zito, Giancarlo/F-9008-2010; Smith, Jonathan D./H-9723-2013	Smith, Jonathan D./0000-0002-0415-386X				BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Buege J A, 1978, Methods Enzymol, V52, P302; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUTTERFIELD DA, 1994, BIOCHEM BIOPH RES CO, V200, P710, DOI 10.1006/bbrc.1994.1508; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DONG LM, 1994, J BIOL CHEM, V269, P22358; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARTMANN H, 1994, BIOCHEM BIOPH RES CO, V200, P1185, DOI 10.1006/bbrc.1994.1576; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; JAECKLE S, 1989, P NATL ACAD SCI USA, V86, P1880, DOI 10.1073/pnas.86.6.1880; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LEHTIMAKI T, 1995, HUM GENET, V95, P39; LOUHIJA J, 1994, ARTERIOSCLER THROMB, V14, P1084, DOI 10.1161/01.ATV.14.7.1084; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MAXWELL SRJ, 1994, ATHEROSCLEROSIS, V111, P79, DOI 10.1016/0021-9150(94)90193-7; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; RINNINGER F, 1989, J BIOL CHEM, V264, P6111; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SMITH JD, 1988, J BIOL CHEM, V263, P8300; STENGARD JH, 1995, CIRCULATION, V91, P265, DOI 10.1161/01.CIR.91.2.265; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; VANBOCKXMEER FM, 1994, ATHEROSCLEROSIS, V110, P195, DOI 10.1016/0021-9150(94)90204-6; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WHITSON JS, 1994, BIOCHEM BIOPH RES CO, V199, P163, DOI 10.1006/bbrc.1994.1209; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; XHIGNESSE M, 1991, ARTERIOSCLER THROMB, V11, P1100, DOI 10.1161/01.ATV.11.4.1100	46	776	797	1	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					55	61		10.1038/ng0996-55	http://dx.doi.org/10.1038/ng0996-55			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782820				2022-12-25	WOS:A1996VF61100021
J	Ozelius, LJ; Hewett, JW; Page, CE; Bressman, SB; Kramer, PL; Shalish, C; deLeon, D; Brin, MF; Raymond, D; Corey, DP; Fahn, S; Risch, NJ; Buckler, AJ; Gusella, JF; Breakefield, XO				Ozelius, LJ; Hewett, JW; Page, CE; Bressman, SB; Kramer, PL; Shalish, C; deLeon, D; Brin, MF; Raymond, D; Corey, DP; Fahn, S; Risch, NJ; Buckler, AJ; Gusella, JF; Breakefield, XO			The early-onset torsion dystonia gene (DYT1) encodes an ATP binding protein	NATURE GENETICS			English	Article							AUTOSOMAL DOMINANT INHERITANCE; TYROSINE-HYDROXYLASE GENE; ASHKENAZI JEWS; EXON AMPLIFICATION; RECEPTOR-BINDING; HUMAN-CHROMOSOME; MESSENGER-RNAS; POINT MUTATION; PARKINSONISM; CONSTRUCTION	Early-onset torsion dystonia is a movement disorder, characterized by twisting muscle contractures, that begins in childhood. Symptoms are believed to result from altered neuronal communication in the basal ganglia, This study identifies the DMI gene on human chromosome 9q34 as being responsible for this dominant disease. Almost all cases of early-onset dystonia have a unique 3-bp deletion that appears to have arisen independently in different ethnic populations. This deletion results in loss of one of a pair of glutamic-acid residues in a conserved region of a novel ATP-binding protein, termed torsinA. This protein has homologues in nematode, rat, mouse and humans, with some resemblance to the family of heat-shock proteins and Clp proteases.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02114; COLUMBIA PRESBYTERIAN MED CTR,DEPT NEUROL,DYSTONIA CLIN RES CTR,NEW YORK,NY 10032; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201; MASSACHUSETTS GEN HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; MT SINAI HOSP,MOVEMENT DISORDERS CTR,NEW YORK,NY 10029; STANFORD UNIV,DEPT GENET,STANFORD,CA 94305	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Columbia University; NewYork-Presbyterian Hospital; Oregon Health & Science University; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Icahn School of Medicine at Mount Sinai; Stanford University	Ozelius, LJ (corresponding author), MASSACHUSETTS GEN HOSP,MOL NEUROGENET UNIT,BOSTON,MA 02114, USA.			Corey, David/0000-0003-4497-6016	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028384, R01NS026656, P01NS024279] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28384, NS24279, NS26656] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; ALMASY L, IN PRESS NEUROLOGY; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; APTE AN, 1993, BIOTECHNIQUES, V15, P890; BELLUS GA, 1995, AM J HUM GENET, V56, P368; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; Brashear A, 1996, MOVEMENT DISORD, V11, P151, DOI 10.1002/mds.870110206; BRESSMAN SB, 1994, NEUROLOGY, V44, P283, DOI 10.1212/WNL.44.2.283; BRESSMAN SB, 1989, ANN NEUROL, V26, P612, DOI 10.1002/ana.410260505; BRESSMAN SB, 1994, ANN NEUROL, V36, P771, DOI 10.1002/ana.410360514; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURKE RE, 1982, NEUROLOGY, V32, P1335, DOI 10.1212/WNL.32.12.1335; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTIAN CD, 1958, NEW ENGL J MED, V259, P828, DOI 10.1056/NEJM195810232591708; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CHUTORIAN AH, 1996, ACTA NEUROPEDIATR, V2, P33; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEAVEN LL, 1986, COLD SPRING HARB SYM, V51, P159, DOI 10.1101/SQB.1986.051.01.019; DOOLING EC, 1975, BRAIN, V98, P29, DOI 10.1093/brain/98.1.29; ELDRIDGE R, 1970, NEUROLOGY, V20, P1; Endo Kotaro, 1995, V14, P120; Fahn S, 1988, Adv Neurol, V50, P1; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fink JK, 1996, AM J HUM GENET, V59, P140; FONTAINE B, 1994, NAT GENET, V6, P267, DOI 10.1038/ng0394-267; Fouad GT, 1996, AM J HUM GENET, V59, P135; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUKAWA Y, 1996, ADV NUROL, V69, P37; Gasser T, 1996, MOVEMENT DISORD, V11, P163, DOI 10.1002/mds.870110208; GRAEBER MB, 1992, P NATL ACAD SCI USA, V89, P8245, DOI 10.1073/pnas.89.17.8245; GREENE P, 1995, MOVEMENT DISORD, V10, P143, DOI 10.1002/mds.870100204; GROSSON CL, 1995, NEUROL DISORD, V6, P27; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; Gusella JF, 1997, MOL MED, V3, P238, DOI 10.1007/BF03401677; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; Hedreen J C, 1988, Adv Neurol, V50, P123; KNAPPSKOG PM, 1995, HUM MOL GENET, V4, P1209, DOI 10.1093/hmg/4.7.1209; KORCZYN AD, 1980, ANN NEUROL, V8, P387, DOI 10.1002/ana.410080409; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAMER PL, 1990, ANN NEUROL, V27, P114, DOI 10.1002/ana.410270203; KRAMER PL, 1994, AM J HUM GENET, V55, P468; KULISEVSKY J, 1993, MOVEMENT DISORD, V8, P239, DOI 10.1002/mds.870080230; LEDOUX MS, 1995, BRAIN RES, V697, P91, DOI 10.1016/0006-8993(95)00792-O; LUDECKE B, 1995, HUM GENET, V95, P123; LUEBE B, 1996, HUM MOL GENET, V5, P1673; MCCORMICK MK, 1993, GENOMICS, V18, P553, DOI 10.1016/S0888-7543(05)80355-6; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; MURRELL J, 1995, GENOMICS, V25, P59, DOI 10.1016/0888-7543(95)80109-Y; NEWMAN PJ, 1988, J CLIN INVEST, V22, P739; NOBREGA JN, 1995, NEUROSCIENCE, V64, P229, DOI 10.1016/0306-4522(94)00334-2; Nobrega JN, 1996, NEUROSCIENCE, V71, P927, DOI 10.1016/0306-4522(95)00511-0; NUTT JG, 1988, MOVEMENT DISORD, V3, P188, DOI 10.1002/mds.870030302; NYGAARD TG, 1993, NAT GENET, V5, P386, DOI 10.1038/ng1293-386; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OZELIUS L, 1989, NEURON, V2, P1427, DOI 10.1016/0896-6273(89)90188-8; OZELIUS LJ, 1992, AM J HUM GENET, V50, P619; Ozelius LJ, 1997, GENOME RES, V7, P483, DOI 10.1101/gr.7.5.483; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; PERIER F, 1995, GENE, V152, P157, DOI 10.1016/0378-1119(94)00697-Q; PRATT GD, 1995, J NEUROCHEM, V64, P2153; RISCH N, 1995, NAT GENET, V9, P152, DOI 10.1038/ng0295-152; RISCH NJ, 1990, AM J HUM GENET, V46, P533; Sambrook J., 2002, MOL CLONING LAB MANU; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; TABADDOR K, 1978, NEUROLOGY, V28, P1249, DOI 10.1212/WNL.28.12.1249; VANDILLA MA, 1990, CYTOMETRY, V11, P208, DOI 10.1002/cyto.990110124; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATKINS H, 1993, AM J HUM GENET, V53, P1180; WILHELMSEN KC, 1991, ANN NEUROL, V29, P124, DOI 10.1002/ana.410290203; Wolfson L I, 1988, Adv Neurol, V50, P177; Zeman W, 1967, Psychiatr Neurol Neurochir, V70, P77	74	781	811	0	22	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1997	17	1					40	48		10.1038/ng0997-40	http://dx.doi.org/10.1038/ng0997-40			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288096				2022-12-25	WOS:A1997XU72400016
J	Lu, B; Figini, M; Emanueli, C; Geppetti, P; Grady, EF; Gerard, NP; Ansell, J; Payan, DG; Gerard, C; Bunnett, N				Lu, B; Figini, M; Emanueli, C; Geppetti, P; Grady, EF; Gerard, NP; Ansell, J; Payan, DG; Gerard, C; Bunnett, N			The control of microvascular permeability and blood pressure by neutral endopeptidase	NATURE MEDICINE			English	Article							ATRIAL-NATRIURETIC-PEPTIDE; NEUROGENIC INFLAMMATION; SUBSTANCE-P; ANTAGONIST; INHIBITOR; ENZYME; RATS	Plasma extravasation from postcapillary venules is one of the earliest steps of inflammation(1). Substance P (SP) and bradykinin (BK) mediate extravasation and cause hypotension(2-6). The cell-surface enzyme neutral endopeptidase (NEP) inactivates both peptides(7,8). Thus, absence of NEP may predispose development of inflammation and hypotension. We examined these possibilities in mice in which the NEP gene was deleted by homologous recombination(9). There was widespread basal plasma extravasation in postcapillary venular endothelia in NEP-/- mice, which was reversed by recombinant NEP and antagonists of SP (NK1) and BK (B2) receptors. Mean arterial blood pressure was 20% lower in NEP-/- animals, but this was unaffected by reintroduction of recombinant NEP and the kinin receptor antagonists. The hypotension was also independent of nitric oxide (NO), because NEP-/- mice treated with a NO synthase inhibitor remained hypotensive relative to the wild type. Thus, NEP has important roles in regulating basal microvascular permeability by degrading SP and BK, and may regulate blood pressure set point through a mechanism that is independent of SP, BK and NO. The use of NEP antagonists as candidate drugs in cardiovascular disease is suggested by the blood pressure data reported herein.	HARVARD UNIV,SCH MED,DEPT PEDIAT,CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; UNIV FERRARA,INST PHARMACOL,I-44100 FERRARA,ITALY; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; EMORY UNIV,DEPT DERMATOL,ATLANTA,GA 30322	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Ferrara; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Emory University			Geppetti, Pierangelo/AHA-7897-2022	Emanueli, Costanza/0000-0002-2392-0702; Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK 43207, DK 46285, DK 39957] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043207, R01DK039957, R37DK039957, R01DK046285] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BORSON DB, 1989, J APPL PHYSIOL, V66, P2653, DOI 10.1152/jappl.1989.66.6.2653; BUNNETT NW, 1988, AM J PHYSIOL, V255, pG676, DOI 10.1152/ajpgi.1988.255.5.G676; BUNNETT NW, 1993, AM J PHYSIOL, V264, pC497; EDMONDSALT X, 1993, EUR J PHARMACOL, V250, P403; FIGINI M, 1994, AM J PHYSIOL, V272, pG785; GARDINER SM, 1992, BRIT J PHARMACOL, V106, P180, DOI 10.1111/j.1476-5381.1992.tb14312.x; GEE NS, 1985, BIOCHEM J, V228, P119, DOI 10.1042/bj2280119; GEPPETTI P, 1993, REGUL PEPTIDES, V47, P1, DOI 10.1016/0167-0115(93)90268-D; HWANG L, 1993, AM J PHYSIOL, V264, pG735, DOI 10.1152/ajpgi.1993.264.4.G735; JORIS I, 1982, STAIN TECHNOL, V57, P177, DOI 10.3109/10520298209066611; KENNY AJ, 1988, FEBS LETT, V232, P1, DOI 10.1016/0014-5793(88)80375-2; LEMBECK F, 1979, N-S ARCH PHARMACOL, V310, P175, DOI 10.1007/BF00500282; LEMBECK F, 1992, BRIT J PHARMACOL, V105, P527, DOI 10.1111/j.1476-5381.1992.tb09013.x; LIFTON RP, 1996, SCIENCE, V272, P666; LOTVALL JO, 1991, EUR J PHARMACOL, V200, P2117; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; MATSAS R, 1986, NEUROSCIENCE, V18, P991, DOI 10.1016/0306-4522(86)90113-2; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; PAYAN DG, 1992, INFLAMMATION BASIC P, P177; RHALEB NE, 1992, EUR J PHARMACOL, V210, P115, DOI 10.1016/0014-2999(92)90661-M; SARIA A, 1983, J NEUROSCI METH, V8, P41, DOI 10.1016/0165-0270(83)90050-X; UMENO E, 1989, J APPL PHYSIOL, V66, P2647, DOI 10.1152/jappl.1989.66.6.2647; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763	26	134	138	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					904	907		10.1038/nm0897-904	http://dx.doi.org/10.1038/nm0897-904			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256283				2022-12-25	WOS:A1997XP01400034
J	Wang, YP; Becker, D				Wang, YP; Becker, D			Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth	NATURE MEDICINE			English	Article							HUMAN-MALIGNANT MELANOMAS; INTEGRIN ALPHA(V)BETA(3); HUMAN MELANOCYTES; EXPRESSION; CELLS; BFGF; DIFFERENTIATION; ORGANIZATION; PROGRESSION; APOPTOSIS	Unlike normal metanocytes, primary and metastatic human melanomas express high levels of basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor-1 (FGFR-1) messenger RNA, and expression of these genes is essential in sustaining the proliferation of malignant melanomas in vitro. To determine whether bFGF and FGFR-1 are also required for tumor formation in these cells, liposome-mediated gene transfer was used to deliver episomal vectors containing antisense-oriented bFGF or FGFR-1 cDNAs into human melanomas, grown as subcutaneous tumors in nude mice. The growth of tumors injected with these constructs was completely arrested or the tumors regressed as a result of blocked intratumoral angiogenesis and subsequent necrosis. Thus, inhibition of bFGF/FGFR-1-mediated signaling may open a new avenue for the treatment of advanced-stage melanomas.			Wang, YP (corresponding author), UNIV PITTSBURGH,DEPT PATHOL,BIOMED SCI TOWER,E1057,211 LOTHROP ST,PITTSBURGH,PA 15213, USA.							ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BECKER D, 1992, ONCOGENE, V7, P2302; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ELDER DE, 1993, SEMIN DIAGN PATHOL, V10, P18; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Folkman J, 1995, MOL BASIS CANC, P206; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GAYNOR R, 1980, NATURE, V286, P400, DOI 10.1038/286400a0; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERLYN M, 1988, EXP CELL RES, V179, P322, DOI 10.1016/0014-4827(88)90271-6; HERLYN M, 1987, LAB INVEST, V56, P461; HOUGHTON AN, 1995, BIOL THERAPY CANC, P576; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIRKWOOD JM, 1995, BIOL THERAPY CANC PR, P388; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MARINCOLA FM, 1995, BIOL THERAPY CANC, P250; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NICKOLOFF RJ, 1993, J CLIN PATHOL, V43, P752; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VIGNOVICH J, 1993, INT J ONCOL, V2, P637; WALGENBACH KJ, 1995, NAT MED, V1, P453, DOI 10.1038/nm0595-453; Wang YP, 1996, CELL GROWTH DIFFER, V7, P1733; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; Yang JP, 1996, GENE THER, V3, P542	36	254	292	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					887	893		10.1038/nm0897-887	http://dx.doi.org/10.1038/nm0897-887			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256280				2022-12-25	WOS:A1997XP01400031
J	Hakem, R; delaPompa, JL; Eli, A; Potter, J; Mak, TW				Hakem, R; delaPompa, JL; Eli, A; Potter, J; Mak, TW			Partial rescue of Brca1(5-6) early embryonic lethality by p53 or p21 null mutation	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; ARREST; INHIBITION; KINASES		AMGEN INST,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,ONTARIO CANC INST,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5G 2C1,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto			De La Pompa, José Luis/F-9719-2014	De La Pompa, José Luis/0000-0001-6761-7265; Hakem, Razqallah/0000-0001-5948-7931				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUDOS CJ, 1996, GENE DEV, V10, P2038; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HARPER JW, 1993, CELL, V75, P805; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kaufman M. H, 1990, POSTIMPLANTATION MAM, P81; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; TSUZUKI T, 1996, P NATL ACAD SCI USA, V93, P6336; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	26	216	223	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					298	302		10.1038/ng0797-298	http://dx.doi.org/10.1038/ng0797-298			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207798				2022-12-25	WOS:A1997XG60900028
J	Heikoop, JC; vandenBoogaart, P; Mulders, JWM; Grootenhuis, PDJ				Heikoop, JC; vandenBoogaart, P; Mulders, JWM; Grootenhuis, PDJ			Structure-based design and protein engineering of intersubunit disulfide bonds in gonadotropins	NATURE BIOTECHNOLOGY			English	Article						protein engineering; rational design; molecular modeling; human choriogonadotropin; luteinizing hormone; follicle stimulating hormone	HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; SIGNAL-TRANSDUCTION; LUTEINIZING-HORMONE; BETA-SUBUNITS; SPECIFICITY; EXPRESSION; EVOLUTION; RECEPTOR; BINDING	Pairs of cystine residues were introduced in the alpha- and beta-subunits of human choriogonadotropin at positions with optimal geometries for the formation of disulfide bonds. Using the homology with luteinizing hormone and follicle stimulating hormone, similar mutations were carried out in these glycoprotein hormones. In nearly all mutants the corresponding disulfide bonds were formed leading to a non-natural, covalent linkage between the alpha- and beta-subunits. The mutants typically display wild-type receptor binding and bioactivity. The mutants with non-natural intersubunit disulfide bonds display enhanced thermostabilities relative to the corresponding heterodimeric glycoprotein hormones, rendering them candidates for long acting gonadotropins with enhanced shelf lives.	NV ORGANON, NL-5340 BH OSS, NETHERLANDS									BenMenahem D, 1996, TRENDS ENDOCRIN MET, V7, P100, DOI 10.1016/1043-2760(96)88667-X; BLUNDELL TL, 1994, TRENDS BIOTECHNOL, V12, P145, DOI 10.1016/0167-7799(94)90073-6; BOLME I, 1997, CONVERSION HETERODIM; CHEN F, 1992, J MOL ENDOCRINOL, V8, P87, DOI 10.1677/jme.0.0080087; COMBARNOUS Y, 1992, ENDOCR REV, V13, P670, DOI 10.1210/edrv-13-4-670; CREIGHTON TE, 1995, TRENDS BIOTECHNOL, V13, P18, DOI 10.1016/S0167-7799(00)88896-4; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; FIDDES JC, 1980, NATURE, V286, P684, DOI 10.1038/286684a0; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; Heikoop JC, 1997, EUR J BIOCHEM, V245, P656, DOI 10.1111/j.1432-1033.1997.00656.x; Higuchi R., 1989, PCR TECHNOLOGY, P61; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MATSUMURA M, 1991, METHOD ENZYMOL, V202, P336; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; OLIJVE W, 1996, MOL HUM REPROD, V2, P374; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PUETT D, 1994, GLYCOPROTEIN HORMONE, P122; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; Shaw A, 1996, CURR OPIN STRUC BIOL, V6, P546, DOI 10.1016/S0959-440X(96)80122-9; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; Sugahara T, 1996, MOL CELL ENDOCRINOL, V125, P71, DOI 10.1016/S0303-7207(96)03944-5; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; VALOVE FM, 1994, ENDOCRINOLOGY, V135, P2657, DOI 10.1210/en.135.6.2657; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	29	41	45	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					658	662		10.1038/nbt0797-658	http://dx.doi.org/10.1038/nbt0797-658			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219269				2022-12-25	WOS:A1997XH58300030
J	Kemp, SJ; Iraqi, F; Darvasi, A; Soller, M; Teale, AJ				Kemp, SJ; Iraqi, F; Darvasi, A; Soller, M; Teale, AJ			Localization of genes controlling resistance to trypanosomiasis in mice	NATURE GENETICS			English	Article							CONGOLENSE; MOUSEPOX	Tsetse fly-transmitted trypanosomes (Trypanosoma spp,) cause 'sleeping sickness' in man and have a serious impact on livestock-based agriculture in large areas of Africa(1). Multigene control of variation in susceptibility to trypanosomiasis is known to occur in mice, where the C57BI/6 (B6) strain is relatively resistant and the A/J (A) and Balb/c (B) strains are susceptible(2,3). Such resistance is also well described among several types of west African cattle(4). We report here the results of genome-wide scans for genes controlling this trait in the B6 mouse using crosses with two different susceptible strains. Regions on mouse chromosomes 5 and 17 were found to be important in determining resistance in both crosses while an additional region on chromosome 1 showed evidence of involvement in only one cross, We confirmed the size of the effect due to chromosome 17 in F3 intercross populations fixed for alternative parental chromosomes, The three loci are of large effect and account for most of the genetic variation in both F2 populations. We propose that they be designated Tir1, Tir2 and Tir3.	INT LIVESTOCK RES INST,NAIROBI,KENYA; JACKSON LAB,BAR HARBOR,ME 04609; HEBREW UNIV JERUSALEM,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	CGIAR; International Livestock Research Institute (ILRI); Jackson Laboratory; Hebrew University of Jerusalem								ALBRIGHT JW, 1981, INFECT IMMUN, V33, P364, DOI 10.1128/IAI.33.2.364-371.1981; Bakhiet M, 1996, J IMMUNOL, V157, P3518; BROWNSTEIN DG, 1995, J VIROL, V69, P6958, DOI 10.1128/JVI.69.11.6958-6964.1995; Darvasi A, 1997, MAMM GENOME, V8, P163, DOI 10.1007/s003359900382; DARVASI A, 1995, GENETICS, V141, P1199; DEGEE ALW, 1988, J IMMUNOL, V140, P283; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DOEBLEY J, 1995, GENETICS, V141, P333; Eshed Y, 1996, GENETICS, V143, P1807; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LARK KG, 1995, P NATL ACAD SCI USA, V92, P4656, DOI 10.1073/pnas.92.10.4656; LEVINE RF, 1981, INFECT IMMUN, V34, P513, DOI 10.1128/IAI.34.2.513-518.1981; LINCOLN S, 1994, WHITEHEAD I TECHNICA, V2; MORRISON WI, 1979, EXP PARASITOL, V48, P364, DOI 10.1016/0014-4894(79)90121-8; MORRISON WI, 1978, CLIN EXP IMMUNOL, V32, P25; MURRAY M, 1984, PREV VET MED, V2, P541, DOI 10.1016/0167-5877(84)90100-4; NANTULYA VM, 1984, INFECT IMMUN, V43, P735, DOI 10.1128/IAI.43.2.735-738.1984; PATERSON E, 1994, NATURE, V335, P721; RIFKIN MR, 1978, P NATL ACAD SCI USA, V75, P3450, DOI 10.1073/pnas.75.7.3450; Sambrook J., 2002, MOL CLONING LAB MANU; WALLACE GD, 1985, J VIROL, V55, P890, DOI 10.1128/JVI.55.3.890-891.1985; *WHIT I MIT CTR GE, 1996, GEN MAP MOUS DAT REL; *WINR INT, 1992, ASS AN AGR SUBS AFR	23	106	107	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					194	196		10.1038/ng0697-194	http://dx.doi.org/10.1038/ng0697-194			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171834				2022-12-25	WOS:A1997XB54300023
J	Milner, N; Mir, KU; Southern, EM				Milner, N; Mir, KU; Southern, EM			Selecting effective antisense reagents on combinatorial oligonucleotide arrays	NATURE BIOTECHNOLOGY			English	Article						antisense; oligonucleotide; optimization; arrays; secondary structure	ANTI-MESSENGER OLIGODEOXYNUCLEOTIDES; RNA TRANSLATION; INHIBITION	An array of 1,938 oligodeoxynucleotides (ONs) ranging in length from monomers to 17-mers was fabricated on the surface of a glass plate and used to measure the potential of oligonucleotide for heteroduplex formation with rabbit beta-globin mRNA. The oligonucleotides were complementary to the first 122 bases of mRNA comprising the 5' UTR and bases 1 to 69 of the first exon. Surprisingly few oligonucleotides gave significant heteroduplex yield. Antisense activity, measured in a RNase H assay and by in vitro translation, correlated well with yield of heteroduplex on the array. These results help to explain the variable success that is commonly experienced in the choice of antisense oligonucleotides. For the optimal ON, the concentration required to inhibit translation by 50% was found to be five times less than for any other ON. We find no obvious features in the mRNA sequence or the predicted secondary structure that can explain the variation in heteroduplex yield. However, the arrays provide a simple empirical method of selecting effective antisense oligonucleotides for any RNA target of known sequence.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University of Oxford								BLAKE KR, 1985, BIOCHEMISTRY-US, V24, P6132, DOI 10.1021/bi00343a015; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CAZENAVE C, 1986, BIOCHIMIE, V68, P1063, DOI 10.1016/S0300-9084(86)80180-8; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KOZAK M, 1994, J MOL BIOL, V235, P95, DOI 10.1016/S0022-2836(05)80019-1; Lima WF, 1997, J BIOL CHEM, V272, P626; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; MANIATIS T, 1992, MOL CLONING LAB MANU, P1418; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1679, DOI 10.1093/nar/20.7.1679; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; PEYMAN A, 1995, BIOL CHEM H-S, V376, P195; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; ROVERA G, 1978, ANAL BIOCHEM, V85, P506, DOI 10.1016/0003-2697(78)90248-8; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; Stull RA, 1996, ANTISENSE NUCLEIC A, V6, P221, DOI 10.1089/oli.1.1996.6.221; STULL RA, 1992, NUCLEIC ACIDS RES, V20, P3501, DOI 10.1093/nar/20.13.3501; THOMPSON S, 1996, UNPUB NUC ACIDS RES; Wagner RW, 1996, NAT BIOTECHNOL, V14, P840, DOI 10.1038/nbt0796-840	20	220	364	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					537	541		10.1038/nbt0697-537	http://dx.doi.org/10.1038/nbt0697-537			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181575				2022-12-25	WOS:A1997XC77200028
J	Schneider, EL; Thomas, JG; Bassuk, JA; Sage, EH; Baneyx, F				Schneider, EL; Thomas, JG; Bassuk, JA; Sage, EH; Baneyx, F			Manipulating the aggregation and oxidation of human SPARC in the cytoplasm of Escherichia coli	NATURE BIOTECHNOLOGY			English	Article						protein folding; chaperone; hsp; disulfide; trxB	DISULFIDE BOND FORMATION; PROTEIN; CELL; THIOREDOXIN; MUTATIONS; PEPTIDES; GROWTH	Human SPARC (secreted protein acidic and rich in cysteine), an extracellular matrix protein containing 14 cysteine residues, was found to partition equally between soluble and insoluble cellular fractions when overexpressed in the Escherichia coli cytoplasm. While the growth temperature and medium pH had little effect on inclusion body formation, co-overproduction of the dnaKJ operon, but not of the groE operon, suppressed aggregation at the expense of intracellular accumulation. Although both forms of the protein were fully reduced in wild-type cells, 70% to 85% of soluble and insoluble SPARC could be converted into oxidized species in a thioredoxin reductase (trxB) null mutant following incubation on ice. Approximately 15% to 20% of SPARC exhibited the electrophoretic mobility of the biologically active protein. Overproduction of the dnaKJ operon in trxB cells decreased the formation of disulfide-bonded SPARC multimers in the aggregated material but not in its soluble counterpart. Our results suggest that the activity responsible for disulfide bond formation in trxB mutants acts at the post-translational level and is able to freely diffuse within inclusion bodies.	UNIV WASHINGTON, DEPT CHEM ENGN, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NIDDK NIH HHS [P50-DK-47659] Funding Source: Medline; NIGMS NIH HHS [GM40711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; Bassuk JA, 1996, ARCH BIOCHEM BIOPHYS, V325, P8, DOI 10.1006/abbi.1996.0002; Bassuk JA, 1996, INT J BIOCHEM CELL B, V28, P1031, DOI 10.1016/1357-2725(96)00036-2; BLUM P, 1992, BIO-TECHNOL, V10, P301, DOI 10.1038/nbt0392-301; DERMAN AI, 1995, J BACTERIOL, V177, P3764, DOI 10.1128/jb.177.13.3764-3770.1995; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; PROBA K, 1995, GENE, V159, P203, DOI 10.1016/0378-1119(95)00018-2; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; STRANDBERG L, 1991, APPL ENVIRON MICROB, V57, P1669, DOI 10.1128/AEM.57.6.1669-1674.1991; Thomas JG, 1996, J BIOL CHEM, V271, P11141, DOI 10.1074/jbc.271.19.11141; Thomas JG, 1996, MOL MICROBIOL, V21, P1185, DOI 10.1046/j.1365-2958.1996.651436.x; THOMAS JG, 1997, UNPUB BIOTECHNOL PRO; WALL JG, 1995, CURR OPIN BIOTECH, V6, P507, DOI 10.1016/0958-1669(95)80084-0	22	26	29	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					581	585		10.1038/nbt0697-581	http://dx.doi.org/10.1038/nbt0697-581			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181583				2022-12-25	WOS:A1997XC77200036
J	Connors, M; Kovacs, JA; Krevat, S; GeaBanacloche, JC; Sneller, MC; Flanigan, M; Metcalf, JA; Walker, RE; Falloon, J; Baseler, M; Stevens, R; Feuerstein, I; Masur, H; Lane, HC				Connors, M; Kovacs, JA; Krevat, S; GeaBanacloche, JC; Sneller, MC; Flanigan, M; Metcalf, JA; Walker, RE; Falloon, J; Baseler, M; Stevens, R; Feuerstein, I; Masur, H; Lane, HC			HIV infection induces changes in CD4(+) T-cell phenotype and depletions within the CD4(+) T-cell repertoire that are not immediately restored by antiviral or immune-based therapies	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERIPHERAL-BLOOD; MEMORY; LYMPHOCYTES; ANTIGEN; NAIVE; SUPERANTIGEN; REPLICATION; SEGMENTS; SUBSETS	Changes in CD4(+) T-cell surface marker phenotype and antigen receptor (TCR) repertoire were examined during the course of HIV infection and following therapy. A preferential decline in naive CD4(+) T cells was noted as disease progressed. Following protease inhibitor therapy, naive CD4(+) T cells increased only if they were present before initiation of therapy. Disruptions of the CD4(+) TCR repertoire were most prevalent in patients with the lowest CD4(+) T-cell counts. Antiviral or IL-12 therapy-induced increases in CD4(+) T-cell counts led to only minor changes in previously disrupted repertoires. Thus, CD4(+) T-cell death mediated by HIV-1 infection may result in a preferential decline in the number of naive CD4(+) T cells and disruptions of the CD4(+) T-cell repertoire that are not immediately corrected by antiviral or immune-based therapies.	NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT CRIT CARE MED,BETHESDA,MD 20892; CLIN PUERTA DE HIERREO,SERV MED INTERNA 1,MADRID,SPAIN; NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Arden Bernhard, 1995, Immunogenetics, V42, P455; Beverley P C, 1992, Semin Immunol, V4, P35; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOU CC, 1994, J ACQ IMMUN DEF SYND, V7, P665; CIBOTTI R, 1994, J EXP MED, V180, P861, DOI 10.1084/jem.180.3.861; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DALGLEISH AG, 1992, LANCET, V339, P824, DOI 10.1016/0140-6736(92)90277-A; DOBRESCU D, 1995, P NATL ACAD SCI USA, V92, P5563, DOI 10.1073/pnas.92.12.5563; DOBRESCU D, 1995, CELL, V82, P753, DOI 10.1016/0092-8674(95)90472-7; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PUISIEUX I, 1994, J IMMUNOL, V153, P2807; RABIN RL, 1995, J CLIN INVEST, V95, P2054, DOI 10.1172/JCI117891; REBAI N, 1994, P NATL ACAD SCI USA, V91, P1529, DOI 10.1073/pnas.91.4.1529; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; SALMON M, 1989, J IMMUNOL, V143, P907; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; Soudeyns H, 1993, Semin Immunol, V5, P175, DOI 10.1006/smim.1993.1021; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STEIS RG, 1991, J NATL CANCER I, V83, P1678, DOI 10.1093/jnci/83.22.1678; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Westby M, 1996, IMMUNOL TODAY, V17, P120, DOI 10.1016/0167-5699(96)80603-7; ZINKERNAGEL RM, 1994, DEV BIOL STAND, V82, P189	40	474	489	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					533	540		10.1038/nm0597-533	http://dx.doi.org/10.1038/nm0597-533			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142122				2022-12-25	WOS:A1997WX54300033
J	Monforte, JA; Becker, CH				Monforte, JA; Becker, CH			High-throughput DNA analysis by time-of-flight mass spectrometry	NATURE MEDICINE			English	Editorial Material							MATRIX				Monforte, JA (corresponding author), GENETRACE SYST INC,333 RAVENSWOOD AVE,MENLO PK,CA 94025, USA.				NHGRI NIH HHS [R01-HG00174] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000174] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Hall JM, 1996, GENOME RES, V6, P781, DOI 10.1101/gr.6.9.781; Hsu LYF, 1992, GENETIC DISORDERS FE, V3rd, P155; HUTHFEHRE T, 1992, RAPID COMMUN MASS SP, V6, P209, DOI 10.1002/rcm.1290060312; KARAS M, 1990, ANAL CHIM ACTA, V241, P175, DOI 10.1016/S0003-2670(00)83645-4; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; McLafferty FW., 1980, INTERPRETATION MASS, V3rd ed, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shaler TA, 1996, ANAL CHEM, V68, P576, DOI 10.1021/ac9502662; WU KJ, 1993, RAPID COMMUN MASS SP, V7, P142, DOI 10.1002/rcm.1290070206	10	58	76	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					360	362		10.1038/nm0397-360	http://dx.doi.org/10.1038/nm0397-360			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055869				2022-12-25	WOS:A1997WL30500043
J	Sandig, V; Brand, K; Herwig, S; Lukas, J; Bartek, J; Strauss, M				Sandig, V; Brand, K; Herwig, S; Lukas, J; Bartek, J; Strauss, M			Adenovirally transferred p6(INK4/CDKN2) and p53 genes cooperate to induce apoptotic tumor cell death	NATURE MEDICINE			English	Article							S-PHASE ENTRY; IN-VIVO; RECOMBINANT ADENOVIRUS; RETINOBLASTOMA-PROTEIN; CANCER CELLS; EXPRESSION; THERAPY; P16(INK4); P21; TRANSDUCTION	Repression of cell cycle progression by tumor suppressors might provide a means for tumor therapy. Here we demonstrate that ectopic overexpression of the p16(INK4/CDKN2) tumor suppressor from an adenovirus vector in various cell lines results in block of cell division and, subsequently, in a gradual reduction of the levels of the product of retinoblastoma susceptibility gene, pRb. Overexpression of p53 and p16(INK4/CDKN2), but not p53 on its own, induces apoptotic death only in tumor cells. Simultaneous adenoviral transfer of p16 and p53 genes leads to inhibition of tumor growth in nude mice. These results suggest that combined delivery of two cooperating genes like p16 and p53 could be the basis for the development of a new strategy for cancer gene therapy.	HUMBOLDT UNIV BERLIN,MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; HEPAVEC GMBH,D-13122 BERLIN,GERMANY; MAX PLANCK GESELL,D-13122 BERLIN,GERMANY; DANISH CANC SOC,DIV CANC BIOL,DEPT CELL CYCLE & CANC,DK-2100 COPENHAGEN,DENMARK	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Max Planck Society; Danish Cancer Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; An B, 1996, CANCER RES, V56, P438; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; CARLSSON G, 1983, J CANCER RES CLIN, V105, P20, DOI 10.1007/BF00391826; CLAYMAN GL, 1995, CANCER RES, V55, P1; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELLEDGE SJ, 1993, CELL, V75, P805; FRIEDMANN T, 1992, CANCER, V70, P1810, DOI 10.1002/1097-0142(19920915)70:4+<1810::AID-CNCR2820701624>3.0.CO;2-3; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HE A, 1994, CANCER RES, V54, P5804; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUARD J, 1995, GENE THER, V2, P107; JIN XM, 1995, CANCER RES, V55, P3250; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KASSEISLER A, 1994, GENE THER, V1, P395; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; KREMER EJ, 1995, BRIT MED BULL, V51, P31, DOI 10.1093/oxfordjournals.bmb.a072951; LIEBER A, 1995, RECOMBINANT DNA METH, V2, P257; LIU TJ, 1994, CANCER RES, V54, P3662; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIYASHITA T, 1995, CELL, V80, P293; MOTUKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABORI T, 1994, NATURE, V368, P753; NEVINS JR, 1992, SCIENCE, V258, P424; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTERSON GA, 1994, ONCOGENE, V9, P3375; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rosenberg S.A., 1992, HUM GENE THER, V3, P75, DOI 10.1089/hum.1992.3.1-75; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG CL, 1995, CANCER RES, V55, P4210; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG WW, 1994, CANCER GENE THER, V1, P1; ZHANG YJ, 1993, HUM GENE THER, V4, P451, DOI 10.1089/hum.1993.4.4-451	51	207	220	1	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					313	319		10.1038/nm0397-313	http://dx.doi.org/10.1038/nm0397-313			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055859				2022-12-25	WOS:A1997WL30500033
J	Bach, FH; Ferran, C; Hechenleitner, P; Mark, W; Koyamada, N; Miyatake, T; Winkler, H; Badrichani, A; Candinas, D; Hancock, WW				Bach, FH; Ferran, C; Hechenleitner, P; Mark, W; Koyamada, N; Miyatake, T; Winkler, H; Badrichani, A; Candinas, D; Hancock, WW			Accommodation of vascularized xenografts: Expression of ''protective genes'' by donor endothelial cells in a host Th2 cytokine environment	NATURE MEDICINE			English	Article							NF-KAPPA-B; SMOOTH-MUSCLE CELLS; LONG-TERM SURVIVAL; HEART ALLOGRAFTS; T-CELLS; CARDIAC ALLOGRAFTS; ANTIBODY THERAPY; ACTIVATION; REJECTION; INHIBITION	Organ xenografts under certain circumstances survive in the presence of anti-graft antibodies and complement, a situation referred to as ''accommodation.'' We find that the endothelial cells (ECs) in hamster hearts that accommodate themselves in rats express genes, such as A20 and bcl-2, that in vitro protect ECs from apoptosis and prevent upregulation in those cells of proinflammatory genes such as cytokines, procoagulant and adhesion molecules. Hearts that are rejected do not express these genes. In addition, vessels of rejected hearts show florid transplant arteriosclerosis whereas those of accommodated hearts do not. Accommodated xenografts have an ongoing T helper cell type 2 (Th2) cytokine immune response, whereas the rejected grafts have a Th1 response. We propose a model for factors that contribute to the survival of xenografts and the avoidance of transplant arteriosclerosis.	NEW ENGLAND DEACONESS HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School	Bach, FH (corresponding author), NEW ENGLAND DEACONESS HOSP,DEPT SURG,SANDOZ CTR IMMUNOBIOL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.			MIYATAKE, TSUKASA/0000-0002-6848-3972	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040152] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40152] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal A, 1996, TRANSPLANTATION, V61, P93, DOI 10.1097/00007890-199601150-00019; ALEXANDRE GPJ, 1991, CLIN TRANSPLANT, V5, P583; ARTHUR RP, 1986, J EXP MED, V163, P774, DOI 10.1084/jem.163.4.774; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; BACH FH, 1991, TRANSPL P, V23, P205; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Dalmasso AP, 1996, XENOTRANSPLANTATION, V3, P54, DOI 10.1111/j.1399-3089.1996.tb00119.x; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; FERRARESSO M, 1994, J IMMUNOL, V153, P3307; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HANCOCK WW, 1992, TRANSPLANTATION, V53, P1276, DOI 10.1097/00007890-199206000-00022; HANCOCK WW, 1993, TRANSPLANTATION, V55, P1112, DOI 10.1097/00007890-199305000-00034; Hancock WW, 1996, AM J PATHOL, V148, P681; HASAN R, 1992, TRANSPLANTATION, V54, P408, DOI 10.1097/00007890-199209000-00004; HE XW, 1995, J CLIN INVEST, V95, P564, DOI 10.1172/JCI117699; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jaattela M, 1996, J IMMUNOL, V156, P1166; JUCKETT MB, 1995, AM J PATHOL, V147, P782; KUPIECWEGLINSKI JW, 1993, J IMMUNOL, V151, P5053; LESNIKOSKI BA, 1995, TRANSPLANT P, V27, P290; MOTTRAM PL, 1995, TRANSPLANTATION, V59, P559; NAUME B, 1994, SCAND J IMMUNOL, V40, P128, DOI 10.1111/j.1365-3083.1994.tb03441.x; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PAPP I, 1992, J IMMUNOL, V148, P1308; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Robson SC, 1996, TRANSPLANT P, V28, P536; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; Shaddy Robert, 1996, Journal of Heart and Lung Transplantation, V15, pS97; SLAPAK M, 1990, TRANSPLANT P, V22, P1425; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; TAKEUCHI T, 1992, TRANSPLANTATION, V53, P1281, DOI 10.1097/00007890-199206000-00023; TSUCHIDA A, 1992, J EXP MED, V175, P81, DOI 10.1084/jem.175.1.81; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Vanhove Bernard, 1994, Xenotransplantation, V1, P17, DOI 10.1111/j.1399-3089.1994.tb00046.x; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Winkler Hans, 1995, Xenotransplantation, V2, P53, DOI 10.1111/j.1399-3089.1995.tb00067.x; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	49	328	346	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					196	204		10.1038/nm0297-196	http://dx.doi.org/10.1038/nm0297-196			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018239	Bronze			2022-12-25	WOS:A1997WF08800039
J	Sabel, BA; Engelmann, R; Humphrey, MF				Sabel, BA; Engelmann, R; Humphrey, MF			In vivo confocal neuroimaging (ICON) of CNS neurons	NATURE MEDICINE			English	Editorial Material							ADULT-RATS; IN-VIVO; CELLS; RECOVERY; HUMANS				Sabel, BA (corresponding author), UNIV MAGDEBURG,INST MED PSYCHOL,LEIPZIGER STR 44,D-39120 MAGDEBURG,GERMANY.		Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543				COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Engelmann R, 1996, EUR J NEUROSCI, V8, P220, DOI 10.1111/j.1460-9568.1996.tb01183.x; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; KISVARDAY ZF, 1994, EUR J NEUROSCI, V6, P1619, DOI 10.1111/j.1460-9568.1994.tb00553.x; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; PURVES D, 1987, J NEUROSCI, V7, P1492; SABEL BA, 1995, EXP BRAIN RES, V106, P93; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; Schmitt U, 1996, RESTOR NEUROL NEUROS, V10, P61, DOI 10.3233/RNN-1996-10201; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; THANOS S, 1994, TRENDS NEUROSCI, V17, P177, DOI 10.1016/0166-2236(94)90098-1; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618	13	49	53	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					244	247		10.1038/nm0297-244	http://dx.doi.org/10.1038/nm0297-244			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018248				2022-12-25	WOS:A1997WF08800050
J	Taylor, RW; Chinnery, PF; Turnbull, DM; Lightowlers, RN				Taylor, RW; Chinnery, PF; Turnbull, DM; Lightowlers, RN			Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids	NATURE GENETICS			English	Article							BINDING PROTEIN; MYOCLONIC EPILEPSY; ESCHERICHIA-COLI; RNALYS MUTATION; GENE-THERAPY; TRANSCRIPTION; DEFECTS; MERRF; MTDNA; PNA	Mitochondrial DNA (mtDNA) is the only extrachromosomal DNA in humans. It is a small (16.5 kb) genome which encodes 13 essential peptides of the respiratory chain, two rRNAs and 22 tRNAs. Defects of this genome are now recognized as important causes of disease and may take the form of point mutations or rearrangements(1-3). There is no effective treatment for patients with mtDNA mutations(4). In the majority of patients with mtDNA defects, both mutant and wild-type molecules are present in the same cell - a phenomenon known as intracellular heteroplasmy. In addition, in the presence of heteroplasmy there is a threshold whereby a certain level of mutant mtDNA is necessary before the disease becomes biochemically and clinically apparent(5-7) Based on the presence of heteroplasmy and the recessive nature of these mutations, we believe it will be possible to treat patients by selectively inhibiting the replication of the mutant mtDNA, thereby allowing propagation of only the wild-type molecule. To confirm the validity of such an approach we synthesised peptide nucleic acids (PNAs) complementary to human mtDNA templates containing a deletion breakpoint or single base mutation, both mutations well documented to cause disease. Using an in vitro replication run-off assay under physiological conditions, the antigenomic PNAs specifically inhibited replication of mutant but not wild-type mtDNA templates. Furthermore, we have shown uptake of these PNAs into cultured human myoblasts. We believe that we have therefore established the potential value of antigenomic PNA therapy for patients with heteroplasmic mtDNA disorders.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT NEUROL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK				Chinnery, Patrick/0000-0002-7065-6617				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BOULET L, 1992, AM J HUM GENET, V51, P1187; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CHRZANOWSKALIGHTOWLERS ZMA, 1995, GENE THER, V2, P311; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; GENUARIO R, 1993, CELL MOL BIOL RES, V39, P625; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; ORUM H, 1993, NUCLEIC ACIDS RES, V21, P5332, DOI 10.1093/nar/21.23.5332; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SEIBEL P, 1995, NUCLEIC ACIDS RES, V23, P10, DOI 10.1093/nar/23.1.10; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200; TORRONI A, 1995, AM J HUM GENET, V57, P507; VESTWEBER D, 1989, NATURE, V338, P170, DOI 10.1038/338170a0; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; WONG TW, 1985, J BIOL CHEM, V260, P1530	30	196	208	0	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					212	215		10.1038/ng0297-212	http://dx.doi.org/10.1038/ng0297-212			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020853				2022-12-25	WOS:A1997WF08700027
J	Ishizaki, J; Nevins, JR; Sullenger, BA				Ishizaki, J; Nevins, JR; Sullenger, BA			Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function	NATURE MEDICINE			English	Article							S-PHASE; RETINOBLASTOMA PROTEIN; CYCLE CONTROL; TRANSCRIPTION; EXPRESSION; EVOLUTION; MOLECULE; RB	The control of cell proliferation is of central importance to the proper development of a multicellular organism, the homeostatic maintenance of tissues, and the ability of certain cell types to respond appropriately to environmental cues. Disruption of normal cell growth control underlies many pathological conditions, including endothelial proliferative disorders in cardiovascular disease as well as the development of malignant tumors. Particularly critical for the control of cell growth is the pathway involving the G(1) cyclin-dependent kinases that regulate the Rb family of proteins, which in turn control E2F transcription factor activity(1-7). Because E2F is critical for regulation of cell proliferation, we sought to identify and to develop specific inhibitors of E2F function that might also be useful in the control of cellular proliferation. Moreover, because the control of E2F activity appears to be the end result of G, regulatory cascades, the ability to inhibit E2F may be particularly effective in impeding a wide variety of proliferative events. We have used in vitro selection to isolate several unique RNA species from high complexity RNA libraries that avidly bind to the E2F family of proteins. These RNAs also inhibit the DNA binding capacity of the E2F proteins. We also show that an E2F RNA ligand can block the induction of S phase in quiescent cells stimulated by serum addition. As such, these data demonstrate the critical role for E2F activity in cell proliferation and suggest that such RNA molecules may be effective as therapeutic entities to control cellular proliferation.	DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute; Duke University								Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1989, METHOD ENZYMOL, V183, P281; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; NEVINS JR, 1992, SCIENCE, V258, P424; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, 1993, GENE, V137, P33, DOI 10.1016/0378-1119(93)90248-2; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	27	59	64	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1386	1389		10.1038/nm1296-1386	http://dx.doi.org/10.1038/nm1296-1386			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946842				2022-12-25	WOS:A1996VW51500049
J	Rouault, JP; Falette, N; Guehenneux, F; Guillot, C; Rimokh, R; Wang, Q; Berthet, C; MoyretLalle, C; Savatier, P; Pain, B; Shaw, P; Berger, R; Samarut, J; Magaud, JP; Ozturk, M; Samarut, C; Puisieux, A				Rouault, JP; Falette, N; Guehenneux, F; Guillot, C; Rimokh, R; Wang, Q; Berthet, C; MoyretLalle, C; Savatier, P; Pain, B; Shaw, P; Berger, R; Samarut, J; Magaud, JP; Ozturk, M; Samarut, C; Puisieux, A			Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway	NATURE GENETICS			English	Article							WILD-TYPE P53; HUMAN-BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; GENE; EXPRESSION; PROTEIN; GROWTH; CELLS; ARREST; LINE	Cell cycle regulation is critical for maintenance of genome integrity. A prominent factor that guarantees genomic stability of cells is p53 (ref. 1). The P53 gene encodes a transcription factor that has a role as a tumour suppressor(2). identification of p53-target genes should provide greater insight into the molecular mechanisms that mediate the tumour suppressor activities of p53. The rodent Pc3/Tis21 gene was initially described as an immediate early gene induced by tumour promoters and growth factors in PC12 and Swiss 3T3 cells(3,4). It is expressed in a variety of cell and tissue types and encodes a remarkably labile protein(4,5). Pc3/Tis21 has a strong sequence similarity to the human antiproliferative BTG1 gene cloned from a chromosomal translocation of a B-cell chronic lymphocytic leukaemia(6). This similarity led us to speculate that BTG1 and the putative human homologue of Pc3/Tis21 (named BTG2) were members of a new family of genes involved in growth control and/or differentiation. This hypothesis was recently strengthened by the identification of a new antiproliferative protein, named TOE, which shares sequence similarity with BTG1 and PC3/TIS21 (ref. 7). Here, we cloned and localized the human BTG2 gene. We show that BTG2 expression is induced through a p53-dependent mechanism and that BTG2 function may be relevant to cell cycle control and cellular response to DNA damage.	CTR LEON BERARD,INSERM U453,CNRS,F-69373 LYON 08,FRANCE; HOP EDOUARD HERRIOT,LAB CYTOGENET MOL,F-69437 LYON 03,FRANCE; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,CNRS UMR49,INRA,F-69373 LYON 08,FRANCE; INST PATHOL,DIV EXPT ONCOL,CH-1011 LAUSANNE,SWITZERLAND; INST GENET MOL,INSERM,U301,F-75010 PARIS,FRANCE; BILKENT UNIV,DEPT MOL BIOL & GENET,TR-06533 BILKENT,ANKARA,TURKEY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Ihsan Dogramaci Bilkent University			Rimokh, Ruth/G-7506-2014; SAVATIER, Pierre/J-4663-2014; Moyret-Lalle, Caroline/G-2742-2013; Samarut, Jacques/AAD-2587-2019; berthet, cyril/T-4842-2017; OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014; Pain, Bertrand/A-7686-2015	Moyret-Lalle, Caroline/0000-0002-8359-2018; berthet, cyril/0000-0003-3166-3141; OZTURK, MEHMET/0000-0002-6092-9706; PUISIEUX, Alain/0000-0002-9938-3798; Pain, Bertrand/0000-0002-1210-8444				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1990, ONCOGENE, V5, P893; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHERIFF D, 1990, P NATL ACAD SCI USA, V87, P8639; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; FREBOURG T, 1992, CANCER RES, V52, P6976; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MATHEWS CG, 1987, NATURE, V325, P524; MATSUDA A, 1996, ONCOGENE, V12, P705; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, CANCER RES, V54, P3131; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARASKEVA C, 1988, INT J CANCER, V41, P908; POWELL SN, 1995, CANCER RES, V55, P1643; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; RAO PN, 1979, EFFECTS DRUGS CELL N, P475; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; SAVATIER P, 1994, ONCOGENE, V9, P809; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEWART N, 1995, ONCOGENE, V10, P109; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; VARNUM BC, 1994, J CELL PHYSIOL, V158, P205, DOI 10.1002/jcp.1041580125; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	44	344	359	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					482	486		10.1038/ng1296-482	http://dx.doi.org/10.1038/ng1296-482			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944033	Green Published			2022-12-25	WOS:A1996VV73000029
J	Vancetto, MDC; deOliveira, JM; Prado, SMA; Fratelli, F; Higashi, HG				Vancetto, MDC; deOliveira, JM; Prado, SMA; Fratelli, F; Higashi, HG			Tetanus toxoid purification: A case study	NATURE BIOTECHNOLOGY			English	Editorial Material									INST BUTANTAN,TECHNOL DEV & PROD DIV,BR-05503900 SAO PAULO,BRAZIL	Instituto Butantan	Vancetto, MDC (corresponding author), INST BUTANTAN,ANAEROB VACCINES SECT,CAIXA POSTAL 65,BR-05503900 SAO PAULO,BRAZIL.							FRATELLI F, 1993, ARQ BIOL TECNOL, V36, P709; PRADO SMA, 1993, B BIOTECNOL, V4, P3; PRADO SMA, 1992, B BIOTECNOL, V3, P11; RAYNAUD M, 1971, ANN I PASTEUR PARIS, V120, P801; VANCETTO MDC, 1994, ARQ BIOL TECNOL, V37, P577; World Health Organization, 1977, MAN PROD CONTR VACC	6	2	2	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					807	808		10.1038/nbt0897-807	http://dx.doi.org/10.1038/nbt0897-807			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255801				2022-12-25	WOS:A1997XM70700038
J	Kontermann, RE; Wing, MG; Winter, G				Kontermann, RE; Wing, MG; Winter, G			Complement recruitment using bispecific diabodies	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; diabody; complement C1q; phage display	IMMUNOSUPPRESSIVE PROPERTIES; MONOCLONAL-ANTIBODY; BINDING-SITE; PHAGOCYTOSIS; ACTIVATION; CLQ; IGG; C1Q; MODULATION; COMPONENT	We describe the engineering of antibody fragments produced in bacteria for recruitment of complement effector functions. From a phage display repertoire we isolated human antibody fragments directed against complement Clq, and linked these to lysozyme-specific antibody fragments, creating bispecific antibodies (diabodies). One diabody was able to recruit Clq, resulting in efficient lysis of lysozyme-coated sheep erythrocytes, and also induced rosette-formation of erythrocytes with human monocytes and phagocytosis after phorbol ester stimulation. These diabodies may have therapeutic applications requiring the activation of complement.	MRC,MOL IMMUNOPATHOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; MRC,CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge			Kontermann, Roland E./F-9263-2014		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEGRE ML, 1992, J IMMUNOL, V148, P3461; ALEGRE ML, 1994, TRANSPLANTATION, V57, P1537; BOBAK DA, 1987, J IMMUNOL, V138, P1150; BOBAK DA, 1988, J IMMUNOL, V136, P1023; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CHATENOUD L, 1990, TRANSPLANTATION, V49, P697, DOI 10.1097/00007890-199004000-00009; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; ERDEI A, 1988, MOL IMMUNOL, V25, P1067, DOI 10.1016/0161-5890(88)90139-3; FANGER MW, 1991, TRENDS BIOTECHNOL, V9, P375, DOI 10.1016/0167-7799(91)90129-6; FANGER MW, 1992, CRIT REV IMMUNOL, V12, P101; GUAN E, 1991, J BIOL CHEM, V266, P20345; Holliger P, 1996, PROTEIN ENG, V9, P299, DOI 10.1093/protein/9.3.299; Holliger P, 1997, NAT BIOTECHNOL, V15, P632, DOI 10.1038/nbt0797-632; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; KONTERMANN RE, 1997, IN PRESS IMMUNOTECHN; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; McGuinness BT, 1996, NAT BIOTECHNOL, V14, P1149, DOI 10.1038/nbt0996-1149; Moreau T, 1996, BRAIN, V119, P225, DOI 10.1093/brain/119.1.225; OIKI S, 1988, J IMMUNOL, V141, P3177; PERISIC O, 1994, STRUCTURE, V2, P1217, DOI 10.1016/S0969-2126(94)00123-5; TENNER AJ, 1982, J IMMUNOL, V128, P2547; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Wing MG, 1996, J CLIN INVEST, V98, P2819, DOI 10.1172/JCI119110; WING MG, 1997, IN PRESS THER IMMUNO; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; XIA MQ, 1991, EUR J IMMUNOL, V21, P1677, DOI 10.1002/eji.1830210714; Zhu ZP, 1996, BIO-TECHNOL, V14, P192, DOI 10.1038/nbt0296-192	30	53	60	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					629	631		10.1038/nbt0797-629	http://dx.doi.org/10.1038/nbt0797-629			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219263				2022-12-25	WOS:A1997XH58300024
J	Melero, I; Shuford, WW; Newby, SA; Aruffo, A; Ledbetter, JA; Hellstrom, KE; Mittler, RS; Chen, LP				Melero, I; Shuford, WW; Newby, SA; Aruffo, A; Ledbetter, JA; Hellstrom, KE; Mittler, RS; Chen, LP			Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors	NATURE MEDICINE			English	Article							RECEPTOR SUPERFAMILY; NECROSIS-FACTOR; COSTIMULATION; GROWTH; EXPRESSION; CYTOKINES; PROTEINS; IMMUNITY; LIGAND; CTLA-4	The 4-1BB glycoprotein is a member of the tumor necrosis factor receptor superfamily(1-4) and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells(5,6). Expression of 4-1BB is restricted to primed CD4(+) and CD8(+) T cells(7), and 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers a dual mitogenic signal for T-cell activation and growth(8-12). These observations suggest an important role for 4-1BB in the amplification of T cell-mediated immune responses. We now show that administration of anti-4-1BB monoclonal antibodies can eradicate established large tumors in mice, including the poorly immunogenic Ag104A sarcoma and the highly tumorigenic P815 masto cytoma. The immune response induced by anti-4-1BB monoclonal antibodies is mediated by both CD8(+) and CD4(+) T cells and is accompanied by a marked augmentation of tumor-selective cytolytic T-cell activity. Our data suggest that a similar approach may be efficacious for immunotherapy of human cancer.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb			Melero, Ignacio/T-7600-2019	Melero, Ignacio/0000-0002-1360-348X				ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DEBENEDETTE MA, 1995, J EXP MED, V181, P985, DOI 10.1084/jem.181.3.985; ELLENHORN JDI, 1988, SCIENCE, V242, P569, DOI 10.1126/science.2902689; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; HURTADO JC, 1995, J IMMUNOL, V155, P3360; Johnston JV, 1996, J EXP MED, V183, P791, DOI 10.1084/jem.183.3.791; KOWN BS, 1989, P NATL ACAD SCI USA, V86, P1963; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; Li YW, 1996, J EXP MED, V183, P639, DOI 10.1084/jem.183.2.639; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; POLLOK KE, 1995, EUR J IMMUNOL, V25, P488, DOI 10.1002/eji.1830250227; POLLOK KE, 1994, EUR J IMMUNOL, V24, P367, DOI 10.1002/eji.1830240215; POLLOK KE, 1993, J IMMUNOL, V150, P771; Schreiber Hans, 1993, P1143; SCHWARZ H, 1995, BLOOD, V85, P1043, DOI 10.1182/blood.V85.4.1043.bloodjournal8541043; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WARD PL, 1989, J EXP MED, V170, P217, DOI 10.1084/jem.170.1.217; YANG GC, 1995, J IMMUNOL, V155, P3897	25	711	883	1	39	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					682	685		10.1038/nm0697-682	http://dx.doi.org/10.1038/nm0697-682			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176498				2022-12-25	WOS:A1997XB97400041
J	Ananthaswamy, HN; Loughlin, SM; Cox, P; Evans, RL; Ullrich, SE; Kripke, ML				Ananthaswamy, HN; Loughlin, SM; Cox, P; Evans, RL; Ullrich, SE; Kripke, ML			Sunlight and skin cancer: Inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens	NATURE MEDICINE			English	Article							XERODERMA-PIGMENTOSUM PATIENTS; SQUAMOUS-CELL CARCINOMAS; TUMOR SUPPRESSOR GENE; ULTRAVIOLET-RADIATION; AMINOBENZOIC ACID; MICE; DNA; PHOTOCARCINOGENESIS; PREVENTION; EXPOSURE	UV-induced mutations in the p53 tumor suppressor gene pray an essential role in skin cancer development. We report here that such mutations cars be detected in UV-irradiated mouse skin months before the gross appearance of skin tumors. Application of SPF-15 sunscreens to mouse skin before each UV irradiation nearly abolished the frequency of p53 mutations. These results indicate that p53 mutation is an early event in UV skin carcinogenesis and that inhibition of this event may serve as an early end point for assessing protective measures against skin cancer development.			Ananthaswamy, HN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,1515 HOLCOMBE BLVD,BOX 178,HOUSTON,TX 77030, USA.							Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; BLUM HF, 1959, CARCINOGENESIS ULTRA; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; *COSM TOIL FRAGR A, 1995, INT COSM INGR DICT; DERIJCKE S, 1989, DERMATOLOGICA, V179, P196, DOI 10.1159/000248359; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; FORBES PD, 1981, J INVEST DERMATOL, V77, P139, DOI 10.1111/1523-1747.ep12479351; FOURTANIER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P549, DOI 10.1111/j.1751-1097.1992.tb04277.x; Fourtanier A, 1996, PHOTOCHEM PHOTOBIOL, V64, P688, DOI 10.1111/j.1751-1097.1996.tb03125.x; FREEMAN SE, 1988, PHOTODERMATOLOGY, V5, P243; GILCHREST BA, 1990, ANNU REV MED, V41, P199; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; KANJILAL S, 1995, CANCER RES, V55, P3604; KANJILAL S, 1993, CANCER RES, V53, P2961; KLIGMAN LH, 1980, J AM ACAD DERMATOL, V3, P30, DOI 10.1016/S0190-9622(80)80221-0; KLIGMAN LH, 1982, J INVEST DERMATOL, V78, P181, DOI 10.1111/1523-1747.ep12506359; KLIGMAN LH, 1986, PHOTODERMATOLOGY, V3, P215; KRESS S, 1992, CANCER RES, V52, P6400; KRIPKE M L, 1991, Journal of Dermatology (Tokyo), V18, P429; KRIPKE ML, 1977, CANCER RES, V37, P1395; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE NJ, 1980, J INVEST DERMATOL, V74, P181, DOI 10.1111/1523-1747.ep12535093; MOLES JP, 1993, ONCOGENE, V8, P583; MORISON WL, 1984, J INVEST DERMATOL, V83, P405, DOI 10.1111/1523-1747.ep12273470; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; Nataraj AJ, 1996, P NATL ACAD SCI USA, V93, P7961, DOI 10.1073/pnas.93.15.7961; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P165; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; PARRISH JA, 1982, PHOTOCHEM PHOTOBIOL, V36, P187, DOI 10.1111/j.1751-1097.1982.tb04362.x; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADY P, 1992, CANCER RES, V52, P3804; Ren ZP, 1996, ONCOGENE, V12, P765; Roberts LK, 1996, PHOTOCHEM PHOTOBIOL, V63, P874, DOI 10.1111/j.1751-1097.1996.tb09645.x; ROWE DE, 1992, J AM ACAD DERMATOL, V26, P976, DOI 10.1016/0190-9622(92)70144-5; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; SATO M, 1993, CANCER RES, V53, P2944; Scotto J, 1978, Natl Cancer Inst Monogr, P169; Urbach F, 1969, LONG TERM FIELD MEAS; URBACH F, 1978, NATL CANCER I MONOGR, V50, P5; VANDERRIET P, 1994, CANCER RES, V54, P25; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WOLF P, 1993, J INVEST DERMATOL, V100, P254, DOI 10.1111/1523-1747.ep12469038; YOUNG AR, 1990, SEMIN DERMATOL, V9, P25; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	48	169	170	2	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					510	514		10.1038/nm0597-510	http://dx.doi.org/10.1038/nm0597-510			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142118				2022-12-25	WOS:A1997WX54300029
J	Benimetskaya, L; Loike, JD; Khaled, Z; Loike, G; Silverstein, SC; Cao, L; Khoury, JE; Cai, TQ; Stein, CA				Benimetskaya, L; Loike, JD; Khaled, Z; Loike, G; Silverstein, SC; Cao, L; Khoury, JE; Cai, TQ; Stein, CA			Mac-1 (CDllb/CD18) is an oligodeoxynucleotide-binding protein	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; ANTISENSE OLIGODEOXYNUCLEOTIDES; TYROSINE PHOSPHORYLATION; OLIGONUCLEOTIDE UPTAKE; SCAVENGER RECEPTORS; MOUSE MODEL; HL-60 CELLS; I-DOMAIN; CD11B/CD18	We have studied the interactions of phosphodiester and phosphorothioate oligodeoxynucleotides with Mac-1 (CD11b/CD18; alpha M beta 2), a heparin-binding integrin found predominately on the surface of polymorphonuclear leukocytes (PMNs), macrophages and natural killer cells. Binding of a homopolymer of thymidine occurred on both the alpha M and beta 2 subunits. Soluble fibrinogen, a natural ligand for Mac-1, was an excellent competitor of the binding of a phosphorothioate oligodeoxynucleotide to both TNF-alpha-activated and nonactivated PMNs. Upregulation of cell-surface Mac-1 expression increased cell-surface binding of oligodeoxynucleotides. Binding was inhibited by anti-Mac-1 monoclonal antibodies, and the increase in cell-surface binding was correlated with a three- to fourfold increase in internalization by PMNs. An oligodeoxynucleotide inhibited beta 2-dependent migration through Matrigel, but the production of reactive oxygen species in PMNs adherent to fibrinogen dramatically increased. Thus, our data demonstrate that Mac-1 is a cell-surface receptor for oligodeoxynucleotides that can mediate their internalization and that this binding may have important functional consequences.	COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Columbia University; Rockefeller University					NCI NIH HHS [CA 60639] Funding Source: Medline; NIAID NIH HHS [AI 20516] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020516, R37AI020516] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTERI D, 1988, J BIOL CHEM, V263, P7007; BATES EJ, 1993, J LEUKOCYTE BIOL, V53, P420, DOI 10.1002/jlb.53.4.420; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; CAI T, 1995, J BIOL CHEM, V270, P14538; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COOMBE DR, 1994, BLOOD, V84, P739; COTTER FE, 1994, ONCOGENE, V9, P3049; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; ElKhoury J, 1996, NATURE, V382, P716; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; KIMURA Y, 1994, J BIOCHEM-TOKYO, V116, P991, DOI 10.1093/oxfordjournals.jbchem.a124658; KNORRE DG, 1985, ADV ENZYME REGUL, V24, P277, DOI 10.1016/0065-2571(85)90082-2; Krieg A M, 1991, Antisense Res Dev, V1, P161; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOIKE J, 1986, AM J PHYSIOL, V251, pC28; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; LOIKE JD, 1995, J EXP MED, V181, P1763, DOI 10.1084/jem.181.5.1763; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MOHRI H, 1993, ARCH BIOCHEM BIOPHYS, V303, P27, DOI 10.1006/abbi.1993.1251; RAPPAPORT J, 1995, KIDNEY INT, V47, P1462, DOI 10.1038/ki.1995.205; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; Sambrook J., 2002, MOL CLONING LAB MANU; SHOJI Y, 1991, NUCLEIC ACIDS RES, V19, P5543, DOI 10.1093/nar/19.20.5543; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, CANCER RES, V53, P2239; STEIN CA, 1993, BIOCHEMISTRY-US, V32, P4855, DOI 10.1021/bi00069a022; TONKINSON JL, 1994, NUCLEIC ACIDS RES, V22, P4268, DOI 10.1093/nar/22.20.4268; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAKUBOV L, 1993, J BIOL CHEM, V268, P18818; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; Zhao Q, 1993, Antisense Res Dev, V3, P53; ZHAO QY, 1994, BLOOD, V84, P3660, DOI 10.1182/blood.V84.11.3660.bloodjournal84113660; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	42	214	218	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					414	420		10.1038/nm0497-414	http://dx.doi.org/10.1038/nm0497-414			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095175				2022-12-25	WOS:A1997WQ82500031
J	Kosaka, H; Seiyama, A				Kosaka, H; Seiyama, A			Elevation of oxygen release by nitroglycerin without an increase in blood flow in the hepatic microcirculation	NATURE MEDICINE			English	Article							HEMOGLOBIN; RATS	The effect of nitroglycerin on oxygen (O-2) release in the micro-circulation was investigated by examining single, unbranched hepatic sinusoids of rats using dual-spot microspectroscopy. Nitroglycerin significantly increased O-2 release from erythrocytes flowing in the sinusoids. Differences in O-2 saturation of hemoglobin per unit length of the sinusoid were significantly enhanced, while there were no significant changes in erythrocyte velocity, hemoglobin concentration or oxyhemoglobin flow into the sinusoids, or in regional hepatic blood flow measured with a laser tissue blood flow meter. No change was noted for hepatic O-2 consumption measured in isolated liver perfused with hemoglobin-free oxygenated buffer. Isosorbide dinitrate showed a similar but slower effect. These findings suggest that nitroglycerin and isosorbide dinitrate enhance O-2 release from erythrocytes without significantly increasing tissue blood flow.	OSAKA UNIV, SCH MED, DEPT PHYSIOL 1, OSAKA 565, JAPAN	Osaka University								CHEN SS, 1993, AM J PHYSIOL, V264, pG375, DOI 10.1152/ajpgi.1993.264.2.G375; Douglas CG, 1912, J PHYSIOL-LONDON, V44, P275; FUJII M, 1993, J BIOL CHEM, V268, P15386; HILLE R, 1979, J BIOL CHEM, V254, P2110; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KHANDELWAL SR, 1993, AM J PHYSIOL, V265, pH1450, DOI 10.1152/ajpheart.1993.265.4.H1450; Kosaka H, 1996, BIOCHEM BIOPH RES CO, V218, P749, DOI 10.1006/bbrc.1996.0133; KOSAKA H, 1994, BIOCHEM BIOPH RES CO, V204, P1055, DOI 10.1006/bbrc.1994.2569; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; KOSAKA H, 1996, METHODS NITRIC OXIDE, P373; KURZ MA, 1993, BIOCHEM J, V292, P545, DOI 10.1042/bj2920545; LIPOWSKY HH, 1978, MICROVASC RES, V15, P93, DOI 10.1016/0026-2862(78)90009-2; OKADA Y, 1976, AM J PHYSIOL, V230, P471, DOI 10.1152/ajplegacy.1976.230.2.471; SCHMIDSCHOENBEIN GW, 1975, MICROVASC RES, V10, P153, DOI 10.1016/0026-2862(75)90003-5; Seiyama A, 1996, AM J PHYSIOL-HEART C, V271, pH1, DOI 10.1152/ajpheart.1996.271.1.H1; Seiyama A, 1996, AM J PHYSIOL-HEART C, V270, pH1704, DOI 10.1152/ajpheart.1996.270.5.H1704; SEIYAMA A, 1994, AM J PHYSIOL, V267, pH944, DOI 10.1152/ajpheart.1994.267.3.H944; WAYLAND H, 1967, J APPL PHYSIOL, V22, P333, DOI 10.1152/jappl.1967.22.2.333; WITTENBE.JB, 1966, J BIOL CHEM, V241, P104	19	25	28	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1997	3	4					456	459		10.1038/nm0497-456	http://dx.doi.org/10.1038/nm0497-456			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095182				2022-12-25	WOS:A1997WQ82500038
J	Fink, DJ; Glorioso, JC				Fink, DJ; Glorioso, JC			Engineering herpes simplex virus vectors for gene transfer to neurons	NATURE MEDICINE			English	Editorial Material							LATENCY-ASSOCIATED TRANSCRIPT; TYPE-1 LATENCY; EXPRESSION; PROMOTER; GANGLIA; MOUSE; RNA		UNIV PITTSBURGH,SCH MED,DEPT MOL GENET & BIOCHEM,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT NEUROL,PITTSBURGH,PA 15261; VET ADM MED CTR,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)								BATCHELOR AH, 1992, J VIROL, V66, P3573, DOI 10.1128/JVI.66.6.3573-3582.1992; Bentz J, 1993, VIRAL FUSION MECH, P201; CHEN XW, 1995, J VIROL, V69, P7899, DOI 10.1128/JVI.69.12.7899-7908.1995; DELUCA NA, 1985, J VIROL, V56, P558, DOI 10.1128/JVI.56.2.558-570.1985; DOBSON AT, 1989, J VIROL, V63, P3844, DOI 10.1128/JVI.63.9.3844-3851.1989; FEDEROFF HJ, 1992, P NATL ACAD SCI USA, V89, P1636, DOI 10.1073/pnas.89.5.1636; Fink DJ, 1996, ANNU REV NEUROSCI, V19, P265; Fraefel C, 1996, J VIROL, V70, P7190, DOI 10.1128/JVI.70.10.7190-7197.1996; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GOINS WF, 1994, J VIROL, V68, P2239, DOI 10.1128/JVI.68.4.2239-2252.1994; HO DY, 1989, P NATL ACAD SCI USA, V86, P7596, DOI 10.1073/pnas.86.19.7596; LEIDEN JM, 1980, J VIROL, V33, P272, DOI 10.1128/JVI.33.1.272-285.1980; Marconi P, 1996, P NATL ACAD SCI USA, V93, P11319, DOI 10.1073/pnas.93.21.11319; Oligino T, 1996, GENE THER, V3, P892; RAMAKRISHNAN R, 1994, J VIROL, V68, P7083, DOI 10.1128/JVI.68.11.7083-7091.1994; Ramakrishnan R, 1996, J VIROL, V70, P6519, DOI 10.1128/JVI.70.9.6519-6523.1996; ROIZMAN B, 1990, P1795; SOARES MK, 1996, J VIROL, V70, P5384; STEVENS JG, 1989, MICROBIOL REV, V53, P318, DOI 10.1128/MMBR.53.3.318-332.1989; Wu NX, 1996, J VIROL, V70, P6358, DOI 10.1128/JVI.70.9.6358-6369.1996	20	60	66	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					357	359		10.1038/nm0397-357	http://dx.doi.org/10.1038/nm0397-357			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055868				2022-12-25	WOS:A1997WL30500042
J	Miyagawa, K; Rosch, J; Stanczyk, F; Hermsmeyer, K				Miyagawa, K; Rosch, J; Stanczyk, F; Hermsmeyer, K			Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm	NATURE MEDICINE			English	Article							ORAL-CONTRACEPTIVES; POSTMENOPAUSAL WOMEN; RHESUS-MONKEYS; PROGESTERONE; PROGESTAGEN; DISEASE; THERAPY; RISK	Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17 beta in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.	OREGON HLTH SCI UNIV,OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,DEPT MED,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,CHARLES DOTTER INST INTERVENT RADIOL,PORTLAND,OR 97201; UNIV SO CALIF,SCH MED,WOMENS & CHILDRENS HOSP,LOS ANGELES,CA 90033	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Children's Hospital Los Angeles; University of Southern California					NHLBI NIH HHS [HL51723] Funding Source: Medline; NICHD NIH HHS [HD18185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams Michael R., 1994, P243; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; GILMORE JP, 1983, HDB PHYSL 2 2, V3, P885; Gorodeski George I., 1994, P199; HEALY B, 1995, JAMA-J AM MED ASSOC, V273, P240, DOI 10.1001/jama.273.3.240; HERMSMEYER K, IN PRESS J AM COLL C; HIROI M, 1975, STEROIDS, V26, P373, DOI 10.1016/0039-128X(75)90082-3; JIANG CW, 1992, EUR J PHARMACOL, V211, P163, DOI 10.1016/0014-2999(92)90524-8; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; LOBO RA, 1994, OBSTET GYNECOL, V84, P987; MASERI A, 1990, CIRCULATION, V81, P1983, DOI 10.1161/01.CIR.81.6.1983; MEIRIK O, 1995, LANCET, V346, P1582; MILLER VM, 1991, AM J PHYSIOL, V261, pR1022, DOI 10.1152/ajpregu.1991.261.4.R1022; MISHRA SK, 1994, J CARDIOVASC PHARM, V24, P1, DOI 10.1097/00005344-199407000-00001; POULTER NR, 1995, LANCET, V346, P1575; RESKO JA, 1974, ENDOCRINOLOGY, V94, P128, DOI 10.1210/endo-94-1-128; RESKO JA, 1975, ENDOCRINOLOGY, V97, P425, DOI 10.1210/endo-97-2-425; SLAYDEN OD, 1993, ENDOCRINOLOGY, V132, P1845, DOI 10.1210/en.132.4.1845; Stanczyk Frank Z., 1994, P69; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WILLIAMS CL, 1995, GOODMAN GILMANS PHAR, P1411; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199	23	225	231	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					324	327		10.1038/nm0397-324	http://dx.doi.org/10.1038/nm0397-324			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055861				2022-12-25	WOS:A1997WL30500035
J	Patience, C; Takeuchi, Y; Weiss, RA				Patience, C; Takeuchi, Y; Weiss, RA			Infection of human cells by an endogenous retrovirus of pigs	NATURE MEDICINE			English	Article							HUMAN SERUM; XENOTRANSPLANTATION; COMPLEMENT; TRANSPLANTATION; INACTIVATION; ANTIBODY; PATIENT	The possible use of pig organs and tissues as xenografts in humans is actively being considered in biomedical research. We therefore examined whether pig endogenous retrovirus (PERV) genomes can be infectiously transmitted to human cells in culture. Two pig kidney cell lines spontaneously produce C-type retrovirus particles. Cell-free retrovirus produced by the PK-15 kidney cell line (PERV-PK) infected pig, mink and human kidney 293 cell lines and co-cultivation of X-irradiated PK-15 cells with human cells resulted in a broader range of human cell infection, including human diploid fibroblasts and B- and T-cell lines. Kidney, heart and spleen tissue obtained from domestic pigs contained multiple copies of integrated PERV genomes and expressed viral RNA. Upon passage in human cells PERV-PK could rescue a Moloney retroviral vector and acquired resistance to lysis by human complement.			Patience, C (corresponding author), INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.							ACHONG BG, 1976, BRIT J CANCER, V34, P203, DOI 10.1038/bjc.1976.144; Allan JS, 1996, NAT MED, V2, P18, DOI 10.1038/nm0196-18; ARMSTRONG JA, 1971, J GEN VIROL, V10, P195, DOI 10.1099/0022-1317-10-2-195; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; BENVENISTE RE, 1975, P NATL ACAD SCI USA, V72, P4090, DOI 10.1073/pnas.72.10.4090; BENVENISTE RE, 1974, NATURE, V248, P17, DOI 10.1038/248017a0; BOSTOCK DE, 1973, J NATL CANCER I, V50, P933, DOI 10.1093/jnci/50.4.933; COFFIN JM, 1985, RNA TUMOR VIRUSES; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; DONAHUE RE, 1992, J EXP MED, V176, P1125, DOI 10.1084/jem.176.4.1125; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FODER WL, 1994, P NATL ACAD SCI USA, V91, P11153; GOODCHILD NL, 1995, VIROLOGY, V206, P164, DOI 10.1016/S0042-6822(95)80031-X; GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3; Gunsalus JR, 1997, NAT MED, V3, P48, DOI 10.1038/nm0197-48; Homer, 1946, ODYSSEY; Institute of Medicine, 1996, XEN SCI ETH PUBL POL; KAWAKAMI TG, 1978, J NATL CANCER I, V61, P1113; KAWAKAMI TG, 1972, NATURE-NEW BIOL, V235, P170, DOI 10.1038/newbio235170a0; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; LEHRMAN S, 1995, NATURE, V378, P756, DOI 10.1038/378756b0; LEVY JA, 1973, SCIENCE, V182, P1151, DOI 10.1126/science.182.4117.1151; LIEBER MM, 1975, VIROLOGY, V66, P616, DOI 10.1016/0042-6822(75)90234-2; LIEBER MM, 1975, P NATL ACAD SCI USA, V72, P2315, DOI 10.1073/pnas.72.6.2315; MAKOWKA L, 1995, TRANSPLANTATION, V59, P1654, DOI 10.1097/00007890-199506270-00002; MCALLISTER RM, 1972, NATURE-NEW BIOL, V235, P3, DOI 10.1038/newbio235003a0; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; MOENNIG V, 1974, VIROLOGY, V57, P179, DOI 10.1016/0042-6822(74)90119-6; *NUFF COUNC BIOETH, 1996, AN TO HUM TRANSPL ET; Patience C, 1996, J VIROL, V70, P2654, DOI 10.1128/JVI.70.4.2654-2657.1996; PATIENCE C, IN PRESS TRENDS GENE; Purcell DFJ, 1996, J VIROL, V70, P887, DOI 10.1128/JVI.70.2.887-897.1996; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; RYAN US, 1995, NAT MED, V1, P967, DOI 10.1038/nm0995-967; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SCADDEN DT, 1990, J VIROL, V64, P424, DOI 10.1128/JVI.64.1.424-427.1990; SILVER J, 1993, NUCLEIC ACIDS RES, V21, P3593, DOI 10.1093/nar/21.15.3593; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simpson GR, 1996, VIROLOGY, V222, P451, DOI 10.1006/viro.1996.0443; STARZL TE, 1993, LANCET, V341, P65, DOI 10.1016/0140-6736(93)92553-6; STOYE JP, 1995, NAT MED, V1, P1100, DOI 10.1038/nm1195-1100a; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; TODARO GJ, 1974, VIROLOGY, V58, P65, DOI 10.1016/0042-6822(74)90141-X; Tristem M, 1996, J VIROL, V70, P8241, DOI 10.1128/JVI.70.11.8241-8246.1996; Tristem M, 1996, BIOTECHNIQUES, V20, P608; WEISS RA, 1978, NATL CANCER I MONOGR, V48, P183; WILKINSON DA, 1994, RETROVIRIDAE, V3, P465	50	897	968	0	45	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					282	286		10.1038/nm0397-282	http://dx.doi.org/10.1038/nm0397-282			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055854				2022-12-25	WOS:A1997WL30500028
J	Howard, TD; Paznekas, WA; Green, ED; Chiang, LC; Ma, N; DeLuna, RIO; Delgado, CG; GonzalezRamos, M; Kline, AD; Jabs, EW				Howard, TD; Paznekas, WA; Green, ED; Chiang, LC; Ma, N; DeLuna, RIO; Delgado, CG; GonzalezRamos, M; Kline, AD; Jabs, EW			Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome	NATURE GENETICS			English	Article							GROWTH-FACTOR RECEPTOR-2; JACKSON-WEISS-SYNDROME; CROUZON-SYNDROME; SYNDROME LOCUS; BALANCED TRANSLOCATIONS; DROSOPHILA EMBRYOS; GENE; CRANIOSYNOSTOSIS; HETEROGENEITY; LOCALIZATION	Saethre-Chotzen syndrome is one of the most common autosomal dominant disorders of craniosynostosis in humans and is characterized by craniofacial and limb anomalies. The locus for Saethre-Chotzen syndrome maps to chromosome 7p21-p22, We have evaluated TWIST; a basic helix-loop-helix transcription factor, as a candidate gene for this condition because its expression pattern and mutant phenotypes in Drosophila and mouse are consistent with the Saethre-Chotzen phenotype. We mapped TWIST to human chromosome 7p21-p22 and mutational analysis reveals nonsense, missense, insertion and deletion mutations in patients. These mutations occur within the basic DNA binding, helix I and loop domains, or result in premature termination of the protein, Studies in Drosophila indicate that twist may affect the transcription of fibroblast growth factor receptors (FGFRs), another gene family implicated in human craniosynostosis. The emerging cascade of molecular components involved in craniofacial and limb development now includes TWIST, which may function as an upstream regulator of FGFRs.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,CTR MED GENET,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,CTR MED GENET,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,CTR MED GENET,BALTIMORE,MD 21287; NIH,GENOME TECHNOL BRANCH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; GENOME THERAPEUT CORP,COLLABORAT RES DIV,WALTHAM,MA 02154; HOSP INFANTIL MEXICO DR FEDERICO GOMEZ,DEPT GENET,MEXICO CITY 06720,DF,MEXICO; SINAI HOSP,DEPT PEDIAT,DIV CLIN GENET,BALTIMORE,MD 21215	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Hospital Infantil de Mexico Federico Gomez; Sinai Hospital of Baltimore				Jabs, Ethylin/0000-0001-8983-5466	NCRR NIH HHS [RR00722] Funding Source: Medline; NICHD NIH HHS [HD24061] Funding Source: Medline; NIDCR NIH HHS [DE11131] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011131] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BRUETON LA, 1992, J MED GENET, V29, P681, DOI 10.1136/jmg.29.10.681; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Chotzen F., 1932, MSCHR KINDERHEILK, V55, P97; COHEN MM, 1986, CRANIOSYNOSTOSIS DIA, P467; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; EMORI Y, 1993, FEBS LETT, V332, P111, DOI 10.1016/0014-5793(93)80494-F; FRANCKE U, 1977, ANN REV BIRTH DEFECT, V13, P241; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; Goodman B. K., 1995, American Journal of Human Genetics, V57, pA114; GORLIN RJ, 1990, SYNDROMES HEAD NECK, P799; GREEN ED, 1995, GENOMICS, V25, P170, DOI 10.1016/0888-7543(95)80123-4; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; KREBS I, 1996, M GEN MAPP SEQ, P140; LEWANDA AF, 1994, GENOMICS, V19, P115, DOI 10.1006/geno.1994.1020; LEWANDA AF, 1994, AM J HUM GENET, V55, P1195; MATTEI MG, 1993, MAMM GENOME, V4, P127, DOI 10.1007/BF00290439; MEYERS GA, 1995, NAT GENET, V11, P462, DOI 10.1038/ng1295-462; MURRAY SS, 1992, J BONE MINER RES, V10, P1132; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; PARK WJ, 1995, HUM MOL GENET, V4, P1229, DOI 10.1093/hmg/4.7.1229; REARDON W, 1993, AM J MED GENET, V47, P633, DOI 10.1002/ajmg.1320470510; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; REID CS, 1993, AM J MED GENET, V47, P637, DOI 10.1002/ajmg.1320470511; ROSE CSP, 1994, HUM MOL GENET, V3, P1405; Saethre H., 1931, DTSCH Z NERVENHEILK, V117, P533, DOI [10.1007/BF01673869, 10.1007/bf01673869]; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; SIMPSON P, 1983, GENETICS, V105, P615; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TSUJI K, 1994, AM J MED GENET, V45, P108; VANHERWERDEN L, 1994, AM J HUM GENET, V54, P669; vonGernet S, 1996, AM J MED GENET, V63, P177; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WANG S, IN PRESS GENE; WILKIE AOM, 1995, J MED GENET, V32, P174, DOI 10.1136/jmg.32.3.174; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I	41	486	499	0	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					36	41		10.1038/ng0197-36	http://dx.doi.org/10.1038/ng0197-36			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988166				2022-12-25	WOS:A1997WA37300018
J	Matsuura, T; Sutcliffe, JS; Fang, P; Galjaard, RJ; Jiang, YH; Benton, CS; Rommens, JM; Beaudet, AL				Matsuura, T; Sutcliffe, JS; Fang, P; Galjaard, RJ; Jiang, YH; Benton, CS; Rommens, JM; Beaudet, AL			De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome	NATURE GENETICS			English	Article							WILLI-SYNDROME REGION; FACTOR-II GENE; LINKAGE ANALYSIS; EXPRESSED GENE; E6 ONCOPROTEIN; SNRPN GENE; IDENTIFICATION; 15Q11-Q13; DEFINE; P53	Angelman syndrome (AS) is associated with maternal deletions of human chromosome 15q11-q13 and with paternal uniparental disomy for this region indicating that deficiency of an imprinted, maternally expressed gene within the critical interval is the likely cause of the syndrome, Although the gene for EG-AP ubiquitin-protein ligase (UBE3A) was mapped to the critical region for AS, evidence of expression from both parental alleles initially suggested that it was an unlikely candidate gene for this disorder, Because attempts to identify any novel maternally expressed transcripts were unsuccessful and because the UBE3A gene remained within a narrowed AS critical region, we searched for mutations in UBE3A in 11 AS patients without known molecular defects (large deletion, uniparental disomy, or imprinting mutation), This analysis tested the possibility that deficiency of an undefined, maternally expressed transcript or isoform of the UBE3A gene could cause AS, Four mutations were identified including a de novo frameshift mutation and a de novo nonsense mutation in exon 3 and two missense mutations of less certain significance, The de novo truncating mutations indicate that UBE3A is the AS gene and suggest the possibility of a maternally expressed gene product in addition to the biallelically expressed transcript, Intragenic mutation of UBE3A in AS is the first example of a genetic disorder of the ubiquitin-dependent proteolytic pathway in mammals, It may represent an example of a human genetic disorder associated with a locus producing functionally distinct imprinted and biallelically expressed gene products.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT MED & MOL GENET,TORONTO,ON M5G 1X8,CANADA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Sutcliffe, James S/C-1348-2012	Sutcliffe, James S/0000-0001-5200-6007	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00188] Funding Source: Medline; NICHD NIH HHS [HD24064] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; Burke LW, 1996, AM J HUM GENET, V58, P777; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Clechanover A., 1994, CELL, V79, P13; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; GLENN CC, 1993, HUM MOL GENET, V2, P1377, DOI 10.1093/hmg/2.9.1377; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; LEDBETTER DH, 1995, METABOLIC MOL BASES, P811; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; MEIJERSHEIJBOER EJ, 1992, J MED GENET, V29, P853, DOI 10.1136/jmg.29.12.853; NAKAO M, 1994, HUM MOL GENET, V3, P309, DOI 10.1093/hmg/3.2.309; NICHOLLS RD, 1994, AM J HUM GENET, V54, P733; OH CE, 1994, J NEUROSCI, V14, P3166; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; SAITOH S, 1992, LANCET, V339, P366, DOI 10.1016/0140-6736(92)91686-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WAGSTAFF J, 1993, AM J HUM GENET, V53, P105; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; WILLIAMS CA, 1995, AM J MED GENET, V56, P237, DOI 10.1002/ajmg.1320560224; WOODAGE T, 1994, GENOMICS, V19, P170, DOI 10.1006/geno.1994.1031	29	635	656	2	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					74	77		10.1038/ng0197-74	http://dx.doi.org/10.1038/ng0197-74			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988172				2022-12-25	WOS:A1997WA37300024
J	Wyand, MS; Manson, KH; Lackner, AA; Desrosiers, RC				Wyand, MS; Manson, KH; Lackner, AA; Desrosiers, RC			Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus	NATURE MEDICINE			English	Article							UPSTREAM U3 SEQUENCES; RHESUS-MONKEYS; SIV VACCINE; NEF GENE; CHALLENGE; MACAQUES; INFECTION; PROTECTION; RESPONSES; ABSENCE	A major safety concern of using live-attenuated vaccine strategies against AIDS is the potential exposure of neonates or fetuses to vaccine virus from the mother, Here we report that high viral loads and disease were observed in only 2 of 18 neonatal monkeys infected with gene-deleted vaccine strains of simian immunodeficiency virus. Pathogenicity was restricted to neonates born to unvaccinated mothers, that is, lacking maternal immunity, and that received extremely high doses of vaccine virus orally. No in utero transmission af vaccine virus was observed in four neonates born to mothers vaccinated during the second trimester. Our results suggest that the live attenuated vaccine approach should remain a viable option for preventing HIV infection and disease in high-risk human populations.	HARVARD UNIV, NEW ENGLAND REG PRIMATE RES CTR, SCH MED, SOUTHBOROUGH, MA 01772 USA; TSI MASON LABS, WORCESTER, MA 01608 USA	Harvard University					NCRR NIH HHS [RR 0 0168] Funding Source: Medline; NIAID NIH HHS [AI 35365, N01-AI O5O84SI] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; CRANAGE M, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P203; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; DANIEL MD, 1994, AIDS RES HUM RETROV, V10, P839, DOI 10.1089/aid.1994.10.839; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Deacon NJ, 1996, SCIENCE, V271, P1791, DOI 10.1126/science.271.5257.1791; DESROSIERS RC, 1995, 10 C CENT GARD RETR, P197; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; GIAVEDONI LD, 1993, J VIROL, V67, P577, DOI 10.1128/JVI.67.1.577-583.1993; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; HORVATH CJ, 1993, J LEUKOCYTE BIOL, V53, P532, DOI 10.1002/jlb.53.5.532; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1994, J VIROL, V68, P2031, DOI 10.1128/JVI.68.3.2031-2037.1994; LEWIS MG, 1994, AIDS RES HUM RETROV, V10, P213, DOI 10.1089/aid.1994.10.213; MILLS KHG, 1993, J MED PRIMATOL, V22, P104; PUTKONEN P, 1993, J MED PRIMATOL, V22, P100; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; STAHLHENNIG C, 1993, AIDS, V7, P787, DOI 10.1097/00002030-199306000-00005; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996	26	96	98	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1997	3	1					32	36		10.1038/nm0197-32	http://dx.doi.org/10.1038/nm0197-32			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986737				2022-12-25	WOS:A1997WA73300033
J	Zeng, YX; Somasundaram, K; ElDeiry, WS				Zeng, YX; Somasundaram, K; ElDeiry, WS			AP2 inhibits cancer cell growth and activates p21(WAF1)/(CIP1) expression	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR AP-2; INDUCIBLE ENHANCER; LEUKEMIA-CELLS; GENE; DIFFERENTIATION; INDUCTION; CARCINOMA; CHROMOSOME-6; PATHWAY; KINASES	The 52-kD Activator Protein (AP2) is a DNA-binding transcription factor(1-3) implicated in signalling terminal differentiation(2-4). Profound developmental abnormalities have been recently observed in AP2-null mice(5-6). The molecular events by which AP2 promotes differentiation or development are, however, unknown. Increased expression of the universal cell cycle inhibitor p21(WAF1/CIP1) occurs in growth-arrested terminally differentiating cells(7-12). In a search for cellular factors that could activate p21 during phorbol ester (TPA)-induced differentiation, we identified AP2 as a regulator of p21 expression. Mutagenesis of an AP2 DNA-binding site within a p21 promoter-luciferase reporter inhibited its activation by either AP2 transfection or TPA stimulation. Endogenous p21 protein levels were elevated and DNA synthesis was inhibited in AP2 versus control vector-transfected cells. Overexpression of AP2 in HepG2 human hepatoblastoma and SW480 human colon adenocarcinoma cells inhibited cell division and stable colony formation. These results link the differentiation-associated factor AP2 to negative cell cycle and growth control, possibly through p21 activation.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MED & GENET,LAB MOL ONCOL & CELL CYCLE REGULAT,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania								BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAWROZ H, 1994, CANCER RES, V54, P1152; Robertson GP, 1996, CANCER RES, V56, P1635; SATO EF, 1995, BBA-MOL CELL RES, V1266, P23, DOI 10.1016/0167-4889(94)00238-A; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; STEINMAN RA, 1994, ONCOGENE, V9, P389; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WILL, 1991, WILLIAMS T, V5, P671; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	32	263	267	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					78	82		10.1038/ng0197-78	http://dx.doi.org/10.1038/ng0197-78			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988173				2022-12-25	WOS:A1997WA37300025
J	Friedman, A; Kaufer, D; Shemer, J; Hendler, I; Soreq, H; TurKaspa, I				Friedman, A; Kaufer, D; Shemer, J; Hendler, I; Soreq, H; TurKaspa, I			Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response	NATURE MEDICINE			English	Article							HUMAN ACETYLCHOLINESTERASE; CHOLINESTERASES; PERMEABILITY; CONSEQUENCES; EXPRESSION; ISCHEMIA; DRUGS; GENE	Pyridostigmine, a carbamate acetylcholinesterase (AChE) inhibitor, is routinely employed in the treatment of the autoimmune disease myasthenia gravis(1). Pyridostigmine is also recommended by most Western armies for use as pretreatment under threat of chemical warfare, because of its protective effect against organophospsphate poisoning(2,3). Because of this drug's quaternary ammonium group, which prevents its penetration through the blood-rain barrier, the symptoms associated with its routine use primarily reflect perturbations in peripheral nervous system functions(1,4). Unexpectedly, under a similar regimen, pyridostigmine administration during the Persian Gulf War resulted in a greater than threefold increase in the frequency of reported central nervous system symptoms(5). This increase was not due to enhanced absorption (or decreased elimination) of the drug, because the inhibition efficacy of serum butyrylcholinesterase was not modified(5). Because previous animal studies have shown stress-induced disruption of the blood-brain barrier(4), an alternative possibility was that the stress situation associated with war allowed pyridostigmine penetration into the brain. Here we report that after mice were subjected to a forced swim protocol (shown previously to simulate stress(7)), an increase in blood-brain barrier permeability reduced the pyridostigmine dose required to inhibit mouse brain AChE activity by 50% to less than 1/100th of the usual dose. Under these conditions, peripherally administered pyridostigmine increased the brain levels of c-fos oncogene and AChE mRNAs. Moreover, in vitro exposure to pyridostigmine increased both electrical excitability and c-fos mRNA levels in brain slices, demonstrating that the observed changes could be directly induced by pyridostigmine. These findings suggest that peripherally acting drugs administered under stress may reach the brain and affect centrally controlled functions.	ISRAEL DEF FORCES MED CORPS,JERUSALEM,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,CHAIM SHEBA MED CTR,IL-52621 TEL HASHOMER,ISRAEL	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Friedman, A (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.			Soreq, Hermona/0000-0002-0955-526X				AGNOLI A, 1983, CLIN NEUROPHARMACOL, V6, P311, DOI 10.1097/00002826-198312000-00005; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; BENNATHAN D, 1991, LIFE SCI, V48, P1493, DOI 10.1016/0024-3205(91)90187-G; BLICK DW, 1994, TOXICOL APPL PHARM, V126, P311, DOI 10.1006/taap.1994.1121; BORLAND RG, 1985, HUM TOXICOL, V4, P293, DOI 10.1177/096032718500400310; BROWN DA, 1983, TRENDS NEUROSCI, V6, P302, DOI 10.1016/0166-2236(83)90144-3; BRUST P, 1991, EXP PATHOL-JENA, V42, P213, DOI 10.1016/S0232-1513(11)80068-X; DEYI X, 1981, FUNDAMENT APPL TOXIC, V1, P217; DIRUHUMBER P, 1979, J PHARM, V31, P295; EHRHARTBORNSTEI.M, 1991, J ENDOCRINOL, V131, P5; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; FRIEDMAN A, 1989, EUR J NEUROSCI, V1, P374, DOI 10.1111/j.1460-9568.1989.tb00802.x; GAVAGHAN H, 1994, NATURE, V369, P8, DOI 10.1038/369008a0; GLICKSON M, 1991, FUNDAM APPL TOXICOL, V16, P288; HARIK SI, 1991, ANN NY ACAD SCI, V640, P47; IWASAKI Y, 1988, ACTA NEUROL SCAND, V78, P236, DOI 10.1111/j.1600-0404.1988.tb03653.x; LOEWENSTEINLICHTENSTEIN Y, 1995, NAT MED, V1, P1082, DOI 10.1038/nm1095-1082; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; MELIA KR, 1994, J NEUROSCI, V14, P5929; NEVILLE LF, 1990, J BIOL CHEM, V265, P20735; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; SCHWARZ M, 1995, PHARMACOL THERAPEUT, V67, P283, DOI 10.1016/0163-7258(95)00019-D; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; SHARABI Y, 1991, ISRAEL J MED SCI, V27, P656; SHARMA HS, 1991, NEUROSCI RES, V10, P211; TAYLOR P, 1990, PHARMACOL BASIS THER, P122; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WHITTAKER M, 1986, MONOGR HUM GENET, P65	28	300	305	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1382	1385		10.1038/nm1296-1382	http://dx.doi.org/10.1038/nm1296-1382			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946841				2022-12-25	WOS:A1996VW51500048
J	Oddoux, C; Struewing, JP; Clayton, CM; Neuhausen, S; Brody, LC; Kaback, M; Haas, B; Norton, L; Borgen, P; Jhanwar, S; Goldgar, D; Ostrer, H; Offit, K				Oddoux, C; Struewing, JP; Clayton, CM; Neuhausen, S; Brody, LC; Kaback, M; Haas, B; Norton, L; Borgen, P; Jhanwar, S; Goldgar, D; Ostrer, H; Offit, K			The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%	NATURE GENETICS			English	Letter							CANCER SUSCEPTIBILITY GENE; OVARIAN-CANCER; BREAST-CANCER; FAMILIES		NYU,MED CTR,DEPT PEDIAT,HUMAN GENET PROGRAM,NEW YORK,NY 10016; NCI,GENET EPIDEMIOL BRANCH,NIH,BETHESDA,MD 20892; UNIV UTAH,SCH MED,DEPT MED INFORMAT,GENET EPIDEMIOL GRP,SALT LAKE CITY,UT 84108; NIH,LAB GENE TRANSFER,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; UNIV CALIF SAN DIEGO,DEPT PEDIAT & REPROD MED,SAN DIEGO,CA 92123; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,BREAST CANC MED SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT SURG,BREAST SERV,NEW YORK,NY 10021; INT AGCY RES CANC,UNIT GENET EPIDEMIOL,LYON 08,FRANCE	New York University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California San Diego; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; World Health Organization; International Agency for Research on Cancer (IARC)			Struewing, Jeffery P/I-7502-2013; Struewing, Jeffery P/C-3221-2008	Struewing, Jeffery P/0000-0002-4848-3334; 	NCI NIH HHS [R01 CA 65673, R01 CA 55914, P20 CA 58232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065673, R01CA055914, P20CA058232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DB, 1996, AM J HUM GENET, V58, P1166; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; KRONN D, 1995, AM J HUM GENET, V57, P1250; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; ODDOUX C, 1995, PRENATAL DIAG, V15, P817, DOI 10.1002/pd.1970150905; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; TONIN P, 1995, AM J HUM GENET, V57, P189; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	16	293	297	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					188	190		10.1038/ng1096-188	http://dx.doi.org/10.1038/ng1096-188			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841192				2022-12-25	WOS:A1996VL44600026
J	Tachibana, M; Takeda, K; Nobukuni, Y; Urabe, K				Tachibana, M; Takeda, K; Nobukuni, Y; Urabe, K			Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics	NATURE GENETICS			English	Article							LOOP-HELIX PROTEIN; MICROPHTHALMIA GENE; TRANSCRIPTION FACTOR; HUMAN HOMOLOG; MAMMALIAN TYROSINASE; MOUSE FIBROBLASTS; MOLECULAR-BASIS; PAIRED DOMAIN; MUTATIONS; DIFFERENTIATION	MITF (microphthalmia-associated transcription factor) encodes a transcription factor with a basic-helix-loop-helix-zipper (bHLH-Zip) motif. MITF mutations occur in patients with Waardenburg syndrome type 2, a disorder associated with melanocyte abnormalities. Here we show that ectopic expression of MITF converts NIH/3T3 fibroblasts into cells with characteristics of melanocytes. MITF transfectants formed foci of morphologically altered cells, which resemble those induced by oncogenes, but did not exhibit malignant phenotypes. Instead, they contained dendritic cells that express melanogenic marker proteins such as tyrosinase and tyrosinase-related protein 1. Most cloned cells of MITF transfectants exhibited dendritic morphology and expressed melanogenic markers, but such properties were not observed in cells transfected with closely related TFE3 cDNA. Our findings indicate that MITF is critically involved in melanocyte differentiation.	NIMH, CLIN NEUROGENET BRANCH, BETHESDA, MD 20892 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA; NCI, MOL & CELLULAR BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tachibana, M (corresponding author), NIDOCD, GENET MOL LAB, NIH, 5 RES COURT, ROCKVILLE, MD 20850 USA.							ARIAS S, 1971, Birth Defects Original Article Series, V7, P87; AROCA P, 1993, J BIOL CHEM, V268, P25650; ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BOUCHARD B, 1989, J EXP MED, V169, P2029, DOI 10.1084/jem.169.6.2029; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; DAVIDSON R, 1968, P NATL ACAD SCI USA, V60, P894, DOI 10.1073/pnas.60.3.894; DAVIDSON R, 1968, J CELL PHYSIOL, V72, P115, DOI 10.1002/jcp.1040720206; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; DONATIEN P, 1993, ARCH DERMATOL RES, V285, P385, DOI 10.1007/BF00372130; FARRER LA, 1992, AM J HUM GENET, V50, P902; GUARINI L, 1992, PIGM CELL RES, P123; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; HOTH CF, 1993, AM J HUM GENET, V52, P455; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; JUNKER S, 1981, J CELL SCI, V47, P207; KEITHLEY EM, 1992, HEARING RES, V59, P171, DOI 10.1016/0378-5955(92)90113-2; KLEIN D, 1983, AM J MED GENET, V14, P231, DOI 10.1002/ajmg.1320140205; McKusick V.A., 1992, MENDELIAN INHERITANC; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; NAKASHIMA S, 1992, LARYNGOSCOPE, V102, P563, DOI 10.1288/00005537-199205000-00016; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PETERS TA, 1995, HEARING RES, V85, P169, DOI 10.1016/0378-5955(95)00043-4; POWERS TP, 1994, MOL CELL BIOL, V14, P1179, DOI 10.1128/MCB.14.2.1179; PUCK TT, 1955, P NATL ACAD SCI USA, V41, P432, DOI 10.1073/pnas.41.7.432; READ AP, 1993, NAT GENET, V5, P8, DOI 10.1038/ng0993-8b; SHAH KN, 1981, J PEDIATR-US, V99, P432, DOI 10.1016/S0022-3476(81)80339-3; SILVERS WK, 1979, COAT COLORS MICE MOD, P268; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; TACHIBANA M, 1992, MOL CELL NEUROSCI, V3, P433, DOI 10.1016/1044-7431(92)90055-7; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1995, HUM MOL GENET, V4, P2131, DOI 10.1093/hmg/4.11.2131; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WINDER AJ, 1991, BIOCHEM BIOPH RES CO, V178, P739, DOI 10.1016/0006-291X(91)90170-C; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1995, ONCOGENE, V10, P123; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	61	212	224	2	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1996	14	1					50	54		10.1038/ng0996-50	http://dx.doi.org/10.1038/ng0996-50			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782819	Green Published			2022-12-25	WOS:A1996VF61100020
J	Shibata, T; Nagano, T				Shibata, T; Nagano, T			Applying very high resolution microfocus X-ray CT and 3-D reconstruction to the human auditory apparatus	NATURE MEDICINE			English	Article							TOMOGRAPHY	Conventional high-resolution X-ray computed tomography (XCT) is an important medical technique because it provides sectional images (tomograms) of internal structures without destroying the specimen. However, it is difficult to observe and to analyze fine structures less than a few cubic millimeters in size because of its low spatial resolution of 0.4 mm. Overcoming this problem would not only enable visualization of human anatomical structures in living subjects by means of computer images but would make it possible to obtain the equivalent of microscopic images by XCT without making microscopic sections of biopsy material, which would allow the examination of the entire body and detection of focal lesions at an early stage. Bonse et al. and Kinney et al. studied absorption contrast microtomography by using synchrotron radiation(1-3) and achieved 8-mu m spatial resolution in human cancellous bone(1). Recently, Momose et al. reported examining the soft tissue of cancerous rabbit liver by a modification of the phase-contrast technique using synchrotron radiation with a spatial resolution of 30 mu m (ref. 4). However, the equipment for synchrotron radiation requires a great deal of space and is very expensive. Aoki et al., on a different tack, reported microtomography of frog embryos by using a conventional laboratory microfocus X-ray source with a spot size of about 2 mu m (ref. 5). As no human tomographic studies by superresolution microfocus XCT (MFXCT) using a normal open-type X-ray source have been reported, we tried using MFXCT with a maximum experimental spatial resolution of 2.5 mu m, especially designed for industrial use, on the auditory ossicles(6) of a human fetus, the smallest and lightest bones in the skeletal system. No XCT studies of fetal auditory ossicles have been reported to date. The fine tomograms with three-dimensional reconstructions obtained showed the existence of an apparently previously undescribed joint between the tympanic ring and the anterior process of the malleus. We hope the early development of this MFXCT for clinical use will make a great contribution to medicine.			Shibata, T (corresponding author), TOKYO WOMENS MED COLL,DEPT ANAT,SHINJUKU KU,KAWADACHO 8-1,TOKYO 162,JAPAN.							AOKI S, 1994, JPN J APPL PHYS 2, V33, pL556, DOI 10.1143/JJAP.33.L556; BARRY JA, 1966, MORRIS HUMAN ANATOMY, P1186; BONSE U, 1994, BONE MINER, V25, P25, DOI 10.1016/S0169-6009(08)80205-X; BRACEWELL RN, 1967, ASTROPHYS J, V150, P427, DOI 10.1086/149346; HINRACHSEN KV, 1990, HUMANEMBRYOLOGIE LEH, P509; KINNEY JH, 1994, NUCL INSTRUM METH A, V347, P480, DOI 10.1016/0168-9002(94)91932-1; KINNEY JH, 1986, 26 SOC PHOT SCI ENG; KUBIK S, 1987, RAUBER KOPSCH ANATOM, V3, P588; Momose A, 1996, NAT MED, V2, P473, DOI 10.1038/nm0496-473; SATO Y, 1956, J OTOLARYNGOL JPN, V59, P953; SLAVKIN HC, 1979, DEV CRANIOFACIAL BIO, P373; SWARTZ JD, 1983, RADIOLOGY, V148, P449, DOI 10.1148/radiology.148.2.6867341; VESALIUS A, 1843, HUMANI CORPORIS FABR	13	31	31	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					933	935		10.1038/nm0896-933	http://dx.doi.org/10.1038/nm0896-933			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705866				2022-12-25	WOS:A1996UZ80400043
J	Morishita, R; Sugimoto, T; Aoki, M; Kida, I; Tomita, N; Moriguchi, A; Maeda, K; Sawa, Y; Kaneda, Y; Higaki, J; Ogihara, T				Morishita, R; Sugimoto, T; Aoki, M; Kida, I; Tomita, N; Moriguchi, A; Maeda, K; Sawa, Y; Kaneda, Y; Higaki, J; Ogihara, T			In vivo transfection of cis element ''decoy'' against nuclear factor-kappa B binding site prevents myocardial infarction	NATURE MEDICINE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; ISCHEMIA-REPERFUSION INJURY; TRANSCRIPTION FACTOR; SMOOTH-MUSCLE; IN-VIVO; GENE-EXPRESSION; POTENTIAL ROLE; MESSENGER-RNA; RAT-HEART; CELLS	The transcriptional factor nuclear factor-kappa B (NF kappa B) plays a pivotal role in the coordinated transactivation of cytokine and adhesion molecule genes that might be Involved in myocardial damage after ischemia and reperfusion. Therefore, we hypothesized that synthetic double-stranded DNA with high affinity for NF kappa B could be introduced in vivo as ''decoy'' cls elements to bind the transcriptional factor and to block the activation of genes mediating myocardial infarction, thus providing effective therapy for myocardial infarction. Treatment before and after infarction by transfection of NF kappa B decoy, but not scrambled decoy, oligodeoxynucleotides before coronary artery occlusion or immediately after reperfusion had a significant inhibitory effect on the area of infarction. Here, we report the first successful in vivo transfer of NF kappa B decoy oligodeoxynucleotides to reduce the extent of myocardial infarction following reperfusion, providing a new therapeutic strategy for myocardial infarction.	OSAKA UNIV,SCH MED,DEPT GERIATR MED,SUITA,OSAKA 565,JAPAN; FUJISAWA PHARMACEUT CO LTD,OSAKA 532,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Osaka University; Astellas Pharmaceuticals; Osaka University; Osaka University								BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BILLUPS KL, 1995, J LAB CLIN MED, V125, P626; BRENNAN DC, 1990, KIDNEY INT, V38, P1039, DOI 10.1038/ki.1990.310; COTRAN RS, 1989, PATHOLOGIC BASIS DIS, P611; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; KUKIELKA GL, 1995, CIRCULATION, V92, P1866, DOI 10.1161/01.CIR.92.7.1866; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Morishita R, 1996, HYPERTENSION, V27, P502, DOI 10.1161/01.HYP.27.3.502; MORISHITA R, 1994, J CLIN INVEST, V94, P824, DOI 10.1172/JCI117402; MORITA M, 1993, AM J PATHOL, V143, P419; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NEWTON RC, 1993, J IMMUNOL METHODS, V161, P257, DOI 10.1016/0022-1759(93)90301-M; OZ MC, 1995, CIRCULATION, V92, P428, DOI 10.1161/01.CIR.92.9.428; SATRIANO J, 1994, J CLIN INVEST, V94, P1629, DOI 10.1172/JCI117505; SAWA Y, 1995, CIRCULATION, V92, P479, DOI 10.1161/01.CIR.92.9.479; SAWA Y, 1994, ANN THORAC SURG, V58, P1386, DOI 10.1016/0003-4975(94)91919-4; SOBEL BE, 1972, CIRCULATION, V46, P640, DOI 10.1161/01.CIR.46.4.640; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; THOMAE KR, 1993, SURGERY, V114, P272; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; WILSON I, 1993, CIRCULATION, V88, P372; YAMADA T, 1995, J CLIN INVEST, V96, P1230, DOI 10.1172/JCI118156; YAMAZAKI T, 1993, AM J PATHOL, V143, P410; YOUKER KA, 1994, CIRCULATION, V89, P2736, DOI 10.1161/01.CIR.89.6.2736	27	549	597	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					894	899		10.1038/nm0897-894	http://dx.doi.org/10.1038/nm0897-894			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256281				2022-12-25	WOS:A1997XP01400032
J	Bell, DM; Leung, KKH; Wheatley, SC; Ng, LJ; Zhou, S; Ling, KW; Sham, MH; Koopman, P; Tam, PPL; Cheah, KSE				Bell, DM; Leung, KKH; Wheatley, SC; Ng, LJ; Zhou, S; Ling, KW; Sham, MH; Koopman, P; Tam, PPL; Cheah, KSE			SOX9 directly regulates the type-II collagen gene	NATURE GENETICS			English	Article							SRY-RELATED GENE; CHONDROCYTE EXPRESSION; ACTIVATION DOMAIN; TRANSGENIC MICE; COL2A1 GENE; BINDING; MOUSE; ENHANCER; MUTATIONS; PROTEIN	Mutations in human SOX9 are associated with campomelic dysplasia (CD), characterised by skeletal malformation and XY sex reversal(1-3). During chondrogenesis in the mouse, Sox9 is coexpressed with Col2a1, the gene encoding type-II collagen, the major cartilage matrix protein(4). Col2a1 is therefore a candidate regulatory target of SOX9. Regulatory sequences required for chondrocyte-specific expression of the type-II collagen gene have been localized to conserved sequences in the first intron in rats, mice and humans(5-8). We show here that SOX9 protein binds specifically to sequences in the first intron of human COL2A1, Mutation of these sequences abolishes SOX9 binding and chondrocyte-specific expression of a COL2A1-driven reporter gene (COL2A1-lacZ) in transgenic mice. Furthermore, ectopic expression of Sox9 trans-activates both a COL2A1-driven reporter gene and the endogenous Col2a1 gene in transgenic mice. These results demonstrate that COL2A1 expression is directly regulated by SOX9 protein in vivo and implicate abnormal regulation of COL2A1 during chondrogenesis as a cause of the skeletal abnormalities associated with campomelic dysplasia.	UNIV HONG KONG,DEPT BIOCHEM,HONG KONG,HONG KONG; UNIV QUEENSLAND,CTR CELLULAR & MOL BIOL,BRISBANE,QLD 4072,AUSTRALIA; UNIV QUEENSLAND,DEPT ANAT SCI,BRISBANE,QLD 4072,AUSTRALIA; CHILDRENS MED RES INST,WENTWORTHVILLE 2145,AUSTRALIA	University of Hong Kong; University of Queensland; University of Queensland; Children's Medical Research Institute - Australia			Leung, Keith/C-4491-2009; Sham, Mai Har/AAX-3781-2020; Cheah, Kathryn/C-4222-2009; Koopman, Peter A/C-9416-2009; Sham, Mai Har/C-4387-2009	Sham, Mai Har/0000-0003-1179-7839; Koopman, Peter A/0000-0001-6939-0914; Bell, Donald/0000-0002-3788-1580				CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; KAMACHI YS, 1995, EMBO J, V14, P1310; KANAI Y, 1996, J CELL BIOL, V133, P1; Kent J, 1996, DEVELOPMENT, V122, P2813; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Nonchev S, 1996, DEVELOPMENT, V122, P543; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; RITVANIEMI P, 1995, ARTHRITIS RHEUM, V38, P999, DOI 10.1002/art.1780380717; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; Schafer AJ, 1996, ANN NY ACAD SCI, V785, P137, DOI 10.1111/j.1749-6632.1996.tb56252.x; SEGHATOLESLAMI MR, 1994, MATRIX BIOL, V14, P753; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WAGNER T, 1994, CELL, V79, P111; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; ZHOU G, 1995, J CELL SCI, V108, P3677	30	731	764	3	49	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					174	178		10.1038/ng0697-174	http://dx.doi.org/10.1038/ng0697-174			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171829				2022-12-25	WOS:A1997XB54300018
J	LowBeer, D; Stoneburner, RL; Mukulu, A				LowBeer, D; Stoneburner, RL; Mukulu, A			Empirical evidence for the severe but localized impact of AIDS on population structure	NATURE MEDICINE			English	Article							DEMOGRAPHIC-IMPACT; INFECTION; UGANDA; COHORT; HIV-1; MORTALITY; DYNAMICS; EPIDEMIC; DISTRICT; SPREAD	Despite considerable speculation on the demographic impact of AIDS, there has been, until now, little scientific evidence to establish its existence or scale. Because of the widespread implications of these predictions, methods to combine demography and epidemiology to study empirical situations have been an urgent priority. This study derives the extent and mechanisms of demographic impacts of AIDS from routine data (the 1991 census) in a severely affected country, Uganda. Three characteristics are of particular note: first, the emergence of demographic impacts much earlier than previously estimated; second, their localization with negative population growth at parish but not at district or national scales; third, a greater impact on the number of children than previously predicted(1,2), due as much to changes in population fertility as mortality. The emergence of demographic impacts at this stage highlights original aspects of the interdependence of HIV infection and demographic growth not previously recorded and the need to target preventive interventions to youth in developing countries.	WHO,GLOBAL PROGRAMME AIDS,SURVEILLANCE EVALUAT & FORECASTING UNIT,CH-1211 GENEVA 27,SWITZERLAND; INT CTR MIGRAT & HLTH,CH-1214 GENEVA,SWITZERLAND; MINIST FINANCE & ECON PLANNING,DEPT STAT,ENTEBBE,UGANDA	World Health Organization	LowBeer, D (corresponding author), UNIV CAMBRIDGE,DEPT GEOG,DOWNING PL,CAMBRIDGE CB2 3EN,ENGLAND.							ANDERSON RM, 1988, NATURE, V332, P228, DOI 10.1038/332228a0; ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; BARNETT T, 1992, AIDS AFRICA; CHIN J, 1991, B WORLD HEALTH ORGAN, V69, P399; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; Demeny Coale AJ., 1966, REGIONAL MODEL LIFE; GIBB D, 1994, AIDS S1, V8, pS275; HUNTER SS, 1990, SOC SCI MED, V31, P681, DOI 10.1016/0277-9536(90)90250-V; MASON CJ, 1995, AIDS, V9, P1061, DOI 10.1097/00002030-199509000-00012; MAY RM, 1985, MATH BIOSCI, V77, P141, DOI 10.1016/0025-5564(85)90093-8; Mertens TE, 1996, B WORLD HEALTH ORGAN, V74, P121; *MIN FIN EC PLANN, 1995, REP UG 1991 POP HOUS; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; OBBO C, 1993, SOC SCI MED, V36, P949, DOI 10.1016/0277-9536(93)90086-J; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011; Stoneburner RL, 1996, AM J EPIDEMIOL, V144, P682, DOI 10.1093/oxfordjournals.aje.a008981; STONEBURNER RL, 1993, AM J EPIDEMIOL, V138, P1093, DOI 10.1093/oxfordjournals.aje.a116827; *SYST INC, 1982, SYST 5 01 WIND; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303; *WHO, 1991, AIDS EP ITS DEM CONS	21	16	16	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					553	557		10.1038/nm0597-553	http://dx.doi.org/10.1038/nm0597-553			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142126				2022-12-25	WOS:A1997WX54300037
J	Sauer, U; Hatzimanikatis, V; Bailey, JE; Hochuli, M; Szyperski, T; Wuthrich, K				Sauer, U; Hatzimanikatis, V; Bailey, JE; Hochuli, M; Szyperski, T; Wuthrich, K			Metabolic fluxes in riboflavin-producing Bacillus subtilis	NATURE BIOTECHNOLOGY			English	Article						Bacillus subtilis; metabolic flux; C-13-labeling; NMR; metabolic engineering	NUCLEAR-MAGNETIC-RESONANCE; CORYNEBACTERIUM-GLUTAMICUM; ESCHERICHIA-COLI; BRANCH POINT; GROWTH; FERMENTATION; PATHWAYS; LEUCINE; VALINE; ACID	The pentose phosphate pathway and the pyruvate shunt were identified as major pathways of glucose catabolism in a recombinant, riboflavin-producing Bacillus subtilis strain. Reactions connecting the tricarboxylic acid cycle and glycolysis, catalyzed by the malic enzyme and phosphoenolpyruvate carboxykinase, consume up to 23% of the metabolized glucose. These are examples of important fluxes that can be accessed explicitly using a novel analysis based on synergistic application of flux balancing and recently introduced techniques of fractional C-13-labeling and two-dimensional nuclear magnetic resonance spectroscopy. The overall flux distribution also suggests that B. subtilis metabolism has an unusually high capacity for the reoxidation of NADPH. Under the conditions investigated, riboflavin formation in B. subtilis is limited by the fluxes through the biosynthetic rather than the central carbon pathways, which suggests a focus for future metabolic engineering of this system.	ETH ZURICH, INST BIOTECHNOL, CH-8093 ZURICH, SWITZERLAND; ETH ZURICH, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich			Hatzimanikatis, Vassily/B-7646-2009; Hatzimanikatis, Vassily/G-6505-2010; Sauer, Uwe/Y-3556-2019	Hatzimanikatis, Vassily/0000-0001-6432-4694; Hochuli, Michel/0000-0001-5227-6154				BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; DIESTERHAFT MD, 1973, J BIOL CHEM, V248, P6062; Eggeling L., 1996, ADV BIOCHEM ENG BIOT, V54, P1; FREESE E, 1969, J BACTERIOL, V99, P745, DOI 10.1128/JB.99.3.745-756.1969; GALAZZO JL, 1990, ENZYME MICROB TECH, V12, P162, DOI 10.1016/0141-0229(90)90033-M; GOEL A, 1993, BIOTECHNOL BIOENG, V42, P686, DOI 10.1002/bit.260420603; Gottschalk G., 1986, BACTERIAL METABOLISM; Hatzimanikatis V, 1996, AICHE J, V42, P1277, DOI 10.1002/aic.690420509; HOLMS WH, 1986, CURR TOP CELL REGUL, V28, P69; ISHINO S, 1991, J GEN APPL MICROBIOL, V37, P157, DOI 10.2323/jgam.37.157; Marx A, 1996, BIOTECHNOL BIOENG, V49, P111, DOI 10.1002/(SICI)1097-0290(19960120)49:2<111::AID-BIT1>3.0.CO;2-T; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; PORTAIS JC, 1993, EUR J BIOCHEM, V217, P457, DOI 10.1111/j.1432-1033.1993.tb18265.x; ROLLIN C, 1995, EUR J BIOCHEM, V227, P488, DOI 10.1111/j.1432-1033.1995.tb20414.x; SASAJIMA K, 1984, BIOTECHNOL GENET ENG, V2, P175, DOI 10.1080/02648725.1984.10647799; Sauer U, 1996, APPL ENVIRON MICROB, V62, P3687, DOI 10.1128/AEM.62.10.3687-3696.1996; SCHLOSSER PM, 1994, BIOTECHNOL PROGR, V10, P141, DOI 10.1021/bp00026a003; SENN H, 1989, FEBS LETT, V249, P113, DOI 10.1016/0014-5793(89)80027-4; Sloma A, 1991, European patent, Patent No. [EP0405370, 0405370, 405370]; STEPHANOPOULOS G, 1993, TRENDS BIOTECHNOL, V11, P392, DOI 10.1016/0167-7799(93)90099-U; Szyperski T, 1996, TRENDS BIOTECHNOL, V14, P453, DOI 10.1016/S0167-7799(96)10056-1; SZYPERSKI T, 1995, EUR J BIOCHEM, V232, P433, DOI 10.1111/j.1432-1033.1995.433zz.x; Tsai PS, 1996, BIOTECHNOL BIOENG, V49, P139; VALLINO JJ, 1993, BIOTECHNOL BIOENG, V41, P633, DOI 10.1002/bit.260410606; VANGULIK WM, 1995, BIOTECHNOL BIOENG, V48, P681, DOI 10.1002/bit.260480617; VARMA A, 1994, BIO-TECHNOL, V12, P994, DOI 10.1038/nbt1094-994; VARMA A, 1993, BIOTECHNOL BIOENG, V42, P59, DOI 10.1002/bit.260420109; VOLK R, 1990, J BIOL CHEM, V265, P19479; WALSH K, 1984, J BIOL CHEM, V259, P9646; WOOD T, 1985, PENTOSE PHOSPHATE PA; WUTHRICH K, 1992, FRONTIERS AND NEW HORIZONS IN AMINO ACID RESEARCH, P41	31	209	219	2	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					448	452		10.1038/nbt0597-448	http://dx.doi.org/10.1038/nbt0597-448			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131624				2022-12-25	WOS:A1997WX23700029
J	Telenti, A; Philipp, WJ; Sreevatsan, S; Bernasconi, C; Stockbauer, KE; Wieles, B; Musser, JM; Jacobs, WR				Telenti, A; Philipp, WJ; Sreevatsan, S; Bernasconi, C; Stockbauer, KE; Wieles, B; Musser, JM; Jacobs, WR			The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol	NATURE MEDICINE			English	Article							STREPTOMYCIN RESISTANCE; RIFAMPICIN-RESISTANCE; SMEGMATIS; MUTATIONS; ARABINOGALACTAN; POLYMERASE	Ethambutol (EMB), a frontline antituberculous drug, targets the mycobacterial cell wall, a unique structure among prokaryotes which consists of an outer layer of mycolic acids covalently bound to peptidoglycan via the arabinogalactan. EMB inhibits the polymerization of cell wall arabinan, and results in the accumulation of the lipid carrier decaprenol phosphoarabinose(1,2), which suggests that the drug interferes with the transfer of arabinose to the cell wall acceptor. Unfortunately, resistance to EMB has been described in up to 4% of clinical isolates of Mycobacterium tuberculosis and is prevalent among isolates from patients with multidrug-resistant tuberculosis(3). We used resistance to EMB as a tool to identify genes participating in the biosynthesis of the mycobacterial cell wall. This approach led to the identification of the embCAB gene cluster, recently proposed to encode for mycobacterial arabinosyl transferases(4). Resistance to EMB results from an accumulation of genetic events determining overexpression of the Emb protein(s), structural mutation in EmbB, or both. Further characterization of these proteins might provide information on targets for new chemotherapeutic agents and might help development of diagnostic strategies for the detection of resistant M. tuberculosis.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED RES INST,BRONX,NY 10461; BAYLOR COLL MED,DEPT PATHOL,SECT MOL PATHOBIOL,HOUSTON,TX 77030	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine	Telenti, A (corresponding author), UNIV BERN,INST MED MICROBIOL,CH-3010 BERN,SWITZERLAND.		Sreevatsan, Srinand/V-6808-2019	Sreevatsan, Srinand/0000-0002-5162-2403; Wieles, Brigitte/0000-0001-9631-3404; Jacobs, William/0000-0003-3321-3080	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037015, R01AI037004] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-37015, AI-37004] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; DERETIC V, 1995, MOL MICROBIOL, V17, P889, DOI 10.1111/j.1365-2958.1995.mmi_17050889.x; EIGLMEIER K, 1993, MOL MICROBIOL, V7, P197, DOI 10.1111/j.1365-2958.1993.tb01111.x; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; GANGADHARAM PR, 1970, AM REV RESPIR DIS, V102, P653; HEIFETS LB, 1986, ANTIMICROB AGENTS CH, V30, P927, DOI 10.1128/AAC.30.6.927; HONORE N, 1994, ANTIMICROB AGENTS CH, V38, P238, DOI 10.1128/AAC.38.2.238; Kocagoz T, 1996, ANTIMICROB AGENTS CH, V40, P1768, DOI 10.1128/AAC.40.8.1768; LAZLO A, IN PRESS INT J TUBER; LEVIN ME, 1993, MOL MICROBIOL, V8, P277, DOI 10.1111/j.1365-2958.1993.tb01572.x; Maddry JA, 1996, RES MICROBIOL, V147, P106, DOI 10.1016/0923-2508(96)80211-7; MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496, DOI 10.1128/CMR.8.4.496; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Takiff HE, 1996, P NATL ACAD SCI USA, V93, P362, DOI 10.1073/pnas.93.1.362; TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; Telenti A, 1997, J CLIN MICROBIOL, V35, P719, DOI 10.1128/JCM.35.3.719-723.1997; TELENTI A, 1993, ANTIMICROB AGENTS CH, V37, P2054, DOI 10.1128/AAC.37.10.2054; Telenti A, 1996, RES MICROBIOL, V147, P73, DOI 10.1016/0923-2508(96)80207-5; TELENTI A, 1997, CLIN CHEST MED, V18; Wilson TM, 1996, MOL MICROBIOL, V19, P1025, DOI 10.1046/j.1365-2958.1996.449980.x; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; ZHANG Y, 1992, NATURE, V358, P501	30	351	391	0	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					567	570		10.1038/nm0597-567	http://dx.doi.org/10.1038/nm0597-567			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142129				2022-12-25	WOS:A1997WX54300040
J	Esler, WP; Stimson, ER; Ghilardi, JR; Felix, AM; Lu, YA; Vinters, HV; Mantyh, PW; Maggio, JE				Esler, WP; Stimson, ER; Ghilardi, JR; Felix, AM; Lu, YA; Vinters, HV; Mantyh, PW; Maggio, JE			A beta deposition inhibitor screen using synthetic amyloid	NATURE BIOTECHNOLOGY			English	Article						Alzheimer's disease; A beta deposition; high-throughput screen; Congo red; structure-activity	ALZHEIMER-DISEASE; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; TRANSGENIC MICE; PEPTIDE; AGGREGATION; INVITRO; PLAQUES	The formation, growth, and maturation of brain amyloid ''senile'' plaques are essential pathological processes in Alzheimer's disease (AD) and key targets for therapeutic intervention, The process of in vitro deposition of A beta at physiological concentrations onto plaques in AD brain preparations has been well characterized, but is cumbersome for drug discovery. We describe here a high-throughput screen for inhibitors of A beta deposition onto a synthetic template (synthaloid) of fibrillar A beta immobilized in a polymer matrix. Synthaloid is indistinguishable from plaques in AD brain (the natural template) in deposition kinetics, pH profile, and structure-activity relationships for both A beta analogs and inhibitors, Synthaloid, in contrast to current A beta aggregation screens, accurately predicted inhibitor potency for A beta deposition onto AD cortex preparations, validating its use in searching for agents that can slow the progression of AD and exposing a previously inaccessible target for drug discovery.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; UNIV MINNESOTA,VA MED CTR,MINNEAPOLIS,MN 55417; UNIV MINNESOTA,DEPT PSYCHIAT,MINNEAPOLIS,MN 55417; VANDERBILT UNIV,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; WILLIAM PATERSON COLL NEW JERSEY,DEPT CHEM & PHYS,WAYNE,NJ 07470; UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,LAB MED,LOS ANGELES,CA 90095	Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; Vanderbilt University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIA NIH HHS [AG10123, AG12435, AG12853] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012853, P30AG010123, P01AG012435] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; Esler WP, 1996, J NEUROCHEM, V66, P723; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Ghilardi JR, 1996, NEUROREPORT, V7, P2607, DOI 10.1097/00001756-199611040-00040; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Maggio JE, 1996, BRAIN PATHOL, V6, P147, DOI 10.1111/j.1750-3639.1996.tb00797.x; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MANTYH PW, 1991, B CLIN NEUROSCI, V56, P73; Naiki H, 1996, LAB INVEST, V74, P374; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; POLLACK SJ, 1995, NEUROSCI LETT, V197, P211, DOI 10.1016/0304-3940(95)11939-T; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; SCHENK DB, 1995, J MED CHEM, V38, P4141, DOI 10.1021/jm00021a001; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; Vinters HV, 1996, BRAIN PATHOL, V6, P179, DOI 10.1111/j.1750-3639.1996.tb00799.x; WELDON DT, 1996, SOC NEUR ABS, V22, P475; Wood SJ, 1996, J BIOL CHEM, V271, P4086; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	37	77	80	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					258	263		10.1038/nbt0397-258	http://dx.doi.org/10.1038/nbt0397-258			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062926				2022-12-25	WOS:A1997WM05000030
J	Holmberg, N; Lilius, G; Bailey, JE; Bulow, L				Holmberg, N; Lilius, G; Bailey, JE; Bulow, L			Transgenic tobacco expressing Vitreoscilla hemoglobin exhibits enhanced growth and altered metabolite production	NATURE BIOTECHNOLOGY			English	Article						hemoglobin; tobacco; oxygen; enhanced growth; nicotine	ESCHERICHIA-COLI; INTRACELLULAR EXPRESSION; NICOTINE; CULTURES; PLANTS; GENE	The gene for Vitreoscilla hemoglobin (VHb) has been introduced and expressed in Nicotiana tabaccum (tobacco). Transgenic tobacco plants expressing VHb exhibited enhanced growth, on average 80-100% more dry weight after 35 days of growth compaired to wild-type controls. Furthermore, germination time is reduced from 6-8 days for wild-type tobacco to 3-4 days and the growth phase from germination to flowering was 3-5 days shorter for the VHb-expressing transgenes. Transgenic plants contained, on average, 30-40% more chlorophyll and 34% more nicotine than controls. VHb expression also resulted in an altered distribution of secondary metabolites: In the transgenic tobacco plants anabasine content was decreased 80% relative to control plants.	CTR CHEM & CHEM ENGN,DEPT PURE & APPL BIOCHEM,S-22100 LUND,SWEDEN; ETH ZURICH,INST BIOTECHNOL,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								AMON DI, 1949, PLANT PHYSIOL, V24, P1; Bailey JE, 1995, CHEM ENG SCI, V50, P4091, DOI 10.1016/0009-2509(96)81834-3; BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; BOGUSZ D, 1988, NATURE, V331, P178, DOI 10.1038/331178a0; BREULING M, 1985, PLANT CELL REP, V4, P220, DOI 10.1007/BF00269294; CHEN RZ, 1994, BIOTECHNOL PROGR, V10, P360, DOI 10.1021/bp00028a003; CHEN W, 1994, BIOTECHNOL PROGR, V10, P308, DOI 10.1021/bp00027a011; CURVALL M, 1982, J CHROMATOGR, V232, P283, DOI 10.1016/S0378-4347(00)84168-7; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FRIESEN JB, 1990, TETRAHEDRON LETT, V44, P6295; HOFFMAN P, 1993, PHOTOSYNTHETICA, V4, P495; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KALLIO PT, 1994, EUR J BIOCHEM, V219, P201, DOI 10.1111/j.1432-1033.1994.tb19931.x; KHOSLA C, 1989, J MOL BIOL, V210, P79, DOI 10.1016/0022-2836(89)90292-1; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OKUBO T, 1978, JIBP SYNTHESIS, V19, P194; PENDSE GJ, 1994, BIOTECHNOL BIOENG, V44, P1367, DOI 10.1002/bit.260441114; ROGERS SG, 1986, METHOD ENZYMOL, V118, P627; SAKI RK, 1988, SCIENCE, V239, P487; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SCHLATMANN JE, 1995, BIOTECHNOL BIOENG, V45, P435, DOI 10.1002/bit.260450508; SHEEN SJ, 1988, J FOOD SCI, V53, P1572, DOI 10.1111/j.1365-2621.1988.tb09328.x; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Tsai PS, 1996, BIOTECHNOL BIOENG, V49, P151, DOI 10.1002/(SICI)1097-0290(19960120)49:2<151::AID-BIT4>3.0.CO;2-P; TSAI PS, 1995, BIOTECHNOL BIOENG, V49, P139; WALDEN R, 1990, Methods in Molecular and Cellular Biology, V1, P175; WEBSTER DA, 1974, J BIOL CHEM, V249, P4257; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217	31	98	121	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					244	247		10.1038/nbt0397-244	http://dx.doi.org/10.1038/nbt0397-244			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062923				2022-12-25	WOS:A1997WM05000027
J	Rice, WG; Turpin, JA; Huang, MJ; Clanton, D; Buckheit, RW; Covell, DG; Wallqvist, A; McDonnell, NB; DeGuzman, RN; Summers, MF; Zalkow, L; Bader, JP; Haugwitz, RD; Sausville, EA				Rice, WG; Turpin, JA; Huang, MJ; Clanton, D; Buckheit, RW; Covell, DG; Wallqvist, A; McDonnell, NB; DeGuzman, RN; Summers, MF; Zalkow, L; Bader, JP; Haugwitz, RD; Sausville, EA			Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACID-BINDING-PROTEINS; REVERSE TRANSCRIPTION; STRAND TRANSFER; ZINC FINGERS; INFECTIVITY; DNA; RNA	Nucleocapsid p7 (NCp7) proteins of human immunodeficiency virus type 1 (HIV-1) contain two zinc binding domains of the sequence Cys-(X)(2)-Cys-(X)(4)-His-(X)(4)-Cys (CCHC)(1,2). The spacing pattern and metal-chelating residues (3 Cys, 1 His) of these nucleocapsid CCHC zinc fingers are highly conserved among retroviruses(1,3,4). These CCHC domains are required during both the early(5,6) and late(7,8) phases of retroviral replication, making them attractive targets for antiviral agents. Toward that end, we have identified a number of antiviral chemotypes that electrophilically attack the sulfur atoms of the zinc-coordinating cysteine residues of the domains(9-14). Such nucleocapsid inhibitors were directly virucidal by preventing the initiation of reverse transcription(15) and blocked formation of infectious virus from cells through modification of CCHC domains within Gag precursors(16). Herein we report that azodicarbonamide (ADA) represents a new compound that inhibits HIV-1 and a broad range of retroviruses by targeting the the nucleocapsid CCHC domains. Vandevelde et al.(17) also recently disclosed that ADA inhibits HIV-1 infection via an unidentified mechanism and that ADA was introduced into Phase I/II clinical trials in Europe for advanced AIDS. These studies distinguish ADA as the first known nucleocapsid inhibitor to progress to human trials and provide a lead compound for drug optimization.	NCI,FREDERICK CANC RES & DEV CTR,SAIC FREDERICK,ANTI AIDS VIRUS DRUG SCREENING LAB,FREDERICK,MD 21702; FREDERICK RES CTR,SO RES INST,VIROL RES GRP,FREDERICK,MD 21701; SAIC FREDERICK,NCI,FREDERICK CANC RES & DEV CTR,DIV BASIC SCI,FREDERICK,MD 21702; UNIV MARYLAND BALTIMORE CTY,HOWARD HUGHES MED INST,BALTIMORE,MD 21228; UNIV MARYLAND BALTIMORE CTY,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21228; GEORGIA INST TECHNOL,DEPT CHEM,ATLANTA,GA 30332; NCI,DEV THERAPEUT PROGRAM,DIV CANC TREATMENT,DIAG & CTR,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Howard Hughes Medical Institute; University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland Baltimore County; University System of Georgia; Georgia Institute of Technology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rice, WG (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,SAIC FREDERICK,LAB ANTIVIRAL DURG MECHANISMS,FREDERICK,MD 21702, USA.		wallqvist, anders/W-2584-2019	wallqvist, anders/0000-0002-9775-7469	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; Gorelick RJ, 1996, J VIROL, V70, P2593, DOI 10.1128/JVI.70.4.2593-2597.1996; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; Rice WG, 1996, J MED CHEM, V39, P3606, DOI 10.1021/jm960375o; Rice WG, 1997, ANTIMICROB AGENTS CH, V41, P419, DOI 10.1128/AAC.41.2.419; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; Rice WG, 1996, REV MED VIROL, V6, P187, DOI 10.1002/(SICI)1099-1654(199612)6:4&lt;187::AID-RMV176&gt;3.0.CO;2-F; South T L, 1990, Adv Inorg Biochem, V8, P199; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; Turpin JA, 1996, J VIROL, V70, P6180, DOI 10.1128/JVI.70.9.6180-6189.1996; Turpin JA, 1997, ANTIVIR CHEM CHEMOTH, V8, P60, DOI 10.1177/095632029700800107; Vandevelde M, 1996, AIDS RES HUM RETROV, V12, P567, DOI 10.1089/aid.1996.12.567; Wallqvist A, 1996, PROTEINS, V25, P403, DOI 10.1002/(SICI)1097-0134(199608)25:4<403::AID-PROT1>3.0.CO;2-E; YOU JC, 1994, J BIOL CHEM, V269, P31491	20	100	110	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					341	345		10.1038/nm0397-341	http://dx.doi.org/10.1038/nm0397-341			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055865	Green Published			2022-12-25	WOS:A1997WL30500039
J	Monckton, DG; Coolbaugh, MI; Ashizawa, KT; Siciliano, MJ; Caskey, CT				Monckton, DG; Coolbaugh, MI; Ashizawa, KT; Siciliano, MJ; Caskey, CT			Hypermutable myotonic dystrophy CTG repeats in transgenic mice	NATURE GENETICS			English	Article							UNSTABLE TRIPLET REPEAT; MACHADO-JOSEPH DISEASE; TRINUCLEOTIDE REPEAT; CAG TRINUCLEOTIDE; EXPANSION; GENE; MOUSE; INSTABILITY; MUTATION; GERMLINE	Myotonic dystrophy (DM) is one of a growing number of inherited human disorders associated with the expansion of triplet repeat DNA sequences(1). Expanded alleles are highly unstable in both the germline and soma, accounting in large part for the unusual genetics of this disorder, its phenotypic variability and probably, the progressive nature of the symptoms(2-7) However, the molecular mechanisms and the genetic factors modulating repeat stability in DM and the other human disorders associated with expanded repeats are not well understood. To provide a model system in which the turnover of triplet repeats could be studied throughout mammalian development, we have generated five transgenic mouse lines incorporating expanded CTG/CAG arrays derived from the human DM locus. Transgene analysis has revealed germline hypermutability, including expansions, deletions and parent-of-origin effects, somatic and early embryonic instability and segregation distortion. Mutational differences between lines and sexes demonstrate that stability, as in humans, is modulated by as yet unidentified cis and trans acting genetic elements.	BAYLOR COLL MED, HOWARD HUGHES MED INST, TEXAS MED CTR, HOUSTON, TX 77030 USA; BAYLOR COLL MED, TEXAS MED CTR, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, TEXAS MED CTR, DEPT MOL GENET, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Monckton, DG (corresponding author), UNIV GLASGOW, INST BIOMED & LIFE SCI, ANDERSON COLL, DIV MOL GENET, 56 DUMBARTON RD, GLASGOW G11 6NU, LANARK, SCOTLAND.		Monckton, Darren/B-4943-2013	Monckton, Darren/0000-0002-8298-8264				Biancalana V., 1992, Human Molecular Genetics, V1, P255, DOI 10.1093/hmg/1.4.255; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Chakraborty R, 1996, AM J HUM GENET, V59, P109; Collick A, 1996, EMBO J, V15, P1163, DOI 10.1002/j.1460-2075.1996.tb00455.x; COLLICK A, 1994, EMBO J, V13, P5745, DOI 10.1002/j.1460-2075.1994.tb06912.x; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; Goldberg YP, 1996, HUM MOL GENET, V5, P177, DOI 10.1093/hmg/5.2.177; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Igarashi S, 1996, HUM MOL GENET, V5, P923, DOI 10.1093/hmg/5.7.923; Ikeuchi T, 1996, AM J HUM GENET, V58, P730; JANSEN G, 1994, AM J HUM GENET, V54, P575; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KELLY R, 1991, P ROY SOC B-BIOL SCI, V245, P235, DOI 10.1098/rspb.1991.0115; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHON KA, 1988, P NATL ACAD SCI USA, V85, P1165, DOI 10.1073/pnas.85.4.1165; MARUYAMA H, 1995, HUM MOL GENET, V4, P807, DOI 10.1093/hmg/4.5.807; MONCKTON DG, 1995, HUM MOL GENET, V4, P1; MONCKTON DG, 1995, CIRCULATION, V91, P513, DOI 10.1161/01.CIR.91.2.513; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PINKERT CA, 1994, TRANSGENIC ANIMAL TE; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140; WONG LJC, 1995, AM J HUM GENET, V56, P114; YU YE, IN PRESS MOUSE GENOM	30	108	112	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1997	15	2					193	196		10.1038/ng0297-193	http://dx.doi.org/10.1038/ng0297-193			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020848				2022-12-25	WOS:A1997WF08700022
J	Imbert, G; Saudou, F; Yvert, G; Devys, D; Trottier, Y; Garnier, JM; Weber, C; Mandel, JL; Cancel, G; Abbas, N; Durr, A; Didierjean, O; Stevanin, G; Agid, Y; Brice, A				Imbert, G; Saudou, F; Yvert, G; Devys, D; Trottier, Y; Garnier, JM; Weber, C; Mandel, JL; Cancel, G; Abbas, N; Durr, A; Didierjean, O; Stevanin, G; Agid, Y; Brice, A			Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats	NATURE GENETICS			English	Article							DOMINANT CEREBELLAR-ATAXIA; TRINUCLEOTIDE CAG REPEAT; MACHADO-JOSEPH DISEASE; AGE-OF-ONSET; HUNTINGTONS-DISEASE; CHROMOSOME 3P12-P21.1; CLINICAL-FEATURES; MUSCULAR-ATROPHY; FMR1 GENE; INSTABILITY	Two forms of the neurodegenerative disorder spinocerebellar ataxia are known to be caused by the expansion of a CAG (polyglutamine) trinucleotide repeat. By screening cDNA expression libraries, using an antibody specific for polyglutamine repeats, we identified six novel genes containing CAG stretches. One of them is mutated in patients with spinocerebellar ataxia linked to chromosome 12q (SCA2). This gene shows ubiquitous expression and encodes a protein of unknown function. Normal SCA2 alleles (17 to 29 CAG repeats) contain one to three CAAs in the repeat. Mutated alleles (37 to 50 repeats) appear particularly unstable, upon both paternal and maternal transmissions. The sequence of three of them revealed pure CAG stretches. The steep inverse correlation between age of onset and CAG number suggests a higher sensitivity to polyglutamine length than in the other polyglutamine expansion diseases.	ULP, INSERM, CNRS, IGBMC, F-67404 ILLKIRCH GRAFFENSTADEN, STRASBOURG, FRANCE; HOP LA PITIE SALPETRIERE, INSERM, U289, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, FEDERAT NEUROL, F-75651 PARIS 13, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Stevanin, Giovanni/E-5038-2016; Trottier, Yvon/H-8852-2016; brice, alexis/AAE-8275-2019; Brice, Alexis/A-2170-2009; SAUDOU, Frédéric/L-3454-2014	Stevanin, Giovanni/0000-0001-9368-8657; brice, alexis/0000-0002-0941-3990; SAUDOU, Frédéric/0000-0001-6107-1046; Trottier, Yvon/0000-0001-7230-4810; Yvert, Gael/0000-0003-1955-4786; Devys, Didier/0000-0001-9655-3512; Cancel-Tassin, Geraldine/0000-0002-9583-6382				ALLOTEY R, 1995, AM J HUM GENET, V57, P185; ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; BELAL S, 1994, NEUROLOGY, V44, P1423, DOI 10.1212/WNL.44.8.1423; BENOMAR A, 1995, NAT GENET, V10, P84, DOI 10.1038/ng0595-84; Biancalana V., 1992, Human Molecular Genetics, V1, P255, DOI 10.1093/hmg/1.4.255; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BROHOLM J, 1994, NEUROLOGY, V44, P1533; BURK K, IN PRESS BRAIN; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DIAZ GO, 1990, NEUROLOGY, V40, P1369, DOI 10.1212/WNL.40.9.1369; Durr A, 1996, ANN NEUROL, V39, P490, DOI 10.1002/ana.410390411; Durr A, 1995, BRAIN, V118, P1573, DOI 10.1093/brain/118.6.1573; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Gastier JM, 1996, GENOMICS, V32, P75, DOI 10.1006/geno.1996.0078; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; Gispert S, 1995, Am J Hum Genet, V57, P972; GUSELLA JF, 1995, CURR OPIN NEUROBIOL, V5, P656, DOI 10.1016/0959-4388(95)80072-7; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HARDING AE, 1982, BRAIN, V105, P1, DOI 10.1093/brain/105.1.1; HOLMBERG M, 1995, HUM MOL GENET, V4, P1441, DOI 10.1093/hmg/4.8.1441; Igarashi S, 1996, HUM MOL GENET, V5, P923, DOI 10.1093/hmg/5.7.923; IHARA T, 1994, JPN J HUM GENET, V39, P305, DOI 10.1007/BF01874049; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; IKEUCHI T, 1995, ANN NEUROL, V37, P769, DOI 10.1002/ana.410370610; IMBERT G, 1994, GENOMICS, V21, P667, DOI 10.1006/geno.1994.1335; JIANG JX, 1995, GENOMICS, V30, P91, DOI 10.1006/geno.1995.0015; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUTER K, 1995, NATURE, V377, P321; KREMER B, 1995, AM J HUM GENET, V57, P343; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI 10.1056/NEJM199405193302001; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; Lezin A, 1996, HUM GENET, V97, P671; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; MARUYAMA H, 1995, HUM MOL GENET, V4, P807, DOI 10.1093/hmg/4.5.807; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; Neri C, 1996, HUM MOL GENET, V5, P1001, DOI 10.1093/hmg/5.7.1001; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; PULST SM, 1993, NAT GENET, V5, P8, DOI 10.1038/ng0993-8c; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; RANEN NG, 1995, AM J HUM GENET, V57, P593; RANUM LPW, 1994, AM J HUM GENET, V55, P244; RANUM LPW, 1995, AM J HUM GENET, V57, P603; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; RIGGINS GJ, 1993, NAT GENET, V3, P273, DOI 10.1038/ng0393-273b; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; TROTTIER Y, 1994, J MED GENET, V31, P377, DOI 10.1136/jmg.31.5.377; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Zoghbi HY, 1991, CURR NEUROL, V11, P121	62	737	760	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1996	14	3					285	291		10.1038/ng1196-285	http://dx.doi.org/10.1038/ng1196-285			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896557				2022-12-25	WOS:A1996VQ14600022
J	Tishon, A; Manchester, M; Scheiflinger, F; Oldstone, MBA				Tishon, A; Manchester, M; Scheiflinger, F; Oldstone, MBA			A model of measles virus-induced immunosuppression: Enhanced susceptibility of neonatal human PBLs	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERIPHERAL-BLOOD LEUKOCYTES; SCID MICE; ANTIBODY-PRODUCTION; DISRUPT FUNCTIONS; HUMAN-LYMPHOCYTES; CELL-CYCLE; INFECTION; MOUSE; SUPPRESSION	Measles virus (MV) still incites one of the most contagious infections of humankind. Despite the development and use of an excellent live attenuated virus vaccine, over one million infants and children continue to die each year from measles(1-3). The main cause of morbidity and mortality is virus-induced immunosuppression of lymphocyte function, which allows secondary infections. Here we report an in vivo model for the study of MV-induced immunosuppression. Human peripheral blood leukocytes (PBLs) grafted onto mice with severe combined immunodeficiency disease (SCID mice) to create hu-PBLS-SCID mice produce human IgG that is suppressed by MV infection. Immunosuppression is dependent on the involvement of live virus and is dramatically more severe for PBLs obtained from newborns than PBLs from adults. Suppression of IgG synthesis by PBLs from newborns occurs as early as ten days after administration of MV to hu-PBLS-SCID mice compared with 44 days required for PBLs from adults. Further, MV infection of SCID mice reconstituted with PBLs from newborns reduces IgG production 26+/-5-fold (mean+/-1 s.e.m.) as compared with only a 6+/-0.5-fold reduction in adults. MV RNA could be detected in live human PBLs recovered from SCID mice as long as 110 days after MV infection began. The profound immunosuppression we observe in PBLs from infants probably contributes to the morbidity and mortality observed in infants vaccinated with measles virus. Further, this model should be useful for accessing the potential immunosuppressive abilities of newly isolated field (wildtype) virus isolates and newly designed vaccines containing attenuated MV or subunit vaccines, as well as in dissecting the role played by maternal antibodies to MV on the ability of the virus to enhance or abort the virus-induced immunosuppression.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Manchester, Marianne/0000-0002-7143-5744	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019185] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BLACK FL, 1989, PROG MED VIROL, V36, P1; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CANNON MJ, 1990, J CLIN INVEST, V85, P1333, DOI 10.1172/JCI114573; CASALI P, 1984, J EXP MED, V159, P1322, DOI 10.1084/jem.159.5.1322; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; DUCHOSAL MA, 1992, CELL IMMUNOL, V139, P468, DOI 10.1016/0008-8749(92)90086-5; GELLIN BG, 1994, J INFECT DIS, V170, pS1, DOI 10.1093/infdis/170.Supplement_1.S1; Griffin D., 1996, FIELDS VIROLOGY, V3rd ed., P1267; HENDRICKSON EA, 1993, AM J PATHOL, V143, P1511; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; MARKOWITZ LE, 1987, PEDIATR INFECT DIS J, V6, P809, DOI 10.1097/00006454-198709000-00001; Markowitz LE, 1994, VACCINES, P229; MCCHESNEY MB, 1989, J INFECT DIS, V159, P757, DOI 10.1093/infdis/159.4.757; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MCCHESNEY MB, 1987, J VIROL, V61, P3441, DOI 10.1128/JVI.61.11.3441-3447.1987; MCCHESNEY MB, 1988, J IMMUNOL, V140, P1269; MCCHESNEY MB, 1986, J EXP MED, V163, P1331; MEIZLIK EH, 1948, AM J DIS CHILD, V76, P83, DOI 10.1001/archpedi.1948.02030030090010; Mims C.A., 1974, BIOL ANIMAL VIRUSES; MOCARSKI ES, 1993, P NATL ACAD SCI USA, V90, P104, DOI 10.1073/pnas.90.1.104; MOSIER DE, 1993, SCIENCE, V260, P689, DOI 10.1126/science.8097595; MOSIER DE, 1993, P NATL ACAD SCI USA, V90, P2443, DOI 10.1073/pnas.90.6.2443; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; REBAI N, 1983, TISSUE ANTIGENS, V22, P107; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SLIFKA MK, 1995, J VIROL, V69, P1895, DOI 10.1128/JVI.69.3.1895-1902.1995; TYOR WR, 1993, P NATL ACAD SCI USA, V90, P8658, DOI 10.1073/pnas.90.18.8658; UEKI Y, 1990, J EXP MED, V171, P19, DOI 10.1084/jem.171.1.19; von Pirquet C, 1908, DEUT MED WOCHENSCHR, V34, P1297; YANAGI Y, 1992, VIROLOGY, V187, P280, DOI 10.1016/0042-6822(92)90316-H	33	24	24	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1250	1254		10.1038/nm1196-1250	http://dx.doi.org/10.1038/nm1196-1250			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898755				2022-12-25	WOS:A1996VQ10100043
J	Hatada, I; Ohashi, H; Fukushima, Y; Kaneko, Y; Inoue, M; Komoto, Y; Okada, A; Ohishi, S; Nabetani, A; Morisaki, H; Nakayama, M; Niikawa, N; Mukai, T				Hatada, I; Ohashi, H; Fukushima, Y; Kaneko, Y; Inoue, M; Komoto, Y; Okada, A; Ohishi, S; Nabetani, A; Morisaki, H; Nakayama, M; Niikawa, N; Mukai, T			An imprinted gene p57(KIP2) is mutated in Beckwith-Wiedemann syndrome	NATURE GENETICS			English	Letter							AUTOSOMAL-DOMINANT INHERITANCE; DEPENDENT KINASE INHIBITOR; WILMS-TUMOR; CHROMOSOME-11; ALLELES; FAMILY; P21		SAITAMA CHILDRENS MED CTR,IWATSUKI,SAITAMA 339,JAPAN; SHINSHU UNIV,SCH MED,MATSUMOTO,NAGANO 390,JAPAN; SAITAMA CANC CTR,INA,SAITAMA 362,JAPAN; OSAKA UNIV,SCH MED,SUITA,OSAKA 565,JAPAN; NAGASAKI UNIV,SCH MED,NAGASAKI 852,JAPAN; OSAKA MED CTR,IZUMI,OSAKA 565,JAPAN; RES INST MATERNAL & CHILD HLTH,IZUMI,OSAKA 565,JAPAN	Saitama Children's Medical Center; Shinshu University; Osaka University; Nagasaki University; Osaka Medical Center for Cancer & Cardiovascular Diseases	Hatada, I (corresponding author), NATL CARDIOVASC CTR,RES INST,5-7-1 FUJISHIRO DAI,SUITA,OSAKA 565,JAPAN.			da shi, xiang zi/0000-0002-2256-905X				BARLOW DP, 1994, TRENDS GENET, V10, P194, DOI 10.1016/0168-9525(94)90255-0; BEST LG, 1981, AM J MED GENET, V9, P291, DOI 10.1002/ajmg.1320090405; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; HARPER JW, 1993, CELL, V75, P805; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LUBINSKY M, 1974, LANCET, V1, P932; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MONGHONG L, 1995, GENE DEV, V9, P639; MOUTOU C, 1992, J MED GENET, V29, P217, DOI 10.1136/jmg.29.4.217; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NICHOLLS RD, 1994, AM J HUM GENET, V54, P733; NIIKAWA N, 1986, AM J MED GENET, V24, P41, DOI 10.1002/ajmg.1320240107; OHLSSON R, 1994, TRENDS GENET, V10, P415, DOI 10.1016/0168-9525(94)90100-7; OKANO Y, 1986, JPN J HUM GENET, V31, P365, DOI 10.1007/BF01907937; PAL N, 1990, ONCOGENE, V5, P1665; PING AJ, 1989, AM J HUM GENET, V44, P720; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PUESCHEL SM, 1984, J PEDIATR-US, V104, P484, DOI 10.1016/S0022-3476(84)81127-0; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SOLTER D, 1988, ANNU REV GENET, V22, P127; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807	34	307	313	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					171	173		10.1038/ng1096-171	http://dx.doi.org/10.1038/ng1096-171			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841187				2022-12-25	WOS:A1996VL44600021
J	Lemere, CA; Lopera, F; Kosik, KS; Lendon, CL; Ossa, J; Saido, TC; Yamaguchi, H; Ruiz, A; Martinez, A; Madrigal, L; Hincapie, L; Arango, JCL; Anthony, DC; Koo, EH; Goate, AM; Selkoe, DJ; Arango, JCV				Lemere, CA; Lopera, F; Kosik, KS; Lendon, CL; Ossa, J; Saido, TC; Yamaguchi, H; Ruiz, A; Martinez, A; Madrigal, L; Hincapie, L; Arango, JCL; Anthony, DC; Koo, EH; Goate, AM; Selkoe, DJ; Arango, JCV			The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology	NATURE MEDICINE			English	Article							AMYLOID-BETA-PROTEIN; SENILE PLAQUES; DISEASE; PRECURSOR; GENE	Missense mutations in the presenilin 1 (PS1) gene cause the most common form of dominant early-onset familial Alzheimer's disease (FAD)(1,2) and are associated with increased levels of amyloid beta-peptides (A beta) ending at residue 42 (A beta 42) in plasma and skin fibroblast media of gene carriers(3). A beta 42 aggregates readily and appears to provide a nidus for the subsequent aggregation of A beta 40 (ref. 4), resulting in the formation of innumerable neuritic plaques. To obtain in vivo information about how PS1 mutations cause AD pathology at such early ages, we characterized the neuropathological phenotype of four PS1-FAD patients from a large Colombian kindred(5) bearing the codon 280 Glu to Ala substitution (Glu280Ala) PS1 mutation(2). Using antibodies specific to the alternative carboxy-termini of A beta, we detected massive deposition of A beta 42, the earliest and predominant form of plaque A beta to occur in AD (ref. 6-8), in many brain regions. Computer-assisted quantification revealed a significant increase in A beta 42 but not A beta 40, burden in the brains from 4 PS1-FAD patients compared with those from 12 sporadic AD patients. Severe cerebellar pathology included numerous A beta 42-reactive plaques, many bearing dystrophic neurites and reactive glia. Our results in brain tissue are consistent with recent biochemical evidence of increased A beta 42 levels in PS1-FAD patients and strongly suggest that mutant PS1 proteins alter the proteolytic processing of the beta-amyloid precursor protein at the C-terminus of A beta to favor deposition of A beta 42.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV ANTIOQUIA,DEPT NEUROL,MEDELLIN,COLOMBIA; UNIV ANTIOQUIA,DEPT BIOCHEM,MEDELLIN,COLOMBIA; UNIV ANTIOQUIA,DEPT PATHOL,MEDELLIN,COLOMBIA; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; TOKYO METROPOLITAN INST MED SCI,DEPT MOL BIOL,TOKYO,JAPAN; GUNMA UNIV,COLL MED CARE & TECHNOL,GUNMA,JAPAN	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universidad de Antioquia; Universidad de Antioquia; Universidad de Antioquia; Washington University (WUSTL); Washington University (WUSTL); Tokyo Metropolitan Institute of Medical Science; Gunma University			Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Anthony, Douglas/0000-0002-3815-2240; Goate, Alison/0000-0002-0576-2472	NIA NIH HHS [AG 06173, AG 00634] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG006173, R01AG006173] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; HALTIA M, 1994, ANN NEUROL, V36, P362, DOI 10.1002/ana.410360307; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LAMPE TH, 1994, ANN NEUROL, V36, P368, DOI 10.1002/ana.410360308; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lopera F, 1994, ACTA NEUROL COLOMB, V10, P173; Mann DMA, 1996, AM J PATHOL, V148, P1257; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Song X.-H., 1995, Society for Neuroscience Abstracts, V21, P1501; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; YAMAGUCHI H, 1995, AMYLOID, V2, P7, DOI 10.3109/13506129509031882	25	419	436	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1146	1150		10.1038/nm1096-1146	http://dx.doi.org/10.1038/nm1096-1146			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837617				2022-12-25	WOS:A1996VK99500039
J	Simon, DB; Karet, FE; RodriguezSoriano, J; Hamdan, JH; DiPietro, A; Trachtman, H; Sanjad, SA; Lifton, RP				Simon, DB; Karet, FE; RodriguezSoriano, J; Hamdan, JH; DiPietro, A; Trachtman, H; Sanjad, SA; Lifton, RP			Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK	NATURE GENETICS			English	Article							RENAL POTASSIUM CHANNELS; DNA; CLONING	Mutations in the Na-K-2Cl cotransporter (NKCC2), a mediator of renal salt reabsorption, cause Bartter's syndrome, featuring salt wasting, hypokalaemic alkalosis, hypercalciuria and low blood pressure. NKCC2 mutations can be excluded in some Bartter's kindreds, prompting examination of regulators of cotransporter activity. One regulator is believed to be ROMK, an ATP-sensitive K+ channel that 'recycles' reabsorbed K+ back to the tubule lumen, Examination of the ROMK gene reveals mutations that co-segregate with the disease and disrupt ROMK function in four Bartter's kindreds. Our findings establish the genetic heterogeneity of Bartter's syndrome, and demonstrate the physiologic role of ROMK in vivo.	YALE UNIV, SCH MED,BOYER CTR MOL MED,HOWARD HUGHES MED INST, DEPT MED, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED,BOYER CTR MOL MED,HOWARD HUGHES MED INST, DEPT GENET, NEW HAVEN, CT 06510 USA; HOSP CRUCES, DEPT PEDIAT, E-48903 BARACALDO, SPAIN; DHARAN HLTH CTR, SPECIALTY PEDIAT SERV DIV, DHAHRAN 31311, SAUDI ARABIA; SCHNEIDER CHILDRENS HOSP, ALBERT EINSTEIN COLL MED, DEPT PEDIAT, I-80131 NAPLES, ITALY; KING FAISAL SPECIALIST HOSP & RES CTR, DEPT PEDIAT, RIYADH 11211, SAUDI ARABIA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Hospital Universitario Cruces; King Faisal Specialist Hospital & Research Center				Karet, Fiona/0000-0002-2457-2869				BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; GIEBISCH G, 1995, KIDNEY INT, V48, P1004, DOI 10.1038/ki.1995.382; HEBERT SC, 1995, KIDNEY INT, V48, P1010, DOI 10.1038/ki.1995.383; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; SHUCK ME, 1994, J BIOL CHEM, V269, P24261; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; YANO H, 1994, MOL PHARMACOL, V45, P854	16	654	668	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1996	14	2					152	156		10.1038/ng1096-152	http://dx.doi.org/10.1038/ng1096-152			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841184				2022-12-25	WOS:A1996VL44600018
J	Vaisse, C; Halaas, JL; Horvath, CM; Darnell, JE; Stoffel, M; Friedman, JM				Vaisse, C; Halaas, JL; Horvath, CM; Darnell, JE; Stoffel, M; Friedman, JM			Leptin activation of Stat3 in the hypothalamus of wildtype and ob/ob mice but not db/db mice	NATURE GENETICS			English	Letter							OBESE GENE; TRANSCRIPTION; PATHWAYS; CLONING; PROTEIN; BINDING; GP130		ROCKEFELLER UNIV,METAB DIS LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,GENET MOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL CELL BIOL LAB,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University			Vaisse, Christian/F-1067-2011	Stoffel, Markus/0000-0003-1304-5817; Horvath, Curt/0000-0003-2449-225X	NIDDK NIH HHS [DK41096] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041096] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	20	888	920	0	32	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					95	97		10.1038/ng0996-95	http://dx.doi.org/10.1038/ng0996-95			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782827				2022-12-25	WOS:A1996VF61100028
J	Roman, M; MartinOrozco, E; Goodman, S; Nguyen, MD; Sato, Y; Ronaghy, A; Kornbluth, RS; Richman, DD; Carson, DA; Raz, E				Roman, M; MartinOrozco, E; Goodman, S; Nguyen, MD; Sato, Y; Ronaghy, A; Kornbluth, RS; Richman, DD; Carson, DA; Raz, E			Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants	NATURE MEDICINE			English	Article							GAMMA PRODUCTION; OLIGONUCLEOTIDES; IMMUNIZATION; IMMUNITY; CYTOKINE; VACCINES; ANTIGEN; CELLS; IFN	An adjuvant role for certain short bacterial immunostimulatory DNA sequences (ISSs) has recently been proposed on the basis of their ability to stimulate T helper-1 (Th1) responses in gene-vaccinated animals. We report here that noncoding, ISS-enriched plasmid DNAs or ISS oligonucleotides (ISS-ODNs) potently stimulate immune responses to coadministered antigens. The ISS-DNAs suppress IgE synthesis, but promote IgG and interferon-gamma (IFN-gamma) production. They furthermore initiate the production of IFN-gamma, IFN-alpha, IFN-beta, and interleukins 12 and 18, all of which foster. Th1 responses and enhance cell-mediated immunity. Consideration should be given to adding noncoding DNA adjuvants to inactivated or subunit viral vaccines that, by themselves, provide only partial protection from infection.	DYNAVAX TECHNOL CORP,SAN DIEGO,CA 92121; FUKUSHIMA MED COLL,DEPT INTERNAL MED 2,FUKUSHIMA 96012,JAPAN; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SAN DIEGO VET AFFAIRS MED CTR,LA JOLLA,CA 92093	Fukushima Medical University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Martin-Orozco, Elena/C-2553-2008	Martin-Orozco, Elena/0000-0002-6303-481X; Kornbluth, Richard/0000-0002-0218-2026	NIAID NIH HHS [AI 29614, AI 37305] Funding Source: Medline; NIAMS NIH HHS [AR 41897] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI029614, R01AI037305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041897] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; Bradley LM, 1996, J IMMUNOL, V157, P1350; BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655; Broide D., 1997, Journal of Allergy and Clinical Immunology, V99, pS129; Burke Rae Lynn, 1993, P367; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; Cowdery J, 1996, J IMMUNOL, V156, P4570; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Feltquate DM, 1997, J IMMUNOL, V158, P2278; Freund J, 1937, P SOC EXP BIOL MED, V37, P509; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GRAHAM BS, 1995, NEW ENGL J MED, V333, P1331, DOI 10.1056/NEJM199511163332007; Halpern MD, 1996, CELL IMMUNOL, V167, P72, DOI 10.1006/cimm.1996.0009; KIMURA Y, 1994, J BIOCHEM-TOKYO, V116, P991, DOI 10.1093/oxfordjournals.jbchem.a124658; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; MANICKAN E, 1995, J IMMUNOL, V155, P259; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUNOZ J, 1964, ADV IMMUNOL, V4, P397, DOI 10.1016/S0065-2776(08)60712-9; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Pertmer TM, 1996, J VIROL, V70, P6119, DOI 10.1128/JVI.70.9.6119-6125.1996; Pisetsky DS, 1996, IMMUNITY, V5, P303, DOI 10.1016/S1074-7613(00)80256-3; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; RAZ E, 1994, CATIONIC LIPID INHIB, P71; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; YAEGASHI Y, 1995, J EXP MED, V181, P953, DOI 10.1084/jem.181.3.953; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072	33	788	936	1	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					849	854		10.1038/nm0897-849	http://dx.doi.org/10.1038/nm0897-849			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256274	Bronze			2022-12-25	WOS:A1997XP01400025
J	Haun, RS				Haun, RS			Steps to building the virtual laboratory	NATURE BIOTECHNOLOGY			English	Editorial Material											Haun, RS (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOL BIOL,4301 W MARKHAM,SLOT 516,LITTLE ROCK,AR 72205, USA.							SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463	1	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					683	684		10.1038/nbt0797-683	http://dx.doi.org/10.1038/nbt0797-683			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219274				2022-12-25	WOS:A1997XH58300035
J	Grob, PM; Cao, YZ; Munchmore, E; Ho, DD; Norris, S; Pav, JW; Shih, CK; Adams, J				Grob, PM; Cao, YZ; Munchmore, E; Ho, DD; Norris, S; Pav, JW; Shih, CK; Adams, J			Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1; PROTECTION; PREVENTION; IMMUNIZATION; LYMPHOCYTES; REPLICATION; CHALLENGE; BURDEN; BLOOD	Chimpanzees were challenged with HIV-1(IIB) while receiving a short regimen of nevirapine (Viramune), a nonnucleoside inhibitor of HIV-1 reverse transcriptase. The untreated, control chimpanzee developed an infection characterized by seroconversion, viremia in peripheral blood mononuclear cells (PBMCs), and plasma positive for viral RNA. In contrast, the three nevirapine-treated chimpanzees remained negative for all viral markers with the exception of nested polymerase chain reaction (PCR) analysis of PBMCs for viral DNA. Although PBMCs from the three nevirapine-treated chimpanzees tested intermittently positive for viral DNA, this PCR signal disappeared and remained negative for the final five months of the study. These data indicate that orally administered nevirapine provided protection from HIV-1 infection in the chimpanzee model.	BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT DRUG METAB & PHARMACOKINET,RIDGEFIELD,CT 06877; ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; LAB EXPT MED & SURG PRIMATES,TUXEDO PK,NY 10987	Boehringer Ingelheim; Rockefeller University	Grob, PM (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT INFLAMMATORY DIS,900 RIDGEBURN RD,RIDGEFIELD,CT 06877, USA.							ARTHUR LO, 1989, J VIROL, V63, P5046, DOI 10.1128/JVI.63.12.5046-5053.1989; Berman PW, 1996, J INFECT DIS, V173, P52, DOI 10.1093/infdis/173.1.52; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; CHEESEMAN SH, 1995, J ACQ IMMUN DEF SYND, V8, P141; CHESSMAN SH, 1993, ANTIMICROB AGENTS CH, V37, P178; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DAA ES, 1991, NEW ENGL J MED, V324, P961; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FULTZ PN, 1992, AIDS RES HUM RETROV, V8, P313, DOI 10.1089/aid.1992.8.313; FULTZ PN, 1991, J INFECT DIS, V163, P441, DOI 10.1093/infdis/163.3.441; GIRARD M, 1995, J VIROL, V69, P6239, DOI 10.1128/JVI.69.10.6239-6248.1995; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; Hattox Susan, 1992, Pharmaceutical Research (New York), V9, pS268; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; ISRAEL ZR, 1994, J VIROL, V68, P1843, DOI 10.1128/JVI.68.3.1843-1853.1994; Jayaraj Andrew, 1992, Pharmaceutical Research (New York), V9, pS334; JOHNSON BK, 1993, AIDS RES HUM RETROV, V9, P375, DOI 10.1089/aid.1993.9.375; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966; LEWIS AD, 1995, TRENDS BIOTECHNOL, V13, P142, DOI 10.1016/S0167-7799(00)88925-8; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MURPHY RL, 1996, EXPERT OPIN INV DRUG, V5, P1183; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; SAKSELA K, 1993, J VIROL, V67, P7423, DOI 10.1128/JVI.67.12.7423-7427.1993; SCHEIF WA, 1994, AIDS RES HUM RETROV, V10, P107; TSAI CC, 1994, J INFECT DIS, V169, P260, DOI 10.1093/infdis/169.2.260; WARD RHR, 1991, NATURE, V352, P434, DOI 10.1038/352434a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	34	32	32	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					665	670		10.1038/nm0697-665	http://dx.doi.org/10.1038/nm0697-665			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176494				2022-12-25	WOS:A1997XB97400037
J	Grossman, Z; Herberman, RB				Grossman, Z; Herberman, RB			T-cell homeostasis in HIV infection is neither failing nor blind: Modified cell counts reflect an adaptive response of the host	NATURE MEDICINE			English	Editorial Material							RECEPTOR LIGAND; AIDS; LYMPHOCYTES; ACTIVATION; TOLERANCE		UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grossman, Z (corresponding author), TEL AVIV UNIV,SACKLER FAC MED,DEPT PHYSIOL & PHARMACOL,IL-69978 TEL AVIV,ISRAEL.		Grossman, Zvi/A-9643-2008					ADLEMAN LM, 1993, J ACQ IMMUN DEF SYND, V6, P144; ARNOLD B, 1993, IMMUNOL TODAY, V14, P12, DOI 10.1016/0167-5699(93)90317-E; Bachmann MF, 1996, EUR J IMMUNOL, V26, P2017, DOI 10.1002/eji.1830260908; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; GERMAIN RN, 1995, IMMUNOLOGIST, V3, P113; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; GROSSMAN Z, 1982, EUR J IMMUNOL, V12, P747, DOI 10.1002/eji.1830120909; Grossman Z, 1996, P NATL ACAD SCI USA, V93, P14747, DOI 10.1073/pnas.93.25.14747; GROSSMAN Z, 1992, P NATL ACAD SCI USA, V89, P10365, DOI 10.1073/pnas.89.21.10365; GROSSMAN Z, 1993, CLIN IMMUNOL IMMUNOP, V69, P123, DOI 10.1006/clin.1993.1160; GROSSMAN Z, 1993, IMMUNOL REV, V133, P45, DOI 10.1111/j.1600-065X.1993.tb01509.x; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KAWAI K, 1995, NATURE, V374, P68, DOI 10.1038/374068a0; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; MADDOX J, 1995, NATURE, V373, P189, DOI 10.1038/373189a0; MALONE JL, 1992, J INFECT DIS, V165, P185, DOI 10.1093/infdis/165.1.185; MARGOLICK JB, 1993, J ACQ IMMUN DEF SYND, V6, P153; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Westby M, 1996, IMMUNOL TODAY, V17, P120, DOI 10.1016/0167-5699(96)80603-7; Westermann J, 1996, IMMUNOL TODAY, V17, P278, DOI 10.1016/0167-5699(96)80545-7; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; 1996, IMMUNOL REV, V149	30	60	61	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					486	490		10.1038/nm0597-486	http://dx.doi.org/10.1038/nm0597-486			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142108				2022-12-25	WOS:A1997WX54300019
J	Simpson, EM; Linder, CC; Sargent, EE; Davisson, MT; Mobraaten, LE; Sharp, JJ				Simpson, EM; Linder, CC; Sargent, EE; Davisson, MT; Mobraaten, LE; Sharp, JJ			Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice	NATURE GENETICS			English	Article							GERM-LINE TRANSMISSION; EMBRYONIC STEM-CELLS; TESTICULAR TERATOMAS; EGF RECEPTOR; DISRUPTION; MUTATION; PROTOONCOGENE; ESTABLISHMENT	Targeted mutagenesis in mice, a powerful tool for the analysis of gene function and human disease, makes extensive use of 129 mouse substrains. Although all are named 129, we document that outcrossing of these substrains, both deliberate and accidental, has lead to extensive genetic variability among substrains and embryonic stem cells derived from them. This clearer understanding of 129 substrain variability allows consideration of its negative impact on targeting technology, including: homologous recombination frequencies, preparation of inbred animals, and availability of appropriate controls. Based on these considerations we suggest a number of recommendations for future experimental design.	JACKSON LAB, BAR HARBOR, ME 04609 USA	Jackson Laboratory			Simpson, Elizabeth/H-1183-2012	Simpson, Elizabeth/0000-0002-0654-4303				ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; BAILEY DW, 1970, TRANSPLANT P, V2, P32; BAILEY DW, 1982, IMMUNOL TODAY, V3, P210, DOI 10.1016/0167-5699(82)90093-7; BAILEY DW, 1960, PLAST RECONSTR SURG, V25, P424; BULTMAN SJ, 1994, GENE DEV, V8, P481, DOI 10.1101/gad.8.4.481; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DIETRICH WF, 1993, COMPLETE GENETIC MAP, P1; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FESTING MFW, 1996, MOUSE GENOME, V94, P523; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; *JACKS LAB, 1996, MOUS GEN DAT MOUS GE; KAWASE E, 1994, INT J DEV BIOL, V38, P385; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Matouk C, 1996, MAMM GENOME, V7, P603, DOI 10.1007/s003359900178; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; McWhir J, 1996, NAT GENET, V14, P223, DOI 10.1038/ng1096-223; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NOMURA T, 1984, ICLAS MANUAL GENETIC, P1; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; SADLACK B, 1995, EUR J IMMUNOL, V25, P3053, DOI 10.1002/eji.1830251111; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SHIROISHI T, 1981, MICROBIOL IMMUNOL, V25, P1327, DOI 10.1111/j.1348-0421.1981.tb00141.x; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Silver L, 1995, MOUSE GENETICS CONCE, P1; Silvers W.K., 1979, COAT COLORS MICE, P1; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEVENS LC, 1954, P NATL ACAD SCI USA, V40, P1080, DOI 10.1073/pnas.40.11.1080; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STEVENS LC, 1957, J NATL CANCER I, V18, P719; STEVENS LC, 1979, MOUSE NEWS LETT, V61, P38; STEVENS LC, 1977, MOUSE NEWS LETT, V57, P35; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; WEHNER JM, 1996, MENT RETARD DEV D R, V4, P1; ZUBERL AR, 1996, MOUSE GENOME, V94, P152	42	575	599	0	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1997	16	1					19	27		10.1038/ng0597-19	http://dx.doi.org/10.1038/ng0597-19			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140391				2022-12-25	WOS:A1997WX02400018
J	Ono, M; Wada, Y; Wu, YM; Nemori, R; Jinbo, Y; Wang, H; Lo, KM; Yamaguchi, N; Brunkhorst, B; Otomo, H; Wesolowski, J; Way, JC; Itoh, I; Gillies, S; Chen, LB				Ono, M; Wada, Y; Wu, YM; Nemori, R; Jinbo, Y; Wang, H; Lo, KM; Yamaguchi, N; Brunkhorst, B; Otomo, H; Wesolowski, J; Way, JC; Itoh, I; Gillies, S; Chen, LB			FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes	NATURE BIOTECHNOLOGY			English	Article						AIDS; disulfonaphthalene; syncytia; CD4; gp120	HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING MONOCLONAL-ANTIBODY; DEXTRAN SULFATE; INFECTION; TYPE-1; GLYCOPROTEIN; REPLICATION; DERIVATIVES; LYMPHOCYTES; INHIBITION	The identification of fusin and other chemokine receptors as coreceptors for HIV-1 has renewed the interest in agents that may prevent viral entry. Polyanionic compounds such as dextran sulfate, curdlan sulfate, and suramin act on the V3 loop of the viral envelope and may prevent its interaction with fusin. These agents show activity against a wide range of HIV-1 strains, but have undesirable circulating half-life, bioavailability, and toxicity. We have developed a small molecule inhibitor of HIV-1 that has several advantages over these other agents. FP-21399 is a novel compound of the bis(disulfonaphthalene) dimethoxybenzene class that blocks entry of HIV into CD4(+) cells and blocks fusion of infected and noninfected CD4(+) cells. This compound only weakly inhibits binding of CD4 and gp120, at concentrations much greater than are required to block viral entry. Furthermore, FP-21399 can block the interaction between gp120 and antibodies directed against the V3 loop, but does not block binding of antibodies directed against the V4 loop. Animal studies demonstrate that FP-21399 is concentrated in lymph nodes, making it a promising compound for anti-HIV therapy. In SCID mice reconstituted with human immune cells, maintenance of HIV-1 infection was blocked by a 5-day treatment with low doses of FP-21399, suggesting that lymph node accumulation may contribute to antiviral activity. Finally, attempts to generate drug-resistant virus in cell culture resulted in only weakly resistant variants with IC50 values that are much lower than concentrations of FP-21399 found in lymph nodes.	FUJI IMMUNOPHARMACEUT CORP, LEXINGTON, MA 02173 USA; FUJI PHOTO FILM CO LTD, ASHIGARA RES LABS, KANAGAWA 225001, JAPAN; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Fujifilm Corporation; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								AOKI T, 1992, AIDS RES HUM RETROV, V8, P605, DOI 10.1089/aid.1992.8.605; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BAITINIC D, 1992, J BIOL CHEM, V267, P6664; CALLAHAN LN, 1991, J VIROL, V65, P1543, DOI 10.1128/JVI.65.3.1543-1550.1991; CARDIN AD, 1991, J BIOL CHEM, V266, P13355; CHANG RS, 1988, P SOC EXP BIOL MED, V189, P304, DOI 10.3181/00379727-189-42811; CHOE H, 1996, CELL, V85, P1185; CLANTON DJ, 1992, J ACQ IMMUN DEF SYND, V5, P771; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DOUGLAS SD, 1990, HEMOTOLOGY, P858; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KINNEYTHOMAS E, 1988, AIDS, V2, P25; LEVINE AM, 1986, ANN INTERN MED, V105, P32, DOI 10.7326/0003-4819-105-1-32; Lin PF, 1996, ANTIMICROB AGENTS CH, V40, P133, DOI 10.1128/AAC.40.1.133; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MOHAN P, 1990, AIDS, V4, P821, DOI 10.1097/00002030-199008000-00021; MOHAN P, 1991, J MED CHEM, V34, P212, DOI 10.1021/jm00105a033; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; THALI M, 1992, J VIROL, V66, P5516, DOI 10.1128/JVI.66.9.5516-5524.1992; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; URYU T, 1993, FRONT BIOM, V1, P101; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356	38	34	36	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					343	348		10.1038/nbt0497-343	http://dx.doi.org/10.1038/nbt0497-343			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094135				2022-12-25	WOS:A1997WQ55400034
J	Munier, FL; Korvatska, E; Djemai, A; LePaslier, D; Zografos, L; Pescia, G; Schorderet, DF				Munier, FL; Korvatska, E; Djemai, A; LePaslier, D; Zografos, L; Pescia, G; Schorderet, DF			Kerato-epithelin mutations in four 5q31-linked corneal dystrophies	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA; SEQUENCE-ANALYSIS; REIS-BUCKLERS; FASCICLIN-I; PROTEIN; BETA-IG-H3; CHROMOSOME-5Q; DEPOSITS; CLONING; CDNA	Granular dystrophy Groenouw type I (CDGG1), Reis-Bucklers (CDL1), lattice type I (CDL1) and Avellino (ACD) are four 5q31-linked human autosomal dominant corneal dystrophies. Clinically, they show progressive opacification of the cornea leading to severe visual handicap. The nature of the deposits remains unknown in spite of amyloid aetiology ascribed to the last two. We generated a YAC contig of the linked region and, following cDNA selection, recovered the beta ig-h3 gene. In six affected families we identified missense mutations. All detected mutations occurred at the CpG dinucleotide of two arginine codons: R555W in one CDGG1, R555Q in one CDRB, R124C in two CDL1 and R124H in two ACD families. This suggests, as the last two diseases are characterized by amyloid deposits, that R124 mutated kerato-epithelin (the product of beta ig-h3) forms amyloidogenic intermediates that precipitate in the cornea. Our data establish a common molecular origin for the 5q31-linked corneal dystrophies.	CHU VAUDOIS, MOL GENET UNIT, CH-1011 LAUSANNE, SWITZERLAND; HOP JULES GONIN, DEPT OPHTHALMOL, CH-1004 LAUSANNE, SWITZERLAND; CTR ETUD POLYMORPHISME HUMAIN, FDN JEAN DAUSSET, F-75010 PARIS, FRANCE; CHU VAUDOIS, DIV MED GENET, CH-1011 LAUSANNE, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Foundation Jean Dausset-CEPH; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)				Le Paslier, Denis/0000-0003-4335-9956				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; BUCHI ER, 1994, CORNEA, V13, P190; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Eiberg Hans, 1994, European Journal of Human Genetics, V2, P132; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; FOLBERG R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1080, DOI 10.1001/archopht.1994.01090200086027; FOLBERG R, 1988, OPHTHALMOLOGY, V95, P46; GALLO G, 1988, MODERN PATHOL, V1, P453; GREGORY CY, 1995, J MED GENET, V32, P224, DOI 10.1136/jmg.32.3.224; KLINTWOR.GK, 1967, AM J PATHOL, V50, P371; Korvatska E, 1996, EUR J HUM GENET, V4, P214; KUCHLE M, 1995, CORNEA, V14, P333; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANNIS MJ, 1981, ARCH OPHTHALMOL-CHIC, V99, P1217, DOI 10.1001/archopht.1981.03930020091008; MOLLER HU, 1989, ACTA OPHTHALMOL, V67, P669; MOLLER HU, 1989, ACTA OPHTHALMOL, V67, P678; ROSENWASSER GOD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1546, DOI 10.1001/archopht.1993.01090110112035; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Small KW, 1996, AM J OPHTHALMOL, V121, P384, DOI 10.1016/S0002-9394(14)70434-9; STOCK EL, 1991, ARCH OPHTHALMOL-CHIC, V109, P354, DOI 10.1001/archopht.1991.01080030056038; STONE EM, 1994, NAT GENET, V6, P47, DOI 10.1038/ng0194-47; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	27	443	475	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					247	251		10.1038/ng0397-247	http://dx.doi.org/10.1038/ng0397-247			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054935				2022-12-25	WOS:A1997WK38600012
J	Nichols, WC; Koller, DL; Slovis, B; Foroud, T; Terry, VH; Arnold, ND; Siemieniak, DR; Wheeler, L; Phillips, JA; Newman, JH; Conneally, PM; Ginsburg, D; Loyd, JE				Nichols, WC; Koller, DL; Slovis, B; Foroud, T; Terry, VH; Arnold, ND; Siemieniak, DR; Wheeler, L; Phillips, JA; Newman, JH; Conneally, PM; Ginsburg, D; Loyd, JE			Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32	NATURE GENETICS			English	Article							HUMAN GENOME; LINKAGE ANALYSIS; MAPS	Primary pulmonary hypertension (PPH), an often fatal disease, is characterized by elevated pulmonary artery pressures in the absence of a secondary cause(1). Endovascular occlusion in the smallest pulmonary arteries occurs by proliferation of cells and matrix, with thrombus and vasospasm(2). Diagnosis is often delayed because the initial symptoms of fatigue and dyspnea on exertion are nonspecific and definitive diagnosis requires invasive procedures. The average life expectancy after diagnosis is two to three years with death usually due to progressive right heart failure(3). The aetiology of the disease is unknown. Although most cases appear to be sporadic, similar to 6% of cases recorded in the NIH Primary Pulmonary Hypertension Registry are inherited in an autosomal dominant manner with reduced penetrance(4-6). Following a genome-wide search using a set of highly polymorphic short tandem repeat (STR) markers and 19 affected individuals from six families, initial evidence for linkage was obtained with two chromosome 2q markers. We subsequently genotyped patients and all available family members for 19 additional markers spanning similar to 40 centiMorgans (cM) on the long arm of chromosome 2. We obtained a maximum two-point lod score of 6.97 at theta=0 with the marker D2S389; multipoint linkage analysis yielded a maximum lod score of 7.86 with the marker D2S311. Haplotype analysis established a minimum candidate interval of similar to 25 cM.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; INDIANA UNIV, SCH MED, DEPT MED & MOL GENET, INDIANAPOLIS, IN 46202 USA; VANDERBILT UNIV, MED CTR, DEPT INTERNAL MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, DEPT PEDIAT, NASHVILLE, TN 37232 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis; Vanderbilt University; Vanderbilt University				Loyd, James/0000-0002-5042-7390	NHLBI NIH HHS [HL48164] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048164] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; BOEHNKE M, 1991, AM J HUM GENET, V48, P22; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DRESDALE DT, 1954, B NEW YORK ACAD MED, V30, P195; DRESDALE DT, 1951, AM J MED, V11, P686, DOI 10.1016/0002-9343(51)90020-4; EMANUEL BS, 1985, P NATL ACAD SCI USA, V82, P3385, DOI 10.1073/pnas.82.10.3385; FERNANDEZRUIZ E, 1993, CYTOGENET CELL GENET, V62, P26, DOI 10.1159/000133437; GIRARD TJ, 1991, J BIOL CHEM, V266, P5036; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LOYD JE, 1988, AM REV RESPIR DIS, V138, P952, DOI 10.1164/ajrccm/138.4.952; LOYD JE, 1995, AM J RESP CRIT CARE, V152, P93, DOI 10.1164/ajrccm.152.1.7599869; LOYD JE, 1984, AM REV RESPIR DIS, V129, P194; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; Morahan G, 1996, SCIENCE, V272, P1811, DOI 10.1126/science.272.5269.1811; MORSE JH, 1992, AM REV RESPIR DIS, V145, P787, DOI 10.1164/ajrccm/145.4_Pt_1.787; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Ott J., 1991, ANAL HUMAN GENETIC L; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837; SOLOMON E, 1985, P NATL ACAD SCI USA, V82, P3330, DOI 10.1073/pnas.82.10.3330; Terwilliger J., 1994, HDB HUMAN GENETIC LI; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213	30	197	213	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					277	280		10.1038/ng0397-277	http://dx.doi.org/10.1038/ng0397-277			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054941				2022-12-25	WOS:A1997WK38600018
J	Mendez, MJ; Green, LL; Corvalan, JRF; Jia, XC; MaynardCurrie, CE; Yang, XD; Gallo, ML; Louie, DM; Lee, DV; Erickson, KL; Luna, J; Roy, CMN; Abderrahim, H; Kirschenbaum, F; Noguchi, M; Smith, DH; Fukushima, A; Hales, JF; Finer, MH; Davis, CG; Zsebo, KM; Jakobovits, A				Mendez, MJ; Green, LL; Corvalan, JRF; Jia, XC; MaynardCurrie, CE; Yang, XD; Gallo, ML; Louie, DM; Lee, DV; Erickson, KL; Luna, J; Roy, CMN; Abderrahim, H; Kirschenbaum, F; Noguchi, M; Smith, DH; Fukushima, A; Hales, JF; Finer, MH; Davis, CG; Zsebo, KM; Jakobovits, A			Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice	NATURE GENETICS			English	Article							YEAST ARTIFICIAL CHROMOSOME; POLYMERASE CHAIN-REACTION; EPIDERMAL GROWTH-FACTOR; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; HEAVY; CELLS; RECOMBINATION; GENES; REPERTOIRE	We constructed two megabase-sized YACs containing large contiguous fragments of the human heavy and kappa (kappa) light chain immunoglobulin (Ig) loci in nearly germline configuration, including approximately 66 V-H and 32 V-kappa genes. We introduced these YACs into Ig-inactivated mice and observed human antibody production which closely resembled that seen in humans in all respects, including gene rearrangement, assembly, and repertoire. Diverse Ig gene usage together with somatic hypermutation enables the mice to generate high affinity fully human antibodies to multiple antigens, including human proteins. Our results underscore the importance of the large Ig fragments with multiple V genes for restoration of a normal humoral immune response. These mice are likely to be a valuable tool for the generation of therapeutic antibodies.	ABGENIX INC,FREMONT,CA 94555; CELL GENESYS INC,FOSTER CITY,CA 94404	Cell Genesys Inc			Pillay, Nischalan/F-9536-2012	Noguchi, Masato/0000-0002-3092-0946				ABERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256; ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; BERMAN JE, 1988, EMBO J, V7, P727, DOI 10.1002/j.1460-2075.1988.tb02869.x; BREZINSCHEK HP, 1995, J IMMUNOL, V155, P190; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BRUGGEMANN M, 1991, EUR J IMMUNOL, V21, P1323, DOI 10.1002/eji.1830210535; Bruggemann M, 1996, IMMUNOL TODAY, V17, P391, DOI 10.1016/0167-5699(96)10025-6; Coligan JE., 1994, CURRENT PROTOCOLS IM; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; COX JPL, 1994, EUR J IMMUNOL, V24, P827, DOI 10.1002/eji.1830240409; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DENDUNNEN JT, 1992, HUM MOL GENET, V1, P19; FEENEY AJ, 1990, J EXP MED, V172, P137; Fishwild DM, 1996, NAT BIOTECHNOL, V14, P845, DOI 10.1038/nbt0796-845; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; Galfre G, 1981, Methods Enzymol, V73, P3; GEMMILL RM, 1991, ADV GENOME BIOL, V1, P217; GILL GN, 1984, J BIOL CHEM, V259, P7755; GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HUBER C, 1993, EUR J IMMUNOL, V23, P2860, DOI 10.1002/eji.1830231120; JAKOBOVITS A, 1994, CURR BIOL, V4, P761, DOI 10.1016/S0960-9822(00)00172-X; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; JAKOBOVITS A, 1993, NATURE, V362, P255, DOI 10.1038/362255a0; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; MATSUDA F, 1993, ADV IMMUNOL, V62, P1; Max Edward E., 1993, P315; MENDEZ M, 1993, GENOME MAPPING SEQUE, V163; MENDEZ MJ, 1995, GENOMICS, V26, P294, DOI 10.1016/0888-7543(95)80214-7; RAY S, 1994, P NATL ACAD SCI USA, V91, P5548, DOI 10.1073/pnas.91.12.5548; Sato J D, 1983, Mol Biol Med, V1, P511; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F, 1986, LAB COURSE MANUAL ME; SILVERMAN GA, 1990, P NATL ACAD SCI USA, V87, P9913, DOI 10.1073/pnas.87.24.9913; TAYLOR LD, 1994, INT IMMUNOL, V6, P579, DOI 10.1093/intimm/6.4.579; TAYLOR LD, 1992, NUCLEIC ACIDS RES, V20, P6287, DOI 10.1093/nar/20.23.6287; TUAILLON N, 1993, P NATL ACAD SCI USA, V90, P3720, DOI 10.1073/pnas.90.8.3720; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WAGNER SD, 1994, EUR J IMMUNOL, V24, P2672, DOI 10.1002/eji.1830241116; WEICHHOLD GM, 1993, GENOMICS, V16, P503, DOI 10.1006/geno.1993.1217; YAMADA M, 1991, J EXP MED, V173, P395, DOI 10.1084/jem.173.2.395	44	287	771	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					146	156		10.1038/ng0297-146	http://dx.doi.org/10.1038/ng0297-146			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020839				2022-12-25	WOS:A1997WF08700013
J	Kunst, CB; Mezey, E; Brownstein, MJ; Patterson, D				Kunst, CB; Mezey, E; Brownstein, MJ; Patterson, D			Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions	NATURE GENETICS			English	Article							SUPEROXIDE-DISMUTASE GENE; TRANSFER-RNA-SYNTHETASE; SACCHAROMYCES-CEREVISIAE; WILD-TYPE; AUTOANTIBODIES; COMPLEX; MODEL; CELLS; YEAST; MICE	A subset of familial and sporadic amyotrophic lateral sclerosis (ALS - a fatal disorder characterised by progressive motor neuron degeneration) cases are due to mutations in the gene encoding Cu,Zn superoxide dismutase (SOD1)(1-4). Two mutations which have been successfully used to generate transgenic mice that develop an ALS-like syndrome are glycine 85 to arginine (G85R) and glycine 93 to alanine (G93A) with the mutant SOD1 allele overexpressed in a normal mouse genetic background(5-7). No ALS-like phenotype is observed in mice overexpressing wild-type SOD1 or mice without any SOD1 activity(6,8,9). These dominant mutations, which do not necessarily decrease SOD1 activity, may confer a gain of function that is selectively lethal to motor neurons(5,10-12). The yeast interaction trap system(13) allowed us to determine whether these mutations in SOD1 caused novel protein interactions not observed with wild-type SOD1 and which might participate in the generation of the ALS phenotype. Two proteins, lysyl-tRNA synthetase and translocon-associated protein delta, interact with mutant forms of SOD1 but not with wild-type SOD1. The specificity of the interactions was confirmed by the coimmunoprecipitation of mutant SOD1 and the expressed proteins. These proteins are expressed in ventral cord, lending support to the relevance of this interaction to motor neuron disease.	UNIV COLORADO,HLTH SCI CTR,ELEANOR ROOSEVELT INST CANC RES,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,HUMAN MED GENET PROGRAM,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80206; NIMH,CELL BIOL LAB,BETHESDA,MD 20892	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Brownstein, Michael/B-8609-2009; Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691	NIA NIH HHS [AG 00029] Funding Source: Medline; NICHD NIH HHS [HD 17449, HD 07197] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CHAN PH, 1990, STROKE, V21; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; FINLEY RL, 1984, GENE PROBES PRACTICA; FREIST W, 1995, BIOL CHEM H-S, V376, P451; FUJII J, 1995, J NEUROCHEM, V64, P1456; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GELPI C, 1994, J IMMUNOL, V152, P1989; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HOLTHUIS JCM, 1995, BIOCHEM J, V312, P205, DOI 10.1042/bj3120205; JONES CT, 1993, LANCET, V342, P1050, DOI 10.1016/0140-6736(93)92905-9; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; PRAMATAROVA A, 1995, AM J HUM GENET, V56, P592; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; REUME AG, 1996, NAT GENET, V13, P43; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SWINGLER RJ, 1995, LANCET, V345, P391, DOI 10.1016/S0140-6736(95)90380-1; TARGOFF IN, 1993, J CLIN INVEST, V91, P2556, DOI 10.1172/JCI116493; TSUDA T, 1994, NEURON, V13, P727, DOI 10.1016/0896-6273(94)90039-6; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	31	107	121	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					91	94		10.1038/ng0197-91	http://dx.doi.org/10.1038/ng0197-91			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988176				2022-12-25	WOS:A1997WA37300028
J	Peters, R; Sikorski, RS				Peters, R; Sikorski, RS			Protein databases on the WWW	NATURE BIOTECHNOLOGY			English	Editorial Material											Peters, R (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					90	90		10.1038/nbt0197-90	http://dx.doi.org/10.1038/nbt0197-90			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035114				2022-12-25	WOS:A1997WA72900031
J	DeRisi, J; Penland, L; Brown, PO; Bittner, ML; Meltzer, PS; Ray, M; Chen, YD; Su, YA; Trent, JM				DeRisi, J; Penland, L; Brown, PO; Bittner, ML; Meltzer, PS; Ray, M; Chen, YD; Su, YA; Trent, JM			Use of a cDNA microarray to analyse gene expression patterns in human cancer	NATURE GENETICS			English	Article							SUPPRESSION	The development and progression of cancer(1-3) and the experimental reversal of tumorigenicity(4,5) are accompanied by complex changes in patterns of gene expression. Microarrays of cDNA provide a powerful tool for studying these complex phenomena(6-8). The tumorigenic properties of a human melanoma cell line, UACC-903, can be suppressed by introduction of a normal human chromosome 6, resulting in a reduction of growth rate, restoration of contact inhibition, and suppression of both soft agar clonogenicity and tumorigenicity in nude mice(4,5,9). We used a high density microarray of 1,161 DNA elements to search for differences in gene expression associated with tumour suppression in this system. Fluorescent probes for hybridization were derived from two sources of cellular mRNA [UACC-903 and UACC-903(+6)] which were labelled with different fluors to provide a direct and internally controlled comparison of the mRNA levels corresponding to each arrayed gene. The fluorescence signals representing hybridization to each arrayed gene were analysed to determine the relative abundance in the two samples of mRNAs corresponding to each gene. Previously unrecognized alterations in the expression of specific genes provide leads for further investigation of the genetic basis of the tumorigenic phenotype of these cells. DNA microarrays, containing 1,161 total elements.	STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; NIH,NATL CTR HUMAN GENOME RES,CANC GENET LAB,BETHESDA,MD 20892	Stanford University; Howard Hughes Medical Institute; Stanford University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)					NHGRI NIH HHS [HG00450] Funding Source: Medline; FDA HHS [2T32BM07276-21] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG000450, R01HG000450] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); FDA HHS; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAVES DT, 1992, AM J PATHOL, V140, P9; HUANG SY, 1995, J INTERF CYTOK RES, V15, P655, DOI 10.1089/jir.1995.15.655; JIANG HP, 1995, ONCOGENE, V10, P1855; KRISTENSEN MS, 1993, CYTOKINE, V5, P520, DOI 10.1016/1043-4666(93)90044-6; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; NAKAO J, 1995, J NEUROCHEM, V6455, P2396; Ray ME, 1996, ONCOGENE, V12, P2527; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHENA M, 1996, P NATL ACAD SCI USA, V93, P10539; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Su YA, 1996, CANCER RES, V56, P3186; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; VIYAYASARADHI S, 1995, J INVEST DERMATOL, V105, P113; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x	22	1604	1890	0	87	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					457	460						4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944026				2022-12-25	WOS:A1996VV73000022
J	Lamb, NE; Freeman, SB; SavageAustin, A; Pettay, D; Taft, L; Hersey, J; Gu, YC; Shen, J; Saker, D; May, KM; Avramopoulos, D; Petersen, MB; Hallberg, A; Mikkelsen, M; Hassold, TJ; Sherman, SL				Lamb, NE; Freeman, SB; SavageAustin, A; Pettay, D; Taft, L; Hersey, J; Gu, YC; Shen, J; Saker, D; May, KM; Avramopoulos, D; Petersen, MB; Hallberg, A; Mikkelsen, M; Hassold, TJ; Sherman, SL			Susceptible chiasmate configurations of chromosome 21 predispose to non-disjunction in both maternal meiosis I and meiosis II	NATURE GENETICS			English	Article							REDUCED RECOMBINATION; DNA POLYMORPHISMS; ABERRANT RECOMBINATION; PARENTAL ORIGIN; MEIOTIC STAGE; NONDISJUNCTION; TRISOMY-21; AGE; MECHANISMS; ETIOLOGY	The cause of non-disjunction of chromosome 21 remains largely unknown. Advanced maternal age is associated with both maternal meiosis I (MI) and meiosis II (MII) non-disjunction events. While reduced genetic recombination has been demonstrated in maternal MI errors, the basis for MII errors remains uncertain. We studied 133 trisomy 21 cases with maternal MII errors to test the hypothesis that segregation at MII may also be influenced by genetic recombination. Our data support a highly significant association: MII non-disjunction involves increased recombination that is largely restricted to proximal 21q. Thus, while absence of a proximal recombination appears to predispose to nondisjunction in MI, the presence of a proximal exchange predisposes to non-disjunction in MII. These findings profoundly affect our understanding of trisomy 21 as they suggest that virtually all maternal non-disjunction results from events occurring in meioisis I.	EMORY UNIV,SCH MED,DEPT GENET & MOL MED,ATLANTA,GA 30322; CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CTR HUMAN GENET,CLEVELAND,OH 44106; EMORY UNIV,SCH MED,DEPT PEDIAT,DIV MED GENET,ATLANTA,GA; INST CHILD HLTH,DEPT GENET,ATHENS,GREECE; JF KENNEDY INST,DANISH CTR HUMAN GENOME RES,GLOSTRUP,DENMARK	Emory University; Case Western Reserve University; Case Western Reserve University; Emory University; Aarhus University			Avramopoulos, Dimitrios/J-4392-2012; Petersen, Michael Bjørn B/D-1483-2017; Shen, Joseph/AAY-5083-2020	Petersen, Michael Bjørn B/0000-0003-0316-8207; Shen, Joseph/0000-0002-5604-7639	NICHD NIH HHS [P01 HD32111] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD032111] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRUZZO MA, 1995, ENVIRON MOL MUTAGEN, V25, P38, DOI 10.1002/em.2850250608; ANTONARAKIS SE, 1993, NAT GENET, V3, P146, DOI 10.1038/ng0293-146; ANTONARAKIS SE, 1991, NEW ENGL J MED, V324, P872, DOI 10.1056/NEJM199103283241302; ANTONARAKIS SE, 1992, AM J HUM GENET, V50, P544; Bridges CB, 1916, GENETICS, V1, P1; CHAKRAVARTI A, 1987, Genomics, V1, P35, DOI 10.1016/0888-7543(87)90102-9; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; FARNET C, 1989, MECH CONSEQUENCES DN; FISHER JM, 1995, AM J HUM GENET, V56, P669; HASSOLD T, 1990, HUM GENET, V85, P648; HASSOLD T, 1995, AM J HUM GENET, V57, P867; HASSOLD T, 1985, AM J HUM GENET, V37, P965; HASSOLD TJ, 1991, AM J HUM GENET, V49, P253; HAWLEY RS, 1993, ANNU REV GENET, V27, P281; HAWLEY RS, 1994, HUM MOL GENET, V3, P1521, DOI 10.1093/hmg/3.9.1521; HENDERSON SA, 1968, NATURE, V217, P22; JABS EW, 1991, GENOMICS, V9, P141, DOI 10.1016/0888-7543(91)90231-3; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LORBER BJ, 1992, AM J HUM GENET, V51, P1265; MACDONALD M, 1994, HUM MOL GENET, V3, P1365, DOI 10.1093/hmg/3.8.1365; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; MASCARI MJ, 1993, AM J HUM GENET, V53, pA260; MIKKELSEN M, 1995, DEV BRAIN DYSFUNCT, V8, P4; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MORTON NE, 1989, ANN HUM GENET, V53, P263, DOI 10.1111/j.1469-1809.1989.tb01793.x; MORTON NE, 1984, GENET RES, V44, P99, DOI 10.1017/S0016672300026276; MORTON NE, 1994, ANN HUM GENET, V54, P39; PETERSEN MB, 1992, AM J HUM GENET, V51, P516; RAO DC, 1977, HUM HERED, V27, P99, DOI 10.1159/000152856; ROBINSON WP, 1993, AM J HUM GENET, V53, P740; ROEDER G, 1989, MOL CYTOGENETIC STUD, P303; SHERMAN SL, 1991, AM J HUM GENET, V49, P608; SHERMAN SL, 1994, HUM MOL GENET, V3, P1529, DOI 10.1093/hmg/3.9.1529; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; VANHUL W, 1993, GENOMICS, V15, P626, DOI 10.1006/geno.1993.1117; WARREN AC, 1987, SCIENCE, V237, P652, DOI 10.1126/science.2955519; Yoon PW, 1996, AM J HUM GENET, V58, P628	37	289	297	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					400	405		10.1038/ng1296-400	http://dx.doi.org/10.1038/ng1296-400			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944019				2022-12-25	WOS:A1996VV73000015
J	Nawroz, H; Koch, W; Anker, P; Stroun, M; Sidransky, D				Nawroz, H; Koch, W; Anker, P; Stroun, M; Sidransky, D			Microsatellite alterations in serum DNA of head and neck cancer patients	NATURE MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; MUTATIONS; PLASMA; PROGRESSION; BLOOD; GENE	Microsatellite DNA alterations are an integral part of neoplastic progression and are valuable as clonal markers for the detection of human cancers(1-3). Moreover, recent evidence suggests that senescent tumor cells may release DNA into the circulation, which is subsequently carried by and therefore enriched in the serum and plasma(4,5). We tested 21 patients with primary head and neck squamous cell carcinoma (HNSCC) by polymerase chain reaction (PCR)-based microsatellite analysis of DNA from lymphocytes and paired serum samples. Patients were scored for alterations as defined by the presence of new alleles (shifts) or loss of heterozygosity (LOH) in serum at each of 12 markers and then compared with primary tumor DNA. Six out of 21 patients (29%) were found to have one or more microsatellite alterations in serum precisely matching those in the primary tumors. All six patients had advanced disease (stage III or IV); five of these patients had nodal metastases, three later developed distant metastases, and four died of disease. Microsatellite analysis of serum represents a novel method for the detection of circulating tumor cell DNA. If these results are confirmed in larger studies, microsatellite markers may be useful in assessing tumor burden in cancer patients.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,DIV HEAD & NECK CANC RES,BALTIMORE,MD 21205; UNIV GENEVA,FAC SCI,PAVILLON ISOTOPES,LAB PLANT BIOCHEM & PHYSIOL,CH-1211 GENEVA 4,SWITZERLAND	Johns Hopkins University; University of Geneva					NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58184-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beahrs OH, 1988, MANUAL STAGING CANCE, P27; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; Califano J, 1996, CANCER RES, V56, P2488; CHEN XQ, 1996, NAT MED, V2, P1034; LEON SA, 1977, CANCER RES, V37, P646; LITT M, 1993, BIOTECHNIQUES, V15, P280; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MERLO A, 1994, CANCER RES, V54, P2098; NAWROZ H, 1994, CANCER RES, V54, P1152; SHAPIRO B, 1983, CANCER, V51, P2216; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67; STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5; STROUN M, 1989, ONCOLOGY, V46, P318; VANDERRIET P, 1994, CANCER RES, V54, P25; VASIOUKHIN V, 1994, BRIT J HAEMATOL, V86, P774, DOI 10.1111/j.1365-2141.1994.tb04828.x; VASIOUKHIN V, 1994, CHALLENGES MODERN ME, P141; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306	20	543	636	2	31	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1035	1037		10.1038/nm0996-1035	http://dx.doi.org/10.1038/nm0996-1035			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782464				2022-12-25	WOS:A1996VF49700041
J	Jonas, WB				Jonas, WB			Researching alternative medicine	NATURE MEDICINE			English	Editorial Material							COMPLEMENTARY MEDICINE; RHEUMATOID-ARTHRITIS; METAANALYSIS; TRIAL				Jonas, WB (corresponding author), NIH,OFF ALTERNAT MED,9000 ROCKVILLE PIKE,BLDG 31,ROOM 5B35,MSC 2182,BETHESDA,MD 20892, USA.							Ader R, 1985, PLACEBO THEORY RES M, P306; Altman Roy D., 1994, Seminars in Arthritis and Rheumatism, V23, P25, DOI 10.1016/S0049-0172(10)80023-X; ANDERSON WH, 1993, AIDS, V74, P561; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; BERMAN BM, 1995, OSTEOARTHR CARTILAGE, V3, P139, DOI 10.1016/S1063-4584(05)80046-9; Blumberg D L, 1995, Altern Ther Health Med, V1, P31; Boissel JP, 1996, CRITICAL LIT REV EFF; BRAUD WG, 1992, SUBTLE ENERGIES, V2, P1; CARLSTON M, 1997, IN PRESS FAM MED; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0; Di Silverio F, 1993, Minerva Urol Nefrol, V45, P143; Dowie J, 1996, BRIT MED J, V313, P170, DOI 10.1136/bmj.313.7050.170a; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1995, ARCH INTERN MED, V155, P2405, DOI 10.1001/archinte.155.22.2405; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FURNHAM A, 1994, J CLIN PSYCHOL, V50, P458, DOI 10.1002/1097-4679(199405)50:3<458::AID-JCLP2270500318>3.0.CO;2-V; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; HALLIDAY J, 1993, COMPLEMENTARY THER S, V1, P32; Jonas WB, 1996, INFLAMM RES, V45, P330, DOI 10.1007/BF02252945; KJELDSENKRAGH J, 1995, SCAND J RHEUMATOL, V24, P85, DOI 10.3109/03009749509099290; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; Lavigne J V, 1992, Arthritis Care Res, V5, P101, DOI 10.1002/art.1790050209; LINDE K, 1994, HUM EXP TOXICOL, V13, P481, DOI 10.1177/096032719401300706; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; Neil Andrew, 1994, Current Opinion in Lipidology, V5, P6, DOI 10.1097/00041433-199402000-00002; RADIN DI, 1989, FOUND PHYS, V19, P1499, DOI 10.1007/BF00732509; TAO XL, 1987, CHIN J MED, V26, P399; TAO XL, 1987, CHUNG HUA NEI KO TSA, V26, P444; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; 1997, INT J TECH ASSESS HL, V13, P111; [No title captured]; 1997, ALTERNATIVE THERAPIE, V3, P49	35	28	28	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					824	827		10.1038/nm0897-824	http://dx.doi.org/10.1038/nm0897-824			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256264				2022-12-25	WOS:A1997XP01400015
J	Suzuki, JI; Isobe, M; Morishita, R; Aoki, M; Horie, S; Okubo, Y; Kaneda, Y; Sawa, Y; Matsuda, H; Ogihara, T; Sekiguchi, M				Suzuki, JI; Isobe, M; Morishita, R; Aoki, M; Horie, S; Okubo, Y; Kaneda, Y; Sawa, Y; Matsuda, H; Ogihara, T; Sekiguchi, M			Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide	NATURE MEDICINE			English	Article							ARTERY DISEASE; INHIBITION; HYPERPLASIA; EXPRESSION; HEART; GENE	Craft coronary arteriosclerosis, which limits the long-term survival of allograft recipients, is characterized by diffuse intimal thickening composed of proliferative smooth muscle cells(1,2). We observed that messenger RNA of the cell cycle regulatory enzyme cyclin-dependent kinase (cdk) 2 kinase, which mediates smooth muscle cell proliferation, was elevated in the thickened intima of coronary arteries of murine heterotopic cardiac allografts. We studied the effects of antisense phosphorothioate oligodeoxynucleotide (ODN) against this enzyme using gene transfer mediated by a hemagglutinating virus of Japan (HVJ)-liposome complex intraluminally delivered to inhibit the intimal hyperplasia. At 30 days after transplantation, antisense cdk2 kinase ODN treatment had dramatically inhibited neointimal formation in the allografts. Expression of vascular cell adhesion molecule-1 was also suppressed by antisense cdk2 kinase. However, these effects were not observed in the sense or scrambled ODN-treated allografts. Thus, an intraluminal administration of antisense ODN directed to a specific cell cycle regulatory gene can inhibit neointimal formation after cardiac transplantation.	SHINSHU UNIV,SCH MED,DEPT INTERNAL MED 1,MATSUMOTO,NAGANO 390,JAPAN; OSAKA UNIV,SCH MED,DEPT GERIATR MED,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 1,SUITA,OSAKA 565,JAPAN	Shinshu University; Osaka University; Osaka University; Osaka University								BOTAS J, 1995, CIRCULATION, V92, P1126, DOI 10.1161/01.CIR.92.5.1126; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Dzau VJ, 1996, P NATL ACAD SCI USA, V93, P11421, DOI 10.1073/pnas.93.21.11421; EICH DM, 1993, CIRCULATION, V87, P261, DOI 10.1161/01.CIR.87.1.261; Furukawa Y, 1996, CIRCULATION, V93, P333, DOI 10.1161/01.CIR.93.2.333; Hosenpud J D, 1993, Transpl Immunol, V1, P237, DOI 10.1016/0966-3274(93)90031-3; HOSENPUD JD, 1995, J HEART LUNG TRANSPL, V14, P805; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; POLLAK R, 1993, NEW ENGL J MED, V328, P1851; SAWA Y, 1995, CIRCULATION, V92, P479, DOI 10.1161/01.CIR.92.9.479; SUZUKI J, IN PRESS J HEART LUN; Suzuki JI, 1996, CIRCULATION, V94, P1118, DOI 10.1161/01.CIR.94.5.1118; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0	20	106	112	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					900	903		10.1038/nm0897-900	http://dx.doi.org/10.1038/nm0897-900			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256282				2022-12-25	WOS:A1997XP01400033
J	FromontRacine, M; Rain, JC; Legrain, P				FromontRacine, M; Rain, JC; Legrain, P			Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens	NATURE GENETICS			English	Article							PROTEIN-PROTEIN INTERACTIONS; SPLICING FACTORS; 2-HYBRID SYSTEM; IDENTIFICATION; COMPLEX; IDENTIFY; PRP11; SM; U6; U2		INST PASTEUR,CNRS URA 1300,LAB METAB,ARN,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				RAIN, Jean-Christophe/0000-0001-8110-0641; Fromont-Racine, Micheline/0000-0001-9906-0334				ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Arning S, 1996, RNA, V2, P794; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; Bordonne R, 1996, GENE, V176, P111, DOI 10.1016/0378-1119(96)00230-2; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; COOPER M, 1995, EMBO J, V14, P2066, DOI 10.1002/j.1460-2075.1995.tb07198.x; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; GARRELS, 1996, YEAST PROTEOME HDB; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; He F, 1996, RNA, V2, P153; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; LEGRAIN P, 1993, SCIENCE, V262, P108, DOI 10.1126/science.8211114; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; Racevskis J, 1996, CELL GROWTH DIFFER, V7, P271; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; RIAN JC, 1996, RNA, V2, P535; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Sourdive DJD, 1997, NUCLEIC ACIDS RES, V25, P1476, DOI 10.1093/nar/25.8.1476; STAHL G, 1995, NUCLEIC ACIDS RES, V23, P1557, DOI 10.1093/nar/23.9.1557; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; vanVenrooij WJ, 1995, CURR OPIN IMMUNOL, V7, P819, DOI 10.1016/0952-7915(95)80054-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wells SE, 1996, GENE DEV, V10, P220, DOI 10.1101/gad.10.2.220	32	674	725	0	32	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					277	282		10.1038/ng0797-277	http://dx.doi.org/10.1038/ng0797-277			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207794				2022-12-25	WOS:A1997XG60900024
J	Davis, KD; Taub, E; Houle, S; Lang, AE; Dostrovsky, JO; Tasker, RR; Lozano, AM				Davis, KD; Taub, E; Houle, S; Lang, AE; Dostrovsky, JO; Tasker, RR; Lozano, AM			Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms	NATURE MEDICINE			English	Article							POSTEROVENTRAL PALLIDOTOMY; NEURONAL-ACTIVITY; DISEASE; SUPPLEMENTARY; APOMORPHINE; TREMOR; AREA	Studies of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in monkeys(1,2) suggest that excessive inhibitory outflow from the internal segment of the globus pallidus (GPi) suppresses the motor thalamus, which reduces activation of the cerebral cortex motor system, resulting in the slowness and poverty of movement of Parkinson's disease (PD)(3). This hypothesis is supported by reports of high rates of spontaneous neuronal discharges and hypermetabolism in GPi (ref. 4-7) and impaired activation of the supplementary motor area (SMA) and dorsolateral prefrontal regions(8,9) in PD patients. Furthermore, lesion or chronic high-frequency electrical (likely inactivating) stimulation of GPi (ref. 10-14) is associated with marked improvements in akinesia and rigidity, and the impaired activation of SMA is reversed when the akinesia is treated with dopamine agonists's. To test whether improvement in motor function with pallidal surgery can be attributed to increased activity in premotor cortical regions, we assessed the changes in regional cerebral blood flow (rCBF) and parkinsonian symptoms during disruption of GPi activity with high-frequency stimulation delivered through implanted brain electrodes. Positron emission tomography (PET) revealed an increase in rCBF in ipsilateral premotor cortical areas during GPi stimulation, which improved rigidity and bradykinesia. These results suggest that disrupting the excessive inhibitory output of the basal ganglia reverses parkinsonism, via a thalamic relay, by activation of brain areas involved in the initiation of movement.	UNIV TORONTO,TORONTO WESTERN HOSP,DIV NEUROSURG,DEPT SURG,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,PET CTR,CLARKE INST PSYCHIAT,TORONTO,ON M5T 1R8,CANADA; UNIV TORONTO,TORONTO WESTERN HOSP,DIV NEUROL,DEPT MED,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto			Lozano, Andres M/A-5058-2012; Lang, Anthony/ABF-8114-2021	Lozano, Andres M./0000-0001-8257-3694; Houle, Sylvain/0000-0002-4231-6316; Lang, Anthony/0000-0003-1229-3667				Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; Beric A, 1996, ADV NEUROL, V69, P123; CEBALLOSBAUMANN AO, 1994, LANCET, V344, P814, DOI 10.1016/S0140-6736(94)92369-8; COLEBATCH JG, 1990, LANCET, V336, P1028, DOI 10.1016/0140-6736(90)92489-5; CRIDLAND RA, 1988, BRAIN RES BULL, V20, P429, DOI 10.1016/0361-9230(88)90132-3; DEIBER MP, 1993, BRAIN, V116, P267, DOI 10.1093/brain/116.1.267; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Eidelberg D, 1996, ANN NEUROL, V39, P450, DOI 10.1002/ana.410390407; EIDELBERG D, 1994, J CEREBR BLOOD F MET, V14, P783, DOI 10.1038/jcbfm.1994.99; EKBLOM A, 1988, J NEUROL NEUROSUR PS, V51, P481, DOI 10.1136/jnnp.51.4.481; FILION M, 1991, BRAIN RES, V547, P142; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Galvez-Jimenez Nestor, 1996, Neurology, V46, pA402; GRAFTON ST, 1995, ANN NEUROL, V37, P776, DOI 10.1002/ana.410370611; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HUTCHISON WD, 1994, NEUROREPORT, V5, P1533, DOI 10.1097/00001756-199407000-00031; JENKINS IH, 1992, ANN NEUROL, V32, P749, DOI 10.1002/ana.410320608; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Lozano A, 1996, J NEUROSURG, V84, P194, DOI 10.3171/jns.1996.84.2.0194; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; Parent A., 1996, CARPENTERS HUMAN NEU, V9th. Edn; PLAYFORD ED, 1993, ADV NEUROL, V60, P506; RASCOL O, 1992, ARCH NEUROL-CHICAGO, V49, P144, DOI 10.1001/archneur.1992.00530260044017; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; Talairach J., 1988, COPLANAR STEREOTAXIC	29	167	173	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					671	674		10.1038/nm0697-671	http://dx.doi.org/10.1038/nm0697-671			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176495				2022-12-25	WOS:A1997XB97400038
J	Weaver, JC; McGrath, P; Adams, S				Weaver, JC; McGrath, P; Adams, S			Gel microdrop technology for rapid isolation of rare and high producer cells	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; SECRETION CAPTURE; HYBRIDOMA CELLS; REPORT WEB; FLUORESCENCE; CLONING; IGG		ONE CELL SYST INC,CAMBRIDGE,MA 02139; MIT,HARVARD MIT DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139	Harvard University; Massachusetts Institute of Technology (MIT)								CARLSSON R, 1989, BIO-TECHNOL, V7, P567, DOI 10.1038/nbt0689-567; GIFT EA, 1995, NAT BIOTECHNOL, V14, P884; GRAY F, 1995, J IMMUNOL METHODS, V182, P155, DOI 10.1016/0022-1759(94)00319-R; KENNEY JS, 1995, BIO-TECHNOL, V13, P787, DOI 10.1038/nbt0895-787; MEILHOC E, 1989, J IMMUNOL METHODS, V121, P167, DOI 10.1016/0022-1759(89)90157-9; NGUYEN BT, 1995, CYTOMETRY, V21, P111, DOI 10.1002/cyto.990210202; OZTURK SS, 1990, HYBRIDOMA, V9, P167, DOI 10.1089/hyb.1990.9.167; PARKS DR, 1979, P NATL ACAD SCI USA, V76, P1962, DOI 10.1073/pnas.76.4.1962; POWELL KT, 1990, BIO-TECHNOL, V8, P333, DOI 10.1038/nbt0490-333; RYAN C, 1995, J CLIN MICROBIOL, V33, P1720, DOI 10.1128/JCM.33.7.1720-1726.1995; SEN S, 1990, ENZYME MICROB TECH, V12, P571, DOI 10.1016/0141-0229(90)90129-E; Sullivan Susan J., 1995, Molecular Biology of the Cell, V6, p445A; UNDERWOOD PA, 1988, J IMMUNOL METHODS, V107, P119; UZGIRIS AJ, 1994, GENOME SCI TECHNOLOG; WEAVER JC, 1988, BIO-TECHNOL, V6, P1084, DOI 10.1038/nbt0988-1084; WEAVER JC, 1990, METHOD ENZYMOL, V2, P234; WEAVER JC, 1995, FLOW CYTOMETRY APPL, P39; WILLIAMS GB, 1990, J CLIN MICROBIOL, V28, P1002, DOI 10.1128/JCM.28.5.1002-1008.1990	18	36	47	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					583	585		10.1038/nm0597-583	http://dx.doi.org/10.1038/nm0597-583			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142132				2022-12-25	WOS:A1997WX54300043
J	Bassett, DE; Boguski, MS; Spencer, F; Reeves, R; Kim, SH; Weaver, T; Hieter, P				Bassett, DE; Boguski, MS; Spencer, F; Reeves, R; Kim, SH; Weaver, T; Hieter, P			Genome cross-referencing and XREFdb: Implications for the identification and analysis of genes mutated in human disease	NATURE GENETICS			English	Article							HOMOLOG; ENCODES; CANCER	Comparative genomics approaches and multi-organismal biology are valuable tools for genetic analysis. Cross-species connections between genes mutated in human disease states and homologues in model organisms can be particularly powerful, as model-organism gene function data and experimental approaches can shed light an the molecular mechanisms defective in the disease. We describe a project that is systematically identifying novel expressed sequence tag (EST) sequences that are highly related to genes in model organisms and mapping them to positions on the mouse and human maps. This process effectively cross-references model organism genes with mapped mammalian phenotypes, facilitating the identification of genes mutated in human disease states via the positional candidate approach. A public database, XREFdb (http://www.ncbi.nlm.nih.gov/XREFdb/), disseminates similarity search, mapping and mammalian phenotype information and increases the rate at which these cross-species connections are established.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR GENET MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,NIH,BETHESDA,MD 20894	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)				Bassett, Douglas/0000-0002-1619-4618	NCI NIH HHS [CA16519] Funding Source: Medline; NHGRI NIH HHS [HG00971-01] Funding Source: Medline; NIGMS NIH HHS [P32GM07814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; BLATTNER F, 1996, MICROB COMP GENOME, V1, P357; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; BOGUSKI MS, 1994, SCIENCE, V265, P1993, DOI 10.1126/science.8091218; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUNABIKI H, 1991, J MOL BIOL, V217, P23; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hieter P, 1996, NAT GENET, V13, P253, DOI 10.1038/ng0796-253; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Mckusick V.A., 1994, MENDELIAN INHERITANC; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540	21	68	72	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	APR	1997	15	4					339	344		10.1038/ng0497-339	http://dx.doi.org/10.1038/ng0497-339			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WQ389	9090377				2022-12-25	WOS:A1997WQ38900010
J	Kang, S; Graham, JM; Olney, AH; Biesecker, LG				Kang, S; Graham, JM; Olney, AH; Biesecker, LG			GLI3 frameshift mutations cause autosomal dominant Pallister-Hall syndrome	NATURE GENETICS			English	Article							CONGENITAL HYPOTHALAMIC HAMARTOBLASTOMA; GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; IMPERFORATE ANUS; GENE; HYPOPITUITARISM; LOCALIZATION; DELETION; 7P13	Pallister-Hail syndrome (PHS, M146510) was first described in 1980 in six newborns. It is a pleiotropic disorder of human development that comprises hypothalamic hamartoma, central polydactyly, and other malformations(1,2). This disorder is inherited as an autosomal dominant trait and has been mapped to 7p13 (S. Kang et al. Autosomal dominant Pallister-Hail syndrome maps to 7p13. Am. J. Hum. Genet. 59, A81 (1996)). colocalizing the PHS locus and the GLI3 zinc finger transcription factor gene(3). Large deletions or translocations resulting in haploinsufficiency of the GLI3 gene have been associated with Greig cephalopolysyndactyly syndrome (GCPS; M175700)(4-6) although no mutations have been identified in GCPS patients with normal karyotypes. Both PHS and GCPS have polysyndactyly, abnormal craniofacial features and are inherited in an autosomal dominant pattern, but they are clinically distinct(7,8). The polydactyly of CCPS is commonly preaxial and that of PHS is typically central or postaxial. No reported cases of CCPS have hypothalamic hamartoma and PHS does not cause hypertelorism or broadening of the nasal root or forehead. The co-localization of the loci for PHS and GCPS led us to investigate GLI3 as a candidate gene for PHS. Herein we report two PHS families with frameshift mutations in GLI3 that are 3' of the zinc finger-encoding domains, including one family with a de novo mutation. These data implicate mutations in GLI3 as the cause of autosomal dominant PHS, and suggest that frameshift mutations of the GLI3 transcription factor gene can alter the development of multiple organ systems in vertebrates.	NIH, NATL HUMAN GENOME RES INST, LAB GENET DIS RES, BETHESDA, MD 20892 USA; CEDARS SINAI MED CTR, DEPT PEDIAT, CTR MED GENET BIRTH DEFECTS, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90048 USA; UNIV NEBRASKA, SCH MED, CTR HUMAN GENET, OMAHA, NE 68198 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Nebraska System			Graham, John M./J-1429-2019					Biesecker LG, 1996, J MED GENET, V33, P585, DOI 10.1136/jmg.33.7.585; Biesecker LG, 1996, AM J MED GENET, V65, P76, DOI 10.1002/(SICI)1096-8628(19961002)65:1<76::AID-AJMG12>3.0.CO;2-O; Biesecker LG, 1996, J MED GENET, V33, P947, DOI 10.1136/jmg.33.11.947; BRUETON L, 1988, AM J MED GENET, V31, P799, DOI 10.1002/ajmg.1320310412; BRUETON LA, 1992, J MED GENET, V29, P635, DOI 10.1136/jmg.29.9.635; CLARREN SK, 1980, AM J MED GENET, V7, P75, DOI 10.1002/ajmg.1320070111; COHN DH, 1990, AM J HUM GENET, V46, P591; Dracopoli NC, 1994, CURRENT PROTOCOLS HU; DUNCAN PA, 1979, AM J DIS CHILD, V133, P818, DOI 10.1001/archpedi.1979.02130080058010; Grebe TA, 1996, AM J MED GENET, V66, P129, DOI 10.1002/(SICI)1096-8628(19961211)66:2<129::AID-AJMG2>3.0.CO;2-M; HALL JG, 1980, AM J MED GENET, V7, P47, DOI 10.1002/ajmg.1320070110; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; PETTIGREW AL, 1991, HUM GENET, V87, P452; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; TOPF KF, 1993, J PEDIATR-US, V123, P943, DOI 10.1016/S0022-3476(05)80392-0; VERLOES A, 1995, J MED GENET, V32, P605, DOI 10.1136/jmg.32.8.605; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; [No title captured]	18	367	376	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					266	268		10.1038/ng0397-266	http://dx.doi.org/10.1038/ng0397-266			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054938				2022-12-25	WOS:A1997WK38600015
J	Russo, MJ; Bayley, H; Toner, M				Russo, MJ; Bayley, H; Toner, M			Reversible permeabilization of plasma membranes with an engineered switchable pore	NATURE BIOTECHNOLOGY			English	Article						membrane permeabilization; metal-actuated switch; alpha-toxin; sucrose	STAPHYLOCOCCAL ALPHA-HEMOLYSIN; FORMING PROTEIN; CELL-MEMBRANES; TOXIN; AUREUS; CHANNELS; MUTAGENESIS	By using an engineered, self-assembling, proteinaceous, 2-nm pore equipped with a metal-actuated switch, a technique to reversibly permeabilize the plasma membrane to small molecules (similar to 1000 Da) has been developed. We have demonstrated the dose-dependent permeabilization of fibroblasts by pores designed to be blocked and unblocked by the addition and removal of mu M concentrations of Zn2+. Further, we have shown that the activity of the switch allows permeabilized cells to maintain viability and ultrastructural integrity following the unconstrained flux of small molecules. This ability to control the transmembrane influx and efflux of molecules and thereby vary the intracellular environment yet maintain cell viability will impact an array of biological and medical problems.	MASSACHUSETTS GEN HOSP, CTR ENGN MED & SURG SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; WORCESTER FDN BIOMED RES, SHREWSBURY, MA 01545 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Worcester Foundation for Biomedical Research				Bayley, Hagan/0000-0003-2499-6116	NIDDK NIH HHS [DK 46270] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046270, R01DK046270] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bashford CL, 1996, J MEMBRANE BIOL, V150, P37, DOI 10.1007/s002329900028; Bayley H, 1995, BIOORG CHEM, V23, P340, DOI 10.1006/bioo.1995.1023; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BISCHOF JC, 1995, BIOPHYS J, V68, P2608, DOI 10.1016/S0006-3495(95)80445-5; CHANG CY, 1995, CHEM BIOL, V2, P391, DOI 10.1016/1074-5521(95)90220-1; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; JOHNSON HL, CURRENT TOPICS NUTR, V6, P405; KUBISCH HM, 1995, J REPROD FERTIL, V104, P133, DOI 10.1530/jrf.0.1040133; LEVIN RL, 1981, CRYOBIOLOGY, V18, P32, DOI 10.1016/0011-2240(81)90004-3; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; MORRIS AP, 1993, AM J PHYSIOL, V264, pC977, DOI 10.1152/ajpcell.1993.264.4.C977; PALMER M, 1993, J BIOL CHEM, V268, P11963; Panchal RG, 1996, NAT BIOTECHNOL, V14, P852, DOI 10.1038/nbt0796-852; PANCHAL RG, 1995, J BIOL CHEM, V270, P23072, DOI 10.1074/jbc.270.39.23072; SUNZEL B, 1995, APMIS, V103, P635, DOI 10.1111/j.1699-0463.1995.tb01416.x; TSONG TY, 1991, BIOPHYS J, V60, P297, DOI 10.1016/S0006-3495(91)82054-9; WALEV I, 1994, MICROB PATHOGENESIS, V17, P187, DOI 10.1006/mpat.1994.1065; WALKER B, 1994, PROTEIN ENG, V7, P91, DOI 10.1093/protein/7.1.91; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107	24	67	89	3	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					278	282		10.1038/nbt0397-278	http://dx.doi.org/10.1038/nbt0397-278			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062930				2022-12-25	WOS:A1997WM05000034
J	Yamamoto, S; Sippel, KC; Berson, EL; Dryja, TP				Yamamoto, S; Sippel, KC; Berson, EL; Dryja, TP			Defects in the rhodopsin kinase gene in the Oguchi form of stationary night blindness	NATURE GENETICS			English	Article							HETEROZYGOUS MISSENSE MUTATION; PROTEIN; ISOPRENYLATION; TRANSDUCTION; PHOTOCURRENT; RODS	Oguchi disease is a recessively inherited form of stationary night blindness due to malfunction of the rod photoreceptor mechanism. Patients with this disease show a distinctive golden-brown colour of the fundus that occurs as the retina adapts to light, called the Mizuo phenomenon. Recently a defect in arrestin, a member of the rod phototransduction pathway, was found to cause this disease in some Japanese patients(1). As rhodopsin kinase works with arrestin in shutting off rhodopsin after it has been activated by a photon of light, it is reasonable to propose that some cases of Oguchi disease might be caused by defects in rhodopsin kinase. This report describes an analysis of the arrestin and rhodopsin kinase genes in three unrelated cases of Oguchi disease. No defects in arrestin were detected, but all three cases had mutations in the rhodopsin kinase gene. Two cases were found to be homozygous for a deletion encompassing exon 5, predicted to lead to a nonfunctional protein. The third case was a compound heterozygote with two allelic mutations, a missense mutation (Val380Asp) affecting a residue in the catalytic domain, and a frameshift mutation (Ser536(4-bp del)) resulting in truncation of the carboxy terminus. Our results indicate that null mutations in the rhodopsin kinase gene are a cause of Oguchi disease and extend the known genetic heterogeneity in congenital stationary night blindness.	HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,OCULAR MOL GENET INST,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB STUDY RETINAL DEGENERAT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary					NEI NIH HHS [EY08683, EY00169] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000169, R37EY000169, R01EY008683] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BERSON EL, 1994, PRINCIPLES PRACTICE, P1214; CARR R E, 1967, Investigative Ophthalmology, V6, P426; CARR RE, 1965, ARCH OPHTHALMOL-CHIC, V73, P646; CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; Dryja TP, 1996, NAT GENET, V13, P358, DOI 10.1038/ng0796-358; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; FULTON AB, 1990, CURR EYE RES, V9, P1211, DOI 10.3109/02713689009003477; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; Khani SC, 1996, GENOMICS, V35, P571, DOI 10.1006/geno.1996.0399; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PENN RD, 1972, BIOPHYS J, V12, P1073, DOI 10.1016/S0006-3495(72)86145-9; RUSHTON WA, 1961, J PHYSIOL-LONDON, V156, P166, DOI 10.1113/jphysiol.1961.sp006666; SIEVING PA, 1995, P NATL ACAD SCI USA, V92, P880, DOI 10.1073/pnas.92.3.880; VANKUIJK FJGM, 1991, INVEST OPHTH VIS SCI, V32, P1962	21	201	207	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					175	178		10.1038/ng0297-175	http://dx.doi.org/10.1038/ng0297-175			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020843				2022-12-25	WOS:A1997WF08700017
J	ElGhouzzi, V; LeMerrer, M; PerrinSchmitt, F; Lajeunie, E; Benit, P; Renier, D; Bourgeois, P; BolcatoBellemin, AL; Munnich, A; Bonaventure, J				ElGhouzzi, V; LeMerrer, M; PerrinSchmitt, F; Lajeunie, E; Benit, P; Renier, D; Bourgeois, P; BolcatoBellemin, AL; Munnich, A; Bonaventure, J			Mutations of the TWIST gene in the Saethre-Chotzen syndrome	NATURE GENETICS			English	Article							SYNDROME LOCUS; PFEIFFER-SYNDROME; JACKSON-WEISS; DNA-BINDING; CRANIOSYNOSTOSIS; LOCALIZATION; DROSOPHILA; EMBRYOS; GROWTH; TRANSLOCATIONS	Saethre-Chotzen syndrome (acrocephalo-syndactyly type III, ACS III) is an autosomal dominant craniosynostosis with brachydactyly, soft tissue syndactyly and facial dysmorphism including ptosis, facial asymmetry and prominent ear crura. ACS III has been mapped to chromosome 7p21-22. Of interest, TWIST, the human counterpart of the murine Twist gene, has been localized on chromosome 7p21 as well, The Twist gene product is a transcription factor containing a basic helix-loop-helix (b-HLH) domain, required in head mesenchyme for cranial neural tube morphogenesis in mice, The co-localisation of ACS III and TWIST prompted us to screen ACS III patients for TWIST gene mutations especially as mice heterozygous for Twist null mutations displayed skull defects and duplication of hind leg digits. Here, we report 21-bp insertions and nonsense mutations of the TWIST gene (S127X, E130X) in seven ACS III probands and describe impairment of head mesenchyme induction by TWIST as a novel pathophysiological mechanism in human craniosynostoses.	INST NECKER,UNITE RECH HANDICAPS GENET ENFANT,INSERM U393,F-75743 PARIS 15,FRANCE; LGME,CNRS,INSERM U184,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			EL GHOUZZI, Vincent/X-4364-2018	EL GHOUZZI, Vincent/0000-0001-5894-8978; Bourgeois, Patrice/0000-0001-6055-7108				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOURGEOIS P, MAMM GENOME, V7, P915; BRUETON LA, 1992, J MED GENET, V29, P681, DOI 10.1136/jmg.29.10.681; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; INOUYE M, 1976, Congenital Anomalies, V16, P171; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; LAJEUNIE E, 1995, NAT GENET, V9, P108, DOI 10.1038/ng0295-108; LEWANDA AF, 1994, GENOMICS, V19, P115, DOI 10.1006/geno.1994.1020; LEWANDA AF, 1994, AM J HUM GENET, V55, P1195; Ma HW, 1996, HUM GENET, V98, P228, DOI 10.1007/s004390050197; Meyers GA, 1996, AM J HUM GENET, V58, P491; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; REARDON W, 1993, AM J MED GENET, V47, P633, DOI 10.1002/ajmg.1320470510; REARDON W, 1994, J MED GENET, V31, P393, DOI 10.1136/jmg.31.5.393; REID CS, 1993, AM J MED GENET, V47, P637, DOI 10.1002/ajmg.1320470511; ROSE CSP, 1994, HUM MOL GENET, V3, P1405; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TSUJI K, 1994, AM J MED GENET, V49, P98, DOI 10.1002/ajmg.1320490119; VANHERWERDEN L, 1994, AM J HUM GENET, V54, P669; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	29	468	476	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					42	46						5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988167				2022-12-25	WOS:A1997WA37300019
J	TerGrigorov, VS; Krifuks, O; Liubashevsky, E; Nyska, A; Trainin, Z; Toder, V				TerGrigorov, VS; Krifuks, O; Liubashevsky, E; Nyska, A; Trainin, Z; Toder, V			A new transmissible AIDS-like disease in mice induced by alloimmune stimuli	NATURE MEDICINE			English	Article							LYMPHOPROLIFERATIVE DISEASE; ACQUIRED IMMUNODEFICIENCY; PATHOGENESIS; MOUSE; HIV; AUTOANTIBODIES; INDUCTION; PREGNANCY; LYMPHOMAS; ANTIBODY	The search for a suitable and reliable animal model for human AIDS that is easy to use on a large scale continues. Here we describe a new condition in mice that closely resembles human AIDS, namely, chronic lymphoproliferation with dramatic depletion of CD4-positive cells, progressive impairment of the immune responses, and Kaposi's sarcoma-like tumors or terminal B-lymphomas. The AIDS-like disease was primarily induced by mating BALB/c female mice to C57BL/6 males during a 1-year period (7-10 allogeneic pregnancies) followed by immunization with paternal lymphocytes. The disease is sexually and vertically transmissible, transferrable by cell-free plasma and is associated with autoimmune reactions to major histocompatibility complex antigens and CD4 cells. We hope that this becomes a model for studying the mechanisms of AIDS immunopathogenesis and immune-based treatment approaches.	TEL AVIV UNIV,SACKLER FAC MED,DEPT EMBRYOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	TerGrigorov, VS (corresponding author), KIMRON VET INST,DEPT PATHOL & IMMUNOL,IL-50250 BET DAGAN,ISRAEL.							ALTAN H, 1994, RES IMMUNOL, V145, P165; BLANK M, 1987, AM J REPROD IMMUNOL, V14, P49; CHAN WL, 1992, J EXP MED, V176, P1203, DOI 10.1084/jem.176.4.1203; CUNNIGHAM RK, 1994, IMMUNOL RES, V13, P21, DOI 10.1007/BF02918221; DALGLEISH AG, 1992, J ROY COLL PHYS LOND, V26, P152; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; GLEICHER N, 1992, AM J REPROD IMMUNOL, V28, P269, DOI 10.1111/j.1600-0897.1992.tb00812.x; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; HABESHAW J, 1992, IMMUNOL TODAY, V13, P207, DOI 10.1016/0167-5699(92)90155-Z; HARANGHERA N, 1994, ADV CANCER RES, V63, P245, DOI 10.1016/S0065-230X(08)60402-9; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HOFFMANN GW, 1991, P NATL ACAD SCI USA, V88, P3060, DOI 10.1073/pnas.88.8.3060; HUNT JS, 1992, CURR OPIN IMMUNOL, V4, P591, DOI 10.1016/0952-7915(92)90032-A; IEVLEVA ES, 1976, INT J CANCER, V17, P798, DOI 10.1002/ijc.2910170617; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; MITSUYASU RT, 1988, BLOOD REV, V2, P222, DOI 10.1016/0268-960X(88)90011-2; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; PATTENGALE PK, 1983, J NATL CANCER I, V70, P164; REED E, 1991, AM J REPROD, V20, P116; REICHERT CM, 1983, AM J PATHOL, V112, P357; SHEARER GM, 1983, NEW ENGL J MED, V308, P223, DOI 10.1056/NEJM198301273080415; SHEARER GM, 1986, MT SINAI J MED, V53, P605; SHIPOVA LY, 1994, EXP TOXICOL PATHOL, V46, P409, DOI 10.1016/S0940-2993(11)80125-9; SLAVIN S, 1978, NATURE, V272, P624, DOI 10.1038/272624a0; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; SUSAL G, 1996, IMMUNOL TODAY, V17, P114; TERGRIGOROV V, 1992, LEUKEMIA S16, V3, P171; TERGRIGOROV V, 1993, J CELL BIOCH S1, V170, P129; TERGRIGOROV VS, 1988, EKSP ONKOL, V6, P44; THACORE HR, 1994, IMMUNOBIOLOGY, V190, P195, DOI 10.1016/S0171-2985(11)80269-X; VOGEL J, 1988, NATURE, V335, P605	32	13	14	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					37	41		10.1038/nm0197-37	http://dx.doi.org/10.1038/nm0197-37			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986738				2022-12-25	WOS:A1997WA73300034
J	Yang, AG; Chen, SY				Yang, AG; Chen, SY			A new class of antigen-specific killer cells	NATURE BIOTECHNOLOGY			English	Article						gene therapy; HIV; cytotoxic cells; immunotoxin	HTLV-III/LAV ENVELOPE; PSEUDOMONAS-AERUGINOSA; CYTOTOXIC LYMPHOCYTES; FUNCTIONAL RECEPTORS; DIPHTHERIA-TOXIN; GENE-THERAPY; EXOTOXIN-A; ANTIBODY; IMMUNOGLOBULIN; EXPRESSION	A new class of antigen-specific killer cells that combines the features of antibody-mediated and cell-mediated immunity was designed. The principle and feasibility of this strategy are illustrated by creating an antigen-specific killer cell to produce and secrete targeted antibody-toxin molecules that recognize and kill human immunodeficiency virus (HIV)-1-infected cells. The transduced lymphocytes, which were able to produce and secrete the targeted toxin proteins, remained viable due to the lack of the target antigen on the cell surface. These transduced cells were found to have selective and potent cytotoxicity to the HIV-infected cells. This approach combines the specificity of antibodies, extreme potency of toxins, and effector-cell properties of T-cells to generate a new class of potent antigen-specific killer cells, which may have broad applications for the treatment of viral infection and other diseases. This study demonstrates the principle that mammalian cells can be genetically modified to produce targeted toxins, indicating that in vivo production of targeted toxins can be achieved to locally or systematically destroy targeted cells.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT CANC BIOL,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center								ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; Chen JD, 1996, HUM GENE THER, V7, P1515, DOI 10.1089/hum.1996.7.13-1515; CHEN SY, 1995, GENE THER, V2, P116; CHEN SY, 1994, P NATL ACAD SCI USA, V91, P5932, DOI 10.1073/pnas.91.13.5932; CHEN SY, 1991, J VIROL, V65, P5902, DOI 10.1128/JVI.65.11.5902-5909.1991; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMBRETSON J, 1993, NATURE, V362, P355; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MANIATIS T, 1986, MOL CLONING; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PEREZ P, 1985, NATURE, V316, P354, DOI 10.1038/316354a0; POLESZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; STITES DP, 1994, IMMUNOLOGY, P40; THALI M, 1991, J VIROL, V65, P6188, DOI 10.1128/JVI.65.11.6188-6193.1991; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YOUNG JD, 1988, IMMUNOL TODAY, V9, P140	34	16	24	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					46	51		10.1038/nbt0197-46	http://dx.doi.org/10.1038/nbt0197-46			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035105				2022-12-25	WOS:A1997WA72900022
J	Huang, YX; Paxton, WA; Wolinsky, SM; Neumann, AU; Zhang, LQ; He, T; Kang, S; Ceradini, D; Jin, ZQ; Yazdanbakhsh, K; Kunstman, K; Erickson, D; Dragon, E; Landau, NR; Phair, J; Ho, DD; Koup, RA				Huang, YX; Paxton, WA; Wolinsky, SM; Neumann, AU; Zhang, LQ; He, T; Kang, S; Ceradini, D; Jin, ZQ; Yazdanbakhsh, K; Kunstman, K; Erickson, D; Dragon, E; Landau, NR; Phair, J; Ho, DD; Koup, RA			The role of a mutant CCR5 allele in HIV-1 transmission and disease progression	NATURE MEDICINE			English	Article							VIRUS TYPE-1 INFECTION; IMMUNODEFICIENCY; COHORT	A 32-nucleotide deletion (Delta 32) within the beta-chemokine receptor 5 (CCR5) gene has been described in subjects who remain uninfected despite extensive exposure to HIV-1. This allele was found to be common in the Caucasian population with a frequency of 0.0808, but was not found in people of African or Asian ancestry. To determine its role in HIV-1 transmission and disease progression, we analyzed the CCR5 genotype of 1252 homosexual men enrolled in the Chicago component of the Multicenter AIDS Cohort Study (MACS). No infected participant was found to be homozygous for the Delta 32 allele, whereas 3.6% of at-risk but uninfected Caucasian participants were homozygous, showing the highly protective role of this genotype against sexual acquisition of HIV-1. No evidence was found to suggest that heterozygotes were protected against HIV-1 infection, but a limited protective role against disease progression was noted. The Delta 32 allele of CCR5 is therefore an important host factor in HIV-1 transmission and pathogenesis.	AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; ROCKEFELLER UNIV,NEW YORK,NY 10016; NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545; NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,LAB IMMUNOCHEM,NEW YORK,NY 10021; ROCHE MOL SYST,BRANCHBURG,NJ 08876	Rockefeller University; Northwestern University; United States Department of Energy (DOE); Los Alamos National Laboratory; New York Blood Center; Roche Holding			paxton, william/R-9747-2019; /ABE-5226-2021; Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697; Paxton, William/0000-0001-5200-0801; Paxton, William/0000-0002-2654-5186	NIAID NIH HHS [AI 32535, AI 35168, AI 45218] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CONNOR RI, IN PRESS J VIROL; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	23	1084	1135	0	76	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1240	1243		10.1038/nm1196-1240	http://dx.doi.org/10.1038/nm1196-1240			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898752				2022-12-25	WOS:A1996VQ10100040
J	Kennard, ML; Feldman, H; Yamada, T; Jefferies, WA				Kennard, ML; Feldman, H; Yamada, T; Jefferies, WA			Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease	NATURE MEDICINE			English	Article							AMYLOID PRECURSOR PROTEIN; CEREBROSPINAL-FLUID; BETA-PROTEIN; MISSENSE MUTATIONS; GENE; FERRITIN; ALUMINUM; TRANSFERRIN; PEPTIDE; LOCUS	Alzheimer's disease is a progressive and incurable disease whose prevalence increases dramatically with age. A biochemical marker for monitoring the onset and progression of the disease would be a valuable tool for disease management. In addition, such a marker might be used as an end point in clinical intervention protocols. Here we provide evidence that the soluble form of the iron binding protein p97 is found in elevated amounts in the serum of Alzheimer's patients compared with healthy controls. This biochemical marker has the potential for identifying subjects afflicted with the disease and possibly for monitoring the onset and longitudinal progression of the disease.	UNIV BRITISH COLUMBIA, BIOTECHNOL LAB, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT ZOOL, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, VANCOUVER HOSP & HLTH SCI CTR, DEPT MED, DIV NEUROL, VANCOUVER, BC V6T 2B5, CANADA; CHIBA UNIV, SCH MED, DEPT NEUROL, CHUO KU, CHIBA 260, JAPAN	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; Chiba University				Feldman, Howard/0000-0002-9258-4538				ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BLASS JP, 1993, NEUROLOGY, V43, pS25; BODOVITZ S, 1995, J NEUROCHEM, V64, P307; BROWN JP, 1981, P NATL ACAD SCI-BIOL, V78, P539, DOI 10.1073/pnas.78.1.539; BROWN JP, 1981, J IMMUNOL, V127, P539; BUSH AI, 1995, SCIENCE, V268, P1921, DOI 10.1126/science.268.5219.1921; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; DEDMAN DJ, 1992, BIOCHEM J, V287, P509, DOI 10.1042/bj2870509; EHMANN WD, 1986, NEUROTOXICOLOGY, V7, P197; FOOD MR, 1994, J BIOL CHEM, V269, P3034; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; GRUNDKEIQBAL I, 1990, ACTA NEUROPATHOL, V81, P105, DOI 10.1007/BF00334497; Jefferies WA, 1996, BRAIN RES, V712, P122, DOI 10.1016/0006-8993(95)01407-1; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KENNARD ML, 1993, BIOTECHNOL BIOENG, V42, P480, DOI 10.1002/bit.260420411; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; KITAGUCHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1453, DOI 10.1016/0006-291X(90)91030-V; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; ROBINSON SR, 1996, ALZHEIMERS RES, V1, P191; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Rothenberger S, 1996, BRAIN RES, V712, P117, DOI 10.1016/0006-8993(96)88505-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; WANG GP, 1991, ACTA NEUROPATHOL, V82, P6, DOI 10.1007/BF00310917; ZUBENKO GS, 1992, J NEUROPATH EXP NEUR, V51, P459, DOI 10.1097/00005072-199207000-00008	46	141	146	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1230	1235		10.1038/nm1196-1230	http://dx.doi.org/10.1038/nm1196-1230			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898750				2022-12-25	WOS:A1996VQ10100038
J	Carvajal, JJ; Pook, MA; dosSantos, M; Doudney, K; Hillermann, R; Minogue, S; Williamson, R; Hsuan, JJ; Chamberlain, S				Carvajal, JJ; Pook, MA; dosSantos, M; Doudney, K; Hillermann, R; Minogue, S; Williamson, R; Hsuan, JJ; Chamberlain, S			The Friedreich's ataxia gene encodes a novel phosphatidylinositol-4-phosphate 5-kinase	NATURE GENETICS			English	Article							4-PHOSPHATE 5-KINASE; KINASE; SEQUENCE; CLONING; ISOFORM	The STM7 gene on chromosome 9 was recently 'excluded' as a candidate for Friedreich's ataxia following the identification of an expanded intronic GAA triplet repeat in the adjacent gene, X25, in patients with the disease. Using RT-PCR, northern and sequence analyses, we now demonstrate that X25 comprises part of the STM7 gene, contributing to at least four splice variants, and report the identification of new coding sequences. Functional analysis of the STM7 recombinant protein corresponding to the reported 2.7-kilobase transcript has demonstrated PtdInsP 5-kinase activity, supporting the idea that the disease is caused by a defect in the phosphoinositide pathway, possibly affecting vesicular trafficking or synaptic transmission.	ST MARYS HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DEPT BIOCHEM & MOL GENET, LONDON W2 1PG, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, LUDWIG INST CANC RES, PROT BIOCHEM GRP, LONDON W1P 8BT, ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London			Carvajal, Jaime J/O-3681-2014; Pook, Mark/A-9144-2009; Doudney, Kit/Q-9728-2019; dos Santos, Maria/B-7426-2012; Hsuan, Justin/C-8825-2009	Carvajal, Jaime J/0000-0002-7277-0317; Pook, Mark/0000-0003-1122-7748; Doudney, Kit/0000-0002-0089-1152; Hsuan, Justin/0000-0001-6083-7564				BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; CHAMBERLAIN S, 1982, J NEUROL NEUROSUR PS, V45, P1136, DOI 10.1136/jnnp.45.12.1136; CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0; CHAMBERLAIN S, 1981, LANCET, V1, P1165; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; MONTERMINI L, 1995, AM J HUM GENET, V57, P1061; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; RODIUS F, 1994, AM J HUM GENET, V54, P1050; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416	20	70	74	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1996	14	2					157	162		10.1038/ng1096-157	http://dx.doi.org/10.1038/ng1096-157			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841185				2022-12-25	WOS:A1996VL44600019
J	Hughes, DE; Dai, AH; Tiffee, JC; Li, HH; Mundy, GR; Boyce, BF				Hughes, DE; Dai, AH; Tiffee, JC; Li, HH; Mundy, GR; Boyce, BF			Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; BONE-RESORPTION; CELL-DEATH; IN-VIVO; OSTEOPOROSIS; TAMOXIFEN; CALVARIA; MASS; RATS	Postmenopausal osteoporosis, the most common bone disease in the developed world(1), is associated with estrogen deficiency. This deficiency induces increased generation and activity of osteoclasts, which perforate bone trabeculae, thus reducing their strength and increasing fracture risk. Estrogen replacement prevents these effects(2), indicating that estrogen negatively regulates osteoclast formation and function, but how it does this is unclear. Because functional osteoclast life span and thus the amount of bone that osteoclasts resorb could also be enhanced following estrogen deficiency, and since sex steroids regulate apoptosis in other target tissues(3), we investigated whether estrogen may affect osteoclast function by promoting apoptosis. 17 beta-Estradiol promoted apoptosis of murine osteoclasts in vitro and in vivo by two- to threefold. Tamoxifen, which has estrogenic effects on bone resorption(4), and transforming growth factor-beta 1 (TGF-beta), whose production by osteoblasts is increased by estrogen(5), had similar effects in vitro. Anti-TGF-beta antibody inhibited TGF-beta-, estrogen- and tamoxifen-induced osteoclast apoptosis, indicating that TGF-beta might mediate this effect. These findings suggest that estrogen may prevent excessive bone loss before and after the menopause by limiting osteoclast life span through promotion of apoptosis. The development of analogues to promote this mechanism specifically could be a useful and novel therapeutic approach to prevent postmenopausal osteoporosis.	UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT ORAL HEAD & NECK PATHOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043510, P01AR039529] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 43510, AR 39529] Funding Source: Medline; NIDDK NIH HHS [DK 45299] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUDREUIL J, 1995, J BONE MINER RES, V10, P971; BONEWALD LF, 1992, EXP HEMATOL, V20, P1249; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; GARRETT IR, 1989, J BONE MINER RES, V4, P789; GOULDING A, 1992, BONE MINER, V18, P143, DOI 10.1016/0169-6009(92)90854-7; GRAINGER DJ, 1995, NAT MED, V1, P1067, DOI 10.1038/nm1095-1067; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; HUGHES DE, 1994, J BONE MINER RES  S1, V9, pS138; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LINDSAY R, 1993, LANCET, V341, P801, DOI 10.1016/0140-6736(93)90571-W; LIU CC, 1991, ANAT REC, V229, P240, DOI 10.1002/ar.1092290211; MELTON LJ, 1995, J BONE MINER RES, V10, P175; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo-129-6-3313; OURSLER MJ, 1994, P NATL ACAD SCI USA, V91, P5227, DOI 10.1073/pnas.91.12.5227; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; Parfitt AM, 1996, J BONE MINER RES, V11, P150; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; POLLARD JW, 1987, CELL TISSUE RES, V249, P533; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1473; TASHJIAN AH, 1985, P NATL ACAD SCI USA, V82, P4535, DOI 10.1073/pnas.82.13.4535; TURNER CH, 1994, ENDOCRINOLOGY, V135, P2001, DOI 10.1210/en.135.5.2001; WESOLOWSKI G, 1995, EXP CELL RES, V219, P679, DOI 10.1006/excr.1995.1279; ZHENG MH, 1995, BONE S, V16, pS93	27	630	684	0	44	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1132	1136		10.1038/nm1096-1132	http://dx.doi.org/10.1038/nm1096-1132			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837613				2022-12-25	WOS:A1996VK99500035
J	McWhir, J; Schnieke, AE; Ansell, R; Wallace, H; Colman, A; Scott, AR; Kind, AJ				McWhir, J; Schnieke, AE; Ansell, R; Wallace, H; Colman, A; Scott, AR; Kind, AJ			Selective ablation of differentiated cells permits isolation of embryonic stem cell lines from murine embryos with a non-permissive genetic background	NATURE GENETICS			English	Letter							TRANSCRIPTION FACTOR; ESTABLISHMENT; TRANSMISSION; EXPRESSION; REGION		PPL THERAPEUT,ROSLIN EH25 9PP,MIDLOTHIAN,SCOTLAND		McWhir, J (corresponding author), ROSLIN INST,DEPT MOL BIOL,ROSLIN EH25 9PS,MIDLOTHIAN,SCOTLAND.			Schnieke, Angelika/0000-0002-5761-9635				ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; BENSHUSHAN E, 1993, MOL CELL BIOL, V13, P891, DOI 10.1128/MCB.13.2.891; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; COWARD P, 1994, NAT GENET, V6, P245, DOI 10.1038/ng0394-245; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; HOGAN B, 1986, MANIPULATING MOUSE E; HOOPER ML, 1990, EMBRYONAL STEM CELLS, P147; IANNACCONE PM, 1994, DEV BIOL, V163, P288, DOI 10.1006/dbio.1994.1146; KAWASE E, 1994, INT J DEV BIOL, V38, P385; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; SUEMORI H, 1987, DEV GROWTH DIFFER, V29, P133; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P563, DOI 10.1071/RD9940563; Yeom YI, 1996, DEVELOPMENT, V122, P881	23	93	115	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					223	226		10.1038/ng1096-223	http://dx.doi.org/10.1038/ng1096-223			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841201				2022-12-25	WOS:A1996VL44600035
J	Raisz, LG				Raisz, LG			Estrogen and bone: New pieces to the puzzle	NATURE MEDICINE			English	Editorial Material							RESORPTION				Raisz, LG (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06030, USA.							CAPUTO CB, 1976, ENDOCRINOLOGY, V98, P1065, DOI 10.1210/endo-98-4-1065; Draper MW, 1996, J BONE MINER RES, V11, P835; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; JILKA RL, 1992, SCIENCE, V257, P8; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P539, DOI 10.1172/JCI118066; KE HZ, 1995, BONE, V17, P491, DOI 10.1016/8756-3282(95)00346-2; KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054; MIYAURA C, 1995, J BONE MINER RES, V10, P1365; OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo-129-6-3313; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; Raisz Lawrence G., 1996, P661; VARGAS S, IN PRESS J BONE MINE; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	15	11	16	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1077	1078		10.1038/nm1096-1077	http://dx.doi.org/10.1038/nm1096-1077			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837601				2022-12-25	WOS:A1996VK99500023
J	Brenner, M				Brenner, M			Placental blood transplant: Who will benefit?	NATURE MEDICINE			English	Editorial Material							UMBILICAL-CORD BLOOD; CELLS				Brenner, M (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.							APPELBAUM FR, 1994, MED ONCOL, V11, P69; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; Butler D, 1996, NATURE, V382, P99, DOI 10.1038/382099a0; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Gluckman E, 1996, NATURE, V382, P108, DOI 10.1038/382108a0; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Laporte JP, 1996, NEW ENGL J MED, V335, P167, DOI 10.1056/NEJM199607183350304	8	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					969	970		10.1038/nm0996-969	http://dx.doi.org/10.1038/nm0996-969			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782448				2022-12-25	WOS:A1996VF49700025
J	Mollenhauer, J; Wiemann, S; Scheurlen, W; Korn, B; Hayashi, Y; Wilgenbus, KK; vonDeimling, A; Poustka, A				Mollenhauer, J; Wiemann, S; Scheurlen, W; Korn, B; Hayashi, Y; Wilgenbus, KK; vonDeimling, A; Poustka, A			DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours	NATURE GENETICS			English	Article							PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; LONG ARM; RECEPTOR; HETEROZYGOSITY; SEQUENCES; DOMAIN; HYBRIDIZATION; PROGRESSION; MELANOMA	Loss of sequences from human chromosome 10q has been associated with the progression of human cancer. Medulloblastoma and glioblastoma multiforme ave the most common malignant brain tumours in children and adults, respectively. In glioblastoma multiforme, the most aggressive form, 80% of the tumours show loss of 10q. We have used representational difference analysis to identify a homozygous deletion at 10q25.3-26.1 in a medulloblastoma cell line and have cloned a novel gene, DMBT1, spanning this deletion. DMBT1 shows homology to the scavenger receptor cysteine-rich (SRCR) superfamily. Intragenic homozygous deletions have been detected in 2/20 medulloblastomas and in 9/39 glioblastomas mutliformes. Lack of DMBT1 expression has been demonstrated in 4/5 brain-tumour cell lines. We suggest that DMBT1 is a putative tumour-suppressor gene implicated in the carcinogenesis of medulloblastoma and glioblastoma multiforme.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV MOL GENOME ANAL, D-69120 HEIDELBERG, GERMANY; CHILDRENS HOSP, D-68167 MANNHEIM, GERMANY; UNIV BONN, MED CTR, DEPT NEUROPATHOL, D-53105 BONN, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Bonn			Abrams, William R/A-5782-2008; Mollenhauer, Jan/G-4452-2012; von Deimling, Andreas/F-7774-2013; Wiemann, Stefan/E-4424-2013	von Deimling, Andreas/0000-0002-5863-540X; Wiemann, Stefan/0000-0003-4683-3174				AlAwqati Q, 1996, AM J PHYSIOL-CELL PH, V270, pC1571, DOI 10.1152/ajpcell.1996.270.6.C1571; Albarosa R, 1996, AM J HUM GENET, V58, P1260; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; AZIZI E, 1995, CANCER, V76, P1571, DOI 10.1002/1097-0142(19951101)76:9<1571::AID-CNCR2820760912>3.0.CO;2-6; BIEGEL JA, 1995, GENE CHROMOSOME CANC, V14, P85, DOI 10.1002/gcc.2870140202; BIEGEL JA, 1989, GENE CHROMOSOME CANC, V1, P139, DOI 10.1002/gcc.2870010206; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cheng H, 1996, ANAT REC, V244, P327; CHUMAKOV IM, 1995, NATURE, V377, P175; COGEN PH, 1990, GENOMICS, V8, P279, DOI 10.1016/0888-7543(90)90283-Z; FUJII YJ, 1994, GENE CHROMOSOME CANC, V11, P205, DOI 10.1002/gcc.2870110402; GRAY IC, 1995, CANCER RES, V55, P4800; HAHN SA, 1995, CANCER RES, V55, P4670; HERBST RA, 1994, CANCER RES, V54, P3111; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KELSELL DP, 1995, ANN HUM GENET, V59, P233, DOI 10.1111/j.1469-1809.1995.tb00743.x; Kleihues P, 1993, HISTOLOGICAL TYPING; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUHL J, 1993, AM J PEDIAT HEMAT SA, V15, P567; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI XJ, 1995, J BIOL CHEM, V270, P17674, DOI 10.1074/jbc.270.30.17674; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NEUMANN E, 1993, CANCER GENET CYTOGEN, V71, P40, DOI 10.1016/0165-4608(93)90200-6; NUNES DP, 1995, BIOCHEM J, V310, P41, DOI 10.1042/bj3100041; PEIFFER SL, 1995, CANCER RES, V55, P1922; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; POUSTKA A, 1990, Methods (Orlando), V1, P204, DOI 10.1016/S1046-2023(05)80136-7; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Schutz BR, 1996, GENE CHROMOSOME CANC, V16, P196; Starling GC, 1996, EUR J IMMUNOL, V26, P738, DOI 10.1002/eji.1830260403; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; THOMAS GA, 1991, CANCER RES, V51, P639; ULLRICH A, 1994, J BIOL CHEM, V269, P18401; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758	41	403	416	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1997	17	1					32	39		10.1038/ng0997-32	http://dx.doi.org/10.1038/ng0997-32			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288095				2022-12-25	WOS:A1997XU72400015
J	Bonnet, D; Dick, JE				Bonnet, D; Dick, JE			Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell	NATURE MEDICINE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; PROGENITOR CELLS; STEM-CELLS; SCID MOUSE; MICE; DIFFERENTIATION; ABNORMALITIES	On the subject of acute myeloid leukemia (AML), there is little consensus about the target cell within the hematopoietic stem cell hierarchy that is susceptible to leukemic transformation, or about the mechanism that underlies the phenotypic, genotypic and clinical heterogeneity. Here we demonstrate that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice)-termed the SCID leukemia-initiating cell, or SL-IC-possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. The SL-ICs from all subtypes of AML analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34(++) CD38(-), similar to the cell-surface phenotype of normal SCID-repopulating cells, suggesting that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation. The SL-ICs were able to differentiate in vivo into leukemic blasts, indicating that the leukemic clone is organized as a hierarchy.	UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5G 1X8, CANADA	University of Toronto	Bonnet, D (corresponding author), HOSP SICK CHILDREN, RES INST, DEPT GENET, 555 UNIV AVE, TORONTO, ON M5G 1X8, CANADA.			Dick, John/0000-0002-9527-8317				BARTRAM CR, 1989, LEUKEMIA, V3, P247; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BERGER R, 1987, CANCER GENET CYTOGEN, V29, P9, DOI 10.1016/0165-4608(87)90026-4; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; CASHMAN J, IN PRESS BLOOD; CESANO A, 1992, ONCOGENE, V7, P827; CIVIN CI, 1984, J IMMUNOL, V133, P157; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FEURINGBUSKE M, 1995, LEUKEMIA, V9, P1318; FIALKOW PJ, 1981, BLOOD, V57, P1068; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; GRIFFIN JD, 1986, BLOOD, V68, P1185; HAASE D, 1995, BLOOD, V86, P2906; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; LAROCHELLE A, 1995, HUM MOL GENET, V4, P163, DOI 10.1093/hmg/4.2.163; MCCULLOCH EA, 1983, BLOOD, V62, P1; MEHROTRA B, 1995, BLOOD, V86, P1139; MOORE MAS, 1973, J NATL CANCER I, V50, P603, DOI 10.1093/jnci/50.3.603; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; SAWYERS CL, 1992, BLOOD, V79, P2089, DOI 10.1182/blood.V79.8.2089.bloodjournal7982089; Sirard C, 1996, BLOOD, V87, P1539, DOI 10.1182/blood.V87.4.1539.bloodjournal8741539; Sutherland HJ, 1996, BLOOD, V87, P4754, DOI 10.1182/blood.V87.11.4754.bloodjournal87114754; TASWELL C, 1981, J IMMUNOL, V126, P1614; Terpstra W, 1996, BLOOD, V87, P2187, DOI 10.1182/blood.V87.6.2187.bloodjournal8762187; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P993; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; VANLOM K, 1993, BLOOD, V82, P884; VORMOOR J, 1994, BLOOD, V83, P2489; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156	38	4937	5459	15	536	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					730	737		10.1038/nm0797-730	http://dx.doi.org/10.1038/nm0797-730			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212098				2022-12-25	WOS:A1997XG76700031
J	Cross, SH; Meehan, RR; Nan, XS; Bird, A				Cross, SH; Meehan, RR; Nan, XS; Bird, A			A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins	NATURE GENETICS			English	Article							CPG BINDING-PROTEIN; DROSOPHILA-TRITHORAX; CHROMOSOMAL PROTEIN; ACUTE LEUKEMIAS; METHYLATED DNA; ALL-1 GENE; SEQUENCE; DOMAIN; PURIFICATION; INVOLVEMENT				Cross, SH (corresponding author), UNIV EDINBURGH,INST CELL & MOL BIOL,KINGS BLDG,MAYFIELD RD,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND.			Cross, Sally/0000-0001-6518-6449; Meehan, Richard/0000-0001-6471-6882; Nan, Xinsheng/0000-0002-0865-7934; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAMMARBACK JA, 1990, J BIOL CHEM, V265, P12763; Harlow E., 1988, ANTIBODIES LAB MANUA; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	31	205	213	1	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					256	259		10.1038/ng0797-256	http://dx.doi.org/10.1038/ng0797-256			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207790				2022-12-25	WOS:A1997XG60900020
J	Chahine, KG				Chahine, KG			Patenting DNA: Just when you thought it was safe	NATURE BIOTECHNOLOGY			English	Editorial Material											Chahine, KG (corresponding author), MADSON & METCALF,170 S MAIN ST,SALT LAKE CITY,UT 84101, USA.							GLOVER DM, 1985, DNA CLONING PRACTICA, V1, P4978; 1987, Patent No. 4666829	2	1	1	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					586	587		10.1038/nbt0697-586	http://dx.doi.org/10.1038/nbt0697-586			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181584				2022-12-25	WOS:A1997XC77200037
J	Massaro, GD; Massaro, D				Massaro, GD; Massaro, D			Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats	NATURE MEDICINE			English	Article							LUNG; DEXAMETHASONE; BINDING	Pulmonary emphysema is a common disease(1) in which destruction of the lung's gas-exchange structures (alveoli)(2) leads to inadequate oxygenation(3), disability(4) and frequently death(1); lung transplantation provides its only remediation. Because treatment of normal rats with all-trans-retinoic acid increases the number of alveoli(5), we tested whether a similar effect would occur in rats with emphysema. Elastase was instilled into rat lungs, producing changes characteristic of human(2) and experimental(6) emphysema: increased lung volume reflecting a loss of lung elastic recoil, larger but fewer alveoli and diminished volume-corrected alveolar surface area due to destruction of alveolar walls. Treatment with all-trans-retinoic acid reversed these changes providing nonsurgical remediation of emphysema and suggesting the possibility of a similar effect in humans.			Massaro, GD (corresponding author), GEORGETOWN UNIV,SCH MED,LUNG BIOL LAB,PRECLIN SCI BLDG,GM-12,3900 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037666, R01HL020366, R37HL020366] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37666, HL 20366] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Christie RV, 1934, J CLIN INVEST, V13, P295, DOI 10.1172/JCI100588; GILCHREST BA, 1994, J CLIN INVEST, V94, P1711, DOI 10.1172/JCI117516; GRUMMER MA, 1995, PEDIATR PULM, V20, P234, DOI 10.1002/ppul.1950200406; Guyer B, 1996, PEDIATRICS, V98, P1007; KAPLAN PD, 1973, J LAB CLIN MED, V82, P349; KARLINSKY JB, 1978, AM REV RESPIR DIS, V117, P1109; MARGRAF LR, 1991, AM REV RESPIR DIS, V143, P391; MASSARO D, 1986, AM J PHYSIOL, V251, pR218, DOI 10.1152/ajpregu.1986.251.2.R218; MASSARO D, 1985, J CLIN INVEST, V76, P1297, DOI 10.1172/JCI112103; Massaro GD, 1996, ANNU REV PHYSIOL, V58, P73; Massaro GD, 1996, AM J PHYSIOL-LUNG C, V270, pL305, DOI 10.1152/ajplung.1996.270.2.L305; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; OKABE T, 1984, EXP CELL RES, V154, P125, DOI 10.1016/0014-4827(84)90673-6; ONG DE, 1976, P NATL ACAD SCI USA, V73, P3976, DOI 10.1073/pnas.73.11.3976; RUSH MG, 1991, ENDOCRINOLOGY, V129, P705, DOI 10.1210/endo-129-2-705; SHOTT S, 1990, STATISTICS HLTH PROF, P229; TENNEY SM, 1963, NATURE, V197, P54, DOI 10.1038/197054a0; THURLBEC.WM, 1967, THORAX, V22, P483, DOI 10.1136/thx.22.6.483; WEST JR, 1951, AM J MED, V10, P481, DOI 10.1016/0002-9343(51)90294-X	19	395	420	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					675	677		10.1038/nm0697-675	http://dx.doi.org/10.1038/nm0697-675			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176496				2022-12-25	WOS:A1997XB97400039
J	Spada, S; Pluckthun, A				Spada, S; Pluckthun, A			Selectively infective phage (SIP) technology: A novel method for in vivo selection of interacting protein-ligand pairs	NATURE MEDICINE			English	Article							DISPLAY; SURFACE		UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich			Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				ADEY NB, 1995, GENE, V156, P27, DOI 10.1016/0378-1119(95)00058-E; Bai C, 1996, METHOD ENZYMOL, V273, P331; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; Duenas M, 1996, IMMUNOLOGY, V89, P1, DOI 10.1046/j.1365-2567.1996.d01-708.x; Duenas M, 1996, MOL IMMUNOL, V33, P279, DOI 10.1016/0161-5890(95)00137-9; DUENAS M, 1994, BIO-TECHNOL, V12, P999, DOI 10.1038/nbt1094-999; Dunn IS, 1996, CURR OPIN BIOTECH, V7, P547, DOI 10.1016/S0958-1669(96)80060-7; GRAMATIKOFF K, 1995, BIOL CHEM H-S, V376, P321; GRAMATIKOFF K, 1994, NUCLEIC ACIDS RES, V22, P5761, DOI 10.1093/nar/22.25.5761; Krebber C, 1995, FEBS LETT, V377, P227, DOI 10.1016/0014-5793(95)01348-2; KREBBER C, 1993, Patent No. 102484; KREBBER C, 1997, J MOL BIOL, V268, P619; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STENGELE I, 1990, J MOL BIOL, V212, P143, DOI 10.1016/0022-2836(90)90311-9	14	30	31	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					694	696		10.1038/nm0697-694	http://dx.doi.org/10.1038/nm0697-694			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176500				2022-12-25	WOS:A1997XB97400043
J	Blankesteijn, WM; EssersJanssen, YPG; Verluyten, MJA; Daemen, MJAP; Smits, JFM				Blankesteijn, WM; EssersJanssen, YPG; Verluyten, MJA; Daemen, MJAP; Smits, JFM			A homologue of Drosophila tissue polarity gene frizzled is expressed in migrating myofibroblasts in the infarcted rat heart	NATURE MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CELLS; HETEROGENEITY	Myocardial infarction results in the formation of granulation tissue in the injured ventricular wall. This tissue contains myofibroblasts in highly organized arrays; their contractile properties may help to prevent the infarct area from dilatation. The mechanisms that control myofibroblast alignment are unknown. We found that myofibroblasts express a homologue of Drosophila tissue polarity gene frizzled (fz2) when migrating into the granulation tissue. The expression is decreased after the cells have aligned. This suggests that fz2 is involved in the spatial control of cardiac wound repair after infarction, possibly through intra- and intercellular transmission of polarity signals as in developing Drosophila. Mutations in the fz2 gene may impair myofibroblast alignment in the infarct area, thereby resulting in ventricular dilatation and aneurism following infarction.	MAASTRICHT UNIV,CARDIOVASC RES INST MAASTRICHT,DEPT PATHOL,NL-6200 MD MAASTRICHT,NETHERLANDS	Maastricht University	Blankesteijn, WM (corresponding author), MAASTRICHT UNIV,CARDIOVASC RES INST MAASTRICHT,DEPT PHARMACOL,POB 616,NL-6200 MD MAASTRICHT,NETHERLANDS.							ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Blankesteijn WM, 1996, J MOL CELL CARDIOL, V28, P1187; BODMER R, 1995, TRENDS CARDIOVAS MED, V5, P21, DOI 10.1016/1050-1738(94)00032-Q; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CLEUTJENS JPM, 1995, AM J PATHOL, V147, P325; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; EYDEN BP, 1993, ULTRASTRUCT PATHOL, V17, P611, DOI 10.3109/01913129309027797; GAUDRON P, 1993, CIRCULATION, V87, P755, DOI 10.1161/01.CIR.87.3.755; GUBB D, 1993, DEVELOPMENT, P269; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; MIEROP LHS, 1986, AM J CARDIOL, V58, P133; PASSIER RCJJ, 1995, AM J PHYSIOL-HEART C, V269, pH1268, DOI 10.1152/ajpheart.1995.269.4.H1268; Pizzuti A, 1996, AM J HUM GENET, V58, P722; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; SUN Y, 1994, CARDIOVASC RES, V28, P1423, DOI 10.1093/cvr/28.9.1423; VRACKO R, 1991, LAB INVEST, V65, P214; Wang YS, 1996, J BIOL CHEM, V271, P4468; WILLEMS IEMG, 1994, AM J PATHOL, V145, P868; WILLEMS IEMG, 1994, LAB INVEST, V71, P127; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060	22	90	97	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					541	544		10.1038/nm0597-541	http://dx.doi.org/10.1038/nm0597-541			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142123				2022-12-25	WOS:A1997WX54300034
J	Boyer, JD; Ugen, KE; Wang, B; Agadjanyan, M; Gilbert, L; Bagarazzi, ML; Chattergoon, M; Frost, P; Javadian, A; Williams, WV; Refaeli, Y; Ciccarelli, RB; McCallus, D; Coney, L; Weiner, DB				Boyer, JD; Ugen, KE; Wang, B; Agadjanyan, M; Gilbert, L; Bagarazzi, ML; Chattergoon, M; Frost, P; Javadian, A; Williams, WV; Refaeli, Y; Ciccarelli, RB; McCallus, D; Coney, L; Weiner, DB			Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE ACTIVITY; IMMUNE-RESPONSES; INFECTION; IMMUNIZATION; MICE; TRANSMISSION; INJECTION; ANTIGEN; INFANT	Novel approaches for the generation of more effective vaccines for HIV-1 are of significant importance. In this report we analyze the immunogenicity and efficacy of an HIV-1 DNA vaccine encoding env, rev and gag/pol in a chimpanzee model system. The immunized animals developed specific cellular and humoral immune responses. Animals were challenged with a heterologous chimpanzee titered stock of HIV-1 SF2 virus and followed for 48 weeks after challenge. Polymerase chain reaction coupled with reverse transcription (RT-PCR) results indicated infection in the control animal, whereas those animals vaccinated with the DNA constructs were protected from the establishment of infection. These studies serve as ait important benchmark for the use of DNA vaccine technology for the production of protective immune responses.	UNIV S FLORIDA,DEPT MED MICROBIOL & IMMUNOL,TAMPA,FL 33612; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; COULSTON FDN,WHITE SANDS RES CTR,ALAMOGORDO,NM 88310; HOSP UNIV PENN,PHILADELPHIA,PA 19104; HARVARD UNIV,DEPT PATHOL,BOSTON,MA 02115; APOLLON INC,MALVERN,PA 19355	State University System of Florida; University of South Florida; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Harvard University	Boyer, JD (corresponding author), UNIV PENN,DEPT PATHOL & LAB MED,505 STELLAR CHANCE BLDG,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.		Weiner, David B/H-8579-2014; Ugen, Kenneth E/H-6544-2011; Bagarazzi, Mark L/AAU-1383-2021	Williams, William/0000-0003-3611-9284				BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; BRINCHMANN JE, 1994, J INFECT DIS, V169, P730, DOI 10.1093/infdis/169.4.730; DUBENSKY TW, 1984, P NATL ACAD SCI-BIOL, V81, P7529, DOI 10.1073/pnas.81.23.7529; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GOEDERT JJ, 1989, LANCET, V2, P1351; GRUTERS RA, 1990, EUR J IMMUNOL, V20, P1038; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HAYNES JR, 1994, AIDS RES HUM RETROV, V10, pS43; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; LOWRIE DB, 1994, VACCINE, V12, P1537, DOI 10.1016/0264-410X(94)90080-9; LU S, 1995, VIROLOGY, V209, P147, DOI 10.1006/viro.1995.1238; LU S, 1996, J VIROL, V70, P378; MICHEL ML, 1995, P NATL ACAD SCI USA, V92, P5307, DOI 10.1073/pnas.92.12.5307; MONTIFIORI DC, 1988, J CLIN MICROBIOL, V6, P231; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; OKUDA K, 1995, AIDS RES HUM RETROV, V11, P933, DOI 10.1089/aid.1995.11.933; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; RAZ E, 1993, P NATL ACAD SCI USA, V90, P4523, DOI 10.1073/pnas.90.10.4523; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; Shibata R, 1996, J VIROL, V70, P4361, DOI 10.1128/JVI.70.7.4361-4369.1996; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Ugen KE, 1997, J INFECT DIS, V175, P63, DOI 10.1093/infdis/175.1.63; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VANDAMME AM, 1995, J VIROL METHODS, V52, P121, DOI 10.1016/0166-0934(94)00151-6; VANDAMME AM, 1994, VERH K ACAD GENEESKD, V3, P231; VINGERHOETS JH, 1995, CLIN EXP IMMUNOL, V100, P425; WANG B, 1995, VIROLOGY, V211, P102, DOI 10.1006/viro.1995.1383; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG B, 1995, HUM GENE THER, V6, P407, DOI 10.1089/hum.1995.6.4-407; Wang B, 1995, ANN NY ACAD SCI, V772, P186, DOI 10.1111/j.1749-6632.1995.tb44744.x; WANG B, 1994, AIDS RES HUM RETROV, V10, pS35; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	40	321	338	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					526	532		10.1038/nm0597-526	http://dx.doi.org/10.1038/nm0597-526			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142121	Bronze			2022-12-25	WOS:A1997WX54300032
J	Cao, YZ; Krogstad, P; Korber, BT; Koup, RA; Muldoon, M; Macken, C; Song, JL; Jin, ZQ; Zhao, JQ; Clapp, S; Chen, ISY; Ho, DD; Ammann, AJ; Mullins, J; Walker, B; Wolinsky, S; Bardeguez, A; Crane, M; Hanson, C; Hamill, H; Luzuriaga, K; Palumbo, P; VanDyke, R; Widmayer, S; Wiznia, A				Cao, YZ; Krogstad, P; Korber, BT; Koup, RA; Muldoon, M; Macken, C; Song, JL; Jin, ZQ; Zhao, JQ; Clapp, S; Chen, ISY; Ho, DD; Ammann, AJ; Mullins, J; Walker, B; Wolinsky, S; Bardeguez, A; Crane, M; Hanson, C; Hamill, H; Luzuriaga, K; Palumbo, P; VanDyke, R; Widmayer, S; Wiznia, A			Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the Prevention of HIV Transmission from Mother to Infant	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; TYPE-1; QUANTITATION	Most HIV-1 infections of children result from mother-to-infant transmission, which may occur perinatally or postnatally, as a consequence of breast feeding(1-8). In this study, the influence of maternal viral load on transmission of infection to infants from non-breast-feeding mothers was examined using samples of plasma and peripheral blood mononuclear cells (PBMCs) collected at several time points during pregnancy and the 6-month period after delivery. These samples were analyzed by several quantitative methods, including virus cultures of PBMCs and polymerase chain reaction (PCR) assays for HIV-1 RNA in plasma and DNA in PBMCs. The risk of transmission increased slightly with a higher viral load, but transmission and nontransmission occurred over the entire range of values for each assay. No threshold value of virus load was identified which discriminated between transmitters and nontransmitters. We also noted a significant rise in viral load and a decline in CD4(+) lymphocytes in the six months after delivery. These findings suggest that a high maternal viral load is insufficient to fully explain vertical transmission of HIV-1. Additional studies are needed to examine the post-partum increase in viremia.	ROCKEFELLER UNIV, AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; LOS ALAMOS NATL LAB, LOS ALAMOS, NM 87545 USA; SANTA FE INST, SANTA FE, NM 87501 USA; UNIV MANCHESTER, INST SCI & TECHNOL, DEPT MATH, MANCHESTER M60 1QD, LANCS, ENGLAND; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA; PEDIAT AIDS FDN, SANTA MONICA, CA USA	Rockefeller University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; United States Department of Energy (DOE); Los Alamos National Laboratory; The Santa Fe Institute; University of Manchester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Wolinsky, Steven/B-2893-2012; Muldoon, Mark R/C-7505-2009; Muldoon, Mark/T-9192-2019; Krogstad, Paul/AAQ-8495-2020	Muldoon, Mark/0000-0002-5004-7195; Korber, Bette/0000-0002-2026-5757				Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KHOURI YF, 1995, J CLIN INVEST, V95, P732, DOI 10.1172/JCI117720; Krogstad P, 1996, AIDS RES HUM RETROV, V12, P977, DOI 10.1089/aid.1996.12.977; KROGSTAD PA, 1995, HIV RES METHODS PRAC, P143; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SCOTT GB, 1995, PEDIATRICS, V96, P977; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; SPRECHER S, 1986, LANCET, V2, P288; STIEHM ER, 1991, J PEDIATR-US, V118, P410, DOI 10.1016/S0022-3476(05)82157-2; VONSEIDLEIN L, 1994, SEMINARS PEDIAT INFE, V5, P78; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037; ZIEGLER JB, 1985, LANCET, V1, P896	19	146	150	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1997	3	5					549	552		10.1038/nm0597-549	http://dx.doi.org/10.1038/nm0597-549			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142125				2022-12-25	WOS:A1997WX54300036
J	Gong, JL; Chen, DS; Kashiwaba, M; Kufe, D				Gong, JL; Chen, DS; Kashiwaba, M; Kufe, D			Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells	NATURE MEDICINE			English	Article							CYTOTOXIC T-LYMPHOCYTES; COLONY-STIMULATING FACTOR; IN-VITRO; ANTIGEN; GENERATION; PEPTIDE	Dendritic cells (DCs) are potent antigen-presenting cells that prime naive cytotoxic T-cells (CTLs)(1). In this study, we have fused DCs with MC38 carcinoma cells. The fusion cells were positive for major histocompatibility (MHC) class I and II, costimulating molecules and intercellular cell adhesion molecule-1 (ICAM-1). The results show that the fusion cells stimulate naive T cells in the primary mixed lymphocyte reaction (MLR) and induce MC38 tumor-specific CTLs in vivo. Antibody-mediated depletion experiments demonstrate that induction of CD4(+) and CD8(+) CTLs protects against challenge with tumor cells. We also show that immunization with the fusion cells induces rejection of established metastases. These findings represent the first demonstration that fusions of DCs and tumor cells can be used in the treatment of cancer.			Gong, JL (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.							AKAGI I, IN PRESS J IMMUNOTHE; BAKKER ABH, 1995, CANCER RES, V55, P5330; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GUO YJ, 1994, SCIENCE, V263, P518, DOI 10.1126/science.7507262; INABA K, 1987, J EXP MED, V166, P182, DOI 10.1084/jem.166.1.182; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; LIU LM, 1993, J EXP MED, V177, P1299, DOI 10.1084/jem.177.5.1299; MACATONIA SE, 1989, J EXP MED, V169, P1255, DOI 10.1084/jem.169.4.1255; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; MEHTADAMANI A, 1994, J IMMUNOL, V153, P996; PORGADOR A, 1995, J EXP MED, V182, P255, DOI 10.1084/jem.182.1.255; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; STEINMAN RM, 1978, P NATL ACAD SCI USA, V75, P5132, DOI 10.1073/pnas.75.10.5132; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TAKAHASHI H, 1993, INT IMMUNOL, V5, P849, DOI 10.1093/intimm/5.8.849; VANVOORHIS WC, 1983, J EXP MED, V158, P174, DOI 10.1084/jem.158.1.174; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7; YOUNG JW, 1990, J EXP MED, V171, P1315, DOI 10.1084/jem.171.4.1315	22	527	579	0	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					558	561		10.1038/nm0597-558	http://dx.doi.org/10.1038/nm0597-558			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142127				2022-12-25	WOS:A1997WX54300038
J	Virtaneva, K; DAmato, E; Miao, IM; Koskiniemi, M; Norio, R; Avanzini, G; Franceschetti, S; Michelucci, R; Tassinari, CA; Omer, S; Pennacchio, LA; Myers, RM; DieguezLucena, JL; Krahe, R; delaChapelle, A; Lehesjoki, AE				Virtaneva, K; DAmato, E; Miao, IM; Koskiniemi, M; Norio, R; Avanzini, G; Franceschetti, S; Michelucci, R; Tassinari, CA; Omer, S; Pennacchio, LA; Myers, RM; DieguezLucena, JL; Krahe, R; delaChapelle, A; Lehesjoki, AE			Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1	NATURE GENETICS			English	Article							DIABETES SUSCEPTIBILITY LOCUS; HUMAN INSULIN GENE; UNVERRICHT-LUNDBORG; LOCALIZATION; LINKAGE; REGION; MUTATION; IDDM2	Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1; MIM 254800) is an autosomal recessive disorder that occurs with a low frequency in many populations but is more common in Finland and the Mediterranean region(1,2). It is characterized by stimulus-sensitive myoclonus and tonic-clonic seizures with onset at age 6-15 years, typical electroencephalographic abnormalities and a variable rate of progression between and within families(3-5). Following the initial mapping of the EPM1 gene to chromosome 21 (ref. 6) and the refinement of the critical region to a small interval(7-9), positional cloning identified the gene encoding cystatin B (CST6), a cysteine protease inhibitor, as the gene underlying EPM1 (ref. 10). Levels of messenger RNA encoded by CST6 were dramatically decreased in patients. A 3' splice site and a stop codon mutation were identified in three families, leaving most mutations uncharacterized(10). In this study, we report a novel type of disease-causing mutation, an unstable 15- to 18-mer minisatellite repeat expansion in the putative promoter region of the CST6 gene. The mutation accounts for the majority of EPM1 patients worldwide. Haplotype data are compatible with a single ancestral founder mutation. The length of the repeat array differs between chromosomes and families, but changes in repeat number seem to be comparatively rare events.	UNIV HELSINKI, DEPT MED GENET, HAARTMAN INST, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, DEPT VIROL, HAARTMAN INST, FIN-00014 HELSINKI, FINLAND; FAMILY FEDERAT FINLAND, DEPT MED GENET, HELSINKI 00100, FINLAND; IST NEUROCHIRURG C BESTA, DEPT NEUROPHYSIOL, I-20133 MILAN, ITALY; UNIV BOLOGNA, BELLARIA HOSP, DEPT NEUROL, I-40139 BOLOGNA, ITALY; KING KHALID HOSP, JEDDAH 21423, SAUDI ARABIA; STANFORD UNIV, DEPT GENET, SCH MED, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA; UNIV MALAGA, FAC MED, DEPT BIOCHEM & MOL BIOL, MALAGA 29080, SPAIN	University of Helsinki; University of Helsinki; Family Federation of Finland; AUSL di Bologna; University of Bologna; King Khalid Hospital; Stanford University; Stanford University; Universidad de Malaga			Michelucci, Roberto/AAB-9074-2020; Franceschetti, Silvana/K-3438-2016	Franceschetti, Silvana/0000-0002-1921-6755; Michelucci, Roberto/0000-0002-9655-7940; Pennacchio, Len/0000-0002-8748-3732; Tassinari, Carlo Alberto/0000-0002-4183-5165	Fondazione Telethon Funding Source: Custom; Telethon [E.0444] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		ANDERMANN, 1990, ANN NEUROL, V28, P113; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Cooper DN, 1995, METABOLIC MOL BASES, P259; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; GACY AM, 1995, CELL, V81, P533; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P333; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P307; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LEHESJOKI AE, 1992, NEUROLOGY, V42, P1545, DOI 10.1212/WNL.42.8.1545; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LEHESJOKI AE, 1994, HUM GENET, V93, P668, DOI 10.1007/BF00201568; LEHESJOKI AE, 1991, P NATL ACAD SCI USA, V88, P3696, DOI 10.1073/pnas.88.9.3696; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NORIO R, 1979, CLIN GENET, V15, P382; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; SOKAL RR, 1991, NATURE, V351, P143, DOI 10.1038/351143a0; Stone NE, 1996, GENOME RES, V6, P218, DOI 10.1101/gr.6.3.218; Virtaneva K, 1996, AM J HUM GENET, V58, P1247; Warren ST, 1996, SCIENCE, V271, P1374, DOI 10.1126/science.271.5254.1374	29	158	161	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1997	15	4					393	396		10.1038/ng0497-393	http://dx.doi.org/10.1038/ng0497-393			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WQ389	9090386				2022-12-25	WOS:A1997WQ38900019
J	Lafreniere, RG; Rochefort, DL; Chretien, N; Rommens, JM; Cochius, JI; Kalviainen, R; Nousiainen, U; Patry, G; Farrell, K; Soderfeldt, B; Federico, A; Hale, BR; Cossio, OH; Sorensen, T; Pouliot, MA; Kmiec, T; Uldall, P; Janszky, J; Pranzatelli, MR; Andermann, F; Andermann, E; Rouleau, GA				Lafreniere, RG; Rochefort, DL; Chretien, N; Rommens, JM; Cochius, JI; Kalviainen, R; Nousiainen, U; Patry, G; Farrell, K; Soderfeldt, B; Federico, A; Hale, BR; Cossio, OH; Sorensen, T; Pouliot, MA; Kmiec, T; Uldall, P; Janszky, J; Pranzatelli, MR; Andermann, F; Andermann, E; Rouleau, GA			Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1	NATURE GENETICS			English	Article							RAMSAY-HUNT-SYNDROME; FRAGILE-X-SYNDROME; DINUCLEOTIDE REPEAT; HUMAN CHROMOSOME-21; RESTRICTION MAP; CGG REPEAT; LONG ARM; INSTABILITY; HUMAN-CHROMOSOME-21; POLYMORPHISM	Progressive myoclonus epilepsy type 1 (EPM1, also known as Unverricht-Lundborg disease) is an autosomal recessive disorder characterized by progressively worsening myoclonic jerks, frequent generalized tonic-clonic seizures, and a slowly progressive decline in cognition(1). Recently, two mutations in the cystatin B gene (also known as stefin B, STFB) mapping to 21q22.3 have been implicated in the EPM1 phenotype: a G-->C substitution in the last nucleotide of intron 1 that was predicted to cause a splicing defect in one family, and a C-->T substitution that would change an Arg codon (CGA) to a stop codon (TCA) at amino acid position 68, resulting in a truncated cystatin B protein in two other families(2). A fourth family showed undetectable amounts of STFB mRNA by northern blot analysis in an affected individual. We present haplotype and mutational analyses of our collection of 20 unrelated EPM1 patients and families from different ethnic groups. We identify four different mutations, the most common of which consists of an unstable similar to 600-900 bp insertion which is resistant to PCR amplification. This insertion maps to a 12-bp polymorphic tandem repeat located in the 5' flanking region of the STFB gene, in the region of the promoter. The size of the insertion varies between different EPM1 chromosomes sharing a common haplotype and a common origin, suggesting some level of meiotic instability over the course of many generations. This dynamic mutation, which appears distinct from conventional trinucleotide repeat expansions, may arise via a novel mechanism related to the instability of tandemly repeated sequences.	MONTREAL GEN HOSP, RES INST, DEPT NEUROL, MONTREAL, PQ H3G 1A4, CANADA; UNIV TORONTO, HOSP SICK CHILDREN, DEPT GENET, TORONTO, ON M5S 1A1, CANADA; NORFOLK & NORWICH HOSP, DEPT NEUROL, NORWICH, NORFOLK, ENGLAND; KUOPIO UNIV HOSP, DEPT NEUROL, SF-70210 KUOPIO, FINLAND; UNIV KUOPIO, VAAJASALO HOSP, DEPT CLIN NEUROPHYSIOL, FIN-70211 KUOPIO, FINLAND; UNIV LAVAL, DEPT NEUROL, QUEBEC CITY, PQ, CANADA; UNIV BRITISH COLUMBIA, DEPT PAEDIAT, VANCOUVER, BC V5Z 1M9, CANADA; LINKOPING UNIV HOSP, DEPT NEUROL, S-58185 LINKOPING, SWEDEN; UNIV SIENA, INST NEUROL SCI, DEPT NEUROL, I-53100 SIENA, ITALY; DEPT PEDIAT NEUROL, INDIANAPOLIS, IN USA; HOSP SANTA CASA MISERICORDIA, CTR NEUROL & NEUROCIRUGIA, CURITIBA, PARANA, BRAZIL; UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT NEUROL, DK-2650 HVIDOVRE, DENMARK; CHILDRENS MEM HLTH INST, DEPT NEUROL, WARSAW, POLAND; DIANALUND EPILEPSY HOSP, CHILD DEPT, DIANALUND, DENMARK; ORSZAGOS NEUROL & PSICHIAT INTEZET, DEPT NEUROL, BUDAPEST, HUNGARY; GEORGE WASHINGTON UNIV, DEPT NEUROL, WASHINGTON, DC 20052 USA; GEORGE WASHINGTON UNIV, DEPT PAEDIAT, WASHINGTON, DC 20052 USA; GEORGE WASHINGTON UNIV, DEPT PHARMACOL, WASHINGTON, DC 20052 USA; MCGILL UNIV, DEPT NEUROL & NEUROSURG, MONTREAL, PQ H3A 2T5, CANADA; MCGILL UNIV, DEPT PEDIAT, MONTREAL, PQ H3A 2T5, CANADA; MONTREAL NEUROL HOSP & INST, EPILEPSY SERV, MONTREAL, PQ H3A 2B4, CANADA; MCGILL UNIV, DEPT HUMAN GENET, MONTREAL, PQ, CANADA; MONTREAL NEUROL HOSP & INST, NEUROGENET UNIT, MONTREAL, PQ H3A 2B4, CANADA	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland; Laval University; University of British Columbia; Linkoping University; University of Siena; University of Copenhagen; Children's Memorial Health Institute; George Washington University; George Washington University; George Washington University; McGill University; McGill University; McGill University; McGill University; McGill University	Lafreniere, RG (corresponding author), MCGILL UNIV, CTR RES NEUROSCI, ROOM L12-144, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.			Kmiec, Tomasz/0000-0001-6958-6239; federico, antonio/0000-0002-5246-1621				ANDERMANN F, 1989, MOVEMENT DISORD, V4, P13, DOI 10.1002/mds.870040104; [Anonymous], 1990, Ann Neurol, V28, P113; AVRAMOPOULOS D, 1993, HUM GENET, V90, P566; CHENG JF, 1994, GENOMICS, V23, P75, DOI 10.1006/geno.1994.1461; COCHIUS JI, 1993, ANN NEUROL, V34, P739, DOI 10.1002/ana.410340519; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GENTON P, 1990, ACTA NEUROL SCAND, V81, P8; ICHIKAWA H, 1993, NAT GENET, V4, P361, DOI 10.1038/ng0893-361; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAFRENIERE RG, 1995, GENOMICS, V29, P288, DOI 10.1006/geno.1995.1248; MUNKE M, 1988, AM J HUM GENET, V42, P542; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PEDERSEN E, 1982, J NEUROL SCI, V53, P305, DOI 10.1016/0022-510X(82)90015-6; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; PETERSEN MB, 1991, HUM GENET, V87, P401; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P2517, DOI 10.1093/nar/19.9.2517; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YASPO ML, 1995, HUM MOL GENET, V4, P1291, DOI 10.1093/hmg/4.8.1291	20	148	151	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					298	302		10.1038/ng0397-298	http://dx.doi.org/10.1038/ng0397-298			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054946				2022-12-25	WOS:A1997WK38600023
J	You, Y; Bergstrom, R; Klemm, M; Lederman, B; Nelson, H; Ticknor, C; Jaenisch, R; Schimenti, J				You, Y; Bergstrom, R; Klemm, M; Lederman, B; Nelson, H; Ticknor, C; Jaenisch, R; Schimenti, J			Chromosomal deletion complexes in mice by radiation of embryonic stem cells	NATURE GENETICS			English	Article							SEX-DETERMINING REGION; MOUSE CHROMOSOME-7; LETHAL MUTATIONS; GENE; LOCUS; INVERSIONS; ECTODERM; ENCODES; PROTEIN; DEFINE	Chromosomal deletions ('deficiencies') are powerful tools in the genetic analysis of complex genomes. They have been exploited extensively in Drosophila melanogaster, an organism in which deficiencies can be efficiently induced and selected(1). Spontaneous deletions in humans have facilitated the dissection of phenotypes in contiguous gene syndromes(2,3) and led to the positional cloning of critical genes(4,5). In mice, deletion complexes created by whole animal irradiation experiments have enabled a systematic characterization of functional units along defined chromosomal regions(6,7). However, classical mutagenesis in mice is logistically impractical for generating deletion sets on a genome-wide scale. Here, we report a high-throughput method for generating radiation-induced deletion complexes at defined regions in the genome using ES cells. Dozens of deletions of up to several centiMorgans, encompassing a specific locus, can be created in a single experiment and transmitted through the germline. The ability to rapidly create deletion complexes along chromosomes will facilitate systematic functional analyses of the mammalian genome.	JACKSON LAB, BAR HARBOR, ME 04609 USA; MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE CTR 9, CAMBRIDGE, MA 02142 USA; SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Jackson Laboratory; Massachusetts Institute of Technology (MIT); Whitehead Institute; Novartis; Sandoz								ASHBURNER M, 1989, DROSOPHILA LAB MAN; ASKEW GR, 1993, MOL CELL BIOL, V13, P4115, DOI 10.1128/MCB.13.7.4115; BELL JA, 1995, MAMM GENOME, V6, P389, DOI 10.1007/BF00355638; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gregorova S, 1996, MAMM GENOME, V7, P107, DOI 10.1007/s003359900029; HAMMER MF, 1989, P NATL ACAD SCI USA, V86, P3261, DOI 10.1073/pnas.86.9.3261; Hamvas R, 1996, MAMM GENOME, V6, pS281; HOLDENER BC, 1995, GENOMICS, V27, P447, DOI 10.1006/geno.1995.1076; HOLDENERKENNY B, 1992, BIOESSAYS, V14, P831, DOI 10.1002/bies.950141208; JOHNSON DR, 1974, GENETICS, V76, P795; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; OVERHAUSER J, 1994, HUM MOL GENET, V3, P247, DOI 10.1093/hmg/3.2.247; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; RINCHIK EM, 1993, MAMM GENOME, V4, P349, DOI 10.1007/BF00360583; RINCHIK EM, 1993, GENETICS, V135, P1117; RUSSELL LB, 1982, GENETICS, V100, P427; SCHMICKEL RD, 1986, J PEDIATR-US, V109, P231, DOI 10.1016/S0022-3476(86)80377-8; SHARAN SK, 1991, GENETICS, V129, P825; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941	24	89	92	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					285	288		10.1038/ng0397-285	http://dx.doi.org/10.1038/ng0397-285			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054943				2022-12-25	WOS:A1997WK38600020
J	Dang, QD; Guinto, ER; DiCera, E				Dang, QD; Guinto, ER; DiCera, E			Rational engineering of activity and specificity in a serine protease	NATURE BIOTECHNOLOGY			English	Article						blood coagulation; protein engineering; thrombin	SUBSTRATE-SPECIFICITY; BLOOD-COAGULATION; STRUCTURAL BASIS; THROMBIN; FIBRINOGEN; THROMBOMODULIN; ANTICOAGULANT; SUBSTITUTION; ACTIVATION; EVOLUTION	The discovery of the Na+-dependent allosteric regulation in serine proteases makes it possible to control catalytic activity and specificity in this class of enzymes in a way never considered before. We demonstrate that rational site-directed mutagenesis of residues controlling Na+ binding can profoundly alter the properties of a serine protease. By suppressing Na+ binding to thrombin, we shift the balance between procoagulant and anticoagulant activities of the enzyme. Those mutants, compared to wild-type, have reduced specificity toward fibrinogen, but enhanced or slightly reduced specificity toward protein C. Because this engineering strategy targets a fundamental regulatory mechanism, it is amenable of extension to other enzymes of biological and pharmacological importance.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)					NHLBI NIH HHS [HL49413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berg DT, 1996, SCIENCE, V273, P1389, DOI 10.1126/science.273.5280.1389; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DOOLITTLE RF, 1987, COLD SPRING HARB SYM, V52, P869, DOI 10.1101/SQB.1987.052.01.095; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; KREM MM, UNPUB CONSERVED WATE; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Lesk AM, 1996, J MOL BIOL, V258, P501, DOI 10.1006/jmbi.1996.0264; MANN KG, 1990, BLOOD, V76, P1; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NG AS, 1993, METHOD ENZYMOL, V222, P341; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Patthy L, 1990, Blood Coagul Fibrinolysis, V1, P153; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; SEEGERS WH, 1980, THROMB RES, V19, P11, DOI 10.1016/0049-3848(80)90399-0; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; VINDIGNI A, UNPUB ENERGETICS THR; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; ZHANG E, 1997, IN PRESS BIOPHYS CHE	37	93	101	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					146	149		10.1038/nbt0297-146	http://dx.doi.org/10.1038/nbt0297-146			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035139				2022-12-25	WOS:A1997WE99800020
J	Tapanainen, JS; Aittomaki, K; Min, J; Vaskivuo, T; Huhtaniemi, IT				Tapanainen, JS; Aittomaki, K; Min, J; Vaskivuo, T; Huhtaniemi, IT			Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility	NATURE GENETICS			English	Article							SERTOLI; NUMBERS; CLONING; CELLS	Gonadal function is controlled by the two pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). While LH mainly regulates gonadal steroidogenesis, FSH is considered essential for folliculogenesis in the female and spermatogenesis in the male. We recently discovered that an inactivating point mutation in the FSH receptor (R) gene causes a recessively inherited form of hypergonadotropic ovarian failure in homozygous females(1). This 566C-->T mutation, predicting an alanine to valine substitution, is located in exon 7 of the FSHR gene, in the region encoding the extracellular domain of the receptor molecule. Functional testing showed a clear-cut reduction in ligand binding and signal transduction by the mutated receptor. Hence, lack of FSH function is incompatible with ovarian follicular maturation and female fertility. In the male, FSH is generally considered essential for the pubertal initiation of spermatogenesis and maintenance of quantitatively normal sperm production in adults(2-5). We report here the first characterization of males homozygous for an inactivating FSHR mutation. They have variable degrees of spermatogenic failure. but, surprisingly, do not show azoospermia or absolute infertility. These results question the essential role of FSH for the initiation of spermatogenesis, and demonstrate that FSH is more important for female than for male fertility.	UNIV HELSINKI,DEPT MED GENET,FIN-00290 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT CLIN GENET,FIN-00290 HELSINKI,FINLAND; UNIV TURKU,INST BIOMED,DEPT PHYSIOL,FIN-20520 TURKU,FINLAND	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Turku	Tapanainen, JS (corresponding author), OULU UNIV HOSP,DEPT OBSTET & GYNECOL,FIN-90220 OULU,FINLAND.							AITTOMAKI K, 1994, AM J HUM GENET, V54, P844; Aittomaki K, 1996, J CLIN ENDOCR METAB, V81, P3722, DOI 10.1210/jc.81.10.3722; AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; BREMNER WJ, 1981, J CLIN INVEST, V68, P1044, DOI 10.1172/JCI110327; Gromoll J, 1996, J CLIN ENDOCR METAB, V81, P1367, DOI 10.1210/jc.81.4.1367; HESS RA, 1993, ENDOCRINOLOGY, V132, P2607, DOI 10.1210/en.132.6.2607; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; MATSUMOTO AM, 1986, J CLIN ENDOCR METAB, V62, P1184, DOI 10.1210/jcem-62-6-1184; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; ORTH JM, 1988, ENDOCRINOLOGY, V122, P787, DOI 10.1210/endo-122-3-787; Sharpe Richard M., 1994, P1363; STEIN LJ, 1991, PHYSIOL BEHAV, V51, P1; WEINBAUER GF, 1991, ENDOCRINOLOGY, V129, P1831, DOI 10.1210/endo-129-4-1831; World Health Organization, 1992, LAB MAN EX HUM SEM S; ZELEZNIK AJ, 1993, OVARY, P41; ZIRKIN BR, 1994, J ANDROL, V15, P273	17	381	390	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					205	206		10.1038/ng0297-205	http://dx.doi.org/10.1038/ng0297-205			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020851				2022-12-25	WOS:A1997WF08700025
J	Hoffman, SL; Crutcher, JM; Puri, SK; Ansari, AA; Villinger, F; Franke, ED; Singh, PP; Finkelman, F; Gately, ML; Dutta, GP; Sedegah, M				Hoffman, SL; Crutcher, JM; Puri, SK; Ansari, AA; Villinger, F; Franke, ED; Singh, PP; Finkelman, F; Gately, ML; Dutta, GP; Sedegah, M			Sterile protection of monkeys against malaria after administration of interleukin-12	NATURE MEDICINE			English	Article							RECOMBINANT HUMAN INTERLEUKIN-12; SCHISTOSOMA-MANSONI; GAMMA-INTERFERON; IFN-GAMMA; IL-12; CELLS; HEPATOCYTES; LYMPHOCYTES; EXPRESSION; INDUCTION	An estimated 300-500 million new infections and 1.5-2.7 million deaths attributed to malaria occur annually in the developing world(1), and every year tens of millions of travelers from countries where malaria is not transmitted visit countries with malaria. Because the parasites that cause malaria have developed resistance to many antimalarial drugs, new methods for prevention are required. Intraperitoneal injection into mice of one dose of 150 ng (approximately 7.5 mu g per kg body weight) recombinant mouse interleukin-12 (rmIL-12) 2 days before challenge with Plasmodium yoelii sporozoites protects 100% of mice against malaria(2). We report that one subcutaneous injection of 10 mu g/kg recombinant human IL-12 (rhIL-12) 2 days before challenge with P. cynomolgi sporozoites protected seven of seven rhesus monkeys. Protection was associated with marked increases in plasma levels of interferon-gamma (IFN-gamma), and relative increases of lymphoid cell messenger RNA coding for IFN-gamma and several other cytokines. We speculate that rIL-12 protects monkeys through IFN-gamma-dependent elimination of P. cynomolgi-infected hepatocytes. This first report of rIL-12-induced protection of primates against: an infectious agent supports assessment of rhIL-12 for immunoprophylaxis of human malaria.	CENT DRUG RES INST,DIV MICROBIOL,LUCKNOW 22601,UTTAR PRADESH,INDIA; EMORY UNIV,WINSHIP CANC CTR,ATLANTA,GA 30322; UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Emory University; University System of Ohio; University of Cincinnati; Roche Holding	Hoffman, SL (corresponding author), USN,MED RES INST,MALARIA PROGRAM,12300 WASHINGTON AVE,ROCKVILLE,MD 20852, USA.		Villasante, Eileen D/G-3602-2011		PHS HHS [1R01-27057-08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; Gately MK, 1996, DRUGS, V52, P18, DOI 10.2165/00003495-199600522-00005; LING P, 1995, J IMMUNOL, V154, P116; MAHESHWARI RK, 1990, B WORLD HEALTH ORGAN, V68, P138; MAHESHWARI RK, 1986, INFECT IMMUN, V53, P628, DOI 10.1128/IAI.53.3.628-630.1986; MALHOTRA K, 1988, INFECT IMMUN, V56, P3305, DOI 10.1128/IAI.56.12.3305-3309.1988; MELLOUK S, 1994, INFECT IMMUN, V62, P4043, DOI 10.1128/IAI.62.9.4043-4046.1994; MELLOUK S, 1991, J IMMUNOL, V146, P3971; MORRIS SC, 1994, J IMMUNOL, V152, P1047; NADEAU RR, 1995, J PHARMACOL EXP THER, V274, P78; PURI SK, 1988, J INTERFERON RES, V8, P201, DOI 10.1089/jir.1988.8.201; SARMIENTO UM, 1994, LAB INVEST, V71, P862; SCHMIDT LH, 1982, AM J TROP MED HYG, V31, P646, DOI 10.4269/ajtmh.1982.31.646; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P10700, DOI 10.1073/pnas.91.22.10700; STEVENSON MM, 1995, J IMMUNOL, V155, P2545; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; VILLINGER F, 1993, CYTOKINE, V5, P469, DOI 10.1016/1043-4666(93)90038-7; VILLINGER F, 1995, J IMMUNOL, V155, P3946; WHO, 1995, WHO FACT SHEET, V94, P1; WU CY, 1994, J IMMUNOL, V152, P1141; WYNN TA, 1995, J IMMUNOL, V154, P4701; WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551	22	118	119	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					80	83		10.1038/nm0197-80	http://dx.doi.org/10.1038/nm0197-80			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986746				2022-12-25	WOS:A1997WA73300042
J	Unseld, M; Marienfeld, JR; Brandt, P; Brennicke, A				Unseld, M; Marienfeld, JR; Brandt, P; Brennicke, A			The mitochondrial genome of Arabidopsis thaliana contains 57 genes in 366,924 nucleotides	NATURE GENETICS			English	Article							II INTRON SEQUENCES; PLANT-MITOCHONDRIA; CHLAMYDOMONAS-REINHARDTII; WHEAT MITOCHONDRIA; DNA; RNA; EXON; TRANSCRIPTION; ORGANIZATION; NUCLEUS	We have determined the complete sequence of the mitochondrial DNA in the model plant species Arabidopsis thaliana, affording access to the first of its three genomes. The 366,924 nucleotides code for 57 identified genes, which cover only 10% of the genome. Introns in these genes add about 8%, open reading frames larger than 100 amino acids represent 10% of the genome, duplications account for 7%, remnants of retrotransposons of nuclear origin contribute 4% and integrated plastid sequences amount to 1% - leaving 60% of the genome unaccounted for. With the significant contribution of duplications, imported foreign DNA and the extensive background of apparently functionless sequences, the mosaic structure of the Arabidopsis thaliana mitochondrial genome features many aspects of size-relaxed nuclear genomes.	INST GENBIOL FORSCH,D-14195 BERLIN,GERMANY; UNIV ULM,D-89069 ULM,GERMANY	Ulm University								BENDICH AJ, 1993, CURR GENET, V24, P279, DOI 10.1007/BF00336777; BINDER S, 1993, J BIOL CHEM, V268, P7849; BLACKBOURN H, 1986, TRENDS PLANT SCI, V1, P291; BLANCHARD JL, 1995, J MOL EVOL, V41, P397, DOI 10.1007/BF00160310; BRANDT P, 1992, MOL GEN GENET, V236, P33, DOI 10.1007/BF00279640; BRENNER SE, 1995, NATURE, V378, P140, DOI 10.1038/378140a0; BRENNICKE A, 1993, FEBS LETT, V325, P140, DOI 10.1016/0014-5793(93)81430-8; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; GOODMAN HM, 1995, P NATL ACAD SCI USA, V92, P10831, DOI 10.1073/pnas.92.24.10831; GRAY MW, 1988, PHILOS T R SOC B, V319, P135, DOI 10.1098/rstb.1988.0038; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P5461, DOI 10.1093/nar/17.14.5461; KLEIN M, 1994, PLANT J, V6, P447, DOI 10.1046/j.1365-313X.1994.06030447.x; Knoop V, 1996, GENETICS, V142, P579; KNOOP V, 1994, J MOL BIOL, V242, P389, DOI 10.1006/jmbi.1994.1589; KNOOP V, 1991, EMBO J, V10, P3483, DOI 10.1002/j.1460-2075.1991.tb04912.x; KNOOP V, 1994, J MOL EVOL, V39, P144; Knoop Volker, 1993, P221; Lang BF, 1996, J MOL BIOL, V261, P607, DOI 10.1006/jmbi.1996.0486; LEVINGS CS, 1990, SCIENCE, V250, P942, DOI 10.1126/science.250.4983.942; LIPPOK B, 1996, BIOL CHEM, V337, P251; MARECHALDROUARD L, 1993, ANNU REV PLANT PHYS, V44, P13, DOI 10.1146/annurev.pp.44.060193.000305; MEYEROWITZ EM, 1994, ARAQBIDOPSIS; MICHAELIS G, 1990, MOL GEN GENET, V223, P211, DOI 10.1007/BF00265056; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; OHTA E, 1993, NUCLEIC ACIDS RES, V21, P1297, DOI 10.1093/nar/21.5.1297; PALMER JD, 1987, CURR GENET, V11, P565, DOI 10.1007/BF00384620; PALMER JD, 1984, NATURE, V307, P411; SUPLICK K, 1990, MOL CELL BIOL, V10, P6381, DOI 10.1128/MCB.10.12.6381; WARD BL, 1981, CELL, V25, P793, DOI 10.1016/0092-8674(81)90187-2; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B	34	705	856	5	60	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					57	61		10.1038/ng0197-57	http://dx.doi.org/10.1038/ng0197-57			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988169				2022-12-25	WOS:A1997WA37300021
J	Taylor, TD; Litt, M; Kramer, P; Pandolfo, M; Angelini, L; Nardocci, N; Davis, S; Pineda, M; Hattori, H; Flett, PJ; Cilio, MR; Bertini, E; Hayflick, SJ				Taylor, TD; Litt, M; Kramer, P; Pandolfo, M; Angelini, L; Nardocci, N; Davis, S; Pineda, M; Hattori, H; Flett, PJ; Cilio, MR; Bertini, E; Hayflick, SJ			Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13	NATURE GENETICS			English	Article							REGIONAL DISTRIBUTION; ALZHEIMERS-DISEASE; SUBSTANTIA NIGRA; HUMAN GENOME; IRON; LINKAGE; BRAIN; GENE; MAP; LOCALIZATION	Hallervorden-Spatz syndrome (HSS) (OMIM #234200) is a rare, autosomal recessive neurodegenerative disorder with brain iron accumulation as a prominent finding. Clinical features include extrapyramidal dysfunction, onset in childhood, and a relentlessly progressive course(1). Histologic study reveals massive iron deposits in the basal ganglia. Systemic and cerebrospinal fluid iron levels are normal, as are plasma levels of ferritin, transferrin and ceruloplasmin. Conversely, in disorders of systemic iron overload, such as haemochromatosis, brain iron is not increased, which suggests that fundamental differences exist between brain and systemic iron metabolism and transport. In normal brain, non-haem iron accumulates regionally and is highest in basal ganglia(2). Pathologic brain iron accumulation is seen in common disorders, including Parkinson's disease(3,4), Alzheimer's disease(5,6) and Huntington disease(7). In order to gain insight into normal and abnormal brain iron transport, metabolism and function, our approach was to map the gene for HSS. A primary genome scan was performed using samples from a large, consanguineous family (HS1) (see Fig. 1). While this family was immensely powerful for mapping, the region demonstrating homozygosity in all affected members spans only 4 cM, requiring very close markers in order to detect linkage. The HSS gene maps to an interval flanked by D20S906 and D20S116 on chromosome 20p12.3-p13. Linkage was confirmed in nine additional families of diverse ethnic backgrounds.	OREGON HLTH SCI UNIV, DEPT MOL & MED GENET, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT NEUROL, PORTLAND, OR 97201 USA; BAYLOR COLL MED, DEPT NEUROL, HOUSTON, TX 77030 USA; IST NAZL NEUROL CARLO BESTA, DEPT CHILD NEUROL, I-20133 MILAN, ITALY; AUCKLAND HOSP, NEUROSERV UNIT, AUCKLAND 1, NEW ZEALAND; HOSP SAN JUAN DIOS, DEPT NEUROPEDIAT, BARCELONA 08034, SPAIN; KYOTO UNIV, SCH MED, DEPT PEDIAT, KYOTO 606, JAPAN; ADELAIDE CHILDRENS HOSP INC, DEPT PEDIAT, ADELAIDE, SA 5006, AUSTRALIA; BAMBINO GESU PEDIAT HOSP, NEUROPHYSIOL UNIT, I-00165 ROME, ITALY	Oregon Health & Science University; Oregon Health & Science University; Baylor College of Medicine; IRCCS Istituto Neurologico Besta; Auckland City Hospital; University of Barcelona; Kyoto University; IRCCS Bambino Gesu			Bertini, Enrico/A-2284-2014; Cilio, Maria Roberta/AAY-6197-2021; Nardocci, Nardo/AAB-9903-2019; Bertini, Enrico/ABG-1278-2020; Davis, Sean/AAD-1801-2021; Pandolfo, Massimo/B-2853-2010; Taylor, Todd/A-7121-2009	Bertini, Enrico/0000-0001-9276-4590; Cilio, Maria Roberta/0000-0003-2481-8053; Nardocci, Nardo/0000-0001-5863-5592; Davis, Sean/0000-0002-8991-6458; Taylor, Todd/0000-0003-4247-6253	NATIONAL EYE INSTITUTE [K11EY000348] Funding Source: NIH RePORTER; NEI NIH HHS [1 K11 EY00348-01] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKSENTIJEVICH I, 1993, AM J HUM GENET, V53, P451; ALVAREZ RA, 1995, GENOMICS, V29, P53, DOI 10.1006/geno.1995.1214; BENHAMIDA C, 1993, NAT GENET, V5, P195, DOI 10.1038/ng1093-195; CHUMAKOV IM, 1995, NATURE, V377, P175; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DEDMAN DJ, 1992, BIOCHEM J, V287, P509, DOI 10.1042/bj2870509; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOOLING EC, 1974, ARCH NEUROL-CHICAGO, V30, P70, DOI 10.1001/archneur.1974.00490310072012; EDWARDS A, 1991, AM J HUM GENET, V49, P746; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HILL JM, 1984, NEUROSCIENCE, V11, P595, DOI 10.1016/0306-4522(84)90046-0; HILL JM, 1985, BRAIN RES, V342, P18, DOI 10.1016/0006-8993(85)91348-4; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KUZNIECKY RI, 1993, NEUROLOGY, V43, P1452, DOI 10.1212/WNL.43.7.1452-a; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LITT M, 1988, AM J HUM GENET, V42, P327; LITT M, 1989, AM J HUM GENET, V44, P397; LITT M, 1993, BIOTECHNIQUES, V15, P280; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Schaffer AA, 1996, HUM HERED, V46, P226, DOI 10.1159/000154358; SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837; SHEVELL M, 1992, NEUROLOGY, V42, P2214, DOI 10.1212/WNL.42.11.2214; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; SWAIMAN KF, 1991, ARCH NEUROL-CHICAGO, V48, P1285, DOI 10.1001/archneur.1991.00530240091029; Terwilliger J., 1994, HDB HUMAN GENETIC LI; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Wunderle V, 1994, Eur J Hum Genet, V2, P242; YANGFENG TL, 1994, CYTOGENET CELL GENET, V66, P170, DOI 10.1159/000133693	35	113	119	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1996	14	4					479	481		10.1038/ng1296-479	http://dx.doi.org/10.1038/ng1296-479			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944032				2022-12-25	WOS:A1996VV73000028
J	StCroix, B; Florenes, VA; Rak, JW; Flanagan, M; Bhattacharya, N; Slingerland, JM; Kerbel, RS				StCroix, B; Florenes, VA; Rak, JW; Flanagan, M; Bhattacharya, N; Slingerland, JM; Kerbel, RS			Impact of the cyclin-dependent kinase inhibitor p27(Kip1) on resistance of tumor cells to anticancer agents	NATURE MEDICINE			English	Article							METASTATIC BREAST-CANCER; GROWTH-FACTOR-BETA; HUMAN MALIGNANCIES; ALKYLATING-AGENTS; DRUG-RESISTANCE; CDK INHIBITORS; IN-VITRO; CHEMOTHERAPY; CHEMOSENSITIVITY; SPHEROIDS	A low proliferating fraction in solid tumors limits the effectiveness of cell cycle-dependent chemotherapeutic agents. To understand the molecular basis of such ''kinetic'' resistance we cultured tumor cells as multicellular spheroids and examined levels of p27(Kip1), a cyclin-dependent kinase inhibitor known to be upregulated by intercellular contact in normal cells. When transferred from monolayer to three-dimensional culture, a consistent upregulation (up to 15-fold) of p27 protein was observed in a panel of mouse and human carcinoma cell lines. Antisense-oligonucleotide-mediated downregulation of p27 in EMT-6 mammary tumor cell spheroids reduced intercellular adhesion, increased cell proliferation, sensitized tumor cells to 4-hydroperoxycyclophosphamide, and restored drug- or radiation-induced cell-cycle perturbations repressed in spheroid culture. Our results implicate p27 as a regulator of drug resistance in solid tumors and suggest that tumor-targeted p27 antagonists may be useful chemosensitizers in conjunction with conventional anticancer therapy.	SUNNYBROOK HLTH SCI CTR,DIV CANC BIOL RES,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA; TORONTO SUNNYBROOK REG CANC CTR,TORONTO,ON,CANADA; GILEAD SCI INC,FOSTER CITY,CA 94404	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Gilead Sciences					NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BRIFFORD M, 1992, CYTOMETRY, V13, P250, DOI 10.1002/cyto.990130306; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; CONTE PF, 1987, J CLIN ONCOL, V5, P339, DOI 10.1200/JCO.1987.5.3.339; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMANCHEBOITREL MT, 1993, CYTOTECHNOLOGY, V12, P347, DOI 10.1007/BF00744672; DIMANCHEBOITREL MT, 1992, INT J CANCER, V50, P677, DOI 10.1002/ijc.2910500502; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Ferrando AA, 1996, HUM GENET, V97, P91; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GORE SD, 1995, CLIN CANCER RES, V1, P295; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIETANEN P, 1995, BRIT J CANCER, V71, P1029, DOI 10.1038/bjc.1995.198; HINZ G, 1983, RADIAT ENVIRON BIOPH, V21, P255, DOI 10.1007/BF01341462; HOFFMAN RM, 1994, CANCER METAST REV, V13, P169, DOI 10.1007/BF00689634; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KAWAMATA N, 1995, CANCER RES, V55, P2266; KERBEL RS, 1994, COLD SPRING HARB SYM, V59, P661, DOI 10.1101/SQB.1994.059.01.076; KIYOKAWA H, 1971, CELL, P85; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; LITTLE JB, 1973, RADIOLOGY, V106, P689, DOI 10.1148/106.3.689; MENDONCA MS, 1990, RADIAT RES, V122, P38, DOI 10.2307/3577580; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OLIVE PL, 1994, CANCER METAST REV, V13, P121, DOI 10.1007/BF00689632; OREILLY SM, 1992, EUR J CANCER, V28A, P681, DOI 10.1016/S0959-8049(05)80124-8; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; REMVIKOS Y, 1989, J NATL CANCER I, V81, P1383, DOI 10.1093/jnci/81.18.1383; REMVIKOS Y, 1993, EUR J CANCER, V29A, P1843, DOI 10.1016/0959-8049(93)90534-M; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SANO Y, 1983, EUR J CANCER CLIN ON, V19, P1451, DOI 10.1016/0277-5379(93)90015-W; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Spirin KS, 1996, CANCER RES, V56, P2400; SPYRATOS F, 1992, CANCER, V69, P470, DOI 10.1002/1097-0142(19920115)69:2<470::AID-CNCR2820690233>3.0.CO;2-L; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TANNOCK I, 1978, CANCER TREAT REP, V62, P1117; Tannock IF, 1994, CURRENT CANC THERAPE, P3; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Tonkinson JL, 1996, CANCER INVEST, V14, P54, DOI 10.3109/07357909609018436; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Zhang W, 1995, CLIN CANCER RES, V1, P1051	51	251	256	1	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1204	1210						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898746				2022-12-25	WOS:A1996VQ10100034
J	Acampora, D; Mazan, S; Avantaggiato, V; Barone, P; Tuorto, F; Lallemand, Y; Brulet, P; Simeone, A				Acampora, D; Mazan, S; Avantaggiato, V; Barone, P; Tuorto, F; Lallemand, Y; Brulet, P; Simeone, A			Epilepsy and brain abnormalities in mice lacking the Otx1 gene	NATURE GENETICS			English	Letter							ANTERIOR NEUROECTODERM; HOMEOBOX GENES; ORTHODENTICLE; LOCALIZATION; DROSOPHILA; FOREBRAIN; REGIONS; EN-2		CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; INST PASTEUR,UNITE EMBRYOL MOL,CNRS,URA 1947,F-75724 PARIS,FRANCE; UNIV NAPLES FEDERICO II,DEPT NEUROL SCI,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Naples Federico II			Tuorto, Francesca/AAJ-2760-2021; Simeone, Antonio/ABG-5269-2020; Acampora, Dario/C-2156-2013	Tuorto, Francesca/0000-0003-1625-1181; Simeone, Antonio/0000-0003-2693-9836; 	Telethon [D.037] Funding Source: Medline	Telethon(Fondazione Telethon)		ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Brunelli S, 1996, NAT GENET, V12, P94, DOI 10.1038/ng0196-94; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DICHTER MA, 1991, HARRISONS PRINCIPLES, P1968; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; FRANTZ GD, 1994, J NEUROSCI, V14, P5725; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HADDON CM, 1991, DEVELOPMENT, V112, P541; HIRTH F, 1995, NEURON, V15, P769, DOI 10.1016/0896-6273(95)90169-8; Hogan B, 1994, MANIPULATING MOUSE E; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KELLY JP, 1985, PRINCIPLES NEURAL SC, P584; Kuhlenbeck H., 1973, CENTRAL NERVOUS SYST; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEENCKE HJ, 1984, EPILEPSIA, V25, P8, DOI 10.1111/j.1528-1157.1984.tb04149.x; Noebels JL, 1996, NEURON, V16, P241, DOI 10.1016/S0896-6273(00)80042-2; OTTMAN R, 1995, NAT GENET, V10, P56, DOI 10.1038/ng0595-56; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PHILLIPS HA, 1995, NAT GENET, V10, P117, DOI 10.1038/ng0595-117; RAYMOND AA, 1995, BRAIN, V118, P629, DOI 10.1093/brain/118.3.629; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROYET J, 1995, DEVELOPMENT, V121, P3561; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; 1989, EPILEPSIA, V30, P391	28	218	222	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					218	222		10.1038/ng1096-218	http://dx.doi.org/10.1038/ng1096-218			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841200				2022-12-25	WOS:A1996VL44600034
J	Yao, SL; Akhtar, AJ; McKenna, KA; Bedi, GC; Sidransky, D; Mabry, M; Ravi, R; Collector, MI; Jones, RJ; Sharkis, SJ; Fuchs, EJ; Bedi, A				Yao, SL; Akhtar, AJ; McKenna, KA; Bedi, GC; Sidransky, D; Mabry, M; Ravi, R; Collector, MI; Jones, RJ; Sharkis, SJ; Fuchs, EJ; Bedi, A			Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34(cdc2) kinase	NATURE MEDICINE			English	Article							WILD-TYPE P53; CANCER-THERAPY; ANTICANCER AGENTS; MICE DEFICIENT; IN-VIVO; M-PHASE; APOPTOSIS; CYCLE; INHIBITION; PHOSPHORYLATION	The induction of tumor cell death by anticancer therapy results from a genetic program of autonomous cell death termed apoptosis. Because the p53 tumor suppressor gene is a critical component for induction of apoptosis in response to DNA damage, its inactivation in cancers may be responsible for their resistance to genotoxic anticancer agents. The cellular response to DNA damage involves a cell-cycle arrest at both the G(1)/S and G(2)/M transitions; these checkpoints maintain viability by preventing the replication or segregation of damaged DNA. The arrest at the G(1) checkpoint is mediated by p53-dependent induction of p21(WAF1/CIP1), whereas the G(2) arrest involves inactivation of p34(cdc2) kinase. following DNA damage, p53-deficient cells fail to arrest at G(1) and accumulate at the G(2)/M transition. We demonstrate that abrogation of G(2) arrest by caffeine-mediated activation of p34(cdc2) kinase results in the selective sensitization of p53-deficient primary and tumor cells to irradiation-induced apoptosis. These data suggest that pharmacologic activation of p34(cdc2) kinase may be a useful therapeutic strategy for circumventing the resistance of p53-deficient cancers to genotoxic anticancer agents.	JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University								BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KHARBANDA S, 1994, CANCER RES, V54, P1412; KINZLER KW, 1994, NEW ENGL J MED, V331, P49, DOI 10.1056/NEJM199407073310113; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOCK RB, 1994, CANCER RES, V54, P4933; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464	29	157	170	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1996	2	10					1140	1143		10.1038/nm1096-1140	http://dx.doi.org/10.1038/nm1096-1140			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837615				2022-12-25	WOS:A1996VK99500037
J	DeLuca, A; Baldi, A; Esposito, V; Howard, CM; Bagella, L; Rizzo, P; Caputi, M; Pass, HI; Giordano, GG; Baldi, F; Carbone, M; Giordano, A				DeLuca, A; Baldi, A; Esposito, V; Howard, CM; Bagella, L; Rizzo, P; Caputi, M; Pass, HI; Giordano, GG; Baldi, F; Carbone, M; Giordano, A			The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas	NATURE MEDICINE			English	Article							SUSCEPTIBILITY GENE; DNA-SEQUENCES; CELL-CYCLE; PRODUCT; SV40; PROTEIN; BINDING	The oncoprotein of simian virus-40, SV40 large T-antigen (Tag), is reported to target and to inactivate growth suppressive proteins such as the retinoblastoma family(1-3) and p53 (ref. 4, 5), leading to transformation of human cell lines in vitro, tumor production in rodents(6), and detection of Tag in several human cancers including mesotheliomas(7,8). The retinoblastoma family contains three members, pRb, p107 and pRb2/p130 (ref. 9), that are phosphorylated in a cell cycle-dependent manner(10,11), have cell growth suppressive properties(12) and bind to specific members of the E2F family and various cyctins(13). Even though mesotheliomas are among the most aggressive human cancers, alterations of important cell-cycle ''controllers,'' such as the Rb family genes, have never been reported in these tumors. We found the presence of SV40-like sequences in 86% of 35 archival specimens of mesothelioma. We also demonstrated that SV40 Tag, isolated from frozen biopsies of human mesothelioma, binds each of the retinoblastoma family proteins, pRb, p107 and pRb2/p130, in four of four specimens. We propose that the tumorigenic potential of SV40 Tag in some human mesotheliomas may arise from its ability to interact with and thereby inactivate several tumor and/or growth suppressive proteins.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,SBARRO INST CANC RES & MOL MED,PHILADELPHIA,PA 19107; UNIV NAPLES 2,FAC MED,IST TISIOL & MALATTIE RESP S MARCATILI,I-80122 NAPLES,ITALY; LOYOLA UNIV,DEPT PATHOL,CANC IMMUNOL PROGRAM,CARDINAL BERNARDIN CANC CTR,MAYWOOD,IL 60153; WAYNE STATE UNIV,KARMANOS CANC INST,DETROIT,MI 48201; UNIV NAPLES 2,FAC MED,IST ANAT PATOL,I-80122 NAPLES,ITALY	Jefferson University; Jefferson University; Universita della Campania Vanvitelli; Loyola University Chicago; Barbara Ann Karmanos Cancer Institute; Wayne State University; Universita della Campania Vanvitelli			De Luca, Antonio/AAD-9562-2020; Giordano, Antonio/F-1927-2010; Baldi, Alfonso/ABG-2397-2021	De Luca, Antonio/0000-0002-3905-6154; Giordano, Antonio/0000-0002-5959-016X; rizzo, paola/0000-0001-7174-9674; Pass, Harvey/0000-0003-3222-3471; BAGELLA, Luigi/0000-0003-2815-037X; Howard, Candace/0000-0001-6537-3551; Esposito, Vincenzo/0000-0003-4696-2363; Baldi, Alfonso/0000-0002-8693-3842	NCI NIH HHS [R01 CA 60999-01A1, R29 CA74283] Funding Source: Medline; NINDS NIH HHS [P01 NS 36466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, CLIN CANCER RES, V2, P1239; BALDI A, IN PRESS CLIN CANC R; BARTEK J, 1992, ONCOGENE, V7, P101; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; CARBONE M, 1994, ONCOGENE, V9, P1781; CARBONE M, IN PRESS ONCOGENE; CARBONE M, 1997, NAT MED, V3, pR30; CLAUDIO PP, 1994, CANCER RES, V54, P5556; CLAUDIO RPP, 1996, CANCER RES, V56, P2003; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; LEWIS AM, 1976, BIOHAZARDS BIOL RES, P96; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SIMMONS DT, 1995, DNA TUMOR VIRUSES ON, P27; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014	22	184	185	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					913	916		10.1038/nm0897-913	http://dx.doi.org/10.1038/nm0897-913			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256285				2022-12-25	WOS:A1997XP01400036
J	Fleming, MD; Trenor, CC; Su, MA; Foernzler, D; Beier, DR; Dietrich, WF; Andrews, NC				Fleming, MD; Trenor, CC; Su, MA; Foernzler, D; Beier, DR; Dietrich, WF; Andrews, NC			Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; INTRACELLULAR PARASITES; NATURAL-RESISTANCE; SYSTEM; INFECTION; PROTEINS; DNA; BCG	Although disorders of iron metabolism are prevalent, iron transport remains poorly understood. To address this problem, we undertook a positional cloning strategy to identify the causative mutation in mice with microcytic anaemia (mk). Homozygous mk/mk mice have microcytic, hypochromic anaemia due to severe defects in intestinal iron absorption and erythroid iron utilization(1-4). We report the identification of a strong candidate gene for mk, and suggest that the phenotype is a consequence of a missense mutation in Nramp2 (ref. 5), a previously identified gene of unknown function. Nramp2 is homologous to Nramp1, a gene active in host defense. If Nramp2 is mk, as the cumulative evidence suggests, our findings have broad implications for the understanding of iron transport and resistance to intracellular pathogens.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Andrews, Nancy/0000-0003-0243-4462; johnson, keith/0000-0002-8578-5921; Su, Maureen/0000-0002-3680-9982; Fleming, Mark/0000-0003-0948-4024	NHLBI NIH HHS [K08 HL03600] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003600] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Cellier M, 1996, TRENDS GENET, V12, P201, DOI 10.1016/0168-9525(96)30042-5; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; EDWARDS JA, 1975, BLOOD, V46, P381; EDWARDS JA, 1972, P SOC EXP BIOL MED, V141, P81; GRUNHEID S, 1995, GENOMICS, V25, P514; GRUNHEID S, 1997, J EXP MED, V185, P717; HANDA S, 1987, GENET RES, V51, P42; HARRISON DE, 1972, BLOOD-J HEMATOL, V40, P893, DOI 10.1182/blood.V40.6.893.893; HOGAN B, 1986, MANIPULATING MOUSE E; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MCFARLAND EC, 1975, MOUSE NEWS LETT, V53, P35; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; RUSSELL ES, 1970, BLOOD-J HEMATOL, V35, P838, DOI 10.1182/blood.V35.6.838.838; RUSSELL ES, 1970, TRANSPLANT P, V2, P144; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; THOMSON ABR, 1971, J LAB CLIN MED, V78, P642; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEINBERG ED, 1993, ASM NEWS, V59, P559; WEST AH, 1992, J BIOL CHEM, V267, P24625	25	971	1002	2	33	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					383	386		10.1038/ng0897-383	http://dx.doi.org/10.1038/ng0897-383			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241278				2022-12-25	WOS:A1997XM90900023
J	Heppner, C; Kester, MB; Agarwal, SK; Debelenko, LV; EmmertBuck, MR; Guru, SC; Manickam, P; Olufemi, SE; Skarulis, MC; Doppman, JL; Alexander, RH; Kim, YS; Saggar, SK; Lubensky, IA; Zhuang, ZP; Liotta, LA; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Burns, AL; Marx, SJ				Heppner, C; Kester, MB; Agarwal, SK; Debelenko, LV; EmmertBuck, MR; Guru, SC; Manickam, P; Olufemi, SE; Skarulis, MC; Doppman, JL; Alexander, RH; Kim, YS; Saggar, SK; Lubensky, IA; Zhuang, ZP; Liotta, LA; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Burns, AL; Marx, SJ			Somatic mutation of the MEN1 gene in parathyroid tumours	NATURE GENETICS			English	Article							ENDOCRINE NEOPLASIA TYPE-1; SUPPRESSOR GENE; TUMORS; CHROMOSOME-11; CARCINOMA; RETINOBLASTOMA; METHYLATION	Primary hyperparathyroidism is a common disorder with an annual incidence of approximately 0.5 in 1,000 (ref. 1), In more than 95% of cases, the disease is caused by sporadic parathyroid adenoma or sporadic hyperplasia. Some cases are caused by inherited syndromes, such as multiple endocrine neoplasia type 1 (MEN1; ref. 2), In most cases, the molecular basis of parathyroid neoplasia is unknown. Parathyroid adenomas are usually monoclonal(3,4), suggesting that one important step in tumour development is a mutation in a progenitor cell, Approximately 30% of sporadic parathyroid tumours show loss of heterozygosity (LOH) for polymorphic markers on 11q13, the site of the MEN1 tumour suppressor gene(4-8). This raises the question of whether such sporadic parathyroid tumours are caused by sequential inactivation of both alleles of the MEN1 gene(9). We recently cloned the MEN1 gene and identified MEN1 germline mutations in fourteen of fifteen kindreds with familial MEN1 (ref. 10). We have studied parathyroid tumours not associated with MEN1 to determine whether somatic mutations in the MEN1 gene are present, Among 33 tumours we found somatic MEN1 gene mutation in 7, while the corresponding MEN1 germline sequence was normal in each patient. All tumours with MEN1 gene mutation showed LOH on 11q13, making the tumour cells hemi- or homozygous for the mutant allele. Thus, somatic MEN1 gene mutation contributes to tumorigenesis in a substantial number of parathyroid tumours not associated with the MEN1 syndrome.	NIDDKD, METAB DIS BRANCH, NIH, BETHESDA, MD 20892 USA; NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA; NHGRI, LAB GENE TRANSFER, NIH, BETHESDA, MD 20892 USA; NIH, CTR CLIN, DEPT DIAGNOST RADIOL, BETHESDA, MD 20892 USA; NCI, SURG BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191				Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; ARNOLD A, 1994, ENDOCRIN METAB CLIN, V23, P93, DOI 10.1016/S0889-8529(18)30118-X; Bates AS, 1997, J CLIN ENDOCR METAB, V82, P818, DOI 10.1210/jc.82.3.818; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Bright RK, 1997, CANCER RES, V57, P995; BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHOMCZYNSKI P, 1995, ANAL BIOCHEM, V225, P163, DOI 10.1006/abio.1995.1126; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; CRYNS VL, 1994, J CLIN ENDOCR METAB, V78, P1320, DOI 10.1210/jc.78.6.1320; Debelenko LV, 1997, CANCER RES, V57, P2238; Dotzenrath C, 1996, J CLIN ENDOCR METAB, V81, P3194, DOI 10.1210/jc.81.9.3194; EmmertBuck MR, 1997, CANCER RES, V57, P1855; Fain PR, 1996, HUM MOL GENET, V5, P1631, DOI 10.1093/hmg/5.10.1631; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; FRIEDMAN E, 1992, CANCER RES, V52, P6804; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; Jakobovitz G, 1996, J CLIN ENDOCR METAB, V81, P3164; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LIDA A, 1995, GENE CHROMOSOME CANC, V12, P73, DOI 10.1002/gcc.2870120114; Lubensky IA, 1996, CANCER RES, V56, P5272; MANICKAM P, IN PRESS HUM GENET; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Metz David C., 1994, P591; Pausova Z, 1996, J CLIN ENDOCR METAB, V81, P2711, DOI 10.1210/jc.81.7.2711; Pearce SHS, 1996, CLIN ENDOCRINOL, V45, P195, DOI 10.1046/j.1365-2265.1996.d01-1561.x; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Tahara H, 1996, J CLIN ENDOCR METAB, V81, P3663, DOI 10.1210/jc.81.10.3663; Tahara H, 1996, CANCER RES, V56, P599; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403	35	338	341	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1997	16	4					375	378		10.1038/ng0897-375	http://dx.doi.org/10.1038/ng0897-375			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241276				2022-12-25	WOS:A1997XM90900021
J	Lee, MH; Nicholson, P				Lee, MH; Nicholson, P			Isolation of genomic DNA from plant tissues	NATURE BIOTECHNOLOGY			English	Editorial Material									NUCLEON BIOSCI,COATBRIDGE ML5 5AD,LANARK,SCOTLAND		Lee, MH (corresponding author), VECTOR LABS INC,30 INGOLD RD,BURLINGAME,CA 94010, USA.								0	1	2	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					805	806		10.1038/nbt0897-805	http://dx.doi.org/10.1038/nbt0897-805			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255800				2022-12-25	WOS:A1997XM70700037
J	Gravel, C; Gotz, R; Lorrain, A; Sendtner, M				Gravel, C; Gotz, R; Lorrain, A; Sendtner, M			Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons	NATURE MEDICINE			English	Article							MOTONEURONS IN-VIVO; FACTOR PREVENTS; CELL-DEATH; REGIONAL DISTRIBUTION; PERIPHERAL-NERVE; SCIATIC-NERVE; MESSENGER-RNA; NEWBORN RATS; MOUSE; BDNF	The neurotrophic factors ciliary neurotrophic factor and brain-derived neurotrophic factor can prevent motor neuron cell death during development(1,2) and after nerve lesion in neonatal rodents(3,4). However, local and systemic application of these factors to newborn rats with damaged motor nerves rescues motor neurons only transiently during the first two weeks after axotomy(5,6). In order to test the effect of continuous delivery of these factors, the effect of localized injection of CNTF- or BDNF-transducing recombinant adenoviruses into the lesioned nerves was investigated. Under such conditions, survival of axotomized motor neurons is maintained for at least 5 weeks. This way of delivery corresponds to the physiological situation in adult rodents, under which endogenous CNTF is present in the cytosol of Schwann cells and BDNF expression is upregulated after nerve lesion, making these factors available to the damaged motor neurons(7,8). Recent results show that overexpression of muscle-derived neurotrophin-3 prevents degeneration of axons and motor endplates, but has only little effect on the number of motor neuron cell bodies in a murine animal model of motor neuron disease(9). Therefore, techniques suitable for tonic exposure to both nerve- and muscle-derived neurotrophic factors may have implications for the design of future therapeutic strategies against human motor neuron disease.	UNIV WURZBURG,KLIN FORSCHERGRP NEUROREGENERAT,DEPT NEUROL,D-97080 WURZBURG,GERMANY; UNIV LAVAL ROBERT GIFFARD,CTR RECH,LAB TRANSFERT GENES,BEAUPORT,PQ G1J 2G3,CANADA	University of Wurzburg; Laval University			Sendtner, Michael/J-1542-2012; Sendtner, Michael/M-8137-2014	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; *ALS CNTF TREATM S, 1995, CLIN NEUROPHARMACOL, V18, P500; CARTER BD, 1995, J BIOL CHEM, V270, P21751, DOI 10.1074/jbc.270.37.21751; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; Dittrich F, 1996, EXP NEUROL, V141, P225, DOI 10.1006/exnr.1996.0157; ERIKSSON NP, 1994, NEUROREPORT, V5, P1445; Haase G, 1997, NAT MED, V3, P429, DOI 10.1038/nm0497-429; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Hirano A., 1979, AMYOTROPHIC LATERAL, P107; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; IKEDA K, 1995, ANN NEUROL, V37, P505, DOI 10.1002/ana.410370413; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215; MITSUMOTO H, 1994, ANN NEUROL, V36, P142, DOI 10.1002/ana.410360205; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1985, TRENDS NEUROSCI, V8, P487, DOI 10.1016/0166-2236(85)90175-4; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; TRIPATHY KS, 1996, NAT MED, V2, P545; VEJSADA R, 1994, NEUROREPORT, V5, P1889, DOI 10.1097/00001756-199410000-00012; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; VILQUIN JT, 1995, HUM GENE THER, V6, P1391, DOI 10.1089/hum.1995.6.11-1391; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202; YAN Q, 1994, J NEUROSCI, V14, P5281	40	155	171	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					765	770		10.1038/nm0797-765	http://dx.doi.org/10.1038/nm0797-765			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212104				2022-12-25	WOS:A1997XG76700037
J	Lubeck, MD; Natuk, R; Myagkikh, M; Kalyan, N; Aldrich, K; Sinangil, F; Alipanah, S; Murthy, SCS; Chanda, PK; Nigida, SM; Markham, PD; ZollaPazner, S; Steimer, K; Wade, M; Reitz, MS; Arthur, LO; Mizutani, S; Davis, A; Hung, PP; Gallo, RC; Eichberg, J; RobertGuroff, M				Lubeck, MD; Natuk, R; Myagkikh, M; Kalyan, N; Aldrich, K; Sinangil, F; Alipanah, S; Murthy, SCS; Chanda, PK; Nigida, SM; Markham, PD; ZollaPazner, S; Steimer, K; Wade, M; Reitz, MS; Arthur, LO; Mizutani, S; Davis, A; Hung, PP; Gallo, RC; Eichberg, J; RobertGuroff, M			Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT ADENOVIRUS; GLYCOPROTEIN GP120; IMMUNE-RESPONSE; LYMPHOCYTES-T; INFECTION; ANTIBODY; MACAQUES; GP160; CELLS	A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1(MN)gp160 recombinants followed by boosting with HIV-1(SF2)gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HIV-1 and a subsequent high-dose SF2 challenge administered 1 year later without an intervening boost. Notably, neutralizing antibody responses against both clinical and laboratory isolates developed in three chimpanzees and persisted until the time of high-dose challenge. The possibility that cytotoxic T-lymphocytes contribute to row-dose protection of a chimpanzee lacking neutralizing antibodies is suggested. Our results validate the live vector priming/subunit booster approach and should stimulate interest in assessing this combination vaccine approach in humans.	WYETH AYERST RES,RADNOR,PA 19087; NCI,TUMOR CELL BIOL LAB,NIH,BETHESDA,MD 20892; CHIRON CORP,EMERYVILLE,CA 94608; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21702; ADV BIOSCI LABS,KENSINGTON,MD 20895; VET AFFAIRS MED CTR,NEW YORK,NY 10010	Pfizer; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Novartis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Zolla-Pazner, Susan/S-1864-2019	Zolla-Pazner, Susan/0000-0002-0750-2666	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036085, R01AI032424] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 36085, AI 32424] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABIMIKU AG, 1995, NAT MED, V1, P321, DOI 10.1038/nm0495-321; ARTHUR LO, 1995, J VIROL, V69, P3117, DOI 10.1128/JVI.69.5.3117-3124.1995; ARTHUR LO, 1989, J VIROL, V63, P5046, DOI 10.1128/JVI.63.12.5046-5053.1989; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; Berman PW, 1996, J INFECT DIS, V173, P52, DOI 10.1093/infdis/173.1.52; BERMAN PW, 1988, P NATL ACAD SCI USA, V85, P5200, DOI 10.1073/pnas.85.14.5200; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BERMAN PW, 1994, AIDS, V8, P591, DOI 10.1097/00002030-199405000-00004; BRUCK C, 1994, VACCINE, V12, P1141, DOI 10.1016/0264-410X(94)90185-6; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHANDA PK, 1979, VIROLOGY, V175, P535; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; CLERICI M, 1991, J IMMUNOL, V146, P2214; DOE B, 1994, EUR J IMMUNOL, V24, P2369, DOI 10.1002/eji.1830241017; ELAMAD Z, 1995, AIDS, V9, P1313, DOI 10.1097/00002030-199512000-00003; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167; GIRARD M, 1995, J VIROL, V69, P6239, DOI 10.1128/JVI.69.10.6239-6248.1995; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; Girard M, 1996, J VIROL, V70, P8229, DOI 10.1128/JVI.70.11.8229-8233.1996; HAIGWOOD NL, 1990, AIDS RES HUM RETROV, V6, P855, DOI 10.1089/aid.1990.6.855; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; LUBECK MD, 1989, P NATL ACAD SCI USA, V86, P6763, DOI 10.1073/pnas.86.17.6763; LUBECK MD, 1994, AIDS RES HUM RETROV, V10, P1443, DOI 10.1089/aid.1994.10.1443; LUBECK MD, 1995, AIDS RES HUM RETROV, V11, P189; Murthy KK, 1996, AIDS RES HUM RETROV, V12, P1341, DOI 10.1089/aid.1996.12.1341; NATUK RJ, 1993, AIDS RES HUM RETROV, V9, P395, DOI 10.1089/aid.1993.9.395; NIEDRIG M, 1993, VACCINE, V11, P67, DOI 10.1016/0264-410X(93)90341-T; ROBERTGUROFF M, 1990, TECHNIQUES HIV RES, P179; RUBIN BA, 1988, VACCINES, P492; SCANDELLA CJ, 1993, AIDS RES HUM RETROV, V9, P1233, DOI 10.1089/aid.1993.9.1233; SHENK T, 1996, FIELDS VIROLOGY, P2111; SORENSEN AB, 1993, J VIROL, V67, P7118; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; ZARLING JM, 1987, J IMMUNOL, V139, P988; ZollaPazner S, 1995, AIDS RES HUM RETROV, V11, P1449, DOI 10.1089/aid.1995.11.1449	42	139	141	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					651	658		10.1038/nm0697-651	http://dx.doi.org/10.1038/nm0697-651			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176492				2022-12-25	WOS:A1997XB97400035
J	Chen, GH; Guan, ZB; Chen, CT; Fu, LT; Sundaresan, V; Arnold, FH				Chen, GH; Guan, ZB; Chen, CT; Fu, LT; Sundaresan, V; Arnold, FH			A glucose-sensing polymer	NATURE BIOTECHNOLOGY			English	Article						diabetes mellitus; biosensor; copper-triazacyclononane; molecular imprinting	DISCRIMINATION; COPPER(II); SENSOR	We have prepared a robust polymer that can be used to measure glucose concentrations in complex biological media. At alkaline pH, the metal-complexing polymer binds glucose and instantly releases protons in proportion to the glucose concentration over a clinically relevant range (0 to 25 mM). The inexpensive polymer is sufficiently selective to provide an easily measurable response to glucose in porcine plasma. The polymer's ability to function at nonphysiological pH (at which the buffer capacity of biological samples is small) makes it possible to design simple and inexpensive sensing devices based on measurement of changes in proton concentration.	CALTECH,DIV CHEM & CHEM ENGN 21041,PASADENA,CA 91125	California Institute of Technology				Arnold, Frances H./0000-0002-4027-364X				BURTIS AC, 1994, TIETZ TXB CLIN CHEM, P1412; DHAL PK, 1992, MACROMOLECULES, V25, P7051, DOI 10.1021/ma00051a050; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; GOUGH DA, 1995, DIABETES, V44, P1005, DOI 10.2337/diab.44.9.1005; JAMES TD, 1995, NATURE, V374, P345, DOI 10.1038/374345a0; Martell A.E., 1992, DETERMINATION USE ST; MAYES AG, 1994, ANAL BIOCHEM, V222, P483, DOI 10.1006/abio.1994.1521; Meyerhoff C, 1996, ENDOCRINOLOGIST, V6, P51, DOI 10.1097/00019616-199601000-00008; PICKUP J, 1993, TRENDS BIOTECHNOL, V11, P285, DOI 10.1016/0167-7799(93)90016-3; POMGAILO AD, 1994, SYNTHESIS POLYM META, P134; WULFF G, 1991, J ORG CHEM, V56, P395, DOI 10.1021/jo00001a071; YANAGIHARA R, 1994, TETRAHEDRON LETT, V35, P9725, DOI 10.1016/0040-4039(94)88370-X; YANG R, 1976, INORG CHEM, V15, P1499, DOI 10.1021/ic50161a007	13	117	122	1	50	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					354	357		10.1038/nbt0497-354	http://dx.doi.org/10.1038/nbt0497-354			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094137				2022-12-25	WOS:A1997WQ55400036
J	Erb, RW; Eichner, CA; WagnerDobler, I; Timmis, KN				Erb, RW; Eichner, CA; WagnerDobler, I; Timmis, KN			Bioprotection of microbial communities from toxic phenol mixtures by a genetically designed pseudomonad	NATURE BIOTECHNOLOGY			English	Article						biodegradation; genetically engineered microorganism; bioprotection	AQUATIC SEDIMENT MICROCOSMS; ENGINEERED PSEUDOMONAD; MICROORGANISMS; 4-CHLOROCATECHOL; DEGRADATION; PATHWAY	Pseudomonas sp. B13 SN45RE is a genetically engineered microorganism (GEM) that is able to simultaneously degrade mixtures of chloro- and methylaromatics ordinarily toxic for microbial communities via a designed novel ortho-cleavage pathway. The utility of the GEM was investigated in a laboratory scale sewage plant fed with mixtures of either 4-chlorophenol and 4-methyphenol or 3-chlorophenol and 4-methylphenol. In the model system the GEM significantly increased the rate and extent of degradation of the phenol mixtures. In the absence of the GEM, shock loads of the phenol mixtures (1 mM of each compound) reduced the numbers of culturable bacteria by three orders of magnitude, completely eliminated protozoa and metazoa, and caused a drastic decrease in oxygen consumption, whereas the presence of the GEM protected the indigenous microbial community and assured continued functioning of the sewage plant.	GBF,NATL RES CTR BIOTECHNOL,DEPT MICROBIOL,BRAUNSCHWEIG,GERMANY	Helmholtz Association; Helmholtz-Center for Infection Research			Wagner-Döbler, Irene/Y-1685-2019	Wagner-Dobler, Irene/0000-0001-5883-2502				BARTELS I, 1984, APPL ENVIRON MICROB, V47, P500, DOI 10.1128/AEM.47.3.500-505.1984; BLASCO R, 1995, J BIOL CHEM, V270, P29229, DOI 10.1074/jbc.270.49.29229; BUCHHOLZ KD, 1993, ENVIRON SCI TECHNOL, V27, P2844, DOI 10.1021/es00049a026; DORN E, 1974, ARCH MICROBIOL, V99, P61, DOI 10.1007/BF00696222; GUDE H, 1979, MICROB ECOL, V5, P225, DOI 10.1007/BF02013529; HEUER H, 1995, MICROB ECOL, V29, P203, DOI 10.1007/BF00167165; KNACKMUSS HJ, 1978, ARCH MICROBIOL, V117, P1, DOI 10.1007/BF00689343; KRUMME ML, 1994, ENVIRON SCI TECHNOL, V28, P1134, DOI 10.1021/es00055a025; NUSSLEIN K, 1992, APPL ENVIRON MICROB, V58, P3380; PEELEN S, 1993, EUR J BIOCHEM, V218, P345, DOI 10.1111/j.1432-1033.1993.tb18383.x; PIEPER DH, 1995, APPL ENVIRON MICROB, V61, P2159, DOI 10.1128/AEM.61.6.2159-2165.1995; PIPKE R, 1992, APPL ENVIRON MICROB, V58, P1259, DOI 10.1128/AEM.58.4.1259-1265.1992; REINEKE W, 1982, J BACTERIOL, V150, P195, DOI 10.1128/JB.150.1.195-201.1982; REINEKE W, 1988, ANNU REV MICROBIOL, V42, P263, DOI 10.1146/annurev.mi.42.100188.001403; ROJO F, 1987, SCIENCE, V238, P1395, DOI 10.1126/science.3479842; Sambrook J., 2002, MOL CLONING LAB MANU; Smith MR, 1990, BIODEGRADATION, V1, P191, DOI 10.1007/BF00058836; TIMMIS KN, 1994, ANNU REV MICROBIOL, V48, P525, DOI 10.1146/annurev.mi.48.100194.002521; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; WAGNERDOBLER I, 1992, APPL ENVIRON MICROB, V58, P1249; WIESER M, 1994, FEMS MICROBIOL LETT, V116, P73, DOI 10.1111/j.1574-6968.1994.tb06678.x	21	48	56	1	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					378	382		10.1038/nbt0497-378	http://dx.doi.org/10.1038/nbt0497-378			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094142				2022-12-25	WOS:A1997WQ55400041
J	Wang, YL; DeMayo, FJ; Tsai, SY; OMalley, BW				Wang, YL; DeMayo, FJ; Tsai, SY; OMalley, BW			Ligand-inducible and liver-specific target gene expression in transgenic mice	NATURE BIOTECHNOLOGY			English	Article						inducible gene system; gene expression; transgenic mice	CELLS; ELEMENTS; RU-486; MIFEPRISTONE; DROSOPHILA; ENHANCER; PROMOTER; SYSTEM	Transgenic mice have been used as models for tissue-specific gene regulation and to examine the molecular and cellular effects of altered expression of specific genes in disease processes such as tumorigenesis. Because of the deleterious effects of constitutive expression of transgenes, which frequently result in prenatal or postnatal death, only a limited number of disease models have been established in transgenic mice. We report an inducible binary transactivation system that permits the control of transgene expression in a tissue-specific and inducible fashion in mice. In this system, transcription of the target transgene is kept silent until turned on by the administration of an exogenous compound. We also demonstrate that expression level of the target gene can be induced three to four orders of magnitude and can be controlled by the administrated compound in a dose-dependent manner.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine			DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BORGDEN RN, 1993, DRUGS, V45, P384; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRUNBERG SM, 1991, J NEUROSURG, V74, P861, DOI 10.3171/jns.1991.74.6.0861; HEIKINHEIMO O, 1993, ANN MED, V25, P71, DOI 10.3109/07853899309147861; KAWAI S, 1987, J PHARMACOL EXP THER, V241, P401; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MURAD F, 1985, GOODMAN GILMANS PHAR, P1366; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; RENEKER LXW, 1995, DEVELOPMENT, V121, P1669; SHI YE, 1993, CONTRACEPTION, V48, P133, DOI 10.1016/0010-7824(93)90004-Q; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SPITZ IM, 1993, NEW ENGL J MED, V329, P404; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	24	184	222	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					239	243		10.1038/nbt0397-239	http://dx.doi.org/10.1038/nbt0397-239			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062922				2022-12-25	WOS:A1997WM05000026
J	Gayther, SA; Mangion, J; Russell, P; Seal, S; Barfoot, R; Ponder, BAJ; Stratton, MR; Easton, D				Gayther, SA; Mangion, J; Russell, P; Seal, S; Barfoot, R; Ponder, BAJ; Stratton, MR; Easton, D			Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene	NATURE GENETICS			English	Article							SUSCEPTIBILITY GENE; APC GENE; POLYPOSIS; PHENOTYPE	The breast cancer susceptibility gene BRCA2 on chromosome 13q12-13 has recently been identified(1). Germline mutations of BRCA2 are predicted to account for approximately 35% of families with multiple case, early onset female breast cancer, and they are also associated with an increased risk of male breast cancer, ovarian cancer, prostate cancer and pancreatic cancer(2-4). Germline mutations of a second cancer susceptibility gene BRCA1 (ref. 5), are associated with a strong predisposition to ovarian cancer as well as female breast cancer(6). Recent studies have suggested that the phenotype in BRCA1 families with respect to the ratio of breast to ovarian cancer varies with the location of the BRCA1 mutation(7,8). To determine whether germline mutations in BRCA2 are associated with a similar variation in phenotypic risk, we have analysed the distribution of mutations in 25 families with multiple cases of breast and/or ovarian cancer ascertained in the United Kingdom and fire. These mutations all lead to premature truncation of BRCA2 as a result of frameshift deletions/insertions or nonsense mutations. Analysis of the mutation distribution along the length of the gene indicates a significant genotype-phenotype correlation. Truncating mutations in families with the highest risk of ovarian cancer relative to breast cancer are clustered in a region of approximately 3.3 kb in exon 11 (P=0.0004). Published data on mutations in 45 other BRCA2-linked families provide support for this correlation.	INST CANC RES,HADDOW LABS,SECT MOL CARCINOGENESIS,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV FORVIE SITE,INST PUBL HLTH,CRC,GENET EPIDEMIOL GRP,CAMBRIDGE CB2 2SR,ENGLAND	University of London; Institute of Cancer Research - UK; University of Cambridge	Gayther, SA (corresponding author), ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,HILLS RD,BOX 238,CAMBRIDGE CB2 2QQ,ENGLAND.							Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; EASTON DF, 1993, AM J HUM GENET, V52, P718; GAYTHER SA, 1994, HUM MOL GENET, V3, P53, DOI 10.1093/hmg/3.1.53; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gayther SA, 1996, AM J HUM GENET, V58, P451; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAGASE H, 1992, CANCER RES, V52, P4055; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	16	352	358	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					103	105		10.1038/ng0197-103	http://dx.doi.org/10.1038/ng0197-103			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988179				2022-12-25	WOS:A1997WA37300031
J	Lee, SW; Sullenger, BA				Lee, SW; Sullenger, BA			Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies	NATURE BIOTECHNOLOGY			English	Article						in vitro selection; decoy RNA; acetylcholine receptor; autoantibody; myasthenia gravis	IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-LINE TE671; MONOCLONAL-ANTIBODIES; GRAVIS; INHIBITION; MODULATION; SELECTION; IMMUNOGLOBULIN; EXPRESSION; EPITOPE	The muscular weakness and fatigability associated with myasthenia gravis are engendered by autoantibodies directed against acetylcholine receptors on muscle cells at neuromuscular junctions. The pathogenic consequences of this immune response can potentially be modulated by molecules that bind such autoantibodies and block their interaction with these receptors. We report the isolation of a small nuclease-resistant RNA molecule that binds both a rat monoclonal antibody that recognizes the main immunogenic region on the acetylcholine receptor, and autoantibodies from patients with myasthenia gravis. Moreover, this RNA can act as a decoy and protect acetylcholine receptors on human cells from the effects of these antibodies.	DUKE UNIV, MED CTR, DEPT EXPT SURG, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA	Duke University; Duke University				Lee, Seong-Wook/0000-0003-1718-7601				DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; DRACHMAN DB, 1982, NEW ENGL J MED, V307, P769, DOI 10.1056/NEJM198209233071301; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; FAMBROUGH DM, 1973, SCIENCE, V182, P293, DOI 10.1126/science.182.4109.293; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gold L., 1993, RNA WORLD, P497; HEINEMANN S, 1977, P NATL ACAD SCI USA, V74, P3090, DOI 10.1073/pnas.74.7.3090; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KAO I, 1977, SCIENCE, V196, P527, DOI 10.1126/science.850793; Lee SW, 1996, J EXP MED, V184, P315, DOI 10.1084/jem.184.2.315; LEE SW, 1995, GENE THER, V2, P377; LEE SW, 1994, J VIROL, V68, P8254, DOI 10.1128/JVI.68.12.8254-8264.1994; LENNON VA, 1991, J IMMUNOL, V146, P2245; LINDSTROM J, 1988, ADV IMMUNOL, V42, P233, DOI 10.1016/S0065-2776(08)60847-0; LISZIEWICZ J, 1991, NEW BIOL, V3, P82; LUTHER MA, 1989, J NEUROSCI, V9, P1082; MAMALAKI A, 1993, EUR J IMMUNOL, V23, P1839, DOI 10.1002/eji.1830230816; PATRICK J, 1973, SCIENCE, V180, P871, DOI 10.1126/science.180.4088.871; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; SAEDI MS, 1990, FEBS LETT, V267, P55, DOI 10.1016/0014-5793(90)80286-R; SOPHIANOS D, 1989, J AUTOIMMUN, V2, P777, DOI 10.1016/0896-8411(89)90004-8; STANLEY EF, 1978, SCIENCE, V200, P1285, DOI 10.1126/science.663610; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; SULLENGER BA, 1991, J VIROL, V65, P6811, DOI 10.1128/JVI.65.12.6811-6816.1991; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TSAI DE, 1992, P NATL ACAD SCI USA, V89, P8864, DOI 10.1073/pnas.89.19.8864; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TZARTOS SJ, 1982, P NATL ACAD SCI-BIOL, V79, P188, DOI 10.1073/pnas.79.1.188; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; VINCENT A, 1987, ANN NY ACAD SCI, V505, P106, DOI DOI 10.1111/J.1749-6632.1987.TB51286.X.PUBMED:2446546; WILLCOX N, 1993, CURR OPIN IMMUNOL, V5, P910, DOI 10.1016/0952-7915(93)90105-2	34	85	94	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					41	45		10.1038/nbt0197-41	http://dx.doi.org/10.1038/nbt0197-41			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035104				2022-12-25	WOS:A1997WA72900021
J	Cheung, MC; Goldberg, JD; Kan, YW				Cheung, MC; Goldberg, JD; Kan, YW			Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood	NATURE GENETICS			English	Article							BETA-THALASSEMIA MUTATIONS; ALPHA-THALASSEMIA; ENZYMATIC AMPLIFICATION; NUCLEATED ERYTHROCYTES; GENE DELETION; DNA; HEMOGLOBIN; SAMPLES; SEQUENCES; ANEMIA	Currently, amniocentesis, chorionic villus sampling (CVS) and fetal blood sampling are used to obtain fetal cells for genetic diagnosis. These invasive procedures pose a small but not negligible risk for the fetus. Efforts have been directed towards the enrichment of fetal cells, such as erythroblasts, from maternal blood and progress has been made in the diagnosis of some chromosomal disorders and in sex determinations. We now report the detection of point mutations in single gene disorders using this method of prenatal diagnosis by enriching fetal cells from maternal blood by magnetic cell sorting followed by isolation of pure fetal cells by microdissection. In two pregnancies at risk for sickle cell anaemia and beta-thalassaemia, we successfully identified the fetal genotypes. Thus, prenatal diagnosis of single gene disorders by recovering fetal cells from maternal circulation appears to be a feasible approach.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT OBSTET & GYNAECOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [DK16666] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016666, R01DK016666] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADINOLFI M, 1995, PRENATAL DIAG, V15, P889, DOI 10.1002/pd.1970151003; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BIANCHI DW, 1993, PRENATAL DIAG, V13, P293, DOI 10.1002/pd.1970130408; Bianchi DW, 1996, PRENATAL DIAG, V16, P289, DOI 10.1002/(SICI)1097-0223(199604)16:4<289::AID-PD843>3.3.CO;2-K; BIANCHI DW, 1995, J PEDIATR-US, V127, P847, DOI 10.1016/S0022-3476(95)70018-8; BIANCHI DW, 1990, P NATL ACAD SCI USA, V87, P3279, DOI 10.1073/pnas.87.9.3279; BUSCH J, 1994, PRENATAL DIAG, V14, P1129, DOI 10.1002/pd.1970141206; CAI SP, 1994, HUM MUTAT, V3, P59, DOI 10.1002/humu.1380030110; CHANG JC, 1982, NEW ENGL J MED, V307, P30, DOI 10.1056/NEJM198207013070105; CHEHAB FF, 1995, PCR STRATEGIES, P30; DELHANTY J, 1995, PRENATAL DIAG, V15, P943, DOI 10.1002/pd.1970151009; DOZY AM, 1979, JAMA-J AM MED ASSOC, V241, P1610, DOI 10.1001/jama.241.15.1610; EVANS MI, 1989, AM J OBSTET GYNECOL, V160, P1332, DOI 10.1016/0002-9378(89)90852-1; GANSHIRTAHLERT D, 1992, AM J OBSTET GYNECOL, V166, P1350; GANSHIRTAHLERT D, 1993, AM J REPROD IMMUNOL, V30, P194; GEIFMANHOLTZMAN O, 1995, PRENATAL DIAG, V15, P261, DOI 10.1002/pd.1970150309; HAWES C, 1994, ANN NY ACAD SCI, V731, P217; HERZENBERG LA, 1979, P NATL ACAD SCI USA, V76, P1453, DOI 10.1073/pnas.76.3.1453; KAN YW, 1976, NEW ENGL J MED, V295, P1165, DOI 10.1056/NEJM197611182952104; KAN YW, 1976, NEW ENGL J MED, V294, P1039, DOI 10.1056/NEJM197605062941905; KAN YW, 1975, NEW ENGL J MED, V292, P1096, DOI 10.1056/NEJM197505222922104; MAGGIO A, 1993, BLOOD, V81, P239; ORKIN SH, 1982, NEW ENGL J MED, V307, P32, DOI 10.1056/NEJM198207013070106; OTTOLENGHI S, 1974, NATURE, V251, P389, DOI 10.1038/251389a0; PIRASTU M, 1983, NEW ENGL J MED, V309, P284, DOI 10.1056/NEJM198308043090506; PRICE JO, 1991, AM J OBSTET GYNECOL, V165, P1731, DOI 10.1016/0002-9378(91)90024-L; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHRODER J, 1974, TRANSPLANTATION, V17, P346, DOI 10.1097/00007890-197404000-00003; SIMPSON JL, 1993, JAMA-J AM MED ASSOC, V270, P2357, DOI 10.1001/jama.270.19.2357; TAYLOR JM, 1974, NATURE, V251, P392, DOI 10.1038/251392a0; THOMAS MR, 1995, PRENATAL DIAG, V15, P641, DOI 10.1002/pd.1970150709; TUTSCHEK B, 1995, PRENATAL DIAG, V15, P951, DOI 10.1002/pd.1970151010; WAIKAN Y, 1978, P NATL ACAD SCI USA, V75, P5631, DOI 10.1073/pnas.75.11.5631; ZHENG YL, 1995, PRENATAL DIAG, V15, P897, DOI 10.1002/pd.1970151004; ZHENG YL, 1993, J MED GENET, V30, P1051, DOI 10.1136/jmg.30.12.1051	36	200	232	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1996	14	3					264	268		10.1038/ng1196-264	http://dx.doi.org/10.1038/ng1196-264			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896554				2022-12-25	WOS:A1996VQ14600019
J	Cocchi, F; DeVico, AL; GarzinoDemo, A; Cara, A; Gallo, RC; Lusso, P				Cocchi, F; DeVico, AL; GarzinoDemo, A; Cara, A; Gallo, RC; Lusso, P			The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SOLUBLE CD4 NEUTRALIZATION; T-CELLS; HTLV-III; TYPE-1; REPLICATION; IDENTIFICATION; MACROPHAGE; TROPISM; LYMPHOCYTES	The ability of CD8(+) T cells derived from human immunodeficiency virus (HIV)-infected patients to produce soluble HIV-suppressive factor(s) (HIV-SF)(1-3) has been suggested as an important mechanism of control of HIV infection in vivo(4,5). The C-C chemokines RANTES, MIP-1 alpha and MIP-1 beta were recently identified as the major components of the HIV-SF produced by both immortalized and primary patient CD8(+) T cells. Whereas they potently inhibit infection by primary and macrophage-tropic HIV-1 isolates, T-cell line-adapted viral strains tend to be insensitive to their suppressive effects(6). Consistent with this discrepancy, two distinct chemokine receptors, namely, CXCR4 (ref. 7) and CCR5 (ref. 8), were recently identified as potential co-receptors for T-cell line-adapted and macrophage-tropic HIV-1 isolates, respectively(9-12). Here, we demonstrate that the third hypervariable domain of the gp120 envelope glycoprotein is a critical determinant of the susceptibility of HIV-1 to chemokines. Moreover, we show that RANTES, MIP-1 alpha. and MIP-1 beta block the entry of HIV-1 into cells and that their antiviral activity is independent of pertussis toxin-sensitive signal transduction pathways mediated by chemokine receptors. The ability of the chemokines to block the early steps of HIV infection could be exploited to develop novel therapeutic approaches for AIDS.	UNIV MARYLAND,BIOTECNOL INST & SCH MED,CTR MED BIOTECHNOL,INST HUMAN VIROL,BALTIMORE,MD 21201; SAN RAFFAELE SCI INST,DIPARTIMENTO RIC BIOL & TECNOL,I-20132 MILAN,ITALY; NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892	University System of Maryland; University of Maryland Baltimore; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Cara, Andrea/M-4865-2015; Cara, Andrea/AAA-4238-2021	Cara, Andrea/0000-0003-4967-1895; Cara, Andrea/0000-0003-4967-1895; Garzino-Demo, Alfredo/0000-0002-4095-6950				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; Carrillo A, 1996, J VIROL, V70, P1301, DOI 10.1128/JVI.70.2.1301-1309.1996; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOMEZ AM, 1994, CLIN EXP IMMUNOL, V97, P68; HWANG SS, 1992, SCIENCE, V257, P535, DOI 10.1126/science.1636088; IVANOFF LA, 1992, VIROLOGY, V187, P423, DOI 10.1016/0042-6822(92)90444-T; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KOITO A, 1994, J VIROL, V68, P2253, DOI 10.1128/JVI.68.4.2253-2259.1994; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; Sambrook J., 2002, MOL CLONING LAB MANU; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STAMATATOS L, 1994, J VIROL, V68, P4973, DOI 10.1128/JVI.68.8.4973-4979.1994; TAKEUCHI Y, 1991, J VIROL, V65, P1710, DOI 10.1128/JVI.65.4.1710-1718.1991; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1989, IMMUNOLOGY, V66, P628; WILLEY RL, 1993, J VIROL, V67, P3639, DOI 10.1128/JVI.67.6.3639-3643.1993	34	450	480	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1244	1247		10.1038/nm1196-1244	http://dx.doi.org/10.1038/nm1196-1244			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898753				2022-12-25	WOS:A1996VQ10100041
J	Pasqualini, R; Bourdoulous, S; Koivunen, E; Woods, VL; Ruoslahti, E				Pasqualini, R; Bourdoulous, S; Koivunen, E; Woods, VL; Ruoslahti, E			A polymeric form of fibronectin has antimetastatic effects against multiple tumor types	NATURE MEDICINE			English	Article							CELL-ADHESION; MELANOMA-CELLS; EXPERIMENTAL METASTASIS; MONOCLONAL-ANTIBODY; SYNTHETIC PEPTIDE; GENE-EXPRESSION; NUDE-MICE; INTEGRIN; RECEPTOR; INHIBITION	Metastasis accounts for most deaths in cancer patients. Tumor cell adhesion to the extracellular matrix through integrins is thought to be a critical step in metastasis and a potential target for therapeutic intervention. We show here that treatment of human osteosarcoma, melanoma and carcinoma cells with a polymeric form of fibronectin (sFN), before inoculation into nude mice, prevented tumor formation. Intraperitoneally administered sFN significantly reduced lung colonization from intravenously injected tumor cells (experimental metastasis) and from subcutaneous tumors in nude mice (spontaneous metastasis). Treatment with sFN blocked cell spreading and migration in vitro suggesting a possible mechanism for the antimetastatic effect.	UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA; UNIV HELSINKI, DEPT BIOSCI, DIV BIOCHEM, FIN-00014 HELSINKI, FINLAND	University of California System; University of California San Diego; University of Helsinki	Pasqualini, R (corresponding author), LA JOLLA CANC RES FDN, BURNHAM INST, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Koivunen, Erkki/0000-0002-6443-9595	NCI NIH HHS [CA 62042, CA 30199, CA 58527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA062042, R01CA058527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BERLIN O, 1993, CANCER RES, V53, P4890; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Burridge K., 1992, Current Biology, V2, P537, DOI 10.1016/0960-9822(92)90020-B; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; deBoer HC, 1995, J BIOL CHEM, V270, P30733, DOI 10.1074/jbc.270.51.30733; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GOTLOIB L, 1995, KIDNEY INT, V47, P1274, DOI 10.1038/ki.1995.182; HAMILTON TC, 1983, CANCER RES, V43, P5379; HARDAN I, 1993, INT J CANCER, V55, P1023, DOI 10.1002/ijc.2910550624; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, SEMIN CANCER BIOL, V4, P277; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; KOMAZAWA H, 1993, CARBOHYD POLYM, V21, P299, DOI 10.1016/0144-8617(93)90063-A; KUMAGAI H, 1991, BIOCHEM BIOPH RES CO, V177, P74, DOI 10.1016/0006-291X(91)91950-H; LIOTTA LA, 1986, CANCER RES, V46, P1; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MITJANS F, 1995, J CELL SCI, V108, P2825; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; SAIKI I, 1989, BRIT J CANCER, V59, P194, DOI 10.1038/bjc.1989.40; SOSZKA T, 1991, EXP CELL RES, V196, P6, DOI 10.1016/0014-4827(91)90449-5; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAMADA KM, 1990, CANCER RES, V50, P4485; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	51	112	115	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1197	1203		10.1038/nm1196-1197	http://dx.doi.org/10.1038/nm1196-1197			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898745				2022-12-25	WOS:A1996VQ10100033
J	Roessler, E; Belloni, E; Gaudenz, K; Jay, P; Berta, P; Scherer, SW; Tsui, LC; Muenke, M				Roessler, E; Belloni, E; Gaudenz, K; Jay, P; Berta, P; Scherer, SW; Tsui, LC; Muenke, M			Mutations in the human Sonic hedgehog gene cause holoprosencephaly	NATURE GENETICS			English	Article							TERMINAL CLEAVAGE PRODUCT; CENTRAL-NERVOUS-SYSTEM; CRITICAL REGION; FLOOR PLATE; POLARIZING ACTIVITY; DROSOPHILA; INDUCTION; PERSPECTIVES; EXPRESSION; DIFFERENTIATION		UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DIV HUMAN GENET & MOL BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; CTR RECH BIOCHIM MACROMOL,CNRS ERS 155,INSERM,U249,F-34033 MONTPELLIER,FRANCE	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			belloni, elena/H-9909-2013; Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013; Jay, Philippe/I-7116-2016; Jay, Philippe/ABD-9223-2020	Scherer, Stephen W./0000-0002-8326-1999; Jay, Philippe/0000-0003-0156-5700; Jay, Philippe/0000-0003-0156-5700; Muenke, Maximilian/0000-0002-7719-6545; Belloni, Elena/0000-0003-3214-0780	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029862, R29HD028732, T32HD007107] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD29862, 5T32HD07107, R29HD28732] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARDINGER HH, 1988, J CRAN GENET DEV BIO, V8, P53; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN MM, 1992, J CRAN GENET DEV BIO, V12, P196; COHEN MM, 1989, TERATOLOGY, V40, P211, DOI 10.1002/tera.1420400304; COHEN MM, 1989, AM J MED GENET, V34, P271, DOI 10.1002/ajmg.1320340232; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, DEVELOPMENT, V121, P2337; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; GURRIERI F, 1993, NAT GENET, V3, P247, DOI 10.1038/ng0393-247; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JOHNSON VP, 1989, AM J MED GENET, V34, P258, DOI 10.1002/ajmg.1320340228; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LYNCH SA, 1995, NAT GENET, V11, P93, DOI 10.1038/ng0995-93; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MUENKE M, 1994, P NATL ACAD SCI USA, V91, P8102, DOI 10.1073/pnas.91.17.8102; MUENKE M, 1995, AM J HUM GENET, V57, P1074; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Muenke Maximilian, 1994, Seminars in Developmental Biology, V5, P293, DOI 10.1006/sedb.1994.1038; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OVERHAUSER J, 1995, AM J HUM GENET, V57, P1080; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Schell U, 1996, HUM MOL GENET, V5, P223, DOI 10.1093/hmg/5.2.223; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8	37	873	897	0	63	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					357	360		10.1038/ng1196-357	http://dx.doi.org/10.1038/ng1196-357			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896572				2022-12-25	WOS:A1996VQ14600037
J	Donovan, MJ; Hahn, R; Tessarollo, L; Hempstead, BL				Donovan, MJ; Hahn, R; Tessarollo, L; Hempstead, BL			Identification of an essential nonneuronal function of neurotrophin 3 in mammalian cardiac development	NATURE GENETICS			English	Letter							NEURAL CREST CELLS; NERVOUS-SYSTEM; TARGETED DISRUPTION; MESSENGER-RNA; TRKC; RECEPTORS; EXPRESSION; HEART; GENE; RAT		NCI,FREDERICK CANC RES & DEV CTR,NEURAL DEV GRP,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Harvard University; Boston Children's Hospital; Cornell University					NINDS NIH HHS [NS30687] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030687] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auerbach, 1991, DEV VASCULAR SYSTEM, P25; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRILL G, 1995, DEVELOPMENT, V121, P2583; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; BROWN NA, 1990, POSTIMPLANTATION MAM, P930; DONOVAN MJ, 1995, AM J PATHOL, V147, P309; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; FRIEDMAN WF, 1988, HEART DIS TXB CARDIO, P895; ICARDO JM, 1992, HEART CARDIOVASCULAR, P1563; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; KAHANE N, 1994, J NEUROBIOL, V25, P571, DOI 10.1002/neu.480250509; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; KIRBY ML, 1993, DEV DYNAM, V198, P296, DOI 10.1002/aja.1001980407; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LAMBALLE F, 1994, J NEUROSCI, V14, P14; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; SCARISBRICK IA, 1993, J NEUROSCI, V13, P875; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TESSAROLLO L, 1994, P NATL ACAD SCI USA, V91, P11844, DOI 10.1073/pnas.91.25.11844; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463; TOJO H, 1995, BRAIN RES, V669, P163, DOI 10.1016/0006-8993(94)01219-8; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A	25	142	152	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					210	213		10.1038/ng1096-210	http://dx.doi.org/10.1038/ng1096-210			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841198	Green Published			2022-12-25	WOS:A1996VL44600032
J	Gulcher, JR; Jonsson, P; Kong, A; Kristjansson, K; Frigge, ML; Karason, A; Einarsdottir, IE; Stefansson, H; Einarsdottir, AS; Sigurdardottir, S; Baldursson, S; Bjornsdottir, S; Hrafnkelsdottir, SM; Jakobsson, F; Benedickz, J; Stefansson, K				Gulcher, JR; Jonsson, P; Kong, A; Kristjansson, K; Frigge, ML; Karason, A; Einarsdottir, IE; Stefansson, H; Einarsdottir, AS; Sigurdardottir, S; Baldursson, S; Bjornsdottir, S; Hrafnkelsdottir, SM; Jakobsson, F; Benedickz, J; Stefansson, K			Mapping of a familial essential tremor gene, FET1, to chromosome 3q13	NATURE GENETICS			English	Letter							POSITRON EMISSION TOMOGRAPHY; HEREDITARY ESSENTIAL TREMOR; LINKAGE ANALYSIS; PREVALENCE; CEREBELLAR; PRIMIDONE	Essential tremor (ET), the most common movement disorder in humans, appears to be inherited as an autosomal dominant trait in many families(1,2). The familial form is called familial essential tremor (FET), which seems similar to sporadic essential tremor. ET is a cause of substantial disability, particularly in the elderly(1). The prevalence of Parkinson's disease and dystonia may be increased in families with ET, but other movement disorders are seldom encountered in these families(3,4). Here we report the results of a genome-wide scan for FET genes in 16 Icelandic families with 75 affected individuals, in whom FET was apparently inherited as a dominant trait. The scan, which was performed with a 10-cM framework map, revealed one locus on chromosome 3q13 to which FET mapped with a genome-wide significance when the data were analysed either parametrically, assuming an autosomal dominant model (Iod score = 3.71), or non-parametrically (NPL Z score = 4.70. P < 6.4 x 10(6)).	DECODE GENET, IS-110 REYKJAVIK, ICELAND; UNIV CHICAGO, DEPT STAT, CHICAGO, IL 60637 USA; REYKJAVIK HOSP, DEPT NEUROL, IS-108 REYKJAVIK, ICELAND; NATL HOSP ICELAND, DEPT NEUROL, IS-101 REYKJAVIK, ICELAND	University of Chicago; Landspitali National University Hospital; Landspitali National University Hospital			Stefansson, Kari/AAE-7187-2019	Stefansson, Hreinn/0000-0002-9331-6666				BAIN PG, 1993, J NEUROL, V241, P54, DOI 10.1007/BF00870673; BAIN PG, 1993, J NEUROL NEUROSUR PS, V56, P868, DOI 10.1136/jnnp.56.8.868; BAIN PG, 1994, BRAIN, V117, P805, DOI 10.1093/brain/117.4.805; Baloh RW, 1996, NEUROLOGY, V46, P458, DOI 10.1212/WNL.46.2.458; Boecker H, 1996, ANN NEUROL, V39, P650, DOI 10.1002/ana.410390515; BRITTON TC, 1994, BRAIN, V117, P39, DOI 10.1093/brain/117.1.39; BUSENBARK KL, 1991, NEUROLOGY, V41, P1982, DOI 10.1212/WNL.41.12.1982; CONWAY D, 1993, MOVEMENT DISORD, V8, P374, DOI 10.1002/mds.870080324; CRITCHLEY M, 1949, BRAIN, V72, P113, DOI 10.1093/brain/72.2.113; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DURR A, 1993, NEUROLOGY, V43, P2212, DOI 10.1212/WNL.43.11.2212; FINDLEY LJ, 1994, HDB TREMOR DISORDERS, P1; HERSKOVI.E, 1969, J NEUROL NEUROSUR PS, V32, P509, DOI 10.1136/jnnp.32.6.509; Im JH, 1996, CLIN NEUROL NEUROSUR, V98, P40, DOI 10.1016/0303-8467(95)00080-1; Jankovic J, 1997, ARCH NEUROL-CHICAGO, V54, P289, DOI 10.1001/archneur.1997.00550150047015; JANKOVIC J, 1995, NEUROLOGY, V45, P645, DOI 10.1212/WNL.45.4.645; JENKINS IH, 1993, ANN NEUROL, V34, P82, DOI 10.1002/ana.410340115; KOLLER WC, 1992, CLIN NEUROPHARMACOL, V15, P81, DOI 10.1097/00002826-199204000-00001; KOLLER WC, 1994, ANN NEUROL, V35, P717, DOI 10.1002/ana.410350613; KOLLER WC, 1989, NEUROLOGY, V39, P1587, DOI 10.1212/WNL.39.12.1587; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LOU JS, 1991, NEUROLOGY, V41, P234, DOI 10.1212/WNL.41.2_Part_1.234; Louis ED, 1996, NEUROLOGY, V46, P1200, DOI 10.1212/WNL.46.5.1200; LOUIS ED, 1995, ARCH NEUROL-CHICAGO, V52, P1201, DOI 10.1001/archneur.1995.00540360079019; RAJPUT AH, 1984, J NEUROL NEUROSUR PS, V47, P466, DOI 10.1136/jnnp.47.5.466; SALEMI G, 1994, NEUROLOGY, V44, P61, DOI 10.1212/WNL.44.1.61; SASSO E, 1990, CLIN NEUROPHARMACOL, V13, P67, DOI 10.1097/00002826-199002000-00007; WHITTEMORE AS, 1994, BIOMETRICS, V50, P118, DOI 10.2307/2533202; WILLS AJ, 1994, ANN NEUROL, V36, P636, DOI 10.1002/ana.410360413	30	192	206	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1997	17	1					84	87		10.1038/ng0997-84	http://dx.doi.org/10.1038/ng0997-84			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288103				2022-12-25	WOS:A1997XU72400023
J	Lang, SM; Iafrate, AJ; StahlHennig, C; Kuhn, EM; Nisslein, T; Kaup, FJ; Haupt, M; Hunsmann, G; Skowronski, J; Kirchhoff, F				Lang, SM; Iafrate, AJ; StahlHennig, C; Kuhn, EM; Nisslein, T; Kaup, FJ; Haupt, M; Hunsmann, G; Skowronski, J; Kirchhoff, F			Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques	NATURE MEDICINE			English	Article							CD4 DOWN-REGULATION; TYPE-1 NEF; T-CELLS; GENE; HIV-1; REPLICATION; LYMPHOCYTES; INFECTION; INDUCTION; PROTEIN	The nef gene of simian immunodeficiency virus (SIV) is essential for high viral load and induction of AIDS in rhesus monkeys. A mutant form of the SIVmac239 Nef, which contains changes in a putative SH3-binding domain (amino acids 104 and 107 have been changed from PxxP to AxxA), does not associate with cellular serine/threonine kinases, but is fully active in CD4 downregulation and associates with the cellular tyrosine kinase Src. Infection of two rhesus macaques with SIVmac239 containing the mutant AxxA-Nef caused AIDS and rapid death in both animals. No reversions were observed in the majority of nef sequences analyzed from different time points during infection and from lymphatic tissues at the time of death. Our findings indicate that the putative SH3-ligand domain in SIVmac Nef and the association with cellular serine/threonine kinases are not important for efficient replication and pathogenicity of SIVmac in rhesus macaques.	UNIV ERLANGEN NURNBERG,INST CLIN & MOL VIROL,D-91054 ERLANGEN,GERMANY; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; GERMAN PRIMATE CTR,D-37077 GOTTINGEN,GERMANY	University of Erlangen Nuremberg; Cold Spring Harbor Laboratory; Deutsches Primatenzentrum (DPZ)			Kirchhoff, Frank/O-8367-2018	Kirchhoff, Frank/0000-0002-7052-2360	PHS HHS [IA-35394] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; CHACKERIAN B, 1995, VIROLOGY, V213, P386, DOI 10.1006/viro.1995.0011; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KIRCHHOFF F, 1994, J VIROL, V68, P2031, DOI 10.1128/JVI.68.3.2031-2037.1994; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; Luo TC, 1996, J VIROL, V70, P6493, DOI 10.1128/JVI.70.9.6493-6496.1996; MARIANI R, 1993, P NATL ACAD SCI USA, V90, P5549, DOI 10.1073/pnas.90.12.5549; Mariani R, 1996, J VIROL, V70, P7752, DOI 10.1128/JVI.70.11.7752-7764.1996; MICHAEL NL, 1995, J VIROL, V69, P6758, DOI 10.1128/JVI.69.11.6758-6769.1995; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MYERS G, 1993, HUMAN RETROVIRUSES A; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; POTTS BJ, 1990, TECHNIQUES HIV RES, P103; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SKOWRONSKI J, 1995, HIV 1 PRACTICAL APPR, P231; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996	40	83	83	1	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					860	865		10.1038/nm0897-860	http://dx.doi.org/10.1038/nm0897-860			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256276				2022-12-25	WOS:A1997XP01400027
J	Westphal, CH; Rowan, S; Schmaltz, C; Elson, A; Fisher, DE; Leder, P				Westphal, CH; Rowan, S; Schmaltz, C; Elson, A; Fisher, DE; Leder, P			atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity	NATURE GENETICS			English	Article							CYCLE CHECKPOINT PATHWAY; ATAXIA-TELANGIECTASIA; CELLULAR-RESPONSES; CANCER-THERAPY; DNA-DAMAGE; MICE; INSTABILITY; GENE	Mutations in atm and p53 cause the human cancer-associated diseases ataxia-telangiectasia(1) and Li-Fraumeni syndrome(2,3), respectively. The two genes are believed to interact in a number of pathways(4-6), including regulation of DNA damage-induced cell-cycle checkpoints(7), apoptosis and radiation sensitivity(8), and cellular proliferation(9). Atm-null mice(10-12), as well as those null for p53(13,14), develop mainly T-cell lymphomas, supporting the view that these genes have similar roles in thymocyte development. To study the interactions of these two genes on an organismal level, we bred mice heterozygous for null alleles of both atm and p53 to produce all genotypic combinations. Mice doubly null for atm and p53 exhibited a dramatic acceleration of tumour formation relative to singly null mice, indicating that both genes collaborate in a significant manner to prevent tumorigenesis. With respect to their roles in apoptosis, loss of atm rendered thymocytes only partly resistant to irradiation-induced apoptosis, whereas additional loss of p53 engendered complete resistance. This implies that the irradiation-induced atm and p53 apoptotic pathways are not completely congruent. Finally-and in contrast to prior predictions(4,6)-atm and p53 do not appear to interact in acute radiation toxicity, suggesting a separate atm effector pathway for this DNA damage response and having implications for the prognosis and treatment of human tumours.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT HEMATOL ONCOL,BOSTON,MA 02115; CHILDRENS HOSP BOSTON,BOSTON,MA 02115; WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Weizmann Institute of Science			Rowan, Sheldon/AAA-3271-2019	Rowan, Sheldon/0000-0002-1123-6743; Elson, Ari/0000-0001-9808-9135	NATIONAL CANCER INSTITUTE [R01CA069531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER; NCI NIH HHS [CA69531] Funding Source: Medline; NIAMS NIH HHS [AR43369] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; CANMAN CE, 1994, CANCER RES, V54, P5054; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CUNLIFFE PN, 1975, BRIT J RADIOL, V48, P374, DOI 10.1259/0007-1285-48-569-374; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MEYN MS, 1995, CANCER RES, V55, P5991; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Westphal CH, 1997, CANCER RES, V57, P1664; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401	28	194	198	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					397	401		10.1038/ng0897-397	http://dx.doi.org/10.1038/ng0897-397			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241281				2022-12-25	WOS:A1997XM90900026
J	Berard, AM; Foger, B; Remaley, A; Shamburek, R; Vaisman, BL; Talley, G; Paigen, B; Hoyt, RF; Marcovina, S; Brewer, HB; SantamarinaFojo, S				Berard, AM; Foger, B; Remaley, A; Shamburek, R; Vaisman, BL; Talley, G; Paigen, B; Hoyt, RF; Marcovina, S; Brewer, HB; SantamarinaFojo, S			High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase	NATURE MEDICINE			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; ESTER TRANSFER PROTEIN; CORONARY ATHEROSCLEROSIS; OXIDATIVE MODIFICATION; HUMAN SERUM; ESTERIFICATION; EXPRESSION; DISEASE; LESIONS	A subset of patients with high plasma HDL concentrations have enhanced rather than reduced atherosclerosis. We have developed a new transgenic mouse model overexpressing human lecithin-cholesteryl acyltransferase (LCAT) that has elevated HDL and increased diet-induced atherosclerosis. LCAT transgenic mouse HDLs are abnormal in both composition and function. Liver uptake of [H-3]cholesteryl ether incorporated in transgenic mouse HDL was reduced by 41% compared with control HDL, indicating ineffective transport of HDL-cholesterol to the liver and impaired reverse cholesterol transport. Analysis of this LCAT-transgenic mouse model provides in vivo evidence for dysfunctional HDL as a potential mechanism leading to increased atherosclerosis in the presence of high plasma HDL levels.	NHLBI, MOL DIS BRANCH, NIH, BETHESDA, MD 20892 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA; NHLBI, LAB ANIM MED & SURG, NIH, BETHESDA, MD 20892 USA; UNIV WASHINGTON, NW LIPID RES LABS, SEATTLE, WA 98103 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Jackson Laboratory; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Washington; University of Washington Seattle			Vaisman, Boris L/B-3453-2008		NHLBI NIH HHS [HL 32087, HL 30086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032087, P01HL030086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAUPOVIC P, 1984, CLIN METABOLIC ASPEC, P1; ALBERS JJ, 1981, J CLIN INVEST, V67, P141, DOI 10.1172/JCI110006; BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; BURSTEIN M, 1970, J LIPID RES, V11, P583; CHEN CH, 1982, J LIPID RES, V23, P680; DELALLERAMOYA M, 1994, ARTERIOSCLER THROMB, V14, P1056, DOI 10.1161/01.ATV.14.7.1056; DUGI KA, IN PRESS J LIPID RES; DUVERGER N, 1993, BIOCHEMISTRY-US, V32, P12372, DOI 10.1021/bi00097a014; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FRUCHART JC, 1992, CLIN CHEM, V38, P793; GLOMSET JA, 1968, J LIPID RES, V9, P155; GLOMSET JA, 1995, METABOLIC MOL BASES; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HIRANO K, 1995, ARTERIOSCL THROM VAS, V15, P1849, DOI 10.1161/01.ATV.15.11.1849; HOEG JM, 1996, P NATL ACAD SCI USA, V271, P4396; HUANG YD, 1995, ARTERIOSCL THROM VAS, V15, P1412, DOI 10.1161/01.ATV.15.9.1412; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KLEIN HG, 1995, J BIOL CHEM, V270, P9443, DOI 10.1074/jbc.270.16.9443; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MARZETTA CA, 1993, ARTERIOSCLER THROMB, V13, P834, DOI 10.1161/01.ATV.13.6.834; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MORTON RE, 1981, J BIOL CHEM, V256, P1992; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; RADER DJ, 1993, LANCET, V342, P1455, DOI 10.1016/0140-6736(93)92933-K; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SAKAI N, 1995, CIRCULATION S, V92; SAKU K, 1985, THROMB RES, V39, P1, DOI 10.1016/0049-3848(85)90116-1; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; TALL AR, 1993, J LIPID RES, V34, P1255; TERPSTRA AHM, 1988, FRESEN Z ANAL CHEM, V330, P149, DOI 10.1007/BF00470729; Tollefson J H, 1986, Methods Enzymol, V129, P797; VAISMAN BL, 1995, J BIOL CHEM, V270, P12269, DOI 10.1074/jbc.270.20.12269; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751	45	181	190	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					744	749		10.1038/nm0797-744	http://dx.doi.org/10.1038/nm0797-744			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212100				2022-12-25	WOS:A1997XG76700033
J	Indolfi, C; Avvedimento, EV; DiLorenzo, E; Esposito, G; Rapacciuolo, A; Giuliano, P; Grieco, D; Cavuto, L; Stingone, AM; Ciullo, I; Condorelli, G; Chiarello, M				Indolfi, C; Avvedimento, EV; DiLorenzo, E; Esposito, G; Rapacciuolo, A; Giuliano, P; Grieco, D; Cavuto, L; Stingone, AM; Ciullo, I; Condorelli, G; Chiarello, M			Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury	NATURE MEDICINE			English	Article							SUCCESSFUL CORONARY ANGIOPLASTY; CYCLIC-AMP; BALLOON ANGIOPLASTY; ARTERIAL INJURY; RAT MODEL; RESTENOSIS; GROWTH; DIFFERENTIATION; PERSPECTIVE; MECHANISMS	Injury of the arterial wall induces the formation of the neointima(1). This structure is generated by the growth of mitogenically activated smooth muscle cells of the arterial wall(2-5). The molecular mechanism underlying the formation of the neointima involves deregulated cell growth, primarily triggered by the injury of the arterial wall(6-9). The activated gene products transmitting the injury-induced mitogenic stimuli have been identified and inhibited by several means: transdominant negative expression vectors, antisense oligodeoxynucleotides, adenovirus-mediated gene transfer, antibodies and inactivating drugs(8,10-12). Results of our study show that local administration of 3',5'-cyclic AMP and phosphodiesterase-inhibitor drugs (aminophylline and amrinone) to rats markedly inhibits neointima formation after balloon injury in vivo and in smooth muscle cells in vitro. The growth inhibitory effect of aminophylline was completely reversed by the inhibition of cAMP-dependent protein kinase A (PKA). These findings indicate an alternative approach to the treatment of diseases associated with injury-induced cell growth of the arterial wall, as stimulation of cAMP signaling is pharmacologically feasible in the clinical setting.	UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOL & PATOL MOL & CELLULARE, I-80131 NAPLES, ITALY; FAC MED & CHIRURG, DIPARTIMENTO MED SPERIMENTALE CLIN, I-88100 CATANZARO, ITALY; JEFFERSON MED COLL, KIMMEL CANC INST, PHILADELPHIA, PA 19107 USA	University of Naples Federico II; Jefferson University	Indolfi, C (corresponding author), UNIV NAPLES FEDERICO II, CATTEDRA CARDIOL, VIA S PANSINI 5, I-80131 NAPLES, ITALY.		Rapacciuolo, Antonio/AAR-8012-2020; Esposito, Giovanni/F-2880-2010; Condorelli, Gianluigi/Q-6736-2017	Rapacciuolo, Antonio/0000-0002-4739-7004; Esposito, Giovanni/0000-0003-0565-7127; Condorelli, Gianluigi/0000-0003-0481-6843; GRIECO, Domenico/0000-0002-7131-5742; INDOLFI, Ciro/0000-0003-1241-6487				ASSENDER JW, 1992, BIOCHEM J, V288, P527, DOI 10.1042/bj2880527; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; CHANG MW, 1995, MOL MED, V1, P172, DOI 10.1007/BF03401565; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1983, LAB INVEST, V49, P208; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; GUITERAS VP, 1987, AM J CARDIOL S, V60, pB50; HERRMAN JPR, 1993, DRUGS, V46, P249, DOI 10.2165/00003495-199346020-00003; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; INDOLFI C, 1995, CIRCULATION, V92, P1230, DOI 10.1161/01.CIR.92.5.1230; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; Indolfi C, 1996, NAT MED, V2, P634, DOI 10.1038/nm0696-634; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Koumi S, 1995, J CLIN INVEST, V96, P2870, DOI 10.1172/JCI118358; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Laird JR, 1996, CIRCULATION, V93, P529, DOI 10.1161/01.CIR.93.3.529; LEIMGRUBER PP, 1986, CIRCULATION, V73, P710, DOI 10.1161/01.CIR.73.4.710; MCBRIDE W, 1988, NEW ENGL J MED, V318, P1734, DOI 10.1056/NEJM198806303182606; MITSUZAWA H, 1994, MOL GEN GENET, V243, P158, DOI 10.1007/BF00280312; *MULT EUR RES TRIA, 1991, CIRCULATION, V86, P100; NUNES GL, 1995, CIRCULATION, V92, P1697, DOI 10.1161/01.CIR.92.7.1697; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; VIRMANI R, 1994, AM HEART J, V127, P163, DOI 10.1016/0002-8703(94)90522-3; WILKINSON L, 1988, SYSTAT SYSTEM STAT; YOKOZAKI H, 1992, CANCER RES, V52, P2504; 1995, GOODMANS GILMANS PHA	42	169	169	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					775	779		10.1038/nm0797-775	http://dx.doi.org/10.1038/nm0797-775			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212106				2022-12-25	WOS:A1997XG76700039
J	Muramoto, T; DeArmond, SJ; Scott, M; Telling, GC; Cohen, FE; Prusiner, SB				Muramoto, T; DeArmond, SJ; Scott, M; Telling, GC; Cohen, FE; Prusiner, SB			Heritable disorder resembling neuronal storage disease in mice expressing prion protein with deletion of an alpha-helix	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; TRANSGENIC MICE; CULTURED-CELLS; TRANSMISSION; CONVERSION; FEATURES; RODENTS; ISOFORM; PLAQUES; SYSTEM	Mice were constructed carrying prion protein (PrP) transgenes with individual regions of putative secondary structure deleted. Transgenic mice with amino-terminal regions deleted remained healthy at >400 days of age, whereas those with either of carboxy-terminal alpha-helices deleted spontaneously developed fatal CNS illnesses similar to neuronal storage diseases. Deletion of either C-terminal helix resulted in PrP accumulation within cytoplasmic inclusions in enlarged neurons. Deletion of the penultimate C-terminal helix resulted in proliferation of rough endoplasmic reticulum. Mice with the C-terminal helix deleted were affected with nerve cell loss in the hippocampus and proliferation of smooth endoplasmic reticulum. Whether children with the human counterpart of this malady will be found remains to be determined.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805	NIA NIH HHS [AG 08967, AG 02132] Funding Source: Medline; NINDS NIH HHS [NS 14069] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014069, P50NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008967, P01AG002132] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bamborough P, 1996, COLD SPRING HARB SYM, V61, P495; BARRY RA, 1986, J INFECT DIS, V154, P518, DOI 10.1093/infdis/154.3.518; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HOLMAN RC, 1995, NEUROEPIDEMIOLOGY, V14, P174, DOI 10.1159/000109793; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; Phillips MJ., 1987, LIVER ATLAS TEXT ULT; PRUSINER SB, 1996, FIELDS VIROLOGY, P2901; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; ROGERS M, 1991, J IMMUNOL, V147, P3568; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	40	106	107	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					750	755		10.1038/nm0797-750	http://dx.doi.org/10.1038/nm0797-750			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212101				2022-12-25	WOS:A1997XG76700034
J	Small, K; Iber, J; Warren, ST				Small, K; Iber, J; Warren, ST			Emerin deletion reveals a common X-chromosome inversion mediated by inverted repeats	NATURE GENETICS			English	Article							FACTOR-VIII GENE; DREIFUSS MUSCULAR-DYSTROPHY; SEVERE HEMOPHILIA-A; NONHOMOLOGOUS RECOMBINATION; PERICENTRIC-INVERSION; COLOR-VISION; HUMAN GENOME; XQ28; IDENTIFICATION; CELLS	Emery-Dreifuss muscular dystrophy (EMD) is an X-linked disorder characterized by contractures, progressive muscle weakness and cardiomyopathy(1-3). The emerin gene, located in human Xq28, is approximately 2 kb in length, is composed of 6 exons and falls within a 219-kb region that has been completely sequenced(4-6). Immediately centromeric to emerin is the 26-kb filamin gene (FLN1), composed of 48 exons and encoding the actin-binding protein 280 (refs 7,8). Flanking this 48-kb FLN1/emerin region are two large inverted repeats, each 11.3 kb, that exhibit >99% sequence identity(6). The high level of genomic detail in this region allowed us to characterize the first complete emerin gene deletion mutation that also involved a partial duplication of the nearby FLN1 gene, This rearrangement could be explained by mispairing of the large inverted repeats, followed by double recombination among one set of mispaired repeats and internal sequences. Furthermore, our characterization of this rare DNA rearrangement revealed a more common result of the mispairing of these large inverted repeats - recombination contained within the inverted repeats leading to the maintenance of repeat sequence homogeneity and inversion of the 48-kb FLN1/emerin region. The presence of this frequent inversion, found in the heterozygous state in 33% of females, helps to explain the discrepancies observed between the genetic and physical map distances in this region of the X chromosome. It also illustrates the biological insights which can be gleaned by sequencing the human genome.	HOWARD HUGHES MED INST,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT GENET,ATLANTA,GA 30322	Howard Hughes Medical Institute; Emory University; Emory University; Emory University			Warren, Stephen T/A-2498-2012					ASHLEY T, 1993, CHROMOSOMA, V102, P112, DOI 10.1007/BF00356028; BIONE S, 1995, HUM MOL GENET, V4, P1859; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Chen EY, 1996, HUM MOL GENET, V5, P659, DOI 10.1093/hmg/5.5.659; COYNE JA, 1991, GENETICS, V129, P791; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DRESSER ME, 1994, GENETICS, V138, P633; EMERY AEH, 1989, J MED GENET, V26, P637, DOI 10.1136/jmg.26.10.637; FILOSA S, 1993, GENOMICS, V17, P6, DOI 10.1006/geno.1993.1276; GORLIN JB, 1993, GENOMICS, V17, P496, DOI 10.1006/geno.1993.1354; HOPKINS LC, 1993, HDB CLIN NEUROBIOLOG, P145; KING M, 1992, HEREDITY, V68, P437, DOI 10.1038/hdy.1992.63; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; Mckusick V.A., 1994, MENDELIAN INHERITANC; NAYLOR JA, 1995, HUM MOL GENET, V4, P1217, DOI 10.1093/hmg/4.7.1217; PARRISH JE, 1995, HUM MOL GENET, V4, P1557, DOI 10.1093/hmg/4.9.1557; PATROSSO MC, 1994, GENOMICS, V21, P71, DOI 10.1006/geno.1994.1226; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; ROGNER UC, 1994, HUM MOL GENET, V3, P2137, DOI 10.1093/hmg/3.12.2137; ROSSITER JP, 1994, HUM MOL GENET, V3, P1035, DOI 10.1093/hmg/3.7.1035; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; SASHI V, 1996, AM J HUM GENET, V58, P1231; WANG LH, 1994, GENOMICS, V22, P590, DOI 10.1006/geno.1994.1432; WILLARD HF, 1994, CYTOGENET CELL GENET, V67, P296; WOODSSAMUELS P, 1991, GENOMICS, V10, P94, DOI 10.1016/0888-7543(91)90489-2; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q; ZETKA MC, 1992, GENETICS, V131, P321	28	109	113	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	MAY	1997	16	1					96	99		10.1038/ng0597-96	http://dx.doi.org/10.1038/ng0597-96			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140403				2022-12-25	WOS:A1997WX02400030
J	Rappuoli, R				Rappuoli, R			Rational design of vaccines	NATURE MEDICINE			English	Editorial Material							MUTANTS				Rappuoli, R (corresponding author), CHIRON VACCINES, VIA FIORENTINA 1, I-53100 SIENA, ITALY.							DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; EDWARDS KM, 1995, PEDIATRICS, V96, P548; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; GRECO D, 1996, INT C INFECT DIS; Greco Donato, 1996, Pediatric Research, V39, p173A; Hewlett EL, 1996, PEDIATRICS, V98, P800; Ibsen PH, 1996, VACCINE, V14, P359, DOI 10.1016/0264-410X(95)00230-X; NOSSAL GJV, 1990, UCLA SYM BI, V113, P309; PIZZA M, 1994, J EXP MED, V180, P2147, DOI 10.1084/jem.180.6.2147; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; Ramon G, 1924, ANN I PASTEUR PARIS, V38, P1	11	37	41	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					374	376		10.1038/nm0497-374	http://dx.doi.org/10.1038/nm0497-374			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095163				2022-12-25	WOS:A1997WQ82500019
J	Pugliese, A; Zeller, M; Fernandez, A; Zalcberg, LJ; Bartlett, RJ; Ricordi, C; Pietropaolo, M; Eisenbarth, GS; Bennett, ST; Patel, DD				Pugliese, A; Zeller, M; Fernandez, A; Zalcberg, LJ; Bartlett, RJ; Ricordi, C; Pietropaolo, M; Eisenbarth, GS; Bennett, ST; Patel, DD			The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes	NATURE GENETICS			English	Article							MOLECULAR-CLONING; II GENE; REGION; AUTOANTIBODIES; EXPRESSION; PROINSULIN; MELLITUS; IDDM; MINISATELLITE; AUTOANTIGEN	Type 1, or insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease associated with loss of tolerance to several pancreatic islet cell molecules, including insulin, glutamic acid decarboxylase (CAD), ICA69 and the tyrosine phosphatase IA-2 (refs 1-3). Among several predisposing loci, IDDM2 maps to the insulin gene (INS) VNTR (variable number of tandem repeats) minisatellite on chromosome 11p15 (refs 4-9). Allelic variation at this VNTR locus correlates with steady-state levels of INS mRNA in pancreas(8,10,11) and transfected rodent cell lines(12-14), but it is difficult to reconcile the association of lower INS mRNA levels in the pancreas with class III VNTRs that are dominantly protective from IDDM(8,15). We show that during fetal development and childhood, mRNAs for insulin and other islet cell autoantigens (GAD, ICA69, IA-2) are expressed at low levels in the human thymus. Critically, we also detect proinsulin and insulin protein. VNTR alleles correlate with differential INS mRNA expression in the thymus where, in contrast to the pancreas, protective class III VNTRs are associated with higher steady-state levels of INS mRNA expression. This finding provides a plausible explanation for the dominant protective effect of class III VNTRs, and suggests that diabetes susceptibility and resistance associated with IDDM2 may derive from the VNTR influence on INS transcription in the thymus. Higher levels of (pro)insulin in the thymus may promote negative selection (deletion) of insulin-specific T-lymphocytes which play a critical role in the pathogenesis of type-1 diabetes.	UNIV PITTSBURGH, CHILDRENS HOSP, DIV IMMUNOGENET, PITTSBURGH, PA 15260 USA; UNIV COLORADO, HLTH SCI CTR, BARBARA DAVIS CTR CHILDHOOD DIABET, DENVER, CO 80262 USA; UNIV OXFORD, NUFFIELD DEPT SURG, WELLCOME TRUST CTR HUMAN GENET, OXFORD, ENGLAND; DUKE UNIV, MED CTR, DEPT MED & IMMUNOL, DURHAM, NC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Oxford; Wellcome Centre for Human Genetics; Duke University	Pugliese, A (corresponding author), UNIV MIAMI, SCH MED, DIABET RES INST, MIAMI, FL USA.		RICORDI, CAMILLO/AAA-4740-2019	Ricordi, Camillo/0000-0001-8092-7153	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U24HD033199] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-3-3199] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; Bennett ST, 1996, J AUTOIMMUN, V9, P415, DOI 10.1006/jaut.1996.0057; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Bui MM, 1996, J AUTOIMMUN, V9, P97, DOI 10.1006/jaut.1996.0012; CASTANO L, 1993, DIABETES, V42, P1202, DOI 10.2337/diabetes.42.8.1202; DEVASKAR SU, 1993, REGUL PEPTIDES, V48, P55, DOI 10.1016/0167-0115(93)90335-6; French MB, 1997, DIABETES, V46, P34, DOI 10.2337/diabetes.46.1.34; GRIFFIN AC, 1995, AM J PATHOL, V147, P845; Hoffman A.R., 1996, SCI AM, V1, P52; JOLICOEUR C, 1994, P NATL ACAD SCI USA, V91, P6707, DOI 10.1073/pnas.91.14.6707; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; KEILACKER H, 1995, HORM METAB RES, V27, P90, DOI 10.1055/s-2007-979915; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KUGLIN B, 1988, DIABETES, V37, P130, DOI 10.2337/diabetes.37.1.130; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; Mally MI, 1996, DIABETOLOGIA, V39, P474, DOI 10.1007/s001250050468; OEHEN SU, 1994, CELL IMMUNOL, V158, P342, DOI 10.1006/cimm.1994.1281; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; Owerbach D, 1996, DIABETES, V45, P544, DOI 10.2337/diabetes.45.5.544; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; POLYCHRONAKOS C, 1995, DIABETOLOGIA, V38, P715, DOI 10.1007/s001250050343; PUGLIESE A, 1994, J AUTOIMMUN, V7, P687, DOI 10.1006/jaut.1994.1053; RABIN DU, 1994, J IMMUNOL, V152, P3183; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; UNDLIEN DE, 1995, DIABETES, V44, P620, DOI 10.2337/diabetes.44.6.620; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Vafiadis P, 1996, J AUTOIMMUN, V9, P397, DOI 10.1006/jaut.1996.0054; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542	34	725	744	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					293	297		10.1038/ng0397-293	http://dx.doi.org/10.1038/ng0397-293			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054945				2022-12-25	WOS:A1997WK38600022
J	Volschenk, H; Viljoen, M; Grobler, J; Petzold, B; Bauer, F; Subden, RE; Young, RA; Lonvaud, A; Denayrolles, M; vanVuuren, HJJ				Volschenk, H; Viljoen, M; Grobler, J; Petzold, B; Bauer, F; Subden, RE; Young, RA; Lonvaud, A; Denayrolles, M; vanVuuren, HJJ			Engineering pathways for malate degradation in Saccharomyces cerevisiae	NATURE BIOTECHNOLOGY			English	Article						wine; malate; malolactic enzyme; malic enzyme; malate permease	MALOLACTIC FERMENTATION; ESCHERICHIA-COLI; SCHIZOSACCHAROMYCES-POMBE; SHUTTLE VECTORS; MALIC ENZYME; HOST STRAINS; CLONING; GENE; WINE; DEACIDIFICATION	Deacidification of grape musts is crucial for the production of well-balanced wines, especially in colder regions of the world. The major acids in wine are tartaric and malic acid. Saccharomyces cerevisiae cannot degrade malic acid efficiently due to the lack of a malate transporter and the low substrate affinity of its malic enzyme, We have introduced efficient pathways for malate degradation in S. cerevisiae by cloning and expressing the Schizosaccharomyces pombe malate permease (mae1) gene with either the S. pombe malic enzyme (mae2) or Lactococcus lactis malolactic (mleS) gene in this yeast, Under aerobic conditions, the recombinant strain expressing the mae1 and mae2 genes efficiently degraded 8 g/L of malate in a glycerol-ethanol medium within 7 days. The recombinant malolactic strain of S. cerevisiae (mae1 and mleS genes) fermented 4.5 g/L of malate in a synthetic grape must within 4 days.	UNIV STELLENBOSCH,DEPT MICROBIOL,ZA-7600 STELLENBOSCH,SOUTH AFRICA; UNIV STELLENBOSCH,INST BIOTECHNOL,ZA-7600 STELLENBOSCH,SOUTH AFRICA; UNIV GUELPH,DEPT MOL BIOL & GENET,GUELPH,ON N1G 2W1,CANADA; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; UNIV BORDEAUX 2,FAC OENOL,F-33405 TALENCE,FRANCE	Stellenbosch University; Stellenbosch University; University of Guelph; Massachusetts Institute of Technology (MIT); Whitehead Institute; UDICE-French Research Universities; Universite de Bordeaux			Bauer, Florian/A-1078-2013; Young, Richard A/F-6495-2012; Volschenk, Heinrich/L-8400-2015	Bauer, Florian/0000-0001-5764-4542; Young, Richard A/0000-0001-8855-8647; Volschenk, Heinrich/0000-0001-9287-0975; Viljoen-Bloom, Marinda/0000-0002-4825-2392; Lonvaud, Aline/0000-0002-9352-3366				Ansanay V, 1996, YEAST, V12, P215, DOI 10.1002/(SICI)1097-0061(19960315)12:3<215::AID-YEA903>3.0.CO;2-M; ANSANAY V, 1993, FEBS LETT, V332, P74, DOI 10.1016/0014-5793(93)80488-G; ARTUS NN, 1985, FEBS LETT, V182, P225, DOI 10.1016/0014-5793(85)80305-7; Beelman R. B., 1979, Advances in Food Research, V25, P1, DOI 10.1016/S0065-2628(08)60234-7; CHIRIO MC, 1990, EUR J BIOCHEM, V194, P293, DOI 10.1111/j.1432-1033.1990.tb19456.x; CROUS JM, 1995, CURR GENET, V28, P467, DOI 10.1007/BF00310817; DAVIS CR, 1985, AM J ENOL VITICULT, V36, P290; DENAYROLLES M, 1995, FEMS MICROBIOL LETT, V125, P3744; FUCK E, 1973, ARCH MIKROBIOL, V89, P223, DOI 10.1007/BF00422202; GALLANDER JF, 1977, AM J ENOL VITICULT, V28, P65; GAO C, 1995, FOOD MICROBIOL, V12, P65, DOI 10.1016/S0740-0020(95)80080-8; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Grobler J, 1995, YEAST, V11, P1485, DOI 10.1002/yea.320111503; HENICKKLING T, 1995, J APPL BACTERIOL, V79, pS29; KUNKEE RE, 1968, WINES VINES, V49, P23; LAING E, 1992, GENE, V121, P35, DOI 10.1016/0378-1119(92)90159-M; MACONI E, 1984, BIOCHEM J, V217, P685; MARTINEAU B, 1995, AM J ENOL VITICULT, V46, P385; MAYER K, 1963, ARCH MIKROBIOL, V46, P321, DOI 10.1007/BF00422193; Moore DD, 1995, GLOB MOB SURV; MURAI T, 1972, J BIOCHEM, V71, P1015, DOI 10.1093/oxfordjournals.jbchem.a129850; Radler F., 1993, WINE MICROBIOLOGY BI, VFleet, P165; Sambrook J., 2002, MOL CLONING LAB MANU; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TEMPERLI A, 1965, BIOCHIM BIOPHYS ACTA, V110, P630, DOI 10.1016/S0926-6593(65)80080-7; VANVUUREN HJJ, 1993, AM J ENOL VITICULT, V44, P99; VILJOEN M, 1994, YEAST, V10, P613, DOI 10.1002/yea.320100506; WILLIAMS SA, 1984, APPL ENVIRON MICROB, V47, P288, DOI 10.1128/AEM.47.2.288-293.1984; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	30	98	111	3	30	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					253	257		10.1038/nbt0397-253	http://dx.doi.org/10.1038/nbt0397-253			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062925				2022-12-25	WOS:A1997WM05000029
J	Humphries, MM; Rancourt, D; Farrar, GJ; Kenna, P; Hazel, M; Bush, RA; Sieving, PA; Sheils, DM; McNally, N; Creighton, P; Erven, A; Boros, A; Gulya, K; Capecchi, MR; Humphries, P				Humphries, MM; Rancourt, D; Farrar, GJ; Kenna, P; Hazel, M; Bush, RA; Sieving, PA; Sheils, DM; McNally, N; Creighton, P; Erven, A; Boros, A; Gulya, K; Capecchi, MR; Humphries, P			Retinopathy induced in mice by targeted disruption of the rhodopsin gene	NATURE GENETICS			English	Article							SCOTOPIC THRESHOLD RESPONSE; RETINITIS-PIGMENTOSA; B-WAVE; ELECTRORETINOGRAM; ROD; MUTATIONS; SUBUNIT; LIGHT; CELLS; CAT	Retinitis pigmentosa (RP) represents the most common mendelian degenerative retinopathy of man, involving death of rod photoreceptors, cone cell degeneration, retinal vessel attenuation and pigmentary deposits(1,2). The patient experiences night blindness, usually followed by progressive loss of visual field. Genetic linkage between an autosomal dominant RP locus and rhodopsin(3), the photoreactive pigment of the rod cells, led to the identification of mutations within the rhodopsin gene in both dominant and recessive forms of Rp(3-7). To better understand the functional and structural role of rhodopsin in the normal retina and in the pathogenesis of retinal disease, we generated mice carrying a targeted disruption of the rhodopsin gene. Rho(-/-) mice do not elaborate rod outer segments, losing their photoreceptors over 3 months. There is no rod ERG response in 8-week-old animals. Rho(+/-) animals retain the majority of their photoreceptors although the inner and outer segments of these cells display some structural disorganization, the outer segments becoming shorter in older mice. These animals should provide a useful genetic background on which to express other mutant opsin transgenes, as well as a model to assess the therapeutic potential of re-introducing functional rhodopsin genes into degenerating retinal tissues.	UNIV DUBLIN TRINITY COLL,DEPT GENET,WELLCOME OCULAR GENET UNIT,DUBLIN 2,IRELAND; ROYAL VICTORIAN EYE & EAR HOSP,RES FDN,DUBLIN 2,IRELAND; UNIV UTAH,MED CTR,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV MICHIGAN,KELLOGG EYE CTR,ANN ARBOR,MI 48109; ATTILA JOZSEF UNIV,DEPT ZOOL & CELL BIOL,H-6722 SZEGED,HUNGARY	Trinity College Dublin; Utah System of Higher Education; University of Utah; University of Michigan System; University of Michigan; Szeged University			Bateson, Jane Farrar/AAO-6147-2020; Gulya, Karoly/M-7629-2018; Farrar, G Jane/B-9832-2011	Gulya, Karoly/0000-0001-6864-4150; 				Aguilar M., 1954, OPT ACTA, V1, DOI [10.1080/713818657, DOI 10.1080/713818657]; BROWN KT, 1968, VISION RES, V8, P633, DOI 10.1016/0042-6989(68)90041-2; BUSH RA, 1995, INVEST OPHTH VIS SCI, V36, P2054; BUSH RA, 1992, CLIN VISION SCI, V7, P393; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; GREEN DG, 1994, VISUAL NEUROSCI, V11, P919, DOI 10.1017/S0952523800003874; Heckenlively JR, 1988, RETINITIS PIGMENTOSA, P125; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; MCWILLIAM P, 1989, GENOMICS, V5, P619, DOI 10.1016/0888-7543(89)90031-1; PAGON RA, 1988, SURV OPHTHALMOL, V33, P137, DOI 10.1016/0039-6257(88)90085-9; PEACHEY NS, 1993, NEUROSCI LETT, V162, P9, DOI 10.1016/0304-3940(93)90547-X; PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0; Sambrook J., 1989, MOL CLONING; SIEVING PA, 1986, J NEUROPHYSIOL, V56, P1049, DOI 10.1152/jn.1986.56.4.1049; SIEVING PA, 1988, INVEST OPHTH VIS SCI, V29, P1608; SIEVING PA, 1991, CLIN VISION SCI, V6, P171; SIEVING PA, 1994, VISUAL NEUROSCI, V11, P519, DOI 10.1017/S0952523800002431; STEINBERG RH, 1991, PROGR RETINAL RES, V10; STOCKTON RA, 1989, J GEN PHYSIOL, V93, P101, DOI 10.1085/jgp.93.1.101; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0	27	441	452	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					216	219		10.1038/ng0297-216	http://dx.doi.org/10.1038/ng0297-216			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020854				2022-12-25	WOS:A1997WF08700028
J	Ledda, MF; Adris, S; Bravo, AI; Kairiyama, C; Bover, L; Chernajovsky, Y; Mordoh, J; Podhajcer, OL				Ledda, MF; Adris, S; Bravo, AI; Kairiyama, C; Bover, L; Chernajovsky, Y; Mordoh, J; Podhajcer, OL			Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells	NATURE MEDICINE			English	Article							EXTRACELLULAR-MATRIX; CARCINOMA-CELLS; ENDOTHELIAL-CELLS; IV COLLAGENASE; BM-40 SPARC; BINDING; FIBRONECTIN; INVASION; LAMININ; PROTEIN	Acquisition of invasive/metastatic potential is a key event in tumor progression. Cell surface glycoproteins and their respective matrix ligands have been implicated in this process. Recent evidence reveals that the secreted glycoprotein SPARC (secreted protein, acidic and rich in cysteine) is highly expressed in different malignant tissues. The present study reports that the suppression of SPARC expression by human melanoma cells using a SPARC antisense expression vector results in a significant decrease in the in vitro adhesive and invasive capacities of tumor cells, completely abolishing their in vivo tumorigenicity. This is the first evidence that SPARC plays a key role in human melanoma invasive-metastatic phenotype development.	CONSEJO NACL INVEST CIENT & TECN, INST INVEST BIOQUIM BUENOS AIRES, INST INVEST BIOQUIM, RA-1405 BUENOS AIRES, DF, ARGENTINA; UNIV BUENOS AIRES, FAC CIENCIAS EXACTAS & NAT, RA-1428 BUENOS AIRES, DF, ARGENTINA; HOSP E PERON, RA-1650 BUENOS AIRES, DF, ARGENTINA; KENNEDY INST, LONDON W6 7DW, ENGLAND	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Oxford				podhajcer, osvaldo/0000-0002-6512-8553				AIBELDA SM, 1993, LAB INVEST, V68, P4; AOKI K, 1995, CANCER RES, V55, P3810; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; EVERITT EA, 1992, EXP CELL RES, V199, P134, DOI 10.1016/0014-4827(92)90471-J; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; Gilat D, 1996, IMMUNOL TODAY, V17, P16, DOI 10.1016/0167-5699(96)80563-9; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; KAMIHAGI K, 1994, BIOCHEM BIOPH RES CO, V200, P423, DOI 10.1006/bbrc.1994.1466; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KOCHEVAR GJ, 1992, CANCER, V69, P2311, DOI 10.1002/1097-0142(19920501)69:9<2311::AID-CNCR2820690918>3.0.CO;2-Q; LAIRD AD, 1994, CANCER RES, V54, P4224; LANE TF, 1992, J BIOL CHEM, V267, P16736; LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LEDDA F, IN PRESS J INVEST DE; MAURER P, 1992, EUR J BIOCHEM, V205, P233, DOI 10.1111/j.1432-1033.1992.tb16773.x; MERCOLA D, 1995, CANCER GENE THER, V2, P47; Mok SC, 1996, ONCOGENE, V12, P1895; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Podhajcer OL, 1996, BREAST, V5, P13, DOI 10.1016/S0960-9776(96)90044-2; PODHAJCER OL, 1995, J INVEST DERMATOL, V104, P340, DOI 10.1111/1523-1747.ep12665371; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; RAO JS, 1993, CANCER RES, V53, P2208; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SEFTOR REB, 1993, CANCER RES, V53, P3411; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; VIDMAR SL, 1991, EUR J BIOCHEM, V201, P71, DOI 10.1111/j.1432-1033.1991.tb16257.x; WEWER UM, 1987, CANCER RES, V47, P5691; YABKOWITZ R, 1993, CANCER RES, V53, P378	40	205	218	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1997	3	2					171	176		10.1038/nm0297-171	http://dx.doi.org/10.1038/nm0297-171			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018235				2022-12-25	WOS:A1997WF08800035
J	Malter, HE; Iber, JC; Willemsen, R; deGraaff, E; Tarleton, JC; Leisti, J; Warren, ST; Oostra, BA				Malter, HE; Iber, JC; Willemsen, R; deGraaff, E; Tarleton, JC; Leisti, J; Warren, ST; Oostra, BA			Characterization of the full fragile X syndrome mutation in fetal gametes	NATURE GENETICS			English	Article							CAG REPEAT LENGTH; MENTAL-RETARDATION; DNA METHYLATION; TRINUCLEOTIDE REPEAT; CGG REPEAT; ABNORMAL METHYLATION; HUNTINGTONS-DISEASE; FMR-1 GENE; GERM-CELLS; INSTABILITY	Fragile X syndrome results from the expansion of the CGG repeat in the FMR1 gene. Expansion has been suggested to be a postzygotic event with the germline protected. From an analysis of intact ovaries of full mutation fetuses, we now show that only full expansion alleles can be detected in oocytes (but in the unmethylated state). Similarly, the testes of a 13-week full mutation fetus show no evidence of premutations while a 17-week full mutation fetus exhibits some germ cells with attributes of premutations. These data discount the hypothesis that the germline is protected from full expansion and suggest full mutation contraction in the immature testis. Thus, full expansion may already exist in the maternal oocyte, or postzygotic expansion, if it occurs, arises quite early in development prior to germline segregation.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,NL-3000 DR ROTTERDAM,NETHERLANDS; GREENWOOD GENET CTR,GREENWOOD,SC 29646; UNIV OULU,OULU,FINLAND	Emory University; Howard Hughes Medical Institute; Emory University; Emory University; Erasmus University Rotterdam; Greenwood Genetic Center; University of Oulu			de Graaff, Esther/D-3287-2011; Warren, Stephen T/A-2498-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521] Funding Source: NIH RePORTER; NICHD NIH HHS [R37HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ASHLEY AE, 1995, AM J HUM GENET, V57, P1414; BACHNER D, 1993, NAT GENET, V4, P115, DOI 10.1038/ng0693-115; BACHNER D, 1993, HUM MOL GENET, V2, P2043, DOI 10.1093/hmg/2.12.2043; BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; BAKKER CE, 1994, CELL, V78, P23; BEAUMONT HM, 1963, J EMBRYOL EXP MORPH, V11, P715; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; Byskov A. G., 1982, GERM CELLS FERTILIZA, P1; CHANDLEY AC, 1991, J MED GENET, V28, P217, DOI 10.1136/jmg.28.4.217; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DEGRAAFF E, 1995, AM J HUM GENET, V57, P609; DEVYS D, 1992, AM J MED GENET, V43, P208, DOI 10.1002/ajmg.1320430134; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; DRISCOLL DJ, 1990, SOMAT CELL MOLEC GEN, V16, P267, DOI 10.1007/BF01233363; FISCH GS, 1995, AM J HUM GENET, V56, P1147; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1995, NAT GENET, V6, P9; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LAIRD CD, 1987, GENETICS, V117, P587; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LUO SY, 1993, SOMAT CELL MOLEC GEN, V19, P393, DOI 10.1007/BF01232750; MACDONALD ME, 1993, J MED GENET, V30, P982, DOI 10.1136/jmg.30.12.982; MIGEON BR, 1991, SOMAT CELL MOLEC GEN, V17, P159, DOI 10.1007/BF01232973; MONK M, 1987, DEVELOPMENT, V99, P371; MORTON NE, 1992, P NATL ACAD SCI USA, V89, P4215, DOI 10.1073/pnas.89.9.4215; NELSON DL, 1993, NAT GENET, V4, P107, DOI 10.1038/ng0693-107; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; REYNIERS E, 1993, NAT GENET, V4, P143, DOI 10.1038/ng0693-143; ROUSSEAU F, 1991, J MED GENET, V28, P830, DOI 10.1136/jmg.28.12.830; ROUSSEAU F, 1994, HUM MOL GENET, V3, P927, DOI 10.1093/hmg/3.6.927; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SNOW K, 1993, AM J HUM GENET, V53, P1217; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; VERHEIJ C, 1995, HUM MOL GENET, V4, P895, DOI 10.1093/hmg/4.5.895; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; WOHRLE D, 1992, HUM GENET, V89, P114, DOI 10.1007/BF00207057; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140	42	147	149	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					165	169		10.1038/ng0297-165	http://dx.doi.org/10.1038/ng0297-165			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020841				2022-12-25	WOS:A1997WF08700015
J	Perrault, I; Rozet, JM; Calvas, P; Gerber, S; Camuzat, A; Dollfus, H; Chatelin, S; Souied, E; Ghazi, I; Leowski, C; Bonnemaison, M; LePaslier, D; Frezal, J; Dufier, JL; Pittler, S; Munnich, A; Kaplan, J				Perrault, I; Rozet, JM; Calvas, P; Gerber, S; Camuzat, A; Dollfus, H; Chatelin, S; Souied, E; Ghazi, I; Leowski, C; Bonnemaison, M; LePaslier, D; Frezal, J; Dufier, JL; Pittler, S; Munnich, A; Kaplan, J			Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis	NATURE GENETICS			English	Article							RECESSIVE RETINITIS-PIGMENTOSA; CHROMOSOME 17P13.1; ALPHA-SUBUNIT; PHOSPHODIESTERASE; LOCALIZATION; RECEPTORS; MAPS	Leber's congenital amaurosis (LCA, MIM 204000(1)), the earliest and most severe form of inherited retinopathy, accounts for at least 5% of all inherited retinal dystrophies(2,3). This autosomal recessive condition is usually recognized at birth or during the first months of life in an infant with total blindness or greatly impaired vision, normal fundus and extinguished electroretinogram (ERG(4)). Nystagmus (pendular type) and characteristic eye poking are frequently observed in the first months of life (digito-ocular sign of Franceschetti(5)). Hypermetropia and keratoconus frequently develop in the course of the disease(6,7). The observation by Waardenburg(8) of nor mal children born to affected parents supports the genetic heterogeneity of LCA. Until now, however, little was known about the pathophysiology of the disease, but LCA is usually regarded as the consequence of either impaired development of photoreceptors or extremely early degeneration of cells that have developed normally(9). We have recently mapped a gene for LCA to chromosome 1.7p13.1 (LCA1) by homozygosity mapping in consanguineous families of North African origin and provided evidence of genetic heterogeneity in our sample, as LCA I accounted for 8/15 LCA families in our series(10,11). Here, we report two missense mutations (F589S) and two frameshift mutations (nt 460 del C, nt 693 del C) of the retinal guanylate cyclase (RETGC, GDB symbol GUC2D) gene in four unrelated LCA1 probands of North African ancestry and ascribe LCA1 to an impaired production of cGMP in the retina, with permanent closure of cGMP-gated cation channels.	HOP NECKER ENFANTS MALAD,UNITE RECH HANDICAPS GENET ENFANT,INSERM U393,F-75743 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,SERV OPHTALMOL,PARIS,FRANCE; INST NATL JEUNES AVEUGLES,PARIS,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; DEPT BIOCHEM & MOL BIOL,MOBILE,AL; DEPT OPHTHALMOL,MOBILE,AL	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite			ROZET, Jean-Michel/E-5737-2016; Pittler, Steven/J-7091-2013; perrault, isabelle/H-3047-2017	ROZET, Jean-Michel/0000-0001-7951-7886; GERBER, Sylvie/0000-0002-6827-1769; Le Paslier, Denis/0000-0003-4335-9956; Dollfus, Helene/0000-0002-2249-895X; Pittler, Steven/0000-0002-8464-9303; perrault, isabelle/0000-0002-8560-1379	NEI NIH HHS [EY 09924] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009924] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CALABRESE G, 1994, GENOMICS, V23, P286, DOI 10.1006/geno.1994.1497; Camuzat A, 1996, HUM GENET, V97, P798; CAMUZAT A, 1995, HUM MOL GENET, V4, P1447, DOI 10.1093/hmg/4.8.1447; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; FITZGIBBON J, 1994, CYTOGENET CELL GENET, V67, P205, DOI 10.1159/000133823; FOXMAN SG, 1985, ARCH OPHTHALMOL-CHIC, V103, P1502; FRANCESCHETTI A, 1958, Ophthalmologica, V135, P610; FRANCESCHETTI A, 1954, Confin Neurol, V14, P184; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468; KAPLAN J, 1990, HUM GENET, V85, P635; KAREL I, 1968, OPHTHALMOLOGICA, V155, P8, DOI 10.1159/000305329; Leber T., 1869, GRAEFES ARCH KLIN EX, V15, P13, DOI 10.1007/BF0272121318; LEE N R, 1987, Investigative Ophthalmology and Visual Science, V28, P344; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; LOLLEY RN, 1990, FASEB J, V4, P3001, DOI 10.1096/fasebj.4.12.1697545; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; MIZUNO K, 1977, AM J OPHTHALMOL, V83, P32, DOI 10.1016/0002-9394(77)90188-X; MURAKAMI A, 1992, BIOCHEM BIOPH RES CO, V187, P234, DOI 10.1016/S0006-291X(05)81483-4; OLIVEIRA L, 1994, GENOMICS, V22, P478, DOI 10.1006/geno.1994.1415; ROZET JM, IN PRESS GENOMICS; SempleRowland SL, 1996, INVEST OPHTH VIS SCI, V37, P3729; SHASTRY BS, 1994, AM J MED GENET, V52, P467, DOI 10.1002/ajmg.1320520413; TOMBRANTINK J, 1994, GENOMICS, V19, P266, DOI 10.1006/geno.1994.1057; WAARDENBURG PJ, 1963, ACTA OPHTHALMOL, V41, P317; WAGNER RS, 1985, ARCH OPHTHALMOL-CHIC, V103, P1507; Yang RB, 1996, GENOMICS, V31, P367, DOI 10.1006/geno.1996.0060; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	30	362	369	0	20	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					461	464		10.1038/ng1296-461	http://dx.doi.org/10.1038/ng1296-461			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944027				2022-12-25	WOS:A1996VV73000023
J	Leonard, WJ				Leonard, WJ			STATs and cytokine specificity	NATURE MEDICINE			English	Editorial Material							PHOSPHORYLATION; TRANSCRIPTION; RECEPTOR; TYROSINE; IL-4				Leonard, WJ (corresponding author), NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892, USA.		Leonard, Warren/AAA-1397-2022					Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Leonard WJ, 1996, ANNU REV MED, V47, P229; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MUI A, 1995, EMBO J, V15, P2425; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P686; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	20	39	46	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					968	969		10.1038/nm0996-968	http://dx.doi.org/10.1038/nm0996-968			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782447				2022-12-25	WOS:A1996VF49700024
J	Knudson, CM; Korsmeyer, SJ				Knudson, CM; Korsmeyer, SJ			Bcl-2 and Bax function independently to regulate cell death	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY; DEFICIENT MICE; APOPTOSIS; SURVIVAL; PROTEIN; THYMOCYTES; HAIR; SELECTION; BCL-X(L); BH1	The BCL-2 family has Various pairs of antagonist and agonist proteins that regulate apoptosis, Whether their function is interdependent is uncertain. Using a genetic approach to address this question, we utilized gain- and loss-of-function models of Bcl-2 and Bax and found that apoptosis and thymic hypoplasia characteristic of Bcl-2-deficient mice are largely absent in mice also deficient in Bax. A single copy of Bax promoted apoptosis in the absence of Bcl-2. In contrast, overexpression of Bcl-2 still repressed apoptosis in the absence of Bax. While an in vivo competition exists between Bax and Bcl-2, each is able to regulate apoptosis independently.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV MOL ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, DIV MOL ONCOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Knudson, Charles Michael/0000-0003-3964-5466	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Boulakia CA, 1996, ONCOGENE, V12, P529; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAMADA S, 1995, CANCER RES, V55, P354; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V12, P2251; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VEISNOVACK D, 1994, AM J PATHOL, V145, P61; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	40	335	342	3	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					358	363		10.1038/ng0897-358	http://dx.doi.org/10.1038/ng0897-358			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241272				2022-12-25	WOS:A1997XM90900017
J	Lofman, C; Rigo, R; Block, M; Hulten, K; Enroth, H; Engstrand, L				Lofman, C; Rigo, R; Block, M; Hulten, K; Enroth, H; Engstrand, L			Bacterium-host interactions monitored by time-lapse photography	NATURE MEDICINE			English	Article							HELICOBACTER-PYLORI INFECTION; HUMAN GASTRIC EPITHELIUM; CANCER		UNIV UPPSALA HOSP,DEPT CLIN MICROBIOL,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,SWEDISH TELEVIS,S-75185 UPPSALA,SWEDEN; UPPSALA UNIV,BIOL MICROSCOPY & IMAGING UNIT,UPPSALA,SWEDEN; KAROLINSKA INST,DEPT MED EPIDEMIOL,S-10521 STOCKHOLM,SWEDEN; SWEDISH INST INFECT DIS CONTROL,S-10521 STOCKHOLM,SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Uppsala University; Karolinska Institutet; Swedish Institute for Infectious Disease Control				Enroth, Helena/0000-0001-7684-5702; Hulten, Kristina/0000-0001-7446-157X				BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; Falk P, 1996, J INTERN MED, V240, P319, DOI 10.1046/j.1365-2796.1996.75881000.x; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; GRAHAM DY, 1994, PREV MED, V23, P712, DOI 10.1006/pmed.1994.1121; HANSSON LE, 1995, GASTROENTEROLOGY, V109, P885, DOI 10.1016/0016-5085(95)90398-4; ISENBERG H D, 1988, Clinical Microbiology Reviews, V1, P40; NOACH LA, 1994, J CLIN PATHOL, V47, P699, DOI 10.1136/jcp.47.8.699	9	19	19	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					930	931		10.1038/nm0897-930	http://dx.doi.org/10.1038/nm0897-930			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256289				2022-12-25	WOS:A1997XP01400040
J	Holden, PH; Asopa, V; Robertson, AGS; Clarke, AR; Tyler, S; Bennett, GS; Brain, SD; Wilcock, GK; Allen, SJ; Smith, SKF; Dawbarn, D				Holden, PH; Asopa, V; Robertson, AGS; Clarke, AR; Tyler, S; Bennett, GS; Brain, SD; Wilcock, GK; Allen, SJ; Smith, SKF; Dawbarn, D			Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor	NATURE BIOTECHNOLOGY			English	Article						protein folding; drug design; nerve growth factor; TrkA binding domain	LEUCINE-RICH MOTIF; EXTRACELLULAR DOMAIN; NEUROTROPHIC FACTOR; BASAL FOREBRAIN; KINASE; BRAIN; SPECIFICITY; CONFERS; FORM	Nerve growth factor (NGF) is involved in the development and maintenance of the nervous system. NGF binds with high affinity to the extracellular region of the tyrosine kinase receptor TrkA, This domain comprises leucine and cysteine rich motifs, followed by two immunoglobulin like (Ig-like) domains, We describe the expression and purification of recombinant Ig-like domains. Fluorescence and circular dichroism spectroscopy show that the protein is folded into a compact globular structure and contains mainly beta-sheet secondary structure. Recombinant protein binds to NGF and can inhibit NGF bioactivity both in vitro and in vivo.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BRISTOL,SCH MED SCI,CTR MOL RECOGNIT,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV LONDON KINGS COLL,DIV BIOMED SCI,PHARMACOL GRP,LONDON SW3 6LX,ENGLAND; UNIV LONDON KINGS COLL,DIV BIOMED SCI,VASC BIOL RES CTR,LONDON SW3 6LX,ENGLAND; FRENCHAY HOSP,DEPT CARE ELDERLY,BRISTOL BS16 1LE,AVON,ENGLAND	University of Bristol; University of Bristol; University of London; King's College London; University of London; King's College London	Holden, PH (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED CARE ELDERLY,MOL NEUROBIOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND.		Brain, Susan/L-3681-2013	Brain, Susan/0000-0002-9684-8342; Allen, Shelley/0000-0001-7870-740X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN SJ, 1994, NEUROSCIENCE, V60, P825, DOI 10.1016/0306-4522(94)90507-X; Bennett GS, 1996, BRIT J PHARMACOL, V119, pP55; BRAIN SD, 1985, BRIT J PHARMACOL, V86, P855, DOI 10.1111/j.1476-5381.1985.tb11107.x; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; FUJIMORI K, 1992, BIOSCI BIOTECH BIOCH, V56, P1985, DOI 10.1271/bbb.56.1985; HATANAKA H, 1988, DEV BRAIN RES, V39, P85, DOI 10.1016/0165-3806(88)90069-7; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; IKEDA K, 1968, J BIOCHEM, V63, P654, DOI 10.1093/oxfordjournals.jbchem.a128825; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEWIN B, 1995, J MOL BIOL, V7, P227; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCDONALD NQ, 1995, J BIOL CHEM, V270, P19669, DOI 10.1074/jbc.270.34.19669; OLSEN L, 1992, J NEURAL TRANSM PARK, V4, P79; OTTEN U, 1984, EUR J PHARMACOL, V106, P199, DOI 10.1016/0014-2999(84)90697-6; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; THOENEN H, 1987, REV PHYSIOL BIOCH P, V109, P145, DOI 10.1007/BFb0031026; TREANOR JJS, 1991, NEUROSCI LETT, V121, P73, DOI 10.1016/0304-3940(91)90652-A; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VALE RD, 1985, METHOD ENZYMOL, V109, P21; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348	36	48	54	1	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					668	672		10.1038/nbt0797-668	http://dx.doi.org/10.1038/nbt0797-668			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219271				2022-12-25	WOS:A1997XH58300032
J	Templeton, NS; Lasic, DD; Frederik, PM; Strey, HH; Roberts, DD; Pavlakis, GN				Templeton, NS; Lasic, DD; Frederik, PM; Strey, HH; Roberts, DD; Pavlakis, GN			Improved DNA: Liposome complexes for increased systemic delivery and gene expression	NATURE BIOTECHNOLOGY			English	Article						gene therapy; cationic liposomes; DNA delivery; in vivo gene expression	ADULT MICE; INVIVO; TRANSFECTION; EFFICIENT; VESICLES; SERIES; LIVER	To increase cationic liposome-mediated intravenous DNA delivery extruded DOTAP:cholesterol liposomes were used to form complexes with DNA, resulting in enhanced expression of the chloramphenicol acetyltransferase gene in most tissues examined. The DNA:liposome ratio, and mild sonication, heating, and extrusion steps used for liposome preparation were crucial for improved systemic delivery. Size fractionation studies showed that maximal gene expression was produced by a homogeneous population of DNA:liposome complexes between 200 to 450 nm in size. Cryo-electron microscopy examination demonstrates that the DNA:liposome complexes have a novel morphology, and that the DNA is condensed on the interior of invaginated liposomes between two lipid bilayers. This structure could account for the high efficiency of gene delivery in vivo and for the broad tissue distribution of the DNA:liposome complexes. Ligands can be placed on the outside of this structure to provide for targeted gene delivery.	LIPSOME CONSULTAT,NEWARK,CA 94560; UNIV LIMBURG,DEPT PATHOL,NL-6200 MD MAASTRICHT,NETHERLANDS; NIH,DCRT,LSB,BETHESDA,MD 20892; NIH,PATHOL LAB,BETHESDA,MD 20892	Hasselt University; Maastricht University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Templeton, NS (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,BOYLES ST,BLDG 535,RM 226A,FREDERICK,MD 21702, USA.		Strey, Helmut/B-5456-2009; Templeton, Nancy S/C-9565-2011; Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Strey, Helmut/0000-0002-6554-5322				Aksentijevich I, 1996, HUM GENE THER, V7, P1111, DOI 10.1089/hum.1996.7.9-1111; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; DRAGSTEN PR, 1987, BIOCHIM BIOPHYS ACTA, V926, P270, DOI 10.1016/0304-4165(87)90213-3; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Felgner PL, 1996, HUM GENE THER, V7, P1791, DOI 10.1089/hum.1996.7.15-1791; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FREDERIK PM, 1991, J MICROSC-OXFORD, V161, P253, DOI 10.1111/j.1365-2818.1991.tb03088.x; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; Hara T, 1995, GENE THER, V2, P784; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; KANEO Y, 1991, CHEM PHARM BULL, V39, P999; Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g; Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Murahashi N, 1996, BIOL PHARM BULL, V19, P418; PHILIP R, 1993, J BIOL CHEM, V268, P16087; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Sambrook J., 1989, MOL CLONING; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; SPANJER HH, 1984, BIOCHIM BIOPHYS ACTA, V774, P49, DOI 10.1016/0005-2736(84)90273-6; SPANJER HH, 1983, BIOCHIM BIOPHYS ACTA, V734, P40, DOI 10.1016/0005-2736(83)90072-X; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; TSUKAMOTO M, 1995, NAT GENET, V9, P243, DOI 10.1038/ng0395-243; Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	30	639	757	4	137	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					647	652		10.1038/nbt0797-647	http://dx.doi.org/10.1038/nbt0797-647			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219267				2022-12-25	WOS:A1997XH58300028
J	Lyko, F; Brenton, JD; Surani, MA; Paro, R				Lyko, F; Brenton, JD; Surani, MA; Paro, R			An imprinting element from the mouse H19 locus functions as a silencer in Drosophila	NATURE GENETICS			English	Article							MELANOGASTER; GENE; DNA; METHYLATION	Genomic imprinting as originally described in Sciara(1) is displayed by many organisms. In mammals, X-inactivation and the parent-of-origin-specific silencing of imprinted genes are examples of this phenomenon(2,3). A heritable chromatin structural modification may be the critical mechanism in such instances of chromosome condensation and preferential gene inactivation. H19 is an imprinted gene(4) in which the repressed paternal allele is hypermethylated and the compacted chromatin is relatively resistant to digestion by nucleases(5-7). In order to uncover underlying conserved epigenetic mechanisms we have introduced a mouse H19 transgene into Drosophila. We show here that a 1.2-kb H19 upstream sequence functions in cis as a parent-of-origin independent silencing element in Drosophila. Strikingly, this cis-acting element is located within an upstream region that is necessary for H19 imprinting in mice(8). These results suggest involvement of an evolutionary conserved mechanism in both gene silencing in Drosophila and imprinting in mice.	UNIV HEIDELBERG,ZMBH,D-69120 HEIDELBERG,GERMANY; WELLCOME CRC INST CANC & DEV BIOL,CAMBRIDGE CB2 1QP,ENGLAND; UNIV CAMBRIDGE,PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND	Ruprecht Karls University Heidelberg; University of Cambridge			Brenton, James D/B-3174-2008	Brenton, James D/0000-0002-5738-6683; Surani, Azim/0000-0002-8640-4318	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; CROUSE HV, 1960, GENETICS, V45, P1429; DANIELS SB, 1985, GENETICS, V109, P95; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; John RM, 1996, CURR OPIN CELL BIOL, V8, P348, DOI 10.1016/S0955-0674(96)80008-1; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; PATEL CV, 1987, ANAL BIOCHEM, V164, P164, DOI 10.1016/0003-2697(87)90381-2; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; REUTER G, 1981, MOL GEN GENET, V182, P516, DOI 10.1007/BF00293947; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J., 2002, MOL CLONING LAB MANU; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	21	99	101	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					171	173		10.1038/ng0697-171	http://dx.doi.org/10.1038/ng0697-171			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171828				2022-12-25	WOS:A1997XB54300017
J	Guo, YJ; Che, XY; Shen, F; Xie, TP; Ma, J; Wang, XN; Wu, SG; Anthony, DD; Wu, MC				Guo, YJ; Che, XY; Shen, F; Xie, TP; Ma, J; Wang, XN; Wu, SG; Anthony, DD; Wu, MC			Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies	NATURE MEDICINE			English	Article							T-CELLS; HEPATOMA-CELLS; CTLA-4; COSTIMULATION; ACTIVATION; CD28; B7	Antitumor immune responses are mediated primarily by T cells(1). Downregulation of the major histocompatiblity complex (MHC) and the molecules that costimulate the immune response is associated with defective signaling by tumor cells for T-cell activation(2-14). In vitro treatment with a combination of cytokines significantly increased the expression of MHC class I and adhesion molecules on tumor cell surfaces. When tumor cells were first incubated with a bispecific monoclonal antibody that binds antigen on tumor cells to CD28 on T cells, the modified tumor cells become immunogenic and are able to stimulate naive T cells, generating tumor-specific cytotoxic T cells in vitro. Immunization with the modified tumor cells elicits an immune response mediated by CD8(+) T cells. This response protected against a challenge with parental tumor cells and cured established tumors. The approach was effective in both low immunogenic and nonimmunogenic tumor model systems. Modification of tumor cells with this two-step procedure may provide a strategy for development of tumor vaccines that is effective for cancer immunotherapy.	SHANGHAI SECOND MILIT MED UNIV,TUMOR IMMUNOL & GENE THERAPY CTR,INST HEPATOBILIARY SURG,SHANGHAI 200433,PEOPLES R CHINA; SHANGHAI SECOND MILIT MED UNIV,CHANGHAI HOSP,SHANGHAI 200433,PEOPLES R CHINA; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CANC RES CTR,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106	Naval Medical University; Naval Medical University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland								ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DARLINGTON GJ, 1980, J NATL CANCER I, V64, P809; GRABBE S, 1995, IMMUNOL TODAY, V16, P117, DOI 10.1016/0167-5699(95)80125-1; GUO YJ, 1994, SCIENCE, V263, P518, DOI 10.1126/science.7507262; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; MACLEAN JA, 1993, J IMMUNOL, V150, P1619; RENNER C, 1994, SCIENCE, V264, P833, DOI 10.1126/science.8171337; RESTIFO NP, 1995, BIOL THERAPY CANC, P3; TAKAHASHI H, 1993, SCIENCE, V259, P1460, DOI 10.1126/science.8451642; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; YANG GC, 1995, J IMMUNOL, V154, P2794	20	44	51	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					451	455		10.1038/nm0497-451	http://dx.doi.org/10.1038/nm0497-451			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095181				2022-12-25	WOS:A1997WQ82500037
J	Daubendiek, SL; Kool, ET				Daubendiek, SL; Kool, ET			Generation of catalytic RNAs by rolling transcription of synthetic DNA nanocircles	NATURE BIOTECHNOLOGY			English	Article						convergent synthesis; rolling circle; hammerhead ribozyme; ASBV viroid	POLYMERASE; INVITRO; OLIGORIBONUCLEOTIDE; BACTERIOPHAGE-T7; RIBOZYMES; CLEAVAGE	Small catalytic RNAs are commonly produced either by transcription of promoter-driven linear DNA templates or by stepwise chemical synthesis on solid supports. We describe a different approach, in which very small chemically synthesized circular DNAs serve as efficient templates for generation of catalytic RNAs in vitro. The circles are 83 nucleotides in size, are single stranded, and contain no canonical RNA polymerase promoters. Despite this, T7 and Escherichia coli RNA polymerases transcribe the circles by a rolling mechanism, producing long concatemeric RNAs (similar to 7,500 nt). During the transcription reaction, the repeating RNAs self-cleave, ultimately reaching monomer length. Despite having self-complementary sequences at their substrate-binding domains, these monomeric 83-nt RNAs are shown to be catalytically active ribozymes that sequence-specifically cleave RNA targets in trans. In addition, a circular vector encoding a repeating (non-self-processing) ribozyme is described; the resulting multimeric ribozyme, targeted to a sequence in the HIV-1 genome, is also catalytically active in trans. This novel approach to the synthesis of catalytic RNAs offers a number of differences and potential advantages over current approaches to RNA synthesis.	UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627; UNIV ROCHESTER,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14627	University of Rochester; University of Rochester				Kool, Eric/0000-0002-7310-2935				ALYAR SE, 1994, J BIOL CHEM, V269, P13179; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DAUBENDIEK SL, 1995, J AM CHEM SOC, V117, P7818, DOI 10.1021/ja00134a032; DAUBENDIEK SL, 1996, UNPUB; DZIANOTT AM, 1989, P NATL ACAD SCI USA, V86, P4823, DOI 10.1073/pnas.86.13.4823; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KRUPP G, 1988, GENE, V72, P75, DOI 10.1016/0378-1119(88)90129-1; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; OHKAWA J, 1993, P NATL ACAD SCI USA, V90, P11302, DOI 10.1073/pnas.90.23.11302; RUBIN E, 1995, NUCLEIC ACIDS RES, V23, P3547, DOI 10.1093/nar/23.17.3547; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SYMONS RH, 1981, NUCLEIC ACIDS RES, V9, P6527, DOI 10.1093/nar/9.23.6527; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0	24	59	90	4	36	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					273	277		10.1038/nbt0397-273	http://dx.doi.org/10.1038/nbt0397-273			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062929				2022-12-25	WOS:A1997WM05000033
J	Yergeau, DA; Hetherington, CJ; Wang, Q; Zhang, P; Sharpe, AH; Binder, M; MarinPadilla, M; Tenen, DG; Speck, NA; Zhang, DE				Yergeau, DA; Hetherington, CJ; Wang, Q; Zhang, P; Sharpe, AH; Binder, M; MarinPadilla, M; Tenen, DG; Speck, NA; Zhang, DE			Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene	NATURE GENETICS			English	Article							ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR; MURINE MYELOPEROXIDASE; NUCLEAR FACTOR; IDENTIFICATION; ENHANCER; PROMOTER; CELLS; BINDS; DNA	Acute myeloid leukaemia (AML) is a major haematopoietic malignancy characterized by the proliferation of a malignant clone of myeloid progenitor cells(1,2). A reciprocal translocation, t(8;21)(q22;q22), observed in the leukaemic cells of approximately 40% of patients with the M2 subtype of AML disrupts both the AML1 (CBFA2) gene on chromosome 21 and the ETO (MTG8) gene on chromosome 8 (refs 3-5). A chimaeric protein is synthesized from one of the derivative chromosomes that contains the N terminus of the AML1 transcription factor, including its DNA-binding domain, fused to most of ETO, a protein of unknown function. We generated mice that mimic human t(8;21) with a 'knock-in' strategy. Mice heterozygous for an AML I-ETO allele (AML1-ETO/+) die in midgestation from haemorrhaging in the central nervous system and exhibit a severe block in fetal liver haematopoiesis. This phenotype is very similar to that resulting from homozygous disruption of the AML1 (Cbfa2) or Cbfb genes(6-8), indicating that AML1-ETO blocks normal AML1 function. However, yolk sac cells from AML1-ETO/+ mice differentiated into macrophages in haematopoietic colony forming unit (CFU) assays, unlike Cbfa2-/- or Cbfb-/- cells, which form no colonies in vitro(6-8). This indicates that AML1-ETO may have other functions besides blocking wild-type AML1, a property that may be important in leukaemogenesis.	HARVARD UNIV, INST MED, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL DEACONESS MED CTR, DIV HEMATOL ONCOL, BOSTON, MA USA; DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; DARTMOUTH COLL SCH MED, DEPT ANAT, HANOVER, NH 03755 USA; DARTMOUTH COLL SCH MED, DEPT PATHOL, HANOVER, NH 03755 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Dartmouth College; Dartmouth College; Dartmouth College; Harvard University; Brigham & Women's Hospital				Tenen, Daniel/0000-0002-6423-3888	NCI NIH HHS [CA41456] Funding Source: Medline; NIAMS NIH HHS [P030AR42689] Funding Source: Medline; NINDS NIH HHS [NS22897] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR042689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022897] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armesilla AL, 1996, J BIOL CHEM, V271, P7781, DOI 10.1074/jbc.271.13.7781; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; HAAS JG, 1992, J IMMUNOL, V149, P237; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROWLEY JD, 1984, CANCER RES, V44, P3159; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	30	291	301	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					303	306		10.1038/ng0397-303	http://dx.doi.org/10.1038/ng0397-303			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054947				2022-12-25	WOS:A1997WK38600024
J	Gosse, ME; Nelson, TF				Gosse, ME; Nelson, TF			Approval times for supplemental indications for recombinant proteins	NATURE BIOTECHNOLOGY			English	Article							DRUG DEVELOPMENT; UNITED-STATES				Gosse, ME (corresponding author), TUFTS UNIV,CTR STUDY DRUG DEV,BOSTON,MA 02111, USA.			Nelson, Toben/0000-0001-9934-7546				CLINTON WJ, 1996, COMMUNICATION   0329; DIMASI JA, 1994, CLIN PHARMACOL THER, V55, P609, DOI 10.1038/clpt.1994.78; DIMASI JA, 1995, CLIN PHARMACOL THER, V58, P1, DOI 10.1016/0009-9236(95)90066-7; DIMASI JA, 1991, J HEALTH ECON, V10, P107, DOI 10.1016/0167-6296(91)90001-4; DiMasi JA, 1996, DRUG INF J, V30, P315; *GAO, 1991, GAOPEMD9114 COMM LAB; Gosse ME, 1996, CLIN PHARMACOL THER, V60, P608, DOI 10.1016/S0009-9236(96)90209-X; Gosse ME, 1996, DRUG INF J, V30, P991; KAITIN KI, 1994, J CLIN PHARMACOL, V34, P120, DOI 10.1002/j.1552-4604.1994.tb03975.x; *KIDN CANC ASS, 1996, PINK SHEET, V58, P14; RAIFORD DS, 1994, FOOD DRUG LAW J, V49, P37; Shulman SR, 1996, PHARMACOECONOMICS, V9, P121, DOI 10.2165/00019053-199609020-00004; 1996, PINK SHEET, V58, P6	13	0	0	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					130	&		10.1038/nbt0297-130	http://dx.doi.org/10.1038/nbt0297-130			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035135				2022-12-25	WOS:A1997WE99800017
J	Mangiarini, L; Sathasivam, K; Mahal, A; Mott, R; Seller, M; Bates, GP				Mangiarini, L; Sathasivam, K; Mahal, A; Mott, R; Seller, M; Bates, GP			Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation	NATURE GENETICS			English	Article							SPINOCEREBELLAR ATAXIA TYPE-1; PALLIDOLUYSIAN ATROPHY DRPLA; ANDROGEN RECEPTOR GENE; TRINUCLEOTIDE REPEAT; ONSET; AGE; EXPANSION; LENGTH; MOSAICISM	Six inherited neurodegenerative diseases are caused by a CAG/polyglutamine expansion, including spinal and bulbar muscular atrophy (SBMA)(1), Huntington's disease (HD)(2), spinocerebellar ataxia type 1 (SCA1)(3), dentatorubral pallidoluysian atrophy (DRPLA)(4,5) Machado-Joseph disease (MJD or SCA3)(6) and SCA2(7-9). Normal and expanded HD allele sizes of 6-39 and 35-121 repeats have been reported(10-13), and the allele distributions for the other diseases are comparable. Intergenerational instability has been described in all cases, and repeats tend to be more unstable on paternal transmission. This may present as larger increases on paternal inheritance as in HD14, or as a tendency to increase on male and decrease on female transmission as in SCA1 (ref.15). Stomatic repeat instability is also appears most pronounced in the CNS16,17. The major exception is the cerebellum, which in HD, DRPLA, SCA1 and MJD has a smaller repeat relative to the other brain regions tested(16-21). Of non-CNS tissues, instability was observed in blood, liver, kidney and colon(16,20,21). A mouse model of CAG repeat instability would be helpful in unravelling its molecular basis although an absence of CAG repeat instability in transgenic mice has so far been reported. These studies include (CAG)(45) in the androgen receptor cDNA(22), (CAG)(44), in the HD cDNA(23), (CAG)(82) in the SCA1 cDNA(24), (CAG)(79) in the SCA3 cDNA and as an isolated (CAC)(79) tract(25).	GUYS HOSP,DIV MED & MOL GENET,LONDON SE1 9RT,ENGLAND; SANGER CTR,HINXTON CB10 1RO,CAMBS,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Wellcome Trust Sanger Institute			Bates, Gillian P/E-1146-2012; Longo, Kenneth A/A-5631-2010	Bates, Gillian P/0000-0002-4041-6305; Mott, Richard/0000-0002-1022-9330				ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; BARRON LH, 1993, J MED GENET, V30, P1003, DOI 10.1136/jmg.30.12.1003; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FARRER LA, 1992, AM J HUM GENET, V50, P528; Goldberg YP, 1996, HUM MOL GENET, V5, P177, DOI 10.1093/hmg/5.2.177; *HDCRG, 1993, CELL, V72, P971; Hogan B, 1994, MANIPULATING MOUSE E; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KRAWCZAK M, 1991, AM J HUM GENET, V49, P735; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MANGIARINI L, 1996, CELL, V87, P497; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; RIESS O, 1993, HUM MOL GENET, V2, P637, DOI 10.1093/hmg/2.6.637; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; SAMPEI K, 1996, NAT GENET, V14, P277; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; Takano H, 1996, AM J HUM GENET, V58, P1212; Tanaka F, 1996, J NEUROL SCI, V135, P43, DOI 10.1016/0022-510X(95)00249-2; TELENIUS H, 1994, NAT GENET, V6, P409, DOI 10.1038/ng0494-409; UENO S, 1995, HUM MOL GENET, V4, P663, DOI 10.1093/hmg/4.4.663	30	254	264	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					197	200		10.1038/ng0297-197	http://dx.doi.org/10.1038/ng0297-197			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020849				2022-12-25	WOS:A1997WF08700023
J	Ryabova, LA; Desplancq, D; Spirin, AS; Pluckthun, A				Ryabova, LA; Desplancq, D; Spirin, AS; Pluckthun, A			Functional antibody production using cell-free translation: Effects of protein disulfide isomerase and chaperones	NATURE BIOTECHNOLOGY			English	Article						cell-free translation system; single-chain antibody; disulfide isomerase; molecular chaperones; protein folding	ESCHERICHIA-COLI; BOND FORMATION; ENDOPLASMIC-RETICULUM; GENE ENCODES; ACTIVE-SITE; CHAIN; BINDING; THIOREDOXIN; IDENTIFICATION; INVITRO	To create a rapid system to test the effect of sequence changes on recombinant antibody binding, we have developed a procedure for producing functional scFv fragments in an Escherichia coli cell-free translation system. Functional antibodies with antigen-binding activity are obtained only if disulfide formation and rearrangement is allowed to take place during the translation reaction. The inclusion of protein disulfide isomerase (PDI) leads to a threefold increase in yield over that obtained in the presence of glutathione redox systems. DsbA had no such effect, indicating that disulfide shuffling, and not net formation, is the crucial yield-limiting step. The addition of the molecular chaperones DnaK and DnaJ increased the amount of soluble protein but not the amount of functional scFv, which appears to be limited entirely by correct disulfide formation. None of these factors significantly influenced total protein synthesis. In the presence of PDI, chaperones, reduced glutathione and oxidized glutathione, 50% of the scFv produced (about 8 mu g/ml in only 15 min) could be recovered from immobilized antigen.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND; RUSSIAN ACAD SCI,INST PROT RES,PUSHCHINO 142292,MOSCOW REG,RUSSIA	University of Zurich; Russian Academy of Sciences			Plückthun, Andreas/C-2746-2009; Spirin, Alexander/A-7307-2016	Plückthun, Andreas/0000-0003-4191-5306; Ryabova, Lyubov/0000-0003-1989-203X				BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CHEN HZ, 1983, METHOD ENZYMOL, V101, P674; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; FREEDMAN RB, 1995, CURR OPIN STRUC BIOL, V5, P85, DOI 10.1016/0959-440X(95)80013-Q; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GLOCKSHUBER R, 1992, BIOCHEMISTRY-US, V31, P1270, DOI 10.1021/bi00120a002; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Hurle Mark R., 1994, Current Opinion in Biotechnology, V5, P428, DOI 10.1016/0958-1669(94)90053-1; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; KITAGAWA T, 1978, J BIOCHEM-TOKYO, V84, P491, DOI 10.1093/oxfordjournals.jbchem.a132151; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lindner Peter, 1992, Methods (Orlando), V4, P41, DOI 10.1016/1046-2023(92)90055-D; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NICHOLLS PJ, 1993, J BIOL CHEM, V268, P5302; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; PROBA K, 1995, GENE, V159, P203, DOI 10.1016/0378-1119(95)00018-2; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; RYABOVA LA, 1995, ANAL BIOCHEM, V226, P184, DOI 10.1006/abio.1995.1208; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TOKATLIDIS K, 1995, PHILOS T ROY SOC B, V348, P89, DOI 10.1098/rstb.1995.0049; TRILL JJ, 1995, CURR OPIN BIOTECH, V6, P553, DOI 10.1016/0958-1669(95)80092-1; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	49	129	151	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					79	84		10.1038/nbt0197-79	http://dx.doi.org/10.1038/nbt0197-79			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035111				2022-12-25	WOS:A1997WA72900028
J	Leister, D; Ballvora, A; Salamini, F; Gebhardt, C				Leister, D; Ballvora, A; Salamini, F; Gebhardt, C			A PCR-based approach for isolating pathogen resistance genes from potato with potential for wide application in plants	NATURE GENETICS			English	Article							F SP LYCOPERSICI; NEMATODE GLOBODERA-ROSTOCHIENSIS; RACE-SPECIFIC RESISTANCE; DISEASE RESISTANCE; PHYTOPHTHORA-INFESTANS; CONFERRING RESISTANCE; CLADOSPORIUM-FULVUM; SOLANUM-TUBEROSUM; VIRUS-RESISTANCE; LINKAGE MAPS	Plant genes for pathogen resistance can be used to engineer disease resistant crops. Oligonucleotides were designed from sequence motifs conserved between resistance genes of tobacco and Arabidopsis thaliana and used as PCR primers in potato DNA. Amplification products were obtained that were homologous to known resistance genes and linked without recombination with the nematode resistance locus Gro1 and the Phytophthora infestans resistance locus R7 of potato. Map positions of PCR-derived potato gene fragments were also correlated with resistance loci of the related tomato and tobacco genomes. Our results indicate that plant resistance genes that are effective against nematodes, fungi,viruses and bacteria may be isolated based on common sequence motifs and PCR methodology.	MAX PLANCK INST ZUCHTUNGSFORSCH, D-50829 COLOGNE, GERMANY	Max Planck Society			Gebhardt, Chris/HGD-6090-2022; Leister, Dario/D-5587-2009	Leister, Dario/0000-0003-1897-8421				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALINTKURTI PJ, 1994, THEOR APPL GENET, V88, P691, DOI 10.1007/BF01253972; BALLVORA A, 1995, MOL GEN GENET, V249, P82, DOI 10.1007/BF00290239; BARONE A, 1990, MOL GEN GENET, V224, P177, DOI 10.1007/BF00271550; BEHARE J, 1991, MOL PLANT MICROBE IN, V4, P489, DOI 10.1094/MPMI-4-489; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BONIERBALE MW, 1988, GENETICS, V120, P1095; BOURNIVAL BL, 1989, THEOR APPL GENET, V78, P489, DOI 10.1007/BF00290832; CHUNWONGSE J, 1994, THEOR APPL GENET, V89, P76, DOI 10.1007/BF00226986; Dixon MS, 1996, CELL, V84, P451, DOI 10.1016/S0092-8674(00)81290-8; ELKHARBOTLY A, 1994, MOL GEN GENET, V242, P749, DOI 10.1007/BF00283432; ELKHARBOTLY A, IN PRESS THEOR APPL; ELLIS JG, 1995, P NATL ACAD SCI USA, V92, P4185, DOI 10.1073/pnas.92.10.4185; Ganal MW, 1995, MOL PLANT MICROBE IN, V8, P886, DOI 10.1094/MPMI-8-0886; GEBHARDT C, 1995, GENET RES, V65, P1, DOI 10.1017/S001667230003295X; GEBHARDT C, 1993, THEOR APPL GENET, V85, P541, DOI 10.1007/BF00220911; GEBHARDT C, 1991, THEOR APPL GENET, V83, P49, DOI 10.1007/BF00229225; GEBHARDT C, 1989, THEOR APPL GENET, V78, P65, DOI 10.1007/BF00299755; GEBHARDT C, 1994, DNA BASED MARKERS PL; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; HAMALAINEN JH, IN PRESS THEOR APPL; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; JONES DA, 1992, TOMATO GENET COOP RE, V42, P19; KALOSHIAN I, 1995, P NATL ACAD SCI USA, V92, P622, DOI 10.1073/pnas.92.2.622; KREIKE CM, 1993, THEOR APPL GENET, V87, P464, DOI 10.1007/BF00215092; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LEONARDSSCHIPPERS C, 1992, MOL GEN GENET, V233, P278, DOI 10.1007/BF00587589; LEONARDSSCHIPPERS C, 1994, GENETICS, V137, P67; LEVESQUE H, 1990, THEOR APPL GENET, V80, P602, DOI 10.1007/BF00224218; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; MESSEGUER R, 1991, THEOR APPL GENET, V82, P529, DOI 10.1007/BF00226787; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; RITTER E, 1990, GENETICS, V125, P645; RITTER E, 1991, MOL GEN GENET, V227, P81, DOI 10.1007/BF00260710; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARFATTI M, 1991, THEOR APPL GENET, V82, P22, DOI 10.1007/BF00231273; SARFATTI M, 1989, THEOR APPL GENET, V78, P755, DOI 10.1007/BF00262574; SEGAL G, 1992, MOL GEN GENET, V231, P179, DOI 10.1007/BF00279789; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STEVENS MR, 1995, THEOR APPL GENET, V90, P451, DOI 10.1007/BF00221989; TANKSLEY SD, 1992, GENETICS, V132, P1141; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; VANBERKEL J, 1994, PLANT PHYSIOL, V104, P445, DOI 10.1104/pp.104.2.445; VANDERBEEK JG, 1994, THEOR APPL GENET, V89, P467, DOI 10.1007/BF00225382; VANDERBIEZEN EA, 1995, MOL GEN GENET, V247, P453, DOI 10.1007/BF00293147; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; YAGHOOBI J, 1995, THEOR APPL GENET, V91, P457, DOI 10.1007/BF00222973; YOUNG ND, 1988, GENETICS, V120, P579; ZAMIR D, 1994, THEOR APPL GENET, V88, P141, DOI 10.1007/BF00225889; ZAMIR D, 1995, TOMATO GENET COOP RE, V43, P51	56	435	513	1	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1996	14	4					421	429		10.1038/ng1296-421	http://dx.doi.org/10.1038/ng1296-421			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944022				2022-12-25	WOS:A1996VV73000018
J	Choate, KA; Medalie, DA; Morgan, JR; Khavari, PA				Choate, KA; Medalie, DA; Morgan, JR; Khavari, PA			Corrective gene transfer in the human skin disorder lamellar ichthyosis	NATURE MEDICINE			English	Article							KERATINOCYTE TRANSGLUTAMINASE; EPIDERMAL-KERATINOCYTES; BARRIER FUNCTION; DIFFERENTIATION; THERAPY; EXPRESSION; ANTIBODIES; TISSUE; CELLS; MICE	Lamellar ichthyosis (LI) is a disfiguring skin disease characterized by abnormal epidermal differentiation and defective cutaneous barrier function(1,2). LI has been associated with loss of keratinocyte transglutaminase 1 (TGase1)(3,4) an enzyme believed necessary for normal formation of the cornified epidermal barrier. Using LI as a prototype for therapeutic cutaneous gene delivery, we have used the human skin/immunodeficient mouse xenograft model to correct the molecular, histologic and functional abnormalities of LI patient skin in vivo. We have used TGase1-deficient primary keratinocytes from LI patients combined with high-efficiency transfer of functional TGase1 to regenerate engineered human LI epidermis on immunodeficient mice. Engineered LI epidermis displayed normal TGase1 expression in vivo, unlike unengineered LI epidermis where TGase1 was absent. Epidermal architecture was also normalized by TGase1 restoration, as was expression of the epidermal differentiation marker filaggrin. Engineered LI skin demonstrated restoration of cutaneous barrier function measures to levels seen in epidermis regenerated by keratinocytes from patients with normal skin, indicating functional correction in vivo of the proposed primary pathophysiologic defect in LI. These results confirm a major role for TGase1 in epidermal differentiation and demonstrate a potential future approach to therapeutic gene delivery in human skin.	STANFORD UNIV,SCH MED,MSLS,DEPT DERMATOL,STANFORD,CA 94305; VET ADM MED CTR,VET AFFAIRS PALO ALTO HLTH CARE SYST,PALO ALTO,CA 94304; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,SURG SERV,CAMBRIDGE,MA 02139; SHRINERS BURN INST,RES CTR,CAMBRIDGE,MA 02139	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Harvard University; Massachusetts General Hospital			Cantero, Domingo/E-5688-2011; Garcia, Manuel Macias/AAV-3578-2021	Cantero, Domingo/0000-0002-1643-2831; Garcia, Manuel Macias/0000-0003-3207-2159; Morgan, Jeffrey/0000-0002-7546-3443				BALE SJ, 1994, J INVEST DERMATOL, V102, pS49, DOI 10.1111/1523-1747.ep12388591; Briggaman R A, 1980, Curr Probl Dermatol, V10, P115; DALE BA, 1987, J INVEST DERMATOL, V88, P307; FENJVES ES, 1994, J INVEST DERMATOL, V103, pS70, DOI 10.1111/1523-1747.ep12399089; Fenjves ES, 1996, J INVEST DERMATOL, V106, P576, DOI 10.1111/1523-1747.ep12344976; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GARLICK JA, 1991, J INVEST DERMATOL, V97, P824, DOI 10.1111/1523-1747.ep12489019; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; Gibson DFC, 1996, J INVEST DERMATOL, V106, P154, DOI 10.1111/1523-1747.ep12329856; GREENHALGH DA, 1994, J INVEST DERMATOL, V103, pS63, DOI 10.1038/jid.1994.12; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KHAVARI PA, IN PRESS DERMATOL CL; KIM YH, 1992, J INVEST DERMATOL, V98, P191, DOI 10.1111/1523-1747.ep12555849; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LAVRIJSEN APM, 1993, BRIT J DERMATOL, V129, P547, DOI 10.1111/j.1365-2133.1993.tb00482.x; MANCINI AJ, 1994, PEDIATR RES, V36, P306, DOI 10.1203/00006450-199409000-00007; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; OTTEY KA, 1995, J INVEST DERMATOL, V104, P401, DOI 10.1111/1523-1747.ep12665893; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; ROOP DR, 1984, J BIOL CHEM, V259, P8037; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; TA BM, 1990, J CELL SCI, V95, P631; TAICHMAN LB, 1994, KERATINOCYTE HDB, P543; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; VOGEL JC, 1993, ARCH DERMATOL, V129, P1478, DOI 10.1001/archderm.129.11.1478; WILLIAMS ML, 1987, DERMATOL CLIN, V5, P155, DOI 10.1016/S0733-8635(18)30772-1	30	134	138	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1263	1267		10.1038/nm1196-1263	http://dx.doi.org/10.1038/nm1196-1263			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898758				2022-12-25	WOS:A1996VQ10100046
J	Edelman, RR; Hatabu, H; Tadamura, E; Li, W; Prasad, PV				Edelman, RR; Hatabu, H; Tadamura, E; Li, W; Prasad, PV			Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging	NATURE MEDICINE			English	Article							PARENCHYMA	The imaging of regional ventilation in the lungs is essential for the evaluation of a variety of pathological conditions, such as emphysema, pneumonia and pulmonary embolism. We propose a novel approach for ventilation scanning, using magnetic resonance imaging (MRI) and inhaled molecular oxygen as a contrast agent, that directly depicts transfer of oxygen across the alveolus into the pulmonary vasculature. Molecular oxygen is only weakly paramagnetic but produces substantial signal changes in the lungs because of their large surface area. Ventilation defects were shown in a patient with bullous emphysema, and ventilation-perfusion mismatches were shown in two patients with pulmonary embolism.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Edelman, RR (corresponding author), BETH ISRAEL HOSP,DEPT RADIOL,AN-234,330 BROOKLINE AVE,BOSTON,MA 02215, USA.			Prasad, Pottumarthi/0000-0002-4214-5465				ALBERT MS, 1994, NATURE, V370, P199, DOI 10.1038/370199a0; ALSOP DC, 1995, MAGNET RESON MED, V33, P678, DOI 10.1002/mrm.1910330513; BERGIN CJ, 1993, J THORAC IMAG, V8, P12, DOI 10.1097/00005382-199324000-00003; BERGIN CJ, 1991, RADIOLOGY, V179, P777, DOI 10.1148/radiology.179.3.2027991; CHIAROTTI G, 1955, NUOVO CIMENTO, V1, P863, DOI 10.1007/BF02731333; GLOVER GH, 1992, MAGNET RESON MED, V28, P275, DOI 10.1002/mrm.1910280209; Goodman LR, 1996, RADIOLOGY, V199, P25, DOI 10.1148/radiology.199.1.8633154; Harris P, 1986, HUMAN PULMONARY CIRC; HATABU H, IN PRESS MAGN RESON; HAYES M, 1980, SEMIN NUCL MED, V10, P243, DOI 10.1016/S0001-2998(80)80004-3; HENNIG J, 1988, MAGN RESON IMAGING, V6, P391, DOI 10.1016/0730-725X(88)90475-4; JAO JC, IN PRESS PHYS MED; Listerud J, 1992, Magn Reson Q, V8, P199; MacFall JR, 1996, RADIOLOGY, V200, P553, DOI 10.1148/radiology.200.2.8685356; MAYO JR, 1992, AM J ROENTGENOL, V159, P951, DOI 10.2214/ajr.159.5.1414805; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; MILIC-EMILI J, 1971, Seminars in Nuclear Medicine, V1, P246	17	313	318	1	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1236	1239		10.1038/nm1196-1236	http://dx.doi.org/10.1038/nm1196-1236			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898751				2022-12-25	WOS:A1996VQ10100039
J	Hoglund, P; Haila, S; Socha, J; Tomaszewski, L; SaarialhoKere, U; KarjalainenLindsberg, ML; Airola, K; Holmberg, C; delaChapelle, A; Kere, J				Hoglund, P; Haila, S; Socha, J; Tomaszewski, L; SaarialhoKere, U; KarjalainenLindsberg, ML; Airola, K; Holmberg, C; delaChapelle, A; Kere, J			Mutations of the Down-regulated in adenoma (DRA) gene cause congenital chloride diarrhoea	NATURE GENETICS			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; LINKAGE DISEQUILIBRIUM; DIASTROPHIC DYSPLASIA; EXPRESSION; HYBRIDIZATION; LOCALIZATION; POPULATIONS; TRANSPORT; ENCODES; FINLAND		CHILD HLTH CTR,DEPT GASTROENTEROL & NUTR,WARSAW,POLAND; UNIV HELSINKI,DEPT DERMATOL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,HAARTMAN INST,DEPT PATHOL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,FIN-00014 HELSINKI,FINLAND	Children's Memorial Health Institute; University of Helsinki; University of Helsinki; University of Helsinki	Hoglund, P (corresponding author), UNIV HELSINKI,HAARTMAN INST,DEPT MED GENET,HAARTMANINKATU 3,FIN-00014 HELSINKI,FINLAND.		Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008	Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271				BIEBERDO.FA, 1972, J CLIN INVEST, V51, P1958, DOI 10.1172/JCI107002; BUCHAN AMJ, 1989, TXB PHYSL, P1438; Byeon MK, 1996, ONCOGENE, V12, P387; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HOGLUND P, 1995, AM J HUM GENET, V57, P95; Hoglund P, 1996, GENOME RES, V6, P202, DOI 10.1101/gr.6.3.202; HOLMBERG C, 1975, J CLIN INVEST, V56, P302, DOI 10.1172/JCI108094; KERE J, 1993, P NATL ACAD SCI USA, V90, P10686, DOI 10.1073/pnas.90.22.10686; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; NORIO R, 1971, Clinical Genetics, V2, P182; PEARSON AJG, 1973, Q J MED, V167, P453; PROSSER IW, 1989, AM J PATHOL, V135, P1073; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; STRONG TV, 1994, J CLIN INVEST, V93, P347, DOI 10.1172/JCI116966; TOMASZEWSKI L, 1987, MAT MED POL, V4, P271; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; TURNBERG LA, 1971, GUT, V12, P544, DOI 10.1136/gut.12.7.544	22	316	321	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					316	319		10.1038/ng1196-316	http://dx.doi.org/10.1038/ng1196-316			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896562				2022-12-25	WOS:A1996VQ14600027
J	Perretti, M; Croxtall, JD; Wheller, SK; Goulding, NJ; Hannon, R; Flower, RJ				Perretti, M; Croxtall, JD; Wheller, SK; Goulding, NJ; Hannon, R; Flower, RJ			Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration	NATURE MEDICINE			English	Article							TRANSENDOTHELIAL MIGRATION; NEUTROPHIL MIGRATION; ANNEXIN-I; DEXAMETHASONE; CELLS; RATS	Polymorphonuclear leukocyte (PMN) migration into sites of inflammation is fundamental to the host defense response. Activation of endothelial cells and PMNs increases the expression or activation of adhesion molecules, culminating in rolling and subsequent adherence of these cells to the vascular wall(1,2). Further activation of adherent PMNs, possibly by endothelial cell ligands, leads, within a few minutes, to extravasation itself. This process is not clearly understood, but adhesion molecules' or related proteins(4), as well as endogenous chemokines(5), may play an important role. The anti-inflammatory glucocorticoids delay extravasation(6), which implies that an inhibitory regulatory system exists. Resting PMNs contain abundant cytoplasmic lipocortin 1 (LC1, also called annexin I)(7), and the activity profile of this protein(8-10) suggests that it could reduce PMN responsiveness. To investigate this we have assessed neutrophil transmigration both in vivo and in vitro and examined the content and subcellular distribution of LC1 in PMNs by fluorescence-activated cell-sorting (FAGS) analysis, western blotting and confocal microscopy. We report that LC1 is mobilized and externalized following PMN adhesion to endothelial monolayers in vitro or to venular endothelium in vivo and that the end point of this process is a negative regulation of PMN transendothelial passage.			Perretti, M (corresponding author), WILLIAM HARVEY RES INST, DEPT BIOCHEM PHARMACOL, CHARTERHOUSE SQ, LONDON EC1M 6BQ, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWNING JL, 1990, PROG CLIN BIOL RES, V349, P27; CARLOS TM, 1994, BLOOD, V84, P2068; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; GOULDING NJ, 1990, LANCET, V335, P1416, DOI 10.1016/0140-6736(90)91445-G; GOULDING NJ, 1990, BIOCHEM SOC T, V18, P1237, DOI 10.1042/bst0181237; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; LEBOUTEILLER PP, 1983, J IMMUNOL METHODS, V61, P301, DOI 10.1016/0022-1759(83)90224-7; LOMAS DA, 1995, J BIOL CHEM, V270, P23437, DOI 10.1074/jbc.270.40.23437; MANCUSO F, 1995, J IMMUNOL, V155, P377; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; PEPINSKY RB, 1990, FEBS LETT, V261, P247, DOI 10.1016/0014-5793(90)80564-Y; PERRETTI M, 1995, BIOCHEM PHARMACOL, V50, P1037, DOI 10.1016/0006-2952(95)00238-U; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 1996, BRIT J PHARMACOL, V118, P605, DOI 10.1111/j.1476-5381.1996.tb15444.x; PERRETTI M, 1993, J IMMUNOL, V150, P992; PERRETTI M, 1992, AGENTS ACTIONS, V35, P71, DOI 10.1007/BF01990954; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SOLITO E, 1991, FEBS LETT, V291, P238, DOI 10.1016/0014-5793(91)81293-H; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEVENS TRJ, 1988, BRIT J PHARMACOL, V93, pP139; VISHWANATH BS, 1992, ENDOCRINOLOGY, V130, P585, DOI 10.1210/en.130.2.585; WANG W, 1994, BIOCHEMISTRY-US, V33, P275, DOI 10.1021/bi00167a036	26	199	206	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1259	1262		10.1038/nm1196-1259	http://dx.doi.org/10.1038/nm1196-1259			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898757				2022-12-25	WOS:A1996VQ10100045
J	Fox, BS; Kantak, KM; Edwards, MA; Black, KM; Bollinger, BK; Botka, AJ; French, TL; Thompson, TL; Schad, VC; Greenstein, JL; Gefter, ML; Exley, MA; Swain, PA; Briner, TJ				Fox, BS; Kantak, KM; Edwards, MA; Black, KM; Bollinger, BK; Botka, AJ; French, TL; Thompson, TL; Schad, VC; Greenstein, JL; Gefter, ML; Exley, MA; Swain, PA; Briner, TJ			Efficacy of a therapeutic cocaine vaccine in rodent models	NATURE MEDICINE			English	Article							DISPOSITION; PHARMACOLOGY; INJECTION; ANIMALS; HUMANS; ABUSE	Cocaine abuse is a major medical and public health concern in the United States, with approximately 2.1 million people dependent on cocaine(1). Pharmacological approaches to the treatment of cocaine addiction have thus far been disappointing(2,3), and new therapies are urgently needed. This paper describes an immunological approach to cocaine addiction. Antibody therapy for neutralization of abused drugs has been described previously(4), including a recent paper demonstrating the induction of anti-cocaine antibodies(5). However, both the rapidity of entry of cocaine into the brain(6) and the high doses of cocaine frequently encountered(7) have created challenges for an antibody-based therapy. Here we demonstrate that antibodies are efficacious in an animal model of addiction. Intravenous cocaine self-administration in rats was inhibited by passive transfer of an anti-cocaine monoclonal antibody. To actively induce anti-cocaine antibodies, a cocaine vaccine was developed that generated a high-titer, long-lasting antibody response in mice. Immunized mice displayed a significant change in cocaine pharmacokinetics, with decreased levels of cocaine measured in the brain of immunized mice only 30 seconds after intravenous (i.v.) administration of cocaine. These data establish the feasibility of a therapeutic cocaine vaccine for the treatment of cocaine addiction.	BOSTON UNIV,DEPT PSYCHOL,BOSTON,MA 02215	Boston University	Fox, BS (corresponding author), IMMULOG PHARMACEUT CORP,610 LINCOLN ST,WALTHAM,MA 02154, USA.			Exley, Mark/0000-0002-5088-1032				BENOWITZ NL, 1993, PHARMACOL TOXICOL, V72, P3, DOI 10.1111/j.1600-0773.1993.tb01331.x; Bergman J., 1990, Behav Pharmacol, V1, P355; BODANSZKY M, 1992, PEPTIDE RES, V5, P134; BONESE KF, 1974, NATURE, V252, P708, DOI 10.1038/252708a0; CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0; CARROLL FI, 1994, PHARM NEWS, V1, P11; GOLDBERG SR, 1983, PHARMACOL BIOCHEM BE, V19, P1011, DOI 10.1016/0091-3057(83)90408-2; Institute of Medicine, 1995, DEV MED TREATM OP CO; JATLOW P, 1988, YALE J BIOL MED, V61, P105; JATLOW P, 1991, LIFE SCI, V48, P1787, DOI 10.1016/0024-3205(91)90217-Y; JEFFCOAT AR, 1989, DRUG METAB DISPOS, V17, P153; JINDAL SP, 1989, J PHARM SCI, V78, P1009, DOI 10.1002/jps.2600781208; JOHANSON CE, 1989, PHARMACOL REV, V41, P3; KANTAK KM, 1992, PHARMACOL BIOCHEM BE, V41, P415, DOI 10.1016/0091-3057(92)90120-5; KATZ J, 1987, METHODS ASSESSING RE, P105; KIRCHNER JG, 1978, TECH CHEM, V14, P736; Nutt DJ, 1996, LANCET, V347, P31, DOI 10.1016/S0140-6736(96)91561-5; OLDENDORF WH, 1992, RES MONOGRAPH, V120, P13; ROTHSTEIN TL, 1983, MOL IMMUNOL, V20, P161, DOI 10.1016/0161-5890(83)90127-X; STEWARD MW, 1986, HDB EXPT IMMUNOLOGY, V1; WITHERS NW, 1995, J CLIN PSYCHOPHARM, V15, P63, DOI 10.1097/00004714-199502000-00010; Woods J. H., 1987, COCAINE CLIN BIOBEHA, P21	22	184	193	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1129	1132		10.1038/nm1096-1129	http://dx.doi.org/10.1038/nm1096-1129			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837612				2022-12-25	WOS:A1996VK99500034
J	Gabrilovich, DI; Chen, HL; Cunningham, HT; Meny, GM; Nadaf, S; Kavanaugh, D; Carbone, DP				Gabrilovich, DI; Chen, HL; Cunningham, HT; Meny, GM; Nadaf, S; Kavanaugh, D; Carbone, DP			Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HUMAN BONE-MARROW; PERMEABILITY FACTOR; LANGERHANS CELLS; DOWN-REGULATION; NECROSIS-FACTOR; BEARING MICE; ANGIOGENESIS; ANTIGEN; CANCER	Inadequate presentation of tumor antigens by host professional antigen-presenting cells (APCs), including dendritic cells (DCs), is one potential mechanism for the escape of tumors from the host immune system. Here, we show that human cancer cell lines release a soluble factor or factors that dramatically affect DC maturation from precursors without affecting the function of relatively mature DCs. One factor responsible for these effects was identified as vascular endothelial growth factor (VEGF). Thus, VEGF may play a broader role in the pathogenesis of cancer than was previously thought, and therapeutic blockade of VEGF action may improve prospects for immunotherapy as well as inhibit tumor neovasculature.	UNIV TEXAS,SW MED CTR,HAMON CTR THERAPEUT ONCOL RES,DALLAS,TX 75325; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75325	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Gabrilovich, Dmitry/ABE-7122-2020		NATIONAL CANCER INSTITUTE [R01CA061242] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 61242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCALAY J, 1991, J IMMUNOL, V146, P1717; Austyn J M, 1993, In Vivo, V7, P193; AXELSSON K, 1995, J NATL CANCER I, V87, P997, DOI 10.1093/jnci/87.13.997; BELLDEGRUN A, 1989, J IMMUNOL, V42, P4520; BERGFELT L, 1994, BRIT J DERMATOL, V130, P273, DOI 10.1111/j.1365-2133.1994.tb02921.x; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; BOCHNER BH, 1995, J NATL CANCER I, V87, P1603, DOI 10.1093/jnci/87.21.1603; BOSSI P, 1995, CANCER RES, V55, P5049; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; COZZOLINO F, 1987, J EXP MED, V166, P303, DOI 10.1084/jem.166.2.303; ERROI A, 1989, INT J CANCER, V41, P65; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P101, DOI 10.1006/cimm.1996.0139; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P111, DOI 10.1006/cimm.1996.0140; GAZDAR AF, 1986, CANCER RES, V46, P6011; Hayhoe FGJ, 1988, HAEMATOLOGICAL CYTOC; Hoehn GT, 1996, ONCOGENE, V12, P903; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; IOANNIDES CG, 1993, CLIN IMMUNOL IMMUNOP, V66, P91, DOI 10.1006/clin.1993.1012; KATO, 1995, CANCER RES, V55, P5687; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; KONDO S, 1994, BBA-MOL CELL RES, V1221, P211, DOI 10.1016/0167-4889(94)90016-7; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; REID CDL, 1990, BLOOD, V76, P1139; REID CDL, 1992, J IMMUNOL, V149, P2681; REYNOLDS NJ, 1995, BRIT J DERMATOL, V133, P157, DOI 10.1111/j.1365-2133.1995.tb02611.x; ROCK KL, 1993, J IMMUNOL, V150, P438; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROZENZWAJG M, 1996, BLOOD, V87, P535; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SHEN H, 1993, BLOOD, V81, P2767; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Szabolcs P, 1996, BLOOD, V87, P4520, DOI 10.1182/blood.V87.11.4520.bloodjournal87114520; Takano S, 1996, CANCER RES, V56, P2185; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TAN KC, 1994, J IMMUNOL, V153, P760; TAS MPR, 1993, CANCER IMMUNOL IMMUN, V36, P108, DOI 10.1007/BF01754410; TORIYAMA K, 1993, J INVEST DERMATOL, V100, P2695; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WATSON GA, 1995, J IMMUNOL, V155, P3124; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	45	1462	1582	2	58	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1096	1103		10.1038/nm1096-1096	http://dx.doi.org/10.1038/nm1096-1096			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837607				2022-12-25	WOS:A1996VK99500029
J	Jobsis, GJ; Keizers, H; Vreijling, JP; deVisser, M; Speer, MC; Wolterman, RA; Baas, F; Bolhuis, PA				Jobsis, GJ; Keizers, H; Vreijling, JP; deVisser, M; Speer, MC; Wolterman, RA; Baas, F; Bolhuis, PA			Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures	NATURE GENETICS			English	Letter							MUSCULAR-DYSTROPHY; BETA-SARCOGLYCAN; CHAIN; LOCALIZATION; COMPLEX; GENE		DUKE UNIV,MED CTR,DIV NEUROL,DURHAM,NC 27710	Duke University	Jobsis, GJ (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROL,POB 22700,NL-1100 DE AMSTERDAM,NETHERLANDS.		Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428				ARTS WF, 1978, J NEUROL, V217, P201, DOI 10.1007/BF00312962; BETHLEM J, 1976, BRAIN, V99, P91, DOI 10.1093/brain/99.1.91; BOERS JM, 1984, THESIS U AMSTERDAM; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HESSLE H, 1984, J BIOL CHEM, V259, P3955; IBRAHIMI A, 1993, BIOCHEM J, V289, P141, DOI 10.1042/bj2890141; Jobsis GJ, 1996, NEUROLOGY, V46, P779, DOI 10.1212/WNL.46.3.779; JOBSIS GJ, 1995, NEUROLOGY, V45, pS881; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MERLINI L, 1994, NEUROMUSCULAR DISORD, V4, P503, DOI 10.1016/0960-8966(94)90091-4; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; MOHIRE MD, 1988, NEUROLOGY, V38, P573, DOI 10.1212/WNL.38.4.573; OZAWA E, 1995, HUM MOL GENET, V4, P1171; Renieri A., 1995, American Journal of Human Genetics, V57, pA9; ROMANIC AM, 1994, J BIOL CHEM, V269, P11614; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Speer MC, 1996, HUM MOL GENET, V5, P1043, DOI 10.1093/hmg/5.7.1043; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; STEINMANN B, 1995, SCIENCE, V267, P258, DOI 10.1126/science.7809634; SWASDISON S, 1989, CELL TISSUE RES, V257, P537, DOI 10.1007/BF00221463; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; VONDERMARK H, 1984, EUR J BIOCHEM, V142, P493; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297	25	197	205	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					113	115		10.1038/ng0996-113	http://dx.doi.org/10.1038/ng0996-113			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782832				2022-12-25	WOS:A1996VF61100033
J	Schwab, ME				Schwab, ME			Bridging the gap in spinal cord regeneration	NATURE MEDICINE			English	Editorial Material							AXONS; INJURY; RAT; METHYLPREDNISOLONE; LESION; GRAFTS; CELLS				Schwab, ME (corresponding author), UNIV ZURICH,BRAIN RES INST,AUGUST FOREL STR 1,POB 732,CH-8029 ZURICH,SWITZERLAND.		Schwab, Martin E/B-6818-2016					BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; KAO CC, 1983, SPINAL CORD RECONSTR; KEIRSTEAD HS, 1992, P NATL ACAD SCI USA, V89, P11664, DOI 10.1073/pnas.89.24.11664; MORRISSEY TK, 1995, J NEUROBIOL, V28, P190, DOI 10.1002/neu.480280206; RICHARDSON PM, 1984, J NEUROCYTOL, V13, P165, DOI 10.1007/BF01148324; SAUVE Y, 1995, J NEUROSCI, V15, P665; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Tello J.F, 1911, TRAB LAB INVEST BIOL, V9, P123; THANOS S, 1992, EUR J NEUROSCI, V4, P691, DOI 10.1111/j.1460-9568.1992.tb00178.x; VARGA ZM, 1995, EUR J NEUROSCI, V7, P2119, DOI 10.1111/j.1460-9568.1995.tb00634.x; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056	16	16	16	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					976	977		10.1038/nm0996-976	http://dx.doi.org/10.1038/nm0996-976			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782452				2022-12-25	WOS:A1996VF49700029
J	Kedes, DH; Operskalski, E; Busch, M; Kohn, R; Flood, J; Ganem, D				Kedes, DH; Operskalski, E; Busch, M; Kohn, R; Flood, J; Ganem, D			The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission	NATURE MEDICINE			English	Article							DNA-SEQUENCES; HOMOSEXUAL MEN; AIDS; FORMS	Striking differences in Kaposi's sarcoma (KS) risk for AIDS patients who acquire HIV via homosexual activity and those whose HIV infections derive from blood product exposure suggest the presence of a sexually transmitted agent other than HIV in the development of KS. Using an immunofluorescence assay, we examined serum samples from 913 patients for the presence of antibody specific for infection by human herpesvirus 8 (HHV8), an agent whose genome is regularly found in KS tissue. The distribution of HHV8 seropositivity conforms to that expected for a sexually transmitted pathogen and tracks closely with the risk for KS development. Our data support the inference that this virus is the etiologic cofactor predicted by the epidemiology of KS.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; TRANSFUS SAFETY STUDY,LOS ANGELES,CA 90032; UNIV SO CALIF,LOS ANGELES,CA 90032; UNIV CALIF SAN FRANCISCO,IRWIN MEM BLOOD CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,DIV SEXUALLY TRANSMITTED DIS,SAN FRANCISCO,CA 94103	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Southern California; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco Department of Public Health					NHLBI NIH HHS [N01-HB-97074, N01-HB-4-7003, N01-HB-4-7002] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097074, N01HB047003, N01HB047002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams V, 1995, LANCET, V346, P1715, DOI 10.1016/S0140-6736(95)92887-1; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boshoff C, 1996, LANCET, V347, P338, DOI 10.1016/S0140-6736(96)90524-3; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; HENLE G, 1974, J INFECT DIS, V130, P231, DOI 10.1093/infdis/130.3.231; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KIEFF E, 1995, VIROLOGY, P2343; LIN JC, 1995, LANCET, V346, P1601, DOI 10.1016/S0140-6736(95)91931-7; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; MOORE P, 1995, AIDS, V10, P175; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; OPERSKALSKI EA, 1995, J INFECT DIS, V172, P648, DOI 10.1093/infdis/172.3.648; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; RICKINSON AB, 1995, VIROLOGY, P2397; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; STRAUSS S, 1995, PRINCIPLES PRACTICE, P1330; WITBY D, 1995, LANCET, V346, P799; ZIEGLER JL, 1984, SEMIN ONCOL, V11, P47	30	614	634	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					918	924		10.1038/nm0896-918	http://dx.doi.org/10.1038/nm0896-918			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705863				2022-12-25	WOS:A1996UZ80400040
J	Ambrosini, G; Adida, C; Altieri, DC				Ambrosini, G; Adida, C; Altieri, DC			A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma	NATURE MEDICINE			English	Article							CELL-DEATH; BCL-2; PROTEIN; STRAND	Inhibitors of programmed cell death (apoptosis) aberrantly prolonging cell viability may contribute to cancer(1) by facilitating the insurgence of mutations and by promoting resistance to therapy(2). Despite the identification of several new apoptosis inhibitors related to bcl-2(2,3) or to the baculovirus IAP gene(4-9), it is not clear whether apoptosis inhibition plays a general role in neoplasia. Here, we describe a new human gene encoding a structurally unique IAP apoptosis inhibitor, designated survivin. Survivin contains a single baculovirus IAP repeat and lacks a carboxyl-terminal RING finger. Present during fetal development, survivin is undetectable in terminally differentiated adult tissues. However, survivin becomes prominently expressed in transformed cell lines and in all the most common human cancers of lung, colon, pancreas, prostate and breast, in vivo. Survivin is also found in approximately 50% of high-grade non-Hodgkin's lymphomas (centroblastic, immunoblastic), but not in low-grade lymphomas (lymphocytic). Recombinant expression of survivin counteracts apoptosis of B lymphocyte precursors deprived of interleukin 3 (IL-3). These findings suggest that apoptosis inhibition may be a general feature of neoplasia and identify survivin as a potential new target for apoptosis-based therapy in cancer and lymphoma.	YALE UNIV,SCH MED,DEPT PATHOL,BOYER CTR MOL MED,NEW HAVEN,CT 06536	Yale University					NHLBI NIH HHS [HL 54131, R01 HL 43773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R01HL043773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adida C, 1996, BLOOD, V88, P1457, DOI 10.1182/blood.V88.4.1457.bloodjournal8841457; ALTIERI DC, 1995, FASEB J, V9, P860, DOI 10.1096/fasebj.9.10.7615156; ASCASO R, 1994, EUR J IMMUNOL, V24, P537, DOI 10.1002/eji.1830240307; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; CELANO P, 1992, J BIOL CHEM, V267, P15092; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GRAHAM GJ, 1995, J THEOR BIOL, V175, P71, DOI 10.1006/jtbi.1995.0122; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Jiang SX, 1996, AM J PATHOL, V148, P837; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIMMELMAN D, 1989, CELL, V59, P687; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEBRUN DP, 1993, AM J PATHOL, V142, P743; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	23	2716	3399	3	220	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					917	921		10.1038/nm0897-917	http://dx.doi.org/10.1038/nm0897-917			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256286				2022-12-25	WOS:A1997XP01400037
J	Chen, YP; Maguire, T; Hileman, RE; Fromm, JR; Esko, JD; Linhardt, RJ; Marks, RM				Chen, YP; Maguire, T; Hileman, RE; Fromm, JR; Esko, JD; Linhardt, RJ; Marks, RM			Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate	NATURE MEDICINE			English	Article							BORNE ENCEPHALITIS-VIRUS; FIBROBLAST GROWTH-FACTOR; RESISTANT MUTANTS; ANTICOAGULANT; BIOSYNTHESIS; GLYCOPROTEIN; ATTACHMENT; SEQUENCE; ADHESION; FEVER	Dengue virus is a human pathogen that has reemerged as an increasingly important public health threat. We found that the cellular receptor utilized by dengue envelope protein to bind to target cells is a highly sulfated type of heparan sulfate. Heparin, highly sulfated heparan sulfate, and the polysulfonate pharmaceutical Suramin effectively prevented dengue virus infection of target cells, indicating that the envelope protein-target cell receptor Interaction is a critical determinant of infectivity. The dengue envelope protein sequence includes two putative glycosaminoglycan-binding motifs at the carboxy terminus; the first could be structurally modeled and formed an unusual extended binding surface of basic amino acids. Similar motifs were also identified in the envelope proteins of other flaviviridae. Developing pharmaceuticals that inhibit target cell binding may be an effective strategy for treating flavivirus infections.	UNIV MICHIGAN, DEPT INTERNAL MED, DIV RHEUMATOL, ANN ARBOR, MI 48109 USA; UNIV OTAGO, HLTH RES COUNCIL, NEW ZEALANDS VIRUS RES GRP, DUNEDIN, NEW ZEALAND; UNIV OTAGO, CTR GENE RES, DUNEDIN, NEW ZEALAND; UNIV IOWA, DIV MED & NAT PROD CHEM, IOWA CITY, IA 52242 USA; UNIV IOWA, DEPT CHEM & BIOCHEM ENGN, IOWA CITY, IA 52242 USA; UNIV CALIF SAN DIEGO, CTR CANC, DIV CELLULAR & MOL MED, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA	University of Michigan System; University of Michigan; University of Otago; University of Otago; University of Iowa; University of Iowa; University of California System; University of California San Diego					NIAID NIH HHS [AI 33189] Funding Source: Medline; NIAMS NIH HHS [AR 41703, AR 20557] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR041703, P60AR020557] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; *CDC, 1996, MMWR-MORBID MORTAL W, V45, pN39; CECILIA D, 1991, VIROLOGY, V181, P70, DOI 10.1016/0042-6822(91)90471-M; CHEN WB, 1990, NUCLEIC ACIDS RES, V18, P5889, DOI 10.1093/nar/18.19.5889; Chen YP, 1996, J VIROL, V70, P8765, DOI 10.1128/JVI.70.12.8765-8772.1996; COUCHMAN JR, 1993, CELL STRUCTURE EXTRA, V1, P33; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; Halstead Scott B., 1992, World Health Statistics Quarterly, V45, P292; HE RT, 1995, J MED VIROL, V45, P451, DOI 10.1002/jmv.1890450417; HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990; HOLZMANN H, 1990, J VIROL, V64, P5156, DOI 10.1128/JVI.64.10.5156-5159.1990; *I MED US COMM EM, 1992, EM INF MICR THREATS; JENNINGS AD, 1994, J INFECT DIS, V169, P512, DOI 10.1093/infdis/169.3.512; JIANG WR, 1993, J GEN VIROL, V74, P931, DOI 10.1099/0022-1317-74-5-931; JJACKSON T, 1996, J VIROL, V70, P5282; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIN B, 1994, VIROLOGY, V202, P855; Linhardt R. J., 1997, CARBOHYDRATES DRUG D, P277; LINHARDT RJ, 1994, CURRENT PROTOCOLS MO, V2; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MCCLAIN DS, 1994, VIROLOGY, V198, P690, DOI 10.1006/viro.1994.1081; MOHAN P, 1991, Antiviral Chemistry and Chemotherapy, V2, P215; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Ojala WH, 1996, J AM CHEM SOC, V118, P2131, DOI 10.1021/ja951121f; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; PORTERFIELD JS, 1986, ADV VIRUS RES, V31, P335, DOI 10.1016/S0065-3527(08)60268-7; RAAKE W, 1989, THROMB RES, V56, P719, DOI 10.1016/0049-3848(89)90289-2; REED L. J., 1938, AMER JOUR HYG, V27, P493; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; Rostand KS, 1997, INFECT IMMUN, V65, P1; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sanchez IJ, 1996, J GEN VIROL, V77, P2541, DOI 10.1099/0022-1317-77-10-2541; STERNBERGH WC, 1995, J VASC SURG, V21, P477, DOI 10.1016/S0741-5214(95)70290-3; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Toida T, 1996, J BIOL CHEM, V271, P32040, DOI 10.1074/jbc.271.50.32040; TYLER KL, 1996, FIELDS VIROLOGY, V1, P173; *WHO, 1996, N117 WHO; WIMMER E, 1994, COLD SPRING HARBOR M, P1	50	763	803	0	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					866	871		10.1038/nm0897-866	http://dx.doi.org/10.1038/nm0897-866			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256277				2022-12-25	WOS:A1997XP01400028
J	Bamshad, M; Lin, RC; Law, DJ; Watkins, WS; Krakowiak, PA; Moore, ME; Franceschini, P; Lala, R; Holmes, LB; Gebuhr, TC; Bruneau, BG; Schinzel, A; Seidman, JG; Seidman, CE; Jorde, LB				Bamshad, M; Lin, RC; Law, DJ; Watkins, WS; Krakowiak, PA; Moore, ME; Franceschini, P; Lala, R; Holmes, LB; Gebuhr, TC; Bruneau, BG; Schinzel, A; Seidman, JG; Seidman, CE; Jorde, LB			Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome	NATURE GENETICS			English	Article							CONSERVED PROTEIN MOTIF; MOUSE BRACHYURY; EEC-SYNDROME; GENE FAMILY; HOMOLOG; DROSOPHILA; EXPRESSION; CLONING; HAND		HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV TURIN,IST DISCIPLINE PEDIAT,SERV GENET CLIN,TURIN,ITALY; OSPED INFANTILE R MARGHERETA,DIV ENDOCRINOL PEDIAT,TURIN,ITALY; MASSACHUSETTS GEN HOSP,GENET & TERATOL UNIT,BOSTON,MA 02114; UNIV ZURICH,INST MED GENET,CH-8001 ZURICH,SWITZERLAND; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; Utah System of Higher Education; University of Utah; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; Harvard University; Massachusetts General Hospital; University of Zurich; Harvard University; Brigham & Women's Hospital	Bamshad, M (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT PEDIAT,SALT LAKE CITY,UT 84112, USA.			Bruneau, Benoit/0000-0002-0804-7597	NHGRI NIH HHS [5-P30-HG00199, HG00209] Funding Source: Medline; PHS HHS [M01-00064] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P30HG000199] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AGUINIK SI, 1996, GENETICS, V144, P249; AGULNIK SI, 1995, GENOMICS, V25, P214, DOI 10.1016/0888-7543(95)80128-9; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; Bamshad M, 1996, AM J MED GENET, V65, P325, DOI 10.1002/(SICI)1096-8628(19961111)65:4<325::AID-AJMG15>3.0.CO;2-W; BAMSHAD M, 1995, HUM MOL GENET, V4, P1973, DOI 10.1093/hmg/4.10.1973; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; BUSS PW, 1995, J MED GENET, V32, P716, DOI 10.1136/jmg.32.9.716; CAMPBELL C, 1995, GENOMICS, V28, P255, DOI 10.1006/geno.1995.1139; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Chapman DL, 1996, DEV BIOL, V180, P534, DOI 10.1006/dbio.1996.0326; FRANCESCHINI P, 1992, AM J MED GENET, V44, P807, DOI 10.1002/ajmg.1320440618; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; GONZALEZ CH, 1976, EUR J PEDIATR, V123, P225, DOI 10.1007/BF00444644; Hamel Ben, 1996, European Journal of Human Genetics, V4, P148; HECHT JT, 1984, CLIN GENET, V25, P63; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HOLT M, 1960, BRIT HEART J, V22, P236; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; KISPERT A, 1994, GENE DEV, V8, P2137, DOI 10.1101/gad.8.18.2137; LAW DJ, 1995, MAMM GENOME, V6, P793, DOI 10.1007/BF00539006; LECK I, 1993, HUMAN MALFORMATIONS, V1, P65; Li QY, 1997, NAT GENET, V15, P21; Morrison K, 1996, HUM MOL GENET, V5, P669, DOI 10.1093/hmg/5.5.669; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Nakatani Y, 1996, DEVELOPMENT, V122, P2023; Pallister P D, 1976, Birth Defects Orig Artic Ser, V12, P247; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; RUDIGER RA, 1970, AM J DIS CHILD, V120, P160; SCHINZEL A, 1987, CLIN GENET, V32, P160; SCHINZEL A, 1987, J MED GENET, V24, P778, DOI 10.1136/jmg.24.12.778; SCHINZEL A, 1987, CLIN GENET, V32, P425; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315	40	418	433	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					311	315		10.1038/ng0797-311	http://dx.doi.org/10.1038/ng0797-311			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207801				2022-12-25	WOS:A1997XG60900031
J	Kang, SM; Schneider, DB; Lin, ZH; Hanahan, D; Dichek, DA; Stock, PG; Baekkeskov, S				Kang, SM; Schneider, DB; Lin, ZH; Hanahan, D; Dichek, DA; Stock, PG; Baekkeskov, S			Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction	NATURE MEDICINE			English	Article							CLASS-II MHC; TRANSGENIC MICE; LYMPHOPROLIFERATIVE SYNDROME; PANCREATIC-ISLETS; DEATH FACTOR; CD95 LIGAND; GENE; APOPTOSIS; MUTATIONS; ANTIGEN	Fas ligand is believed to mediate immune privilege in a variety of tissues, including the eye, testis, and a subset of tumors. We tested whether expression of Pas ligand on pancreatic islets either following adenoviral or germline gene transfer could confer immune privilege after transplantation. Islets were infected with an adenoviral vector containing the murine Pas ligand cDNA (AdFasL), and were transplanted into allogenic diabetic hosts. Paradoxically, AdFasL-infected islets underwent accelerated neutrophilic rejection. The rejection was T cell and B cell independent and required Fas protein expression by host cells, but not on islets. Similarly, transgenic mice expressing Fas ligand in pancreatic beta cells developed massive neutrophilic infiltrates and diabetes at a young age. Thus, Fas ligand expression on pancreatic islets results in neutrophilic infiltration and islet destruction. These results have important implications for the development of Fas ligand-based immunotherapies.	UNIV CALIF SAN FRANCISCO,DEPT SURG,TRANSPLANTAT RES LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Baekkeskov, Steinunn/0000-0003-0878-3188; Dichek, David/0000-0002-5224-2736	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041822, R01DK047043] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK 41822, R01 DK 47043] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALLISON J, IN PRESS P NATL ACAD; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CSETE ME, 1995, TRANSPLANTATION, V59, P263, DOI 10.1097/00007890-199501270-00019; Dong G, 1996, J BIOL CHEM, V271, P29969, DOI 10.1074/jbc.271.47.29969; EFRAT S, 1991, ENDOCRINOLOGY, V128, P897, DOI 10.1210/endo-128-2-897; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; Graham FL, 1991, METHOD MOL BIOL, P109; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HANSEN WA, 1989, DIABETES RES CLIN EX, V10, P53; HESSE UJ, 1986, TRANSPLANTATION, V41, P271; IWAI K, 1994, BLOOD, V84, P1201; JOLICOEUR C, 1994, P NATL ACAD SCI USA, V91, P6707, DOI 10.1073/pnas.91.14.6707; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LILES WC, 1995, J IMMUNOL, V155, P3289; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; OSORIO RW, 1994, TRANSPLANT P, V26, P752; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Sekine C, 1996, BIOCHEM BIOPH RES CO, V228, P14, DOI 10.1006/bbrc.1996.1610; SHIROKI R, 1994, TRANSPLANTATION, V57, P1555; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUTHERLAND DER, 1981, DIABETOLOGIA, V20, P161; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Yamada K, 1996, DIABETOLOGIA, V39, P1306, DOI 10.1007/s001250050574	44	413	431	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					738	743		10.1038/nm0797-738	http://dx.doi.org/10.1038/nm0797-738			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212099				2022-12-25	WOS:A1997XG76700032
J	Kim, JJ; Bagarazzi, ML; Trivedi, N; Hu, Y; Kazahaya, K; Wilson, DM; Ciccarelli, R; Chattergoon, MA; Dang, KS; Mahalingam, S; Chalian, AA; Agadjanyan, MG; Boyer, JD; Wang, B; Weiner, DB				Kim, JJ; Bagarazzi, ML; Trivedi, N; Hu, Y; Kazahaya, K; Wilson, DM; Ciccarelli, R; Chattergoon, MA; Dang, KS; Mahalingam, S; Chalian, AA; Agadjanyan, MG; Boyer, JD; Wang, B; Weiner, DB			Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes	NATURE BIOTECHNOLOGY			English	Article						DNA vaccines; immune responses; costimulatory molecules	ANTIGEN-PRESENTING CELLS; HUMAN MYOBLASTS; ADHESION MOLECULES; INTERFERON-GAMMA; HEPATITIS-B; EXPRESSION; CD28; INDUCTION; MUSCLE; B7-1	Nucleic acid immunization is a novel vaccination technique to induce antigen-specific immune responses. We have developed expression cassettes for cell surface markers CD80 and CD86, two functionally related costimulatory molecules that play an important role in the induction of T cell-mediated immune responses, Coimmunization of these expression plasmids, along with plasmid DNA encoding for HIV-1 antigens, did not result in any significant change in the humoral response; however, we observed a dramatic increase in cytotoxic T-lymphocyte (CTL) induction as well as T-helper cell proliferation after the coadministration of CD86 genes. In contrast, coimmunization with a CD80 expression cassette resulted in a minor, but positive increase in T-helper cell or CTL responses. This strategy may be of value for the generation of rationally designed vaccines and immune therapeutics.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM ENGN,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,PHILADELPHIA,PA 19104; APOLLON INC,MALVERN,PA 19355	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Bagarazzi, Mark L/AAU-1383-2021; Weiner, David B/H-8579-2014	Mahalingam, Sundarasamy/0000-0003-4460-3949				Agadjanyan M G, 1991, Biomed Sci, V2, P361; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BEAUCHAMP JR, 1992, AM J PATHOL, V140, P387; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; Conry RM, 1996, GENE THER, V3, P67; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GOEBELS N, 1992, J IMMUNOL, V149, P661; HOHLFELD R, 1990, AM J PATHOL, V136, P503; HOHLFELD R, 1994, IMMUNOL TODAY, V15, P269, DOI 10.1016/0167-5699(94)90006-X; Huang AYC, 1996, J EXP MED, V183, P769, DOI 10.1084/jem.183.3.769; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kim JJ, 1997, J IMMUNOL, V158, P816; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; LANIER LL, 1995, J IMMUNOL, V154, P97; LARSEN CP, 1994, J IMMUNOL, V152, P5208; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MANTEGAZZA R, 1991, NEUROLOGY, V41, P1128, DOI 10.1212/WNL.41.7.1128; MARGOLIS HS, 1993, J INFECT DIS, V168, P9, DOI 10.1093/infdis/168.1.9; MICHAELIS D, 1993, AM J PATHOL, V143, P1142; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; ROY R, 1991, TRANSPLANT P, V23, P799; SHIRAI M, 1992, J IMMUNOL, V148, P1657; STACK RM, 1994, J IMMUNOL, V152, P5723; TAKAHASHI H, 1992, SCIENCE, V255, P333, DOI 10.1126/science.1372448; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Wang B, 1995, AIDS, V9 Suppl A, pS159; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG B, 1994, AIDS RES HUM RETROV, V10, pS35; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WU TC, 1995, J EXP MED, V182, P1415, DOI 10.1084/jem.182.5.1415; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996; ZAROZINSKI CC, 1995, J IMMUNOL, V154, P4010	44	197	214	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					641	646						6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219266				2022-12-25	WOS:A1997XH58300027
J	Wurtman, RJ				Wurtman, RJ			What went right: Why is HIV a treatable disease?	NATURE MEDICINE			English	Editorial Material							PROTEASE; AIDS											BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Bush, 1945, SCI THE ENDLESS FRON, DOI DOI 10.1016/j.techsoc.2019.03.007; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P165; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; DIMASI JA, 1996, AM J THER, V3, P1; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KRAMER L, 1994, REPORTS HOLOCAUST; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Shulman SR, 1995, FOOD DRUG LAW J, V50, P503; SHULTZ R, 1982, BAND PLAYED ON; TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0; WURTMAN RJ, 1995, NAT MED, V1, P1122, DOI 10.1038/nm1195-1122; YOUNG JJ, 1985, AIDS PUBLIC DEBATE, P47	15	7	7	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					714	717						4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212090				2022-12-25	WOS:A1997XG76700023
J	Mavingui, P; Flores, M; Romero, D; MartinezRomero, E; Palacios, R				Mavingui, P; Flores, M; Romero, D; MartinezRomero, E; Palacios, R			Generation of Rhizobium strains with improved symbiotic properties by random DNA amplification (RDA)	NATURE BIOTECHNOLOGY			English	Article						combinatorial chemistry; DNA amplification; bacterial selection; nodulation; symbiotic competitiveness	LEGUMINOSARUM BIOVAR PHASEOLI; NODULATION COMPETITIVENESS; HOST-RANGE; GENE AMPLIFICATION; REGIONS AMPLICONS; BACILLUS-SUBTILIS; PLASMID; MELILOTI; IDENTIFICATION; CIAT899	To select for bacterial strains with enhanced phenotypes, random fragments of a whole genome, or a defined region of the genome, are cloned in a nonreplicating vector. The resulting plasmids are integrated by recombination into the homologous DNA region of the original strain. Integration gives rise to a nontandem direct duplication of the corresponding DNA region separated by the vector moiety of the plasmid. Recombination between the direct repeats leads to tandem duplication and further amplification of the entire integrated DNA, including the vector. Bacteria harboring the amplified DNA are selected by increasing the dosage of an antibiotic corresponding to a resistance marker of the integrated vector. Pooled strains carrying amplifications are then challenged with a selective pressure for the desired phenotype. After repeated selection cycles, the most fit strains are isolated. We used this process, which we called random DNA amplification, to select Rhizobium strains with increased competitiveness for nodule formation. Derivatives containing randomly amplified DNA regions of the symbiotic plasmid of Rhizobium tropici CFN299 strain were generated. Pools of amplified strains were inoculated onto various tropical legumes. After several cycles of selection through plants, amplified derivatives showing an increased competitiveness for nodule formation with the leguminous plant Macroptilium atropurpureum were obtained.	NATL AUTONOMOUS UNIV MEXICO, NITROGEN FIXAT RES CTR, DEPT MOL GENET, CUERNAVACA, MORELOS, MEXICO	Universidad Nacional Autonoma de Mexico				Romero, David/0000-0002-1685-4305; martinez-romero, esperanza/0000-0002-2295-2606				ALBERTINI AM, 1985, J BACTERIOL, V162, P1203, DOI 10.1128/JB.162.3.1203-1211.1985; ANDERSON RP, 1977, ANNU REV MICROBIOL, V31, P473, DOI 10.1146/annurev.mi.31.100177.002353; BANFALVI Z, 1981, MOL GEN GENET, V184, P318; BEATTIE GA, 1993, J GEN MICROBIOL, V139, P529, DOI 10.1099/00221287-139-3-529; BROMFIELD ESP, 1985, J BACTERIOL, V164, P410, DOI 10.1128/JB.164.1.410-413.1985; CORN PG, 1993, J INFECT DIS, V167, P356, DOI 10.1093/infdis/167.2.356; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; DOWLING DN, 1986, ANNU REV MICROBIOL, V40, P131, DOI 10.1146/annurev.mi.40.100186.001023; ECKHARDT T, 1978, PLASMID, V1, P584, DOI 10.1016/0147-619X(78)90016-1; FAHRAEUS G, 1957, J GEN MICROBIOL, V16, P374, DOI 10.1099/00221287-16-2-374; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; FLORES M, 1988, J BACTERIOL, V170, P1191, DOI 10.1128/jb.170.3.1191-1196.1988; FLORES M, 1993, P NATL ACAD SCI USA, V90, P4932, DOI 10.1073/pnas.90.11.4932; FLORES M, 1987, J BACTERIOL, V169, P5782, DOI 10.1128/jb.169.12.5782-5788.1987; FolchMallol JL, 1996, MOL PLANT MICROBE IN, V9, P151, DOI 10.1094/MPMI-9-0151; GENIAUX E, 1995, INT J SYST BACTERIOL, V45, P392, DOI 10.1099/00207713-45-2-392; GHOSAL D, 1985, P NATL ACAD SCI USA, V82, P1638, DOI 10.1073/pnas.82.6.1638; HERNANDEZLUCAS I, 1995, APPL ENVIRON MICROB, V61, P2775, DOI 10.1128/AEM.61.7.2775-2779.1995; HIRSCH PR, 1980, J GEN MICROBIOL, V120, P403; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HONEYCUTT RJ, 1993, J BACTERIOL, V175, P6945, DOI 10.1128/jb.175.21.6945-6952.1993; KALLIO P, 1987, APPL MICROBIOL BIOT, V27, P64; Laeremans T, 1996, MOL PLANT MICROBE IN, V9, P492, DOI 10.1094/MPMI-9-0492; MARTINEZ E, 1987, J BACTERIOL, V169, P2828, DOI 10.1128/jb.169.6.2828-2834.1987; MartinezRomero E, 1996, CRIT REV PLANT SCI, V15, P113, DOI 10.1080/713608131; MARTINEZROMERO E, 1991, INT J SYST BACTERIOL, V41, P417, DOI 10.1099/00207713-41-3-417; MEKALANOS JJ, 1983, CELL, V35, P253, DOI 10.1016/0092-8674(83)90228-3; NEUBERGER MS, 1981, J GEN MICROBIOL, V122, P181; PETERSON BC, 1985, J BACTERIOL, V161, P1042, DOI 10.1128/JB.161.3.1042-1048.1985; PETES TD, 1988, ANNU REV GENET, V22, P147, DOI 10.1146/annurev.ge.22.120188.001051; ROMERO D, 1991, J BACTERIOL, V173, P2435, DOI 10.1128/jb.173.8.2435-2441.1991; ROMERO D, 1995, J BACTERIOL, V177, P973, DOI 10.1128/jb.177.4.973-980.1995; ROSENBERG C, 1981, MOL GEN GENET, V184, P326, DOI 10.1007/BF00272926; ROTH JR, 1996, ESCHERICHIA COLI SAL, P2256; SANJUAN J, 1991, MOL PLANT MICROBE IN, V4, P365, DOI 10.1094/MPMI-4-365; SCHULTZE M, 1994, INT REV CYTOL, V156, P1, DOI 10.1016/S0074-7696(08)62252-4; Simon R., 1990, Molecular biology of symbiotic nitrogen fixation., P13; SIMON R, 1986, METHOD ENZYMOL, V118, P640; SONTI RV, 1989, GENETICS, V123, P19; TRIPLETT EW, 1990, MOL PLANT MICROBE IN, V3, P199, DOI 10.1094/MPMI-3-199; VANRHIJN PJS, 1993, J BACTERIOL, V175, P438, DOI 10.1128/JB.175.2.438-447.1993; VARGAS C, 1990, MOL MICROBIOL, V4, P1899, DOI 10.1111/j.1365-2958.1990.tb02039.x; WAELKENS F, 1995, MOL PLANT MICROBE IN, V8, P147, DOI 10.1094/MPMI-8-0147	44	35	40	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					564	569		10.1038/nbt0697-564	http://dx.doi.org/10.1038/nbt0697-564			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181580				2022-12-25	WOS:A1997XC77200033
J	Matthijs, G; Schollen, E; Pardon, E; VeigaDaCunha, M; Jaeken, J; Cassiman, JJ; VanSchaftingen, E				Matthijs, G; Schollen, E; Pardon, E; VeigaDaCunha, M; Jaeken, J; Cassiman, JJ; VanSchaftingen, E			Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome)	NATURE GENETICS			English	Article							SERUM TRANSFERRIN	Carbohydrate-deficient glycoprotein syndrome type 1 (CDG1 or Jaeken syndrome) is the prototype of a class of genetic multisystem disorders characterized by defective glycosylation of glycoconjugates(1-4). It is mostly a severe disorder which presents neonatally. There is a severe encephalopathy with axial hypotonia, abnormal eye movements and pronounced psychomotor retardation, as well as a peripheral neuropathy, cerebellar hypoplasia and retinitis pigmentosa. The patients show a peculiar distribution of subcutaneous fat, nipple retraction and hypogonadism. There is a 20% lethality in the first years of life due to severe infections, liver insufficiency or cardiomyopathy(2,3,5). CDG1 shows an autosomal recessive mode of inheritance and has been mapped to chromosome 16p(6,7). Most patients show a deficiency of phosphomannomutase (PMM)(8), an enzyme necessary for the synthesis of GDP-mannose. We have cloned the PMM1 gene, which is on chromosome 22q13 (ref, 9), We now report the identification of a second human PMM gene, PMM2, which is located on 16p13 and which encodes a protein with 66% identity to PMM1. We found eleven different missense mutations in PMM2 in 16 CDG1 patients from different geographical origins and with a documented phosphomannomutase deficiency. Our results give conclusive support to the biochemical finding that the phosphomannomutase deficiency is the basis for CDG1.	INT INST CELLULAR & MOL PATHOL, PHYSIOL CHEM LAB, B-1200 BRUSSELS, BELGIUM; UNIV CATHOLIQUE LOUVAIN, B-1200 BRUSSELS, BELGIUM; KATHOLIEKE UNIV LEUVEN HOSP, DEPT PEDIAT, B-3000 LOUVAIN, BELGIUM	Universite Catholique Louvain; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven	Matthijs, G (corresponding author), CATHOLIC UNIV LEUVEN, CTR HUMAN GENET, CAMPUS GASTHUISBERG, B-3000 LOUVAIN, BELGIUM.		Van+Schaftingen, Emile/AAF-5532-2020	Matthijs, Gert/0000-0001-6710-1912; Van Schaftingen, Emile/0000-0002-6199-7647				CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; DOGGETT NA, 1995, NATURE, V377, P335; JAEKEN J, 1984, CLIN CHIM ACTA, V144, P245, DOI 10.1016/0009-8981(84)90059-7; JAEKEN J, 1980, PEDIATR RES, V14, P179, DOI 10.1203/00006450-198002000-00117; JAEKEN J, 1993, J INHERIT METAB DIS, V16, P813, DOI 10.1007/BF00714272; Jaeken J, 1997, J MED GENET, V34, P73, DOI 10.1136/jmg.34.1.73; JAEKEN J, IN PRESS J INHER MET; JAEKEN J, IN PRESS EUR J PEDIA; KEPES F, 1988, J BIOL CHEM, V263, P9155; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LONGMIRE JL, 1993, GENET ANAL-BIOMOL E, V10, P69, DOI 10.1016/1050-3862(93)90037-J; MARTINSSON T, 1994, HUM MOL GENET, V3, P2037; Matthijs G, 1996, GENOMICS, V35, P597, DOI 10.1006/geno.1996.0404; Matthijs G, 1997, GENOMICS, V40, P41, DOI 10.1006/geno.1996.4536; Sambrook J., 2002, MOL CLONING LAB MANU; STIBLER H, 1994, J NEUROL NEUROSUR PS, V57, P552, DOI 10.1136/jnnp.57.5.552; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; WADA Y, 1992, BIOCHEM BIOPH RES CO, V189, P832, DOI 10.1016/0006-291X(92)92278-6; YAMASHITA K, 1993, J BIOL CHEM, V268, P5783	19	274	278	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1997	16	1					88	92		10.1038/ng0597-88	http://dx.doi.org/10.1038/ng0597-88			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140401				2022-12-25	WOS:A1997WX02400028
J	Braverman, N; Steel, G; Obie, C; Moser, A; Moser, H; Gould, SJ; Valle, D				Braverman, N; Steel, G; Obie, C; Moser, A; Moser, H; Gould, SJ; Valle, D			Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata	NATURE GENETICS			English	Article							ORNITHINE-DELTA-AMINOTRANSFERASE; SIGNAL IMPORT RECEPTOR; TARGETING SIGNAL; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; 3-KETOACYL-COA THIOLASE; BIOGENESIS DISORDERS; HANSENULA-POLYMORPHA; ZELLWEGER SYNDROME; GENE	Rhizomelic chondrodysplasia punctata (RCDP) is a rare autosomal recessive phenotype that comprises complementation group 11 of the peroxisome biogenesis disorders (PBD). PEX7, a candidate gene for RCDP identified in yeast, encodes the receptor for peroxisomal matrix proteins with the type-2 peroxisome targeting signal (PTS2). By homology probing we identified human and murine PEX7 genes and found that expression of either corrects the PTS2-import defect characteristic of RCDP cells. In a collection of 36 RCDP probands, we found two inactivating PEX7 mutations: one, L292ter, was present in 26 of the probands, all with a severe phenotype; the second, A218V, was present in three probands, including two with a milder phenotype. A third mutation, G217R, whose functional significance is yet to be determined, was present in five probands, all compound heterozygotes with L292ter. We conclude that PEX7 is responsible for RCDP (PBD CG11) and suggest a founder effect may explain the high frequency of L292ter.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,KENNEDY KRIEGER INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University					NCRR NIH HHS [RR00052, RR00722] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barth PG, 1996, AM J MED GENET, V62, P164, DOI 10.1002/(SICI)1096-8628(19960315)62:2<164::AID-AJMG9>3.0.CO;2-W; BRODY LC, 1992, J BIOL CHEM, V267, P3302; BRUL S, 1988, J CLIN INVEST, V81, P1710, DOI 10.1172/JCI113510; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooper DN, 1995, METABOLIC MOL BASES, P259; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; DODT G, IN PRESS NEW YORK AC; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ENGELHARDT JF, 1991, J BIOL CHEM, V266, P752; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABER KN, 1995, FEBS LETT, V357, P115, DOI 10.1016/0014-5793(94)01317-T; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Fukuda S, 1996, AM J HUM GENET, V59, P1210; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRAY RGF, 1992, J INHERIT METAB DIS, V15, P931, DOI 10.1007/BF01800236; HEIKOOP JC, 1990, J CLIN INVEST, V86, P126, DOI 10.1172/JCI114674; HEIKOOP JC, 1991, BIOCHIM BIOPHYS ACTA, V1097, P69; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Hieter P, 1996, NAT GENET, V13, P253, DOI 10.1038/ng0796-253; HOEFLER G, 1988, J PEDIATR-US, V112, P726, DOI 10.1016/S0022-3476(88)80689-9; Innis MA, 1990, PCR PROTOCOLS GUIDE; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; MAQUAT LE, 1995, RNA, V1, P453; MARYNEN P, 1995, GENOMICS, V30, P366, DOI 10.1006/geno.1995.0032; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MOSER AB, 1995, J PEDIATR-US, V127, P13, DOI 10.1016/S0022-3476(95)70250-4; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; Motley AM, 1996, BBA-MOL BASIS DIS, V1315, P153, DOI 10.1016/0925-4439(95)00114-X; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NUOFFER JM, 1994, J INHERIT METAB DIS, V17, P60, DOI 10.1007/BF00735395; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; PIKE MG, 1990, J PEDIATR-US, V116, P88, DOI 10.1016/S0022-3476(05)81651-8; POLLTHE BT, 1991, J INHERIT METAB DIS, V14, P361, DOI 10.1007/BF01811703; POULOS A, 1995, J PEDIATR-US, V127, P596, DOI 10.1016/S0022-3476(95)70121-4; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMOZAWA N, 1993, AM J HUM GENET, V52, P843; SHIMOZAWA N, 1992, SCIENCE, V255, P11325; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SMEITINK JAM, 1992, J INHERIT METAB DIS, V15, P377, DOI 10.1007/BF02435981; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANDERS RJA, 1992, J INHERIT METAB DIS, V15, P389, DOI 10.1007/BF02435984; WANDERS RJA, 1994, J INHERIT METAB DIS, V17, P315, DOI 10.1007/BF00711817; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	69	330	335	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	APR	1997	15	4					369	376		10.1038/ng0497-369	http://dx.doi.org/10.1038/ng0497-369			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WQ389	9090381				2022-12-25	WOS:A1997WQ38900014
J	Dittrich, B; Buiting, K; Korn, B; Rickard, S; Buxton, J; Saitoh, S; Nicholls, RD; Poustka, A; Winterpacht, A; Zabel, B; Horsthemke, B				Dittrich, B; Buiting, K; Korn, B; Rickard, S; Buxton, J; Saitoh, S; Nicholls, RD; Poustka, A; Winterpacht, A; Zabel, B; Horsthemke, B			Imprint switching on human chromosome 15 may involve alternative transcripts of the SNRPN gene	NATURE GENETICS			English	Article							PRADER-WILLI-SYNDROME; FAMILIAL ANGELMAN SYNDROME; DNA METHYLATION; EXPRESSED GENE; REGION; DELETIONS; 15Q11-Q13; MOUSE; MUTATIONS; DEFINE	Imprinting on human chromosome 15 is regulated by an imprinting centre, which has been mapped to a 100-kb region including exon 1 of SNRPN. From this region we have identified novel transcripts, which represent alternative transcripts of the SNRPN gene, The novel exons lack protein coding potential and are expressed from the paternal chromosome only. We have also identified intragenic deletions and a paint mutation in patients who have Angelman or Prader-Willi syndrome due to a parental imprint switch failure. This suggests that imprint switching on human chromosome 15 may involve alternative SNRPN transcripts.	UNIV ESSEN GESAMTHSCH KLINIKUM,INST HUMANGENET,D-45122 ESSEN,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,D-6900 HEIDELBERG,GERMANY; INST CHILD HLTH,LONDON,ENGLAND; CASE WESTERN RESERVE UNIV,DEPT GENET,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CTR HUMAN GENET,CLEVELAND,OH; UNIV MAINZ,KINDERKLIN,D-6500 MAINZ,GERMANY	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of London; University College London; Case Western Reserve University; University Hospitals of Cleveland; Johannes Gutenberg University of Mainz			Buxton, Jessica/L-9849-2019	Saitoh, Shinji/0000-0001-6911-3351	NICHD NIH HHS [HD31491] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031491] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; BUITING K, 1994, HUM MOL GENET, V3, P893, DOI 10.1093/hmg/3.6.893; CHAILLET JR, 1991, GENOMICS, V11, P773, DOI 10.1016/0888-7543(91)90090-2; CHAN CTJ, 1993, J MED GENET, V30, P895, DOI 10.1136/jmg.30.11.895; CLAYTONSMITH J, 1992, AM J MED GENET, V44, P256, DOI 10.1002/ajmg.1320440236; DITTRICH B, 1993, HUM MOL GENET, V2, P1995, DOI 10.1093/hmg/2.12.1995; DITTRICH B, 1992, HUM GENET, V90, P313; DRISCOLL DJ, 1992, GENOMICS, V13, P917, DOI 10.1016/0888-7543(92)90001-9; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; GLENN CC, 1993, HUM MOL GENET, V2, P1377, DOI 10.1093/hmg/2.9.1377; Glenn CC, 1996, AM J HUM GENET, V58, P335; HORSTHEMKE B, 1987, HUM GENET, V76, P257; HORSTHEMKE B, 1995, PARENATL IMPRINTING; KAPLAN LC, 1987, AM J MED GENET, V28, P45, DOI 10.1002/ajmg.1320280107; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; LEDBETTER DH, 1981, NEW ENGL J MED, V304, P325, DOI 10.1056/NEJM198102053040604; MAGENIS RE, 1987, AM J MED GENET, V28, P829, DOI 10.1002/ajmg.1320280407; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MUTIRANGURA A, 1993, GENOMICS, V18, P546, DOI 10.1016/S0888-7543(11)80011-X; NAKAO M, 1994, HUM MOL GENET, V3, P309, DOI 10.1093/hmg/3.2.309; NICHOLLS RD, 1993, P NATL ACAD SCI USA, V90, P2050, DOI 10.1073/pnas.90.5.2050; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; PEMBREY M, 1989, J MED GENET, V26, P73, DOI 10.1136/jmg.26.2.73; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; REIS A, 1994, AM J HUM GENET, V54, P741; SAITOH S, 1992, LANCET, V339, P366, DOI 10.1016/0140-6736(92)91686-3; SAITOH S, P NATL ACAD SCI USA, V93, P7811; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; WAGSTAFF J, 1993, AM J HUM GENET, V53, P105; WAGSTAFF J, 1992, NAT GENET, V1, P291, DOI 10.1038/ng0792-291; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877	37	209	213	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					163	170		10.1038/ng1096-163	http://dx.doi.org/10.1038/ng1096-163			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841186				2022-12-25	WOS:A1996VL44600020
J	Gustavsson, P; Willig, TN; vanHaeringen, A; Tchernia, G; Dianzani, I; Donner, M; Elinder, G; Henter, JI; Nilsson, PG; Gordon, L; Skeppner, G; vantVeerKorthof, L; Kreuger, A; Dahl, N				Gustavsson, P; Willig, TN; vanHaeringen, A; Tchernia, G; Dianzani, I; Donner, M; Elinder, G; Henter, JI; Nilsson, PG; Gordon, L; Skeppner, G; vantVeerKorthof, L; Kreuger, A; Dahl, N			Diamond-Blackfan anaemia: Genetic homogeneity for a gene on chromosome 19q13 restricted to 1.8 Mb	NATURE GENETICS			English	Article							CONGENITAL HYPOPLASTIC-ANEMIA; HYBRIDIZATION; MUTATIONS	Diamond-Blackfan anaemia (DEA; MIM#205900) is a rare disorder manifested as a pure red-cell aplasia in the neonatal period or in infancy(1-3). The clinical hallmark of DBA is a selective decrease in erythroid precursors and anaemia. Other lineages are usually normal and the peripheral white blood cell count is normal. In approximately one-third of cases, the disease is associated with a wide variety of congenital anomalies and malformations(3-7). Most cases are sporadic, but 10-20% of them follow a recessive or a dominant inheritance pattern(5). A female with DBA and a chromosomal translocation involving chromosome 19q was recently identified(8). We undertook a linkage analysis with chromosome 19 markers in multiplex DBA families of Swedish, French, Dutch, Arabic and Italian origin. Significant linkage to chromosome 19q13 was established for dominant and recessive inherited DBA with a peak rod score at D19S197 (Z(max)=7.08, theta=0.00). Within this region, a submicroscopic de novo deletion of 3.3 Mb was identified in a patient with DBA. The deletion coincides with the translocation break-point and, together with key recombinations, restricts the DBA gene to a 1.8-Mb region. The results suggest that, despite its clinical heterogeneity, DBA is genetically homogeneous for a gene in 19q13.	UNIV UPPSALA,CHILDRENS HOSP,DEPT CLIN GENET,S-75185 UPPSALA,SWEDEN; HOP BICETRE,DEPT HEMATOL,LE KREMLIN BICETR,FRANCE; HOP BICETRE,DEPT PAEDIAT,LE KREMLIN BICETR,FRANCE; LEIDEN UNIV HOSP,DEPT CLIN GENET,LEIDEN,NETHERLANDS; UNIV TURIN,DEPT PAEDIAT,I-10124 TURIN,ITALY; UNIV TURIN,DEPT GENET,I-10124 TURIN,ITALY; UNIV LUND HOSP,ASTRID LINDGREN CHILD CTR,LUND,SWEDEN; UNIV LUND HOSP,DEPT MED,LUND,SWEDEN; LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94551; OREBRO REG HOSP,DEPT PAEDIAT,OREBRO,SWEDEN; UNIV UPPSALA,CHILDRENS HOSP,DEPT PAEDIAT,S-75185 UPPSALA,SWEDEN	Uppsala University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Leiden University; Leiden University Medical Center (LUMC); University of Turin; University of Turin; Lund University; Skane University Hospital; Lund University; Skane University Hospital; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Uppsala University				Henter, Jan-Inge/0000-0002-0629-2126				ALTER BP, 1980, AM J PEDIAT HEMATOL, V2, P121; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BAL SE, 1996, BRIT J HAEMATOL, V94, P645; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DAVANZO M, 1994, PEDIATR HEMAT ONCOL, V11, P189, DOI 10.3109/08880019409141655; Diamond L K, 1976, Adv Pediatr, V22, P349; Diamond L. K., 1938, AM J DIS CHILD, V56, P464; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eber SW, 1996, NAT GENET, V13, P214, DOI 10.1038/ng0696-214; GLADER BE, 1988, BRIT J HAEMATOL, V68, P165, DOI 10.1111/j.1365-2141.1988.tb06184.x; GOJIC V, 1994, AM J MED GENET, V50, P87, DOI 10.1002/ajmg.1320500119; GREINIX HT, 1993, BRIT J HAEMATOL, V84, P515, DOI 10.1111/j.1365-2141.1993.tb03109.x; GUSTAVSSON P, IN PRESS J MED GENET; HALPERIN DS, 1989, AM J PEDIAT HEMATOL, V11, P380; Janov AJ, 1996, MEDICINE, V75, P77, DOI 10.1097/00005792-199603000-00004; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; Mohrenweiser Harvey, 1996, Cytogenetics and Cell Genetics, V74, P161, DOI 10.1159/000134408; Ott J., 1991, ANAL HUMAN GENETIC L; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; Young N. S., 1994, APLASTIC ANEMIA ACQU	23	72	72	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					368	371		10.1038/ng0897-368	http://dx.doi.org/10.1038/ng0897-368			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241274				2022-12-25	WOS:A1997XM90900019
J	Yoshizawa, T; Handa, Y; Uematsu, Y; Takeda, S; Sekine, K; Yoshihara, Y; Kawakami, T; Arioka, K; Sato, H; Uchiyama, Y; Masushige, S; Fukamizu, A; Matsumoto, T; Kato, S				Yoshizawa, T; Handa, Y; Uematsu, Y; Takeda, S; Sekine, K; Yoshihara, Y; Kawakami, T; Arioka, K; Sato, H; Uchiyama, Y; Masushige, S; Fukamizu, A; Matsumoto, T; Kato, S			Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning	NATURE GENETICS			English	Article							D ENDOCRINE SYSTEM; GENE-EXPRESSION; SIGNALING PATHWAYS; NUCLEAR RECEPTORS; RESISTANT RICKETS; ESTROGEN-RECEPTOR; 1,25-DIHYDROXYVITAMIN-D3; BINDING; DIFFERENTIATION; RXR	1 alpha,25-Dihydroxyvitamin D-3[1 alpha,25(OH)(2)D-3], an active form of vitamin D, has roles in many biological phenomena such as calcium homeostasis and bone formation(1-3), which are thought to be mediated by the 1 alpha,25(OH)(2)D-3 receptor (VDR), a member of the nuclear hormone receptors superfamily(4-6). However, the molecular basis for the actions of 1 alpha,25(OH)(2)D-3 in bone formation, its role during development and VDR genetic polymorphisms for predicting bone mineral density(7) are uncertain. To investigate the functional role of VDR, we generated mice deficient in VDR by gene targeting. We report here that in VDR null mutant mice, no defects in development and growth were observed before weaning, irrespective of reduced expression of vitamin D target genes. After weaning, however, mutants failed to thrive, with appearance of alopoecia, hypocalcaemia and infertility, and bone formation was severely impaired as a typical feature of vitamin D-dependent rickets type II (refs 8,9). Unlike humans with this disease, most of the null mutant mice died within 15 weeks after birth, and uterine hypoplasia with impaired folliculogenesis was found in female reproductive organs. These defects, such as alopoecia and uterine hypoplasia, were not observed in vitamin D-deficient animals. The findings establish a critical role for VDR in growth, bone formation and female reproduction in the post-weaning stage.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; TOKYO UNIV AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN; CHUGAI PHARMACEUT CO LTD, FUJI GOTENBA RES LABS, SHIZUOKA 412, JAPAN; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN; UNIV TOKUSHIMA, DEPT INTERNAL MED 1, TOKUSHIMA 770, JAPAN	University of Tokyo; Tokyo University of Agriculture; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Tsukuba; Tokushima University			fukamizu, akiyoshi/J-5350-2012; takeda, shu/B-5195-2012	fukamizu, akiyoshi/0000-0002-8786-6020; Yoshizawa, Tatsuya/0000-0002-5728-1996; Sekine, Keisuke/0000-0001-5133-0876				ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; BERESFORD JN, 1986, ENDOCRINOLOGY, V119, P1776, DOI 10.1210/endo-119-4-1776; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DELVIN EE, 1987, EUR J BIOCHEM, V163, P659, DOI 10.1111/j.1432-1033.1987.tb10915.x; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; ERICKSON GF, 1986, SEMIN REPROD ENDOCR, V4, P233, DOI 10.1055/s-2007-1022504; Eriebacher Adrian, 1995, Cell, V80, P371; Frohman LA, 1995, ENDOCRINOLOGY METABO, V3rd; HARADA H, 1995, ENDOCRINOLOGY, V136, P5329, DOI 10.1210/en.136.12.5329; Hawa NS, 1996, CLIN ENDOCRINOL, V45, P85; HENRY HL, 1984, ANNU REV NUTR, V4, P493, DOI 10.1146/annurev.nu.04.070184.002425; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATO S, 1995, MOL CELL BIOL, V15, P5858; KAWASHIMA H, 1981, NATURE, V291, P327, DOI 10.1038/291327a0; KOJIMA R, 1994, J BIOL CHEM, V269, P3270; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MALLOY PJ, 1994, J CLIN ENDOCR METAB, V78, P313, DOI 10.1210/jc.78.2.313; MALLOY PJ, 1990, J CLIN INVEST, V86, P2071, DOI 10.1172/JCI114944; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARTIN L, 1973, J ENDOCRINOL, V56, P133, DOI 10.1677/joe.0.0560133; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; REEVE L, 1983, J BIOL CHEM, V258, P3615; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459	30	859	895	0	48	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					391	396		10.1038/ng0897-391	http://dx.doi.org/10.1038/ng0897-391			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241280				2022-12-25	WOS:A1997XM90900025
J	Degani, H; Gusis, V; Weinstein, D; Fields, S; Strano, S				Degani, H; Gusis, V; Weinstein, D; Fields, S; Strano, S			Mapping pathophysiological features of breast tumors by MRI at high spatial resolution	NATURE MEDICINE			English	Article							GD-DTPA; QUANTITATIVE-ANALYSIS; ANGIOGENESIS; PERMEABILITY; ENHANCEMENT; PARAMETERS; CARCINOMA	Magnetic resonance imaging (MRI) is a noninvasive method that reveals anatomical details in vivo and detects lesions for diagnosis. Although standard breast MRI cannot clearly delineate breast cancer, contrast-enhanced MRI enables the detection of breast masses with high sensitivity(1,2). Dynamic studies demonstrated that malignant lesions were characterized by a faster signal enhancement rate than benign ones(3). Dynamic MRI of human breast cancer in mice revealed high heterogeneity in the distribution of contrast-enhanced curves and derived pathophysiological features, indicating the importance of high spatial resolution(4,5). With clinical MRI, it is difficult to achieve simultaneously high spatial and temporal resolution. In previous dynamic studies, the emphasis was on high temporal resolution and mainly empiric analyses(6-12). We describe here a new model-based method that optimizes spatial resolution by using only three time points, and yet characterizes tumor heterogeneity in terms of microvascular permeability and extracellular fraction. Mapping these pathophysiological features may aid diagnosis and prognosis assessment, while the high spatial resolution may improve the capacity to detect smaller lesions. The method was tested in human breast tumors implanted in mice and in a limited number of benign and malignant breast lesions of patients.	HADASSAH MED CTR,DEPT RADIOL,IL-91240 JERUSALEM,ISRAEL; KAPLAN HOSP,DEPT RADIOL,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center	Degani, H (corresponding author), WEIZMANN INST SCI,DEPT REGULAT BIOL,POB 26,IL-76100 REHOVOT,ISRAEL.							BRIX G, 1991, J COMPUT ASSIST TOMO, V15, P621, DOI 10.1097/00004728-199107000-00018; BUCKLEY DL, 1994, MAGNET RESON MED, V32, P646, DOI 10.1002/mrm.1910320514; DEGANI H, 1994, J MAGN RESON IMAGING, V4, P116; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; FROUGE C, 1994, INVEST RADIOL, V29, P1043, DOI 10.1097/00004424-199412000-00006; FURMAN E, 1991, CANCER COMMUN, V3, P287, DOI 10.3727/095535491820873001; FurmanHaran E, 1996, JMRI-J MAGN RESON IM, V6, P195, DOI 10.1002/jmri.1880060135; FurmanHaran E, 1996, P NATL ACAD SCI USA, V93, P6247, DOI 10.1073/pnas.93.13.6247; HARMS SE, 1993, JMRI-J MAGN RESON IM, V3, P277, DOI 10.1002/jmri.1880030139; HEYWANGKOBRUNNER SH, 1994, INVEST RADIOL, V29, P94, DOI 10.1097/00004424-199401000-00019; HOFFMANN U, 1995, MAGNET RESON MED, V33, P506, DOI 10.1002/mrm.1910330408; HULKA CA, 1995, RADIOLOGY, V197, P33, DOI 10.1148/radiology.197.1.7568850; KAISER WA, 1989, RADIOLOGY, V170, P681, DOI 10.1148/radiology.170.3.2916021; KELTZ F, 1996, J MAGN RESON IMAGING, V6, P743; LARSSON HBW, 1990, MAGNET RESON MED, V16, P117, DOI 10.1002/mrm.1910160111; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; LucasQuesada FA, 1996, JMRI-J MAGN RESON IM, V6, P753, DOI 10.1002/jmri.1880060508; POON CS, 1992, J NATL CANCER I, V84, P777, DOI 10.1093/jnci/84.10.777; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; TOFTS PS, 1995, MAGN RESON MED, V33, P564, DOI 10.1002/mrm.1910330416; WEIDMANN HJ, 1984, PHYSIOL CHEM PHYS M, V16, P167; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	23	220	241	0	31	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					780	782		10.1038/nm0797-780	http://dx.doi.org/10.1038/nm0797-780			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212107				2022-12-25	WOS:A1997XG76700040
J	Ghetie, V; Popov, S; Borvak, J; Radu, C; Matesoi, D; Medesan, C; Ober, RJ; Ward, ES				Ghetie, V; Popov, S; Borvak, J; Radu, C; Matesoi, D; Medesan, C; Ober, RJ; Ward, ES			Increasing the serum persistence of an IgG fragment by random mutagenesis	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; pharmacokinetics; phage display; surface plasmon resonance	NEONATAL FC RECEPTOR; IMMUNOGLOBULIN-G; ESCHERICHIA-COLI; BINDING-SITE; ANTIBODY; RAT; LOCALIZATION; PROTEINS; COMPLEX; FETAL	The major histocompatibility complex (MHC) class I-related receptor FcRn is involved in regulating serum gammaglobulin (IgG) levels in mice. With the aim of increasing the serum half-life of a recombinant murine Fc gamma 1 fragment, the affinity far binding to FcRn at pH 6.0 has been increased by random mutagenesis of Thr252, Thr254, and Thr256 followed by selection using bacteriophage display. These residues were chosen as they are in proximity to the FcRn-IgG (Fc) interaction site. Two mutants with higher affinity (due to lower off-rates) than the wild-type Fc have been isolated and analyzed in pharmacokinetic studies in mice. The mutant with the highest affinity has a significantly longer serum half-life than the wild type fragment, despite its lower off-rate from FcRn at pH 7.4. The results provide support for the involvement of FcRn in the homeostasis of serum IgGs in mice. The indications that a homologous FcRn regulates IgG levels in humans suggest that this approach has implications for increasing the serum persistence of therapeutic antibodies.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CTR CANC IMMUNOBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Radu, Caius/D-3936-2013	Radu, Caius/0000-0002-9338-5397; Ober, Raimund/0000-0002-1290-7430; Ward, E. Sally/0000-0003-3232-7238	NIAID NIH HHS [AI 39167] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039167] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GF, 1984, J BACTERIOL, V160, P1181, DOI 10.1128/JB.160.3.1181-1183.1984; BRAMBELL FW, 1964, NATURE, V203, P1352, DOI 10.1038/2031352a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; DELSENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISRAEL EJ, 1995, J IMMUNOL, V154, P6246; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kabat EA, 1991, SEQUENCES PROTEINS I; KIM JK, 1994, EUR J IMMUNOL, V24, P2429, DOI 10.1002/eji.1830241025; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; Kristoffersen EK, 1996, EUR J IMMUNOL, V26, P1668, DOI 10.1002/eji.1830260741; Leach JL, 1996, J IMMUNOL, V157, P3317; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; Medesan C, 1997, J IMMUNOL, V158, P2211; Medesan C, 1996, EUR J IMMUNOL, V26, P2533, DOI 10.1002/eji.1830261038; Popov S, 1996, MOL IMMUNOL, V33, P521, DOI 10.1016/0161-5890(96)00004-1; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; ROBERTS DM, 1990, J CELL BIOL, V111, P1867, DOI 10.1083/jcb.111.5.1867; RODEWALD R, 1984, J CELL BIOL, V99; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; SIRNISTER NE, 1996, EUR J IMMUNOL, V26, P1527; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; WALLACE KH, 1980, BIOCHEM J, V188, P9, DOI 10.1042/bj1880009; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WARD ES, 1994, MOL IMMUNOL, V32, P147; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	33	191	374	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					637	640		10.1038/nbt0797-637	http://dx.doi.org/10.1038/nbt0797-637			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219265				2022-12-25	WOS:A1997XH58300026
J	duSart, D; Cancilla, MR; Earle, E; Mao, JI; Saffery, R; Tainton, KM; Kalitsis, P; Martyn, J; Barry, AE; Choo, KHA				duSart, D; Cancilla, MR; Earle, E; Mao, JI; Saffery, R; Tainton, KM; Kalitsis, P; Martyn, J; Barry, AE; Choo, KHA			A functional neo-centromere formed through activation of a latent human centromere and consisting of non-alpha-satellite DNA	NATURE GENETICS			English	Article							SUPERNUMERARY MARKER CHROMOSOMES; PROTEIN CENP-C; ANTICENTROMERE ANTIBODIES; SACCHAROMYCES-CEREVISIAE; KINETOCHORE CENTROMERE; INSITU HYBRIDIZATION; HUMAN AUTOANTIBODIES; MAMMALIAN-CELLS; FISSION YEAST; PHYSICAL MAP	We recently described a human marker chromosome containing a functional neo-centromere that binds anticentromere antibodies, but is devoid of centromeric alpha-satellite repeats and derived from a hitherto non-centromeric: region of chromosome 10q25. Chromosome walking using cloned single-copy DNA from this region enabled us to identify the antibody-binding domain of this centromere. Extensive restriction mapping indicates that this domain has an identical genomic organization to the corresponding normal chromosomal region, suggesting a mechanism for the origin of this centromere through the activation of a latent centromere that exists within 10q25.	ROYAL CHILDRENS HOSP,MURDOCH INST RES BIRTH DEFECTS,PARKVILLE,VIC 3052,AUSTRALIA; GENOME THERAPEUT CORP,COLLABORAT RES DIV,WALTHAM,MA 02154	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne			Saffery, Richard/GLS-1976-2022; Kalitsis, Paul/C-1916-2015	Saffery, Richard/0000-0002-9510-4181; Kalitsis, Paul/0000-0001-5569-0609; Barry, Alyssa/0000-0002-1189-2310				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALEIXANDRE C, 1987, HUM GENET, V77, P46; ARCHIDIACONO N, 1994, SITU HYBRIDIZATION P, P1; BALDINI A, 1993, HUM GENET, V90, P577; BALDINI A, 1991, CYTOGENET CELL GENET, V58, P1868; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BLENNOW E, 1994, AM J HUM GENET, V54, P877; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; BROWN MT, 1995, GENE, V160, P111, DOI 10.1016/0378-1119(95)00163-Z; BROWN W, 1995, TRENDS GENET, V11, P337, DOI 10.1016/S0168-9525(00)89100-3; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; CALLEN DF, 1992, AM J MED GENET, V43, P709, DOI 10.1002/ajmg.1320430412; CHOO KHA, IN PRESS CENTROMERE; CLARKE L, 1985, ANNU REV GENET, V19, P29, DOI 10.1146/annurev.ge.19.120185.000333; CROLLA JA, 1992, J MED GENET, V29, P699, DOI 10.1136/jmg.29.10.699; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DUTRILLAUX B, 1979, HUM GENET, V48, P251, DOI 10.1007/BF00272830; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; FRITZLER MJ, 1980, AM J MED, V69, P520, DOI 10.1016/0002-9343(80)90462-3; GRADY DL, 1992, P NATL ACAD SCI USA, V89, P1695, DOI 10.1073/pnas.89.5.1695; HAAF T, 1994, HUM MOL GENET, V3, P697, DOI 10.1093/hmg/3.5.697; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; HEARTLEIN MW, 1988, MOL CELL BIOL, V8, P3611, DOI 10.1128/MCB.8.9.3611; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KINGWELL B, 1987, CHROMOSOMA, V95, P403, DOI 10.1007/BF00333991; LARIN Z, 1994, HUM MOL GENET, V3, P689, DOI 10.1093/hmg/3.5.689; MAGNANI I, 1993, CLIN GENET, V43, P180; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MOIR DT, 1994, GENOMICS, V22, P1, DOI 10.1006/geno.1994.1338; MOROI Y, 1981, J CELL BIOL, V90, P254, DOI 10.1083/jcb.90.1.254; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; NELSON M, 1991, NUCLEIC ACIDS RES, V19, P2045, DOI 10.1093/nar/19.suppl.2045; OHASHI H, 1994, AM J HUM GENET, V55, P1202; PAGE SL, 1995, HUM MOL GENET, V4, P289, DOI 10.1093/hmg/4.2.289; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; PALMER DK, 1985, MOL CELL BIOL, V5, P173, DOI 10.1128/MCB.5.1.173; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; RAUCH A, 1992, CLIN GENET, V42, P84; SEARLE AG, 1989, ANN HUM GENET, V53, P89, DOI 10.1111/j.1469-1809.1989.tb01777.x; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; STEINER NC, 1993, MOL CELL BIOL, V13, P4578, DOI 10.1128/MCB.13.8.4578; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; TROWELL HE, 1993, HUM MOL GENET, V2, P1639, DOI 10.1093/hmg/2.10.1639; TYLERSMITH C, 1993, NAT GENET, V5, P368, DOI 10.1038/ng1293-368; VERMA RS, 1992, GENOMICS, V14, P113, DOI 10.1016/S0888-7543(05)80291-5; VOULLAIRE LE, 1993, AM J HUM GENET, V52, P1153; WEVRICK R, 1989, P NATL ACAD SCI USA, V86, P9394, DOI 10.1073/pnas.86.23.9394; WEVRICK R, 1991, NUCLEIC ACIDS RES, V19, P2295, DOI 10.1093/nar/19.9.2295; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yang CH, 1996, MOL CELL BIOL, V16, P3576; ZHENG CJ, 1994, GENOMICS, V22, P55, DOI 10.1006/geno.1994.1345	65	266	278	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					144	153						10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171825				2022-12-25	WOS:A1997XB54300014
J	Steiner, G; Schoenberg, MP; Linn, JF; Mao, L; Sidransky, D				Steiner, G; Schoenberg, MP; Linn, JF; Mao, L; Sidransky, D			Detection of bladder cancer recurrence by microsatellite analysis of urine	NATURE MEDICINE			English	Article								A reliable, noninvasive method for monitoring patients with transitional cell carcinoma (TCC) of the bladder would be of great clinical benefit. Cystoscopy is currently the ''gold standard,'' but it is invasive, expensive and uncomfortable for the patient. Recently, we demonstrated a novel approach for the detection of primary bladder cancer based on microsatellite analysis of urine DNA. To determine the feasibility of this technique for following-up patients with TCC, we tested serial urine samples from 21 patients who had been treated for bladder cancer with 20 polymorphic microsatellite markers in a blinded fashion. We detected recurrent lesions in 10 out of 11 patients and correctly predicted the existence of a neoplastic cell population in the urine of two patients, 4 and 6 months before cystoscopic evidence of the tumor. The assay was negative in 10 of 10 patients who had no evident cancer. Microsatellite analysis of urine sediment represents a novel and potentially powerful clinical tool for the detection of recurrent bladder cancer.	JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, DIV HEAD & NECK CANC RES, BALTIMORE, MD 21205 USA	Johns Hopkins University	Steiner, G (corresponding author), JOHNS HOPKINS UNIV HOSP, DEPT UROL, JAMES BUCHANAN BRADY UROL INST, 600 N WOLFE ST, BALTIMORE, MD 21287 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358				*AM JOINT COMM CAN, 1988, MAN STAG CANC, P171; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CUTLER SJ, 1982, AUA MONOGRAPHS BLADD, V1, P35; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HRUBAN RH, 1994, NEW ENGL J MED, V330, P1276, DOI 10.1056/NEJM199405053301805; HUDSON MA, 1996, ADULT PEDIAT UROLOGY, P643; Loh CS, 1996, BRIT J UROL, V77, P655, DOI 10.1046/j.1464-410X.1996.09275.x; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MAO L, 1994, CANCER RES, V54, P1634; MURPHY WM, 1984, CANCER, V53, P1555, DOI 10.1002/1097-0142(19840401)53:7<1555::AID-CNCR2820530723>3.0.CO;2-G; PAPANICOLAOU GN, 1945, SCIENCE, V101, P519, DOI 10.1126/science.101.2629.519; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAROSDY MF, 1995, J UROLOGY, V154, P379, DOI 10.1016/S0022-5347(01)67054-X; Soloway MS, 1996, J UROLOGY, V156, P363, DOI 10.1016/S0022-5347(01)65851-8; WANG Y, IN PRESS J ELECTROPH	15	217	223	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					621	624		10.1038/nm0697-621	http://dx.doi.org/10.1038/nm0697-621			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176487				2022-12-25	WOS:A1997XB97400030
J	Silvestrini, MC; Cardone, F; Maras, B; Pucci, P; Barra, D; Brunori, M; Pocchiari, M				Silvestrini, MC; Cardone, F; Maras, B; Pucci, P; Barra, D; Brunori, M; Pocchiari, M			Identification of the prion protein allotypes which accumulate in the brain of sporadic and familial Creutzfeldt-Jakob disease patients	NATURE MEDICINE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; AMYLOIDOTIC POLYNEUROPATHY; TRANSTHYRETIN PREALBUMIN; SCRAPIE AGENT; PRP; GENE; VARIANT; FIBRILS; PROPAGATION; RESISTANT	A characteristic feature of Creutzfeldt-jakob disease (CJD) is the accumulation in the brain of the amyloid protease-resistant protein PrPres. PrPres derives from a host-encoded, protease-sensitive isoform, PrPsen. Mutations of this protein are linked to familial variants of the disease, and the presence of a methionine or valine residue at the polymorphic position 129 may be critical in sporadic CJD cases. We found that in the brain of patients heterozygous for the mutation in which isoleucine is substituted for valine at codon 210 (Val210Ile), the PrPres is formed by both the wild-type and mutant PrPsen. We also found that in a sporadic CJD patient, who was heterozygous (Met/Val) at position 129, PrPres is also formed by both allotypes. These data associate transmissible spongiform encephalopathies with other amyloidosis, although the nature of the transmissible agent remains unsettled.	IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY; CNR,CTR MOL BIOL,I-00185 ROME,ITALY; UNIV NAPLES,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI,I-00185 ROME,ITALY	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Sapienza University Rome			Cardone, Franco/D-1724-2009; Pocchiari, Maurizio/J-8443-2018; Maras, Bruno/A-2020-2010; Barra, Donatella/D-1236-2011	Cardone, Franco/0000-0002-2376-0470; Pocchiari, Maurizio/0000-0002-7269-2486; PUCCI, Pietro/0000-0002-5885-1495; Brunori, Maurizio/0000-0002-7795-1635				Barbanti P, 1996, NEUROLOGY, V47, P734, DOI 10.1212/WNL.47.3.734; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; COME JH, 1994, J AM CHEM SOC, V116, P4109, DOI 10.1021/ja00088a069; DIRINGER H, 1994, ANN NY ACAD SCI, V724, P246, DOI 10.1111/j.1749-6632.1994.tb38915.x; DWULET FE, 1986, J CLIN INVEST, V78, P880, DOI 10.1172/JCI112675; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FURUKAWA H, 1995, MOL BRAIN RES, V30, P385, DOI 10.1016/0169-328X(95)00034-P; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; GAJDUSEK DC, 1984, MOL NEUROBIOL, V8, P1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GOLDFARB LG, 1993, P NATL ACAD SCI USA, V90, P4451, DOI 10.1073/pnas.90.10.4451; GOLDFARB LG, 1995, ANNU REV MED, V46, P57; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KITAMOTO T, 1991, NEUROLOGY, V41, P306, DOI 10.1212/WNL.41.2_Part_1.306; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; Manuelidis L, 1996, VIROLOGY, V216, P46, DOI 10.1006/viro.1996.0033; Mastrianni JA, 1996, NEUROLOGY, V47, P1305, DOI 10.1212/WNL.47.5.1305; MASULLO C, 1994, ANN NY ACAD SCI, V724, P358, DOI 10.1111/j.1749-6632.1994.tb38931.x; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Petraroli R, 1996, AM J HUM GENET, V58, P888; POCCHIARI M, 1993, ANN NEUROL, V34, P802, DOI 10.1002/ana.410340608; POCCHIARI M, 1994, MOL ASPECTS MED, V15, P195, DOI 10.1016/0098-2997(94)90042-6; PRELLI F, 1990, BIOCHEM BIOPH RES CO, V170, P301, DOI 10.1016/0006-291X(90)91274-V; PRUSINER SB, 1994, P NATL ACAD SCI USA, V91, P4611, DOI 10.1073/pnas.91.11.4611; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SALVATORE M, 1994, HUM GENET, V94, P375, DOI 10.1007/BF00201596; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; TAWARA S, 1983, BIOCHEM BIOPH RES CO, V116, P880, DOI 10.1016/S0006-291X(83)80224-1; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; WESTERMARK P, 1987, CLIN EXP IMMUNOL, V69, P695; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; XI YG, 1992, NATURE, V356, P598, DOI 10.1038/356598a0; XI YG, 1994, J NEUROL SCI, V124, P171, DOI 10.1016/0022-510X(94)90323-9	47	58	58	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					521	525		10.1038/nm0597-521	http://dx.doi.org/10.1038/nm0597-521			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142120				2022-12-25	WOS:A1997WX54300031
J	Wilkinson, JQ; Lanahan, MB; Clark, DG; Bleecker, AB; Chang, C; Meyerowitz, EM; Klee, HJ				Wilkinson, JQ; Lanahan, MB; Clark, DG; Bleecker, AB; Chang, C; Meyerowitz, EM; Klee, HJ			A dominant mutant receptor from Arabidopsis confers ethylene insensitivity in heterologous plants	NATURE BIOTECHNOLOGY			English	Article						ethylene; receptor; ripening; senescence; abscission	FIGWORT MOSAIC-VIRUS; NEVER-RIPE; ETR1 GENE; TOMATO; EXPRESSION; MUTATION	Ethylene (C2H4) is a gaseous hormone that affects many aspects of plant growth and development. Ethylene perception requires specific receptors and a signal transduction pathway to coordinate downstream responses. The etr1-1 gene of Arabidopsis encodes a mutated receptor that confers dominant ethylene insensitivity. Evidence is presented here that etr1-1 also causes significant delays in fruit. ripening, flower senescence, and flower abscission when expressed in tomato and petunia plants. The ability of etr1-1 to function in heterologous plants suggests that this pathway of hormone recognition and response is highly consented and can be manipulated.	UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; CALTECH,DIV BIOL 156 29,PASADENA,CA 91125; UNIV MARYLAND,DEPT PLANT BIOL,COLLEGE PK,MD 20742; UNIV WISCONSIN,DEPT BOT,MADISON,WI 53706; UNIV FLORIDA,DEPT ENVIRONM HORT,GAINESVILLE,FL 32611; MONSANTO CO,CEREGEN TECHNOL,CHESTERFIELD,MO 63198	State University System of Florida; University of Florida; California Institute of Technology; University System of Maryland; University of Maryland College Park; University of Wisconsin System; University of Wisconsin Madison; State University System of Florida; University of Florida; Monsanto			Meyerowitz, Elliot M/A-7118-2009; Klee, Harry/A-7912-2008					Abeles F, 1992, ETHYLENE PLANT BIOL; BARRY G, 1992, J CELL BIOCH SF, V16, P202; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; Bleecker AB, 1996, PLANT PHYSIOL, V111, P653, DOI 10.1104/pp.111.3.653; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CLARK D, IN PRESS PLANT MOL B; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; LANAHAN MB, 1994, PLANT CELL, V6, P521, DOI 10.1105/tpc.6.4.521; MCCORMICK S, 1986, PLANT CELL REP, V5, P81, DOI 10.1007/BF00269239; RICHINS RD, 1987, NUCLEIC ACIDS RES, V15, P8451, DOI 10.1093/nar/15.20.8451; SANGER M, 1990, PLANT MOL BIOL, V14, P433, DOI 10.1007/BF00028779; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SINGH A, 1992, PLANT PHYSIOL, V99, P38, DOI 10.1104/pp.99.1.38; TANG XY, 1994, PLANT CELL, V6, P1227, DOI 10.1105/tpc.6.9.1227; THEOLOGIS A, 1992, CELL, V70, P181, DOI 10.1016/0092-8674(92)90093-R; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; YEN HC, 1995, PLANT PHYSIOL, V107, P1343, DOI 10.1104/pp.107.4.1343; ZAREMBINSKI TI, 1994, PLANT MOL BIOL, V26, P1579, DOI 10.1007/BF00016491	21	239	266	0	41	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					444	447		10.1038/nbt0597-444	http://dx.doi.org/10.1038/nbt0597-444			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131623				2022-12-25	WOS:A1997WX23700028
J	Bargou, RC; Jurchott, K; Wagener, C; Bergmann, S; Metzner, S; Bommert, K; Mapara, MY; Winzer, KJ; Dietel, M; Dorken, B; Royer, HD				Bargou, RC; Jurchott, K; Wagener, C; Bergmann, S; Metzner, S; Bommert, K; Mapara, MY; Winzer, KJ; Dietel, M; Dorken, B; Royer, HD			Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression	NATURE MEDICINE			English	Article							P-GLYCOPROTEIN; BINDING-PROTEIN; RESISTANCE; TISSUE; SEQUENCE; CELLS	Breast cancers are either primarily resistant to chemotherapy (intrinsic resistance), or respond to chemotherapy but later recur with a multidrug-resistant phenotype because of overexpression of the multidrug transporter P-glycoprotein(1). The MDR1 gene encoding P-glycoprotein may be transcriptionally regulated by a Y-box transcription factor(2). We now report that, in multidrug-resistant MCF-7 breast cancer cells, nuclear localization of YB-1 is associated with MDR-1 gene expression. In drug-sensitive MCF-7 cells, however, YB-1 was localized to the cytoplasm. Regulated overexpression of YB-1 in drug-sensitive diploid breast epithelial cells induced MDR-1 gene expression and multidrug resistance. In 27 out of 27 untreated primary breast cancers, YB-1 protein was expressed in the cytoplasm although it was undetectable in normal breast tissue of these patients. In a subgroup of tumors (9/27), however, YB-1 was also localized to the nucleus and, in these cases, high levels of P-glycoprotein were present. These results show that in a subset of untreated primary breast cancers, nuclear localization of YB-1 protein is associated with intrinsic multidrug resistance. Our data show that YB-1 has an important role in controlling MDR1 gene transcription and this finding provides a basis for the analysis of molecular mechanisms responsible for intrinsic multidrug resistance in human breast cancer.	HUMBOLDT UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,ROBERT ROSSLE KLIN,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,UNIV KLINIKUM CHARITE,INST PATHOL,D-10117 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,UNIV KLINIKUM CHARITE,D-10117 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin			Royer, Hans-dieter/AAH-6293-2019; mapara, markus/A-2134-2013; Bommert, Kurt/G-9247-2011	Jurchott, Karsten/0000-0003-1589-0037				ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BITTL A, 1995, ANTICANCER RES, V15, P1007; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grinstein E, 1996, J BIOL CHEM, V271, P9215, DOI 10.1074/jbc.271.16.9215; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LEE CH, 1994, COLD SPRING HARB SYM, V59, P607, DOI 10.1101/SQB.1994.059.01.069; MADDEN MJ, 1993, J BIOL CHEM, V268, P8209; PINEDO HM, 1995, NEW ENGL J MED, V333, P1417, DOI 10.1056/NEJM199511233332111; ROYER HD, 1991, NUCLEIC ACIDS RES, V19, P2363, DOI 10.1093/nar/19.9.2363; SANFILIPPO O, 1991, EUR J CANCER, V27, P155, DOI 10.1016/0277-5379(91)90476-T; SCHNEIDER J, 1994, J NATL CANCER I, V86, P850, DOI 10.1093/jnci/86.11.850; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; VANGROENIGEN M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P138, DOI 10.1016/0167-4781(93)90280-Q; VERELLE P, 1991, J NATL CANCER I, V83, P111; WEINSTEIN RS, 1991, CANCER RES, V51, P2720; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	20	351	376	1	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					447	450		10.1038/nm0497-447	http://dx.doi.org/10.1038/nm0497-447			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095180				2022-12-25	WOS:A1997WQ82500036
J	Purdue, PE; Zhang, JW; Skoneczny, M; Lazarow, PB				Purdue, PE; Zhang, JW; Skoneczny, M; Lazarow, PB			Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor	NATURE GENETICS			English	Article							DIHYDROXYACETONE PHOSPHATE ACYLTRANSFERASE; PEROXISOMAL 3-KETOACYL-COA THIOLASE; SACCHAROMYCES-CEREVISIAE; SKIN FIBROBLASTS; ACYL-COA; PROTEIN; IMPORT; BIOGENESIS; IDENTIFICATION; DISORDERS	The rhizomelic form of chondrodysplasia punctata (RCDP) is an autosomal recessive disease of peroxisome biogenesis characterized by deficiencies in several peroxisomal proteins, including the peroxisomal enzymes of plasmalogen biosynthesis and peroxisomal 3-ketoacyl thiolase(1). In cultured fibroblasts from patients with this disorder, both the peroxisomal targeting and proteolytic removal of the amino-terminal type 2 peroxisomal targeting sequence (PTS2) of thiolase are defective, whereas the biogenesis of proteins targeted by carboxyterminal type 1 peroxisomal targeting sequences (PTS1) is unimpaired. We have previously isolated a Saccharomyces cerevisiae peroxisomal biogenesis mutant, pex7 (formerly peb1/pas7)(2), which demonstrates a striking similarity to the cellular phenotype of RCDP fibroblasts in that PTS1 targeting is functional, but the peroxisomal packaging of PTS2 targeted thiolase is lacking. Complementation of this mutant has led to the identification of the protein ScPex7p(3,4), a PTSZ receptor(5,6). In this paper we report cloning of the human orthologue of ScPEX7, and demonstrate that this is the defective gene in RCDP. We show that expression of human PEX7 in RCDP cells rescues PTSZ targeting and restores some activity of dihydroxyacetone phosphate acyltransferase (DHAP-AT), a peroxisomal enzyme of plasmalogen biosynthesis, and we identify the mutations responsible for loss of function of PEX7 in a compound heterozygote RCDP patient. These results imply that several peroxisomal proteins are targeted by PTSZ signals and that the various biochemical and clinical defects in RCDP result from a defect in the receptor for this class of PTS.	CUNY MT SINAI SCH MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Skoneczny, Marek/S-5390-2019	Skoneczny, Marek/0000-0001-9922-2276	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019394, R37DK019394] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19394] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALFE A, 1990, PEDIATR RES, V27, P304, DOI 10.1203/00006450-199003000-00023; BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; BOGUSKI MS, 1994, SCIENCE, V265, P1993, DOI 10.1126/science.8091218; HEYMANS HSA, 1985, NEW ENGL J MED, V313, P187; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAZAROW PB, 1995, J NEUROPATH EXP NEUR, V54, P720, DOI 10.1097/00005072-199509000-00015; LAZAROW PB, 1995, METABOLIC BASIS INHE, V7, P2287; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; POOLE B, 1971, J BIOL CHEM, V246, P6587; PRICE VE, 1962, J BIOL CHEM, V237, P3468; PURDUE PE, 1990, J CELL BIOL, V111, P2341, DOI 10.1083/jcb.111.6.2341; PURDUE PE, 1992, EUR J BIOCHEM, V207, P757, DOI 10.1111/j.1432-1033.1992.tb17106.x; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; SCHUTGENS RBH, 1984, BIOCHEM BIOPH RES CO, V120, P179, DOI 10.1016/0006-291X(84)91430-X; SCHUTGENS RBH, 1986, BIOCHIM BIOPHYS ACTA, V879, P286, DOI 10.1016/0005-2760(86)90217-1; SINGH I, 1991, ARCH BIOCHEM BIOPHYS, V286, P277, DOI 10.1016/0003-9861(91)90041-G; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; WEBBER KO, 1992, METHOD ENZYMOL, V209, P92; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	27	218	219	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	APR	1997	15	4					381	384		10.1038/ng0497-381	http://dx.doi.org/10.1038/ng0497-381			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WQ389	9090383				2022-12-25	WOS:A1997WQ38900016
J	Sarid, R; Sato, T; Bohenzky, RA; Russo, JJ; Chang, Y				Sarid, R; Sato, T; Bohenzky, RA; Russo, JJ; Chang, Y			Kaposi's sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; EPSTEIN-BARR-VIRUS; HUMAN B-CELLS; DNA-SEQUENCES; CASTLEMANS DISEASE; PROTEIN; APOPTOSIS; GENE; CLONING; SAIMIRI	Kaposi's sarcoma-associated herpesvirus (KSHV) is a newly discovered herpesvirus etiologically associated with Kaposi's sarcoma (KS) and two lymphoproliferative disorders. We describe a KSHV vbcl-2 gene with homology to the proto-oncogene bcl-2. It is expressed in KS lesions and in cell lines derived from primary effusion lymphomas. Using yeast and human cells we demonstrate the ability of KSHV vBcl-2 protein to suppress Bar toxicity. We show that KSHV vBcl-2 heterodimerizes with human Bcl-2 in a yeast two-hybrid system. These results suggest that KSHV vBcl-2 plays an anti-apoptotic role in virus infected cells.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT OTOLARYNGOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLUMBIA GENOME CTR, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University			Chang, Yuan/F-4146-2011	Chang, Yuan/0000-0003-1125-4041	NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER; NCI NIH HHS [CA67391] Funding Source: Medline; NIGMS NIH HHS [R01 GM5514-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOSHOFF C, 1995, LANCET, V345, P1043; BOYD JM, 1995, ONCOGENE, V11, P1921; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DELELLIS L, 1995, J INFECT DIS, V172, P1605, DOI 10.1093/infdis/172.6.1605; FRIZZERA G, 1985, J CLIN ONCOL, V3, P1202, DOI 10.1200/JCO.1985.3.9.1202; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNTER J, 1996, BIOL CHEM, V271, P8521; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; MILLER G, 1990, VIROLOGY, P1921; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SATO T, 1994, GENE, V140, P291, DOI 10.1016/0378-1119(94)90561-4; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO T, 1994, P NATL ACAD SCI USA, V92, P2016; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Strauchen JA, 1996, ANN INTERN MED, V125, P822, DOI 10.7326/0003-4819-125-10-199611150-00006; SZOMOLANYI E, 1987, J VIROL, V61, P3485, DOI 10.1128/JVI.61.11.3485-3490.1987; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	53	277	291	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1997	3	3					293	298		10.1038/nm0397-293	http://dx.doi.org/10.1038/nm0397-293			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055856				2022-12-25	WOS:A1997WL30500030
J	Seino, KI; Kayagaki, N; Okumura, K; Yagita, H				Seino, KI; Kayagaki, N; Okumura, K; Yagita, H			Antitumor effect of locally produced CD95 ligand	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; HUMAN FAS LIGAND; GENE-TRANSFER; ANTI-FAS; MONOCLONAL-ANTIBODY; INTERFERON-GAMMA; FACTOR-ALPHA; T-CELLS; EXPRESSION	Activation of the cell-surface antigen CD95 induces apoptosis of CD95-bearing tumor cells. In this study, we investigated the antitumor effect of locally produced CD95 ligand (CD95L) on CD95-negative tumor cells in vivo. Introduction of CD95L cDNA into murine tumor cells did not affect growth in vitro but caused rejection in vivo. Neutrophils were primarily responsible for this rejection. A CD8(+) T cell-mediated protective immunity against subsequent challenge with parental tumor cells was also elicited. These results provide evidence for the potential utility of CD95L in tumor eradication and also reveal a proinflammatory function of CD95L.	JUNTENDO UNIV,SCH MED,BUNKYO KU,TOKYO 113,JAPAN; UNIV TSUKUBA,SCH MED,DEPT SURG,TSUKUBA,IBARAKI 305,JAPAN; JAPAN SCI & TECHNOL CORP,CREST,CHIYODA KU,TOKYO 101,JAPAN	Juntendo University; University of Tsukuba; Japan Science & Technology Agency (JST)			seino, kenichiro/F-8823-2012					ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; ASHER AL, 1991, J IMMUNOL, V146, P3227; Baker MB, 1996, J EXP MED, V183, P2645, DOI 10.1084/jem.183.6.2645; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; CAVALLO F, 1992, J IMMUNOL, V149, P3627; COLOMBO MP, 1994, IMMUNOL TODAY, V15, P48, DOI 10.1016/0167-5699(94)90131-7; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRESHAM HD, 1991, J IMMUNOL, V146, P3911; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; HOCK H, 1993, P NATL ACAD SCI USA, V90, P2774, DOI 10.1073/pnas.90.7.2774; IWAI K, 1994, BLOOD, V84, P1201; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; LICHTENSTEIN A, 1985, INT J CANCER, V35, P121, DOI 10.1002/ijc.2910350119; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LOWRANCE JH, 1994, J EXP MED, V180, P1693, DOI 10.1084/jem.180.5.1693; LUGER TA, 1990, J INVEST DERMATOL, V95, pS100, DOI 10.1111/1523-1747.ep12874944; MAASS G, 1995, P NATL ACAD SCI USA, V92, P5540, DOI 10.1073/pnas.92.12.5540; MCKENZIE RC, 1990, J INVEST DERMATOL, V95, pS105, DOI 10.1111/1523-1747.ep12874955; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; SAITO K, 1996, EUR J IMMUNOL, V20, P3096; Seino K, 1996, INT IMMUNOL, V8, P1347, DOI 10.1093/intimm/8.9.1347; SEUNG LP, 1995, P NATL ACAD SCI USA, V92, P6254, DOI 10.1073/pnas.92.14.6254; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TEPPER RI, 1992, SCIENCE, V257, P548, DOI 10.1126/science.1636093; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	43	286	297	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					165	170		10.1038/nm0297-165	http://dx.doi.org/10.1038/nm0297-165			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018234				2022-12-25	WOS:A1997WF08800034
J	Fender, P; Ruigrok, RWH; Gout, E; Buffet, S; Chroboczek, J				Fender, P; Ruigrok, RWH; Gout, E; Buffet, S; Chroboczek, J			Adenovirus dodecahedron, a new vector for human gene transfer	NATURE BIOTECHNOLOGY			English	Article						adenovirus penton; dodecahedron; gene therapy	PENTON BASE PROTEIN; CELLS; TYPE-2; FIBER; RELEASE; DNA; GENOME	Recombinant adenovirus is one of most efficient delivery vehicles for gene therapy. However, the initial enthusiasm for the use of recombinant adenovirus for gene therapy has been tempered by strong immune responses that develop to the virus and virus-infected cells. Even though recombinant adenoviruses are replication-defective, they introduce into the recipient cell, together with the gene of interest, viral genetes that might lead to fortuitous recombination if the recipient is infected by wild-type adenovirus, We propose the use of a dodecahedron made of adenovirus pentons or penton bases as an alternative vector for human gene therapy. The penton is a complex of two oligomeric proteins, a penton base and fiber, involved in the cell attachment, internalization, and liberation of virus into the cytoplasm, The dodecahedron retains many of the advantages of adenovirus for gene transfer such as efficiency of entry, efficient release of DNA from endosomes, and wide range of cell and tissue targets. Because it consists of only one or two adenovirus proteins instead of the 11 contained in an adenovirus virion and it does not contain the viral genome, it is potentially a safer alternative to recombinant adenovirus.	INST BIOL STRUCT,F-38027 GRENOBLE,FRANCE; EUROPEAN MOL BIOL LAB,GRENOBLE OUTSTN,F-38042 GRENOBLE 9,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL)			Chroboczek, Jadwiga/M-6554-2014	Fender, Pascal/0000-0002-6698-3367				BAI M, 1993, J VIROL, V67, P5198, DOI 10.1128/JVI.67.9.5198-5205.1993; BOUDIN ML, 1982, VIROLOGY, V116, P589, DOI 10.1016/0042-6822(82)90151-9; BOULANGER PA, 1976, INTERVIROLOGY, V7, P126, DOI 10.1159/000149946; CAILLETBOUDIN ML, 1989, J MOL BIOL, V208, P195, DOI 10.1016/0022-2836(89)90095-8; CHARDONN.Y, 1970, VIROLOGY, V40, P462, DOI 10.1016/0042-6822(70)90189-3; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; CUZANGE A, 1994, GENE, V146, P257, DOI 10.1016/0378-1119(94)90302-6; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; FITZGERALD DJP, 1983, P NATL ACAD SCI-BIOL, V80, P4134, DOI 10.1073/pnas.80.13.4134; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; Gelderblom H, 1967, J Gen Virol, V1, P553, DOI 10.1099/0022-1317-1-4-553; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; GREBER UF, 1996, CELL, V15, P1766; HENRY L, 1994, J VIROL, V48, P5239; HONG SS, 1995, EMBO J, V14, P4714, DOI 10.1002/j.1460-2075.1995.tb00153.x; HORWITZ MS, 1990, VIROLOGY, P01679; KARAYAN L, 1994, VIROLOGY, V202, P782, DOI 10.1006/viro.1994.1400; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; LYON M, 1978, VIROLOGY, V87, P81, DOI 10.1016/0042-6822(78)90160-5; NORRBY E, 1969, J GEN VIROL, V5, P221, DOI 10.1099/0022-1317-5-2-221; NORRBY E, 1968, VIROLOGY, V36, P201, DOI 10.1016/0042-6822(68)90137-2; NORRBY E, 1964, VIROLOGY, V1, P236; PETTERSSON U, 1973, J MOL BIOL, V73, P125, DOI 10.1016/0022-2836(73)90164-2; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Possee RD., 1992, BACULOVIRUS EXPRESSI; RUIGROK RWH, 1990, J MOL BIOL, V215, P289; SCHOEHN G, IN PRESS EMBO J; SETH P, 1994, J VIROL, V68, P1204, DOI 10.1128/JVI.68.2.1204-1206.1994; SIGNAS C, 1985, J VIROL, V53, P672; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WOHLFART C, 1988, J VIROL, V62, P2321, DOI 10.1128/JVI.62.7.2321-2328.1988; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YOSHIMURA K, 1993, J BIOL CHEM, V268, P2300	38	123	130	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					52	56		10.1038/nbt0197-52	http://dx.doi.org/10.1038/nbt0197-52			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035106				2022-12-25	WOS:A1997WA72900023
J	Hoyle, R				Hoyle, R			Commissioner Kessler's agbio legacy	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					2	2		10.1038/nbt0197-2	http://dx.doi.org/10.1038/nbt0197-2			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035091	Bronze			2022-12-25	WOS:A1997WA72900003
J	Moisan, MP; Courvoisier, H; Bihoreau, MT; Gauguier, D; Hendley, ED; Lathrop, M; James, MR; Mormede, P				Moisan, MP; Courvoisier, H; Bihoreau, MT; Gauguier, D; Hendley, ED; Lathrop, M; James, MR; Mormede, P			A major quantitative trait locus influences hyperactivity in the WKHA rat	NATURE GENETICS			English	Article							ATTENTION-DEFICIT DISORDER; CHILDHOOD HYPERACTIVITY; MICE	The syndrome of hyperactivity describes behavioural disorders existing mainly in children and characterized by increased levels of motor activity, inattention and impulsivity(1,2). Overall the aetiology is poorly understood due to the heterogeneity of the pathology although psychological, biological and social factors acting singly or in concert are generally thought to be involved. In animal studies the observed hyperactivity phenotype results from relative participation of exploration, emotionality and general activity(3). Studies using brain lesions(3), neuropharmacology(4) and gene knock-out strategies(5,6) have shown that specific elements of the brain dopaminergic system can subserve hyperactivity. Evidence of a genetic contribution comes from family(7,8) and twin studies(9) but also from the ability to select divergent animal lines on the basis of their differential activity. The Wistar-Kyoto (WKY) and Wistar-Kyoto hyperactive (WKHA) rats are such strains - distinct for their low and high activity scores in a novel environment, respectively(10). Here, we report the detection of a major hyperactivity-related QTL on chromosome 8, explaining 29% of the variance of an intercross between these strains. This study represents the first behavioural QTL analysis in rat and provides a new starting point for biologically categorizing different forms of hyperactivity.	WELLCOME TRUST CTR HUMAN GENET,OXFORD X3 7BN,ENGLAND; UNIV VERMONT,COLL MED,DEPT PHYSIOL & BIOPHYS,BURLINGTON,VT 05405	University of Oxford; Wellcome Centre for Human Genetics; University of Vermont	Moisan, MP (corresponding author), INST FRANCOIS MAGENDIE,INSERM,INRA,F-33077 BORDEAUX,FRANCE.		Mormede, Pierre/K-5537-2015; Gauguier, Dominique/G-2190-2016; Moisan, Marie-Pierre/AAO-9971-2021; Mormede, Pierre/N-3918-2019	Mormede, Pierre/0000-0003-0345-1432; Gauguier, Dominique/0000-0001-6156-9530; Moisan, Marie-Pierre/0000-0001-7315-5319; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIEDERMAN J, 1992, ARCH GEN PSYCHIAT, V49, P728; BIHOREAU MT, UNPUB; CASTANON N, 1993, AM J PHYSIOL, V265, pR1304, DOI 10.1152/ajpregu.1993.265.6.R1304; CHURCHILL GA, 1994, GENETICS, V138, P963; COOK EH, 1995, AM J HUM GENET, V56, P993; COURVOISIER H, IN PRESS BRAIN RES; FARAONE SV, 1991, AM J PSYCHIAT, V148, P112; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; GIROS B, 1996, NATURE, V379, P303; HENDLEY ED, 1991, AM J PHYSIOL, V261, pH583, DOI 10.1152/ajpheart.1991.261.2.H583; HENDLEY ED, 1993, BRAIN RES, V586, P44; Hess EJ, 1996, J NEUROSCI, V16, P3104, DOI 10.1523/jneurosci.16-09-03104.1996; KELLEY AE, 1989, NEUROMETHODS, V13, P95; KNOTT SA, 1992, HEREDITY, V68, P313, DOI 10.1038/hdy.1992.45; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; MOGENSON GJ, 1984, BEHAV NEURAL BIOL, V42, P52, DOI 10.1016/S0163-1047(84)90424-2; NELSON JC, 1995, PLANT GENOME, V4, pA315; SCHACHAR R, 1991, J CHILD PSYCHOL PSYC, V32, P155, DOI 10.1111/j.1469-7610.1991.tb00007.x; THAPAR A, 1995, BEHAV GENET, V25, P537, DOI 10.1007/BF02327577; VANDIJKEN HH, 1992, PHYSIOL BEHAV, V51, P787, DOI 10.1016/0031-9384(92)90117-K; VOELLER KKS, 1991, J CHILD NEUROL, V6, pS2, DOI 10.1177/0883073891006001S01; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4	24	78	80	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					471	473		10.1038/ng1296-471	http://dx.doi.org/10.1038/ng1296-471			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944030				2022-12-25	WOS:A1996VV73000026
J	Nagle, DL; Karim, MA; Woolf, EA; Holmgren, L; Bork, P; Misumi, DJ; McGrail, SH; Dussault, BJ; Perou, CM; Boissy, RE; Duyk, GM; Spritz, RA; Moore, KJ				Nagle, DL; Karim, MA; Woolf, EA; Holmgren, L; Bork, P; Misumi, DJ; McGrail, SH; Dussault, BJ; Perou, CM; Boissy, RE; Duyk, GM; Spritz, RA; Moore, KJ			Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome	NATURE GENETICS			English	Article							PROTEIN-KINASE; FIBROBLASTS; RAPAMYCIN		MILLENNIUM PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,DEPT PEDIAT,MADISON,WI 53706; EUROPEAN MOL BIOL LABS,HEIDELBERG,GERMANY; MAX DELBRUCK CTR MOL MED,BERLIN,GERMANY; UNIV UTAH,SCH MED,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132; UNIV CINCINNATI,COLL MED,DEPT DERMATOL,CINCINNATI,OH 45267	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Utah System of Higher Education; University of Utah; University System of Ohio; University of Cincinnati			Bork, Peer/F-1813-2013; Perou, Charles M/H-9934-2014	Bork, Peer/0000-0002-2627-833X; Perou, Charles M/0000-0001-9827-2247				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Barrat FJ, 1996, AM J HUM GENET, V59, P625; Beguez-Cesar AB, 1943, B SOC CUBANA PEDIAT, V15, P900; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Bork P, 1996, METHOD ENZYMOL, V266, P162; BRANDT EJ, 1975, J CELL BIOL, V67, P774, DOI 10.1083/jcb.67.3.774; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; CHEDIAK M M, 1952, Rev Hematol, V7, P362; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Fukai K, 1996, AM J HUM GENET, V59, P620; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HIGASHI O, 1954, Tohoku J Exp Med, V59, P315; Holcombe R F, 1994, Immunodeficiency, V5, P131; JONES KL, 1992, CLIN IMMUNOL IMMUNOP, V65, P219, DOI 10.1016/0090-1229(92)90150-M; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUTZNER MA, 1966, HEREDITY, V58, P299; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NOVAK EK, 1984, BLOOD, V63, P536; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PENNER JD, 1987, AM J MED GENET, V28, P445, DOI 10.1002/ajmg.1320280222; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEIN L, 1995, UNPUB; STEINBRINCK W, 1948, DEUT ARCH KLIN MED, V193, P577; SWANK RT, 1978, AM J PATHOL, V92, P755; WILLINGHAM MC, 1981, EXP CELL RES, V136, P157, DOI 10.1016/0014-4827(81)90047-1; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; ZHAO HQ, 1994, LAB INVEST, V71, P25; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	37	361	374	0	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					307	311		10.1038/ng1196-307	http://dx.doi.org/10.1038/ng1196-307			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896560	Green Submitted			2022-12-25	WOS:A1996VQ14600025
J	Saha, K; Sova, P; Chao, W; Chess, L; Volsky, DJ				Saha, K; Sova, P; Chao, W; Chess, L; Volsky, DJ			Generation of CD4(+) and CD8(+) T-cell clones from PBLs of HIV-1 infected subjects using herpesvirus saimiri	NATURE MEDICINE			English	Article							LYMPHOCYTES-T; VIRUS; IMMUNODEFICIENCY; IMMORTALIZATION; REPLICATION; TRANSFORMATION; PATHOGENESIS		COLUMBIA UNIV COLL PHYS & SURG,ST LUKES ROOSEVELT HOSP,MOL VIROL LAB,NEW YORK,NY 10019; COLUMBIA UNIV COLL PHYS & SURG,DIV RHEUMATOL,NEW YORK,NY 10019	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS031492] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BROKER BM, 1993, J IMMUNOL, V151, P1184; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; DECARLI M, 1993, J IMMUNOL, V151, P5022; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HASELTINE WA, 1988, J ACQ IMMUN DEF SYND, V1, P217; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MEDVECZKY P, 1984, J VIROL, V52, P938, DOI 10.1128/JVI.52.3.938-944.1984; MEINL E, 1995, IMMUNOL TODAY, V16, P55, DOI 10.1016/0167-5699(95)80087-5; MITTRUCKER HW, 1993, INT IMMUNOL, V5, P985, DOI 10.1093/intimm/5.8.985; NICK S, 1993, VIROLOGY, V194, P875, DOI 10.1006/viro.1993.1334; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROIZMAN B, 1990, VIROLOGY; ROSENBERG ZF, 1991, FASEB J, V5, P2383; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SAHA K, 1992, J VIROL, V66, P2639, DOI 10.1128/JVI.66.5.2639-2646.1992; SAHA K, IN PRESS J IMMUNOL; SHEARER GM, 1991, AIDS, V5, P245, DOI 10.1097/00002030-199103000-00001; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; TOSO JF, 1995, J INFECT DIS, V172, P964, DOI 10.1093/infdis/172.4.964; Volsky DJ, 1996, J VIROL, V70, P3823, DOI 10.1128/JVI.70.6.3823-3833.1996; WALKER BD, 1990, AIDS, V4, P177, DOI 10.1097/00002030-199003000-00001; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E	29	28	29	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1272	1275		10.1038/nm1196-1272	http://dx.doi.org/10.1038/nm1196-1272			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898759				2022-12-25	WOS:A1996VQ10100049
J	Jin, H; May, M; Tranebjaerg, L; Kendall, E; Fontan, G; Jackson, J; Subramony, SH; Arena, F; Lubs, H; Smith, S; Stevenson, R; Schwartz, C; Vetrie, D				Jin, H; May, M; Tranebjaerg, L; Kendall, E; Fontan, G; Jackson, J; Subramony, SH; Arena, F; Lubs, H; Smith, S; Stevenson, R; Schwartz, C; Vetrie, D			A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness	NATURE GENETICS			English	Letter							DNA MARKERS; AGAMMAGLOBULINEMIA; CHROMOSOME; TRANSCRIPTION; EXPRESSION; REGION; ATAXIA; XQ22		GUYS & ST THOMAS HOSP,DIV MED & MOL GENET,LONDON SE1 9RT,ENGLAND; GREENWOOD GENET CTR,JC SELF RES INST,GREENWOOD,SC 29646; UNIV TROMSO HOSP,DEPT MED GENET,N-9038 TROMSO,NORWAY; HOSP LA PAZ,IMMUNOL UNIT,E-28046 MADRID,SPAIN; UNIV MISSISSIPPI,MED CTR,DEPT PREVENT MED,DIV MED GENET,JACKSON,MS 39216; UNIV MISSISSIPPI,MED CTR,DEPT NEUROL,JACKSON,MS 39216; UNIV MIAMI,SCH MED,DEPT PEDIAT,DIV GENET,MIAMI,FL	Guy's & St Thomas' NHS Foundation Trust; Greenwood Genetic Center; UiT The Arctic University of Tromso; University Hospital of North Norway; Hospital Universitario La Paz; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Miami				Vetrie, David/0000-0003-2075-4662				ARTS WFM, 1993, ANN NEUROL, V33, P535, DOI 10.1002/ana.410330519; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; JIN H, 1995, HUM MOL GENET, V4, P693, DOI 10.1093/hmg/4.4.693; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; MOHR JAN, 1960, ACTA GENET ET STATIST MED, V10, P54; PHILIPPE C, 1993, GENOMICS, V17, P147, DOI 10.1006/geno.1993.1296; RENIER WO, 1982, J MENT DEFIC RES, V26, P27; ROBERTS RG, 1992, GENOMICS, V13, P942, DOI 10.1016/0888-7543(92)90005-D; SCHMIDLEY JW, 1987, NEUROLOGY, V37, P1344, DOI 10.1212/WNL.37.8.1344; SCRIBANU N, 1975, ADV NEUROL DYSTONIA, V14, P235; SIDERAS P, 1992, J IMMUNOL, V149, P244; TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1994, GENOMICS, V19, P42, DOI 10.1006/geno.1994.1010; VETRIE D, 1993, GENOMICS, V15, P631, DOI 10.1006/geno.1993.1118; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1996, NUCLEIC ACIDS RES, V24, P160, DOI 10.1093/nar/24.1.160; VORECHOVSKY I, 1994, GENOMICS, V21, P517, DOI 10.1006/geno.1994.1310; WELLS CR, 1986, ARCH NEUROL-CHICAGO, V43, P943, DOI 10.1001/archneur.1986.00520090071021	21	198	207	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					177	180		10.1038/ng1096-177	http://dx.doi.org/10.1038/ng1096-177			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841189				2022-12-25	WOS:A1996VL44600023
J	Chen, XQ; Stroun, M; Magnenat, JL; Nicod, LP; Kurt, AM; Lyautey, J; Lederrey, C; Anker, P				Chen, XQ; Stroun, M; Magnenat, JL; Nicod, LP; Kurt, AM; Lyautey, J; Lederrey, C; Anker, P			Microsatellite alterations in plasma DNA of small cell lung cancer patients	NATURE MEDICINE			English	Article							INSTABILITY; MUTATIONS; MARKERS	Microsatellite instability is an important characteristic of many tumor types(1-8) especially those associated with hereditary non-polyposis colorectal carcinoma (HNPCC) syndrome(6-8). Microsatellite alterations in 50% of primary small cell lung carcinoma (SCLC) have been found. These alterations were also found in the sputum(4). Because neoplastic characteristics such as decreased strand stability(9) and ras mutations(10-12) have been found in the plasma DNA of cancer patients, we looked for microsatellite alterations in the plasma of SCLC patients. A microsatellite alteration was present in 16 out of 21 (76%) SCLC tumors and in 15 out of 21 (71%) plasma samples. In one case, the alteration was present only in the plasma DNA. If confirmed in larger studies, microsatellite analysis of plasma DNA might constitute a new tool for tumor staging, management and, possibly, detection.	FAC SCI GENEVA,LAB PLANT BIOCHEM & PHYSIOL,CH-1211 GENEVA,SWITZERLAND; UNIV GENEVA,FAC MED,DEPT MED,DIV RESP,CH-1205 GENEVA,SWITZERLAND; UNIV GENEVA,FAC MED,DEPT PATHOL,CH-1205 GENEVA,SWITZERLAND	University of Geneva; University of Geneva; University of Geneva			Nicod, Laurent/ABD-3360-2020	Nicod, Laurent P/0000-0002-0905-916X				KOLODNER RD, 1995, CANCER RES, V55, P242; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MERLO A, 1994, CANCER RES, V54, P2098; NAGEL S, 1995, CANCER RES, V55, P2866; NAWROZ H, 1996, NAT MED, V2, P1036; PELTOMAKI P, 1993, CANCER RES, V53, P5853; SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67; STROUN M, 1989, ONCOLOGY, V46, P318; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASYUKHIN V, 1994, CHALLENGES MODERN ME, P141; VASYUKHIN V, 1994, BRIT J HAEMATOL, V86, P774; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	14	534	665	1	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1033	1035						3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782463				2022-12-25	WOS:A1996VF49700040
J	Risinger, JI; Umar, A; Boyd, J; Berchuck, A; Kunkel, TA; Barrett, JC				Risinger, JI; Umar, A; Boyd, J; Berchuck, A; Kunkel, TA; Barrett, JC			Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair	NATURE GENETICS			English	Letter							DNA MISMATCH REPAIR; SIMPLE REPETITIVE DNA; MICROSATELLITE INSTABILITY; CELL-LINE; TUMOR-CELLS; GENE; YEAST; CARCINOMAS; TRACTS; GTBP		NIEHS,MOL GENET LAB,RES TRIANGLE PK,NC 27709; NIEHS,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599; UNIV PENN,MED CTR,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104; DUKE UNIV,DIV GYNECOL ONCOL,DEPT OBSTET & GYNECOL,DURHAM,NC 27710	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Duke University			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; ESCHELMAN JR, 1995, CURR OPIN ONCOL, V7, P83; FUJII H, 1989, J BIOL CHEM, V264, P10057; HAWN MT, 1995, CANCER RES, V55, P3721; HIROAKA LR, 1995, GENOMICS, V25, P220; IACCARINO I, CURR BIOL, V6, P484; *J HOPK U, 1995, GEN DAT HUM GEN DAT; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KATABUCHI H, 1995, CANCER RES, V55, P5556; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER R, 1996, IN PRESS GENES DEV; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, GENOMICS, V31, P395; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Rhyu MS, 1996, J NATL CANCER I, V88, P240, DOI 10.1093/jnci/88.5.240; RISINGER JI, 1995, CANCER RES, V55, P5664; RISINGER JI, 1993, CANCER RES, V53, P5100; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; UMAR A, 1994, J BIOL CHEM, V269, P14367; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Watanabe A, 1996, GENOMICS, V31, P311, DOI 10.1006/geno.1996.0053	39	162	164	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					102	105		10.1038/ng0996-102	http://dx.doi.org/10.1038/ng0996-102			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782829				2022-12-25	WOS:A1996VF61100030
J	Cranston, A; Bocker, T; Reitmair, A; Palazzo, J; Wilson, T; Mak, T; Fishel, R				Cranston, A; Bocker, T; Reitmair, A; Palazzo, J; Wilson, T; Mak, T; Fishel, R			Female embryonic lethality in mice nullizygous for both Msh2 and p53	NATURE GENETICS			English	Letter							CELL-CYCLE CHECKPOINT; GENE; TUMORIGENESIS; PROTEIN; TUMORS; INACTIVATION; DEFICIENCY; MUTATIONS; SPECTRUM; CANCER	The mutator hypothesis of tumorigenesis suggests that loss of chromosomal stability or maintenance functions results in elevated mutation rates, leading to the accumulation of the numerous mutations required for multistep carcinogenesis' The human DNA mismatch repair (MMR) genes are highly conserved homologues of the Escherichia coli MutHLS system, which contribute to genomic stability by surveillance and repair of replication misincorporation errors and exogenous DNA damage(2), Mutations in one of these MMR genes, hMSH2, account for about half of all cases of genetically linked hereditary non-polyposis colorectal cancer(3,4). Loss of function of p53 has also been proposed to increase cellular hypermutability, thereby accelerating carcinogenesis(5), although a clear role for p53 in genomic instability remains controversial(2). p53 is mutated frequently in a wide range of human cancers, including colonic tumours(6), Both Msh2- and p53-targeted knockout mice are viable and susceptible to cancer(7-11). Here we demonstrate that combined Msh(2) and p53 ablation (Msh2(-/-)p53(-/-)) results in developmental arrest of all female embryos at 9.5 days. In contrast, male Msh2(-/-)p53(-/-) mice are viable, but succumb to tumours significantly earlier (t(1/2) is 73 days) than either Msh2(-/-) or p53(-/-) littermates. Furthermore, the frequency of microsatellite instability (MSI) in tumours from Msh2(-/-)p53(-/-) mice is not significantly different than in Msh2(-/-) mice. Synergism in tumorigenesis and independent segregation of the MSI phenotype suggest that Msh2 and p53 are not genetically epistatic.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,DEPT IMMUNOL & MICROBIOL,GENET & MOL BIOL PROGRAM,PHILADELPHIA,PA 19107; UNIV TORONTO,AMGEN INST ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107	Jefferson University; University of Toronto; Jefferson University					NATIONAL CANCER INSTITUTE [R01CA056542, F32CA073134, R01CA067007] Funding Source: NIH RePORTER; NCI NIH HHS [CA73134, CA56542, R01 CA067007, CA67007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLYTH K, 1995, ONCOGENE, V10, P1717; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; HAWN MT, 1995, CANCER RES, V55, P3721; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAHTI MN, 1994, AM J HUM GENET, V55, P659; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOEB LA, 1991, CANCER RES, V51, P3075; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marra G, 1996, ONCOGENE, V13, P2189; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; PURDIE CA, 1994, ONCOGENE, V9, P603; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; TAGAKI N, 1974, EXP CELL RES, V86, P127; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; THEILER K, 1972, P168; WILLIAMS BO, 1994, COLD SPRING HARB SYM, V59, P449, DOI 10.1101/SQB.1994.059.01.050; WILLIAMS BO, 1994, CELL, V79, P329	29	65	65	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1997	17	1					114	118		10.1038/ng0997-114	http://dx.doi.org/10.1038/ng0997-114			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288110				2022-12-25	WOS:A1997XU72400030
J	Wang, P; Sergeeva, MV; Lim, L; Dordick, JS				Wang, P; Sergeeva, MV; Lim, L; Dordick, JS			Biocatalytic plastics as active and stable materials for biotransformations	NATURE BIOTECHNOLOGY			English	Article						enzyme stabilization; biocatalytic plastics; organic solvents	ORGANIC-SOLVENTS; CHYMOTRYPSIN; ENZYMES; STABILITY; POLYMERS	Enzyme-containing polymeric materials have been developed that have high activity and stability in both aqueous and organic media. These biocatalytic plastics, containing oc-chymotrypsin and subtilisin Carlsberg, can contain up to 50% (w/w) total protein in plastic materials such as poly(methyl methacrylate, styrene, vinyl acetate, and ethyl vinyl ether). The activation achieved in organic solvents by incorporating proteases in plastic matrices allows for the efficient synthesis of peptides, and sugar and nucleoside esters. The marriage of enzyme technology with polymer chemistry opens up an array of unique applications for plastic enzymes, including active and stable biocatalysts in paints, coatings, resins, foams, and beads, as well as membranes, fibers, and tubings.	UNIV IOWA,DEPT CHEM & BIOCHEM ENGN,IOWA CITY,IA 52242; UNIV IOWA,CTR BIOCATALYSIS & BIOPROC,IOWA CITY,IA 52242	University of Iowa; University of Iowa								Allcock H.R., 1990, CONT POLYM CHEM; Blanch HW, 1995, BIOCH ENG; CLARK DS, 1994, TRENDS BIOTECHNOL, V12, P439, DOI 10.1016/0167-7799(94)90018-3; DORDICK JS, 1989, ENZYME MICROB TECH, V11, P194, DOI 10.1016/0141-0229(89)90094-X; FIELDS R, 1971, BIOCHEM J, V124, P581, DOI 10.1042/bj1240581; GABEL D, 1974, FEBS LETT, V49, P280, DOI 10.1016/0014-5793(74)80530-2; ITO Y, 1992, MAKROMOL CHEM-RAPID, V13, P315; ITO Y, 1993, BIOTECHNOL PROGR, V9, P128, DOI 10.1021/bp00020a003; KLIBANOV AM, 1990, ACCOUNTS CHEM RES, V23, P114, DOI 10.1021/ar00172a004; MARTINEK K, 1977, BIOCHIM BIOPHYS ACTA, V485, P1, DOI 10.1016/0005-2744(77)90188-7; MATSUURA J, 1993, J AM CHEM SOC, V115, P1261, DOI 10.1021/ja00057a006; MEYER JD, 1995, BIOPOLYMERS, V35, P451, DOI 10.1002/bip.360350504; MORIS F, 1993, J ORG CHEM, V58, P653, DOI 10.1021/jo00055a018; Odian G., 1991, PRINCIPLES POLYM, V3; ORTHGEISS E, 1990, BIOTECHNOL BIOENG, V40, P91; PARADKAR VM, 1994, J AM CHEM SOC, V116, P5009, DOI 10.1021/ja00090a065; PARADKAR VM, 1994, BIOTECHNOL BIOENG, V43, P529, DOI 10.1002/bit.260430614; PINA C, 1989, Biotechnology Techniques, V3, P333, DOI 10.1007/BF01875632; RICH JO, 1995, BIOTECHNOL BIOENG, V45, P426, DOI 10.1002/bit.260450507; Rich JO, 1996, ANN NY ACAD SCI, V799, P226, DOI 10.1111/j.1749-6632.1996.tb33205.x; Stepanov VM, 1996, PURE APPL CHEM, V68, P1335, DOI 10.1351/pac199668061335; TAKAHASHI K, 1985, J ORG CHEM, V50, P3414, DOI 10.1021/jo00218a036; TRAMPER J, 1992, BIOCATALYSIS NONCONV; Wangikar PP, 1997, J AM CHEM SOC, V119, P70, DOI 10.1021/ja962620z; Wangikar PP, 1996, BIOTECHNOL BIOENG, V50, P329; Wiseman A., 1985, HDB ENZYME BIOTECHNO; YANG Z, 1995, J AM CHEM SOC, V117, P4843, DOI 10.1021/ja00122a014	27	119	129	3	35	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					789	793		10.1038/nbt0897-789	http://dx.doi.org/10.1038/nbt0897-789			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255796				2022-12-25	WOS:A1997XM70700033
J	Fan, HR; Oro, AE; Scott, MP; Khavari, PA				Fan, HR; Oro, AE; Scott, MP; Khavari, PA			Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog	NATURE MEDICINE			English	Article							BASEMENT-MEMBRANE PROTEINS; DROSOPHILA; POLARITY; FAMILY; MODEL; TRANSCRIPTION; EPITHELIA; DISEASE; BIOLOGY; ANTIGEN	Hedgehog (HH) signaling proteins mediate inductive events during animal development(1-11). Mutation of the only known HH receptor gene, Patched (PTC) has recently been implicated in inherited and sporadic forms of the most common human cancer, basal cell carcinoma (BCC)(12-14). In Drosophila, HH acts by inactivating PTC function(1,3), raising the possibility that overexpression of Sonic Hedgehog (SHH) in human epidermis might have a tumorigenic effect equivalent to loss of PTC function. We used retroviral transduction of normal human keratinocytes to constitutively express SHH. SHH-expressing cells demonstrated increased expression of both the known HH target, BMP-2B, as well as bcl-2, a protein prominently expressed by keratinocytes in BCCs. These keratinocytes were then used to regenerate human skin transgenic for long terminal repeat-driven SHH (LTR-SHH) on immune-deficient mice. LTR-SHH human skin consistently displays the abnormal specific histologic features seen in BCCs, including downgrowth of epithelial buds into the dermis, basal cell palisading and separation of epidermis from the underlying dermis. In addition, LTR-SHH skin displays the gene expression abnormalities previously described for human BCCs, including decreased BP180/BPAG2 and laminin 5 adhesion proteins and expression of basal epidermal keratins. These data indicate that expression of SHH in human skin recapitulates features of human BCC in vivo, suggest that activation of this conserved signaling pathway contributes to the development of epithelial neoplasia and describe a new transgenic human tissue model of neoplasia.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University	Fan, HR (corresponding author), VET AFFAIRS PALO ALTO HLTH CARE SYST,3801 MIRANDA AVE,PALO ALTO,CA 94304, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043799, R01AR043799] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 43799] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Arbeit JM, 1996, CANCER SURV, V26, P7; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BUMBROT DA, 1995, MOL CELL BIOL, V5, P2294; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Choate KA, 1996, HUM GENE THER, V7, P2247, DOI 10.1089/hum.1996.7.18-2247; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; DALE BA, 1987, J INVEST DERMATOL, V88, P307; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAIRLEY JA, 1995, BRIT J DERMATOL, V133, P385, DOI 10.1111/j.1365-2133.1995.tb02665.x; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, DEVELOPMENT, V117, P283; JINNAH HA, 1994, J NEUROSCI, V14, P1164; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Lever WF, 1990, HISTOPATHOLOGY SKIN, P622; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; MARINKOVICH MP, 1993, LAB INVEST, V69, P295; McMahon AP, 1996, NAT MED, V2, P1308, DOI 10.1038/nm1296-1308; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P161, DOI 10.1016/0190-9622(91)70022-T; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; MORALESDUCRET CRJ, 1995, ARCH DERMATOL, V131, P909, DOI 10.1001/archderm.131.8.909; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORO AE, IN PRESS SCIENCE, V276, P817; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; PURKIS PE, 1990, J CELL SCI, V97, P39; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; SAVOIA P, 1993, J INVEST DERMATOL, V101, P352, DOI 10.1111/1523-1747.ep12365531; SNOUWAERT JN, 1995, AM J RESP CRIT CARE, V151, pS59, DOI 10.1164/ajrccm/151.3_Pt_2.S59; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0	45	222	234	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					788	792		10.1038/nm0797-788	http://dx.doi.org/10.1038/nm0797-788			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212109				2022-12-25	WOS:A1997XG76700042
J	Lee, B; Thirunavukkarasu, K; Zhou, L; Pastore, L; Baldini, A; Hecht, J; Geoffroy, V; Ducy, P; Karsenty, G				Lee, B; Thirunavukkarasu, K; Zhou, L; Pastore, L; Baldini, A; Hecht, J; Geoffroy, V; Ducy, P; Karsenty, G			Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia	NATURE GENETICS			English	Article							AUTOSOMAL SEX REVERSAL; TGF-BETA-SUPERFAMILY; SRY-RELATED GENE; DROSOPHILA SEGMENTATION; CAMPOMELIC DYSPLASIA; RUNT; FAMILY; MICRODELETION; EXPRESSION; MEMBER		UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DIV MED GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System	Lee, B (corresponding author), BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030, USA.		Pastore, Lucio/AAF-3487-2019; K, Thirunavukkarasu/AAA-7615-2019; Geoffroy, Valerie/P-1521-2014; Pastore, Lucio/F-4668-2010; genes, anthony/F-2541-2012; Baldini, Antonio/M-2355-2015	Pastore, Lucio/0000-0001-6894-9317; Geoffroy, Valerie/0000-0003-3920-7482; Baldini, Antonio/0000-0002-5330-0256				Ahn MY, 1996, GENE, V168, P279, DOI 10.1016/0378-1119(95)00751-2; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Baldini A, 1994, Methods Mol Biol, V33, P75; DEMARCHI JM, 1994, HUM MUTAT, V4, P281, DOI 10.1002/humu.1380040409; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Francomano CA, 1996, CURR OPIN GENET DEV, V6, P301, DOI 10.1016/S0959-437X(96)80006-2; GELB BD, 1995, AM J MED GENET, V58, P200, DOI 10.1002/ajmg.1320580222; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Innis MA, 1990, PCR PROTOCOLS GUIDE; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jones K. L., 1997, SMITHS RECOGNIZABLE; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rousseau F, 1996, HORM RES, V45, P108, DOI 10.1159/000184768; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TSAI CC, 1994, DEVELOPMENT, V120, P1671; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0	30	417	438	4	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					307	310		10.1038/ng0797-307	http://dx.doi.org/10.1038/ng0797-307			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207800				2022-12-25	WOS:A1997XG60900030
J	NybergHoffman, C; Shabram, P; Li, W; Giroux, D; AguilarCordova, E				NybergHoffman, C; Shabram, P; Li, W; Giroux, D; AguilarCordova, E			Sensitivity and reproducibility in adenoviral infectious titer determination	NATURE MEDICINE			English	Article							GENE-THERAPY; TOXICITY		CTR CELL & GENE THERAPY,HOUSTON,TX 77030; TEXAS CHILDRENS CANC CTR,HOUSTON,TX 77030; CANJI INC,SAN DIEGO,CA 92121; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine					NCI NIH HHS [CA-58204] Funding Source: Medline; NHLBI NIH HHS [HL-51754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLISON AC, 1959, BIOCHIM BIOPHYS ACTA, V40, P400; CHUCK AS, 1996, HUM GENE THER, V6, P1527; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; Durham HD, 1996, EXP NEUROL, V140, P14, DOI 10.1006/exnr.1996.0110; Goodman JC, 1996, HUM GENE THER, V7, P1241, DOI 10.1089/hum.1996.7.10-1241; Graham FL, 1991, METHOD MOL BIOL, P109; GREEN M, 1963, VIROLOGY, V20, P199, DOI 10.1016/0042-6822(63)90157-0; HORWITZ MS, 1990, VIROLOGY, V2, P1679; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; MARSHALL AG, 1975, BIOPHYSICAL CHEM PRI; MCALLISTER RM, 1966, P SOC EXP BIOL MED, V122, P455, DOI 10.3181/00379727-122-31160; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; OLIVER CJ, 1976, BIOCHIM BIOPHYS ACTA, V437, P598; SCHNEIDER MD, 1993, CIRCULATION, V88, P1937, DOI 10.1161/01.CIR.88.4.1937; SCHULICK AH, 1995, CIRCULATION, V91, P2407, DOI 10.1161/01.CIR.91.9.2407; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; Strayer DS, 1997, BIOTECHNIQUES, V22, P447, DOI 10.2144/97223bm16; Toloza EM, 1996, CANCER GENE THER, V3, P11; TRAPNELL BC, 1996, NATCHER C CTR P, V1, P59; WINTERS WD, 1971, J GEN VIROL, V10, P181, DOI 10.1099/0022-1317-10-2-181; [No title captured]	24	168	199	1	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					808	811		10.1038/nm0797-808	http://dx.doi.org/10.1038/nm0797-808			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212113				2022-12-25	WOS:A1997XG76700047
J	Pastural, E; Barrat, FJ; DufourcqLagelouse, R; Certain, S; Sanal, O; Jabado, N; Seger, R; Griscelli, C; Fischer, A; DesaintBasile, G				Pastural, E; Barrat, FJ; DufourcqLagelouse, R; Certain, S; Sanal, O; Jabado, N; Seger, R; Griscelli, C; Fischer, A; DesaintBasile, G			Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene	NATURE GENETICS			English	Article							UNCONVENTIONAL MYOSIN; PARTIAL ALBINISM; IMMUNODEFICIENCY; INVOLVEMENT; LOCUS		HOP NECKER ENFANTS MALAD,INSERM U429,UNITE RECH DEV NORMAL & PATHOL SYST IMMUNITAIRE,F-75743 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,UNITE IMMUNOL & HEMATOL PEDIAT,F-75743 PARIS 15,FRANCE; HACETTEPE CHILDRENS HOSP MED CTR,ANKARA,TURKEY; UNIV KINDERSPITAL ZURICH,ABT IMMUNOL HAMATOL,CH-8032 ZURICH,SWITZERLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Hacettepe University; University Children's Hospital Zurich			Jabado, Nada/AAN-4026-2020; de Saint Basile, Genevieve/G-9731-2017	DOGNIAUX, Stephanie/0000-0003-3309-1204; de Saint Basile, Genevieve/0000-0002-1913-5269				Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Barrat FJ, 1996, AM J HUM GENET, V59, P625; BEJAOUI M, 1989, ARCH FR PEDIATR, V46, P733; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; ELEJALDE BR, 1979, AM J MED GENET, V3, P65, DOI 10.1002/ajmg.1320030112; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Evans L. L., 1995, Molecular Biology of the Cell, V6, p145A; GRISCELLI C, 1978, AM J MED, V65, P691, DOI 10.1016/0002-9343(78)90858-6; HARALDSSON A, 1991, EUR J PEDIATR, V150, P419, DOI 10.1007/BF02093723; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; HURVITZ H, 1993, EUR J PEDIATR, V152, P402, DOI 10.1007/BF01955897; JENKINS NA, 1981, NATURE, V293, P370, DOI 10.1038/293370a0; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KLEIN C, 1994, J PEDIATR-US, V125, P886, DOI 10.1016/S0022-3476(05)82003-7; KRUGLYAK L, 1995, AM J HUM GENET, V56, P519; MANI F, 1994, BRAZ J MED BIOL RES, V27, P2639; Maniatis T., 1982, MOL CLONING; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOORE KJ, 1995, CYTOGENET CELL GENET, V69, P53, DOI 10.1159/000133937; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; STROBEL MC, 1990, MOL CELL BIOL, V10, P501, DOI 10.1128/MCB.10.2.501; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WINDHORST DB, 1973, J INVEST DERMATOL, V60, P529, DOI 10.1111/1523-1747.ep12703609	26	332	339	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					289	292		10.1038/ng0797-289	http://dx.doi.org/10.1038/ng0797-289			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207796				2022-12-25	WOS:A1997XG60900026
J	Miller, H				Miller, H			The EPA's war on bioremediation	NATURE BIOTECHNOLOGY			English	Editorial Material											Miller, H (corresponding author), STANFORD UNIV,INST INT STUDIES,STANFORD,CA 94305, USA.								0	6	6	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					486	486		10.1038/nbt0697-486	http://dx.doi.org/10.1038/nbt0697-486			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181556	Bronze			2022-12-25	WOS:A1997XC77200006
J	Martinson, JJ; Chapman, NH; Rees, DC; Liu, YT; Clegg, JB				Martinson, JJ; Chapman, NH; Rees, DC; Liu, YT; Clegg, JB			Global distribution of the CCR5 gene 32-basepair deletion	NATURE GENETICS			English	Article							DISEASES; HIV	A mutant allele of the beta-chemokine receptor gene CCR5 bearing a 32-basepair (bp) deletion (denoted Delta ccr5) which prevents cell invasion by the primary transmitting strain of HIV-1 has recently been characterized(1-3). Homozygotes for the mutation are resistant to infection, even after repeated high-risk exposures(1,4), but this resistance appears not to be total, as isolated cases of HIV-positive deletion homozygotes are now emerging(5), The consequence of the heterozygous state is not clear, but it may delay the progression to AIDS in infected individuals(2,3,6,7). A gene frequency of approximately 10% was found for Delta ccr5 in populations of European descent, but no mutant alleles were reported in indigenous non-European populations, As the total number of non-European samples surveyed was small in comparison with the Europeans the global distribution of this mutation is far from clear. We have devised a rapid PCR assay for Delta ccr5 and used it to screen 3,342 individuals from a globally-distributed range of populations. We find that Delta ccr5 is not confined to people of European descent but is found at frequencies of 2-5% throughout Europe, the Middle East and the Indian subcontinent (Fig. 1). Isolated occurrences are seen elsewhere throughout the world, but these most likely represent recent European gene flow into the indigenous populations, The inter-population differences in Delta ccr5 frequency may influence the pattern of HIV transmission and so will need to be incorporated into future predictions of HIV levels.	UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT HUMAN GENET,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Martinson, JJ (corresponding author), JOHN RADCLIFFE HOSP,INST MOL MED,MRC,MOL HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		; Rees, David/B-6789-2011	Martinson, Jeremy/0000-0003-4673-7238; Rees, David/0000-0003-3647-1050	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COX DW, 1995, METABOLIC MOL BASES, P4125; Cox MJ, 1996, BRIT J HAEMATOL, V92, P1022, DOI 10.1046/j.1365-2141.1996.4961037.x; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Fauci AS, 1996, NAT MED, V2, P966, DOI 10.1038/nm0996-966; FLINT J, 1993, HUM GENET, V91, P91; Hill CM, 1996, NATURE, V382, P668, DOI 10.1038/382668a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kimura MA, 1985, NEUTRAL THEORY MOL E; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MORRAL N, 1994, NAT GENET, V7, P169, DOI 10.1038/ng0694-169; MOTULSKY AG, 1995, NAT GENET, V9, P99, DOI 10.1038/ng0295-99; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	32	422	442	0	40	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	MAY	1997	16	1					100	103		10.1038/ng0597-100	http://dx.doi.org/10.1038/ng0597-100			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140404				2022-12-25	WOS:A1997WX02400031
J	Klein, KA; Reiter, RE; Redula, J; Morad, H; Zhu, XL; Brothman, AR; Lamb, DJ; Marcelli, M; Belldegrun, A; Witte, ON; Sawyers, CL				Klein, KA; Reiter, RE; Redula, J; Morad, H; Zhu, XL; Brothman, AR; Lamb, DJ; Marcelli, M; Belldegrun, A; Witte, ON; Sawyers, CL			Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice	NATURE MEDICINE			English	Article							(EBV)-ASSOCIATED LYMPHOPROLIFERATIVE DISEASE; CIRCULATING TUMOR-CELLS; RECEPTOR GENE; NUDE-MICE; GROWTH-FACTORS; CARCINOMA; MODEL; LNCAP; MUTATION; MOUSE	Prostate cancer mortality results from metastasis to bone and hormone-independent tumor growth. Models to study these progressive changes are lacking. Here we describe the propagation of advanced human prostate cancer by direct transfer of surgical samples from patients into immune-deficient male SCID mice. Explants from six of eight patients formed prostate tumors and two showed unique cytogenetic, biologic and molecular features that were retained through six or more passages. One grew in an androgen-independent fashion, whereas the second formed tumors that regressed following castration then regrew. Micrometastatic disease was detected in the hematopoietic tissues of half of the recipient mice. Thus selected specimens of advanced human prostate cancer can be propagated in SCID mice in a manner that recapitulates the clinical transition from androgen-sensitive to androgen-independent growth, accompanied by micrometastasis.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT UROL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & MOL GENET,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV UTAH,SCH MED,DEPT PEDIAT,SALT LAKE CITY,UT 84132; UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT UROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Sawyers, Charles/G-5327-2016; marcelli, marco/AGR-6853-2022		NCI NIH HHS [R01 CA 68615, R01-CA46269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068615, R01CA046269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; BAIOCCHI RA, 1994, P NATL ACAD SCI USA, V91, P5577, DOI 10.1073/pnas.91.12.5577; Brandt B, 1996, CANCER RES, V56, P4556; BRINKMANN AO, 1995, J STEROID BIOCHEM, V53, P443, DOI 10.1016/0960-0760(95)00090-M; BROTHMAN AR, 1990, CANCER RES, V50, P3795; Cher ML, 1996, CANCER RES, V56, P3091; Cooney KA, 1996, CANCER RES, V56, P1142; DEBRUYNE FM, 1993, SCAND J UROL NEPHROL, V162, P115; DEBRUYNE FM, 1993, SCAND J UROL NEPHROL, V162, P65; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GHOSSEIN RA, 1995, J CLIN ONCOL, V13, P1195, DOI 10.1200/JCO.1995.13.5.1195; GLEAVE ME, 1992, CANCER RES, V52, P1598; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; KATZ AE, 1994, UROLOGY, V43, P765, DOI 10.1016/0090-4295(94)90132-5; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; Liu AY, 1996, INT J CANCER, V65, P85, DOI 10.1002/(SICI)1097-0215(19960103)65:1<85::AID-IJC15>3.3.CO;2-E; LUBEROFF DM, 1995, PROSTATE, V1, P32; MARCELLI M, 1995, ENDOCRINOLOGY, V136, P1040, DOI 10.1210/en.136.3.1040; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; MICALE MA, 1993, CANCER GENET CYTOGEN, V69, P7, DOI 10.1016/0165-4608(93)90103-S; Nagabhushan M, 1996, CANCER RES, V56, P3042; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; PANG S, 1995, HUM GENE THER, V6, P1417, DOI 10.1089/hum.1995.6.11-1417; PRETLOW TG, 1991, CANCER RES, V51, P3814; PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 2002, MOL CLONING LAB MANU; SEIDEN MV, 1994, J CLIN ONCOL, V12, P2634, DOI 10.1200/JCO.1994.12.12.2634; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; Sutherland RW, 1996, J UROLOGY, V156, P828, DOI 10.1016/S0022-5347(01)65830-0; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; vanWeerden WM, 1996, AM J PATHOL, V149, P1055; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WAKASUGI H, 1995, JPN J CANCER RES, V86, P1086, DOI 10.1111/j.1349-7006.1995.tb03025.x; WARE JL, 1989, PATHOL IMMUNOPATH R, V8, P231, DOI 10.1159/000157154; WOOD DP, 1994, CANCER, V74, P2533, DOI 10.1002/1097-0142(19941101)74:9<2533::AID-CNCR2820740922>3.0.CO;2-D; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319	43	328	441	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					402	408		10.1038/nm0497-402	http://dx.doi.org/10.1038/nm0497-402			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095173				2022-12-25	WOS:A1997WQ82500029
J	Motley, AM; Hettema, EH; Hogenhout, EM; Brites, P; tenAsbroek, ALMA; Wijburg, FA; Baas, F; Heijmans, HS; Tabak, HF; Wanders, RJA; Distel, B				Motley, AM; Hettema, EH; Hogenhout, EM; Brites, P; tenAsbroek, ALMA; Wijburg, FA; Baas, F; Heijmans, HS; Tabak, HF; Wanders, RJA; Distel, B			Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor	NATURE GENETICS			English	Article							MAMMALIAN-CELL MUTANT; SACCHAROMYCES-CEREVISIAE; IMPORT DEFICIENCIES; DISORDERS; REPEAT; FAMILY; COMPLEMENTATION; THIOLASE; MEMBER; BIOGENESIS	Rhizomelic chondrodysplasia punctata (RCDP) is an autosomal recessive disease characterized clinically by a disproportionately short stature primarily affecting the proximal parts of the extremities, typical dysmorphic facial appearance, congenital contractures and severe growth and mental retardation. Although some patients have single enzyme deficiencies, the majority of RCDP patients (86%) belong to a single complementation group (CG11, also known as complementation group I, Amsterdam nomenclature(1)). Cells from CG11 show a tetrad of biochemical abnormalities: a deficiency of i) dihydroxyacetonephosphate acyltransferase, ii) alkyldihydroxyacetonephosphate synthase, iii) phytanic acid alpha-oxidation and iv) inability to import peroxisomal thiolase. These deficiencies indicate involvement of a component required for correct targeting of these peroxisomal proteins. Deficiencies in peroxisomal targeting are also found in Saccharomyces cerevisiae pex5 and pex7 mutants(2-6), which show differential protein import deficiencies corresponding to two peroxisomal targeting sequences (PTS1 and PTS2). These mutants lack their PTS1 and PTS2 receptors, respectively. Like S. cerevisiae pex7 cells, RCDP cells from CG11 cannot import a PTSZ reporter protein(7). Here we report the cloning of PEX7 encoding the human PTSZ receptor, based on its similarity to two yeast orthologues. All RCDP patients from CG11 with detectable PEX7 mRNA were found to contain mutations in PEX7. A mutation resulting in C-terminal truncation of PEX7 cosegregates with the disease and expression of PEX7 in RCDP fibroblasts from CG11 rescues the PTSZ protein import deficiency. These findings prove that mutations in PEX7 cause RCDP, CG11.	UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,NL-1100 DE AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROL,NL-1100 DE AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PEDIAT,NL-1100 DE AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam			Brites, Pedro/K-4231-2013; Baas, Frank/F-9574-2010	Brites, Pedro/0000-0003-1754-1543; Baas, Frank/0000-0003-3912-5428; Wijburg, Frits/0000-0002-0950-1368				Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1996, BBA-REV BIOMEMBRANES, V1286, P269, DOI 10.1016/S0304-4157(96)00012-3; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ELGERSMA Y, 1975, J BIOL CHEM, V271, P263; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; HEUS JJ, 1990, CURR GENET, V18, P517, DOI 10.1007/BF00327022; IJLST L, 1994, BBA-LIPID LIPID MET, V1215, P347, DOI 10.1016/0005-2760(94)90064-7; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; SHIMOZAWA N, 1993, AM J HUM GENET, V52, P843; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WANDERS RJA, 1992, J INHERIT METAB DIS, V15, P389, DOI 10.1007/BF02435984; WANDERS RJA, 1994, J INHERIT METAB DIS, V17, P315, DOI 10.1007/BF00711817; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	33	213	215	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	APR	1997	15	4					377	380		10.1038/ng0497-377	http://dx.doi.org/10.1038/ng0497-377			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WQ389	9090382				2022-12-25	WOS:A1997WQ38900015
J	Dalsgaard, K; Uttenthal, A; Jones, TD; Xu, F; Merryweather, A; Hamilton, WDO; Langeveld, JPM; Boshuizen, RS; Kamstrup, S; Lomonossoff, GP; Porta, C; Vela, C; Casal, JI; Meloen, RH; Rodgers, PB				Dalsgaard, K; Uttenthal, A; Jones, TD; Xu, F; Merryweather, A; Hamilton, WDO; Langeveld, JPM; Boshuizen, RS; Kamstrup, S; Lomonossoff, GP; Porta, C; Vela, C; Casal, JI; Meloen, RH; Rodgers, PB			Plant-derived vaccine protects target animals against a viral disease	NATURE BIOTECHNOLOGY			English	Article						cowpea mosaic virus; parvovirus; plant vaccine; protection; peptide epitope; chimeric virus particles	COWPEA MOSAIC-VIRUS; B-CELL EPITOPES; CANINE PARVOVIRUS; RECOMBINANT VACCINE; SYNTHETIC PEPTIDE; SURFACE; EXPRESSION; ANTIBODIES; PARTICLE; TERMINUS	The successful expression of animal or human virus epitopes on the surface of plant viruses has recently been demonstrated. These chimeric virus particles (CVPs) could represent a cost-effective and safe alternative to conventional animal cell-based vaccines. We report the insertion of oligonucleotides coding for a short linear epitope from the VP2 capsid protein of mink enteritis virus (MEV) into an infectious cDNA clone of cowpea mosaic virus and the successful expression of the epitope on the surface of CVPs when propagated in the black-eyed bean, Vigna unguiculata. The efficacy of the CVPs was established by the demonstration that one subcutaneous injection of 1 mg of the CVPs in mink conferred protection against clinical disease and virtually abolished shedding of virus after challenge with virulent MEV, demonstrating the potential utility of plant CVPs as the basis for vaccine development. The epitope used occurs in three different virus species-MEV, canine parvovirus, and feline panleukopenia virus-and thus the same vaccine could be used in three economically important viral hosts-mink, dogs, and cats, respectively.	DANISH VET LAB,DK-1790 COPENHAGEN,DENMARK; AXIS GENET PLC,CAMBRIDGE CB2 4AZ,ENGLAND; ID DLO,INST ANIM SCI & HLTH,NL-8200 AB LELYSTAD,NETHERLANDS; INGENASA,E-28037 MADRID,SPAIN; JOHN INNES CTR PLANT SCI RES,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dalsgaard, K (corresponding author), DANISH VET INST VIRUS RES,DK-4771 KALVEHAVE,DENMARK.		Casal, Ignacio/M-2312-2014	Casal, Ignacio/0000-0003-1085-2840				CASAL JI, 1995, J VIROL, V69, P7274, DOI 10.1128/JVI.69.11.7274-7277.1995; CHRISTENSEN J, 1994, J GEN VIROL, V75, P149, DOI 10.1099/0022-1317-75-1-149; COTMORE SF, 1987, ADV VIRUS RES, V33, P91, DOI 10.1016/S0065-3527(08)60317-6; DALSGAARD K, 1974, ARCH GES VIRUSFORSCH, V44, P243, DOI 10.1007/BF01240612; DESSENS JT, 1993, J GEN VIROL, V74, P889, DOI 10.1099/0022-1317-74-5-889; DETURISO JAL, 1991, J GEN VIROL, V72, P2445, DOI 10.1099/0022-1317-72-10-2445; DETURISO JAL, 1992, J VIROL, V66, P2748; FITCHEN J, 1995, VACCINE, V13, P1051, DOI 10.1016/0264-410X(95)00075-C; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1994, J VIROL, V68, P4506, DOI 10.1128/JVI.68.7.4506-4513.1994; LANGEVELD JPM, 1995, VACCINE, V13, P1033, DOI 10.1016/0264-410X(95)00021-R; LANGEVELD JPM, 1993, J VIROL, V67, P765, DOI 10.1128/JVI.67.2.765-772.1993; LANGEVELD JPM, 1994, VACCINE, V12, P1473, DOI 10.1016/0264-410X(94)90158-9; Lin TW, 1996, FOLD DES, V1, P179, DOI 10.1016/S1359-0278(96)00030-2; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; MCLAIN L, 1995, AIDS RES HUM RETROV, V11, P327, DOI 10.1089/aid.1995.11.327; McLain L, 1996, VACCINE, V14, P799, DOI 10.1016/0264-410X(95)00229-T; MELOEN RH, 1995, PEPSCAN DETERMINE T; MENGELING WL, 1979, AM J VET RES, V40, P204; PARADISO PR, 1981, J VIROL, V39, P800, DOI 10.1128/JVI.39.3.800-807.1981; PARRISH CR, 1994, SEMIN VIROL, V5, P121, DOI 10.1006/smvy.1994.1013; Pearson R. C., 1987, VIRUS INFECTIONS CAR, P349; PORTA C, 1994, VIROLOGY, V202, P949, DOI 10.1006/viro.1994.1417; Sambrook J., 2002, MOL CLONING LAB MANU; SEMANCIK JS, 1966, VIROLOGY, V30, P698, DOI 10.1016/0042-6822(66)90174-7; SORENSEN KJ, 1980, ACTA VET SCAND, V21, P312; Stauffacher C.V., 1987, CRYSTALLOGRAPHY MOL, P293; TURPEN TH, 1995, BIO-TECHNOL, V13, P53, DOI 10.1038/nbt0195-53; USHA R, 1993, VIROLOGY, V197, P366, DOI 10.1006/viro.1993.1598; UTTENTHAL A, 1988, ARCH VIROL, V99, P153, DOI 10.1007/BF01311066; VANKAMMEN A, 1978, COWPEA MOSAIC VIRUS; [No title captured]	33	200	234	2	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					248	252		10.1038/nbt0397-248	http://dx.doi.org/10.1038/nbt0397-248			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062924				2022-12-25	WOS:A1997WM05000028
J	Liepinsh, E; Otting, G				Liepinsh, E; Otting, G			Organic solvents identify specific ligand binding sites on protein surfaces	NATURE BIOTECHNOLOGY			English	Article						nuclear magnetic resonance; protein solvation; nuclear Overhauser effect	EGG-WHITE LYSOZYME; NUCLEAR-MAGNETIC-RESONANCE; NEUTRON-DIFFRACTION; CRYSTAL-STRUCTURE; HEN LYSOZYME; HYDRATION; UREA; RESOLUTION; COMPLEXES	Enzymes frequently recognize substrates and pharmaceutical drugs through specific binding interactions in deep pockets on the protein surface. We show how the specificity-determining substrate binding site of hen egg-white lysozyme (HEWL) can be readily identified in aqueous solution by nuclear magnetic resonance spectroscopy using small organic solvent molecules as detection probes. Exchange of magnetization between the H-1 nuclei of the protein and the ligands through dipole-dipole interactions is observed which allows the modeling of their position and orientation at the binding site. Combined with site-specific binding constants measured by titration experiments with different organic solvents, the method can provide important information for rational drug design. In addition, the lifetime of nonspecific interactions of HEWL with organic solvents is shown to be in the sub-nanosecond time range.	KAROLINSKA INST, DEPT BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet			Otting, Gottfried/H-8413-2014	Otting, Gottfried/0000-0002-0563-0146				Allen KN, 1996, J PHYS CHEM-US, V100, P2605, DOI 10.1021/jp952516o; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BRIAND J, 1991, CHEM PHYS LETT, V185, P276, DOI 10.1016/S0009-2614(91)85060-A; CHEETHAM JC, 1992, J MOL BIOL, V224, P613, DOI 10.1016/0022-2836(92)90548-X; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GEEN H, 1991, J MAGN RESON, V93, P93, DOI 10.1016/0022-2364(91)90034-Q; HADFIELD AT, 1994, J MOL BIOL, V243, P856, DOI 10.1006/jmbi.1994.1688; Imoto T., 1972, ENZYMES, V7, P665; KELLY JA, 1979, NATURE, V282, P875, DOI 10.1038/282875a0; KUNDROT CE, 1987, J MOL BIOL, V193, P157, DOI 10.1016/0022-2836(87)90634-6; LEHMANN MS, 1985, BIOCHEMISTRY-US, V24, P5862, DOI 10.1021/bi00342a026; LEHMANN MS, 1989, BIOCHEMISTRY-US, V28, P7028, DOI 10.1021/bi00443a037; LIEPINSH E, 1994, J AM CHEM SOC, V116, P9670, DOI 10.1021/ja00100a036; LUMB KJ, 1994, J MOL BIOL, V235, P1072, DOI 10.1006/jmbi.1994.1058; LUMB KJ, 1992, J MOL BIOL, V227, P9, DOI 10.1016/0022-2836(92)90677-C; MAENAKA K, 1995, J MOL BIOL, V247, P281, DOI 10.1006/jmbi.1994.0139; Mattos C, 1996, NAT BIOTECHNOL, V14, P595, DOI 10.1038/nbt0596-595; OTTING G, 1992, J AM CHEM SOC, V114, P7093, DOI 10.1021/ja00044a021; OTTING G, 1991, Journal of Biomolecular NMR, V1, P209, DOI 10.1007/BF01877232; OTTING G, 1995, ACCOUNTS CHEM RES, V28, P171, DOI 10.1021/ar00052a002; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; PIKE ACW, 1994, PROTEIN SCI, V3, P706; REDFIELD C, 1988, BIOCHEMISTRY-US, V27, P122, DOI 10.1021/bi00401a020; SMITH RJ, 1989, J CHEM SOC CHEM COMM, P682, DOI 10.1039/c39890000682; WESCOTT CR, 1994, BIOCHIM BIOPHYS ACTA, V1286, P1; XIA TH, 1992, THESIS ETH ZURICH SW; YONATH A, 1978, BIOPHYS STRUCT MECH, V4, P27, DOI 10.1007/BF00538838	30	98	100	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					264	268		10.1038/nbt0397-264	http://dx.doi.org/10.1038/nbt0397-264			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062927				2022-12-25	WOS:A1997WM05000031
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Transgenics on the Internet	NATURE BIOTECHNOLOGY			English	Editorial Material									MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	Sikorski, R (corresponding author), NCI, HOWARD HUGHES MED INST, BETHESDA, MD 20892 USA.								0	3	6	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					289	289		10.1038/nbt0397-289	http://dx.doi.org/10.1038/nbt0397-289			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062932	Bronze			2022-12-25	WOS:A1997WM05000037
J	Golub, ES				Golub, ES			Genetically enhanced food for thought	NATURE BIOTECHNOLOGY			English	Editorial Material									PURDUE UNIV,W LAFAYETTE,IN 47907; ORTHO BIOTEC,RARITAN,NJ	Purdue University System; Purdue University; Purdue University West Lafayette Campus									0	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					112	112		10.1038/nbt0297-112	http://dx.doi.org/10.1038/nbt0297-112			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035119	Bronze			2022-12-25	WOS:A1997WE99800005
J	Magliani, W; Conti, S; DeBernardis, F; Gerloni, M; Bertolotti, D; Mozzoni, P; Cassone, A; Polonelli, L				Magliani, W; Conti, S; DeBernardis, F; Gerloni, M; Bertolotti, D; Mozzoni, P; Cassone, A; Polonelli, L			Therapeutic potential of antiidiotype single chain antibodies with yeast killer toxin activity	NATURE BIOTECHNOLOGY			English	Article						yeast killer toxin; recombinant antiidiotypic antibodies; fungicidal peptides; experimental vaginitis; therapeutic treatment	ANTI-IDIOTYPIC ANTIBODIES; CANDIDA-ALBICANS; MONOCLONAL-ANTIBODIES; PHAGE; LIBRARIES; VACCINATION; RECEPTORS; INFECTION	Single chain fragment (ScFv) antiidiotypic antibodies (antilds) of a killer toxin (KT) from the yeast Pichia anomala have been produced by recombinant DNA methodology from the splenic lymphocytes of mice immunized by idiotypic vaccination with a KT-neutralizing monoclonal antibody (Mab KT4). ScFv KT-like antilds (KTIdAb) react with specific Candida albicans KT cell wall receptors (KTR) exerting a candidacidal activity in vitro could be neutralized by adsorption with Mab KT4. ScFv KTldAb displayed an effective therapeutic activity in an experimental model of rat candidal vaginitis.	UNIV PARMA,IST MICROBIOL,FAC MED & CHIRURG,I-43100 PARMA,ITALY; IST SUPER SANITA,BATTERIOL & MICOL MED LAB,I-00161 ROME,ITALY	University of Parma; Istituto Superiore di Sanita (ISS)			Gerloni, Mara/AAG-1526-2020; DE BERNARDIS, FLAVIA/C-9589-2016; Cassone, Antonio/J-4666-2019; Conti, Stefania/N-3558-2015	DE BERNARDIS, FLAVIA/0000-0001-9440-8629; Conti, Stefania/0000-0001-9973-8352				ALIOUAT EM, 1993, IMMUNOTHER INFECT DI, V5, P102; ARMSTRONG D, 1993, CLIN INFECT DIS, V17, pS318, DOI 10.1093/clinids/17.Supplement_2.S318; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Bona CA, 1984, RECEPTOR BIOCH METHO, V14, P141; BRINKMANN U, 1994, BBA-REV CANCER, V1198, P27, DOI 10.1016/0304-419X(94)90004-3; CASSONE A, 1995, INFECT IMMUN, V63, P2619, DOI 10.1128/IAI.63.7.2619-2624.1995; CASSONE A, IN PRESS IMMUNOL TOD; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DEBERNARDIS F, 1990, J INFECT DIS, V161, P1276, DOI 10.1093/infdis/161.6.1276; FIDEL PL, 1993, INFECT IMMUN, V61, P1990, DOI 10.1128/IAI.61.5.1990-1995.1993; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MONROE JG, 1986, IMMUNOL INVEST, V15, P263, DOI 10.3109/08820138609026688; NISONOFF A, 1984, NEW HORIZONS MICROBI, P119; POLJAK RJ, 1994, P NATL ACAD SCI USA, V91, P1599, DOI 10.1073/pnas.91.5.1599; POLONELLI L, 1986, J CLIN MICROBIOL, V24, P866, DOI 10.1128/JCM.24.5.866-869.1986; POLONELLI L, 1990, J IMMUNOL METHODS, V132, P205, DOI 10.1016/0022-1759(90)90031-P; POLONELLI L, 1988, J CLIN MICROBIOL, V26, P602, DOI 10.1128/JCM.26.3.602-604.1988; POLONELLI L, 1991, J MED VET MYCOL, V29, P235; POLONELLI L, 1993, SCAND J IMMUNOL, V37, P105, DOI 10.1111/j.1365-3083.1993.tb01671.x; POLONELLI L, 1994, J IMMUNOL, V152, P3175; Polonelli L, 1996, J IMMUNOL, V156, P1880; POLONELLI L, 1987, J CLIN MICROBIOL, V25, P460, DOI 10.1128/JCM.25.2.460-462.1987; POLONELLI L, IN PRESS CLIN DIAGN; TETI G, 1992, HYBRIDOMA, V11, P13, DOI 10.1089/hyb.1992.11.13	28	108	116	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					155	158		10.1038/nbt0297-155	http://dx.doi.org/10.1038/nbt0297-155			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035141				2022-12-25	WOS:A1997WE99800022
J	Greenfield, A; Scott, D; Pennisi, D; Ehrmann, I; Ellis, P; Cooper, L; Simpson, E; Koopman, P				Greenfield, A; Scott, D; Pennisi, D; Ehrmann, I; Ellis, P; Cooper, L; Simpson, E; Koopman, P			An H-YDb epitope is encoded by a novel mouse Y chromosome gene	NATURE GENETICS			English	Article							CLASS-I MOLECULES; X-INACTIVATION; EXPRESSION; ANTIGEN; REGION; MICE; DIFFERENTIATION; PEPTIDE; TPR; SPERMATOGENESIS	Rejection of male tissue grafts by genotypically identical female mice has been explained by the existence of a male-specific transplantation antigen, H-Y (ref. 1), but the molecular nature of H-Y antigen has remained obscure. Hya, the murine locus controlling H-Y expression, has been localized to Delta Sxr(b), a deletion interval of the short arm of the Y chromosome(2). In mice, H-Y antigen comprises at least four distinct epitopes, each recognized by a specific T lymphocyte clone. It has recently been shown that one of these epitopes, H-YKk, is a peptide encoded by the Y-linked Smcy gene, presented at the cell surface with the H-2K(k) major histocompatibility complex (MHC) molecule(3). However, deletion mapping and the analysis of variable inactivation of H-Y epitopes has suggested that the Hya locus may be genetically complex(4,5). Here we describe a novel mouse Y chromosome gene which we call Uty (ubiquitously transcribed tetratricopeptide repeat gene on the Y chromosome). We identify the peptide WMHHNMDLI derived from the UTY protein as an H-Y epitope, H-YDb. Our data formally demonstrate that H-Y antigen is the product of more than one gene on the Y chromosome.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, MRC, CTR CLIN SCI, LONDON W12 0NN, ENGLAND; UNIV QUEENSLAND, DEPT ANAT SCI, BRISBANE, QLD 4072, AUSTRALIA; UNIV QUEENSLAND, CTR CELLULAR & MOL BIOL, BRISBANE, QLD 4072, AUSTRALIA	Imperial College London; University of Queensland; University of Queensland			Koopman, Peter A/C-9416-2009; Greenfield, Andy/F-5099-2017	Koopman, Peter A/0000-0001-6939-0914; Greenfield, Andy/0000-0002-1477-1776; Pennisi, David/0000-0001-8247-2965; Simpson, Elizabeth/0000-0002-2118-3139				AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BISHOP CE, 1988, SEX DETERMINATION MO, P119; BURGOYNE P, 1993, SEX CHROMOSOMES SEX, P353; BURGOYNE PS, 1993, DEVELOPMENT, V117, P341; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; EICHWALD EJ, 1955, TRANSPLAN B, V2, P121; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENECH M, 1991, NUCLEIC ACIDS RES, V19, P6737, DOI 10.1093/nar/19.24.6737; GAVIN MA, 1994, EUR J IMMUNOL, V24, P2124, DOI 10.1002/eji.1830240929; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KentFirst MG, 1996, NAT GENET, V14, P128, DOI 10.1038/ng1096-128; KING TR, 1994, GENOMICS, V24, P159, DOI 10.1006/geno.1994.1593; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; MCLAREN A, 1988, P NATL ACAD SCI USA, V85, P6442, DOI 10.1073/pnas.85.17.6442; MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0; MITCHELL MJ, 1992, GENOMICS, V12, P26, DOI 10.1016/0888-7543(92)90402-E; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCOTT D, 1991, IMMUNOGENETICS, V33, P54, DOI 10.1007/BF00211696; SCOTT DM, 1992, IMMUNOGENETICS, V36, P86, DOI 10.1007/BF00215284; SCOTT DM, 1995, NATURE, V376, P695, DOI 10.1038/376695a0; SIMPSON E, 1995, EUR J IMMUNOL, V25, P2813, DOI 10.1002/eji.1830251015; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5	32	154	160	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1996	14	4					474	478		10.1038/ng1296-474	http://dx.doi.org/10.1038/ng1296-474			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944031				2022-12-25	WOS:A1996VV73000027
J	Kaartinen, V; Mononen, I; Voncken, JW; Noronkoski, T; GonzalezGomez, I; Heisterkamp, N; Groffen, J				Kaartinen, V; Mononen, I; Voncken, JW; Noronkoski, T; GonzalezGomez, I; Heisterkamp, N; Groffen, J			A mouse model for the human lysosomal disease aspartylglycosaminuria	NATURE MEDICINE			English	Article							STORAGE DISEASE; MICE; ASPARTYLGLUCOSAMINURIA; GLYCOSYLASPARAGINASE; GENE	Aspartylglycosaminuria (AGU), the most common disorder of glycoprotein degradation in humans, is caused by mutations in the gene encoding the lysosomal enzyme glycosylasparaginase (Aga)(1). The resulting enzyme deficiency allows aspartylglucosamine (GlcNAc-Asn) and other glycoasparagines to accumulate in tissues and body fluids, from early fetal life onward(1). The clinical course is characterized by normal early development, slowly progressing to severe mental and motor retardation in early adulthood(2,3). The exact pathogenesis of AGU in humans is unknown and neither therapy nor an animal model for this debilitating and ultimately fatal disease exists. Through targeted disruption of the mouse Ago gene in embryonic stem cells, we generated mice that completely lack Aga activity. At the age of 5-10 months a massive accumulation of GlcNAc-Asn was detected along with lysosomal vacuolization, axonal swelling in the gracile nucleus and impaired neuromotor coordination. A significant number of older male mice had massively swollen bladders, which was not caused by obstruction, but most likely related to the impaired function of the nervous system. These findings are consistent with the pathogenesis of AGU and provide further data explaining the impaired neurological function in AGU patients.	CHILDRENS HOSP LOS ANGELES,RES INST,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV KUOPIO,DEPT CHEM,FIN-70211 KUOPIO,FINLAND; KUOPIO UNIV HOSP,DEPT CLIN CHEM,FIN-70211 KUOPIO,FINLAND	Children's Hospital Los Angeles; University of Eastern Finland; Kuopio University Hospital			Kaartinen, Vesa/AAU-5396-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X				ARSTILA AU, 1972, ACTA NEUROPATHOL, V20, P207, DOI 10.1007/BF00686902; AULA P, 1982, GENETIC ERRORS GLYCO, P123; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; ENOMAA N, 1995, HUM GENE THER, V6, P723, DOI 10.1089/hum.1995.6.6-723; FISHER KJ, 1991, J BIOL CHEM, V266, P12105; Guastavino J.-M., 1992, V8, P375; HALTIA M, 1975, ACTA NEUROPATHOL, V31, P243, DOI 10.1007/BF00684563; INDRAVASU S, 1968, NEUROLOGY, V18, P693, DOI 10.1212/WNL.18.7.693; KAARTINEN V, 1990, ANAL BIOCHEM, V190, P98, DOI 10.1016/0003-2697(90)90140-5; KAARTINEN V, 1989, J CHROMATOGR, V490, P292; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; MONONEN I, 1995, FASEB J, V9, P428, DOI 10.1096/fasebj.9.5.7896015; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; OYNAGI K, 1991, ACTA NEUROPATHOL, V85, P331; Papaioannou V., 1993, Gene targeting: a practical approach., P107; TENHUNEN K, 1995, GENOMICS, V30, P244, DOI 10.1006/geno.1995.9881; THOMAS GH, 1995, METABOLIC MOL BASES, P2545; WURST W, 1993, GENE TARGETING PRACT, P31; YAMAZAKI K, 1988, P SOC EXP BIOL MED, V187, P209	20	30	30	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1375	1378		10.1038/nm1296-1375	http://dx.doi.org/10.1038/nm1296-1375			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946839				2022-12-25	WOS:A1996VW51500046
J	Davies, HG; Richter, RJ; Keifer, M; Broomfield, CA; Sowalla, J; Furlong, CE				Davies, HG; Richter, RJ; Keifer, M; Broomfield, CA; Sowalla, J; Furlong, CE			The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin	NATURE GENETICS			English	Article							ENZYMATIC-HYDROLYSIS; CHLORPYRIFOS-OXON; ARYLESTERASE; TOXICITY; METABOLITES; RESISTANCE; PARATHION; RATS		UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT OCCUPAT & ENVIRONM MED,SEATTLE,WA 98195; USAMRICD,ABERDEEN,MD	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ARNZTEN CJ, 1982, HERBICIDE RESISTANCE, P194; BENKE GM, 1975, TOXICOL APPL PHARM, V31, P254, DOI 10.1016/0041-008X(75)90161-1; BURNETT WT, 1994, TOXICOLOGIST, V14, P390; COSTA LG, 1990, TOXICOL APPL PHARM, V103, P66, DOI 10.1016/0041-008X(90)90263-T; COSTA LG, 1987, NATO ASI SERIES H, V13, P263; FURLONG CE, 1989, ANAL BIOCHEM, V180, P242, DOI 10.1016/0003-2697(89)90424-7; FURLONG CE, 1988, AM J HUM GENET, V43, P230; Gomaa H M, 1969, Residue Rev, V29, P171; HAMA H, 1980, APPL ENTOMOL ZOOL, V15, P249, DOI 10.1303/aez.15.249; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; KITCHEN BJ, 1973, BIOCHEM J, V135, P93, DOI 10.1042/bj1350093; LADU BN, 1986, ANN BIOL CLIN-PARIS, V44, P369; LI WF, 1993, J TOXICOL ENV HEALTH, V40, P337, DOI 10.1080/15287399309531798; LI WF, 1995, TOXICOL LETT, V76, P219, DOI 10.1016/0378-4274(95)80006-Y; MAIN AR, 1956, CAN J BIOCHEM PHYS, V34, P197; MALLINCKRODT MG, 1988, TOXICOL ENVIRON CHEM, V18, P79; MCCOLLIS.SB, 1974, FOOD COSMET TOXICOL, V12, P45, DOI 10.1016/0015-6264(74)90321-6; MUELLER RF, 1983, AM J HUM GENET, V35, P393; MURPHY SD, 1980, TOXICOLOGY BASIC SCI, P357; RUIZ J, 1995, LANCET, V346, P869, DOI 10.1016/S0140-6736(95)92709-3; Serrato M, 1995, J CLIN INVEST, V96, P3005, DOI 10.1172/JCI118373; SHISHIDO T, 1972, PESTIC BIOCHEM PHYS, V2, P39, DOI 10.1016/0048-3575(72)90005-3; SMOLEN A, 1991, DRUG METAB DISPOS, V19, P107; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TAFURI J, 1987, ANN EMERG MED, V16, P193, DOI 10.1016/S0196-0644(87)80015-X; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; *WHO, 1986, WHOVBC86926; World Health Organization (WHO), 1990, PUBL HLTH IMP PEST U; ZECH R, 1974, COMP BIOCHEM PHYSIOL, V48, P427, DOI 10.1016/0305-0491(74)90277-6	29	507	525	0	46	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					334	336		10.1038/ng1196-334	http://dx.doi.org/10.1038/ng1196-334			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896566				2022-12-25	WOS:A1996VQ14600031
J	Cormier, RT; Hong, KH; Halberg, RB; Hawkins, TL; Richardson, P; Mulherkar, R; Dove, WF; Lander, ES				Cormier, RT; Hong, KH; Halberg, RB; Hawkins, TL; Richardson, P; Mulherkar, R; Dove, WF; Lander, ES			Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis	NATURE GENETICS			English	Letter							MOUSE SMALL-INTESTINES; ENHANCING FACTOR; ADENOMATOUS POLYPOSIS; MAJOR MODIFIER; NEOPLASIA; MUTATION; LOCUS; GENE; LOCALIZATION; PROTEIN	Individuals inheriting the same mutation predisposing to cancer may show very different outcomes, ranging from early aggressive cancer to disease-free survival. Experimental mouse models can provide a powerful tool to identify factors in the environment and genetic background that account for such modifications. The Min mouse strain(1), in which the Apc(Min) mutation disrupts the mouse homologue of the human familial polyposis gene(2), develops intestinal neoplasms whose multiplicity is strongly affected by genetic background(3). We previously mapped(4,5) a strong modifier locus, Mom1 (modifier of Min-1), to a 4-cM region on mouse chromosome 4 containing a candidate gene Pla2g2a encoding a secretory phospholipase(6). Here, we report that a cosmid transgene overexpressing Pla2g2a caused a reduction in tumour multiplicity and size, comparable to that conferred by a single copy of the resistance allele of Mom1. These results offer strong evidence that this secretory phospholipase can provide active tumour resistance, The association of Pla2g2a with Mom1 thus withstands a strong functional test and is likely to represent the successful identification of a polymorphic quantitative trait locus in mammals.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; WHITEHEAD INST BIOMED RES,CAMBRIDGE CTR 9,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CANC RES INST,LAB GENET ENGN,MUMBAI,INDIA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA063677, R37CA063677] Funding Source: NIH RePORTER; NCI NIH HHS [CA07075, CA63677, CA50585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1996, J BIOL, V215, P403; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DOVE WF, 1987, GENETICS, V116, P5; Dove WF, 1997, CANCER RES, V57, P812; Dudley ME, 1996, INT J CANCER, V65, P249, DOI 10.1002/(SICI)1097-0215(19960117)65:2<249::AID-IJC20>3.0.CO;2-7; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gould KA, 1996, GENETICS, V144, P1769; Gould KA, 1996, GENETICS, V144, P1777; Gould KA, 1996, CELL GROWTH DIFFER, V7, P1361; HALBERG R, 1992, J MOL BIOL, V228, P840, DOI 10.1016/0022-2836(92)90868-K; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; LANDER ES, 1989, GENETICS, V121, P185; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Rhodin J.A., 1974, HISTOLOGY TEXT ATLAS; Sambrook J., 2002, MOL CLONING LAB MANU; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; Spirio LN, 1996, CANCER RES, V56, P955; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Tomlinson IPM, 1996, ANN HUM GENET, V60, P369, DOI 10.1111/j.1469-1809.1996.tb00434.x; WAGLE A, 1989, CELL BIOL INT REP, V13, P309, DOI 10.1016/0309-1651(89)90154-9	29	269	278	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1997	17	1					88	91		10.1038/ng0997-88	http://dx.doi.org/10.1038/ng0997-88			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288104				2022-12-25	WOS:A1997XU72400024
J	Thomas, M; Northrup, SR; Hornsby, PJ				Thomas, M; Northrup, SR; Hornsby, PJ			Adrenocortical tissue formed by transplantation of normal clones of bovine adrenocortical cells in scid mice replaces the essential functions of the animals' adrenal glands	NATURE MEDICINE			English	Article							STEROID 17-ALPHA-HYDROXYLASE; EXPRESSION; MOUSE; SENESCENCE; DELIVERY; GENES; RAT	Xenotransplanted adrenocortical tissue of clonal origin was formed in immunodeficient (scid) mice by using techniques of cell transplantation. The experiments reported here used a single clone of bovine adrenocortical cells, but 5 of 20 other randomly selected clones also formed tissue. Most adrenalectomized animals bearing transplanted cells survived indefinitely, demonstrating that the cells restored the animals' capacity to survive in the absence of sodium supplementation. Formation of well-vascularized tissue at the site of transplantation was associated with stable levels of cortisol in the blood, replacing the mouse glucocorticoid (corticosterone). Ultrastructurally, the cultured cells before transplantation had characteristics of rapidly growing cells, but tissue formed in vivo showed features associated with active steroidogenesis. These experiments show that an endocrine tissue can be derived from a single, normal somatic cell.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	Thomas, M (corresponding author), BAYLOR COLL MED, HUFFINGTON CTR AGING, HOUSTON, TX 77030 USA.		Thomas, Michael/N-5468-2018	Thomas, Michael/0000-0003-2901-824X				Aebischer P, 1996, NAT MED, V2, P696, DOI 10.1038/nm0696-696; APKARIAN R P, 1986, Scanning Electron Microscopy, P1381; BOSMA MJ, 1989, SCID MOUSE CHARACTER; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; BUTCHER RN, 1988, J IMMUNOL METHODS, V107, P245, DOI 10.1016/0022-1759(88)90225-6; CHENG CY, 1992, ENDOCRINOLOGY, V130, P2883, DOI 10.1210/en.130.5.2883; CRANE GM, 1995, NAT MED, V1, P1322, DOI 10.1038/nm1295-1322; DUNN TB, 1970, JNCI-J NATL CANCER I, V44, P1323; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FRIEND DS, 1972, J CELL BIOL, V53, P148, DOI 10.1083/jcb.53.1.148; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMMOND KD, 1987, J RECEPTOR RES, V7, P667, DOI 10.3109/10799898709056778; HOMSBY PJ, 1985, ADRENAL CORTEX, P1; HORNSBY PJ, 1991, METHOD ENZYMOL, V206, P371; HORNSBY PJ, 1987, P NATL ACAD SCI USA, V84, P1580, DOI 10.1073/pnas.84.6.1580; HORNSBY PJ, 1986, J CELL PHYSIOL, V129, P395, DOI 10.1002/jcp.1041290319; HORNSBY PJ, 1992, J STEROID BIOCHEM, V43, P385; HORNSBY PJ, 1994, CELL TISSUE CULTUR B, V17; Idelman S, 1970, Int Rev Cytol, V27, P181, DOI 10.1016/S0074-7696(08)61248-6; KEENEY DS, 1995, ENDOCRINOLOGY, V136, P4872, DOI 10.1210/en.136.11.4872; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LI CH, 1972, BIOCHEM BIOPH RES CO, V49, P835, DOI 10.1016/0006-291X(72)90486-X; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MARTIN A, 1993, J CLIN ENDOCR METAB, V77, P305, DOI 10.1210/jc.77.2.305; MOULLIER P, 1995, NAT MED, V1, P353, DOI 10.1038/nm0495-353; Neville A.M., 1982, HUMAN ADRENAL CORTEX; PAULY JE, 1957, ENDOCRINOLOGY, V60, P247, DOI 10.1210/endo-60-2-247; PAVLATH GK, 1994, J CELL BIOL, V127, P1923, DOI 10.1083/jcb.127.6.1923; PERKINS LM, 1988, ENDOCRINOLOGY, V123, P2675, DOI 10.1210/endo-123-6-2675; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Potten C. S., 1997, STEM CELLS; REAVEN E, 1989, J LIPID RES, V30, P1551; RYAN RF, 1989, EXP CELL RES, V180, P36, DOI 10.1016/0014-4827(89)90210-3; TAIT JF, 1979, J ENDOCRINOL, V83, pP3; UHLER M, 1983, J BIOL CHEM, V258, P9444; VANWEERDEN WM, 1992, LIFE SCI, V50, P857, DOI 10.1016/0024-3205(92)90204-3; VOGT PM, 1994, P NATL ACAD SCI USA, V91, P9307, DOI 10.1073/pnas.91.20.9307; VOLPE R, 1993, HORM METAB RES, V25, P623, DOI 10.1055/s-2007-1002192; WINN SR, 1994, P NATL ACAD SCI USA, V91, P2324, DOI 10.1073/pnas.91.6.2324; Wright N. A., 1984, BIOL EPITHELIAL CELL, V1	41	84	87	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1997	3	9					978	983		10.1038/nm0997-978	http://dx.doi.org/10.1038/nm0997-978			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288723				2022-12-25	WOS:A1997XT84200029
J	Klesert, TR; Otten, AD; Bird, TD; Tapscott, SJ				Klesert, TR; Otten, AD; Bird, TD; Tapscott, SJ			Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP	NATURE GENETICS			English	Article							MESSENGER-RNA; TRIPLET REPEAT; RETROVIRAL VECTORS; GENE-TRANSFER; CTG REPEAT; TRANSCRIPTION; PROTEIN; MUSCLE; MYOD; MUTATION	Myotonic dystrophy, or dystrophia myotonica (DM), is an autosomal dominant multisystem disorder caused by the expansion of a CTC trinucleotide repeat in the 3' untranslated region of the DMPK protein kinase gene on chromosome 19q13.3 (refs 1-3). Although the DM mutation was identified more than five years ago, the pathogenic mechanisms underlying this most prevalent form of hereditary adult neuromuscular disease remain elusive(4). Previous work from our laboratory demonstrated that a DNase I-hypersensitive site located adjacent to the repeats on the wild-type allele is eliminated by repeat expansion(5), indicating that large CTG-repeat arrays may be associated with a local chromatin environment that represses gene expression, Here we report that the hypersensitive site contains an enhancer element that regulates transcription of the adjacent DMAHP(6) homeobox gene. Analysis of DMAHP expression in the cells of DM patients with loss of the hypersensitive sire revealed a two- to fourfold reduction in steady-state DMAHP transcript levels relative to wild-type controls. Allele-specific analysis of DMAHP expression showed that steady-state transcript levels from the expanded allele were greatly reduced in comparison to those from the wildtype allele, Together, these results demonstrate that CTG-repeat expansions can suppress local gene expression and implicate DMAHP in DM pathogenesis.	FRED HUTCHINSON CANC RES CTR,DIV MOL MED,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DIV CLIN RES,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98105; UNIV WASHINGTON,SCH MED,DEPT NEUROL,SEATTLE,WA 98105; VET ADM PUDGET SOUND HLTH CARE SYST,NEUROL SECT,SEATTLE,WA 98108	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Tapscott, Stephen/0000-0002-0319-0968				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BHAGWATI S, 1996, BIOCHIM BIOPHYS ACTA, V137, P155; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; BRASLER AR, 1989, CURRENT PROTOCOLS MO; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GILMAN M, 1993, CURRENT PROTOCOLS MO; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; Harris S, 1996, HUM MOL GENET, V5, P1417, DOI 10.1093/hmg/5.Supplement_1.1417; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Kawakami K, 1996, NUCLEIC ACIDS RES, V24, P303, DOI 10.1093/nar/24.2.303; Kawakami K, 1996, FEBS LETT, V393, P259, DOI 10.1016/0014-5793(96)00899-X; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NOVELLI G, 1993, BIOCHEM MOL BIOL INT, V29, P291; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Thornton C. A., 1996, American Journal of Human Genetics, V59, pA33; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434	31	197	201	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					402	406		10.1038/ng0897-402	http://dx.doi.org/10.1038/ng0897-402			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241282				2022-12-25	WOS:A1997XM90900027
J	Crameri, A; Dawes, G; Rodriguez, E; Silver, S; Stemmer, WPC				Crameri, A; Dawes, G; Rodriguez, E; Silver, S; Stemmer, WPC			Molecular evolution of an arsenate detoxification pathway DNA shuffling	NATURE BIOTECHNOLOGY			English	Article						combinatorial chemistry; sexual PCR; molecular libraries; metabolic engineering	IN-VITRO; PROTEIN; RESISTANCE	Functional evolution of an arsenic resistance operon has been accomplished by DNA shuffling, involving multiple rounds of in vitro recombination and mutation of a pool of related sequences, followed by selection for increased resistance in vivo. Homologous recombination is achieved by random fragmentation of the PCR templates and reassembly by primerless PCR. Plasmid-determined arsenate resistance from plasmid pl258 encoded by genes arsR, arsB, and arsC was evolved in Escherichia coli. Three rounds of shuffling and selection resulted in cells that grew in up to 0.5 M arsenate, a 40-fold increase in resistance, Whereas the native plasmid remained episomal, the evolved operon reproducibly integrated into the bacterial chromosome. In the absence of shuffling, no increase in resistance was observed after four selection cycles, and the control plasmid remained episomal. The integrated ars operon had 13 mutations. Ten mutations were located in arsB, encoding the arsenite membrane pump, resulting in a fourfold to sixfold increase in arsenite resistance, While arsC, the arsenate reductase gene, contained no mutations, its expression level was increased, and the rate of arsenate reduction was increased 12-fold. These results show that DNA shuffling can improve the function of pathways by complex and unexpected mutational mechanisms that may be activated by point mutation. These mechanisms may be difficult to explain and are likely to be overlooked by rational design.	MAXYGEN INC,SANTA CLARA,CA 95051; AFFYMAX RES INST,PALO ALTO,CA 94304; UNIV ILLINOIS,DEPT IMMUNOL & MICROBIOL,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Silver, Simon/0000-0002-5692-3125				CERVANTES C, 1994, FEMS MICROBIOL REV, V15, P355, DOI 10.1016/0168-6445(94)90069-8; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1996, NAT MED, V2, P100, DOI 10.1038/nm0196-100; JI GY, 1992, J BACTERIOL, V174, P3684, DOI 10.1128/JB.174.11.3684-3694.1992; JI GY, 1992, P NATL ACAD SCI USA, V89, P9474, DOI 10.1073/pnas.89.20.9474; RAWLINGS DE, 1995, BIO-TECHNOL, V13, P773, DOI 10.1038/nbt0895-773; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, BIO-TECHNOL, V13, P549, DOI 10.1038/nbt0695-549; WU JH, 1992, J BIOL CHEM, V267, P12570; ZHANG J, 1997, IN PRESS P NATL ACAD	11	130	351	0	24	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					436	438		10.1038/nbt0597-436	http://dx.doi.org/10.1038/nbt0597-436			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131621				2022-12-25	WOS:A1997WX23700026
J	Brown, S				Brown, S			Metal-recognition by repeating polypeptides	NATURE BIOTECHNOLOGY			English	Article						biosensors; peptide display; LamB; Escherichia coli; gold; chromium	ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; PROTEINS; GENE; GOLD; ACID; MUTAGENESIS; REPLICATION; INSERTION; RECEPTOR	Attachment of proteins to metal surfaces has the potential to improve our understanding of protein adhesion and has applications in sensor technology. Repeating polypeptides able to bind to metallic gold or chromium were selected from a population of approximately 5 million different polypeptides. Each polypeptide contained several direct repeats of identical peptide units 14 or 28 amino acids long. The metal-recognizing polypeptides were found to retain their binding properties when freed from the protein used to select them. One gold-binding polypeptide's avidity for gold was found to be dependent on the number of repeats and the presence of salt.			Brown, S (corresponding author), UNIV COPENHAGEN,DEPT MOL CELL BIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN K,DENMARK.		Brown, Stanley/F-2728-2011	Brown, Stanley/0000-0002-8453-8144				BOUGESBOCQUET B, 1984, J CELL BIOCHEM, V24, P217, DOI 10.1002/jcb.240240304; BOULAIN JC, 1986, MOL GEN GENET, V205, P339, DOI 10.1007/BF00430448; BROWN S, 1992, P NATL ACAD SCI USA, V89, P8651, DOI 10.1073/pnas.89.18.8651; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COUGHLIN RT, 1983, BIOCHEMISTRY-US, V22, P2002, DOI 10.1021/bi00277a041; Creighton T. E., 1993, PROTEINS STRUCTURES; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; FENTER P, 1994, SCIENCE, V266, P1216, DOI 10.1126/science.266.5188.1216; FIRE A, 1995, P NATL ACAD SCI USA, V92, P4641, DOI 10.1073/pnas.92.10.4641; GEDDES NJ, 1994, J IMMUNOL METHODS, V175, P149, DOI 10.1016/0022-1759(94)90358-1; GILLET D, 1992, PROTEIN ENG, V5, P273, DOI 10.1093/protein/5.3.273; HANDLEY DA, 1983, P SOC EXP BIOL MED, V174, P1; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE H, 1971, BIOCHIM BIOPHYS ACTA, V242, P519, DOI 10.1016/0005-2744(71)90144-6; LOCKSHON D, 1985, J MOL BIOL, V181, P63, DOI 10.1016/0022-2836(85)90324-9; LUCAS F, 1957, BIOCHEM J, V66, P468, DOI 10.1042/bj0660468; MCCONNELL SJ, 1995, J MOL BIOL, V250, P460, DOI 10.1006/jmbi.1995.0390; Miller J.H., 1972, EXPT MOL GENETICS; NAKAI H, 1988, J BIOL CHEM, V263, P9831; PAABO S, 1990, J BIOL CHEM, V265, P4718; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sigal GB, 1996, ANAL CHEM, V68, P490, DOI 10.1021/ac9504023; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WATTERSON JR, 1994, GEOLOGY, V22, P1144, DOI 10.1130/0091-7613(1994)022<1144:ARBBPI>2.3.CO;2; Wells JA, 1996, SCIENCE, V273, P449, DOI 10.1126/science.273.5274.449	29	391	430	2	104	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					269	272		10.1038/nbt0397-269	http://dx.doi.org/10.1038/nbt0397-269			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062928				2022-12-25	WOS:A1997WM05000032
J	Pshezhetsky, AV; Richard, C; Michaud, L; Igdoura, S; Wang, SP; Elsliger, MA; Qu, JY; Leclerc, D; Gravel, R; Dallaire, L; Potier, M				Pshezhetsky, AV; Richard, C; Michaud, L; Igdoura, S; Wang, SP; Elsliger, MA; Qu, JY; Leclerc, D; Gravel, R; Dallaire, L; Potier, M			Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis	NATURE GENETICS			English	Article							CULTURED HUMAN-FIBROBLASTS; ACID-PHOSPHATASE; BACTERIAL SIALIDASES; CONSERVED SEQUENCES; BETA-GALACTOSIDASE; ESCHERICHIA-COLI; NEURAMINIDASE; GENE; PROTEIN; CELLS	Sialidase (neuraminidase, EC 3.2.1.18) catalyses the hydrolysis of terminal sialic acid residues of glyconjugates. Sialidase has been well studied in viruses and bacteria where it destroys the sialic acid-containing receptors at the surface of host cells(1-3), and mobilizes bacterial nutrients(4). In mammals, three types of sialidases, lysosomal, plasma membrane and cytosolic, have been described(5-7). For lysosomal sialidase in humans, the primary genetic deficiency results in an autosomal recessive disease, sialidosis, associated with tissue accumulation and urinary excretion of sialylated oligosaccharides and glycolipids. Sialidosis includes two main clinical variants: late-onset, sialidosis type I, characterized by bilateral macular cherry-red spots and myoclonus(8,9), and infantile-onset, sialidosis type II, characterized by skeletal dysplasia, mental retardation and hepatosplenomegaly(10-12). We report the identification of human lysosomal sialidase cDNA, its cloning, sequencing and expression. Examination of six sialidosis patients revealed three mutations, one frameshift insertion and two missense. We mapped the lysosomal sialidase gene to human chromosome 6 (6p21.3), which is consistent with the previous chromosomal assignment of this gene in proximity to the HLA locus.	MCGILL UNIV, DEPT PEDIAT & HUMAN GENET, MONTREAL CHILDRENS HOSP, RES INST, MONTREAL, PQ, CANADA	McGill University	Pshezhetsky, AV (corresponding author), UNIV MONTREAL, HOP ST JUSTINE, DEPT PEDIAT, SERV GENET MED, 3175 CHEMIN ST CATHERINE, MONTREAL, PQ H3T 1C5, CANADA.		Leclerc, Daniel/AAB-4524-2021; Leclerc, Daniel/B-6375-2012	Leclerc, Daniel/0000-0002-9766-8941; A, Pshezhetsky/0000-0002-6612-1062; Elsliger, Marc Andre/0000-0002-1989-7626				AERTS JMFG, 1988, BIOCHIM BIOPHYS ACTA, V964, P303, DOI 10.1016/0304-4165(88)90030-X; BECK M, 1984, EUR J PEDIATR, V143, P135, DOI 10.1007/BF00445802; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORFIELD T, 1992, GLYCOBIOLOGY, V2, P509, DOI 10.1093/glycob/2.6.509; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; DAGROSA RM, 1988, BIOCHEM BIOPH RES CO, V157, P770, DOI 10.1016/S0006-291X(88)80316-4; DURAND P, 1977, HELV PAEDIATR ACTA, V32, P391; FERRARI J, 1994, GLYCOBIOLOGY, V4, P367, DOI 10.1093/glycob/4.3.367; GALEN JE, 1992, INFECT IMMUN, V60, P406, DOI 10.1128/IAI.60.2.406-415.1992; GOTTSCHALK A, 1949, NATURE, V164, P232, DOI 10.1038/164232a0; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HIRAIWA M, 1993, J BIOCHEM-TOKYO, V114, P901, DOI 10.1093/oxfordjournals.jbchem.a124274; Hirst GK, 1941, SCIENCE, V94, P22, DOI 10.1126/science.94.2427.22; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LICHTER P, 1992, HUMAN CYTOGENETICS P, V1, P157; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maniatis T., 1982, MOL CLONING; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P794, DOI 10.1093/oxfordjournals.jbchem.a123127; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; NEOTE K, 1990, J BIOL CHEM, V265, P20799; OBRIEN JS, 1978, CLIN GENET, V14, P55; OOHIRA T, 1985, HUM GENET, V70, P341, DOI 10.1007/BF00295374; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROGGENTIN P, 1993, MOL MICROBIOL, V9, P915, DOI 10.1111/j.1365-2958.1993.tb01221.x; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; ROTHE B, 1991, MOL GEN GENET, V226, P190, DOI 10.1007/BF00273603; SAMOLLOW PB, 1987, IMMUNOGENETICS, V26, P188, DOI 10.1007/BF00365910; SCHNEIDERJAKOB HR, 1991, BIOL CHEM H-S, V372, P443, DOI 10.1515/bchm3.1991.372.1.443; SOSA MA, 1993, J BIOL CHEM, V268, P12537; TILL JS, 1987, J CLIN NEURO-OPHTHAL, V7, P40; TRIGGSRAINE BL, 1991, AM J HUM GENET, V49, P1041; VARGHESE JN, 1988, J MOL BIOL, V200, P201, DOI 10.1016/0022-2836(88)90344-0; VERHEIJEN FW, 1983, BIOCHEM BIOPH RES CO, V117, P470, DOI 10.1016/0006-291X(83)91224-X; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WOMACK JE, 1981, SCIENCE, V212, P63, DOI 10.1126/science.7209520	41	167	171	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					316	320		10.1038/ng0397-316	http://dx.doi.org/10.1038/ng0397-316			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054950				2022-12-25	WOS:A1997WK38600027
J	Weidemann, A; Paliga, K; Durrwang, U; Czech, C; Evin, G; Masters, CL; Beyreuther, K				Weidemann, A; Paliga, K; Durrwang, U; Czech, C; Evin, G; Masters, CL; Beyreuther, K			Formation of stable complexes between two Alzheimer's disease gene products: Presenilin-2 and beta-amyloid precursor protein	NATURE MEDICINE			English	Article							MISSENSE MUTATIONS; IDENTIFICATION; PEPTIDE; CELLS; COMPARTMENT; LOCUS	Mutations in the presenilin genes are associated with early onset familial Alzheimer's disease and lead to increased accumulation of beta A4 peptide, the proteolytic product of the amyloid precursor protein (APP). To test whether presenilins interfere with APP metabolism, presenilin-2 (PS2) was coexpressed with APP in mammalian cells. Analysis of PS2 immunoprecipitates revealed that a fraction of APP was associated with the PS2 immunocomplexes. This non-covalent association was specific for the APP family of proteins and restricted to immature forms, occuring probably during transit through the endoplasmic reticulum. Additionally, coexpression with PS2 resulted in a decrease of APP secretion, suggesting a direct participation of presenilins in the intracellular sorting, trafficking and processing of APP molecules.	RHONE POULENC RORER,VITRY SUR SEINE,FRANCE; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	Sanofi-Aventis; University of Melbourne	Weidemann, A (corresponding author), UNIV HEIDELBERG,ZENTRUM MOL BIOL,INF 282,D-69120 HEIDELBERG,GERMANY.		Evin, Genevieve M/E-5891-2013	Czech, Christian/0000-0001-7746-0134				CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM TW, 1996, NEUROBIOL AGING, V17, P155; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; KONIG G, 1992, J BIOL CHEM, V267, P10804; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Simons M, 1996, J NEUROSCI, V16, P899; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; THINAKARAN G, 1996, NEURON, V17, P1; Van Broeckhoven C, 1995, NAT GENET, V11, P230; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	36	198	204	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					328	332		10.1038/nm0397-328	http://dx.doi.org/10.1038/nm0397-328			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055862				2022-12-25	WOS:A1997WL30500036
J	Fischer, M; Goldschmitt, J; Peschel, C; Brakenhoff, JPG; Kallen, KJ; Wollmer, A; Grotzinger, J; RoseJohn, S				Fischer, M; Goldschmitt, J; Peschel, C; Brakenhoff, JPG; Kallen, KJ; Wollmer, A; Grotzinger, J; RoseJohn, S			A bioactive designer cytokine for human hematopoietic progenitor cell expansion	NATURE BIOTECHNOLOGY			English	Article						cytokine; cytokine receptor; designer protein; expansion; hematopoietic progenitor cells	CILIARY NEUROTROPHIC FACTOR; HUMAN IL-6 RECEPTOR; SIGNAL-TRANSDUCTION; HUMAN INTERLEUKIN-6; BINDING; INVOLVEMENT; CLONING; CHAIN; GP130	Efficient expansion of hematopoietic progenitor cells requires, at least, the simultaneous stimulation of the receptors c-kit and gp130, While c-kit is activated by SCF; gp130, in cells which do not express sufficient amounts of IL-6R, can be activated by the complex of soluble IL-6R (sIL-6R) and IL-6, The therapeutic use of IL-6/sIL-6R, however, has been hampered by the high concentrations of the sIL-6R protein required, We have designed a fusion protein of sIL-6R and IL-6, linked by a flexible peptide chain, that was expressed to high levels, On gp130 expressing cells the fusion protein turned out to be fully active at 100 to 1,000-fold lower concentration than the combination of unlinked IL-6 and IL-6R. The fusion protein was used to effectively expand human hematopoietic progenitor cells ex vivo in a dose dependent fashion.	UNIV MAINZ, DEPT MED 1, SECT PATHOPHYSIOL, D-55101 MAINZ, GERMANY; UNIV MAINZ, DEPT MED 3, D-55101 MAINZ, GERMANY; CENT LAB NETHERLANDS, NL-1066 CX AMSTERDAM, NETHERLANDS; RHEIN WESTFAL TH AACHEN, DEPT BIOCHEM, D-52057 AACHEN, GERMANY	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; RWTH Aachen University			Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EHLERS M, 1994, J IMMUNOL, V153, P1744; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GROTZINGER J, 1996, IN PRESS PROTEINS; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; ISHIBASHI T, 1989, BLOOD, V74, P1241; KELLER U, 1994, BLOOD, V84, P2189; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; MACKIEWICZ A, 1995, P N Y ACAD SCI, V762, P1; Oppmann B, 1996, J IMMUNOL METHODS, V195, P153, DOI 10.1016/0022-1759(96)00110-X; PORGADOR A, 1992, CANCER RES, V52, P3679; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; SUI XW, 1995, P NATL ACAD SCI USA, V92, P2859, DOI 10.1073/pnas.92.7.2859; Tajima S, 1996, J EXP MED, V184, P1357, DOI 10.1084/jem.184.4.1357; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Vollmer P, 1996, J IMMUNOL METHODS, V199, P47, DOI 10.1016/S0022-1759(96)00163-9; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	31	421	477	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					142	145		10.1038/nbt0297-142	http://dx.doi.org/10.1038/nbt0297-142			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035138				2022-12-25	WOS:A1997WE99800019
J	Lee, MP; Hu, RJ; Johnson, LA; Feinberg, AP				Lee, MP; Hu, RJ; Johnson, LA; Feinberg, AP			Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements	NATURE GENETICS			English	Article							FACTOR-II GENE; WILMS-TUMOR; IGF2; H19; RELAXATION; EXPRESSION; DNA	Genomic imprinting is an epigenetic chromosomal modification in the gamete or zygote causing preferential expression of a specific parental allele in somatic cells of the offspring. We and others have identified three imprinted human genes on 11p15.5, IGF2 (refs 1-4), H19 (refs 1,5), and p57(KIP2) (ref. 6), although the latter gene is separated by 700 kb from the other two, and it is unclear whether there are other imprinted genes within this large interval. We previously mapped an embryonal tumour suppressor gene to this region(7), as well as five balanced germline chromosomal rearrangement breakpoints from patients with Beckwith-Wiedemann syndrome (BWS)(8), a condition characterized by prenatal overgrowth and cancer. We isolated the upstream exons of the previously identified gene KVLQT1, which causes the familial cardiac defect long-QT (LQT) syndrome. We found that KVLQT1 spans much of the interval between p57(KIP2) and IGF2, and that it is also imprinted. We demonstrated that the gene is disrupted by chromosomal chromosomal translocation in an embryonal rhabdoid tumour. Furthermore, the lack of parent-of-origin effect in LQT syndrome appears to be due to relative lack of imprinting in the affected tissue, cardiac muscle, representing a novel mechanism for variable penetrance of a human disease gene.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Feinberg, Andrew/AAY-7666-2020	Feinberg, Andrew/0000-0002-8364-1991	NATIONAL CANCER INSTITUTE [R01CA054358, R37CA054358] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA054358, CA54358] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; Dittrich B, 1996, NAT GENET, V14, P163, DOI 10.1038/ng1096-163; FEINBERG AP, 1994, J CELL SCI S, V18, P7; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; HATADA H, 1996, NAT GENET, V14, P171; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Mannens M., 1994, European Journal of Human Genetics, V2, P3; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; THOMPSON JS, IN PRESS CANC RES; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	28	263	282	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					181	185		10.1038/ng0297-181	http://dx.doi.org/10.1038/ng0297-181			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020845				2022-12-25	WOS:A1997WF08700019
J	MacLean, M; Anderson, J; Davies, C				MacLean, M; Anderson, J; Davies, C			Making malaria research bite	NATURE MEDICINE			English	Editorial Material									WELLCOME TRUST RES LABS, PRISM, LONDON NW1 2BE, ENGLAND	University of London; University College London								ANDERSON J, 1996, 7 PRISM; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; BRADLEY D, 1994, CDR REV, V4, P169; BRUCECHWATT LJ, 1987, ESSENTIAL MALARIOLOG; Garner P, 1996, PARASITOL TODAY, V12, P211, DOI 10.1016/0169-4758(96)30006-9; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; Hoffman SL, 1997, NAT MED, V3, P80, DOI 10.1038/nm0197-80; LEWISON G, 1995, BENCHMARKING INFORMA; McMichael A.J., 1996, CLIMATE CHANGE HUMAN; MICHAUD C, 1996, INVESTING HLTH RES D; MURRAY CJL, 1996, GLOBAL COMP ASSESSME; NEVILLE CG, 1996, J TROP MED INTL HLTH, V1, P139; Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0; SINDEN RE, Patent No. 15237; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; Wadman M, 1996, NATURE, V379, P287, DOI 10.1038/379287a0; WHO, 1996, WORLD HLTH REP 1996; 1996, NATURE, V380, P99	18	5	5	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1997	3	1					14	16		10.1038/nm0197-14	http://dx.doi.org/10.1038/nm0197-14			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986727	Bronze			2022-12-25	WOS:A1997WA73300023
J	Saxena, R; Brown, LG; Hawkins, T; Alagappan, RK; Skaletsky, H; Reeve, MP; Reijo, R; Rozen, S; Dinulos, MB; Disteche, CM; Page, DC				Saxena, R; Brown, LG; Hawkins, T; Alagappan, RK; Skaletsky, H; Reeve, MP; Reijo, R; Rozen, S; Dinulos, MB; Disteche, CM; Page, DC			The DAZ gene cluster on the human Y chromosome arose from an autosomal gene that was transposed, repeatedly amplified and pruned	NATURE GENETICS			English	Article							AFRICAN POPULATIONS; SEX DETERMINATION; DNA; LOCALIZATION; PROBE; MAP; DROSOPHILA; INTERVAL-6; HAPLOTYPES; DELETIONS	It is widely believed that most or all Y-chromosomal genes were once shared with the X chromosome. The DAZ gene is a candidate for the human Y-chromosomal Azoospermia Factor (AZF). We report multiple copies of DAZ (>99% identical in DNA sequence) clustered in the AZF region and a functional DAZ homologue (DAZH) on human chromosome 3. The entire gene family appears to be expressed in germ cells. Sequence analysis indicates that the Y-chromosomal DAZ cluster arose during primate evolution by (i) transposing the autosomal gene to the Y, (ii) amplifying and pruning exons within the transposed gene and (iii) amplifying the modified gene. These results challenge prevailing views of sex chromosome evolution, suggesting that acquisition of autosomal fertility genes is an important process in Y chromosome evolution.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; MIT,WHITEHEAD INST,CTR GENOME RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Washington; University of Washington Seattle			Saxena, Richa/AAG-7279-2020; Rozen, Steven G./J-5939-2013	Saxena, Richa/0000-0003-2233-1065; Reijo Pera, Renee/0000-0002-6487-1329; Rozen, Steven G./0000-0002-4288-0056				Affara N, 1996, CYTOGENET CELL GENET, V73, P33; BENERECETTI ASS, 1993, ANN HUM GENET, V57, P55, DOI 10.1111/j.1469-1809.1993.tb00886.x; BISHOP C, 1984, J MOL BIOL, V173, P403, DOI 10.1016/0022-2836(84)90388-7; Bull J. J., 1983, EVOLUTION SEX DETERM; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burgoyne PS, 1996, NATURE, V381, P740, DOI 10.1038/381740a0; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; CHARLESWORTH D, 1980, GENET RES, V35, P205, DOI 10.1017/S0016672300014051; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HACKSTEIN JHP, 1995, TRENDS GENET, V11, P195, DOI 10.1016/S0168-9525(00)89043-5; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JOHNSON MD, 1989, AM J OBSTET GYNECOL, V161, P1732, DOI 10.1016/0002-9378(89)90959-9; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LUCOTTE G, 1991, MOL CELL PROBE, V5, P359, DOI 10.1016/S0890-8508(06)80007-1; LUCOTTE G, 1989, AM J HUM GENET, V45, P16; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; MENKE D, IN PRESS AM J HUM GE; NGO KY, 1986, AM J HUM GENET, V38, P407; Ohno S., 1967, SEX CHROMOSOMES SEX; PAGE DC, 1987, DEVELOPMENT, V101, P151; PALMER S, 1995, NAT GENET, V10, P472, DOI 10.1038/ng0895-472; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; Reijo R, 1996, GENOMICS, V35, P346, DOI 10.1006/geno.1996.0366; RICE WR, 1994, SCIENCE, V263, P230, DOI 10.1126/science.8284674; RICE WR, 1992, SCIENCE, V256, P1436, DOI 10.1126/science.1604317; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; RUGARLI EI, 1995, NAT GENET, V10, P466, DOI 10.1038/ng0895-466; SEBOUN E, 1986, COLD SPRING HARB SYM, V51, P237, DOI 10.1101/SQB.1986.051.01.029; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SKARE J, 1990, AM J MED GENET, V36, P394, DOI 10.1002/ajmg.1320360405; SPURDLE A, 1992, AM J HUM GENET, V50, P107; STEINEMANN M, 1992, P NATL ACAD SCI USA, V89, P7591, DOI 10.1073/pnas.89.16.7591; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; VERGNAUD G, 1986, AM J HUM GENET, V38, P109; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; Winge O, 1927, J GENET, V18, P1, DOI 10.1007/BF03052599	44	360	377	1	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					292	299		10.1038/ng1196-292	http://dx.doi.org/10.1038/ng1196-292			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896558				2022-12-25	WOS:A1996VQ14600023
J	Satsangi, J; Parkes, M; Louis, E; Hashimoto, L; Kato, N; Welsh, K; Terwilliger, JD; Lathrop, GM; Bell, JI; Jewell, DP				Satsangi, J; Parkes, M; Louis, E; Hashimoto, L; Kato, N; Welsh, K; Terwilliger, JD; Lathrop, GM; Bell, JI; Jewell, DP			Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12	NATURE GENETICS			English	Letter							DEPENDENT DIABETES-MELLITUS; ULCERATIVE-COLITIS; CROHNS-DISEASE; POLYGENIC DISEASE; GENES; PREVALENCE; TRAITS; TWINS; HLA		WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND; CHURCHILL HOSP,NUFFIELD DEPT SURG,TRANSPLANT IMMUNOL UNIT,OXFORD OX3 7LJ,ENGLAND; COLUMBIA UNIV,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10032; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; Columbia University; Columbia University; University of Oxford	Satsangi, J (corresponding author), RADCLIFFE INFIRM,GASTROENTEROL UNIT,NUFFIELD DEPT MED,WOODSTOCK RD,OXFORD OX2 6HE,ENGLAND.			Parkes, Miles/0000-0002-6467-0631	NHGRI NIH HHS [HG000008] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Calkins BM, 1995, INFLAMM BOWEL DIS, P31; CONNELL WR, 1994, GUT, V35, P1419, DOI 10.1136/gut.35.10.1419; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FUTAMI S, 1995, DIGEST DIS SCI, V40, P814, DOI 10.1007/BF02064985; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; HYER RN, 1991, AM J HUM GENET, V48, P243; KNAPP M, 1994, HUM HERED, V44, P44, DOI 10.1159/000154188; KRUGLYAK L, 1995, NAT GENET, V11, P241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PROBERT CSJ, 1993, GUT, V34, P1547, DOI 10.1136/gut.34.11.1547; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; RIENSHAGEN M, 1996, GUT, V38, P538; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; SATSANGI J, 1994, GUT, V35, P696, DOI 10.1136/gut.35.5.696; Satsangi J, 1996, GUT, V38, P148, DOI 10.1136/gut.38.1.148; SATSANGI J, 1994, EUR J GASTROEN HEPAT, V6, P413; Satsangi J, 1996, GUT, V38, P738, DOI 10.1136/gut.38.5.738; Satsangi J, 1996, LANCET, V347, P1212, DOI 10.1016/S0140-6736(96)90734-5; TODD JA, 1995, P NATL ACAD SCI USA, V92, P8560, DOI 10.1073/pnas.92.19.8560; TOYODA H, 1993, GASTROENTEROLOGY, V104, P741, DOI 10.1016/0016-5085(93)91009-7; TYSK C, 1991, GASTROENTEROLOGY, V100, P419, DOI 10.1016/0016-5085(91)90211-3; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; WEEKS DE, 1995, TRENDS GENET, V11, P513, DOI 10.1016/S0168-9525(00)89163-5; YANG H, 1993, GUT, V34, P517, DOI 10.1136/gut.34.4.517	29	636	649	2	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					199	202		10.1038/ng1096-199	http://dx.doi.org/10.1038/ng1096-199			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841195				2022-12-25	WOS:A1996VL44600029
J	Hantraye, P; Brouillet, E; Ferrante, R; Palfi, S; Dolan, R; Matthews, RT; Beal, MF				Hantraye, P; Brouillet, E; Ferrante, R; Palfi, S; Dolan, R; Matthews, RT; Beal, MF			Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons	NATURE MEDICINE			English	Article							DOPAMINERGIC-NEURONS; SUPEROXIDE-DISMUTASE; 7-NITRO INDAZOLE; RAT STRIATUM; NEUROTOXICITY; DISEASE; LESIONS; MODEL; PEROXYNITRITE; MECHANISMS	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces clinical, biochemical and neuropathologic changes reminiscent of those which occur in idiopathic Parkinson's disease. 7-Nitroindazole (7-NI) is a relatively selective inhibitor of the neuronal isoform of nitric oxide synthase (NOS) that blocks MPTP neurotoxicity in mice. We now show that 7-NI protects against profound striatal dopamine depletions and loss of tyrosine hydroxylase-positive neurons in the substantia nigra in MPTP-treated baboons. Furthermore, 7-NI protected against MPTP-induced motor and frontal-type cognitive deficits. These results strongly implicate a role of nitric oxide in MPTP neurotoxicity and suggest that inhibitors of neuronal NOS might be useful in treating Parkinson's disease.	MASSACHUSETTS GEN HOSP, NEUROL SERV, NEUROCHEM LAB, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; SERV HOSP FREDERIC JOLIOT, CEA, CNRS URA 2210, ORSAY, FRANCE; VET AFFAIRS MED CTR, GERIATR RES EDUC CLIN CTR, BEDFORD, MA USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University			Brouillet, Emmanuel/B-4784-2014	Brouillet, Emmanuel/0000-0001-6322-7403	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P01NS016367, P50NS016367, P50NS010828] Funding Source: NIH RePORTER; NIA NIH HHS [AG 12922-01] Funding Source: Medline; NINDS NIH HHS [NS 16367, NS 10828] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BEAL MF, 1990, NEUROSCI LETT, V108, P36; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BLOEM BR, 1990, J NEUROL SCI, V97, P273, DOI 10.1016/0022-510X(90)90225-C; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; FERRANTE RJ, 1993, EXP NEUROL, V119, P46, DOI 10.1006/exnr.1993.1006; FORNO LS, 1986, ANN NEUROL, V20, P449, DOI 10.1002/ana.410200403; GERMAN DC, 1988, NEUROSCIENCE, V24, P161, DOI 10.1016/0306-4522(88)90320-X; HANTRAYE P, 1993, NEUROSCIENCE, V53, P169, DOI 10.1016/0306-4522(93)90295-Q; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LIN AMY, 1995, J NEUROCHEM, V65, P2043; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LONART G, 1994, J NEUROCHEM, V63, P2108; PALFI S, IN PRESS J NEUROSCI; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; SCHNEIDER JS, 1992, VULN BRAIN ENV, P293; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; Schulz JB, 1995, J NEUROSCI, V15, P8419; SILVA MT, 1995, BRIT J PHARMACOL, V114, P257, DOI 10.1111/j.1476-5381.1995.tb13219.x; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; VARASTET M, 1994, NEUROSCIENCE, V63, P47, DOI 10.1016/0306-4522(94)90006-X; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P300, DOI 10.1006/abbi.1994.1241	29	382	388	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1996	2	9					1017	1021		10.1038/nm0996-1017	http://dx.doi.org/10.1038/nm0996-1017			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782460				2022-12-25	WOS:A1996VF49700037
J	Albrecht, U; Sutcliffe, JS; Cattanach, BM; Beechey, CV; Armstrong, D; Eichele, G; Beaudet, AL				Albrecht, U; Sutcliffe, JS; Cattanach, BM; Beechey, CV; Armstrong, D; Eichele, G; Beaudet, AL			Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons	NATURE GENETICS			English	Letter							PRADER-WILLI SYNDROMES; FACTOR-II GENE; PROTEIN; CLONING; ORIGIN	Angelman syndrome (AS) is a human genetic disorder characterized by mental retardation, seizures, inappropriate laughter, abnormal gait, tremor and ataxia(1-3). There is strong genetic evidence that the disorder is associated with a maternally expressed, imprinted gene mapping to chromosome 15q11-13. Affected patients demonstrate varied molecular abnormalities including large maternal deletions, uniparental paternal disomy (UPD), imprinting mutations(4) and loss of function mutations of E6-associated-protein (E6-AP) ubiquitin-protein ligase (UBE3A)(5,6). All of these abnormalities are associated with loss of maternal expression of UBE3A. Although mutations in UBE3A cause AS, indicating that maternal-specific expression of UBE3A is essential for a normal phenotype, evidence for maternal-specific expression of UBE3A has been lacking(7,8). Using mice with partial paternal UPD encompassing Ube3a to differentiate maternal and paternal expression, we found by in situ hybridization that expression of Ube3a in Purkinje cells, hippocampal neurons and mitral cells of the olfactory bulb in UPD mice was markedly reduced compared to non-UPD littermates. In contrast, expression of Ube3a in other regions of the brain was only moderately or not at all reduced in UPD mice. The major phenotypic features of AS correlate with the loss of maternal-specific expression of Ube3a in hippocampus and cerebellum as revealed in the mouse model.	BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; MRC, MAMMALIAN GENET UNIT, DIDCOT OX11 0RD, OXON, ENGLAND	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; MRC Harwell			Sutcliffe, James S/C-1348-2012; Albrecht, Urs/A-9831-2011	Sutcliffe, James S/0000-0001-5200-6007; Albrecht, Urs/0000-0002-0663-8676				Albrecht U, 1997, MOL CELLULAR METHODS, P23; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; Cattanach BM, 1997, MAMM GENOME, V8, P472, DOI 10.1007/s003359900479; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JAY V, 1991, NEUROLOGY, V41, P416, DOI 10.1212/WNL.41.3.416; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KYRIAKIDES T, 1992, ACTA NEUROPATHOL, V83, P675, DOI 10.1007/BF00299421; LEDBETTER DH, 1995, METABOLIC MOL BASES, P811; MAGENIS RE, 1987, AM J MED GENET, V28, P829, DOI 10.1002/ajmg.1320280407; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; NAKAO M, 1994, HUM MOL GENET, V3, P309, DOI 10.1093/hmg/3.2.309; NICHOLLS RD, 1994, AM J HUM GENET, V54, P733; REIS A, 1994, AM J HUM GENET, V54, P741; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Sutcliffe JS, 1997, GENOME RES, V7, P368, DOI 10.1101/gr.7.4.368; VANHILLE B, 1993, BIOCHEM BIOPH RES CO, V197, P15, DOI 10.1006/bbrc.1993.2434; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; Williams C A, 1995, Curr Probl Pediatr, V25, P216, DOI 10.1016/S0045-9380(06)80036-8; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; ZACKOWSKI JL, 1993, AM J MED GENET, V46, P7, DOI 10.1002/ajmg.1320460104	23	375	383	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1997	17	1					75	78		10.1038/ng0997-75	http://dx.doi.org/10.1038/ng0997-75			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288101				2022-12-25	WOS:A1997XU72400021
J	Botto, M; Hawkins, PN; Bickerstaff, MCM; Herbert, J; Bygrave, AE; McBride, A; Hutchinson, WL; Tennent, GA; Walport, MJ; Pepys, MB				Botto, M; Hawkins, PN; Bickerstaff, MCM; Herbert, J; Bygrave, AE; McBride, A; Hutchinson, WL; Tennent, GA; Walport, MJ; Pepys, MB			Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; AA-AMYLOIDOSIS; SYSTEMIC AMYLOIDOSIS; BETA-FIBRILLOSES; ENHANCING FACTOR; FEMALE PROTEIN; INVIVO; MOUSE; SAP; PENTRAXINS	The tissue amyloid deposits that characterize systemic amyloidosis, Alzheimer's disease and the transmissible spongiform encephalopathies always contain serum amyloid P component (SAP) bound to the amyloid fibrils. We have previously proposed that this normal plasma protein may contribute to amyloidogenesis by stabilizing the deposits. Here we show that the induction of reactive amyloidosis is retarded in mice with targeted deletion of the SAP gene. This first demonstration of the participation of SAP in pathogenesis of amyloidosis in vivo confirms that inhibition of SAP binding to amyloid fibrils is an attractive therapeutic target in a range of serious human diseases.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,IMMUNOL MED UNIT,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,RHEUMATOL UNIT,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,RADIOL SCI UNIT,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London; Imperial College London			Hawkins, Philip N/C-5573-2008	Walport, Mark/0000-0001-7220-5273				AXELRAD MA, 1982, LAB INVEST, V47, P139; BALTZ ML, 1980, CLIN EXP IMMUNOL, V39, P355; BENSON MD, 1977, J CLIN INVEST, V59, P412, DOI 10.1172/JCI108654; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; CASPI D, 1987, ARTHRITIS RHEUM, V30, P1303, DOI 10.1002/art.1780301115; CATHCART ES, 1967, P SOC EXP BIOL MED, V125, P1123; COE JE, 1990, J EXP MED, V171, P1257, DOI 10.1084/jem.171.4.1257; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; CORIA F, 1988, LAB INVEST, V58, P454; DUONG T, 1989, ACTA NEUROPATHOL, V78, P429, DOI 10.1007/BF00688180; Frank MM., 1994, SAMTERS IMMUNOLOGIC, VFifth, P637; Fricker J, 1997, LANCET, V349, P480; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GANOWIAK K, 1994, BIOCHEM BIOPH RES CO, V199, P306, DOI 10.1006/bbrc.1994.1229; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; HAWKINS PN, 1990, CLIN EXP IMMUNOL, V81, P325; HAWKINS PN, 1991, CLIN EXP IMMUNOL, V84, P308; HAWKINS PN, 1995, EUR J NUCL MED, V22, P595, DOI 10.1007/BF01254559; HAWKINS PN, 1993, ARTHRITIS RHEUM, V36, P842, DOI 10.1002/art.1780360616; HAWKINS PN, 1988, J EXP MED, V167, P903, DOI 10.1084/jem.167.3.903; HAWKINS PN, 1990, J CLIN INVEST, V86, P1862, DOI 10.1172/JCI114917; HIND CRK, 1984, LANCET, V2, P376; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HUTCHINSON WL, 1994, J CLIN INVEST, V94, P1390, DOI 10.1172/JCI117474; JANIGAN DT, 1965, AM J PATHOL, V47, P159; KALARIA RN, 1991, NEUROPATH APPL NEURO, V17, P189, DOI 10.1111/j.1365-2990.1991.tb00714.x; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KISILEVSKY R, 1995, AMYLOID, V2, P128, DOI 10.3109/13506129509031899; KITAMOTO T, 1985, ACTA NEUROPATHOL, V67, P272, DOI 10.1007/BF00687812; NELSON SR, 1991, CLIN CHIM ACTA, V200, P191, DOI 10.1016/0009-8981(91)90090-Y; PEPYS MB, 1979, IMMUNOLOGY, V37, P637; PEPYS MB, 1994, P NATL ACAD SCI USA, V91, P5602, DOI 10.1073/pnas.91.12.5602; PEPYS MB, 1979, NATURE, V278, P259, DOI 10.1038/278259a0; PEPYS MB, IN PRESS AMYLOID INT; PEPYS MB, 1986, AMYLOIDOSIS, P43; SNEL FWJJ, 1989, CLIN EXP IMMUNOL, V76, P296; TAN SY, 1995, AM J KIDNEY DIS, V26, P267, DOI 10.1016/0272-6386(95)90647-9; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; VIGUSHIN DM, 1994, AMYLOID AMYLOIDOSIS, P685	41	209	220	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					855	859		10.1038/nm0897-855	http://dx.doi.org/10.1038/nm0897-855			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256275				2022-12-25	WOS:A1997XP01400026
J	Thornton, CA; Wymer, JP; Simmons, Z; McClain, C; Moxley, RT				Thornton, CA; Wymer, JP; Simmons, Z; McClain, C; Moxley, RT			Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene	NATURE GENETICS			English	Article							TRIPLET REPEAT; REGION; MUTATION; MUSCLE; CELLS	Myotonic dystrophy, or dystrophia myotonica (DM), is a highly variable multisystem disease in which the classic adult-onset form displays progressive muscle wasting, cataracts, heart block, gonadal atrophy,insulin resistance and neuropsychiatric impairment. Its genetic basis is an expansion of CTG trinucleotide repeats in the DMPK protein kinase gene(1-5). Among the triplet repeat expansion disorders, DM is distinguished by the extended length of the repeat tract (5-13 kb in postmortem tissue(6,7)) and its location in the 3' untranslated region of the gene that contains it(8). The pathophysiological mechanism for multisystem degeneration in DM is not understood. In contrast to the profound muscle wasting that characterizes advanced DM, only minor histopathological abnormalities have occurred in DMPK knockout mice or in mice that overexpress a human DMPK transgene(9,10), making it unlikely that changes in DMPK activity provide a unitary explanation for the disease. A DNAse hypersensitive site that maps 0.7 kb downstream (centromeric) from the CTC repeats is eliminated on DM chromosomes(11). This finding indicates that the repeat expansion may alter the adjacent chromatin structure and raises the possibility that it may also affect the expression of flanking genes. An interesting candidate flanking gene is DMAHP, a recently discovered homeodomain-encoding gene(12). We show here that DMAHP expression in myoblasts, muscle and myocardium is reduced by the DM mutation in cis, and the magnitude of this effect depends on the extent of CTG repeat expansion. These observations support the hypothesis that DMAHP participates in the pathophysiology of DM.	PENN STATE UNIV,COLL MED,DIV NEUROL,HERSHEY,PA 17033; UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Rochester	Thornton, CA (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT NEUROL,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG010463] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00044] Funding Source: Medline; NIA NIH HHS [P60AG10463] Funding Source: Medline; NINDS NIH HHS [NS01558] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHIZAWA T, 1993, NEUROLOGY, V43, P2674, DOI 10.1212/WNL.43.12.2674; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; Ciaraldi TP, 1995, J CLIN INVEST, V96, P2820, DOI 10.1172/JCI118352; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Kawakami K, 1996, NUCLEIC ACIDS RES, V24, P303, DOI 10.1093/nar/24.2.303; Kawakami K, 1996, FEBS LETT, V393, P259, DOI 10.1016/0014-5793(96)00899-X; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; NEVILLE CE, 1994, HUM MOL GENET, V3, P45; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; THORNTON CA, 1994, ANN NEUROL, V35, P104, DOI 10.1002/ana.410350116; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P699	23	180	186	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					407	409		10.1038/ng0897-407	http://dx.doi.org/10.1038/ng0897-407			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241283				2022-12-25	WOS:A1997XM90900028
J	Aitman, TJ; Gotoda, T; Evans, AL; Imrie, H; Heath, KE; Trembling, PM; Truman, H; Wallace, CA; Rahman, A; Dore, C; Flint, J; Kren, V; Zidek, V; Kurtz, TW; Pravenec, M; Scott, J				Aitman, TJ; Gotoda, T; Evans, AL; Imrie, H; Heath, KE; Trembling, PM; Truman, H; Wallace, CA; Rahman, A; Dore, C; Flint, J; Kren, V; Zidek, V; Kurtz, TW; Pravenec, M; Scott, J			Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats	NATURE GENETICS			English	Article							FAMILIAL COMBINED HYPERLIPIDEMIA; RECOMBINANT INBRED STRAINS; NITRIC-OXIDE SYNTHASE; UPPER-BODY OBESITY; INSULIN-RESISTANCE; BLOOD-PRESSURE; GENETIC-MAP; LINKAGE MAP; APOLIPOPROTEIN; CHROMOSOME-4	Coronary heart disease, hypertension, non-insulin-dependent diabetes and obesity are major causes of ill health in industrial societies, Disturbances of carbohydrate and lipid metabolism are a common feature of these disorders(1-9). The bases for these disturbances and their roles in disease pathogenesis are poorly understood, The spontaneously hypertensive rat (SHR), a widely used animal model of essential hypertension(10), has a global defect in insulin action on glucose metabolism and shows reduced catecholamine action on lipolysis in fat cells(11-14). In our study we used cellular defects in carbohydrate and lipid metabolism to dissect the genetics of defective insulin and catecholamine action in the SHR strain. In a genome screen for loci linked to insulin and catecholamine action, we identified two quantitative trait loci (QTLs) for defective insulin action, on chromosomes 4 and 12. We found that the major (and perhaps only) genetic determinant of defective control of lipolysis in SHR maps to the same region of chromosome 4. These linkage results were ascertained in at least two independent crosses. As the SHR strain manifests many of the defining features of human metabolic Syndrome X, in which hypertension associates with insulin resistance, dyslipidaemia and abdominal obesity, the identification of genes for defective insulin and catecholamine action in SHR may facilitate gene identification in this syndrome and in related human conditions, such as type-2 diabetes and familial combined hyperlipidaemia.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED STAT & EVALUAT,LONDON W12 0NN,ENGLAND; INST MOL MED,OXFORD OX3 9DU,ENGLAND; CHARLES UNIV,FAC MED 1,DEPT BIOL,PRAGUE 12800 2,CZECH REPUBLIC; ACAD SCI CZECH REPUBL,INST PHYSIOL,CR-14220 PRAGUE 4,CZECH REPUBLIC; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143	Imperial College London; Imperial College London; University of Oxford; Charles University Prague; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; University of California System; University of California San Francisco	Aitman, TJ (corresponding author), HAMMERSMITH HOSP,MRC,CTR CLIN SCI,MOL MED GRP,LONDON W12 0NN,ENGLAND.		Pravenec, Michal/B-1666-2012; Heath, K. E./ABG-4658-2020; Zidek, Vaclav/C-6685-2012; Heath, Karen Elise/K-7760-2014; Dore, Caroline J/J-4716-2012	Pravenec, Michal/0000-0001-9197-5871; Heath, K. E./0000-0002-5816-7044; Heath, Karen Elise/0000-0002-5816-7044; Dore, Caroline J/0000-0001-9796-4970; Aitman, Timothy/0000-0002-7875-4502; Trembling, Paul/0000-0002-5016-4607				Aitman TJ, 1997, ARTERIOSCL THROM VAS, V17, P748, DOI 10.1161/01.ATV.17.4.748; BECKERS MC, 1994, GENOMICS, V23, P685, DOI 10.1006/geno.1994.1557; Belknap JK, 1996, BEHAV GENET, V26, P149, DOI 10.1007/BF02359892; Bottger A, 1996, J CLIN INVEST, V98, P856, DOI 10.1172/JCI118858; CABEZAS MC, 1993, J CLIN INVEST, V92, P160, DOI 10.1172/JCI116544; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; DECINGOLANI GEC, 1988, METABOLISM, V37, P318, DOI 10.1016/0026-0495(88)90130-8; Dohi Y, 1996, HYPERTENSION, V28, P732, DOI 10.1161/01.HYP.28.5.732; EVANS DJ, 1984, J CLIN INVEST, V74, P1515, DOI 10.1172/JCI111565; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Galli J, 1996, NAT GENET, V12, P31, DOI 10.1038/ng0196-31; Gauguier D, 1996, NAT GENET, V12, P38, DOI 10.1038/ng0196-38; GOLDMUNTZ EA, 1995, MAMM GENOME, V6, P459, DOI 10.1007/BF00360654; GORDON RD, 1995, NAT GENET, V11, P6, DOI 10.1038/ng0995-6; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; HUBNER N, 1995, MAMM GENOME, V6, P758, DOI 10.1007/BF00354306; HUNT SC, 1989, ARTERIOSCLEROSIS, V9, P335, DOI 10.1161/01.ATV.9.3.335; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; Kirkwood TBL, 1979, BIOMETRICS, V35, P908; KLOCKE R, 1993, GENOMICS, V18, P568, DOI 10.1016/S0888-7543(05)80358-1; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; MARTIN ML, 1991, J CLIN INVEST, V88, P609, DOI 10.1172/JCI115345; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCLAUGHLIN MG, 1995, CIRCULATION, V92, P1; PATERNOSTRO G, 1995, CARDIOVASC RES, V30, P205, DOI 10.1016/0008-6363(95)00019-4; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; PRAVENEC M, 1989, J HYPERTENS, V7, P217; Pravenec M, 1996, MAMM GENOME, V7, P117, DOI 10.1007/s003359900031; PRAVENEC M, 1995, J CLIN INVEST, V96, P1973, DOI 10.1172/JCI118244; RAO RH, 1993, DIABETES, V42, P1364, DOI 10.2337/diabetes.42.9.1364; Reaven Gerald M., 1996, New England Journal of Medicine, V334, P374; REAVEN GM, 1989, DIABETES, V38, P1155, DOI 10.2337/diabetes.38.9.1155; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; REYNISDOTTIR S, 1994, DIABETOLOGIA, V37, P428, DOI 10.1007/s001250050128; REYNISDOTTIR S, 1995, J CLIN INVEST, V95, P2161, DOI 10.1172/JCI117905; RIESS O, 1994, GENOMICS, V19, P298, DOI 10.1006/geno.1994.1061; RODBELL M, 1964, J BIOL CHEM, V239, P375; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; Scott J, 1996, NATURE, V379, P113, DOI 10.1038/379113a0; Simon JS, 1996, MAMM GENOME, V7, P380, DOI 10.1007/s003359900109; Todd JA, 1996, NATURE, V384, P407, DOI 10.1038/384407a0; YAMORI Y, 1984, HDB HYPERTENSION, V4, P224	47	131	135	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					197	201		10.1038/ng0697-197	http://dx.doi.org/10.1038/ng0697-197			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171835				2022-12-25	WOS:A1997XB54300024
J	Lu, XP; Fanjul, A; Picard, N; Pfahl, M; Rungta, D; NaredHood, K; Carter, B; Piedrafita, J; Tang, SP; Fabbrizio, E; Pfahl, M				Lu, XP; Fanjul, A; Picard, N; Pfahl, M; Rungta, D; NaredHood, K; Carter, B; Piedrafita, J; Tang, SP; Fabbrizio, E; Pfahl, M			Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACID; LIGANDS	Lung cancer causes more than 140,000 deaths annually in the United States alone, and the prognosis for non-small cell lung cancer (NSCLC) is particularly poor(1). Therapies using small molecules that preferentially kill lung tumor cells by inducing cellular suicide (apoptosis) would therefore be highly desirable. Retinoids have shown promise as cancer preventive and cancer therapeutic agents(2-5). Retinoid signals are mediated by two classes of nuclear receptors: the retinoic acid receptors (RAR alpha, beta, and gamma) and the retinoid X receptors (RXR alpha, beta and gamma)(5-8). These receptors usually bind as heterodimers to specific DNA sequences(9) and/or interact with other transcriptional regulators, such as AP-1 (ref. 10) to regulate gene transcription. Synthetic retinoids can be made that activate only specific portions of the complex retinoid response network(11-15) and activate selective biological programs. To Identify retinoids with novel biological activities, we used a high-throughput ''biological activity fingerprint'' screen on a large library of retinoids and retinoid-related molecules (RRMs). We identified new structures that are highly effective against lung cancer cells in vitro. Inducing apoptosis. We show here for one of these compounds that it is very effective against a human NSCLC in vivo in an animal model. These new molecules show a distinct pattern of receptor signaling.	GALDERMA RES INC,SAN DIEGO,CA 92121; SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA 92121; MAXIA PHARMACEUT INC,SAN DIEGO,CA 92121	Galderma R&D SNC					NCI NIH HHS [CA 55681] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; GINSBERG RJ, 1993, CANC PRINCIPLES PRAC, V1, P673; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LOTAN R, 1994, CANCER RES, V54, pS1987; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; PFAHL M, 1994, VITAM HORM, V49, P327; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFAHL M, 1996, HORM HEALTH DIS, P127; SHROOT B, 1990, Patent No. 4920140; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	24	89	90	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					686	690		10.1038/nm0697-686	http://dx.doi.org/10.1038/nm0697-686			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176499				2022-12-25	WOS:A1997XB97400042
J	Liaw, D; Marsh, DJ; Li, J; Dahia, PLM; Wang, SI; Zheng, ZM; Bose, S; Call, KM; Tsou, HC; Peacocke, M; Eng, C; Parsons, R				Liaw, D; Marsh, DJ; Li, J; Dahia, PLM; Wang, SI; Zheng, ZM; Bose, S; Call, KM; Tsou, HC; Peacocke, M; Eng, C; Parsons, R			Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome	NATURE GENETICS			English	Article							LHERMITTE-DUCLOS DISEASE	Cowden disease (CD) is an autosomal dominant cancer predisposition syndrome associated with an elevated risk for tumours of the breast, thyroid and skin(1-2). Lhermitte-Duclos disease (LDD) cosegregates with a subset of CD families and is associated with macrocephaly, ataxia and dysplastic cerebellar gangliocytomatosis(3-4). The common feature of these diseases is a predisposition to hamartomas, benign tumours containing differentiated but disorganized cells indigenous to the tissue of origin. Linkage analysis has determined that a single locus within chromosome 10q23 is likely to be responsible for both of these diseases(5). A candidate tumour suppressor gene (PTEN) within this region is mutated in sporadic brain, breast and prostate cancer(6). Another group has independently isolated the same gene, termed MMAC1, and also found somatic mutations throughout the gene in advanced sporadic cancers(7). Mutational analysis of PTEN in CD kindreds has identified germline mutations in four of five families, We found nonsense and missense mutations that are predicted to disrupt the protein tyrosine/dual-specificity phosphatase domain of this gene. Thus, PTEN appears to behave as a tumour suppressor gene in the germline. Our data also imply that PTEN may play a role in organizing the relationship of different cell types within an organ during development.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT DERMATOL,NEW YORK,NY 10032; CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; GENOME THERAPEUT CORP,WALTHAM,MA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Columbia University; Columbia University; Columbia University			Pinheiro, Maísa/E-7424-2012; Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931; Parsons, Ramon/0000-0002-6656-3514; Eng, Charis/0000-0002-3693-5145				CARLSON HE, 1986, AM J HUM GENET, V38, P908; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; ENG C, IN PRESS J GENET COU; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LLOYD KM, 1963, ANN INTERN MED, V58, P136, DOI 10.7326/0003-4819-58-1-136; Longy M, 1996, ANN GENET-PARIS, V39, P35; MALLORY SB, 1995, DERMATOL CLIN, V13, P27, DOI 10.1016/S0733-8635(18)30103-7; Marsh DJ, 1997, CANCER RES, V57, P500; MULVIHILL JJ, 1977, CANCER, V40, P1867, DOI 10.1002/1097-0142(197710)40:4+<1867::AID-CNCR2820400816>3.0.CO;2-P; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; PADBERG GW, 1991, ANN NEUROL, V29, P517, DOI 10.1002/ana.410290511; STARINK TM, 1986, CLIN GENET, V29, P222; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4	16	1560	1615	1	84	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	MAY	1997	16	1					64	67		10.1038/ng0597-64	http://dx.doi.org/10.1038/ng0597-64			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140396				2022-12-25	WOS:A1997WX02400023
J	Savka, MA; Farrand, SK				Savka, MA; Farrand, SK			Modification of rhizobacterial populations by engineering bacterium utilization of a novel plant-produced resource	NATURE BIOTECHNOLOGY			English	Article						Agrobacterium tumefaciens; pseudomonads; opine concept; rhizosphere ecology	PSEUDOMONAS-SYRINGAE; TRANSGENIC TOBACCO; PLASMID; COLONIZATION; RHIZOSPHERE; CATABOLISM; MUTANTS; STRAIN; ROOTS	The ability to catabolize distinct nutrients produced by a plant may be a factor in the successful colonization of that host by a bacterium when in competition with other rhizosphere microorganisms. We tested this hypothesis by examining the influence of a novel substrate produced by a transgenic plant on root colonization by near-isogenic bacteria, differing only in their ability to use the resource. When inoculated alone, both bacteria colonized the roots of the normal and transgenic plants with equal kinetics and to indistinguishable levels. When the two bacteria were coinoculated, the catabolizer reached a population density significantly higher than that of the noncatabolizer on the roots of the resource-producing plant. No such advantage was observed on the roots of normal plants. These results support the theory that resources produced and exuded by a plant host can confer a selective advantage to microorganisms that use the substrate.	UNIV ILLINOIS,DEPT CROP SCI,URBANA,IL 61801; UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV W FLORIDA,DEPT BIOL,PENSACOLA,FL 32514	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; State University System of Florida; University of West Florida								BOWEN GD, 1976, ANNU REV PHYTOPATHOL, V14, P121, DOI 10.1146/annurev.py.14.090176.001005; DESSAUX Y, 1987, MOL GEN GENET, V208, P301, DOI 10.1007/BF00330457; Dessaux Y., 1992, MOL SIGNALS PLANT MI, P109; DOWLING DN, 1986, ANNU REV MICROBIOL, V40, P131, DOI 10.1146/annurev.mi.40.100186.001023; ELLIS JG, 1984, MOL GEN GENET, V181, P466; GUYON P, 1993, MOL PLANT MICROBE IN, V6, P92, DOI 10.1094/MPMI-6-092; HWANG IY, 1994, APPL ENVIRON MICROB, V60, P913, DOI 10.1128/AEM.60.3.913-920.1994; JOHNSTON AWB, 1988, MOL GENETICS PLANT M, P374; LINDOW SE, 1987, APPL ENVIRON MICROB, V53, P2520, DOI 10.1128/AEM.53.10.2520-2527.1987; LYNCH JM, 1990, PLANT SOIL, V129, P1, DOI 10.1007/BF00011685; MURPHY JP, 1995, SOIL BIOL BIOCHEM, V27, P5525; MURPHY PJ, 1992, MOL SIGNALS PLANT MI, P377; OConnell KP, 1996, TRENDS BIOTECHNOL, V14, P83, DOI 10.1016/0167-7799(96)80928-0; Oger P, 1997, NAT BIOTECHNOL, V15, P369, DOI 10.1038/nbt0497-369; PETIT A, 1978, MOL GEN GENET, V167, P147, DOI 10.1007/BF00266908; ROSSBACH S, 1995, MOL PLANT MICROBE IN, V4, P549; RYDER MH, 1984, J BIOL CHEM, V259, P9704; SALOMON F, 1984, EMBO J, V3, P141, DOI 10.1002/j.1460-2075.1984.tb01774.x; SAVKA MA, 1992, PLANT PHYSIOL, V98, P784, DOI 10.1104/pp.98.2.784; SAVKA MA, 1990, PHYTOPATHOLOGY, V80, P503, DOI 10.1094/Phyto-80-503; SAVKA MA, 1993, THESIS U ILLINOIS UR; SCOTT DB, 1987, J BACTERIOL, V169, P278, DOI 10.1128/jb.169.1.278-282.1987; TATE ME, 1982, CARBOHYD RES, V104, P105, DOI 10.1016/S0008-6215(00)82224-7; Tempe J., 1979, PLASMIDS MED ENV COM, P353; TEPFER D, 1988, J BACTERIOL, V170, P1153, DOI 10.1128/jb.170.3.1153-1161.1988; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; VANEGERAAT AWSM, 1975, PLANT SOIL, V42, P381, DOI 10.1007/BF00010013; WILSON M, 1995, APPL ENVIRON MICROB, V61, P2151, DOI 10.1128/AEM.61.6.2151-2158.1995; WILSON M, 1994, APPL ENVIRON MICROB, V60, P4468, DOI 10.1128/AEM.60.12.4468-4477.1994; ZAMBRYSKI P, 1988, ANNU REV GENET, V22, P1, DOI 10.1146/annurev.ge.22.120188.000245	30	91	106	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					363	368		10.1038/nbt0497-363	http://dx.doi.org/10.1038/nbt0497-363			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094139				2022-12-25	WOS:A1997WQ55400038
J	Ravussin, E; Pratley, RE; Maffei, M; Wang, H; Friedman, JM; Bennett, PH; Bogardus, C				Ravussin, E; Pratley, RE; Maffei, M; Wang, H; Friedman, JM; Bennett, PH; Bogardus, C			Relatively low plasma leptin concentrations precede weight gain in Pima Indians	NATURE MEDICINE			English	Article							OBESE GENE-PRODUCT; INSULIN-RESISTANCE; PROTEIN; MICE; RNA	Leptin, the product of the ob gene(1), is a hormone, produced by adipose cells, that inhibits food intake(2-5) and increases energy expenditure(2,3) in rodents. In humans, plasma leptin concentrations correlate closely with the size of the adipose tissue depot; however, there is considerable variation in plasma leptin concentrations at any given degree of fatness(6,7). To investigate whether individuals prone to weight gain are hypoleptinemic, we measured fasting plasma leptin concentrations in two groups of weight-matched nondiabetic Pima Indians followed for approximately 3 years, 19 of whom subsequently gained weight and 17 of whom maintained their weight. After we adjusted for initial percent body fat, mean plasma leptin concentration was lower in those who gained weight than in those whose weight was stable. These data indicate that relatively low plasma leptin concentrations may play a role in the development of obesity in Pima Indians, a population prone to obesity.	ROCKEFELLER UNIV,GENET MOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Ravussin, E (corresponding author), NIDDKD,CLIN DIABET & NUTR SECT,NIH,4212 N 16TH ST,PHOENIX,AZ 85016, USA.		Ravussin, Eric/N-1985-2017; Steib, Lori/B-6628-2014; Friedman, Jeffrey M/E-5784-2011; Bennett, Peter/AAH-9605-2021	Ravussin, Eric/0000-0003-2129-547X; Steib, Lori/0000-0001-8274-318X; 				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NEEL JV, 1962, AM J HUM GENET, V14, P353; Norman RA, 1996, DIABETES, V45, P1229, DOI 10.2337/diabetes.45.9.1229; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; SCHWARTZ MW, 1995, J CLIN ENDOCR METAB, V80, P1571, DOI 10.1210/jc.80.5.1571; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SPRAUL M, 1993, J CLIN INVEST, V92, P1730, DOI 10.1172/JCI116760; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STIRLING B, 1995, DIABETES, V44, P999, DOI 10.2337/diabetes.44.8.999; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; TARTAGLIA LA, 1995, CELL, V85, P1265; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	28	229	233	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					238	240		10.1038/nm0297-238	http://dx.doi.org/10.1038/nm0297-238			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018247				2022-12-25	WOS:A1997WF08800047
J	Archer, DR; Cuddon, PA; Lipsitz, D; Duncan, ID				Archer, DR; Cuddon, PA; Lipsitz, D; Duncan, ID			Myelination of the canine central nervous system by glial cell transplantation: A model for repair of human myelin disease	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; DEFICIENT RAT; OLIGODENDROCYTES; ENVIRONMENTS; SURVIVAL; LESIONS; CNS	There is a lack of effective means of promoting remyelination of the central nervous system (CNS) in humans with chronic demyelinating disease. We have investigated the ability of transplanted glia to myelinate areas of the CNS equivalent to focal demyelinated lesions in multiple sclerosis (MS). In these studies we show that transplantation of oligodendrocytes or their progenitors into the CNS of a neonatal or adult canine myelin mutant results in repair of large areas similar in size to many MS plaques. Progenitor or pre-progenitor cells of the oligodendrocyte lineage have the greatest capacity for myelination following grafting, although cells of neonatal origin may also be used. Such an approach may therefore have therapeutic value in the repair of focal lesions in human myelin disease.	EMORY UNIV,DEPT PEDIAT,ATLANTA,GA 30322; COLORADO STATE UNIV,COLL VET MED,FT COLLINS,CO 80523; UNIV WISCONSIN,SCH VET MED,DEPT MED SCI,MADISON,WI 53706	Emory University; Colorado State University; University of Wisconsin System; University of Wisconsin Madison								ARCHER DR, 1994, EXP NEUROL, V125, P268, DOI 10.1006/exnr.1994.1029; BLAKEMORE WF, 1995, GLIA, V13, P79, DOI 10.1002/glia.440130202; BLAKEMORE WF, 1983, VIRUSES DEMYELINATIN, P167; COMPSTON A, 1994, ANN NEUROL, V36, pS146, DOI 10.1002/ana.410360736; Duncan Ian D., 1995, P990; DUNCAN ID, 1992, DEV NEUROSCI-BASEL, V14, P114, DOI 10.1159/000111655; DUNCAN ID, 1995, BRAIN PATHOL, V5, P301, DOI 10.1111/j.1750-3639.1995.tb00607.x; DUNCAN ID, IN PRESS J ANAT; EVERCOOREN AB, 1996, GLIA, V16, P147; FABRE JW, 1995, NAT MED, V1, P403, DOI 10.1038/nm0595-403; FRANKLIN RJM, 1993, SEMIN NEUROSCI, V5, P443; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; HAMMANG JP, 1994, METH NEUROSCI, V21, P281; Honmou O, 1996, J NEUROSCI, V16, P3199; ISACSON O, 1995, NAT MED, V1, P1189, DOI 10.1038/nm1195-1189; KIDD D, 1993, NEUROLOGY, V43, P2632, DOI 10.1212/WNL.43.12.2632; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Li D. W., 1994, Society for Neuroscience Abstracts, V20, P884; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; NADON NL, 1990, DEVELOPMENT, V110, P529; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; PRINEAS JW, 1993, BRAIN, V116, P681, DOI 10.1093/brain/116.3.681; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; ROSENBLUTH J, 1993, J NEUROCYTOL, V22, P967, DOI 10.1007/BF01218354; SATOH J, 1994, J NEUROSCI RES, V39, P260, DOI 10.1002/jnr.490390304; Seilhean D, 1996, ACTA NEUROPATHOL, V91, P82; TONTSCH U, 1994, P NATL ACAD SCI USA, V91, P11616, DOI 10.1073/pnas.91.24.11616; UTZSCHNEIDER DA, 1994, P NATL ACAD SCI USA, V91, P53, DOI 10.1073/pnas.91.1.53; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; Wood MJA, 1996, NEUROSCIENCE, V70, P775, DOI 10.1016/S0306-4522(96)83014-4	30	115	119	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					54	59		10.1038/nm0197-54	http://dx.doi.org/10.1038/nm0197-54			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986741				2022-12-25	WOS:A1997WA73300037
J	Bomsel, M				Bomsel, M			Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier	NATURE MEDICINE			English	Article							ADHESION MOLECULES; TRANSMISSION; HIV; MECHANISMS; RECEPTOR; PROTEIN; TYPE-1; FUSION	Contact between various epithelial cell lines and HIV chronically infected mononuclear cell lines results in a massive and rapid budding of HIV virions toward the epithelium followed by their internalization into epithelial endosome-like structures, Here it is shown that as early as 30 minutes after apical contact, primary virus isolates generated from primary peripheral blood leukocytes from HIV-infected patients can cross an epithelial cell line barrier using transcytosis, the characteristic epithelial transcellular vesicular pathway. As the next step in the spread of infection, transcytosed HIV particles can productively infect mononuclear cells located at the basolateral side of the epithelial barrier. These observations suggest an alternative, rapid and efficient mechanism for transmission of HIV across an intact epithelial barrier.			Bomsel, M (corresponding author), INST COCHIN GENET MOL, U332, 22 RUE MECHAIN, F-75014 PARIS, FRANCE.		Bomsel, Morgane/GSN-1948-2022	Bomsel, Morgane/0000-0002-9577-7474				AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760; APODACA G, 1995, INFECT IMMUN, V63, P1541, DOI 10.1128/IAI.63.4.1541-1551.1995; BALL JM, 1995, IN VITRO CELL DEV-AN, V31, P196; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1991, Current Opinion in Cell Biology, V3, P647, DOI 10.1016/0955-0674(91)90036-X; BOURINBAIAR AS, 1991, J ACQ IMMUN DEF SYND, V4, P56; CARLOS TM, 1994, BLOOD, V84, P2068; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; FAIS S, 1995, AIDS, V9, P329, DOI 10.1097/00002030-199509040-00003; Fawcett D., 1994, TXB HISTOLOGY; FERREIRA RD, 1990, GASTROENTEROLOGY, V98, P1255, DOI 10.1016/0016-5085(90)90342-X; FOLKS TM, 1988, J IMMUNOL, V140, P1117; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; HAROUSE JM, 1995, J VIROL, V69, P7383, DOI 10.1128/JVI.69.12.7383-7390.1995; MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; PEARCEPRATT R, 1994, J VIROL, V68, P2898, DOI 10.1128/JVI.68.5.2898-2905.1994; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; RUSSOMARIE F, 1993, P NATL ACAD SCI USA, V90, P8194, DOI 10.1073/pnas.90.17.8194; Shattock RJ, 1996, J INFECT DIS, V174, P54, DOI 10.1093/infdis/174.1.54; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; van der Bijl P, 1996, J CELL BIOL, V132, P813, DOI 10.1083/jcb.132.5.813; WESTON SA, 1992, CYTOMETRY, V13, P739, DOI 10.1002/cyto.990130710; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992; YAHI N, 1991, J VIROL METHODS, V34, P193, DOI 10.1016/0166-0934(91)90099-L; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	32	409	426	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1997	3	1					42	47		10.1038/nm0197-42	http://dx.doi.org/10.1038/nm0197-42			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986739				2022-12-25	WOS:A1997WA73300035
J	Schug, MD; Mackay, TFC; Aquadro, CF				Schug, MD; Mackay, TFC; Aquadro, CF			Low mutation rates of microsatellite loci in Drosophila melanogaster	NATURE GENETICS			English	Article							GENETIC-LINKAGE MAP; TANDEM REPEAT LOCI; POLYGENIC MUTATION; INBRED STRAINS; MODERN HUMANS; POLYMORPHISM; POPULATIONS; DIVERGENCE; EVOLUTION; DNA	Analysis of variation at microsatellite DNA loci is widely used in studies of parentage(1), linkage(2) and evolutionary history(3-5). The utility of microsatellites is primarily due to high levels of allelic diversity. believed to reflect mutation rates orders of magnitude higher than base pair substitutions at single-copy genes. For humans(6-14). mice(15-16), rats(17) and pigs(18) microsatellite mutation rates have been estimated at 10(-3)-10(-5). However. a recent study comparing microsatellite variation in humans with non-human primates suggests that microsatellite mutation rates may vary considerably across taxa(19,20). We measured mutation rates of 24 microsatellite loci in mutation accumulation lines of Drosophila melanogaster. Surprisingly, only a single mutation was detected after screening 157,680 allele-generations. yielding an estimated average mutation rate per locus of 6.3 x 10(-6), a mutation rate considerably lower than reported for various mammals. We propose that the comparatively low mutation rate is primarily a function of short microsatellite repeat lengths in the D. melanogaster genome.	N CAROLINA STATE UNIV,DEPT GENET,RALEIGH,NC 27695	University of North Carolina; North Carolina State University	Schug, MD (corresponding author), CORNELL UNIV,GENET & DEV SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM 17872, GM 45344, R01 GM036431, GM 36431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANCHS I, 1994, HUM MUTAT, V3, P365, DOI 10.1002/humu.1380030407; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; Casella G, 1992, STAT INFERENCE; CHANG BHJ, 1994, P NATL ACAD SCI USA, V91, P827, DOI 10.1073/pnas.91.2.827; Cooper KW, 1950, BIOL DROSOPHILA, P1; DALLAS JF, 1992, MAMM GENOME, V3, P452, DOI 10.1007/BF00356155; DEITRICH W, 1992, GENETICS, V131, P423; DOVER G, 1995, NAT GENET, V10, P254, DOI 10.1038/ng0795-254; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; ELLEGREN H, 1995, MAMM GENOME, V6, P376, DOI 10.1007/BF00364807; England PR, 1996, GENET RES, V67, P285, DOI 10.1017/S0016672300033760; GLOOR GB, 1993, GENETICS, V135, P81; GOLDSTEIN DB, 1995, NUCLEIC ACIDS RES, V23, P3882, DOI 10.1093/nar/23.19.3882; GOLDSTEIN DB, 1995, P NATL ACAD SCI USA, V92, P6723, DOI 10.1073/pnas.92.15.6723; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; KREITMAN M, 1983, NATURE, V304, P412, DOI 10.1038/304412a0; KWIATKOWSKI DJ, 1992, GENOMICS, V12, P229, DOI 10.1016/0888-7543(92)90370-8; LIN H, 1993, DEV BIOL, V159, P140, DOI 10.1006/dbio.1993.1228; MACKAY TFC, 1994, GENETICS, V136, P937; MACKAY TFC, 1995, GENETICS, V139, P849; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHTANI MM, 1993, HUM MOL GENET, V2, P431, DOI 10.1093/hmg/2.4.431; NUZHDIN SV, 1994, GENET RES, V63, P139, DOI 10.1017/S0016672300032249; PETRUKHIN KE, 1993, GENOMICS, V15, P76, DOI 10.1006/geno.1993.1012; QUELLER DC, 1993, TRENDS ECOL EVOL, V8, P285, DOI 10.1016/0169-5347(93)90256-O; ROY MS, 1994, MOL BIOL EVOL, V11, P553; RUBENSZTEIN DC, 1995, NAT GENET, V10, P337; SERIKAWA T, 1992, GENETICS, V131, P701; SINGH RS, 1989, ANNU REV GENET, V23, P425, DOI 10.1146/annurev.ge.23.120189.002233; Sonnenblick B., 1950, BIOL DROSOPHILA, P62; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STRAUB RE, 1993, GENOMICS, V15, P48, DOI 10.1006/geno.1993.1008; TAKAHATA N, 1995, THEOR POPUL BIOL, V48, P198, DOI 10.1006/tpbi.1995.1026; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123	37	190	196	0	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JAN	1997	15	1					99	102		10.1038/ng0197-99	http://dx.doi.org/10.1038/ng0197-99			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988178				2022-12-25	WOS:A1997WA37300030
J	Semina, EV; Reiter, R; Leysens, NJ; Alward, WLM; Small, KW; Datson, NA; SiegelBartelt, J; BierkeNelson, D; Bitoun, P; Zabel, BU; Carey, JC; Murray, JC				Semina, EV; Reiter, R; Leysens, NJ; Alward, WLM; Small, KW; Datson, NA; SiegelBartelt, J; BierkeNelson, D; Bitoun, P; Zabel, BU; Carey, JC; Murray, JC			Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome	NATURE GENETICS			English	Article							IN-SITU HYBRIDIZATION; MESSENGER-RNA; CLEFT-PALATE; EVOLUTIONARY CONSERVATION; WAARDENBURG SYNDROME; HOMEODOMAIN PROTEIN; EXPRESSION PATTERNS; MOUSE EMBRYO; MAJOR LOCUS; BOX GENE	Rieger syndrome (RIEG) is an autosomal-dominant human disorder that includes anomalies of the anterior chamber of the eye, dental hypoplasia and a protuberant umbilicus. We report the human cDNA and genomic characterization of a new homeobox gene, RIEG, causing this disorder. Six mutations in RIEG were found in individuals with the disorder. The cDNA sequence of Rieg, the murine homologue of RIEG, has also been isolated and shows strong homology with the human sequence. In mouse embryos Rieg mRNA localized in the periocular mesenchyme, maxillary and mandibular epithelia, and umbilicus, all consistent with RIEG abnormalities. The gene is also expressed in Rathke's pouch, vitelline vessels and the limb mesenchyme. RIEG characterization provides opportunities for understanding ocular, dental and umbilical development and the pleiotropic interactions of pituitary and limb morphogenesis.	UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOL SCI,IOWA CITY,IA 52242; UNIV IOWA,DEPT OPHTHALMOL,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,MED CTR,DEPT OPHTHALMOL,JULES STEIN EYE INST,LOS ANGELES,CA 90095; LEIDEN UNIV,SECTIE ANTHROPOGENET,SYLVIUS LAB,NL-2333 AL LEIDEN,NETHERLANDS; HOSP SICK CHILDREN,DEPT CLIN GENET,TORONTO,ON M5G 1X8,CANADA; DULUTH CLIN,DULUTH,MN 55805; HOP JEAN VERDIER,F-93143 BONDY,FRANCE; UNIV MAINZ,KLINIKUM JOHANNES GUTENBERG,DEPT PEDIAT,D-55101 MAINZ,GERMANY; UNIV UTAH,HLTH SCI CTR,DEPT PEDIAT,SALT LAKE CITY,UT 84132	University of Iowa; University of Iowa; University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Leiden University; Leiden University - Excl LUMC; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Johannes Gutenberg University of Mainz; Utah System of Higher Education; University of Utah			Datson, Nicole A./O-8797-2014; Alward, Wallace/AAY-4149-2020	Alward, Wallace/0000-0001-6368-9018; Bitoun, Pierre/0000-0001-6557-6826; Datson, Nicole/0000-0003-2887-0238	NIDCR NIH HHS [DE08559, DE09170] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE008559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008559, P50DE009170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alkemade P., 1969, DYSGENESIS MESODERMA; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; Bedell MA, 1996, NAT GENET, V12, P229, DOI 10.1038/ng0396-229; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Brunelli S, 1996, NAT GENET, V12, P94, DOI 10.1038/ng0196-94; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; CRAWFORD RA, 1967, BRIT J OPHTHALMOL, V51, P438, DOI 10.1136/bjo.51.7.438; DARWIN C, 1893, ANIMALS PLANTS DOMES, V1, P434; DATSON N, IN PRESS AM J HUM GE; Dixon J, 1996, NAT GENET, V12, P130; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EIBERG H, 1987, CLIN GENET, V32, P129; FEINGOLD M, 1969, PEDIATRICS, V44, P564; FITCH N, 1978, J MED GENET, V15, P30, DOI 10.1136/jmg.15.1.30; GASSER DL, 1991, J CRAN GENET DEV BIO, V11, P366; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HANES SD, 1994, MOL CELL BIOL, V14, P3364, DOI 10.1128/MCB.14.5.3364; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEON E, 1995, HUM MOL GENET, V4, P1435, DOI 10.1093/hmg/4.8.1435; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JIN YS, 1994, NATURE, V372, P780, DOI 10.1038/372780a0; JURILOFF DM, 1995, MAMM GENOME, V6, P63, DOI 10.1007/BF00303246; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KAROLYI J, 1994, J CRANIOFAC GENET DE, V13, P1; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRESPI YP, 1979, AM J GASTROENTEROL, V71, P608; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LEUSSINK B, 1995, MECH DEVELOP, V52, P51, DOI 10.1016/0925-4773(95)00389-I; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; MOORE GE, 1987, NATURE, V326, P91, DOI 10.1038/326091a0; MUENKE M, 1994, P NATL ACAD SCI USA, V91, P8102, DOI 10.1073/pnas.91.17.8102; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; MURRAY JC, 1995, AM J HUM GENET, V57, P227, DOI 10.2134/agronj1965.00021962005700020028x; MURRAY JC, 1990, AM J HUM GENET, V46, P486; MURRAY JC, 1992, NAT GENET, V2, P46, DOI 10.1038/ng0992-46; NOHNO T, 1993, DEV BIOL, V158, P254, DOI 10.1006/dbio.1993.1184; Padanilam B. J., 1992, Human Molecular Genetics, V1, P407, DOI 10.1093/hmg/1.6.407; PASTERIS NG, 1994, CELL, V79, P669; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; Phillips JC, 1996, AM J HUM GENET, V59, P613; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; QIU MS, 1995, GENE DEV, V9, P2523, DOI 10.1101/gad.9.20.2523; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Rieger H, 1935, Z AUGENHEILKD, V86, P333; ROGERS RC, 1988, P GREENWOOD GENET CT, V7, P9; SADEGHIN.A, 1974, J PEDIATR-US, V85, P644, DOI 10.1016/S0022-3476(74)80507-X; SAITO T, 1995, MOL CELL NEUROSCI, V6, P280, DOI 10.1006/mcne.1995.1022; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SEMINA E, IN PRESS AM J HUM GE; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMEONE A, 1994, NEURON, V13, P81; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Slaney SF, 1996, AM J HUM GENET, V58, P923; SLAVKIN HC, 1993, AM J MED GENET, V47, P689, DOI 10.1002/ajmg.1320470521; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; THEILER K, 1989, HOUSE MOUSE; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; VOSSIUS A, 1883, KLIN MONATSBL AUGENH, V21, P233; Winter RM, 1996, NAT GENET, V12, P124, DOI 10.1038/ng0296-124; ZHAO GQ, 1994, MECH DEVELOP, V48, P245, DOI 10.1016/0925-4773(94)90063-9	72	702	726	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					392	399		10.1038/ng1296-392	http://dx.doi.org/10.1038/ng1296-392			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944018				2022-12-25	WOS:A1996VV73000014
J	Stickens, D; Clines, G; Burbee, D; Ramos, P; Thomas, S; Hogue, D; Hecht, JT; Lovett, M; Evans, GA				Stickens, D; Clines, G; Burbee, D; Ramos, P; Thomas, S; Hogue, D; Hecht, JT; Lovett, M; Evans, GA			The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes	NATURE GENETICS			English	Article							DIRECT SELECTION; COMPLEX GENOMES; CHROMOSOME-11; MAP; MARKERS; LOCUS; HUMAN-CHROMOSOME-11; HETEROZYGOSITY; LOCALIZATION	Hereditary multiple exostoses (EXT) is an autosomal dominant condition characterized by short stature and the development of bony protuberances at the ends of all the long bones. Three genetic loci have been identified by genetic linkage analysis at chromosomes 8q24.1, 11p11-13 and 19p. The EXT1 gene on chromosome 8 was recently identified and characterized. Here, we report the isolation and characterization of the EXT2 gene. This gene shows striking sequence similarity to the EXT1 gene, and we have identified a four base deletion segregating with the phenotype. Both EXT1 and EXT2 show significant homology with one additional expressed sequence tag, defining a new multigene family of proteins with potential tumour suppressor activity.	UNIV TEXAS, SW MED CTR, MCDERMOTT CTR HUMAN GROWTH & DEV, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SCH MED, DEPT PEDIAT, HOUSTON, TX 77225 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System					NHGRI NIH HHS [HG00202, HG00368] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000368] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Altschul SF, 1990, J MOL BIOL, V215, P403; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COOK A, 1993, AM J HUM GENET, V53, P71; DELMASTRO RG, 1995, GENOME RES, V5, P185, DOI 10.1101/gr.5.2.185; EVANS GA, 1989, P NATL ACAD SCI USA, V86, P5030, DOI 10.1073/pnas.86.13.5030; EVANS GA, IN PRESS GENOME ANAL; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HECHT JT, 1995, AM J HUM GENET, V56, P1125; HENNEKAM RCM, 1991, J MED GENET, V28, P262, DOI 10.1136/jmg.28.4.262; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KOOTH R, 1961, AM J HUM GENET, V13, P340; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEMERRER M, 1994, HUM MOL GENET, V3, P717, DOI 10.1093/hmg/3.5.717; LENNON G, IN PRESS GENOMICS; LEONE NC, 1987, J HERED, V78, P171, DOI 10.1093/oxfordjournals.jhered.a110351; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LONGMIRE J, 1993, GENET ANAL TECH APPL, V10, P49; LOVETT M, 1994, TRENDS GENET, V10, P352, DOI 10.1016/0168-9525(94)90131-7; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUDECKE HJ, 1995, HUM MOL GENET, V4, P31, DOI 10.1093/hmg/4.1.31; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; QIN S, 1993, GENOMICS, V16, P580, DOI 10.1006/geno.1993.1233; QUACKENBUSH J, 1995, GENOMICS, V29, P512, DOI 10.1006/geno.1995.9974; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; SCHMALE GA, 1994, J BONE JOINT SURG AM, V76A, P986, DOI 10.2106/00004623-199407000-00005; SMITH MW, 1994, NAT GENET, V7, P40, DOI 10.1038/ng0594-40; SMITH MW, 1993, GENOMICS, V17, P699, DOI 10.1006/geno.1993.1392; SOLOMON L, 1961, J BONE JOINT SURG BR, V43, P700, DOI 10.1302/0301-620X.43B4.700; WICKLUND CL, 1995, AM J MED GENET, V55, P43, DOI 10.1002/ajmg.1320550113; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; WUYTS W, 1995, AM J HUM GENET, V57, P382	33	268	289	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1996	14	1					25	32		10.1038/ng0996-25	http://dx.doi.org/10.1038/ng0996-25			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782816				2022-12-25	WOS:A1996VF61100017
J	David, G; Abbas, N; Stevanin, G; Durr, A; Yvert, G; Cancel, G; Weber, C; Imbert, G; Saudou, F; Antoniou, E; Drabkin, H; Gemmill, R; Giunti, P; Benomar, A; Wood, N; Ruberg, M; Agid, Y; Mandel, JL; Brice, A				David, G; Abbas, N; Stevanin, G; Durr, A; Yvert, G; Cancel, G; Weber, C; Imbert, G; Saudou, F; Antoniou, E; Drabkin, H; Gemmill, R; Giunti, P; Benomar, A; Wood, N; Ruberg, M; Agid, Y; Mandel, JL; Brice, A			Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion	NATURE GENETICS			English	Article							DOMINANT CEREBELLAR-ATAXIA; PALLIDOLUYSIAN ATROPHY DRPLA; MACHADO-JOSEPH DISEASE; PIGMENTARY MACULAR DYSTROPHY; RETINAL DEGENERATION; CHROMOSOME 3P12-P21.1; HUNTINGTONS-DISEASE; SEQUENCES; LOCUS; ANTICIPATION	The gene for spinocerebellar ataxia 7 (SCA7) has been mapped to chromosome 3q12-13. By positional cloning, we have identified a new gene of unknown function containing a CAG repeat that is expanded in SCA7 patients. On mutated alleles, CAG repeat size is highly variable, ranging from 38 to 130 repeats, whereas on normal alleles it ranges from 7 to 17 repeats. Gonadal instability in SCA7 is greater than that observed in any of the seven known neuro-degenerative diseases caused by translated CAG repeat expansions, and is markedly associated with paternal transmissions. SCA7 is the first such disorder in which the degenerative process also affects the retina.	HOP LA PITIE SALPETRIERE, INSERM U289, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, FEDERAT NEUROL, F-75651 PARIS 13, FRANCE; ULP, INSERM, IGBMC, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA; INST NEUROL, LONDON WC1N 3BG, ENGLAND; HOP SPECIAL, SERV NEUROL, RABAT, MOROCCO	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of London; University College London; Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat			Brice, Alexis/A-2170-2009; SAUDOU, Frédéric/L-3454-2014; Wood, Nicholas W/C-2505-2009; Stevanin, Giovanni/E-5038-2016; brice, alexis/AAE-8275-2019; Giunti, Paola/E-5526-2012	SAUDOU, Frédéric/0000-0001-6107-1046; Wood, Nicholas W/0000-0002-9500-3348; Stevanin, Giovanni/0000-0001-9368-8657; brice, alexis/0000-0002-0941-3990; Giunti, Paola/0000-0003-3508-4788; Yvert, Gael/0000-0003-1955-4786; Cancel-Tassin, Geraldine/0000-0002-9583-6382	NHGRI NIH HHS [R01 HG000358] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000358] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BENOMAR A, 1994, ANN NEUROL, V35, P439, DOI 10.1002/ana.410350411; BENOMAR A, 1995, NAT GENET, V10, P84, DOI 10.1038/ng0595-84; BERCIANO J, 1982, J NEUROL SCI, V53, P253, DOI 10.1016/0022-510X(82)90011-9; CANCEL G, 1995, AM J HUM GENET, V57, P809; Cancel G, 1997, HUM MOL GENET, V6, P709, DOI 10.1093/hmg/6.5.709; Chong SS, 1997, HUM MOL GENET, V6, P301, DOI 10.1093/hmg/6.2.301; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; David G, 1996, AM J HUM GENET, V59, P1328; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Durr A, 1996, CURR OPIN NEUROL, V9, P290; ENEVOLDSON TP, 1994, BRAIN, V117, P445, DOI 10.1093/brain/117.3.445; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOUW LG, 1995, NAT GENET, V10, P89, DOI 10.1038/ng0595-89; HARDING AE, 1993, ADV NEUROL, V61, P1; HARDING AE, 1982, BRAIN, V105, P1, DOI 10.1093/brain/105.1.1; HOLMBERG M, 1995, HUM MOL GENET, V4, P1441, DOI 10.1093/hmg/4.8.1441; Igarashi S, 1996, HUM MOL GENET, V5, P923, DOI 10.1093/hmg/5.7.923; IKEUCHI T, 1995, SEMIN CELL BIOL, V6, P37, DOI 10.1016/1043-4682(95)90013-6; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Jobsis GJ, 1997, J NEUROL NEUROSUR PS, V62, P367, DOI 10.1136/jnnp.62.4.367; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KONIGSMARK BW, 1970, MEDICINE, V49, P227, DOI 10.1097/00005792-197005000-00003; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krols L, 1997, HUM GENET, V99, P225, DOI 10.1007/s004390050344; LEEFLANG EP, 1995, HUM MOL GENET, V4, P1519; Lindblad K, 1996, GENOME RES, V6, P965, DOI 10.1101/gr.6.10.965; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mandel JL, 1997, NATURE, V386, P767, DOI 10.1038/386767a0; Maniatis T, 1989, MOL CLONING; MARTIN JJ, 1994, ACTA NEUROPATHOL, V88, P277; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ruberg M, 1997, J NEUROCHEM, V68, P2098; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Stevanin G, 1996, HUM MOL GENET, V5, P1887, DOI 10.1093/hmg/5.12.1887; Stevanin G, 1997, AM J HUM GENET, V60, P1548; Takiyama Y, 1997, HUM MOL GENET, V6, P1063, DOI 10.1093/hmg/6.7.1063; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	44	615	640	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1997	17	1					65	70		10.1038/ng0997-65	http://dx.doi.org/10.1038/ng0997-65			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288099				2022-12-25	WOS:A1997XU72400019
J	Hawkins, GA; Hoffman, LM				Hawkins, GA; Hoffman, LM			Base excision sequence scanning	NATURE BIOTECHNOLOGY			English	Editorial Material							MITOCHONDRIAL-DNA				Hawkins, GA (corresponding author), EPICTR TECHNOL,1202 ANN ST,MADISON,WI 53713, USA.							[Anonymous], HUMAN GENE MUTATION; BERTRANPETIT J, 1995, ANN HUM GENET, V59, P63, DOI 10.1111/j.1469-1809.1995.tb01606.x; HAWKINS GA, 1997, IN PRESS EPICENTRE F; Nei M, 1996, ANNU REV GENET, V30, P371, DOI 10.1146/annurev.genet.30.1.371; WILSON MR, 1995, BIOTECHNIQUES, V18, P662	5	26	28	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					803	804		10.1038/nbt0897-803	http://dx.doi.org/10.1038/nbt0897-803			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255799				2022-12-25	WOS:A1997XM70700036
J	Winter, H; Rogers, MA; Langbein, L; Stevens, HP; Leigh, IM; Labreze, C; Roul, S; Taieb, A; Krieg, T; Schweizer, J				Winter, H; Rogers, MA; Langbein, L; Stevens, HP; Leigh, IM; Labreze, C; Roul, S; Taieb, A; Krieg, T; Schweizer, J			Mutations in the hair cortex keratin hHb6 cause the inherited hair disease monilethrix	NATURE GENETICS			English	Article							HUMAN TYPE-I; ICHTHYOSIS BULLOSA; INTERMEDIATE FILAMENTS; ROD DOMAIN; GENE; SEQUENCE; SIEMENS; 2E; EXPRESSION; FOLLICLE	Pathogenic mutations in a large number of human epithelial keratins have been well characterized. However, analogous mutations in the hard alpha-keratins of hair and nail have not yet been described. Monilethrix is a rare autosomal dominant hair defect with variable expression. Hairs from affected individuals show a beaded structure of alternating elliptical nodes and constrictions (internodes). These internodes exhibit a high propensity to weathering and fracture. Strong evidence that trichocyte keratin defects might underlie this hair disorder was provided by genetic linkage analyses that mapped this disease to the type-ii keratin gene cluster on 12q13. All affected individuals from a four-generation British family with monilethrix, previously linked to the type-it keratin gene cluster, as well as three unrelated single monilethrix patients, exhibited a heterozygous point mutation in the gene far type-Il hair cortex keratin hHb6, leading to lysine substitution of a highly conserved glutamic acid residue in the helix termination motif (Glu 410 Lys). In a three-generation French family with monilethrix of a milder and variable phenotype, we detected another heterozygous point mutation in the same glutamic acid codon of hHb6, which resulted in a conservative aspartic acid substitution (Glu 410 Asp). These mutations provide the first direct evidence for involvement of hair keratins in hair disease.	GERMAN CANC RES CTR,DIV CELL BIOL,D-69120 HEIDELBERG,GERMANY; ACAD DEPT DERMATOL,LONDON E1 2AT,ENGLAND; ROYAL LONDON SCH MED & DENT,LONDON E1 2AT,ENGLAND; HOP PELLEGRIN ENFANTS,UNITE DERMATOL PEDIAT,F-33076 BORDEAUX,FRANCE; UNIV COLOGNE,DEPT DERMATOL,D-50924 COLOGNE,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); University of London; Queen Mary University London; CHU Bordeaux; University of Cologne	Winter, H (corresponding author), GERMAN CANC RES CTR,DIV TUMOUR CELL REGULAT,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.		Rogers, Michael A./J-9803-2012; TAIEB, ALAIN/AAB-1085-2021	Rogers, Michael A./0000-0002-3728-2107; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DEBERKER DAR, 1993, BRIT J DERMATOL, V128, P327; FINK P, 1995, BBA-GENE STRUCT EXPR, V1264, P12, DOI 10.1016/0167-4781(95)00122-W; GUMMER CI, 1981, BRIT J DERMATOL, V105, P529, DOI 10.1111/j.1365-2133.1981.tb00796.x; HATZFELD M, 1991, J CELL SCI, V99, P351; HEALY E, 1995, HUM MOL GENET, V4, P2399, DOI 10.1093/hmg/4.12.2399; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; ITO M, 1990, J INVEST DERMATOL, V95, P186, DOI 10.1111/1523-1747.ep12477967; Korge B. P., 1996, Journal of Investigative Dermatology, V106, P843; KREMER H, 1994, J INVEST DERMATOL, V103, P286, DOI 10.1111/1523-1747.ep12394414; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; MCKEE GM, 1961, J CUTAN DIS SYPH, V34, P444; MCKEE GM, 1961, J CUTAN DIS INCL SYP, V34, P506; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; MCLEAN WHI, 1994, J INVEST DERMATOL, V103, P277, DOI 10.1111/1523-1747.ep12394307; POWELL B, 1992, DEVELOPMENT, V114, P417; Richard G, 1996, J INVEST DERMATOL, V107, P812, DOI 10.1111/1523-1747.ep12330568; ROCK B, 1992, TXB DERMATOLOGY, P1353; ROGERS MA, 1995, EXP CELL RES, V220, P357, DOI 10.1006/excr.1995.1326; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; Rogers MA, 1996, J INVEST DERMATOL, V107, P633, DOI 10.1111/1523-1747.ep12584243; ROGERS MA, 1995, MOL BIOL REP, V20, P155, DOI 10.1007/BF00990548; ROTHNAGEL JA, 1994, NAT GENET, V7, P485, DOI 10.1038/ng0894-485; STEINERT PM, 1993, BIOCHEM BIOPH RES CO, V197, P840, DOI 10.1006/bbrc.1993.2555; STEINERT PM, 1995, INTERMEDIATE FILAMEN, P145; Stevens HP, 1996, J INVEST DERMATOL, V106, P795, DOI 10.1111/1523-1747.ep12346400; WINTER H, 1994, EXP CELL RES, V212, P190, DOI 10.1006/excr.1994.1134	26	145	150	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					372	374		10.1038/ng0897-372	http://dx.doi.org/10.1038/ng0897-372			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241275				2022-12-25	WOS:A1997XM90900020
J	Christoffersen, RE				Christoffersen, RE			Translating genomics information into therapeutics: A key role for oligonucleotides	NATURE BIOTECHNOLOGY			English	Editorial Material											Christoffersen, RE (corresponding author), RIBOZYME PHARMACEUT,2950 WILDERNESS PL,BOULDER,CO 80301, USA.								0	22	23	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					483	484		10.1038/nbt0697-483	http://dx.doi.org/10.1038/nbt0697-483			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181554				2022-12-25	WOS:A1997XC77200004
J	Qian, F; Germino, FJ; Cai, YQ; Zhang, XB; Somlo, S; Germino, GG				Qian, F; Germino, FJ; Cai, YQ; Zhang, XB; Somlo, S; Germino, GG			PKD1 interacts with PKD2 through a probable coiled-coil domain	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; PROTEIN; LOCUS	Autosomal dominant polycystic kidney disease (ADPKD) describes a group of at least three genetically distinct disorders with almost identical clinical features(1-6) that collectively affects 1:1,000 of the population(7). Affected individuals typically develop large cystic kidneys and approximately one half develop end-stage renal disease by their seventh decade. It has been suggested that the diseases result from defects in interactive factors involved in a common pathway. The recent discovery of the genes for the two most common forms of ADPKD has provided an opportunity to test this hypothesis(5,6,8-10). We describe a previously unrecognized coiled-coil domain within the C terminus of the PKD1 gene product, polycystin, and demonstrate that it binds specifically to the C terminus of PKD2. Homotypic interactions involving the C terminus of each are also demonstrated. We show that naturally occurring pathogenic mutations of PKD1 and PKD2 disrupt their associations. We have characterized the structural basis of their heterotypic interactions by deletional and site-specific mutagenesis. Our data suggest that PKD1 and PKD2 associate physically in vivo and may be partners of a common signalling cascade involved in tubular morphogenesis.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV NEPHROL, BALTIMORE, MD 21205 USA; UNIV MED & DENT NEW JERSEY, DEPT MED, NEW BRUNSWICK, NJ 08901 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL GENET, DIV NEPHROL, BRONX, NY 10461 USA	Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Germino, Gregory/0000-0002-3609-5588				BOGDANOVA N, 1995, HUM GENET, V95, P645; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DEALMEIDA S, 1995, HUM GENET, V96, P83, DOI 10.1007/BF00214191; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Essers L, 1996, TRENDS GENET, V12, P449, DOI 10.1016/0168-9525(96)99997-7; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Peral B, 1996, AM J HUM GENET, V58, P86; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; WARD CJ, 1994, CELL, V77, P881	19	530	543	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					179	183		10.1038/ng0697-179	http://dx.doi.org/10.1038/ng0697-179			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171830				2022-12-25	WOS:A1997XB54300019
J	Weil, D; Kussel, P; Blanchard, S; Levy, G; LeviAcobas, F; Drira, M; Ayadi, H; Petit, C				Weil, D; Kussel, P; Blanchard, S; Levy, G; LeviAcobas, F; Drira, M; Ayadi, H; Petit, C			The autosomal recessive isolated deafness, DFNB2, and the Usher 1B syndrome are allelic defects of the myosin-VIIA gene	NATURE GENETICS			English	Article							MUTATION; LOCALIZATION; EXPRESSION; HOMOLOG; PATIENT; PROTEIN; MOTOR; IV	Hereditary non-syndromic profound deafness affects about 1 in 2000 children prior to language acquisition. In 80% of the cases, the mode of transmission is autosomal recessive. The number of genes involved in these recessive forms of isolated deafness (DFNB genes) has been estimated to between 30 and 100. So far, ten DFNB genes have been mapped to human chromosomes, one of which has been isolated(2). By linkage analysis of a single family whose members were affected with profound deafness, some of them presenting with vestibular dysfunction, DFNB2 has been mapped to chromosome 11q13 (ref. 3), The gene responsible for a form of Usher syndrome type I, USH1B, has been assigned to the same chromosomal region(4). Usher syndrome associates profound congenital deafness and vestibular dysfunction with retinitis pigmentosa. In the homologous murine region are located the shaker-1 mutations responsible for deafness and vestibular dysfunction. It has been demonstrated that the murine shaker-1 and human USH1B phenotypes result from mutations in the gene encoding myosin-VIIA(5,6). Based on mapping data as well as on the similarities between the phenotypes of DFNB2-affected patients and shaker-1 mouse mutants, we have proposed that a defective myosin-VIIA may also be responsible for DFNB2 (ref. 1). Sequence analysis of each of the coding exons of the myosin-VIIA gene (MYO7A) was thus undertaken in the DFNB2-affected family. In the last nucleotide of exon 15, a G to A transition was detected, a type of mutation that is known to decrease the efficiency of splicing(7-14). Accordingly, this result shows that different mutations in MYO7A result in either an isolated or a syndromic form of deafness.	INST PASTEUR, CNRS URA 1968, UNITE GENET DEFICITS SENSORIELS, F-75724 PARIS 15, FRANCE; FAC MED, LAB IMMUNOL & BIOL MOL, SFAX 3029, TUNISIA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Sfax				Petit, Christine/0000-0002-9069-002X				ANDREWS LG, 1992, J BIOL CHEM, V267, P7834; Chaib H, 1996, HUM MOL GENET, V5, P1061, DOI 10.1093/hmg/5.7.1061; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; ENGLE LJ, 1994, GENOMICS, V19, P407, DOI 10.1006/geno.1994.1088; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KUIVANIEMI H, 1995, J INVEST DERMATOL, V105, P352, DOI 10.1111/1523-1747.ep12320704; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMMINK HH, 1994, HUM MOL GENET, V3, P1269, DOI 10.1093/hmg/3.8.1269; Levy G, 1997, HUM MOL GENET, V6, P111, DOI 10.1093/hmg/6.1.111; LIND B, 1993, BLOOD, V82, P2423; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SAHLY I, 1997, IN PRESS ANAT EMBRYO; SATOKATA I, 1995, HUM MOL GENET, V4, P1993, DOI 10.1093/hmg/4.10.1993; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; Tamagawa Y, 1996, HUM MOL GENET, V5, P849, DOI 10.1093/hmg/5.6.849; Vale Ronald D., 1993, P175; VIDAUD M, 1989, P NATL ACAD SCI USA, V86, P1041, DOI 10.1073/pnas.86.3.1041; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wayne S, 1996, HUM MOL GENET, V5, P1689, DOI 10.1093/hmg/5.10.1689; WEIL D, 1990, J BIOL CHEM, V265, P16007; WEIL D, 1989, J BIOL CHEM, V264, P16804; Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	28	302	316	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1997	16	2					191	193		10.1038/ng0697-191	http://dx.doi.org/10.1038/ng0697-191			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171833				2022-12-25	WOS:A1997XB54300022
J	Zhou, P; Goldstein, S; Devadas, K; Tewari, D; Notkins, AL				Zhou, P; Goldstein, S; Devadas, K; Tewari, D; Notkins, AL			Human CD4(+) cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression	NATURE MEDICINE			English	Article							LYMPHOCYTE CHEMOATTRACTANT FACTOR; HUMAN LYMPHOKINES; MIGRATION; REPLICATION; MODULATION; RECEPTOR; DOMAINS	Interleukin-16 (IL-16) is secreted by activated CD8+ T lymphocytes and acts on CDC T lymphocytes, monocytes and eosinophils. Recently, the C-terminal 130-amino acid portion of IL-16 was shown to suppress HIV-1 replication in vitro. To explore the potential of human IL-16 for gene therapy, this portion was transfected into HIV-1-susceptible CD4(+) jurkat cells by means of a mammalian expression vector. The stable transfectants synthesized and secreted IL-16 protein. The expression of IL-16 did not alter growth rate and CD4 expression; however, HIV replication was inhibited by as much as 99%. Furthermore, during the initial phase of the infection, equal amounts of HIV-1 proviral DNA were found in cells transfected with IL-16 and with vector alone. In contrast, the 2-kilobase HIV-1 transcripts were markedly reduced and the 4-kb and 9-kb transcripts were undetectable in the cells transfected with IL-16. These findings indicate that IL-16-mediated inhibition of HIV-1 is not at the level of viral entry or reverse transcription, but at messenger RNA expression.	NIAID,IMMUNODEFICIENCY VIRUS SECT,INFECT DIS LAB,NIH,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Zhou, P (corresponding author), NIDR,BRANCH ORAL INFECT & IMMUN,NIH,BETHESDA,MD 20892, USA.							BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Bannert N, 1996, NATURE, V381, P30, DOI 10.1038/381030a0; Bazan JF, 1996, NATURE, V381, P29, DOI 10.1038/381029a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CENTER DM, 1982, J IMMUNOL, V128, P2563; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CRUIKSHANK W, 1982, J IMMUNOL, V128, P2569; CRUIKSHANK WW, 1991, J IMMUNOL, V146, P2928; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; ENNEN J, 1994, P NATL ACAD SCI USA, V91, P7207, DOI 10.1073/pnas.91.15.7207; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1994, J VIROL, V68, P2503, DOI 10.1128/JVI.68.4.2503-2512.1994; KWOK S, 1990, TRANSFUSION, V30, P491, DOI 10.1046/j.1537-2995.1990.30690333477.x; LABERGE S, 1995, J IMMUNOL, V155, P2902; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Maniatis T., 1982, MOL CLONING; OBEELIN E, 1996, NATURE, V382, P833; Oravecz T, 1996, J IMMUNOL, V157, P1329; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Shaheen F, 1996, J VIROL, V70, P3392, DOI 10.1128/JVI.70.6.3392-3400.1996; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; ZHOU P, 1993, P NATL ACAD SCI USA, V90, P2681, DOI 10.1073/pnas.90.7.2681	31	97	102	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					659	664		10.1038/nm0697-659	http://dx.doi.org/10.1038/nm0697-659			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176493				2022-12-25	WOS:A1997XB97400036
J	Iafrati, MD; Karas, RH; Aronovitz, M; Kim, S; Sullivan, TR; Lubahn, DB; ODonnell, TF; Korach, KS; Mendelsohn, ME				Iafrati, MD; Karas, RH; Aronovitz, M; Kim, S; Sullivan, TR; Lubahn, DB; ODonnell, TF; Korach, KS; Mendelsohn, ME			Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; ATHEROSCLEROTIC CORONARY-ARTERIES; NITRIC-OXIDE; MOUSE; EXPRESSION; ESTRADIOL; GENE; 17-BETA-ESTRADIOL; TRANSCRIPTION; ENDOTHELIUM	The atheroprotective effects of estrogen in women are well recognized(1), but the underlying mechanisms responsible are not well understood. Blood vessel cells express the classic estrogen receptor, ER alpha (ref. 2-6), and are directly affected by estrogen, which inhibits the development of atherosclerotic and injury-induced vascular lesions(7,8). We have generated mice in which the ER alpha gene is disrupted(9) and have used a mouse model of carotid arterial injury to compare the effects of estrogen on wild-type and estrogen receptor-deficient mice. Increases in vascular medial area and smooth muscle cell proliferation were quantified following vascular injury in ovariectomized mice treated with vehicle or with physiologic levels of 17 beta-estradiol. Suprisingly, in both wild-type and estrogen receptor-deficient mice, 17 beta-estradiol markedly inhibited to the same degree all measures of vascular injury. These data demonstrate that estrogen inhibits vascular injury by a novel mechanism that is independent of the classic estrogen receptor, ER alpha.	TUFTS UNIV NEW ENGLAND MED CTR,MOL CARDIOL RES CTR,TUPPER RES INST,BOSTON,MA 02111; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT CHILD HLTH,COLUMBIA,MO 65201; NIEHS,REPROD & DEV TOXICOL LAB,NIH,RES TRIANGLE PK,NC 27709	Tufts Medical Center; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)				Korach, Kenneth/0000-0002-7765-418X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056069] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL 30386, R01 HL 56069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; Arnal JF, 1996, P NATL ACAD SCI USA, V93, P4108, DOI 10.1073/pnas.93.9.4108; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CaulinGlaser T, 1996, J CLIN INVEST, V98, P36, DOI 10.1172/JCI118774; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V620, P472; Chen SJ, 1996, CIRCULATION, V93, P577, DOI 10.1161/01.CIR.93.3.577; COLBURN P, 1978, SCIENCE, V201, P817, DOI 10.1126/science.684408; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; FARHAT MY, 1992, BRIT J PHARMACOL, V107, P679, DOI 10.1111/j.1476-5381.1992.tb14506.x; FISCHERDZOGA K, 1983, EXP MOL PATHOL, V39, P355, DOI 10.1016/0014-4800(83)90064-3; GRABER R, 1993, CELL SIGNAL, V5, P181, DOI 10.1016/0898-6568(93)90069-X; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; HORWITZ KB, 1982, J CLIN INVEST, V69, P750, DOI 10.1172/JCI110513; JIANG CW, 1991, BRIT J PHARMACOL, V104, P1033, DOI 10.1111/j.1476-5381.1991.tb12545.x; Johns A, 1996, ENDOCRINOLOGY, V137, P4511, DOI 10.1210/en.137.10.4511; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; Koike H, 1996, J VASC SURG, V23, P477, DOI 10.1016/S0741-5214(96)80014-0; Kolodgie FD, 1996, AM J PATHOL, V148, P969; KULPER GGJ, 1996, P NATL ACAD SCI USA, V93, P5925; LINDNER V, 1993, CIRC RES, V73, P792, DOI 10.1161/01.RES.73.5.792; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Moraghan T, 1996, ENDOCRINOLOGY, V137, P5174, DOI 10.1210/en.137.11.5174; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; ORIMO A, 1993, BIOCHEM BIOPH RES CO, V195, P730, DOI 10.1006/bbrc.1993.2106; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; TOUCHETTE N, 1990, J NIH RES, V2, P71; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; WEHLING M, 1995, CIRC RES, V76, P973, DOI 10.1161/01.RES.76.6.973; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; WILLIAMS JK, 1992, J AM COLL CARDIOL, V20, P452, DOI 10.1016/0735-1097(92)90116-5; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975	44	387	399	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					545	548		10.1038/nm0597-545	http://dx.doi.org/10.1038/nm0597-545			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142124				2022-12-25	WOS:A1997WX54300035
J	Harrington, JJ; VanBokkelen, G; Mays, RW; Gustashaw, K; Willard, HF				Harrington, JJ; VanBokkelen, G; Mays, RW; Gustashaw, K; Willard, HF			Formation of de novo centromeres and construction of first-generation human artificial microchromosomes	NATURE GENETICS			English	Article							ALPHA-SATELLITE DNA; YEAST CENTROMERE; CENP-C; DROSOPHILA MINICHROMOSOME; FUNCTIONAL-ANALYSIS; MOLECULAR-CLONING; FISSION YEAST; GENE-TRANSFER; HUMAN-CELLS; CHROMOSOMES	We have combined long synthetic arrays of alpha satellite DNA with telomeric DNA and genomic DNA to generate artificial chromosomes in human HT1080 cells. The resulting linear microchromosomes contain exogenous alpha satellite DNA, are mitotically and cytogenetically stable in the absence of selection for up to six months in culture, bind centromere proteins specific for active centromeres, and are estimated to be 6-10 megabases in size, approximately one-fifth to one-tenth the size of endogenous human chromosomes. We conclude that this strategy results in the formation of de novo centromere activity and that the microchromosomes so generated contain all of the sequence elements required for stable mitotic chromosome segregation and maintenance. This first-generation system for the construction of human artificial chromosomes should be suitable for dissecting the sequence requirements of human centromeres, as well as developing constructs useful for therapeutic applications.	CASE WESTERN RESERVE UNIV,DEPT GENET,SCH MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CTR HUMAN GENET,SCH MED,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106; ATHERSYS INC,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland					NHGRI NIH HHS [HG00107] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; [Anonymous], 1996, B MED ETHICS; BARNETT MA, 1993, NUCLEIC ACIDS RES, V21, P27, DOI 10.1093/nar/21.1.27; BEACH D, 1980, NATURE, V284, P185, DOI 10.1038/284185a0; BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; FEATHERSTONE T, 1993, GENOMICS, V17, P267, DOI 10.1006/geno.1993.1321; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FRIEDMANN T, 1994, GENE THER, V1, P217; GREIG GM, 1992, GENOMICS, V12, P573, DOI 10.1016/0888-7543(92)90450-7; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; HAHN PJ, 1992, GENET ANAL-BIOMOL E, V9, P17, DOI 10.1016/1050-3862(92)90025-Z; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; HOFER BHOFE, 1987, EUR J BIOCHEM, V67, P307; IJDO JW, 1991, NUCLEIC ACIDS RES, V19, P4780, DOI 10.1093/nar/19.17.4780; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; LARIN Z, 1994, HUM MOL GENET, V3, P689, DOI 10.1093/hmg/3.5.689; MACGREGOR GR, 1995, DEVELOPMENT, V121, P1487; MANN C, 1983, P NATL ACAD SCI-BIOL, V80, P228, DOI 10.1073/pnas.80.1.228; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; McGuigan A, 1996, NUCLEIC ACIDS RES, V24, P2271, DOI 10.1093/nar/24.12.2271; MUNZ PL, 1991, VIROLOGY, V183, P160, DOI 10.1016/0042-6822(91)90129-Y; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NEIL DL, 1990, NUCLEIC ACIDS RES, V18, P1421, DOI 10.1093/nar/18.6.1421; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; SADLER JR, 1980, GENE, V8, P279, DOI 10.1016/0378-1119(80)90005-0; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; Sambrook J., 1989, MOL CLONING; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STRAUSS M, 1994, GENE THER, V1, P156; Sullivan B. A., 1996, American Journal of Human Genetics, V59, pA14; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; SUN TQ, 1994, NAT GENET, V8, P33, DOI 10.1038/ng0994-33; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; Taylor SS, 1996, CHROMOSOMA, V105, P70, DOI 10.1007/BF02509516; TYLERSMITH C, 1993, NAT GENET, V5, P368, DOI 10.1038/ng1293-368; TYLERSMITH C, 1993, CURR OPIN GENET DEV, V3, P390, DOI 10.1016/0959-437X(93)90110-B; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156; WEVRICK R, 1989, P NATL ACAD SCI USA, V86, P9394, DOI 10.1073/pnas.86.23.9394; Willard HF, 1996, P NATL ACAD SCI USA, V93, P6847, DOI 10.1073/pnas.93.14.6847; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; WILSON JH, 1982, MOL CELL BIOL, V2, P1258, DOI 10.1128/MCB.2.10.1258; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	63	532	653	0	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	APR	1997	15	4					345	355		10.1038/ng0497-345	http://dx.doi.org/10.1038/ng0497-345			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WQ389	9090378				2022-12-25	WOS:A1997WQ38900011
J	Stricker, NL; Christopherson, KS; Yi, BA; Schatz, PJ; Raab, RW; Dawes, G; Bassett, DE; Bredt, DS; Li, M				Stricker, NL; Christopherson, KS; Yi, BA; Schatz, PJ; Raab, RW; Dawes, G; Bassett, DE; Bredt, DS; Li, M			PDZ domain of neuronal nitric oxide synthase recognizes novel C-terminal peptide sequences	NATURE BIOTECHNOLOGY			English	Article						neurotoxicity; NO; PDZ; peptide display	MESSENGER MOLECULE; PROTEIN; LIBRARIES; BRAIN; LIGANDS	PDZ domains are multifunctional protein-interaction motifs that often bind to the C-terminus of protein targets. Nitric oxide (NO), an endogenous signaling molecule, plays critical roles in nervous, immune, and cardiovascular function. Although there are numerous physiological functions for neuron-derived NO, produced primarily by the neuronal NO synthase (nNOS), excess nNOS activity mediates brain injury in cerebral ischemia and in animal models of Parkinson's disease. Subcellular localization of nNOS activity must therefore be tightly regulated. To determine ligands for the PDZ domain of nNOS, we screened 13 billion distinct peptides and found that the nNOS-PDZ domain binds tightly to peptides ending Asp-X-Val. This differs from the only known (Thr/Ser)-X-Val consensus that interacts with PDZ domains from PSD-95. Preference for Asp at the -2 peptide position is mediated by Tyr-77 of nNOS. A Y77D78 to H(77)E(78) substitution changes the binding specificity from Asp-X-Val to Thr-X-Val. Guided by the Asp-X-Val consensus, candidate nNOS interacting proteins have been identified including glutamate and melatonin receptors. Our results demonstrate that PDZ domains have distinct peptide binding specificity.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL & NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143; AFFYMAX RES INST,DEPT MOL BIOL,PALO ALTO,CA 94304	Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Bassett, Douglas/0000-0002-1619-4618				AOKI C, 1993, BRAIN RES, V620, P97, DOI 10.1016/0006-8993(93)90275-R; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chao DS, 1996, J EXP MED, V184, P609, DOI 10.1084/jem.184.2.609; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RICHARME G, 1982, BIOCHEM BIOPH RES CO, V105, P476, DOI 10.1016/0006-291X(82)91459-0; Schatz PJ, 1996, METHOD ENZYMOL, V267, P171; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SPARKS AB, 1995, METHOD ENZYMOL, V255, P498; VESELY DL, 1981, MOL CELL BIOCHEM, V35, P55, DOI 10.1007/BF02358188; ZHOU SY, 1995, METHOD ENZYMOL, V254, P523	35	207	213	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					336	342		10.1038/nbt0497-336	http://dx.doi.org/10.1038/nbt0497-336			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094134				2022-12-25	WOS:A1997WQ55400033
J	Helmlinger, G; Yuan, F; Dellian, M; Jain, RK				Helmlinger, G; Yuan, F; Dellian, M; Jain, RK			Interstitial pH and pO(2) gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation	NATURE MEDICINE			English	Article							EXTRACELLULAR PH; NONINVASIVE MEASUREMENT; CYTO-TOXICITY; SCID MICE; OXYGEN; CARCINOMA; GROWTH; SPHEROIDS; GLUCOSE; CELLS	The partial pressure of oxygen (pO(2)) and pH play critical roles in tumor biology and therapy. We report here the first combined, high-resolution (less than or equal to 10 mu m) measurements of interstitial pH and pO(2) profiles between adjacent vessels in a human tumor xenograft, using fluorescence ratio imaging and phosphorescence quenching microscopy. We found (1) heterogeneity in shapes of pH and pO(2) profiles; (2) a discordant relation between local pH profiles and corresponding pO(2) profiles, yet a strong correlation between mean pH and pO(2) profiles; (3) no correlation between perivascular pH/pO(2) and nearest vessel blood flow; and (4) well-perfused tumor vessels that were hypoxic and, consequently, large hypoxic areas in the surrounding interstitium. Such multiparameter measurements of the in vivo microenvironment provide unique insights into biological processes in tumors and their response to treatment.			Helmlinger, G (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT RADIAT ONCOL, EDWIN L STEELE LAB, BOSTON, MA 02114 USA.		Jain, Rakesh K/I-1384-2017; Yuan, Fan/A-1287-2011	Jain, Rakesh K/0000-0001-7571-3548; 	NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-56591] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKER H, 1987, CANCER RES, V47, P3504; Brizel DM, 1996, CANCER RES, V56, P941; CASCIARI JJ, 1992, J CELL PHYSIOL, V151, P386, DOI 10.1002/jcp.1041510220; CASCIARI JJ, 1988, CANCER RES, V48, P3905; CHAPLIN DJ, 1987, INT J RADIAT ONCOL, V13, P579, DOI 10.1016/0360-3016(87)90075-7; DALY PF, 1989, CANCER RES, V49, P770; Dellian M, 1996, BRIT J CANCER, V74, P1206, DOI 10.1038/bjc.1996.518; DEWHIRST MW, 1992, RADIAT RES, V130, P171, DOI 10.2307/3578274; ENGIN K, 1994, INT J RADIAT ONCOL, V29, P125, DOI 10.1016/0360-3016(94)90234-8; ENGIN K, 1995, INT J HYPERTHER, V11, P211, DOI 10.3109/02656739509022457; Evans SM, 1996, CANCER RES, V56, P405; Gerweck LE, 1996, CANCER RES, V56, P1194; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; GULLINO PM, 1967, CANCER RES, V27, P1041; GULLINO PM, 1964, CANCER RES, V24, P780; HAWKINS RA, 1988, CANCER METAST REV, V7, P119, DOI 10.1007/BF00046482; Hoeckel Michael, 1993, Radiotherapy and Oncology, V26, P45; JAHDE E, 1989, CANCER RES, V49, P2965; Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079; JAIN RK, 1984, JNCI-J NATL CANCER I, V73, P429, DOI 10.1093/jnci/73.2.429; KARURI AR, 1993, BRIT J CANCER, V68, P1080, DOI 10.1038/bjc.1993.485; Krtolica A, 1996, CANCER RES, V56, P1168; LEUNIG M, 1992, CANCER RES, V52, P6553; LOEFFLER DA, 1992, BRIT J CANCER, V66, P619, DOI 10.1038/bjc.1992.326; MARTIN GR, 1994, CANCER RES, V54, P5670; SCHWICKERT G, 1995, CANCER RES, V55, P4757; Shimizu S, 1996, CANCER RES, V56, P2161; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SKARSGARD LD, 1995, ANTICANCER RES, V15, P219; Song Chang W., 1993, P25; SUIT H, 1995, BLOOD SUBSTITUTES, P187; SUTHERLAND RM, 1986, CANCER RES, V46, P5320; TANNOCK IF, 1989, CANCER RES, V49, P4373; TEICHER BA, 1981, CANCER RES, V41, P73; TORRES IP, 1994, P NATL ACAD SCI USA, V91, P2081, DOI 10.1073/pnas.91.6.2081; TORRES IP, 1993, AM J PHYSIOL, V265, pH1434, DOI 10.1152/ajpheart.1993.265.4.H1434; TURNER GA, 1979, EXPERIENTIA, V35, P1657, DOI 10.1007/BF01953252; VANDERKOOI JM, 1987, J BIOL CHEM, V262, P5476; VAUPEL P, 1989, CANCER RES, V49, P6449; VAUPEL PW, 1981, CANCER RES, V41, P2008; Warburg O., 1931, METABOLISM TUMORS; WARD KA, 1988, INT J HYPERTHER, V4, P223, DOI 10.3109/02656738809051100; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; YOUNG PR, 1992, BIOCHIM BIOPHYS ACTA, V1139, P163, DOI 10.1016/0925-4439(92)90096-6; Zheng L, 1996, AM J PHYSIOL-HEART C, V271, pH365, DOI 10.1152/ajpheart.1996.271.1.H365	47	1244	1294	4	197	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					177	182		10.1038/nm0297-177	http://dx.doi.org/10.1038/nm0297-177			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018236				2022-12-25	WOS:A1997WF08800036
J	Li, QY; NewburyEcob, RA; Terrett, JA; Wilson, DI; Curtis, ARJ; Yi, CH; Gebuhr, T; Bullen, PJ; Robson, SC; Strachan, T; Bonnet, D; Lyonnet, S; Young, ID; Raeburn, JA; Buckler, AJ; Law, DJ; Brook, JD				Li, QY; NewburyEcob, RA; Terrett, JA; Wilson, DI; Curtis, ARJ; Yi, CH; Gebuhr, T; Bullen, PJ; Robson, SC; Strachan, T; Bonnet, D; Lyonnet, S; Young, ID; Raeburn, JA; Buckler, AJ; Law, DJ; Brook, JD			Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family	NATURE GENETICS			English	Article							CONSERVED PROTEIN MOTIF; HEART-HAND SYNDROME; MESODERM FORMATION; DROSOPHILA-MELANOGASTER; INSITU HYBRIDIZATION; WAARDENBURG SYNDROME; MOUSE BRACHYURY; OPTOMOTOR-BLIND; GRAM SYNDROME; SYNDROME MAPS	Holt-Gram syndrome is a developmental disorder affecting the heart and upper limb, the gene for which was mapped to chromosome 12 two years ago. We have now identified a gene for this disorder (HOS1). The gene (TBX5) is a member of the Brachyury (T) family corresponding to the mouse Tbx5 gene. We have identified six mutations, three in HOS families and three in sporadic HOS cases. Each of the mutations introduces a premature stop codon in the TBX5 gene product. Tissue in situ hybridization studies on human embryos from days 26 to 52 of gestation reveal expression of TBX5 in heart and limb. consistent with a role in human embryonic development.	UNIV NOTTINGHAM, QUEENS MED CTR, SCH MED, DEPT GENET, NOTTINGHAM NG7 2UH, ENGLAND; UNIV NOTTINGHAM, CITY HOSP, NHS TRUST, CTR GENET MED, NOTTINGHAM NG5 1PB, ENGLAND; ROYAL HOSP SICK CHILDREN, DEPT CLIN GENET, BRISTOL BS2 8JJ, AVON, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT HUMAN GENET, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT FETAL MED, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; HOP NECKER ENFANTS MALAD, DEPT PEDIAT, INSERM U393, F-75743 PARIS, FRANCE; MASSACHUSETTS GEN HOSP, DEPT NEUROGENET, CHARLESTOWN, MA USA	University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Bristol Royal Hospital For Children; Newcastle University - UK; Newcastle University - UK; University of Michigan System; University of Michigan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Harvard University; Massachusetts General Hospital			Lyonnet, Stanislas/H-5483-2017; Wilson, David/A-6264-2010	Lyonnet, Stanislas/0000-0001-5426-9417; Wilson, David/0000-0001-8779-2060; Brook, John David/0000-0002-5946-6740	NHGRI NIH HHS [HG00209] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AGULNIK SI, 1995, GENOMICS, V25, P214, DOI 10.1016/0888-7543(95)80128-9; Agulnik SI, 1996, GENETICS, V144, P249; ARMOUR JAL, 1994, HUM MOL GENET, V3, P599, DOI 10.1093/hmg/3.4.599; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BAMSHAD M, 1995, HUM MOL GENET, V4, P1973, DOI 10.1093/hmg/4.10.1973; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Bellus GA, 1996, NAT GENET, V14, P174, DOI 10.1038/ng1096-174; BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; BONNET D, 1994, NAT GENET, V6, P405, DOI 10.1038/ng0494-405; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; Burn J, 1996, CURR OPIN GENET DEV, V6, P322, DOI 10.1016/S0959-437X(96)80009-8; CAMPBELL C, 1995, GENOMICS, V28, P255, DOI 10.1006/geno.1995.1139; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; DELAFUENTE SR, 1980, HUM GENET, V55, P43; Dixon J, 1996, NAT GENET, V12, P130; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; Edwards YH, 1996, GENOME RES, V6, P226, DOI 10.1101/gr.6.3.226; ELREFAEY H, 1995, NEW ENGL J MED, V332, P983, DOI 10.1056/NEJM199504133321502; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; FRIEDMAN WF, 1992, HEART DIS TXB CARDIO, V2, P865; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HOLT M, 1960, BRIT HEART J, V22, P236; HURST JA, 1991, J MED GENET, V28, P406, DOI 10.1136/jmg.28.6.406; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JAMIESON CR, 1994, NAT GENET, V8, P357, DOI 10.1038/ng1294-357; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Larsen WJ, 1993, HUMAN EMBRYOLOGY, P479; LAW DJ, 1995, MAMM GENOME, V6, P793, DOI 10.1007/BF00539006; Li QY, 1996, GENOMICS, V32, P218, DOI 10.1006/geno.1996.0108; LI QY, 1988, CHINESE J PLANT PATH, V18, P225; Lyons GE, 1996, CURR OPIN GENET DEV, V6, P454, DOI 10.1016/S0959-437X(96)80067-0; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; Morrison K, 1996, HUM MOL GENET, V5, P669, DOI 10.1093/hmg/5.5.669; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NewburyEcob RA, 1996, J MED GENET, V33, P300, DOI 10.1136/jmg.33.4.300; Notenboom RGE, 1996, DEVELOPMENT, V122, P321; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; PASTERIS NG, 1994, CELL, V79, P669; PFLUGFELDER GO, 1990, GENETICS, V126, P91; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; PFLUGFELDER GO, 1992, P NATL ACAD SCI USA, V89, P1199, DOI 10.1073/pnas.89.4.1199; PYERITZ RE, 1992, HEART DIS TXB CARDIO, V2, P1622; REARDON W, 1994, NAT GENET, V8, P95; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SILENGO MC, 1990, CLIN GENET, V38, P105; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOOTHILL PW, 1994, LANCET, V343, P1096, DOI 10.1016/S0140-6736(94)90205-4; STOTTLER CJ, 1995, AM J HUM GENET SA56, V57; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; SWAROOP A, 1993, CYTOGENET CELL GENET, V64, P292, DOI 10.1159/000133595; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TEMTAMY S, 1978, BIRTH DEFECTS, V14, P241; TERRETT JA, 1994, NAT GENET, V6, P401, DOI 10.1038/ng0494-401; TERRETT JA, 1995, AM J HUM GENET, V59, P1337; THIERFELDER L, 1995, CURRENT PROTOCOLS HU, V2; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VERMA RS, 1989, HUMAN CHROMOSOMES MA; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WARREN W, 1995, CURRENT PROTOCOLS HU, V2; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WILLISON K, 1990, TRENDS GENET, V6, P104, DOI 10.1016/0168-9525(90)90106-G; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOLPERT L, 1994, SCIENCE, V266, P571, DOI 10.1126/science.7939707	86	674	691	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1997	15	1					21	29						9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988164				2022-12-25	WOS:A1997WA37300016
J	Basile, AS; Huang, JM; Xie, C; Webster, D; Berlin, C; Skolnick, P				Basile, AS; Huang, JM; Xie, C; Webster, D; Berlin, C; Skolnick, P			N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss	NATURE MEDICINE			English	Article							NMDA-ANTAGONIST; OTOTOXIC DRUGS; RECEPTOR; COCHLEA; IFENPRODIL; EPILEPSY; NEURONS; SITE; CPP	The use of aminoglycoside antibiotics is limited by ototoxicity that can produce permanent hearing loss. We report that concurrent administration of N-methyl-D-aspartate (NMDA) antagonists markedly attenuates both the hearing loss and destruction of cochlear hair cells in guinea pigs treated with aminoglycoside antibiotics. These findings indicate that aminoglycoside-induced hearing loss is mediated, in part, through an excitotoxic process. The high correlation (Spearman correlation coefficient: 0.928; P < 0.01) obtained between the relative cochleotoxicities of a series of aminoglycosides in humans and the potencies of these compounds to produce a polyamine-like enhancement of [H-3]dizocilpine binding to NMDA receptors is consistent with this hypothesis, and provides a simple in vitro assay that can predict this aspect of aminoglycoside-induced ototoxicity.	LOUISIANA STATE UNIV,KRESGE HEARING RES INST S,DEPT OTORHINOLARYNGOL & BIOCOMMUN,NEW ORLEANS,LA 70112	Louisiana State University System	Basile, AS (corresponding author), NIDDKD,NEUROSCI LAB,NIH,BETHESDA,MD 20892, USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000007] Funding Source: NIH RePORTER; NIDCD NIH HHS [T32-DC-0007] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Akiyoshi M, 1976, Jpn J Antibiot, V29, P771; BAMONTE F, 1980, ARCH OTO-RHINO-LARYN, V228, P163, DOI 10.1007/BF00454224; BEGG EJ, 1995, BRIT J CLIN PHARMACO, V39, P597; BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; BROWN AM, 1989, HEARING RES, V42, P143, DOI 10.1016/0378-5955(89)90140-8; BRUMMETT RE, 1990, ARCH OTOLARYNGOL, V116, P406; BRUMMETT RE, 1978, J ANTIMICROB CHEMOTH, V4, P73, DOI 10.1093/jac/4.suppl_A.73; CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHERKOFSKY SC, 1995, J PHARM SCI, V85, P1231; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DESROCHERS CS, 1982, ACTA OTO-LARYNGOL, V93, P233, DOI 10.3109/00016488209130877; Ernfors P, 1996, NAT MED, V2, P463, DOI 10.1038/nm0496-463; EYBALIN M, 1993, PHYSIOL REV, V73, P309, DOI 10.1152/physrev.1993.73.2.309; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; HASHIMOTO K, 1994, EUR J PHARM-MOLEC PH, V266, P67, DOI 10.1016/0922-4106(94)90211-9; HENLEY CM, 1995, BRAIN RES REV, V20, P68, DOI 10.1016/0165-0173(94)00006-B; HODGES GR, 1984, AMINOGLYCOSIDE ANTIB, P153; HUANG JM, 1995, HEARING RES, V88, P61, DOI 10.1016/0378-5955(95)00099-P; KIANG NYS, 1976, ANN OTO RHINOL LARYN, V85, P752, DOI 10.1177/000348947608500605; LENOIR M, 1984, HEARING RES, V13, P123, DOI 10.1016/0378-5955(84)90103-5; LIM DJ, 1986, AM J OTOLARYNG, V7, P73, DOI 10.1016/S0196-0709(86)80037-0; LOSCHER W, 1988, EUR J PHARMACOL, V152, P9, DOI 10.1016/0014-2999(88)90830-8; OLIVEIRA JAA, 1989, AUDIOVESTIBULAR TOXI, P223; OLIVEIRA JAA, 1989, AUDIOVESTIBULAR TOXI, P71; PATAT A, 1994, INT CLIN PSYCHOPHARM, V9, P155, DOI 10.1097/00004850-199409000-00003; PUEL JL, 1991, HEARING RES, V51, P255, DOI 10.1016/0378-5955(91)90042-8; PULLAN LM, 1992, J NEUROCHEM, V59, P2087; Revai Katalin, 1995, Orvosi Hetilap, V136, P2615; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; ROMANO C, 1994, NEUROPHARMACOLOGY PO, P81; SAFIEDDINE S, 1992, NEUROREPORT, V3, P1145, DOI 10.1097/00001756-199212000-00029; SCATTON B, 1994, DIRECT ALLOSTERIC CO, P139; SCHACHT J, 1993, OTOLARYNG CLIN N AM, V26, P845; Stringer SP, 1991, OTOLARYNGOLOGY, P1653; SVEINBJORNSDOTTIR S, 1993, EPILEPSY RES, V16, P165, DOI 10.1016/0920-1211(93)90031-2; USAMI S, 1995, NEUROREPORT, V6, P1161, DOI 10.1097/00001756-199505300-00022; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	39	122	129	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1338	1343		10.1038/nm1296-1338	http://dx.doi.org/10.1038/nm1296-1338			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946832				2022-12-25	WOS:A1996VW51500039
J	Strand, S; Hofmann, WJ; Hug, H; Muller, M; Otto, G; Strand, D; Mariani, SM; Stremmel, W; Krammer, PH; Galle, PR				Strand, S; Hofmann, WJ; Hug, H; Muller, M; Otto, G; Strand, D; Mariani, SM; Stremmel, W; Krammer, PH; Galle, PR			Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?	NATURE MEDICINE			English	Article							MEDIATED CYTOTOXICITY; T-CELL; MONOCLONAL-ANTIBODY; FAS; INDUCTION; PERFORIN; CARCINOMA; PATHWAYS; ANTIGEN; MICE	The CD95 (APO-1/Fas) system is an important mediator of T-cell cytotoxicity. We investigated this system in 22 hepatocellular carcinomas (HCCs) from patients. All HCCs had partially or completely lost the expression of the CD95 receptor constitutively expressed by normal liver cells and might thus evade CD95-mediated killing. We also considered a new mechanism of immune evasion, namely, the active destruction of T-lymphocytes by tumor cells expressing CD95 ligand (CD95L). CD95L messenger RNA and protein could be detected in the HCCs. In coculture experiments, HepG2 hepatoblastoma cells, expressing CD95L mRNA after treatment with cytostatic drugs, killed CD95(+) jurkat lymphocytes. Our data suggest that tumor cells can evade immune attack by downregulation of the CD95 receptor and killing of lymphocytes through expression of CD95L.	UNIV HEIDELBERG HOSP,DEPT GASTROENTEROL,D-69115 HEIDELBERG,GERMANY; UNIV HEIDELBERG,INST PATHOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,ZMBH,CTR MOL BIOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG HOSP,DEPT SURG,D-69120 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAMME,D-69120 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,DEPT DEV GENET,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)			Galle, Peter R/T-5292-2018	Galle, Peter R/0000-0001-8294-0992; Stremmel, Wolfgang/0000-0002-8545-1753				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; APASOV S, 1993, CURR OPIN IMMUNOL, V5, P404, DOI 10.1016/0952-7915(93)90060-6; Badley AD, 1996, J VIROL, V70, P199, DOI 10.1128/JVI.70.1.199-206.1996; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; DHEIN J, 1992, J IMMUNOL, V149, P3166; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GALLE PR, 1995, J EXP MED, V182, P223; GILETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STALDER T, 1994, J IMMUNOL, V152, P1127; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; VOLKMANN M, 1994, ONCOGENE, V9, P195; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0	30	850	878	0	41	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1361	1366		10.1038/nm1296-1361	http://dx.doi.org/10.1038/nm1296-1361			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946836				2022-12-25	WOS:A1996VW51500043
J	Hamdy, S; Aziz, Q; Rothwell, JC; Singh, KD; Barlow, J; Hughes, DG; Tallis, RC; Thompson, DG				Hamdy, S; Aziz, Q; Rothwell, JC; Singh, KD; Barlow, J; Hughes, DG; Tallis, RC; Thompson, DG			The cortical topography of human swallowing musculature in health and disease	NATURE MEDICINE			English	Article							MAGNETIC STIMULATION; MOTOR CORTEX; DYSPHAGIA; STROKE; ORGANIZATION; MONKEY; BRAIN	Because no detailed information exists regarding the topographic representation of swallowing musculature on the human cerebral cortex in health or disease, we used transcranial magnetic stimulation to study the cortical topography of human oral, pharyngeal and esophageal musculature in 20 healthy individuals and the topography of pharyngeal musculature in two stroke patients, one with and one without dysphagia. Our results demonstrate that swallowing musculature is discretely and somatotopically represented on the motor and premotor cortex of both hemispheres but displays interhemispheric asymmetry, independent of handedness. Following stroke, dysphagia appeared to be associated with smaller pharyngeal representation on the intact hemisphere, which increases in size with recovery of swallowing.	UNIV MANCHESTER, HOPE HOSP, DEPT GASTROENTEROL, MANCHESTER M6 8HD, LANCS, ENGLAND; UNIV MANCHESTER, HOPE HOSP, DEPT NEURORADIOL, MANCHESTER M6 8HD, LANCS, ENGLAND; UNIV MANCHESTER, HOPE HOSP, DEPT GERIATR MED, MANCHESTER M6 8HD, LANCS, ENGLAND; INST NEUROL, MRC, HUMAN MOVEMENT & BALANCE UNIT, LONDON WC1N 3BG, ENGLAND; ASTON UNIV, DEPT VIS SCI, BIRMINGHAM B4 7ET, W MIDLANDS, ENGLAND	University of Manchester; University of Manchester; University of Manchester; University of London; University College London; Aston University			Singh, Krish/D-1066-2009; Hamdy, Shaheen/O-5039-2014; Aziz, Qasim/AAC-4730-2020	Hamdy, Shaheen/0000-0001-9640-7427; Rothwell, John/0000-0003-1367-6467; Singh, Krishna/0000-0002-3094-2475; Aziz, Qasim/0000-0002-2718-2065				ALBERTS M J, 1992, Dysphagia, V7, P170, DOI 10.1007/BF02493452; AZIZ Q, 1995, GASTROENTEROLOGY, V109, P1437, DOI 10.1016/0016-5085(95)90628-2; AZIZ Q, 1994, AM J PHYSIOL-GASTR L, V267, pG827, DOI 10.1152/ajpgi.1994.267.5.G827; BARER DH, 1989, J NEUROL NEUROSUR PS, V52, P236, DOI 10.1136/jnnp.52.2.236; BARKER AT, 1985, LANCET, V1, P1106; BASTIAN HC, 1898, TREATISE APHASIA OTH, P87; BISHOP DVM, 1990, HANDEDNESS DEV DISOR, P27; BRADSHAW JL, 1983, HUMAN CEREBRAL ASYMM, P21; BRIDGERS SL, 1991, ELECTROEN CLIN NEURO, P170; DOTY RW, 1956, J NEUROPHYSIOL, V19, P44, DOI 10.1152/jn.1956.19.1.44; GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; HAST MH, 1974, BRAIN RES, V73, P229, DOI 10.1016/0006-8993(74)91046-4; JALINOUS R, 1991, J CLIN NEUROPHYSIOL, V8, P10, DOI 10.1097/00004691-199101000-00004; Jean A., 1990, NEUROPHYSIOLOGY JAWS, P294; JOHNSON ER, 1992, ARCH PHYS MED REHAB, V73, P419; LEVY WJ, 1991, ELECTROEN CLIN NEURO, P51; Martin Ruth E., 1993, Dysphagia, V8, P195, DOI 10.1007/BF01354538; MCGUINNESS E, 1980, J COMP NEUROL, V193, P591, DOI 10.1002/cne.901930302; MEADOWS JC, 1973, J NEUROL NEUROSUR PS, V36, P853, DOI 10.1136/jnnp.36.5.853; *MED RES COUNC, 1976, AIDS EX PER NERV SYS, P6; MESULAM MM, 1982, J COMP NEUROL, V212, P38, DOI 10.1002/cne.902120104; MILLER AJ, 1977, J DENT RES, V56, P1154, DOI 10.1177/00220345770560100401; MUFSON EJ, 1981, NEUROSCIENCE, V6, P1231, DOI 10.1016/0306-4522(81)90184-6; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Robbins J, 1988, Dysphagia, V3, P11, DOI 10.1007/BF02406275; SATZ P, 1979, SCIENCE, V203, P1131, DOI 10.1126/science.424744; SHIPLEY MT, 1982, BRAIN RES BULL, V8, P139, DOI 10.1016/0361-9230(82)90040-5; SUMI T, 1969, BRAIN RES, V15, P107, DOI 10.1016/0006-8993(69)90313-8; WANG XB, 1994, J PHYS-CONDENS MAT, V6, P10185, DOI 10.1088/0953-8984/6/46/034; WOOLSEY CN, 1979, J NEUROSURG, V51, P476, DOI 10.3171/jns.1979.51.4.0476; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238	32	321	349	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1217	1224		10.1038/nm1196-1217	http://dx.doi.org/10.1038/nm1196-1217			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898748				2022-12-25	WOS:A1996VQ10100036
J	Sanpei, K; Takano, H; Igarashi, S; Sato, T; Oyake, M; Sasaki, H; Wakisaka, A; Tashiro, K; Ishida, Y; Ikeuchi, T; Koide, R; Saito, M; Sato, A; Tanaka, T; Hanyu, S; Takiyama, Y; Nishizawa, M; Shimizu, N; Nomura, Y; Segawa, M; Iwabuchi, K; Eguchi, I; Tanaka, H; Takahashi, H; Tsuji, S				Sanpei, K; Takano, H; Igarashi, S; Sato, T; Oyake, M; Sasaki, H; Wakisaka, A; Tashiro, K; Ishida, Y; Ikeuchi, T; Koide, R; Saito, M; Sato, A; Tanaka, T; Hanyu, S; Takiyama, Y; Nishizawa, M; Shimizu, N; Nomura, Y; Segawa, M; Iwabuchi, K; Eguchi, I; Tanaka, H; Takahashi, H; Tsuji, S			Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT	NATURE GENETICS			English	Article							DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DOMINANT CEREBELLAR-ATAXIA; CAG REPEAT; DISEASE; DNA; TRINUCLEOTIDE; ANTICIPATION; HYBRIDIZATION; AMPLIFICATION; HETEROGENEITY	Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant, neurodegenerative disorder that affects the cerebellum and other areas of the central nervous system. We have devised a novel strategy, the direct identification of repeat expansion and cloning technique (DIRECT), which allows selective detection of expanded CAG repeats and cloning of the genes involved. By applying DIRECT, we identified an expanded CAG repeat Of the gene for SCA2. CAG repeats of normal alleles range in size from 15 to 24 repeat units, while those of SCA2 chromosomes are expanded to 35 to 59 repeat units. The SCA2 cDNA is predicted to code for 1,313 amino acids - with the CAG repeats coding for a polyglutamine tract. DIRECT is a robust strategy for identification of pathologically expanded trinucleotide repeats and will dramatically accelerate the search for causative genes of neuropsychiatric diseases caused by trinucleotide repeat expansions.	NIIGATA UNIV,BRAIN RES INST,DEPT NEUROL,NIIGATA 951,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT PATHOL,NIIGATA 951,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT PATHOL 1,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; NIIGATA UNIV,SCH MED,DEPT PSYCHIAT,NIIGATA 951,JAPAN; JICHI MED SCH,DEPT NEUROL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; TEIKYO UNIV,SCH MED,ICHIHARA HOSP,DEPT NEUROL,ICHIHARA 29901,JAPAN; SEGAWA NEUROL CLIN CHILDREN,CHIYODA KU,TOKYO 101,JAPAN; KANAGAWA REHABIL CTR,DEPT NEUROL & PSYCHIAT,ATSUGI,KANAGAWA 24301,JAPAN	Niigata University; Niigata University; Hokkaido University; Niigata University; Jichi Medical University; Teikyo University				Sato, Toshiya/0000-0001-7844-9930				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASSETT AS, 1994, AM J HUM GENET, V54, P864; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GOUW LG, 1994, NEUROLOGY, V44, P1441, DOI 10.1212/WNL.44.8.1441; IHARA T, 1994, JPN J HUM GENET, V39, P305, DOI 10.1007/BF01874049; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MCINNIS MG, 1993, AM J HUM GENET, V53, P385; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ONODERA O, 1995, AM J HUM GENET, V57, P1050; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PULST SM, 1993, NAT GENET, V5, P8, DOI 10.1038/ng0993-8c; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; RANUM LPW, 1994, NAT GENET, V8, P280, DOI 10.1038/ng1194-280; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANPEI K, 1995, BIOCHEM BIOPH RES CO, V212, P341, DOI 10.1006/bbrc.1995.1975; SCHALLING M, 1993, NAT GENET, V4, P135, DOI 10.1038/ng0693-135; Takano H, 1996, AM J HUM GENET, V58, P1212; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; 1993, CELL, V72, P971	37	624	643	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					277	284		10.1038/ng1196-277	http://dx.doi.org/10.1038/ng1196-277			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896556				2022-12-25	WOS:A1996VQ14600021
J	daSilva, SM; Hacker, A; Harley, V; Goodfellow, P; Swain, A; LovellBadge, R				daSilva, SM; Hacker, A; Harley, V; Goodfellow, P; Swain, A; LovellBadge, R			Sox9 expression during gonadal development implies a conserved role for the gene in testis differentiation in mammals and birds	NATURE GENETICS			English	Article							AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; INHIBITING SUBSTANCE GENE; DETERMINING REGION; Y-CHROMOSOME; CAMPOMELIC DYSPLASIA; FEMALE MICE; NUCLEAR RECEPTOR; FETAL MOUSE; XY	Heterozygous mutations in SOX9 lead to a human dwarfism syndrome, Campomelic dysplasia. Consistent with a role in sex determination, we find that Sox9 expression closely follows differentiation of Sertoli cells in the mouse testis, in experimental sex reversal when fetal ovaries are grafted to adult kidneys and in the chick where there is no evidence for a Sry gene. Our results imply that Sox9 plays an essential role in sex determination, possibly immediately downstream of Sry in mammals, and that it functions as a critical Sertoli cell differentiation factor, perhaps in all vertebrates.	NATL INST MED RES, MRC, DIV DEV GENET, LONDON NW7 1AA, ENGLAND; UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE CB2 3EH, ENGLAND	MRC National Institute for Medical Research; University of Cambridge			Harley, Vincent/B-8092-2018	Harley, Vincent/0000-0002-2405-1262; Swain, Amanda/0000-0001-8666-1608; Morais da Silva, Sara/0000-0001-8337-9893; Lovell-Badge, Robin/0000-0001-9364-4179	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; Behringer RR, 1995, PHILOS T ROY SOC B, V350, P285, DOI 10.1098/rstb.1995.0163; BERKOVITZ GD, 1992, HUM GENET, V88, P411, DOI 10.1007/BF00215675; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BUEHR M, 1993, DEVELOPMENT, V117, P273; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLINTON M, 1994, ANIM GENET, V25, P361, DOI 10.1111/j.1365-2052.1994.tb00374.x; Collignon J, 1996, DEVELOPMENT, V122, P509; CORIAT AM, 1994, J EXP ZOOL, V270, P112, DOI 10.1002/jez.1402700112; DRESSER WD, 1995, HUM MOL GENET, V4, P1513; ELBRECHT A, 1992, SCIENCE, V255, P467, DOI 10.1126/science.1734525; Eusebe DC, 1996, J BIOL CHEM, V271, P4798, DOI 10.1074/jbc.271.9.4798; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; Graves JAM, 1995, PHILOS T R SOC B, V350, P305, DOI 10.1098/rstb.1995.0166; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Harlow E., 1988, ANTIBODIES LAB MANUA; HOUSTON CS, 1983, AM J MED GENET, V15, P3, DOI 10.1002/ajmg.1320150103; HUNT PA, 1991, CHROMOSOMA, V100, P293, DOI 10.1007/BF00360527; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Johnston CM, 1995, PHILOS T R SOC B, V350, P297, DOI 10.1098/rstb.1995.0165; JOST A, 1972, J REPROD FERTIL, V29, P349, DOI 10.1530/jrf.0.0290349; JUST W, 1995, NAT GENET, V11, P117, DOI 10.1038/ng1095-117; Karl J, 1995, PHILOS T ROY SOC B, V350, P235, DOI 10.1098/rstb.1995.0157; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KRISHAN A, 1965, CHROMOSOMA, V17, P258; KWOK C, 1995, AM J HUM GENET, V57, P1028; LANOS HM, 1993, INT J DEV BIOL; LAVAL SH, 1995, P NATL ACAD SCI USA, V92, P10403, DOI 10.1073/pnas.92.22.10403; LovellBadge R, 1995, PHILOS T R SOC B, V350, P205, DOI 10.1098/rstb.1995.0153; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MAHADEVAIAH SK, 1993, J REPROD FERTIL, V97, P151, DOI 10.1530/jrf.0.0970151; MCELREAVEY K, 1993, EUR J BIOCHEM, V218, P769, DOI 10.1111/j.1432-1033.1993.tb18432.x; McLaren A, 1995, PHILOS T R SOC B, V350, P229, DOI 10.1098/rstb.1995.0156; MEYERSWALLEN VN, 1995, J HERED, V86, P369, DOI 10.1093/oxfordjournals.jhered.a111605; OHNO S, 1960, EXP CELL RES, V19, P180, DOI 10.1016/0014-4827(60)90048-3; PALMER SJ, 1991, DEVELOPMENT, V112, P265; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; TAKETO T, 1986, PROGR DEV BIOL A, P171; TAKETOHOSOTANI T, 1985, J EXP ZOOL, V236, P229, DOI 10.1002/jez.1402360213; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VIGIER B, 1987, DEVELOPMENT, V100, P43; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	58	642	649	1	28	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1996	14	1					62	68		10.1038/ng0996-62	http://dx.doi.org/10.1038/ng0996-62			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782821				2022-12-25	WOS:A1996VF61100022
J	Kuhl, PR; GriffithCima, LG				Kuhl, PR; GriffithCima, LG			Tethered epidermal growth factor as a paradigm for growth factor-induced stimulation from the solid phase	NATURE MEDICINE			English	Article							FACTOR RECEPTOR; TYROSINE KINASE; RAT HEPATOCYTES; CELLS; MITOGENESIS; CULTURE; ADULT; INTERNALIZATION; TRANSIENT; BINDING	We have tethered epidermal growth factor (EGF) to a solid substrate in a manner permitting the factor to retain its biological activity as assessed by both mitogenic and morphological assays. Mouse EGF was covalently coupled to aminosilane-modified glass via star poly(ethylene oxide) (PEG), which allows the ligand to retain significant mobility and active conformation. Tethered EGF was as effective as soluble EGF in eliciting DNA synthesis and cell rounding responses of primary rat hepatocytes under different surface conditions. In contrast, physically adsorbed EGF at comparable surface concentrations showed no activity. Presentation of growth factors in this manner may help to expedite their clinical use by permitting greater control of temporal and spatial availability in the extracellular environment.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; MIT,CTR BIOMED ENGN,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)				Griffith, Linda/0000-0002-1801-5548	NIGMS NIH HHS [GM 50047] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050047] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHARONOV A, 1978, J BIOL CHEM, V253, P3970; ALLGOR SS, 1996, THESIS MIT; BLANC P, 1992, GASTROENTEROLOGY, V102, P1340; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CIMA LG, 1991, BIOTECHNOL BIOENG, V38, P145, DOI 10.1002/bit.260380207; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; GLADHAUG IP, 1987, EUR J BIOCHEM, V164, P267, DOI 10.1111/j.1432-1033.1987.tb11054.x; KNAUER DJ, 1984, J BIOL CHEM, V269, P5623; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LAWRENCE WT, 1994, CLIN DERMATOL, V12, P157, DOI 10.1016/0738-081X(94)90266-6; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; Lopina ST, 1996, BIOMATERIALS, V17, P559, DOI 10.1016/0142-9612(96)88706-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTI U, 1989, HEPATOLOGY, V9, P126, DOI 10.1002/hep.1840090122; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; MEYERINGOLD W, 1993, TRENDS BIOTECHNOL, V11, P387, DOI 10.1016/0167-7799(93)90098-T; MORIARITY DM, 1980, ARCH BIOCHEM BIOPHYS, V203, P506, DOI 10.1016/0003-9861(80)90208-8; PIERCE GF, 1995, ANNU REV MED, V46, P467; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; SCHAUDIES RP, 1985, J CELL PHYSIOL, V124, P493, DOI 10.1002/jcp.1041240320; SMITH KA, 1988, INTERLEUKIN, V2, P1; STENGER DA, 1992, J AM CHEM SOC, V114, P8435, DOI 10.1021/ja00048a013; STOLZ DB, 1994, J CELL BIOCHEM, V55, P445, DOI 10.1002/jcb.240550405; TOMOMURA A, 1987, J CELL PHYSIOL, V130, P221, DOI 10.1002/jcp.1041300208; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; WILEY HS, 1989, J BIOL CHEM, V264, P912	28	260	269	0	26	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1022	1027		10.1038/nm0996-1022	http://dx.doi.org/10.1038/nm0996-1022			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782461				2022-12-25	WOS:A1996VF49700038
J	Plass, C; Shibata, H; Kalcheva, I; Mullins, L; Kotelevtseva, N; Mullins, J; Kato, R; Sasaki, H; Hirotsune, S; Okazaki, Y; Held, WA; Hayashizaki, Y; Chapman, VM				Plass, C; Shibata, H; Kalcheva, I; Mullins, L; Kotelevtseva, N; Mullins, J; Kato, R; Sasaki, H; Hirotsune, S; Okazaki, Y; Held, WA; Hayashizaki, Y; Chapman, VM			Identification of Grf1 on mouse chromosome 9 as an imprinted gene by RLGS-M	NATURE GENETICS			English	Letter							DNA METHYLATION; SCANNING METHOD; REGION; EXPRESSION; GENOMES; GROWTH; MICE; LOCI		INST PHYS & CHEM RES,RIKEN,GENOME SCI LAB,TSUKUBA,IBARAKI 305,JAPAN; UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; KYUSHU UNIV,INST GENET INFORMAT,HIGASHI KU,FUKUOKA 812,JAPAN	RIKEN; University of Edinburgh; Kyushu University	Plass, C (corresponding author), ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,ELM & CARLTON ST,BUFFALO,NY 14263, USA.		Hayashizaki, Yoshihide/N-6590-2015; Plass, Christoph/H-7192-2014	Mullins, Linda/0000-0002-6743-8707	NATIONAL CANCER INSTITUTE [R01CA068612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051881, R01GM033160] Funding Source: NIH RePORTER; NCI NIH HHS [CA68612-01] Funding Source: Medline; NIGMS NIH HHS [GM33160-13, GM51881-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Beechey C. V., 1996, Mammalian Genome, V94, P96; Beechey C. V., 1993, Mouse Genome, V91, P102; CATTANACH BM, 1986, J EMBRYOL EXP MORPH, V97, P137; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ECKERT WA, 1991, MOL CELL BIOL, V11, P2229, DOI 10.1128/MCB.11.4.2229; FEIL R, 1994, DEVELOPMENT, V120, P2933; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GARIBOLDI M, 1994, GENOMICS, V21, P451, DOI 10.1006/geno.1994.1295; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HAYASHIZAKI Y, 1993, ELECTROPHORESIS, V14, P251, DOI 10.1002/elps.1150140145; HAYASHIZAKI Y, 1992, GENOMICS, V14, P733, DOI 10.1016/S0888-7543(05)80176-4; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; HIROTSUNE S, 1993, BIOCHEM BIOPH RES CO, V194, P1406, DOI 10.1006/bbrc.1993.1981; KALCHEVA I, 1995, CYTOGENET CELL GENET, V68, P19, DOI 10.1159/000133881; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; PIERCE JC, 1992, METHOD ENZYMOL, V216, P549; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SHIBATA H, 1995, ELECTROPHORESIS, V16, P210, DOI 10.1002/elps.1150160136; SHIBATA H, 1994, MAMM GENOME, V5, P797, DOI 10.1007/BF00292016; SOLTER D, 1988, ANNU REV GENET, V22, P127; Stoeger R., 1993, Cell, V73, P61; VILLAR AJ, 1994, NAT GENET, V8, P373, DOI 10.1038/ng1294-373; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0	30	162	169	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					106	109		10.1038/ng0996-106	http://dx.doi.org/10.1038/ng0996-106			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782830				2022-12-25	WOS:A1996VF61100031
J	Remmers, EF; Longman, RE; Du, Y; OHare, A; Cannon, GW; Griffiths, MM; Wilder, RL				Remmers, EF; Longman, RE; Du, Y; OHare, A; Cannon, GW; Griffiths, MM; Wilder, RL			A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats	NATURE GENETICS			English	Letter							RHEUMATOID-ARTHRITIS; EXPERIMENTAL-MODEL; IMMUNE-RESPONSE; II COLLAGEN; DISEASE-SUSCEPTIBILITY; IMMUNOGENETIC CONTROL; AUTOIMMUNE-DISEASES; GENETIC DISSECTION; MOUSE CHROMOSOME-6; BB RAT		UNIV UTAH, VET AFFAIRS MED CTR, RES SERV, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT MED RHEUMATOL, SALT LAKE CITY, UT 84132 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Remmers, EF (corresponding author), NIAMSD, INFLAMMATORY JOINT DIS SECT, ARTHRIT & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA.			Remmers, Elaine F/0000-0002-9522-1249				BAKER D, 1995, J IMMUNOL, V155, P4046; DALLASPEDRETTI A, 1995, P NATL ACAD SCI USA, V92, P1386, DOI 10.1073/pnas.92.5.1386; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; Griffiths M M, 1988, Int Rev Immunol, V4, P1, DOI 10.3109/08830188809044766; GRIFFITHS MM, 1984, J IMMUNOL, V133, P3043; GRIFFITHS MM, 1992, J IMMUNOL, V149, P309; GRIFFITHS MM, 1981, ARTHRITIS RHEUM, V24, P781, DOI 10.1002/art.1780240605; GRIFFITHS MM, 1981, J IMMUNOGENET, V8, P463; GRIFFITHS MM, 1984, J IMMUNOL, V132, P2830; HOLMDAHL R, 1989, APMIS, V97, P575, DOI 10.1111/j.1699-0463.1989.tb00446.x; JACOB HJ, 1992, NAT GENET, V2, P56, DOI 10.1038/ng0992-56; KONO DH, 1994, P NATL ACAD SCI USA, V91, P10168, DOI 10.1073/pnas.91.21.10168; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LINCOLN SE, 1992, GENOMICS, V14, P604, DOI 10.1016/S0888-7543(05)80158-2; McCarty DJ, 1993, ARTHRITIS ALLIED CON, P525; MOUNTZ JD, 1993, IMMUNOL TODAY, V14, P532, DOI 10.1016/0167-5699(93)90182-K; NABOZNY GH, 1994, ADV EXP MED BIOL, V347, P55; PETTERSSON A, 1995, J AUTOIMMUN, V8, P493, DOI 10.1016/0896-8411(95)90004-7; REMMERS EF, 1993, MAMM GENOME, V4, P265, DOI 10.1007/BF00417433; SERIKAWA T, 1992, GENETICS, V131, P701; STUART JM, 1984, ANNU REV IMMUNOL, V2, P199, DOI 10.1146/annurev.iy.02.040184.001215; SUDWEEKS JD, 1993, P NATL ACAD SCI USA, V90, P3700, DOI 10.1073/pnas.90.8.3700; TANEJA V, 1993, SCAND J RHEUMATOL, V22, P152, DOI 10.3109/03009749309099263; TEUSCHER C, 1985, IMMUNOGENETICS, V22, P417, DOI 10.1007/BF00418088; THOMAS DJB, 1983, ANN RHEUM DIS, V42, P297, DOI 10.1136/ard.42.3.297; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857; WALKER DJ, 1986, ANN RHEUM DIS, V45, P323, DOI 10.1136/ard.45.4.323; WOLLEY PH, 1991, CURR OPIN RHEUMATOL, V3, P407; WOOLEY PH, 1988, CRC CR REV IMMUNOL, V8, P1	30	182	187	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1996	14	1					82	85		10.1038/ng0996-82	http://dx.doi.org/10.1038/ng0996-82			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782824				2022-12-25	WOS:A1996VF61100025
J	Callan, MFC; Steven, J; Krausa, P; Wilson, JDK; Moss, PAH; Gillespie, GM; Bell, JI; Rickinson, AB; McMichael, AJ				Callan, MFC; Steven, J; Krausa, P; Wilson, JDK; Moss, PAH; Gillespie, GM; Bell, JI; Rickinson, AB; McMichael, AJ			Large clonal expansions of CD8(+) T cells in acute infectious mononucleosis	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; VARIABLE REGION GENES; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIGEN RECEPTOR GENES; MONOCLONAL-ANTIBODIES; CHAIN; LYMPHOCYTES; EXPRESSION; IDENTIFICATION; PERSISTENCE	Primary infection with Epstein-Barr virus often results in the clinical syndrome of acute infectious mononucleosis (glandular fever). This illness is characterized by a striking lymphocytosis, the nature of which has been controversial. We show that large monoclonal or oligoclonal populations of CD8(+) T cells account for a significant proportion of the lymphocytosis and provide molecular evidence that these populations have been driven by antigen. The results suggest that the selective and massive expansion of a few dominant clones of CD8(+) T cells is an important feature of the primary response to this virus.	UNIV BIRMINGHAM,CRC,INST CANC STUDIES,SCH MED,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	University of Birmingham	Callan, MFC (corresponding author), JOHN RADCLIFFE HOSP,INST MOL MED,MOL IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARGAET VP, 1994, J EXP MED, V180, P2335, DOI 10.1084/jem.180.6.2335; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; CALLAN MFC, 1993, P NATL ACAD SCI USA, V90, P10454, DOI 10.1073/pnas.90.22.10454; CALLAN MFC, 1995, EUR J IMMUNOL, V25, P1529, DOI 10.1002/eji.1830250609; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CARREL S, 1986, EUR J IMMUNOL, V16, P649, DOI 10.1002/eji.1830160610; CHEN ZW, 1995, J EXP MED, V182, P21, DOI 10.1084/jem.182.1.21; CHOI YW, 1991, P NATL ACAD SCI USA, V88, P8357, DOI 10.1073/pnas.88.19.8357; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CLARKE GR, 1994, EUR J IMMUNOL, V24, P837, DOI 10.1002/eji.1830240410; CONCANNON P, 1986, P NATL ACAD SCI USA, V83, P6598, DOI 10.1073/pnas.83.17.6598; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DIU A, 1993, EUR J IMMUNOL, V23, P1422, DOI 10.1002/eji.1830230703; FERRADINI L, 1991, EUR J IMMUNOL, V21, P935, DOI 10.1002/eji.1830210412; HESSE J, 1983, SCAND J INFECT DIS, V15, P335, DOI 10.3109/inf.1983.15.issue-4.03; HINGORANI R, 1993, J IMMUNOL, V151, P5762; KIMURA N, 1987, EUR J IMMUNOL, V17, P375, DOI 10.1002/eji.1830170312; LAI PK, 1975, J HYG-CAMBRIDGE, V74, P329, DOI 10.1017/S0022172400046842; LEE SP, 1993, J VIROL, V67, P7428, DOI 10.1128/JVI.67.12.7428-7435.1993; LEHNER PJ, 1995, J EXP MED, V181, P79, DOI 10.1084/jem.181.1.79; LI YX, 1991, J EXP MED, V174, P1537, DOI 10.1084/jem.174.6.1537; MAKENSEN A, 1994, J CLIN INVEST, V98, P1397; Maryanski JL, 1996, IMMUNITY, V4, P47, DOI 10.1016/S1074-7613(00)80297-6; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MORLEY JK, 1995, J IMMUNOL, V154, P6182; MOSKOPHIDIS D, 1993, EUR J IMMUNOL, V23, P3306, DOI 10.1002/eji.1830231237; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NIEDOBITEK G, 1994, LANCET, V343, P333, DOI 10.1016/S0140-6736(94)91167-3; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; ROMAGNE F, 1992, EUR J IMMUNOL, V22, P2749, DOI 10.1002/eji.1830221043; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; SADLER AM, 1994, TISSUE ANTIGENS, V44, P148, DOI 10.1111/j.1399-0039.1994.tb02372.x; SIU G, 1986, J EXP MED, V164, P1600, DOI 10.1084/jem.164.5.1600; SMITH TJ, 1993, BLOOD, V81, P1521; STRANG G, 1987, EUR J IMMUNOL, V17, P1007, DOI 10.1002/eji.1830170717; TOMKINSON BE, 1987, J IMMUNOL, V139, P3802; UEHARA T, 1992, BLOOD, V80, P452; VENKITARAMAN AR, 1985, J MED VIROL, V15, P11, DOI 10.1002/jmv.1890150103; VINEY JL, 1992, HYBRIDOMA, V11, P701, DOI 10.1089/hyb.1992.11.701	43	382	387	1	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1996	2	8					906	911		10.1038/nm0896-906	http://dx.doi.org/10.1038/nm0896-906			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UZ804	8705861				2022-12-25	WOS:A1996UZ80400038
J	Ohno, K; Sawai, K; Iijima, Y; Levin, B; Meruelo, D				Ohno, K; Sawai, K; Iijima, Y; Levin, B; Meruelo, D			Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A	NATURE BIOTECHNOLOGY			English	Article						gene therapy vector; alphavirus; targeting; protein A	RETROVIRAL VECTORS; EXPRESSION VECTORS; GENE-EXPRESSION; RECEPTOR; ANTIBODIES; NEUROVIRULENCE; PATHOGENESIS; GENERATION; MICE; RNA	Sindbis virus can infect a broad range of insect and vertebrate cell types due to the widespread distribution of the cellular receptor for the virus. The development of Sindbis virus vectors that target specific cell types could have important implications for the design of gene therapy strategies. To achieve this goal we have designed and constructed Sindbis virus particles displaying the IgG-binding domain of protein A. The protein A-envelope chimeric Sindbis virus vector has minimal infectivities against baby hamster kidney and human cell lines. When used in conjunction with monoclonal antibodies that react with cell-surface antigens, however, the protein A-envelope chimeric virus was able to infect human cell lines with high efficiency. Infection rates were 90% or higher for human lymphoblastoid cells. A variety of cells could be targeted by changing the monoclonal antibody without generating a new recombinant virus.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University					NCI NIH HHS [CA68498, CA22247] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA022247, R01CA068498, R01CA022247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; BREDENBEEK PJ, 1992, SEMIN VIROL, V3, P297; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; DUBUISSON J, 1993, J VIROL, V67, P3363, DOI 10.1128/JVI.67.6.3363-3374.1993; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; LEVINE B, 1992, J VIROL, V66, P6429, DOI 10.1128/JVI.66.11.6429-6435.1992; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LOWENADLER B, 1987, GENE, V58, P87, DOI 10.1016/0378-1119(87)90032-1; LUSTIG S, 1988, J VIROL, V62, P2329, DOI 10.1128/JVI.62.7.2329-2336.1988; Marin M, 1996, J VIROL, V70, P2957, DOI 10.1128/JVI.70.5.2957-2962.1996; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; OLMSTED RA, 1986, VIROLOGY, V148, P245, DOI 10.1016/0042-6822(86)90322-3; POLO JM, 1988, J VIROL, V62, P2124, DOI 10.1128/JVI.62.6.2124-2133.1988; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SOMIA NV, 1995, P NATL ACAD SCI USA, V92, P7570, DOI 10.1073/pnas.92.16.7570; STANLEY J, 1985, J VIROL, V56, P110, DOI 10.1128/JVI.56.1.110-119.1985; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; SURCLIA A, 1982, TRENDS BIOCHEM SCI, V7, P74; UBOL S, 1991, J VIROL, V65, P6913, DOI 10.1128/JVI.65.12.6913-6921.1991; WANG KS, 1991, VIROLOGY, V181, P694, DOI 10.1016/0042-6822(91)90903-O; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607	25	133	166	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					763	767		10.1038/nbt0897-763	http://dx.doi.org/10.1038/nbt0897-763			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255791				2022-12-25	WOS:A1997XM70700028
J	Irvine, AD; Corden, LD; Swensson, O; Swensson, B; Moore, JE; Frazer, DG; Smith, FJD; Knowlton, RG; Christophers, E; Rochels, R; Uitto, J; McLean, WHI				Irvine, AD; Corden, LD; Swensson, O; Swensson, B; Moore, JE; Frazer, DG; Smith, FJD; Knowlton, RG; Christophers, E; Rochels, R; Uitto, J; McLean, WHI			Mutations in cornea-specific keratin K3 or K12 genes cause Meesmann's corneal dystrophy	NATURE GENETICS			English	Article							EXPRESSION; DISEASE; DIFFERENTIATION; LINKAGE; CELLS	The intermediate filament cytoskeleton of corneal epithelial cells is composed of cornea-specific keratins K3 and K12 (refs 1,2). Meesmann's corneal dystrophy (MCD) is an autosomal dominant disorder causing fragility of the anterior corneal epithelium(3,4), where K3 and K12 are specifically expressed(5). We postulated that dominant-negative mutations in these keratins might be the cause of MCD. K3 was mapped to the type-II keratin gene cluster on 12q; and K12 to the type-I keratin cluster on 17q using radiation hybrids. We obtained linkage to the K12 locus in Meesmann's original German kindred (Z(max) = 7.53; theta = 0) and we also showed that the phenotype segregated with either the K12 or the K3 locus in two Northern Irish pedigrees. Heterozygous missense mutations in K3 (E509K) and in K12 (V143L; R135T) completely co-segregated with MCD in the families and were not found in 100 normal unrelated chromosomes. All mutations occur in the highly conserved keratin helix boundary motifs, where dominant mutations in other keratins have been found to severely compromise cytoskeletal function, leading to keratinocyte fragility phenotypes. Our results demonstrate for the first time the molecular basis of Meesmann's corneal dystrophy.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,EPITHELIAL GENET GRP,PHILADELPHIA,PA 19107; BELFAST CITY HOSP,DEPT DERMATOL,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND; UNIV DUNDEE,INST MED SCI,DEPT PHYSIOL & ANAT,CANC RES CAMPAIGN LABS,CRC,CELL STRUCT RES GRP,DUNDEE DD1 4HN,SCOTLAND; CHRISTIAN ALBRECHTS UNIV KIEL,DEPT OPHTHALMOL,D-24105 KIEL,GERMANY; ROYAL GRP HOSP,DEPT OPHTHALMOL,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MOL PHARMACOL & BIOCHEM,PHILADELPHIA,PA 19107	Jefferson University; Belfast City Hospital; University of Dundee; University of Kiel; Jefferson University			Irvine, Alan D/A-3982-2008; McLean, William HI/C-6352-2009	Irvine, Alan D/0000-0002-9048-2044; McLean, William Henry Irwin/0000-0001-5539-5757	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHALOINDUFAU C, 1990, CELL DIFFER DEV, V32, P97, DOI 10.1016/0922-3371(90)90103-4; Christiano A M, 1996, Exp Dermatol, V5, P1, DOI 10.1111/j.1600-0625.1996.tb00086.x; Corden L D, 1996, Exp Dermatol, V5, P297, DOI 10.1111/j.1600-0625.1996.tb00133.x; FINE BS, 1977, AM J OPHTHALMOL, V83, P633, DOI 10.1016/0002-9394(77)90128-3; HEON E, 1995, HUM MOL GENET, V4, P485, DOI 10.1093/hmg/4.3.485; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; Kao WWY, 1996, INVEST OPHTH VIS SCI, V37, P2572; KAO WWY, 1994, J BIOL CHEM, V269, P24627; KLINGE EM, 1987, J MOL EVOL, V24, P319, DOI 10.1007/BF02134130; Lane E. Birgitte, 1993, P237; LEVY E, 1991, NEW ENGL J MED, V325, P1780; LIU CY, 1993, CURR EYE RES, V12, P963, DOI 10.3109/02713689309029222; MCKUSICK VA, 1997, OMIM ON LINE MENDELI; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; MCLEAN WHI, 1995, NAT GENET, V9, P273, DOI 10.1038/ng0395-273; Meesmann A, 1939, KLIN MONATSBL AUGENH, V103, P361; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Nishida K, 1996, INVEST OPHTH VIS SCI, V37, P1800; QUINLAN RA, 1994, INTERMEDIATE FILAMEN; RODRIGUES M, 1987, DIFFERENTIATION, V34, P60, DOI 10.1111/j.1432-0436.1987.tb00051.x; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; Shearman AM, 1996, HUM MOL GENET, V5, P1667, DOI 10.1093/hmg/5.10.1667; SKRETTING G, 1992, BIOCHEM BIOPH RES CO, V182, P583, DOI 10.1016/0006-291X(92)91772-I; Small KW, 1996, AM J OPHTHALMOL, V121, P384, DOI 10.1016/S0002-9394(14)70434-9; STONE EM, 1994, NAT GENET, V6, P47, DOI 10.1038/ng0194-47; SUN TT, 1984, TRANSFORMED PHENOTYP, P169; TOMA NMG, 1995, HUM MOL GENET, V4, P2395, DOI 10.1093/hmg/4.12.2395; TREMBLAY M, 1982, CAN J OPHTHALMOL, V17, P24; Vance JM, 1996, AM J HUM GENET, V58, P757	30	173	182	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					184	187		10.1038/ng0697-184	http://dx.doi.org/10.1038/ng0697-184			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171831				2022-12-25	WOS:A1997XB54300020
J	Lynch, DH; Andreasen, A; Maraskovsky, E; Whitmore, J; Miller, RE; Schuh, JCL				Lynch, DH; Andreasen, A; Maraskovsky, E; Whitmore, J; Miller, RE; Schuh, JCL			Flt3 ligand induces tumor regression and antitumor immune responses in vivo	NATURE MEDICINE			English	Article							DENDRITIC CELLS	Daily treatment of mice with recombinant human Flt3 ligand (huFlt3L) results in a dramatic numerical increase in the number of dendritic cells (DCs) in vivo. Since DCs are pivotal in the induction of immune responses, we tested whether Flt3L treatment of mice challenged with a syngeneic methylcholanthrene (MCA)-induced fibrosarcoma would augment the generation of effective antitumor immune responses in vivo. Flt3L treatment not only induced complete tumor regression in a significant proportion of mice, but also decreased tumor growth rate in the remaining mice. A preliminary characterization of the cellular mechanisms involved suggests that Flt3L may be important in the treatment of cancer in situ through the generation of specific antitumor immune responses.	IMMUNEX RES & DEV CORP,DEPT BIOMETR,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOL IMMUNOL,SEATTLE,WA 98101		Lynch, DH (corresponding author), IMMUNEX RES & DEV CORP,DEPT IMMUNOBIOL,51 UNIV ST,SEATTLE,WA 98101, USA.			Schuh, JoAnn C. L./0000-0002-2399-8518				Brasel K, 1996, BLOOD, V88, P2004, DOI 10.1182/blood.V88.6.2004.bloodjournal8862004; BRASEL K, 1995, LEUKEMIA, V9, P1212; BRENT L, 1966, PROC R SOC SER B-BIO, V165, P413, DOI 10.1098/rspb.1966.0074; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; Liu B, 1996, J IMMUNOL, V156, P1117; LYMAN SD, 1995, INT J HEMATOL, V62, P63; LYNCH DH, 1991, EUR J IMMUNOL, V21, P1403, DOI 10.1002/eji.1830210612; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; MCKENNA HJ, 1996, BONE MARROW TRANSPL, P85; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; PARDOLL DM, 1995, ANNU REV IMMUNOL, V13, P399, DOI 10.1146/annurev.immunol.13.1.399; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; THOMSON AW, 1995, STEM CELLS, V13, P622, DOI 10.1002/stem.5530130607; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	19	264	293	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					625	631		10.1038/nm0697-625	http://dx.doi.org/10.1038/nm0697-625			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176488				2022-12-25	WOS:A1997XB97400031
J	Pasqualini, R; Koivunen, E; Ruoslahti, E				Pasqualini, R; Koivunen, E; Ruoslahti, E			alpha v Integrins as receptors for tumor targeting by circulating ligands	NATURE BIOTECHNOLOGY			English	Article						phage display; tumor targeting; RGD; angiogenesis; integrins	ENDOTHELIAL-CELLS; CANCER-THERAPY; SOLID TUMORS; ANGIOGENESIS; METASTASIS; ALPHA(V)BETA(3); GLYCOPROTEIN; VASCULATURE; ANTIBODIES; GROWTH	Phage displaying an Arg-Gly-Asp (RGD)-containing peptide with a high affinity for av integrins homed to tumors when injected intravenously into tumor-bearing mice. A substantially higher amount of av-directed RGD phage than control phage was recovered from malignant melanomas and breast carcinoma. Antibodies detected the av-directed RGD phage in tumor blood vessels, but not in several normal tissues. These results show that the alpha v integrins present in tumor blood vessels can bind circulating ligands and that RGD peptides selective for these integrins may be suitable tools in tumor targeting for diagnostic and therapeutic purposes.	UNIV HELSINKI, DEPT BIOSCI, DIV BIOCHEM, FIN-00014 HELSINKI, FINLAND	University of Helsinki	Pasqualini, R (corresponding author), BURNHAM INST, LA JOLLA CANC RES CTR, LA JOLLA, CA 92037 USA.			Koivunen, Erkki/0000-0002-6443-9595	NCI NIH HHS [CA 30199, CA 28896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, P01CA028896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLIE CT, 1995, BRIT J CANCER, V72, P257, DOI 10.1038/bjc.1995.323; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BUCKLE R, 1994, ANN ONCOL          S, V4, P45; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CONFORTI G, 1992, BLOOD, V80, P437; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GETER MR, 1973, NATURE, V246, P221; Goetz DJ, 1996, INT J CANCER, V65, P192, DOI 10.1002/(SICI)1097-0215(19960117)65:2<192::AID-IJC11>3.0.CO;2-G; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; LAPPI DA, 1995, SEMIN CANCER BIOL, V6, P279, DOI 10.1006/scbi.1995.0036; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NICOLSON GL, 1990, CANCER RES, V50, P515; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PAULI BU, 1990, CANCER METAST REV, V9, P175, DOI 10.1007/BF00046359; PRICE JE, 1990, CANCER RES, V50, P717; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; RETTIG WJ, 1992, P NATL ACAD SCI USA, V89, P10832, DOI 10.1073/pnas.89.22.10832; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SHOCKLEY TR, 1991, ANN NY ACAD SCI, V618, P367, DOI 10.1111/j.1749-6632.1991.tb27257.x; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	32	666	771	0	93	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					542	546		10.1038/nbt0697-542	http://dx.doi.org/10.1038/nbt0697-542			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181576				2022-12-25	WOS:A1997XC77200029
J	Tomizuka, K; Yoshida, H; Uejima, H; Kugoh, H; Sato, K; Ohguma, A; Hayasaka, M; Hanaoka, K; Oshimura, M; Ishida, I				Tomizuka, K; Yoshida, H; Uejima, H; Kugoh, H; Sato, K; Ohguma, A; Hayasaka, M; Hanaoka, K; Oshimura, M; Ishida, I			Functional expression and germline transmission of a human chromosome fragment in chimaeric mice	NATURE GENETICS			English	Article							YEAST ARTIFICIAL CHROMOSOME; DEVELOPMENTAL REGULATION; MONOCLONAL-ANTIBODIES; LINE TRANSMISSION; STEM-CELLS; GENE; MOUSE; SEQUENCE; CHAIN; CLONES	Human chromosomes or chromosome fragments derived from normal fibroblasts were introduced into mouse embryonic stem (ES) cells via microcell-mediated chromosome transfer (MMCT) and viable chimaeric mice were produced from them. Transferred chromosomes were stably retained, and human genes, including immunoglobulin (Ig) kappa, heavy, lambda genes, were expressed in proper tissue-specific manner in adult chimaeric tissues. In the case of a human chromosome (hChr.) 2-derived fragment, it was found to be transmitted to the offspring through the germline. Our study demonstrates that MMCT allows for introduction of very large amounts of foreign genetic material into mice. This novel procedure will facilitate the functional analyses of human genomes in vivo.	KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOL & CELL GENET,YONAGO,TOTTORI 683,JAPAN; KITASATO UNIV,SCH SCI,DEPT BIOSCI,MOL EMBRYOL LAB,SAGAMIHARA,KANAGAWA 228,JAPAN	Kirin Brewery Company Limited; Tottori University; Kitasato University								BENHAM FJ, 1983, EMBO J, V2, P1963, DOI 10.1002/j.1460-2075.1983.tb01685.x; BERCHTOLD MW, 1985, P NATL ACAD SCI USA, V82, P1414, DOI 10.1073/pnas.82.5.1414; Brown W, 1996, CURR OPIN GENET DEV, V6, P281, DOI 10.1016/S0959-437X(96)80003-7; COOK GP, 1994, NAT GENET, V7, P162, DOI 10.1038/ng0694-162; DEVLIN BH, 1989, J BIOL CHEM, V264, P13896; DEWEY MJ, 1977, P NATL ACAD SCI USA, V74, P5564, DOI 10.1073/pnas.74.12.5564; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; DORIN JR, 1992, HUM MOL GENET, V1, P53, DOI 10.1093/hmg/1.1.53; EPSTEIN CJ, 1982, P NATL ACAD SCI-BIOL, V79, P4376, DOI 10.1073/pnas.79.14.4376; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GROPP A, 1983, J EXP ZOOL, V228, P253, DOI 10.1002/jez.1402280210; HANAOKA K, 1986, DEV GROWTH DIFFER, V28, P223; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HATTORI M, 1985, NUCLEIC ACIDS RES, V13, P7813, DOI 10.1093/nar/13.21.7813; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; HUNT P, 1995, HUM MOL GENET, V4, P2007, DOI 10.1093/hmg/4.11.2007; ILLMENSEE K, 1979, P NATL ACAD SCI USA, V76, P879, DOI 10.1073/pnas.76.2.879; ILLMENSEE K, 1978, P NATL ACAD SCI USA, V75, P1914, DOI 10.1073/pnas.75.4.1914; JAKOBOVITS A, 1993, NATURE, V362, P255, DOI 10.1038/362255a0; JONSSON JJ, 1991, NUCLEIC ACIDS RES, V19, P5015, DOI 10.1093/nar/19.18.5015; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KLEIN R, 1993, EUR J IMMUNOL, V23, P3248, DOI 10.1002/eji.1830231231; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; LENGAUER C, 1992, GENOMICS, V13, P826, DOI 10.1016/0888-7543(92)90160-T; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; LOWE JB, 1985, J BIOL CHEM, V260, P3413; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; Mendez MJ, 1997, NAT GENET, V15, P146, DOI 10.1038/ng0297-146; PRITCHARD C, 1986, EMBO J, V5, P979, DOI 10.1002/j.1460-2075.1986.tb04312.x; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SIMINOVITCH KA, 1985, NATURE, V316, P260, DOI 10.1038/316260a0; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090; TOMATSU S, 1989, GENE, V80, P353; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; Uchida Masaki, 1995, Animal Science and Technology, V66, P361; WAGNER SD, 1994, EUR J IMMUNOL, V24, P2672, DOI 10.1002/eji.1830241116; WATANABE S, 1995, BIOCHEM BIOPH RES CO, V213, P130, DOI 10.1006/bbrc.1995.2107; WILLIAMS SC, 1993, EUR J IMMUNOL, V23, P1456, DOI 10.1002/eji.1830230709; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; [No title captured]	48	208	284	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					133	143		10.1038/ng0697-133	http://dx.doi.org/10.1038/ng0697-133			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171824				2022-12-25	WOS:A1997XB54300013
J	Moghaddam, MF; Grant, DF; Cheek, JM; Greene, JF; Williamson, KC; Hammock, BD				Moghaddam, MF; Grant, DF; Cheek, JM; Greene, JF; Williamson, KC; Hammock, BD			Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase	NATURE MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; BURN TOXIN; INDUCTION; INJURY; LIVER; RAT; 9,10-EPOXY-12-OCTADECENOATE; BIOSYNTHESIS; GLUTATHIONE; EXPRESSION	Leukotoxin is a linoleic acic oxide produced by leukocytes and has been associated with the multiple organ failure and adult respiratory distress syndrome seen in some severe burn patients. Leukotoxin has been reported to be toxic when injected into animals intravenously. Herein, we report that this lipid is not, directly cytotoxic in at least two in vitro systems. Using a baculovirus expression system we demonstrate that leukotoxin is only cytotoxic in the presence of epoxide hydrolases. In addition, it is the diol metabolite that proves toxic to pulmonary alveolar epithelial cells, suggesting a critical role for the diol in leukotoxin-associated respiratory disease, In vivo data also support the toxicity of leukotoxin diol. For the first time we demonstrate that soluble epoxide hydrolase can bioactivate epoxides to diols that are apparently cytotoxic. Thus leukotoxin should be regarded as a protoxin corresponding to the more toxic diol. This clearly has implications for designing new clinical interventions.	LAWRENCE LIVERMORE NATL LAB,DEPT ENTOMOL,DAVIS,CA 95616; LAWRENCE LIVERMORE NATL LAB,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616; LAWRENCE LIVERMORE NATL LAB,DEPT VET ANAT PHYSIOL & CELL BIOL,DAVIS,CA 95616; DUPONT AGR PROD,EXPT STN,WILMINGTON,DE 19880; UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72205	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; DuPont; University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, R01ES002710, R37ES002710] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02710, ES04699, ES05707] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; BORHAN B, 1995, ANAL BIOCHEM, V231, P188, DOI 10.1006/abio.1995.1520; BORHAN B, 1993, TETRAHEDRON, V49, P2601, DOI 10.1016/S0040-4020(01)86339-0; CASALS C, 1990, BIOCHIM BIOPHYS ACTA, V1023, P290, DOI 10.1016/0005-2736(90)90425-N; CHEEK JM, 1994, TOXICOL APPL PHARM, V125, P59, DOI 10.1006/taap.1994.1049; CHEEK JM, 1989, AM J PHYSIOL, V256, pC688, DOI 10.1152/ajpcell.1989.256.3.C688; FUKUSHIMA A, 1988, CARDIOVASC RES, V22, P213, DOI 10.1093/cvr/22.3.213; GIBSON GG, 1990, BIOCHEM SOC T, V18, P97, DOI 10.1042/bst0180097; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; Grant DF, 1996, BIOCHEM PHARMACOL, V51, P503, DOI 10.1016/0006-2952(95)02227-9; GRANT DF, 1993, J BIOL CHEM, V268, P17628; HAMMOCK BD, 1983, TOXICOL APPL PHARM, V71, P254, DOI 10.1016/0041-008X(83)90342-3; HAMMOCK BD, IN PRESS COMPREHENSI, pCH18; HAYAKAWA M, 1990, BIOCHEM INT, V21, P573; HAYAKAWA M, 1986, BIOCHEM BIOPH RES CO, V137, P424, DOI 10.1016/0006-291X(86)91227-1; ISHIZAKI T, 1995, AM J PHYSIOL-LUNG C, V269, pL65, DOI 10.1152/ajplung.1995.269.1.L65; ISHIZAKI T, 1995, AM J PHYSIOL-LUNG C, V268, pL123, DOI 10.1152/ajplung.1995.268.1.L123; ISHIZAKI T, 1995, BIOCHEM BIOPH RES CO, V210, P133, DOI 10.1006/bbrc.1995.1637; Jerina D.M., 1977, ORIGINS HUMAN CANCER, P639; JIANING H, 1988, LUNG, V166, P327; KAUR S, 1985, DRUG METAB DISPOS, V13, P711; KOSAKA K, 1994, MOL CELL BIOCHEM, V139, P141, DOI 10.1007/BF01081737; Moghaddam MF, 1996, BBA-GEN SUBJECTS, V1290, P327, DOI 10.1016/0304-4165(96)00037-2; MULLIN C, 1980, ARCH BIOCHEM BIOPHYS, V216, P423; NELSON SD, 1990, ANNU REV PHARMACOL, V30, P169; OZAWA T, 1986, BIOCHEM BIOPH RES CO, V134, P1071, DOI 10.1016/0006-291X(86)90360-8; OZAWA T, 1991, ADV PROSTAG THROMB L, V21, P569; PACHT ER, 1991, CHEST, V100, P1397, DOI 10.1378/chest.100.5.1397; SAKAI T, 1995, AM J PHYSIOL-LUNG C, V269, pL326, DOI 10.1152/ajplung.1995.269.3.L326; SEVANIAN A, 1979, LIPIDS, V14, P634, DOI 10.1007/BF02533449; TAYLOR AE, 1970, AM J PHYSIOL, V218, P1133, DOI 10.1152/ajplegacy.1970.218.4.1133; VOGELBINDEL U, 1982, EUR J BIOCHEM, V126, P425	32	240	252	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					562	566		10.1038/nm0597-562	http://dx.doi.org/10.1038/nm0597-562			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142128	Green Published			2022-12-25	WOS:A1997WX54300039
J	Kidder, LH; Kalasinsky, VF; Luke, JL; Levin, IW; Lewis, EN				Kidder, LH; Kalasinsky, VF; Luke, JL; Levin, IW; Lewis, EN			Visualization of silicone gel in human breast tissue using new infrared imaging spectroscopy	NATURE MEDICINE			English	Article							IMPLANTS; MICROSPECTROSCOPY; SYMPTOMS; DISEASES; RISK	Between 1 and 2 million women in the United States have silicone breast implants. Complications include capsular contracture and calcification and possibly connective tissue diseases such as scleroderma and rheumatoid arthritis, a subject of some controversy(1-7). In order to accurately assess the role of silicone in any histopathologic change, it is necessary to confirm its presence and to identify other foreign materials in the capsular tissue. Although light microscopy is used to visualize regions of tissue containing foreign inclusions, their chemical identity can only be determined using analytical techniques such as infrared or Raman microscopy. However, these conventional microprobe techniques record spectra only at single points and require an a priori knowledge of the locations of the inclusion to be probed. To significantly extend the capabilities of both infrared spectroscopy and optical microscopy, we have developed a new infrared imaging system that completely integrates these two methods. In this manuscript we highlight the ability of the technique to screen rapidly and to determine accurately the presence, size and chemical composition of silicone gel inclusions in human breast tissue.	NIDDKD,CHEM PHYS LAB,NIH,BETHESDA,MD 20892; ARMED FORCES INST PATHOL,DEPT ENVIRONM & TOXICOL PATHOL,WASHINGTON,DC 20306	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Defense			lewis, neil/G-1274-2017	lewis, neil/0000-0002-3049-0667				BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; CENTENO JA, 1993, APPL SPECTROSC, V47, P341, DOI 10.1366/0003702934066613; DUGOWSON CE, 1992, ARHTRITIS RHEUM S, V35, P566; FRANK CJ, 1993, APPL SPECTROSC, V47, P387, DOI 10.1366/0003702934334958; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GABRIEL SE, 1993, ARTHRITIS RHEUM, V36, pS70; GOLDSTEIN SR, IN PRESS J MICROSC; HARDT NS, 1994, MODERN PATHOL, V7, P669; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; HOCHBERG MC, 1993, ARTHRITIS RHEUM, V36, pS71; Levin I. W, 1983, ADV RAMAN INFRARED S, V11, P1; LEWIS EN, 1995, ANAL CHEM, V67, P3377, DOI 10.1021/ac00115a003; LEWIS EN, 1836, Patent No. 537703; Morris M.D., 1993, MICROSCOPIC SPECTROS; PARKER FS, 1983, APPLICATIONS INFRARE; PETERS W, 1995, ANN PLAS SURG, V34, P578, DOI 10.1097/00000637-199506000-00003; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; Schaeberle MD, 1996, ANAL CHEM, V68, P1829, DOI 10.1021/ac951245a	18	114	117	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					235	237		10.1038/nm0297-235	http://dx.doi.org/10.1038/nm0297-235			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018246				2022-12-25	WOS:A1997WF08800046
J	Lee, IM; Klopmeyer, M; Bartoszyk, IM; GundersenRindal, DE; Chou, TS; Thomson, KL; Eisenreich, R				Lee, IM; Klopmeyer, M; Bartoszyk, IM; GundersenRindal, DE; Chou, TS; Thomson, KL; Eisenreich, R			Phytoplasma induced free-branching in commercial poinsettia cultivars	NATURE BIOTECHNOLOGY			English	Article						phytoplasma; branching poinsettia; branching agent; poinsettia mosaic virus; nested-PCR	GRAFT-TRANSMISSIBLE AGENT; MYCOPLASMALIKE ORGANISMS	Free-branching poinsettia cultivars that produce numerous axillary shoots are essential for propagating desirable multi-flowered poinsettias (Euphorbia pulcherrima Wild. Klotz). For more than a decade, a biological agent has been suspected to cause free-branching in poinsettias. Attempts to identify the branching agent have failed. Isolation of the pathogen was accomplished using a living host and it was concluded that an unculturable phytoplasma is the cause of free-branching in poinsettias. This is the first reported example of a pathogenic phytoplasma as the causal agent of a desirable and economically important trait.	BALL FLORAPLANT,W CHICAGO,IL 60185		Lee, IM (corresponding author), ARS,MOL PLANT PATHOL LAB,USDA,BELTSVILLE,MD 20705, USA.							DOLE JM, 1991, J AM SOC HORTIC SCI, V116, P307, DOI 10.21273/JASHS.116.2.307; DOLE JM, 1992, J AM SOC HORTIC SCI, V117, P972, DOI 10.21273/JASHS.117.6.972; DOLE JM, 1993, CAN J BOT, V71, P1097, DOI 10.1139/b93-128; ECKE P, 1990, POINSETTA MANUAL; FULTON RW, 1980, PHYTOPATHOLOGY, V70, P321, DOI 10.1094/Phyto-70-321; GRIFFITHS HM, 1994, CAN J PLANT PATHOL, V16, P255, DOI 10.1080/07060669409500728; Gundersen D. E., 1996, Phytopathologia Mediterranea, V35, P144; KAPLAN JK, 1992, AGR RES, V12, P4; Koenig R., 1980, Plant Disease, V64, P782, DOI 10.1094/PD-64-782; KOENIG R, 1986, AAB DISCRIPTIONS PLA, V311; Lee I.-M., 1995, Phytopathology, V85, P1179; LEE IM, 1995, PHYTOPATHOLOGY, V85, P728, DOI 10.1094/Phyto-85-728; LEE IM, 1993, PHYTOPATHOLOGY, V83, P834, DOI 10.1094/Phyto-83-834; LEE IM, 1993, PHYTOPATHOLOGY, V83, P829, DOI 10.1094/Phyto-83-829; Lee Ing-Ming, 1992, P379; McCoy RE, 1989, MYCOPLASMAS, DOI DOI 10.1016/B978-0-12-078405-9.50019-7; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Preil W., 1988, Acta Horticulturae, P99; PREIL W, 1982, GARTENBAUWISSENSCHAF, V47, P241; RUIZSIFRE GV, 1993, THESIS OKLAHOMA STAT; STIMART DP, 1983, J AM SOC HORTIC SCI, V108, P419; *USDA, 1996, FLOR CORPS 1995 SUMM	22	53	59	0	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					178	182		10.1038/nbt0297-178	http://dx.doi.org/10.1038/nbt0297-178			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035146				2022-12-25	WOS:A1997WE99800027
J	Liu, Y; Mounkes, LC; Liggitt, HD; Brown, CS; Solodin, I; Heath, TD; Debs, RJ				Liu, Y; Mounkes, LC; Liggitt, HD; Brown, CS; Solodin, I; Heath, TD; Debs, RJ			Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery	NATURE BIOTECHNOLOGY			English	Article						gene transfer; cationic liposomes; gene therapy	COLONY-STIMULATING FACTOR; CYSTIC-FIBROSIS; DNA-TRANSFECTION; CELLS; MICE; EXPRESSION; THERAPY; CHOLESTEROL; INVIVO; SERUM	We have characterized the relationships between the design of cationic liposomes as a gene transfer vehicle, their resulting biodistribution and processing in animals, and the level and sites of gene expression they produce. By redesigning conventional cationic liposomes, incorporating cholesterol (chol) as the neutral lipid and preparing them as multilamellar vesicles (MLV), we increased the efficiency of cationic liposome:DNA complex (CLDC)-mediated gene delivery, Expression of the luciferase gene increased up to 1,740-fold and of the human granulocyte-colony stimulating factor (hG-CSF) gene up to 569-fold due to prolonged circulation time of injected CLDC, and increased uptake and retention in tissues. The level of gene expression per microgram of DNA taken up per tissue was 1,000-fold higher in lung than in liver, indicating that in addition to issues of delivery and retention of injected DNA, tissue-specific host factors also play a central role in determining the efficiency of expression. Vascular endothelial cells, monocytes, and macrophages are the cell types most commonly transfected by intravenous injection of CLDC.	CALIF PACIFIC MED RES INST,SAN FRANCISCO,CA 94115; UNIV WASHINGTON,DEPT COMPARAT MED,SEATTLE,WA 98195; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [R01 CA58914] Funding Source: Medline; NIDDK NIH HHS [R01 DK49550, R01 DK45917] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049550, R01DK045917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BENNETT MJ, 1995, BIOSCIENCE REP, V15, P47, DOI 10.1007/BF01200214; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; CANONICO AE, 1994, J APPL PHYSIOL, V77, P415, DOI 10.1152/jappl.1994.77.1.415; CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CONARY JT, 1994, J CLIN INVEST, V93, P1834, DOI 10.1172/JCI117169; DEBS RJ, 1987, AM REV RESPIR DIS, V135, P731; FASBENDER AJ, 1995, AM J PHYSIOL-LUNG C, V269, pL45, DOI 10.1152/ajplung.1995.269.1.L45; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P71434; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hofland HEJ, 1996, P NATL ACAD SCI USA, V93, P7305, DOI 10.1073/pnas.93.14.7305; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JIAO SS, 1992, EXP NEUROL, V115, P400, DOI 10.1016/0014-4886(92)90205-5; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KAWAKAMI M, 1990, BLOOD, V76, P1962; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13965; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; LOGAN JJ, 1995, GENE THER, V2, P38; MAYHEW E, 1979, CANCER TREAT REP, V63, P1923; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P1130; PAUKSEN K, 1994, BRIT J HAEMATOL, V88, P256, DOI 10.1111/j.1365-2141.1994.tb05015.x; PETROS WP, 1992, PHARMACOTHERAPY, V12, pS32; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; Sambrook J., 2002, MOL CLONING LAB MANU; SENIOR J, 1982, LIFE SCI, V30, P2123, DOI 10.1016/0024-3205(82)90455-6; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; SON K, 1994, P NATL ACAD SCI USA, V91, P12669, DOI 10.1073/pnas.91.26.12669; SORSCHER EJ, 1994, HUM GENE THER, V5, P1259, DOI 10.1089/hum.1994.5.10-1259; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; WEIS J, 1991, J CELL BIOL, V113, P1385, DOI 10.1083/jcb.113.6.1385; Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	45	356	387	0	40	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					167	173		10.1038/nbt0297-167	http://dx.doi.org/10.1038/nbt0297-167			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035144				2022-12-25	WOS:A1997WE99800025
J	Greene, NDE; Copp, AJ				Greene, NDE; Copp, AJ			Inositol prevents folate-resistant neural tube defects in the mouse	NATURE MEDICINE			English	Article							CURLY-TAIL MOUSE; PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; RETINOID BINDING-PROTEINS; CRABP-I; DIFFERENTIAL PATTERN; ACID RECEPTORS; DOUBLE-BLIND; MUTANT MICE; YOLK-SAC; EMBRYOS	Clinical trials demonstrate that up to 70% of neural tube defects (NTDs) can be prevented by folic acid supplementation in early pregnancy, whereas the remaining NTDs are resistant to folate. Here, we show that a second vitamin, myo-inositol, is capable of significantly reducing the incidence of spinal NTDs in curly tail mice, a genetic model of folate-resistant NTDs. Inositol increases flux through the inositol/lipid cycle, stimulating protein kinase C activity and upregulating expression of retinoic acid receptor beta, specifically in the caudal portion of the embryonic hindgut. This reduces the delay in closure of the posterior neuropore, the embryonic defect that is known to lead directly to spina bifida in curly tail embryos. Our findings reveal a molecular pathway of NTD prevention and suggest the possible efficacy of combined treatment with folate and inositol in overcoming the majority of human NTDs.	UNIV LONDON,INST CHILD HLTH,NEURAL DEV UNIT,LONDON WC1N 1EH,ENGLAND	University of London; University College London			Copp, Andrew/C-4174-2008	Copp, Andrew/0000-0002-2544-9117; Greene, Nicholas D.E./0000-0002-4170-5248	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD028882] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 28882] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		BENJAMIN J, 1995, AM J PSYCHIAT, V152, P1084; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BROOK FA, 1991, DEVELOPMENT, V113, P671; CHEN WH, 1995, DEVELOPMENT, V121, P681; CHEN WH, 1994, DEV DYNAM, V199, P93, DOI 10.1002/aja.1001990203; COCKROFT DL, 1992, TERATOLOGY, V45, P223, DOI 10.1002/tera.1420450216; COCKROFT DL, 1988, TERATOLOGY, V38, P281, DOI 10.1002/tera.1420380312; Cockroft DL, 1990, POSTIMPLANTATION MAM, P15; COPP AJ, 1985, J EMBRYOL EXP MORPH, V88, P39; COPP AJ, 1988, DEVELOPMENT, V104, P297; COPP AJ, 1988, DEVELOPMENT, V104, P285; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DOLLE P, 1990, DEVELOPMENT, V110, P1133; ESSIEN FB, 1993, J NUTR, V123, P27, DOI 10.1093/jn/123.1.27; ESTIBEIRO JP, 1993, DEVELOPMENT, V119, P113; ESTIBEIRO JP, 1990, POSTIMPLANTATION MAM, P173; GRUNEBERG H, 1954, J GENET, V52, P52, DOI 10.1007/BF02981490; HUBER BE, 1983, CANCER RES, V43, P5552; KUCERA J, 1971, J REPROD MED, V7, P61; KURIE JM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P203, DOI 10.1016/0167-4889(93)90142-C; LEONARD L, 1995, DEV BIOL, V168, P514, DOI 10.1006/dbio.1995.1099; LETTS VA, 1995, GENOMICS, V29, P719, DOI 10.1006/geno.1995.9946; LEVINE J, 1995, AM J PSYCHIAT, V152, P792; LYN S, 1994, DEV DYNAM, V199, P280, DOI 10.1002/aja.1001990404; NEUMANN PE, 1994, NAT GENET, V6, P357, DOI 10.1038/ng0494-357; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Peeters MCE, 1996, ANAT EMBRYOL, V193, P123; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; PINTER E, 1986, AM J OBSTET GYNECOL, V155, P691, DOI 10.1016/S0002-9378(86)80001-1; REECE EA, 1993, CLIN PERINATOL, V20, P517, DOI 10.1016/S0095-5108(18)30381-6; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SELLER MJ, 1994, CIBA F SYMP, V181, P161; SELLER MJ, 1981, LIFE SCI, V29, P1607, DOI 10.1016/0024-3205(81)90061-8; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; VANSTRAATEN HWM, 1995, J NUTR, V125, P2733; WALD N, 1991, LANCET, V338, P131; WILKINSON D, 1992, IN SITU HYBRIDISATIO; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	40	172	177	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					60	66		10.1038/nm0197-60	http://dx.doi.org/10.1038/nm0197-60			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986742				2022-12-25	WOS:A1997WA73300038
J	Griffiths, M; Beaumont, N; Yao, SYM; Sundaram, M; Boumah, CE; Davies, A; Kwong, FYP; Coe, I; Cass, CE; Young, JD; Baldwin, SA				Griffiths, M; Beaumont, N; Yao, SYM; Sundaram, M; Boumah, CE; Davies, A; Kwong, FYP; Coe, I; Cass, CE; Young, JD; Baldwin, SA			Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs	NATURE MEDICINE			English	Article							FUNCTIONAL EXPRESSION; SPECIFICITY; SYSTEM; CELLS; GENE	In most mammalian cells nucleoside uptake occurs primarily via broad-specificity, es (e, equilibrative; s, sensitive to NBMPR inhibition) transporters that are potently inhibited by nitroben-zylthioinosine (NBMPR)(1). These transporters are essential for nucleotide synthesis by salvage pathways in hemopoietic and other cells that lack de novo pathways and are the route of cellular uptake for many cytotoxic nucleosides used in cancer and viral chemotherapy(1). They play an important role in adenosine-mediated regulation of many physiological processes, including neurotransmission and platelet aggregation, and are a target for coronary vasodilator drugs. We have previously reported the purification of the prototypic es transporter from human erythrocytes(2) and have shown that this glycoprotein of apparent M(r) 55,000 is immunologically related to nucleoside transporters from several other species and tissues, including human placenta(3,4). Here we report the isolation of a human placental cDNA encoding a 456-residue glycoprotein with functional characteristics typical of an es-type transporter. It is predicted to possess 11 membrane-spanning regions and is homologous to several proteins of unknown function in yeast, nematodes, plants and mammals. Because of its central role in the uptake both of adenosine and of chemotherapeutic nucleosides, study of this protein should not only provide insights into the physiological roles of nucleoside transport but also open the way to improved therapies.	UNIV LEEDS, DEPT BIOCHEM & MOL BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; UNIV ALBERTA, DEPT PHYSIOL, MEMBRANE TRANSPORT GRP, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT ONCOL, EDMONTON, AB T6G 2H7, CANADA	University of Leeds; University of Alberta; University of Alberta; University of Alberta								BARROS LF, 1995, PFLUG ARCH EUR J PHY, V429, P394, DOI 10.1007/BF00374155; BRYSON HM, 1993, DRUGS, V46, P872, DOI 10.2165/00003495-199346050-00007; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; HANSEN SEW, 1987, EUR J BIOCHEM, V168, P385, DOI 10.1111/j.1432-1033.1987.tb13431.x; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; KAYE SB, 1994, J CLIN ONCOL, V12, P1527, DOI 10.1200/JCO.1994.12.8.1527; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; KWONG FYP, 1992, J BIOL CHEM, V267, P21954; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OUELLETTE BFF, 1993, GENOME, V36, P32, DOI 10.1139/g93-005; ROSS SR, 1993, DRUGS, V45, P737, DOI 10.2165/00003495-199345050-00009; RUSTUM YM, 1992, PHARMACOL THERAPEUT, V56, P307, DOI 10.1016/0163-7258(92)90022-R; WILLIAMS JB, 1995, BIOCHEM BIOPH RES CO, V213, P325, DOI 10.1006/bbrc.1995.2133; YOUNG JD, 1983, BIOSCIENCE REP, V3, P309, DOI 10.1007/BF01122895	20	341	356	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1997	3	1					89	93		10.1038/nm0197-89	http://dx.doi.org/10.1038/nm0197-89			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986748				2022-12-25	WOS:A1997WA73300044
J	Matthews, D; Fry, L; Powles, A; Weber, J; McCarthy, M; Fisher, E; Davies, K; Williamson, R				Matthews, D; Fry, L; Powles, A; Weber, J; McCarthy, M; Fisher, E; Davies, K; Williamson, R			Evidence that a locus for familial psoriasis maps to chromosome 4q	NATURE GENETICS			English	Letter							SUSCEPTIBILITY; POLYMORPHISMS; GENETICS; 17Q; DNA		ST MARYS HOSP,DEPT DERMATOL,LONDON W2 1NY,ENGLAND; MARSHFIELDS MED RES FDN,MARSHFIELDS,WI 54449; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QV,ENGLAND; ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA	Imperial College London; University of Oxford; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Matthews, D (corresponding author), ST MARYS HOSP,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,DEPT BIOCHEM & MOL GENET,LONDON W2 1PG,ENGLAND.		Fisher, Elizabeth MC/C-2168-2008; McCarthy, Mark/M-3763-2015	Fisher, Elizabeth MC/0000-0003-2850-9936; McCarthy, Mark/0000-0002-4393-0510				BRANDRUP F, 1982, ACTA DERM-VENEREOL, V62, P229; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DUBOVSKY J, 1995, HUM MOL GENET, V4, P449, DOI 10.1093/hmg/4.3.449; ELDER JT, 1994, ARCH DERMATOL, V130, P216, DOI 10.1001/archderm.130.2.216; FARBER EM, 1974, ARCH DERMATOL, V109, P207, DOI 10.1001/archderm.109.2.207; FRY L, 1992, ATLAS PSORIASIS; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HELLGREN I, 1967, PREVALENCE SEX AGE O; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HUDSON T, 1995, SCIENCE, V270, P5244; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Lomholt G, 1963, PSORIASIS PREVALENCE; MATTHEWS D, 1995, J MED GENET, V32, P546, DOI 10.1136/jmg.32.7.546; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAIR RP, 1995, HUM HERED, V45, P219, DOI 10.1159/000154293; NORLIND R, 1953, ACTA RHEUMATOL SCAND, V1, P135; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; WEBER JL, 1989, AM J HUM GENET, V44, P388	20	170	178	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					231	233		10.1038/ng1096-231	http://dx.doi.org/10.1038/ng1096-231			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841203				2022-12-25	WOS:A1996VL44600037
J	Navaratnam, DS; Su, HS; Scott, SP; Oberholtzer, JC				Navaratnam, DS; Su, HS; Scott, SP; Oberholtzer, JC			Proliferation in the auditory receptor epithelium mediated by a cyclic AMP-dependent signaling pathway	NATURE MEDICINE			English	Article							HAIR-CELL REGENERATION; AVIAN INNER-EAR; ACOUSTIC TRAUMA; CHICK COCHLEA; IDENTIFICATION; OTOTOXICITY; PATTERNS; CULTURES; PAPILLA	Loss of receptor hair cells in the cochlea accounts for a significant proportion of hearing impairment in the population(1). Hair cells can be lost as a consequence of viral or bacterial insult, aging, and damage from intense sound or aminoglycoside antibiotics. The generation of replacement hair cells following damage by sound or drugs has been clearly demonstrated in birds(2-4); the chick is the best-studied model for auditory hair cell regeneration(5). New hair cells arise as progeny from an otherwise nondividing supporting cell population proliferate by the damage(6-12) Functional hearing accompanies this cellular recovery process(13,14), The signals and pathways responsible for regenerative proliferation are unknown. Here we show that proliferation is induced in the undamaged receptor epithelium by agents that increase cyclic AMP levels, and that following this stimulation hair cells become labeled with proliferation markers. This remarkable proliferative response is blocked by inhibitors of the cAMP-regulated protein kinase A (PKA). In addition we show that the proliferative response induced by in vitro gentamicin damage is also significantly blocked by PKA inhibitors. These observations are the first to identify a signaling pathway that plays a role in regenerative proliferation in the auditory receptor epithelium.	UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, DIV NEUROPATHOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Scott, Sean-Patrick/0000-0002-8480-1547	NIDCD NIH HHS [K08 DC 00069, R01 DC 02755] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000069, R01DC002755] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARTOLAMI S, 1991, J COMP NEUROL, V314, P777, DOI 10.1002/cne.903140410; BHAVE SA, 1995, J NEUROSCI, V15, P4618; CORWIN JT, 1991, CIBA F SYMP, V160, P103; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; COTANCHE DA, 1994, ANAT EMBRYOL, V189, P1; DARTT DA, 1984, J PHYSIOL-LONDON, V352, P375, DOI 10.1113/jphysiol.1984.sp015297; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FORGE A, 1993, J NEUROCYTOL, V22, P854, DOI 10.1007/BF01186357; GIROD DA, 1989, HEARING RES, V42, P175, DOI 10.1016/0378-5955(89)90143-3; HASHINO E, 1992, HEARING RES, V59, P46, DOI 10.1016/0378-5955(92)90101-R; HASHINO E, 1993, J CELL SCI, V105, P23; HENTRICH F, 1985, N-S ARCH PHARMACOL, V330, P245, DOI 10.1007/BF00572440; JORGENSEN JM, 1988, NATURWISSENSCHAFTEN, V75, P319, DOI 10.1007/BF00367330; LAMBERT PR, 1994, LARYNGOSCOPE, V104, P701; LIPPE WR, 1991, HEARING RES, V56, P203, DOI 10.1016/0378-5955(91)90171-5; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MCFADDEN EA, 1989, HEARING RES, V41, P205, DOI 10.1016/0378-5955(89)90012-9; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; OESTERLE EC, 1993, HEARING RES, V70, P85, DOI 10.1016/0378-5955(93)90054-5; RAPHAEL Y, 1992, J NEUROCYTOL, V21, P663, DOI 10.1007/BF01191727; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; STONE JS, 1994, J COMP NEUROL, V341, P50, DOI 10.1002/cne.903410106; TUCCI DL, 1990, OTOLARYNG HEAD NECK, V103, P443, DOI 10.1177/019459989010300317; YAMASHITA H, 1995, P NATL ACAD SCI USA, V92, P3152, DOI 10.1073/pnas.92.8.3152	25	46	49	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1996	2	10					1136	1139		10.1038/nm1096-1136	http://dx.doi.org/10.1038/nm1096-1136			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837614				2022-12-25	WOS:A1996VK99500036
J	Syrengelas, AD; Chen, TT; Levy, R				Syrengelas, AD; Chen, TT; Levy, R			DNA immunization induces protective immunity against B-cell lymphoma	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; IDIOTYPIC VACCINATION; GENE IMMUNIZATION; FUSION PROTEIN; INDUCTION; VACCINES; ANTIGEN; RESPONSES; ANTIBODY; REGION	Idiotypic determinants of the immunoglobulin expressed on the surface of B-cell lymphomas are tumor-specific antigens (TSAs), which can be targeted by immunotherapy. Immunization with DNA constructs encoding the idiotype (Id) of a murine B-cell lymphoma induced specific anti-id antibody responses and protected mice against tumor challenge. Use of DNA encoding an Id/CM-CSF (idiotype/granuiocyte-macrophage colony-stimulating factor) fusion protein improved vaccine efficacy, and xenogeneic immunoglobulin constant region determinants were required for immunogenicity. These results indicate that DNA may be a simple and efficacious means of inducing immune responses against a weak, otherwise unrecognized tumor antigen, provided that additional stimuli are included with the DNA.			Syrengelas, AD (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV ONCOL,ROOM M207,STANFORD,CA 94305, USA.			Levy, Ronald/0000-0003-2061-0650	NCI NIH HHS [CA 33399] Funding Source: Medline; NIAID NIH HHS [5T32 AI 07290] Funding Source: Medline; NIGMS NIH HHS [GM 07365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033399, R37CA033399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGMAN Y, 1977, EUR J IMMUNOL, V7, P413, DOI 10.1002/eji.1830070702; CHEN TT, 1994, J IMMUNOL, V153, P4775; CHEN TT, 1995, J IMMUNOL, V154, P3105; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HAWKINS RE, 1994, BLOOD, V83, P3279; HAWKINS RE, 1993, J IMMUNOTHER, V14, P273, DOI 10.1097/00002371-199311000-00004; Irvine KR, 1996, J IMMUNOL, V156, P238; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; REFF ME, 1994, BLOOD, V83, P435; REITAN SK, 1995, EUR J IMMUNOL, V25, P1601, DOI 10.1002/eji.1830250620; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SLAVIN S, 1978, NATURE, V272, P624, DOI 10.1038/272624a0; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; TAO MH, 1993, NATURE, V362, P755, DOI 10.1038/362755a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WATANABE A, 1993, J IMMUNOL, V151, P2871; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105	23	225	247	1	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1038	1041		10.1038/nm0996-1038	http://dx.doi.org/10.1038/nm0996-1038			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782465				2022-12-25	WOS:A1996VF49700042
J	Gray, MD; Shen, JC; KamathLoeb, AS; Blank, A; Sopher, BL; Martin, GM; Oshima, J; Loeb, LA				Gray, MD; Shen, JC; KamathLoeb, AS; Blank, A; Sopher, BL; Martin, GM; Oshima, J; Loeb, LA			The Werner syndrome protein is a DNA helicase	NATURE GENETICS			English	Letter							ESCHERICHIA-COLI RECQ; GENETIC-CHARACTERIZATION; BINDING-PROTEIN; CELLS; RECOMBINATION; HOMOLOG	Werner syndrome (WS) is an uncommon autosomal recessive disorder characterized by premature aging. The clinical manifestations of WS, including atherosclerosis and osteoporosis, appear early in adulthood, and death in the fourth to sixth decade commonly ensues from myocardial infarction or cancer(1,2). In accord with the aging phenotype, cells from WS patients have a reduced replicative life span in culture(3), Genomic instability is observed at the cytogenetic level in the form of chromosome breaks and translocations(4) and at the molecular level by multiple large deletions(5). The Werner syndrome gene (WRN) has recently been cloned(6), The predicted product is a 1,432-amino-acid protein whose central domain is homologous to members of the RecQ family of DNA helicases, Such homology does not necessarily mean that WRN encodes an active helicase. For example, the Saccharomyces cerevisiae RAD26 gene protein(7) and the human transcription-repair coupling factor CSB (Cockayne syndrome B)(8) are highly homologous to known helicases, yet neither encodes an active helicase. Moreover, the Bloom's syndrome gene (BLM)(9), discovered before WRN, is also homologous to the RecQ family of DNA helicases, though we still await demonstration that it encodes an active helicase, Here we report that the WS protein does indeed catalyze DNA unwinding.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NCI NIH HHS [1-F32-CA67482] Funding Source: Medline; NIA NIH HHS [AG017151, AG08303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA067482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG008303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berenblum I, 1938, BIOCHEM J, V32, P295, DOI 10.1042/bj0320295; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSON SW, 1986, J BIOL CHEM, V261, P169; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	27	498	508	0	36	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1997	17	1					100	103		10.1038/ng0997-100	http://dx.doi.org/10.1038/ng0997-100			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288107				2022-12-25	WOS:A1997XU72400027
J	Takai, T; Yokota, T; Yasue, M; Nishiyama, C; Yuuki, T; Mori, A; Okudaira, H; Okumura, Y				Takai, T; Yokota, T; Yasue, M; Nishiyama, C; Yuuki, T; Mori, A; Okudaira, H; Okumura, Y			Engineering of the major house dust mite allergen Der f2 for allergen-specific immunotherapy	NATURE BIOTECHNOLOGY			English	Article						allergen engineering; protein design; T-cell proliferation; immunotherapy	T-CELL EPITOPES; DER-P-II; DERMATOPHAGOIDES-FARINAE; IMMUNOGLOBULIN-E; HUMAN IGE; LOCALIZATION; RECOGNITION; ACTIVATION; ANTIBODIES; RECEPTORS	A major problem with allergen-specific immunotherapy involving repeated injections of allergens is the risk of an anaphylactic reaction, We engineered the major house dust mite allergen, Der f 2, to reduce its capacity to induce skin test reactivity and histamine release from peripheral blood basophils in allergic patients. The engineered allergen, in which the disulfide bond that linked the N- and C-terminal sequences of Der f 2 was disrupted, retained T-cell epitopes essential for immunotherapy and ability to stimulate T-cell proliferation. Such engineered allergens are potentially useful for safer and more effective immunotherapy for allergies.	UNIV TOKYO, FAC MED, DEPT MED & PHYS THERAPY, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	Takai, T (corresponding author), ASAHI BREWERY CO LTD, BIOSCI RES & DEV LAB, 1-1-21 MIDORI, MORIYA, IBARAKI 30201, JAPAN.		Takai, Toshiro/K-5690-2013	Takai, Toshiro/0000-0001-8363-0355				AKAGAWA M, 1992, BIOSCI BIOTECH BIOCH, V56, P1725, DOI 10.1271/bbb.56.1725; BODMER JG, 1995, VOX SANG, V69, P359, DOI 10.1111/j.1423-0410.1995.tb00376.x; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DREDOG S, 1985, ALLERGY, V40, P55; HAIDA M, 1985, J ALLERGY CLIN IMMUN, V75, P686, DOI 10.1016/0091-6749(85)90094-6; Hoyne GF, 1995, CURR OPIN IMMUNOL, V7, P757, DOI 10.1016/0952-7915(95)80044-1; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Mori A, 1996, J IMMUNOL, V156, P2400; MORI A, 1997, IN PRESS BLOOD; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62, DOI 10.1159/000236804; Nishiyama C, 1995, MOL IMMUNOL, V32, P1021, DOI 10.1016/0161-5890(95)00091-7; NISHIYAMA C, 1993, INT ARCH ALLERGY IMM, V101, P159, DOI 10.1159/000236514; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1993, CURR OPIN IMMUNOL, V5, P968, DOI 10.1016/0952-7915(93)90114-8; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OBRIEN RM, 1995, IMMUNOLOGY, V86, P176; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SUKO M, 1995, INT ARCH ALLERGY IMM, V107, P278, DOI 10.1159/000237002; TAKAI T, 1997, IN PRESS MOL IMMUNOL; Tsitoura DC, 1996, J IMMUNOL, V157, P2160; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; VOOHORST R, 1967, J ALLERGY, V39, P325; YAMASHITA N, 1989, INT ARCH ALLER A IMM, V88, P173, DOI 10.1159/000234776; YSSEL H, 1992, J IMMUNOL, V148, P738; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757; YUUKI T, 1990, Japanese Journal of Allergology, V39, P557	41	149	161	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					754	758		10.1038/nbt0897-754	http://dx.doi.org/10.1038/nbt0897-754			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255789				2022-12-25	WOS:A1997XM70700026
J	Wilson, RB; Roof, DM				Wilson, RB; Roof, DM			Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; FRIEDREICHS ATAXIA; CRITICAL REGION; PET MUTANTS; VITAMIN-E; PROTEIN; RNA; MUTATIONS; MENADIONE; MEDICINE	Friedreich's ataxia (FRDA) is an autosomal recessive degenerative disorder that primarily affects the nervous system and heart. Patients with FRDA have point mutations or trinucleotide repeat expansions in both alleles of FRDA, which encodes a protein termed frataxin. We show that the yeast frataxin homologue, which we have named YFH1, localizes to mitochondria and is required to maintain mitochondrial DNA, The YFH1-homologous domain of frataxin functions in yeast and a disease-associated missense mutation of this domain, or the corresponding domain in YFH1, reduces function. Our data suggest that mitochondrial dysfunction contributes to FRDA pathophysiology.	UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	Wilson, RB (corresponding author), UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.							Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BARBEAU A, 1984, CAN J NEUROL SCI, V11, P646, DOI 10.1017/S0317167100035228; BARBEAU A, 1980, CAN J NEUROL SCI, V7, P455, DOI 10.1017/S0317167100023064; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; GARN H, 1994, J IMMUNOL METHODS, V168, P253, DOI 10.1016/0022-1759(94)90062-0; GENGA A, 1986, J BIOL CHEM, V261, P9328; JAHN B, 1995, J CLIN MICROBIOL, V33, P661, DOI 10.1128/JCM.33.3.661-667.1995; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; KOOBS DH, 1978, ARCH PATHOL LAB MED, V102, P66; LAMARCHE JB, 1980, CAN J NEUROL SCI, V7, P389, DOI 10.1017/S0317167100022927; LUFT R, 1995, BBA-MOL BASIS DIS, V1271, P1, DOI 10.1016/0925-4439(95)00002-L; Mastrogiacomo F, 1996, NEURODEGENERATION, V5, P27, DOI 10.1006/neur.1996.0004; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; MONTERMINI L, 1995, AM J HUM GENET, V57, P1061; MUELLER DM, 1987, CURR GENET, V11, P359, DOI 10.1007/BF00378178; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Rose MD., 1990, METHODS YEAST GENETI; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; SANYAL A, 1995, MOL GEN GENET, V246, P56, DOI 10.1007/BF00290133; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON M, 1984, P NATL ACAD SCI-BIOL, V81, P8, DOI 10.1073/pnas.81.1.8; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; TAPPEL AL, 1972, ANN NY ACAD SCI, V203, P12, DOI 10.1111/j.1749-6632.1972.tb27851.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; ZEVIANI M, 1992, J INHERIT METAB DIS, V15, P456, DOI 10.1007/BF01799604; [No title captured]	33	300	312	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					352	357		10.1038/ng0897-352	http://dx.doi.org/10.1038/ng0897-352			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241271				2022-12-25	WOS:A1997XM90900016
J	Gold, L; Alper, J				Gold, L; Alper, J			Drug discovery - Keeping pace with genomics through combinatorial chemistry	NATURE BIOTECHNOLOGY			English	Editorial Material											Gold, L (corresponding author), NEXSTAR PHARMACEUT,BOULDER,CO 80302, USA.							Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; 1996, NATURE BIOTECHNOLOGY, V14, P1199	4	13	13	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					297	297		10.1038/nbt0497-297	http://dx.doi.org/10.1038/nbt0497-297			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094108				2022-12-25	WOS:A1997WQ55400006
J	Manolios, N; Collier, S; Taylor, J; Pollard, J; Harrison, LC; Bender, V				Manolios, N; Collier, S; Taylor, J; Pollard, J; Harrison, LC; Bender, V			T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease	NATURE MEDICINE			English	Article							ANTIBODY	This study describes a novel method of inhibiting T-cell function by the use of peptides rationally designed from the T-cell antigen receptor (TCR) alpha-chain transmembrane sequence involved with TCR receptor assembly. The most effective peptide (core peptide, CP) modulating in vitro and in vivo T-cell function contained nine amino acids two of which, lysine and arginine, were hydrophilic and separated by four hydrophobic amino acids. CP without chemical modification or conjugation was able to enter non-T and T cells. Conjugation of CP at the carboxyl terminus with palmitic acid resulted in a greater inhibition of cell interleukin-2 (IL-2) production in vitro than peptide alone. When examined for effects in vivo, CP reduced clinical signs of inflammation in three T cell-mediated disease models including adjuvant-induced arthritis, experimental allergic neuritis, and cyclophosphamide-induced diabetes in NOD/Lt(F) mice. This peptide or its analogues has potential as a therapeutic agent in human inflammatory and autoimmune disorders.	UNIV SYDNEY,NEUROPHYSIOL INST,SYDNEY,NSW 2006,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; CSIRO,DIV BIOMOL ENGN,SYDNEY,NSW 2113,AUSTRALIA	University of Sydney; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Manolios, N (corresponding author), ROYAL N SHORE HOSP,DEPT RHEUMATOL,SYDNEY,NSW 2065,AUSTRALIA.			Manolios, Nicholas/0000-0002-6525-7830; Taylor, Jude/0000-0003-2796-0768				BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; HOLMDAHL R, 1992, CLIN EXP IMMUNOL, V88, P96; HONEYMAN MC, 1993, SPRINGER SEMIN IMMUN, V14, P253; KIKUTANI H, 1992, ADV IMMUNOL, V51, P285, DOI 10.1016/S0065-2776(08)60490-3; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; PEARSON CM, 1961, J EXP MED, V113, P485, DOI 10.1084/jem.113.3.485; SAMELSON LE, 1987, J IMMUNOL, V139, P2708; SPIES JM, 1995, J NEUROIMMUNOL, V57, P77, DOI 10.1016/0165-5728(94)00164-J; WHITEHOUSE MW, 1990, AGENTS ACTIONS, V31, P47, DOI 10.1007/BF02003221; WHITTAKER RG, 1993, PEPTIDE RES, V6, P125	14	89	100	1	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					84	88		10.1038/nm0197-84	http://dx.doi.org/10.1038/nm0197-84			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986747				2022-12-25	WOS:A1997WA73300043
J	Zhuchenko, O; Bailey, J; Bonnen, P; Ashizawa, T; Stockton, DW; Amos, C; Dobyns, WB; Subramony, SH; Zoghbi, HY; Lee, CC				Zhuchenko, O; Bailey, J; Bonnen, P; Ashizawa, T; Stockton, DW; Amos, C; Dobyns, WB; Subramony, SH; Zoghbi, HY; Lee, CC			Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha(1A)-voltage-dependent calcium channel	NATURE GENETICS			English	Article							CAG REPEAT; P-TYPE; CHROMOSOME 19P; CA2+ CHANNELS; GENE; DISEASE; NEURONS; MAPS; ATROPHY; REGION	A polymorphic CAG repeat was identified in the human alpha(1A) voltage-dependent calcium channel subunit, To test the hypothesis that expansion of this CAG repeat could be the cause of an inherited progressive ataxia, we genotyped a large number of unrelated controls and ataxia patients. Eight unrelated patients with late onset ataxia had alleles with larger repeat numbers (21-27) compared to the number of repeats (4-16) in 475 non-ataxia individuals, Analysis of the repeat length in families of the affected individuals revealed that the expansion segregated with the phenotype in every patient, We identified six isoforms of the human alpha(1A) calcium channel subunit. The CBG repeat is within the open reading frame and is predicted to encode glutamine in three of the isoforms. We conclude that a small polyglutamine expansion in the human alpha(1A) calcium channel is most likely the cause of a newly classified autosomal dominant spinocerebellar ataxia, SCAG.	BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT NEUROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, HOUSTON, TX 77030 USA; VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; UNIV MINNESOTA, SCH MED, DEPT NEUROL & PEDIAT, MINNEAPOLIS, MN 55455 USA; UNIV MISSISSIPPI, MED CTR, JACKSON, MS 39216 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Minnesota System; University of Minnesota Twin Cities; University of Mississippi; University of Mississippi Medical Center			Dobyns, William/AAI-2768-2020; Dobyns, William Brian/ABC-6525-2021	Dobyns, William/0000-0002-7681-2844; Zoghbi, Huda/0000-0002-0700-3349	NINDS NIH HHS [NS27699] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027699] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Diriong S, 1995, GENOMICS, V30, P605, DOI 10.1006/geno.1995.1284; Elliott MA, 1996, ANN NEUROL, V39, P100, DOI 10.1002/ana.410390115; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOUSMAN D, 1995, NAT GENET, V10, P3, DOI 10.1038/ng0595-3; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KRAMER PL, 1995, AM J HUM GENET, V57, P182; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARGOLIS RL, 1995, SOMAT CELL MOLEC GEN, V21, P279, DOI 10.1007/BF02255782; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1994, J NEUROSCI, V14, P2844; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PEREZREYES E, 1994, FEBS LETT, V342, P119, DOI 10.1016/0014-5793(94)80484-2; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STEVANIN G, 1994, AM J HUM GENET, V54, P11; Subramony SH, 1996, MOVEMENT DISORD, V11, P174, DOI 10.1002/mds.870110210; TELENIUS H, 1993, HUM MOL GENET, V2, P1535, DOI 10.1093/hmg/2.10.1535; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; TWELLS R, 1994, HUM MOL GENET, V3, P177, DOI 10.1093/hmg/3.1.177; VAHEDI K, 1995, ANN NEUROL, V37, P289, DOI 10.1002/ana.410370304; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; ZOGHBI HY, IN PRESS ADV HUM GEN	44	1277	1326	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1997	15	1					62	69		10.1038/ng0197-62	http://dx.doi.org/10.1038/ng0197-62			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WA373	8988170				2022-12-25	WOS:A1997WA37300022
J	Kane, C; Shepherd, RM; Squires, PE; Johnson, PRV; James, RFL; Milla, PJ; AynsleyGreen, A; Lindley, KJ; Dunne, MJ				Kane, C; Shepherd, RM; Squires, PE; Johnson, PRV; James, RFL; Milla, PJ; AynsleyGreen, A; Lindley, KJ; Dunne, MJ			Loss of functional K-ATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy	NATURE MEDICINE			English	Article							INSULIN-SECRETING CELLS; SULFONYLUREA RECEPTOR; CYSTIC-FIBROSIS; NESIDIOBLASTOSIS; MUTATIONS; FORM; GENE	Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a disorder of childhood associated with inappropriate hypersecretion of insulin by the pancreas. The pathogenesis of the condition has hitherto remained controversial. We show here that insulin-secreting cells from a homogeneous group of five infants with PHHI lack ATP-sensitive K+ channel (K-ATP) activity. As a consequence, PHHI beta-cells are spontaneously electrically active with high basal cytosolic Ca2+ concentrations due to Ca2+ influx. Our findings define the pathogenesis of this disease as a novel K+ channel disorder.	UNIV SHEFFIELD,DEPT BIOMED SCI,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT SURG,LEICESTER LE2 7LX,LEICS,ENGLAND; UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of Sheffield; University of Leicester; University of London; University College London				Squires, Paul/0000-0003-4547-6777	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; AYNSLEYGREEN A, 1981, DEV MED CHILD NEUROL, V23, P372; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; BRANDT AM, 1993, COMPOS STRUCT, V25, P51, DOI 10.1016/0263-8223(93)90150-O; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KAISER N, 1990, DIABETOLOGIA, V33, P482, DOI 10.1007/BF00405110; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; Lebrun P, 1996, J PHARMACOL EXP THER, V277, P156; Lindley KJ, 1996, ARCH DIS CHILD, V74, P373, DOI 10.1136/adc.74.5.373; MATHEW PM, 1988, CLIN PEDIATR, V27, P148, DOI 10.1177/000992288802700307; Morris AAM, 1996, ARCH DIS CHILD, V75, P115, DOI 10.1136/adc.75.2.115; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Sempoux C, 1995, DIABETES METAB, V21, P402; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SPITZ L, 1992, ARCH DIS CHILD, V67, P201, DOI 10.1136/adc.67.2.201; SQUIRES PE, 1994, PFLUG ARCH EUR J PHY, V427, P181, DOI 10.1007/BF00585959; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; THORNTON PS, 1995, PEDIATR RES, V37, pA100; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WOOLF DA, 1991, ARCH DIS CHILD, V66, P529, DOI 10.1136/adc.66.4.529	26	218	221	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1344	1347		10.1038/nm1296-1344	http://dx.doi.org/10.1038/nm1296-1344			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946833				2022-12-25	WOS:A1996VW51500040
J	Tian, JD; ClareSalzler, M; Herschenfeld, A; Middleton, B; Newman, D; Mueller, R; Arita, S; Evans, C; Atkinson, MA; Mullen, Y; Sarvetnick, N; Tobin, AJ; Lehmann, PV; Kaufman, DL				Tian, JD; ClareSalzler, M; Herschenfeld, A; Middleton, B; Newman, D; Mueller, R; Arita, S; Evans, C; Atkinson, MA; Mullen, Y; Sarvetnick, N; Tobin, AJ; Lehmann, PV; Kaufman, DL			Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice	NATURE MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; NOD MICE; IMMUNE-RESPONSE; T-CELLS; IMMUNOTHERAPY; PATHOGENESIS; IMMUNIZATION; TOLERANCE; INSULITIS; MELLITUS	In nonobese diabetic (NOD) mice, beta-cell reactive T-helper type 1 (Th1) responses develop spontaneously and gradually spread, creating a cascade of responses that ultimately destroys the beta-cells. The diversity of the autoreactive T-cell repertoire creates a major obstacle to the development of therapeutics. We show that even in the presence of established Th1 responses, it is possible to induce autoantigen-specific anti-inflammatory Th2 responses. Immune deviation of T-cell responses to the beta-cell autoantigen glutamate decarboxylase (GAD65), induced an active form of self-tolerance that was associated with an inhibition of disease progression in prediabetic mice and prolonged survival of syngeneic islet grafts in diabetic NOD mice. Thus, modulation of autoantigen-specific Th1/Th2 balances may provide a minimally invasive means of downregulating established pathogenic autoimmune responses.	UNIV CALIF LOS ANGELES, DEPT NEUROL & PHYSIOL SCI, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT MOL & MED PHARMACOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT PSYCHIAT & BEHAV SCI, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT SURG, LOS ANGELES, CA 90095 USA; UNIV FLORIDA, DEPT PATHOL, GAINESVILLE, FL 32609 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; CASE WESTERN RESERVE UNIV, DEPT PATHOL, CLEVELAND, OH 44106 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University System of Florida; University of Florida; Scripps Research Institute; Case Western Reserve University			Kaufman, Daniel/AAU-1228-2021	Kaufman, Daniel/0000-0002-9844-5918				BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; Daniel D, 1996, P NATL ACAD SCI USA, V93, P956, DOI 10.1073/pnas.93.2.956; ELIAS D, 1994, LANCET, V343, P704, DOI 10.1016/S0140-6736(94)91582-2; ELLIOTT JF, 1994, DIABETES, V43, P1494, DOI 10.2337/diabetes.43.12.1494; FAIRCHILD PJ, 1994, IMMUNOLOGY, V81, P487; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; LACY PE, 1993, DIABETES REV, V1, P76; LEE DS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P157, DOI 10.1016/0167-4781(93)90056-J; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUIR A, 1995, J CLIN INVEST, V95, P628, DOI 10.1172/JCI117707; PALMER JP, 1993, DIABETES REV, V1, P104; PLEAU JM, 1995, CLIN IMMUNOL IMMUNOP, V76, P90, DOI 10.1006/clin.1995.1092; QIN HY, 1993, J IMMUNOL, V150, P2072; RABINOVITCH A, 1994, DIABETES, V43, P613, DOI 10.2337/diabetes.43.5.613; RAMSDELL F, 1992, SCIENCE, V257, P1130, DOI 10.1126/science.257.5073.1130; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; Rossini A.A., 1993, DIABETES REV ALEX, V1, P43; SUTHERLAND DER, 1993, DIABETES REV, V1, P152; THAI AC, 1993, DIABETES REV, V1, P1; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TISCH R, 1994, P NATL ACAD SCI USA, V91, P437, DOI 10.1073/pnas.91.2.437; WICKER LS, 1986, DIABETES, V35, P855, DOI 10.2337/diabetes.35.8.855; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	29	221	230	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1348	1353		10.1038/nm1296-1348	http://dx.doi.org/10.1038/nm1296-1348			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946834				2022-12-25	WOS:A1996VW51500041
J	Hicks, GG; Shi, EG; Li, XM; Li, CH; Pawlak, M; Ruley, HE				Hicks, GG; Shi, EG; Li, XM; Li, CH; Pawlak, M; Ruley, HE			Functional genomics in mice by tagged sequence mutagenesis	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; DEVELOPMENTALLY-REGULATED GENES; BINDING-PROTEIN; MOUSE EMBRYO; DNA METHYLATION; MESSENGER-RNA; DROSOPHILA; FUSION; KINASE; TRANSCRIPTION	Most mammalian genes will soon be characterized as cDNA sequences with little information about their function. To utilize this sequence information for large-scale functional studies,a gene trap retrovirus shuttle vector has been developed to disrupt genes expressed in murine embryonic stem (ES) cells. A library of mutant clones was isolated, and regions of genomic DMA adjacent to 400 independent provirus inserts were cloned and sequenced. The flanking sequences, designated 'promoter-proximal sequence tags', or PSTs, identified 63 specific genes and anonymous cDNAs disrupted as a result of virus integration. The efficiency of tagged sequence mutagenesis suggests that many of the 10,000-20,000 genes expressed in ES cells can be targeted, providing defined mutations for the analysis of gene functions in vivo. In addition, PSTs provide the first expressed sequence tags derived from genomic DNA, and define gene features such as exon boundaries and promoters that are missing from cDNA sequences.	VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232	Vanderbilt University				Hicks, Geoffrey/0000-0003-4688-2312				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1643; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; Chen J, 1996, ONCOGENE, V12, P979; CHEN J, 1994, METH MOL G, V4, P123; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; DENG JM, 1995, TRANSGENIC RES, V4, P264, DOI 10.1007/BF01969120; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; Forrester LM, 1996, P NATL ACAD SCI USA, V93, P1677, DOI 10.1073/pnas.93.4.1677; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GASCA S, 1995, DEV GENET, V17, P141, DOI 10.1002/dvg.1020170206; GIBBS RA, 1995, NAT GENET, V11, P121, DOI 10.1038/ng1095-121; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; Green MC., 1989, GENETIC VARIANTS STR, P12; HICKS GG, 1995, METHOD ENZYMOL, V254, P263; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LEWIN B, 1975, CELL, V4, P77, DOI 10.1016/0092-8674(75)90113-0; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKUSICK VA, 1988, MENDELIAN INHERITANC; MONK M, 1987, DEVELOPMENT, V99, P371; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NEHLS M, 1994, CURR BIOL, V4, P983, DOI 10.1016/S0960-9822(00)00222-0; NUSSBAUM RL, 1987, P NATL ACAD SCI USA, V84, P6521, DOI 10.1073/pnas.84.18.6521; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; REDDY S, 1992, P NATL ACAD SCI USA, V89, P6721, DOI 10.1073/pnas.89.15.6721; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; RENDAHL KG, 1992, J NEUROSCI, V12, P390; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; Scherer CA, 1996, CELL GROWTH DIFFER, V7, P1393; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; TAKEUCHI T, 1995, GENE DEV, V9, P1211, DOI 10.1101/gad.9.10.1211; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; WURST W, 1995, GENETICS, V139, P889; YANG YS, 1993, MOL CELL BIOL, V13, P5593, DOI 10.1128/MCB.13.9.5593; Yotov WV, 1996, GENE DEV, V10, P1763, DOI 10.1101/gad.10.14.1763; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; [No title captured]	58	100	117	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	AUG	1997	16	4					338	344		10.1038/ng0897-338	http://dx.doi.org/10.1038/ng0897-338			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241269				2022-12-25	WOS:A1997XM90900014
J	Nilsson, M; Krejci, K; Koch, J; Kwiatkowski, M; Gustavsson, P; Landegren, U				Nilsson, M; Krejci, K; Koch, J; Kwiatkowski, M; Gustavsson, P; Landegren, U			Padlock probes reveal single-nucleotide differences, parent of origin and in situ distribution of centromeric sequences in human chromosomes 13 and 21	NATURE GENETICS			English	Article							ALPHA-SATELLITE DNA; IN-SITU; LABELING PRINS; ORGANIZATION; LIGASE; OLIGONUCLEOTIDES; IDENTIFICATION; HYBRIDIZATION; CONSTRUCTION; POLYMORPHISM		DANISH CANC SOC,DEPT CYTOGENET,DK-8000 AARHUS C,DENMARK; UPPSALA CHILDRENS HOSP,DEPT CLIN GENET,UPPSALA,SWEDEN	Danish Cancer Society	Nilsson, M (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT MED GENET,BEIJER LAB,BOX 589,S-75123 UPPSALA,SWEDEN.		Landegren, Ulf D/A-8197-2019	Nilsson, Mats/0000-0001-9985-0387				BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; CHARLIEU JP, 1992, GENOMICS, V14, P515, DOI 10.1016/S0888-7543(05)80256-3; CONNOLLY BA, 1987, TETRAHEDRON LETT, V28, P463, DOI 10.1016/S0040-4039(00)95757-5; Finelli P, 1996, GENOMICS, V38, P325, DOI 10.1006/geno.1996.0635; FIRE A, 1995, P NATL ACAD SCI USA, V92, P4641, DOI 10.1073/pnas.92.10.4641; GREIG GM, 1993, J MOL EVOL, V37, P464, DOI 10.1007/BF00160427; JORGENSEN AL, 1987, P NATL ACAD SCI USA, V84, P1075, DOI 10.1073/pnas.84.4.1075; KOCH J, 1995, CYTOGENET CELL GENET, V71, P142, DOI 10.1159/000134094; KOCH JE, 1989, CHROMOSOMA, V98, P259, DOI 10.1007/BF00327311; Kwiatkowski M, 1996, NUCLEIC ACIDS RES, V24, P4632, DOI 10.1093/nar/24.23.4632; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Liu DY, 1996, J AM CHEM SOC, V118, P1587, DOI 10.1021/ja952786k; LOU J, 1996, NUCLEIC ACIDS RES, V24, P3071; MARCAIS B, 1991, J MOL EVOL, V33, P42, DOI 10.1007/BF02100194; MARCAIS B, 1991, HUM GENET, V86, P311; NILSSON M, 1994, SCIENCE, V265, P2085, DOI 10.1126/science.7522346; OKeefe CL, 1996, HUM MOL GENET, V5, P1793, DOI 10.1093/hmg/5.11.1793; PELLESTOR F, 1994, HUM GENET, V94, P346; PELLESTOR F, 1995, HUM GENET, V95, P12; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; SUND C, 1988, NUCLEOS NUCLEOT, V7, P655, DOI 10.1080/07328318808056303; TROWELL HE, 1993, HUM MOL GENET, V2, P1639, DOI 10.1093/hmg/2.10.1639; WEVRICK R, 1989, P NATL ACAD SCI USA, V86, P9394, DOI 10.1073/pnas.86.23.9394; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; WU DY, 1989, GENE, V76, P245, DOI 10.1016/0378-1119(89)90165-0	25	127	143	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					252	255		10.1038/ng0797-252	http://dx.doi.org/10.1038/ng0797-252			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207789				2022-12-25	WOS:A1997XG60900019
J	Wojnowski, L; Zimmer, AM; Beck, TW; Hahn, H; Bernal, R; Rapp, UR; Zimmer, A				Wojnowski, L; Zimmer, AM; Beck, TW; Hahn, H; Bernal, R; Rapp, UR; Zimmer, A			Endothelial apoptosis in Braf-deficient mice	NATURE GENETICS			English	Article							RECEPTOR TYROSINE KINASE; B-RAF; BLOOD-VESSELS; DIFFERENTIATION; VASCULOGENESIS; EXPRESSION; TUMORS; GROWTH; CELLS; MYC		NIMH,NATL HUMAN GENOME RES INST,GENET SECT,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,SAIC FREDERICK,INTRAMURAL RES SUPPORT PROGRAM,FREDERICK,MD 21702; UNIV WURZBURG,INST MED RADIAT & CELL RES,D-97078 WURZBURG,GERMANY	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Wurzburg			Bernal, Ricardo A/B-2124-2010; Zimmer, Andreas/B-8357-2009	Bernal, Ricardo A./0000-0001-5849-8647				ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; MODAK SP, 1972, EXP CELL RES, V75, P307, DOI 10.1016/0014-4827(72)90434-X; NODEN DM, 1990, ANN NY ACAD SCI, V588, P236, DOI 10.1111/j.1749-6632.1990.tb13214.x; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PAWSON T, 1994, BIOCHEM SOC T, V22, P455, DOI 10.1042/bst0220455; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Sanders EJ, 1995, INT REV CYTOL, V163, P105, DOI 10.1016/S0074-7696(08)62210-X; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186	24	250	264	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					293	297		10.1038/ng0797-293	http://dx.doi.org/10.1038/ng0797-293			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207797				2022-12-25	WOS:A1997XG60900027
J	Burnett, AL; Calvin, DC; Chamness, SL; Liu, JX; Nelson, RJ; Klein, SL; Dawson, VL; Dawson, TM; Snyder, SH				Burnett, AL; Calvin, DC; Chamness, SL; Liu, JX; Nelson, RJ; Klein, SL; Dawson, VL; Dawson, TM; Snyder, SH			Urinary bladder urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans	NATURE MEDICINE			English	Article							IMMUNOHISTOCHEMICAL LOCALIZATION; NADPH DIAPHORASE; RAT; INNERVATION; ORGANS; PENIS; GENE	Idiopathic voiding disorders affect up to 10-15% of men and women. We describe bladder abnormalities in mice with targeted deletion of the gene for neuronal nitric oxide synthase which model the clinical disorders. The mice possess hypertrophic dilated bladders and dysfunctional urinary outlets which do not relax in response to electrical field stimulation or L-arginine. The mice also display increased urinary frequency.	JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT UROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT PHYSIOL & PSYCHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Dawson, Valina/Y-9757-2019	Nelson, Randy/0000-0002-8194-4016; Dawson, Valina/0000-0002-2915-3970	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-22201] Funding Source: Medline; NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALM P, 1993, ACTA PHYSIOL SCAND, V148, P421, DOI 10.1111/j.1748-1716.1993.tb09578.x; BENNETT BC, 1995, J UROLOGY, V153, P2004, DOI 10.1016/S0022-5347(01)67391-9; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BURNETT AL, 1995, UROLOGY, V45, P435, DOI 10.1016/S0090-4295(99)80012-0; BURNETT AL, 1993, J UROLOGY, V150, P73, DOI 10.1016/S0022-5347(17)35401-0; Burnett AL, 1996, MOL MED, V2, P288, DOI 10.1007/BF03401627; BURNETT AL, 1995, BIOL REPROD, V52, P1, DOI 10.1095/biolreprod52.1.1; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; COUILLARD DR, 1905, UROLOGIC CLIN N AM E, P593; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; GULBENKIAN S, 1987, J AUTONOM NERV SYST, V18, P235, DOI 10.1016/0165-1838(87)90122-6; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KAPLAN SA, 1995, UROL CLIN N AM, V22, P309; KOUTTS J, 1974, SEMIN HEMATOL, V11, P115; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; PERSSON K, 1993, BRIT J PHARMACOL, V110, P521, DOI 10.1111/j.1476-5381.1993.tb13842.x; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; TURNERWARWICK R, 1979, UROLOGIC CLIN N AM C, P13; VIZZARD MA, 1994, BRAIN RES, V646, P279, DOI 10.1016/0006-8993(94)90090-6	19	114	119	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					571	574		10.1038/nm0597-571	http://dx.doi.org/10.1038/nm0597-571			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142130				2022-12-25	WOS:A1997WX54300041
J	Brismar, H; Ulfhake, B				Brismar, H; Ulfhake, B			Fluorescence lifetime measurements in confocal microscopy of neurons labeled with multiple fluorophores	NATURE BIOTECHNOLOGY			English	Article						neuropeptides; primary sensory neuron; immunohistochemistry; colocalization	VARIABLE-FREQUENCY PHASE; SENSORY NEURONS; MODULATION DATA; DORSAL HORN; SUBSTANCE-P; SPINAL-CORD; RESOLUTION; NEUROPEPTIDES; COEXISTENCE; LAMINAE	In order to resolve multiple fluorophores by their lifetimes in discrete tissue domains, the labeling intensity must be sufficiently strong and the intensity-difference between the labels must not be too large, the rate of fading should be similar for all fluorophores, and the lifetimes of the fluorophores should be sufficiently discrete. We could readily distinguish Cyanine-3.18 (Cy-3), Lissamine Rhodamine (LRSC), and Texas Red when they were not colocalized in tissue profiles. Colocalization of Cy-3 and LRSC, as well as Cy3 and Texas Red, could also be distinguished, while the combination of LRSC and Texas Red was more difficult. We have used fluorescence lifetime recordings in confocal microscopy to detect different neuropeptides in neurons. We demonstrate that somatostatin and galanin are colocalized in axon profiles of the spinal cord dorsal horn.	KAROLINSKA INST,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet	Brismar, H (corresponding author), ROYAL INST TECHNOL,S-10044 STOCKHOLM,SWEDEN.		Brismar, Hjalmar/E-8524-2011; Ulfhake, Brun/AAG-8969-2020	Brismar, Hjalmar/0000-0003-0578-4003; Ulfhake, Brun/0000-0001-5037-7461	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-41301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1993, NEUROPROTOCOLS; ARVIDSSON U, 1990, SYNAPSE, V6, P237, DOI 10.1002/syn.890060305; ASLUND N, 1987, APPL OPTICS, V26, P3232; ASLUND N, 1994, SPIE P, V2184; BRISMAR H, 1995, J HISTOCHEM CYTOCHEM, V43, P699, DOI 10.1177/43.7.7608524; BUUMANN EP, 1992, SCANNING, V14, P155; CAMERON AA, 1988, NEUROSCIENCE, V27, P969, DOI 10.1016/0306-4522(88)90200-X; FLORIJN RJ, 1995, CYTOMETRY, V19, P77; GADELLA TWJ, 1993, BIOPHYS CHEM, V48, P221, DOI 10.1016/0301-4622(93)85012-7; GHIGGINO KP, 1992, REV SCI INSTRUM, V63, P2999, DOI 10.1063/1.1142599; GRATTON E, 1984, BIOPHYS J, V46, P479, DOI 10.1016/S0006-3495(84)84044-8; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; Hunt S. P., 1983, CHEM NEUROANATOMY, P53; JU G, 1987, CELL TISSUE RES, V247, P417; KOLLNER M, 1992, CHEM PHYS LETT, V200, P199, DOI 10.1016/0009-2614(92)87068-Z; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAKOWICZ JR, 1992, ANAL BIOCHEM, V202, P316, DOI 10.1016/0003-2697(92)90112-K; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MORGAN CG, 1991, J MICROSC, V165, P49; MOSSBERG K, 1990, J HISTOCHEM CYTOCHEM, V38, P179, DOI 10.1177/38.2.1967620; O'Connor D. V., 1984, TIME CORRELATED SING; OIDA T, 1993, BIOPHYS J, V64, P676, DOI 10.1016/S0006-3495(93)81427-9; SASAKI K, 1991, APPL SPECTROSC, V45, P1041, DOI 10.1366/0003702914336336; SPENCER RD, 1969, ANN NY ACAD SCI, V158, P361, DOI 10.1111/j.1749-6632.1969.tb56231.x; TODD AJ, 1993, PROG NEUROBIOL, V41, P609, DOI 10.1016/0301-0082(93)90045-T; TUCHSCHERER MM, 1989, J NEUROSCI, V9, P195; WEBER G, 1981, J PHYS CHEM-US, V85, P949, DOI 10.1021/j150608a006; WESSENDORF MW, 1990, ANAL NEURONAL MICROC; Willis WD, 1991, SENSORY MECH SPINAL; XU Z, 1994, THESIS KAROLINSKA I	31	26	28	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					373	377		10.1038/nbt0497-373	http://dx.doi.org/10.1038/nbt0497-373			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094141				2022-12-25	WOS:A1997WQ55400040
J	Chinnaiyan, AM; Woffendin, C; Dixit, VM; Nabel, GJ				Chinnaiyan, AM; Woffendin, C; Dixit, VM; Nabel, GJ			The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; ACTIVATION-INDUCED APOPTOSIS; CD4(+) T-CELLS; INFECTED-CELLS; VIRUS; AIDS; THERAPY; PATHOGENESIS; HYPOTHESIS; CED-3	Accelerated programmed cell death, or apoptosis, contributes to the CD4(+) T-cell depletion characteristic of infection by human immunodeficiency virus (HIV). It has therefore been proposed that limiting apoptosis may represent a therapeutic modality for HIV infection. We found, however, that T leukemia cells or peripheral blood mononuclear cells (PBMCs) exposed to HIV-1 underwent enhanced viral replication in the presence of the cell death inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk). Furthermore, z-VAD-fmk, which targets the pro-apoptotic interleukin-1 beta-converting enzyme (ICE)-like proteases, stimulated endogenous virus production in activated PBMCs derived from HIV-1-infected asymptomatic individuals. These findings suggest that programmed cell death may serve as a beneficial host mechanism to limit HIV spread and that strategies to inhibit it may have deleterious consequences for the infected host.	UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIGMS NIH HHS [GM 07863] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEISEN JC, 1992, IMMUNOL TODAY, V13, P388, DOI 10.1016/0167-5699(92)90086-M; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; AMEISEN JC, 1995, ADV EXP MED BIOL, V374, P139; ANDRIEU JM, 1995, J INFECT DIS, V171, P523, DOI 10.1093/infdis/171.3.523; ANTONI BA, 1995, J VIROL, V69, P2384, DOI 10.1128/JVI.69.4.2384-2392.1995; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Corbeil J, 1996, J EXP MED, V183, P39, DOI 10.1084/jem.183.1.39; ESTAQUIER J, 1994, P NATL ACAD SCI USA, V91, P9431, DOI 10.1073/pnas.91.20.9431; ESTAQUIER J, 1995, J EXP MED, V182, P1759, DOI 10.1084/jem.182.6.1759; Estaquier J, 1996, BLOOD, V87, P4959, DOI 10.1182/blood.V87.12.4959.bloodjournal87124959; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LU W, 1995, AIDS, V9, P35, DOI 10.1097/00002030-199501000-00005; MALORNI W, 1993, FEBS LETT, V327, P75, DOI 10.1016/0014-5793(93)81043-Y; MARTIN SJ, 1995, ADV EXP MED BIOL, V374, P129; MARTIN SJ, 1994, J IMMUNOL, V152, P330; Meyaard L, 1995, Curr Top Microbiol Immunol, V200, P213; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OYAIZU N, 1993, BLOOD, V82, P3392; PANTALEO G, 1995, NAT MED, V1, P118, DOI 10.1038/nm0295-118; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Sandstrom PA, 1996, J VIROL, V70, P4617, DOI 10.1128/JVI.70.7.4617-4622.1996; SARIN A, 1994, J IMMUNOL, V153, P862; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMSON AW, 1995, ADV EXP MED BIOL, V374, P211; WANG YJ, 1993, PROG FOOD NUTR SCI, V17, P351; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YANG YL, 1995, P NATL ACAD SCI USA, V92, P3051, DOI 10.1073/pnas.92.7.3051; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	48	75	78	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1997	3	3					333	337		10.1038/nm0397-333	http://dx.doi.org/10.1038/nm0397-333			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055863				2022-12-25	WOS:A1997WL30500037
J	Fisher, KJ; Jooss, K; Alston, J; Yang, YP; Haecker, SE; High, K; Pathak, R; Raper, SE; Wilson, JM				Fisher, KJ; Jooss, K; Alston, J; Yang, YP; Haecker, SE; High, K; Pathak, R; Raper, SE; Wilson, JM			Recombinant adeno-associated virus for muscle directed gene therapy	NATURE MEDICINE			English	Article							ADENOASSOCIATED VIRUS; PHENOTYPIC CORRECTION; NONDIVIDING CELLS; SYSTEMIC DELIVERY; EXPRESSION; VECTORS; TRANSDUCTION; INTEGRATION; DNA; MYOBLASTS	Although gene transfer with adeno-associated virus (AAV) vectors has typically been low, transduction can be enhanced in the presence of adenovirus gene products through the formation of double stranded, non-integrated AAV genomes. We describe the unexpected finding of high level and stable transgene expression in mice following intramuscular injection of purified recombinant AAV (rAAV). The rAAV genome is efficiently incorporated into nuclei of differentiated muscle fibers where it persists as head-to-tail concatamers. Fluorescent in situ hybridization of muscle tissue suggests single integration sites. Neutralizing antibody against AAV capsid proteins does not prevent readministration of vector. Remarkably, no humoral or cellular immune responses are elicited to the neoantigenic transgene product E. coli beta-galactosidase. The favorable biology of rAAV in muscle-directed gene therapy described in this study expands the potential of this vector for the treatment of inherited and acquired diseases.	UNIV PENN HLTH SYST,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT SURG,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT PEDIAT,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; The Wistar Institute			High, Katherine A./AAB-9322-2020; Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				ALEXANDER IE, 1994, J VIROL, V68, P8282, DOI 10.1128/JVI.68.12.8282-8287.1994; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BERNS KI, 1990, MICROBIOL REV, V54, P316, DOI 10.1128/MMBR.54.3.316-329.1990; BLAU HM, 1990, ADV EXP MED BIOL, V280, P167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; Gussoni E, 1996, NAT BIOTECHNOL, V14, P1012, DOI 10.1038/nbt0896-1012; HOWE JR, 1995, J BIOL CHEM, V270, P14168, DOI 10.1074/jbc.270.23.14168; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; KOTIN RM, 1994, HUM GENE THER, V5, P793, DOI 10.1089/hum.1994.5.7-793; KUMAR S, 1991, J MOL BIOL, V222, P45, DOI 10.1016/0022-2836(91)90736-P; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; MILLER JL, 1994, P NATL ACAD SCI USA, V91, P10183, DOI 10.1073/pnas.91.21.10183; MUZCYZKA N, 1992, CURR TOP MICROBIOL I, V158, P97; PODSAKOFF G, 1994, J VIROL, V68, P5656, DOI 10.1128/JVI.68.9.5656-5666.1994; RICE SA, 1985, J VIROL, V56, P767, DOI 10.1128/JVI.56.3.767-778.1985; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; RUSSELL DW, 1994, P NATL ACAD SCI USA, V91, P8915, DOI 10.1073/pnas.91.19.8915; RUSSELL DW, 1995, P NATL ACAD SCI USA, V92, P5719, DOI 10.1073/pnas.92.12.5719; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; TRATSCHIN JD, 1985, MOL CELL BIOL, V5, P3251, DOI 10.1128/MCB.5.11.3251; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Yang YP, 1996, HUM MOL GENET, V5, P1703, DOI 10.1093/hmg/5.11.1703; YAO SN, 1994, GENE THER, V1, P99	33	555	598	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					306	312		10.1038/nm0397-306	http://dx.doi.org/10.1038/nm0397-306			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055858				2022-12-25	WOS:A1997WL30500032
J	Gourdon, G; Radvanyi, F; Lia, AS; Duros, C; Blanche, M; Abitbol, M; Junien, C; HofmannRadvanyi, H				Gourdon, G; Radvanyi, F; Lia, AS; Duros, C; Blanche, M; Abitbol, M; Junien, C; HofmannRadvanyi, H			Moderate intergenerational and somatic instability of a 55-CTG repeat in transgenic mice	NATURE GENETICS			English	Article							MYOTONIC-DYSTROPHY PATIENTS; DNA MISMATCH REPAIR; CTG REPEAT; TRINUCLEOTIDE REPEAT; (CTG)(N) REPEAT; TRIPLET REPEAT; EXPANSION; GENE; SIZE; SEX	Myotonic dystrophy (DM) is associated with the expansion of a (CTG)n trinucleotide repeat in the 3' untranslated region (UTR) of the DM protein kinase gene (DMPK)(1). The (CTG)n repeat is polymorphic and varies in size between 5 and 37 repeats in unaffected individuals' whereas in affected patients there are between 50 and 4,000 CTGs(2,3), The size of the (CTC)n repeat, which increases through generations, generally correlates with clinical severity and age of onset(4). The instability of the CTG repeat appears to depend on its size as well as on the sex of the transmitting parent(5-9). Moreover, mitotic instability analysis of different human DM tissues shows length mosaicism between different cell lineages(3,6,10-14). The molecular mechanisms of triplet instability remain elusive. To investigate the role of genomic sequences in instability, we produced transgenic mice containing a 45-kb genomic segment with a 55-CTG repeat cloned from a mildly affected patient. In contrast to other mouse models containing CAG repeats within cDNAs, these mice showed both intergenerational and somatic repeat instability(15-17).	HOP NECKER ENFANTS MALAD,INSERM UR383,LAMY,F-75743 PARIS 15,FRANCE; INST CURIE,UMR 144,CNRS,PARIS,FRANCE; UNIV PARIS 05,FAC NECKER,CTR RECH THERAPEUT OPHTALMOL,F-75270 PARIS 06,FRANCE; HOP AMBROISE PARE,BIOCHIM LAB,BOULOGNE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP			Gourdon, Genevieve/F-2996-2013	Gourdon, Genevieve/0000-0002-3319-1347; Radvanyi, Francois/0000-0002-5696-6424				ANVRET M, 1993, HUM MOL GENET, V2, P1397, DOI 10.1093/hmg/2.9.1397; ASHIZAWA T, 1993, NEUROLOGY, V43, P2674, DOI 10.1212/WNL.43.12.2674; ASHIZAWA T, 1994, NEUROLOGY, V44, P120, DOI 10.1212/WNL.44.1.120; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BARCELO JM, 1993, HUM MOL GENET, V2, P705, DOI 10.1093/hmg/2.6.705; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUNNER HG, 1993, AM J HUM GENET, V53, P1016; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; Goldberg YP, 1996, HUM MOL GENET, V5, P177, DOI 10.1093/hmg/5.2.177; GOURDON G, 1994, NUCLEIC ACIDS RES, V22, P4139, DOI 10.1093/nar/22.20.4139; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; HARPER PS, 1992, AM J HUM GENET, V51, P10; HARRIS H, 1996, HUM MOL GENET, V5, P1417; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; JANSEN G, 1994, AM J HUM GENET, V54, P575; LAVEDAN C, 1993, LANCET, V341, P237, DOI 10.1016/0140-6736(93)90097-Z; LAVEDAN C, 1993, AM J HUM GENET, V52, P875; MATHIEU J, 1990, NEUROLOGY, V40, P839, DOI 10.1212/WNL.40.5.839; MONCKTON DG, 1995, HUM MOL GENET, V4, P1; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THORNTON CA, 1994, ANN NEUROL, V35, P104, DOI 10.1002/ana.410350116; WOHRLE D, 1995, HUM MOL GENET, V4, P1147, DOI 10.1093/hmg/4.7.1147; WONG LJC, 1995, AM J HUM GENET, V56, P114	30	92	93	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					190	192		10.1038/ng0297-190	http://dx.doi.org/10.1038/ng0297-190			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020847				2022-12-25	WOS:A1997WF08700021
J	Zhang, X; Gaubin, M; Briant, L; Srikantan, V; Murali, R; Saragovi, U; Weiner, D; Devaux, C; Autiero, M; PiatierTonneau, D; Greene, MI				Zhang, X; Gaubin, M; Briant, L; Srikantan, V; Murali, R; Saragovi, U; Weiner, D; Devaux, C; Autiero, M; PiatierTonneau, D; Greene, MI			Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes	NATURE BIOTECHNOLOGY			English	Article						CD4 and HIV gp 120 interaction; rational drug design; AIDS	CLASS-II ANTIGENS; HLA-DR; MUTATIONAL ANALYSIS; ATOMIC-STRUCTURE; CELL ACTIVATION; HIV-1 INFECTION; SITE; ANTIBODY; GLYCOPROTEIN; MOLECULE	CD4 functions as a major T-cell surface receptor for human immunodeficiency virus by binding the human immunodeficiency virus type 1 (HIV-1) envelope protein gp120 with relatively high affinity, We have developed constrained aromatically modified analogs of the secondary structures of the first domain of CD4 in order to analyze surfaces involved in binding of gp120, Complementarity determining-like regions (CDRs) of the D1 domain of CD4 were reproduced as synthetic aromatically modified exocyclic (AMEs) forms. The exocyclic CDR3.AME(82-89), derived from the CDR3 (residues 82-89) region of CD4 D1 domain, specifically inhibited binding of recombinant gp120 to both recombinant soluble CD4, and CD4(+) Jurkat cells, and blocked syncytium formation and virus particle production caused by HIV-1 infection, We have previously shown that the CDR3.AME analog binds to the CD4 CDR3 region and creates a disabled CD4 heterodimer, We propose that the AME prevents the formation of an essential homodimeric surface needed for efficient HIV binding, Additionally the disabled CD4 receptor may be less able to signal the cell to allow HIV replication and HIV infection, Such compounds may represent a new receptor specific approach to modulate biological functions.	UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, CTR RECEPTOR BIOL, PHILADELPHIA, PA 19104 USA; CNRS, UPR 420, VILLEJUIF, FRANCE; CNRS, ERS 155, LAB IMMUNOL INFECT RETROVIRALES, MONTPELLIER, FRANCE; UNIFORMED SERV UNIV HLTH SCI, DEPT SURG, BETHESDA, MD 20814 USA; MCGILL UNIV, DEPT PHARMACOL, MONTREAL, PQ H3A 2T5, CANADA	University of Pennsylvania; University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Uniformed Services University of the Health Sciences - USA; McGill University			Murali, Ramachandran/D-1132-2009; Briant, Laurence/AAB-9281-2021	Murali, Ramachandran/0000-0002-8384-2793; Briant, Laurence/0000-0002-1995-3501				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; AUTIERO M, 1995, INT IMMUNOL, V7, P191, DOI 10.1093/intimm/7.2.191; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHAO BH, 1989, J BIOL CHEM, V264, P5812; CHEN SX, 1992, P NATL ACAD SCI USA, V89, P5872, DOI 10.1073/pnas.89.13.5872; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; CORBEAU P, 1990, J VIROL, V64, P1459, DOI 10.1128/JVI.64.4.1459-1464.1990; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOUGALL WC, 1994, TRENDS BIOTECHNOL, V12, P372, DOI 10.1016/0167-7799(94)90038-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; HABEEB AFSA, 1973, ANAL BIOCHEM, V56, P60, DOI 10.1016/0003-2697(73)90169-3; HOULGATTE R, 1994, J IMMUNOL, V152, P4475; JANEWAY CA, 1989, IMMUNOL TODAY, V10, P234, DOI 10.1016/0167-5699(89)90260-0; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANGEDIJK JPM, 1993, J BIOL CHEM, V268, P16875; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231, DOI 10.1128/JCM.26.2.231-235.1988; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; REED L. J., 1938, AMER JOUR HYG, V27, P493; REPKE H, 1992, J IMMUNOL, V149, P1809; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SRIKANTAN V, 1994, AIDS, V8, P1525, DOI 10.1097/00002030-199411000-00002; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TSUI P, 1992, J BIOL CHEM, V267, P9361; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	44	37	49	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					150	154		10.1038/nbt0297-150	http://dx.doi.org/10.1038/nbt0297-150			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035140				2022-12-25	WOS:A1997WE99800021
J	Correale, J; Gilmore, W; Lopez, J; Li, SQ; McMillan, M; Weiner, LP				Correale, J; Gilmore, W; Lopez, J; Li, SQ; McMillan, M; Weiner, LP			Defective post-thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN LYMPHOCYTES-T; GROWTH-FACTOR-BETA; SELF-TOLERANCE; DEMYELINATING DISEASES; MONOCLONAL-ANTIBODY; CELL ACTIVATION; INDUCTION; RECEPTOR; ANERGY	We have recently isolated a panel of T-cell clones from chronic progressive multiple sclerosis (MS) patients that are capable of functioning as antigen-presenting cells and of expressing the costimulatory molecules B7-1 and B7-2. In this report we show that these T-cell clones are resistant to inhibitory regulation, including the induction of anergy and sensitivity to tumor growth factor-beta (TCF-beta)-induced growth inhibition. The resistance to anergy induction was associated with expression of B7 costimulatory molecules. These data suggest that lack of responsiveness to peripheral inhibitory signals may account for the entry of autoimmune diseases into a chronic progressive phase.	UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT CELL & NEUROBIOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California	Correale, J (corresponding author), UNIV SO CALIF,SCH MED,DEPT NEUROL,1333 SAN PABLO ST,MCK 142,LOS ANGELES,CA 90033, USA.		Correale, Jorge/AAG-4245-2020; Gilmore, Wendy/AAB-5562-2020					BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLACKMAN MA, 1991, P NATL ACAD SCI USA, V88, P6682, DOI 10.1073/pnas.88.15.6682; BOSSU P, 1993, J IMMUNOL, V151, P7233; BURNS J, 1983, CELL IMMUNOL, V81, P435, DOI 10.1016/0008-8749(83)90250-2; CHEN CY, 1994, IMMUNITY, V1, P147, DOI 10.1016/1074-7613(94)90108-2; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; CORREALE J, 1995, NEUROLOGY, V45, P1370, DOI 10.1212/WNL.45.7.1370; CORREALE J, IN PRESS J NEUROIMMU; DAYAN CM, 1993, J IMMUNOL, V151, P1606; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; HOLLSBERG P, 1994, J IMMUNOL, V153, P566; JENKINS MK, 1990, J IMMUNOL, V144, P16; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KROEMER G, 1992, IMMUNOL TODAY, V13, P401, DOI 10.1016/0167-5699(92)90090-T; KUIPER HM, 1995, RES IMMUNOL, V146, P180, DOI 10.1016/0923-2494(96)80255-0; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; MARCOS MAR, 1988, IMMUNOL TODAY, V9, P204, DOI 10.1016/0167-5699(88)91214-5; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLER SD, 1995, IMMUNOL REV, V144, P225, DOI 10.1111/j.1600-065X.1995.tb00071.x; Miller SD, 1995, IMMUNITY, V3, P739, DOI 10.1016/1074-7613(95)90063-2; MOSMANN TR, 1991, IMMUNOL RES, V10, P183, DOI 10.1007/BF02919690; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; OLSSON T, 1992, EUR J IMMUNOL, V22, P1083, DOI 10.1002/eji.1830220431; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RACKE MK, 1991, J IMMUNOL, V146, P3012; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; VANDENBARK AA, 1995, J IMMUNOL, V155, P5861; VANKEMENADE FJ, 1993, EUR J IMMUNOL, V23, P635, DOI 10.1002/eji.1830230309; WILLIAMS ME, 1992, J IMMUNOL, V149, P1921	40	17	17	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1354	1360		10.1038/nm1296-1354	http://dx.doi.org/10.1038/nm1296-1354			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946835				2022-12-25	WOS:A1996VW51500042
J	Kalaydjieva, L; Hallmayer, J; Chandler, D; Savov, A; Nikolova, A; Angelicheva, D; King, RHH; Ishpekova, B; Honeyman, K; Calafell, F; Shmarov, A; Petrova, J; Turnev, I; Hristova, A; Moskov, M; Stancheva, S; Petkova, I; Bittles, AH; Georgieva, V; Middleton, L; Thomas, PK				Kalaydjieva, L; Hallmayer, J; Chandler, D; Savov, A; Nikolova, A; Angelicheva, D; King, RHH; Ishpekova, B; Honeyman, K; Calafell, F; Shmarov, A; Petrova, J; Turnev, I; Hristova, A; Moskov, M; Stancheva, S; Petkova, I; Bittles, AH; Georgieva, V; Middleton, L; Thomas, PK			Gene mapping in Gypsies identifies a novel demyelinating neuropathy on chromosome 8q24	NATURE GENETICS			English	Letter							LINKAGE ANALYSIS; INHERITANCE		MED UNIV,LAB MOL PATHOL,BU-1431 SOFIA,BULGARIA; MED UNIV,DEPT NEUROL,BU-1431 SOFIA,BULGARIA; MED UNIV,DEPT OPHTHALMOL,BU-1431 SOFIA,BULGARIA; MED UNIV,DEPT MED GENET,BU-1431 SOFIA,BULGARIA; GRAYLANDS UWA CLIN RES UNIT,PERTH,WA 6010,AUSTRALIA; NEUROSCI & BRAIN RES FDN,CTR HYG,BU-1431 SOFIA,BULGARIA; ROYAL FREE HOSP,SCH MED,DEPT CLIN NEUROSCI,LONDON NW3 2PF,ENGLAND; UNIV BARCELONA,FAC BIOL,DEPT ANTHROPOL,E-08028 BARCELONA,SPAIN; CYPRUS INST NEUROL & GENET,CY-1683 NICOSIA,CYPRUS	Medical University Sofia; Medical University Sofia; Medical University Sofia; Medical University Sofia; University of Western Australia; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Barcelona	Kalaydjieva, L (corresponding author), EDITH COWAN UNIV,DEPT HUMAN BIOL,JOONDALUP CAMPUS,PERTH,WA 6027,AUSTRALIA.		Calafell, Francesc/C-8595-2014	Calafell, Francesc/0000-0002-1083-9438; Bittles, Alan/0000-0002-8176-2730				CORNELL J, 1984, CLIN GENET, V25, P163; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; Fraser, 1995, GYPSIES; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380; Ionasescu VV, 1996, MUSCLE NERVE, V19, P319, DOI 10.1002/(SICI)1097-4598(199603)19:3<319::AID-MUS6>3.3.CO;2-H; Kenrick D., 1972, DESTINY EUROPES GYPS; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Liegeois Jean-Pierre, 1994, ROMA GYPSIES TRAVELL; MARUSHIAKOKVA E, 1993, GYPSIES BULGARIA; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; POTT A, 1884, ZIGEUNER EUROPEN ASI; Risch N, 1996, NAT GENET, V12, P351, DOI 10.1038/ng0496-351; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777	17	164	170	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					214	217		10.1038/ng1096-214	http://dx.doi.org/10.1038/ng1096-214			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841199				2022-12-25	WOS:A1996VL44600033
J	Roa, BB; Boyd, AA; Volcik, K; Richards, CS				Roa, BB; Boyd, AA; Volcik, K; Richards, CS			Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2	NATURE GENETICS			English	Letter							OVARIAN-CANCER; BREAST-CANCER; FAMILIES				Roa, BB (corresponding author), BAYLOR COLL MED,DEPT MOL & HUMAN GENET,BAYLOR DNA DIAGNOST LAB,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							Berman DB, 1996, AM J HUM GENET, V58, P1166; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; DEMARCHI JM, 1994, HUM MUTAT, V4, P281, DOI 10.1002/humu.1380040409; DEMARCHI JM, IN PRESS HUM MUT; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	15	566	578	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					185	187		10.1038/ng1096-185	http://dx.doi.org/10.1038/ng1096-185			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841191				2022-12-25	WOS:A1996VL44600025
J	Wieczorek, AM; Waterman, JLF; Waterman, MJF; Halazonetis, TD				Wieczorek, AM; Waterman, JLF; Waterman, MJF; Halazonetis, TD			Structure-based rescue of common tumor-derived p53 mutants	NATURE MEDICINE			English	Article							DNA-BINDING FUNCTION; IN-VIVO; MUTATIONS; FORMS; TRANSFORMATION; SUPPRESSOR; COMPLEX; DOMAIN	The p53 tumor suppressor protein induces cell-cycle arrest or cell death in response to DNA-damaging agents, such as radiation and many of the chemotherapeutics used in cancer therapy(1,2). The function of p53 is dependent on its ability to bind DNA in a sequence-specific manner(3), but in one-half of all human tumors, its sequence-specific DNA binding domain is compromised by single-amino acid substitutions(4). The nature of these substitutions, which target residues that directly contact DNA or that stabilize the structure of the DNA binding domain(5), has raised concerns as to whether the function of p53 mutants could ever be rescued(6). Nevertheless, pharmaceuticals that restore function to p53 mutants could specifically suppress proliferation of cancer cells in patients. To determine whether tumor-derived p53 mutants are irreversibly inactivated, we introduced basic residues in their DNA binding domains, aiming to establish novel contacts between p53 and the DNA phosphate backbone. In three of the seven most common p53 mutants, replacement of Thr284 with Arg significantly enhanced DNA binding affinity, without affecting DNA binding specificity, and rescued their transactivation and tumor suppressor functions. Thus, many tumor-derived p53 mutants retain their sequence-specific DNA binding determinants and can be activated to suppress tumor growth.	WISTAR INST ANAT & BIOL,DEPT MOL ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,PROGRAM MOL BIOL & GENET,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania; University of Pennsylvania			Halazonetis, Thanos/D-7923-2011					CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; NIEWOLIK D, 1995, ONCOGENE, V10, P881; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158	20	81	86	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1143	1146		10.1038/nm1096-1143	http://dx.doi.org/10.1038/nm1096-1143			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837616				2022-12-25	WOS:A1996VK99500038
J	Arai, H; Chan, SY; Bishop, DK; Nabel, GJ				Arai, H; Chan, SY; Bishop, DK; Nabel, GJ			Inhibition of the alloantibody response by CD95 ligand	NATURE MEDICINE			English	Article							LIMITING DILUTION ANALYSIS; TUMOR-NECROSIS-FACTOR; HUMAN B-LYMPHOCYTES; FAS-LIGAND; T-CELLS; INDUCED APOPTOSIS; GRAFT-REJECTION; ACTIVATION; DEATH; DISCRIMINATE	We investigated the effect of Fas/APO1-ligand (CD95L) gene transfer on allogeneic immune responses in vivo. A colon carcinoma cell line from BALB/c mice, CT26, was stably transfected with a vector encoding mouse CD95L and was inoculated into C57BL/6 mice. CD95L expression markedly reduced allogeneic cytotoxic T lymphocyte and helper T lymphocyte activity directed toward CT26. Strikingly, expression of CD95L on these allogeneic tumors completely inhibited the generation of alloantibodies of both IgM and IgG subclasses. Thus, CD95L inhibited alloantibody production and conferred localized immune suppression through this mechanism. These results provide insight into the role of CD95L in regulating the alloantibody response and the generation of local immune responses.	UNIV MICHIGAN,HOWARD HUGHES MED INST,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT SURG,SECT GEN SURG,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031946] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI31946] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bishop D K, 1995, Transpl Immunol, V3, P222, DOI 10.1016/0966-3274(95)80028-X; BISHOP DK, 1994, TRANSPLANTATION, V58, P576, DOI 10.1097/00007890-199409150-00009; BISHOP DK, 1989, TRANSPLANTATION, V47, P671, DOI 10.1097/00007890-198904000-00020; BRADLEY JA, 1992, IMMUNOL TODAY, V13, P434, DOI 10.1016/0167-5699(92)90069-J; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHAN SY, 1995, TRANSPLANTATION, V59, P1155, DOI 10.1097/00007890-199504270-00014; CLEARY AM, 1995, J IMMUNOL, V155, P3329; DANIEL PT, 1994, J IMMUNOL, V152, P5624; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ELLISON JW, 1982, NUCLEIC ACIDS RES, V10, P4071, DOI 10.1093/nar/10.13.4071; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OROSZ CG, 1989, TRANSPLANTATION, V47, P189, DOI 10.1097/00007890-198901000-00039; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SAYEGH MH, 1994, TRANSPLANTATION, V57, P1295, DOI 10.1097/00007890-199405150-00001; SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	32	76	83	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					843	848		10.1038/nm0897-843	http://dx.doi.org/10.1038/nm0897-843			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256273				2022-12-25	WOS:A1997XP01400024
J	Jenuth, JP; Peterson, AC; Shoubridge, EA				Jenuth, JP; Peterson, AC; Shoubridge, EA			Tissue-specific selection for different mtDNA genotypes in heteroplasmic mice	NATURE GENETICS			English	Article							MITOCHONDRIAL-DNA; TRANSCRIPTION; SEGREGATION	Mammalian mitochondrial DNA (mtDNA) is a highly polymorphic, high-copy-number genome that is maternally inherited. New mutations in mtDNA segregate rapidly in the female germline due to a genetic bottleneck in early oogenesis(1-3) and as a result most individuals are homoplasmic for a single species of mtDNA. Sequence variants thus accumulate along maternal lineages without genetic recombination. Most of the extant variation in mtDNA in mammalian populations has been assumed to be neutral with respect to selection(4); however, comparisons of the ratio of replacement to silent nucleotide substitutions between species suggest that the evolution of mammalian mtDNA is not strictly neutral(5). To test directly whether polymorphic mtDNAs behave as neutral variants, we examined the segregation of two different mtDNA genotypes in the tissues of heteroplasmic mice. We find evidence for random genetic drift in some tissues, but in others strong, tissue-specific and age-related, directional selection for different mtDNA genotypes in the same animal. These surprising data suggest that the coding sequence of mtDNA may represent a compromise between the competing demands of different tissues and point to the existence of unknown, tissue-specific nuclear genes important in the interaction between the nuclear and mitochondrial genomes.	MONTREAL NEUROL INST,MONTREAL,PQ H3A 2B4,CANADA; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 1B1,CANADA; MCGILL UNIV,MOL ONCOL GRP,MONTREAL,PQ H3A 1A1,CANADA	McGill University; McGill University; McGill University								ASHLEY MV, 1989, NUCLEIC ACIDS RES, V17, P7325, DOI 10.1093/nar/17.18.7325; BIRKY CW, 1983, GENETICS, V103, P513; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; DESTORDEUR E, 1989, MOL GEN GENET, V220, P127, DOI 10.1007/BF00260866; DUKES KR, 1995, THESIS U FLORIDA; HARDING AE, 1992, AM J HUM GENET, V50, P629; HAUSWIRTH WW, 1982, P NATL ACAD SCI-BIOL, V79, P4686, DOI 10.1073/pnas.79.15.4686; Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; LI H, 1991, Methods (Orlando), V2, P49, DOI 10.1016/S1046-2023(05)80125-2; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; MERRIWETHER DA, 1991, J MOL EVOL, V33, P543, DOI 10.1007/BF02102807; Nachman MW, 1996, GENETICS, V142, P953; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; ZAJICEK G, 1985, LIVER, V5, P293	21	300	313	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	MAY	1997	16	1					93	95		10.1038/ng0597-93	http://dx.doi.org/10.1038/ng0597-93			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WX024	9140402				2022-12-25	WOS:A1997WX02400029
J	Oger, P; Petit, A; Dessaux, Y				Oger, P; Petit, A; Dessaux, Y			Genetically engineered plants producing opines alter their biological environment	NATURE BIOTECHNOLOGY			English	Article						transgenic plants; rhizosphere; plant-bacteria interactions	AGROBACTERIUM-RHIZOGENES; TRANSGENIC TOBACCO; PSEUDOMONAS-PUTIDA; CARBON SOURCE; HAIRY ROOT; GROWTH; BACTERIA; PLASMIDS; STRAIN; SOIL	Little is known about the consequences of releasing genetically engineered plants (GEP) into the environment. Using opine-producing GEP, we show that transgenic plants alter their biological environment, more precisely the root-associated bacterial populations. The alterations were both transgene-specific and target population-specific. Therefore, assessment studies on the introduction of a given transgene into a GEP will be valid on the given transgene. Evidence of any transgene-associated biological effect will depend on the determination of the pertinent target populations, the identification of which is a key step of such studies.	NATL CTR SCI RES, INST PLANT SCI, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay			Oger, Phil/AAR-4752-2020; Oger, Phil M/C-8138-2012	Oger, Phil M/0000-0001-6298-6870				BREVET J, 1988, PLASMID, V19, P75, DOI 10.1016/0147-619X(88)90046-7; Brevet J., 1988, Molecular Plant-Microbe Interactions, V1, P75, DOI 10.1094/MPMI-1-075; CARDARELLI M, 1987, MOL GEN GENET, V209, P475, DOI 10.1007/BF00331152; COLBERT SF, 1993, APPL ENVIRON MICROB, V59, P2064, DOI 10.1128/AEM.59.7.2064-2070.1993; COLBERT SF, 1993, APPL ENVIRON MICROB, V59, P2056, DOI 10.1128/AEM.59.7.2056-2063.1993; Curl E. A., 1986, RHIZOSPHERE; DESSAUX Y, 1987, MOL GEN GENET, V208, P301, DOI 10.1007/BF00330457; Dessaux Y., 1992, MOL SIGNALS PLANT MI, P109; DOMMERGUE YR, 1970, ECOLOGIE MICROBIENNE; GAUDIN V, 1994, PLANT PHYSIOL BIOCH, V32, P11; GLICKMANN E, 1995, APPL ENVIRON MICROB, V61, P793, DOI 10.1128/AEM.61.2.793-796.1995; GUYON P, 1993, MOL PLANT MICROBE IN, V6, P92, DOI 10.1094/MPMI-6-092; Hiltner L., 1904, ARBEITEN DTSCH LANDW, V98, P59, DOI DOI 10.12691/AEES-1-6-1; KUNG SD, 1993, TRANSGENIC PLANTS, V2; MOREL G, 1951, AM J BOT, V38, P141, DOI 10.2307/2437837; NAUTIYAL CS, 1990, APPL ENVIRON MICROB, V56, P2576, DOI 10.1128/AEM.56.8.2576-2579.1990; OConnell KP, 1996, TRENDS BIOTECHNOL, V14, P83, DOI 10.1016/0167-7799(96)80928-0; OGER P, 1995, THESIS U PARIS SUD O; PETIT A, 1987, MOL GEN GENET, V207, P245, DOI 10.1007/BF00331585; PETIT A, 1978, MOL GEN GENET, V167, P147, DOI 10.1007/BF00266908; POTRYKUS I, 1991, ANNU REV PLANT PHYS, V42, P205, DOI 10.1146/annurev.pp.42.060191.001225; SAVKA MA, 1992, PLANT PHYSIOL, V98, P784, DOI 10.1104/pp.98.2.784; Savka MA, 1996, MOL PLANT MICROBE IN, V9, P310, DOI 10.1094/MPMI-9-0310; SAVKA MA, NATURE BIOTECHNOLOGY, V15, P363; SPENA A, 1987, EMBO J, V6, P3891, DOI 10.1002/j.1460-2075.1987.tb02729.x; TATE ME, 1982, CARBOHYD RES, V104, P105, DOI 10.1016/S0008-6215(00)82224-7; TREMBLAY G, 1987, APPL ENVIRON MICROB, V53, P1519, DOI 10.1128/AEM.53.7.1519-1524.1987; VAUDEQUINDRANSART V, 1995, MOL PLANT MICROBE IN, V8, P311, DOI 10.1094/MPMI-8-0311; WHITE FF, 1980, J BACTERIOL, V141, P1134, DOI 10.1128/JB.141.3.1134-1141.1980; WILSON M, 1995, APPL ENVIRON MICROB, V61, P2151, DOI 10.1128/AEM.61.6.2151-2158.1995; WILSON M, 1994, APPL ENVIRON MICROB, V60, P4468, DOI 10.1128/AEM.60.12.4468-4477.1994; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	32	125	176	0	23	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					369	372		10.1038/nbt0497-369	http://dx.doi.org/10.1038/nbt0497-369			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094140				2022-12-25	WOS:A1997WQ55400039
J	Comuzzie, AG; Hixson, JE; Almasy, L; Mitchell, BD; Mahaney, MC; Dyer, TD; Stern, MP; MacCluer, JW; Blangero, J				Comuzzie, AG; Hixson, JE; Almasy, L; Mitchell, BD; Mahaney, MC; Dyer, TD; Stern, MP; MacCluer, JW; Blangero, J			A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2	NATURE GENETICS			English	Article							APOLIPOPROTEIN-B GENE; OBESE GENE; PEDIGREE ANALYSIS; ADIPOSE-TISSUE; OB GENE; WEIGHT; EXPRESSION; PROTEIN; POLYMORPHISM; INHERITANCE	Obesity is a major predisposing factor for the development of several chronic diseases including non-insulin dependent diabetes mellitus (NIDDM) and coronary heart disease (CHD). Leptin is a serum protein which is secreted by adipocytes(1-4) and thought to play a role in the regulation of body fat(5-8). Leptin levels in humans have been found to be highly correlated with an individual's total adiposity(8,9). We performed a genome-wide scan and conducted multipoint linkage analysis using a general pedigree-based variance component approach to identify genes with measurable effects on quantitative variation in leptin levels in Mexican Americans. A microsatellite polymorphism, D2S1788, mapped to chromosome 2p21 (approximately 74 cM from the tip of the short arm) and showed strong evidence of linkage with serum leptin levels with a lod score of 4.95 (P = 9 x 10(-7)). This locus accounted for 47% of the variation in serum leptin levels, with a residual additive genetic component contributing an additional 24%. This region contains several potential candidate genes for obesity, including glucokinase regulatory protein (GCKR) and pro-opiomelanocortin (POMC). Our results show strong evidence of linkage of this region of chromosome 2 with serum leptin levels and indicate that this region could contain an important human obesity gene.	UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV CLIN EPIDEMIOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Comuzzie, AG (corresponding author), SW FDN BIOMED RES, DEPT GENET, POB 760549, SAN ANTONIO, TX 78245 USA.		Almasy, Laura/V-3156-2019; Blangero, John/ABA-7175-2021; Mitchell, Braxton/CAF-0876-2022	Hixson, James/0000-0002-0849-9315; Mitchell, Braxton/0000-0003-4920-4744	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045522, P01HL028972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015803] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45522, HL28972] Funding Source: Medline; NIGMS NIH HHS [GM15803] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS CI, 1994, AM J HUM GENET, V54, P535; Blangero J, 1996, 6 SW FDN BIOM RES PO; BOTTINI E, 1990, HUM BIOL, V62, P403; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; COMUZZIE AG, 1995, GENET EPIDEMIOL, V12, P475, DOI 10.1002/gepi.1370120505; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Davis S, 1996, AM J HUM GENET, V58, P867; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; Duggirala R, 1996, AM J HUM GENET, V59, P694; Frisancho AR, 1990, ANTHROPOMETRIC STAND; FULKER DW, 1995, AM J HUM GENET, V56, P1224; Green P, 1990, DOCUMENTATION CRI MA; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HASSTEDT SJ, 1989, AM J HUM GENET, V45, P917; HAUTANEN A, 1993, J INTERN MED, V234, P461, DOI 10.1111/j.1365-2796.1993.tb00779.x; HAZUDA HP, 1991, AM J CLIN NUTR, V53, pS1529, DOI 10.1093/ajcn/53.6.1529S; HOPPER JL, 1982, ANN HUM GENET, V46, P373, DOI 10.1111/j.1469-1809.1982.tb01588.x; Klein S, 1996, DIABETES, V45, P984, DOI 10.2337/diabetes.45.7.984; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; Ma ZM, 1996, CLIN CHEM, V42, P942; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MAHANEY MC, 1995, CIRCULATION, V92, P3240, DOI 10.1161/01.CIR.92.11.3240; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; Mitchell BD, 1996, ARTERIOSCL THROM VAS, V16, P281, DOI 10.1161/01.ATV.16.2.281; Mitchell Braxton D., 1993, Ethnicity and Disease, V3, P22; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V214, P1260, DOI 10.1006/bbrc.1995.2422; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; POULIOT MC, 1994, ARTERIOSCLER THROMB, V14, P527, DOI 10.1161/01.ATV.14.4.527; PRICE RA, 1990, HUM BIOL, V62, P747; RAJPUTWILLIAMS J, 1988, LANCET, V2, P1442; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; RICE T, 1993, AM J HUM GENET, V52, P967; SAHA N, 1993, CLIN GENET, V44, P113; WARNER JP, 1995, MAMM GENOME, V6, P532, DOI 10.1007/BF00356171; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	41	391	405	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					273	276		10.1038/ng0397-273	http://dx.doi.org/10.1038/ng0397-273			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054940				2022-12-25	WOS:A1997WK38600017
J	Franken, M; Estabrooks, A; Cavacini, L; Sherburne, B; Wang, F; Scadden, DT				Franken, M; Estabrooks, A; Cavacini, L; Sherburne, B; Wang, F; Scadden, DT			Epstein-Barr virus-driven gene therapy for EBV-related lymphomas	NATURE MEDICINE			English	Article							SIGNAL-BINDING-PROTEIN; CELLS; EXPRESSION; CANCER; INFECTION; ELEMENTS; INVITRO	Genetic alterations in malignant tissues are potential targets for gene-based cancer therapies. Alternatively, aberrant expression of certain specific genes associated with malignant transformation may be envisioned to enhance the expression of chemosensitizing drugs. Epstein-Barr virus (EBV)-related B-cell lymphomas are fatal complications of immunosuppression due to AIDS, organ transplantation or congenital immune abnormalities. The malignant cells latently infected with EBV typically express the transcription factor EBNA2 as one of nine latent viral genes. We tested whether an EBNA2-responsive EBV promoter may selectively target EBV-related lymphoma cells by virus-regulated expression of a suicide gene. Using the BamC promoter driving a hygromycin-thymidine kinase fusion gene or controls, we demonstrated that sensitivity to ganciclovir was selectively enhanced in cells expressing EBNA2. Further, there was complete macroscopic regression of established B-cell lymphomas in mice with severe combined immunodeficiency disease (SCID mice) treated with a single course of ganciclovir. These data provide in vitro and in vivo support for a model of exploiting the molecular basis of tumor development to enhance the specificity of gene therapy.	HARVARD UNIV, SCH MED, CAMBRIDGE, MA 02138 USA; MASSACHUSETTS GEN HOSP, MGH CANC CTR, AIDS RES CTR, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL CANCER INSTITUTE [R01CA055520] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 55520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASHIR R, 1993, NEUROLOGY, V43, P2358, DOI 10.1212/WNL.43.11.2358; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CARBONE A, 1993, J CLIN ONCOL, V11, P1674, DOI 10.1200/JCO.1993.11.9.1674; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DaCosta LT, 1996, P NATL ACAD SCI USA, V93, P4192, DOI 10.1073/pnas.93.9.4192; Deisseroth A B, 1994, Hum Gene Ther, V5, P1507; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; GHOSH D, 1990, J VIROL, V64, P1855, DOI 10.1128/JVI.64.4.1855-1858.1990; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HAMILTONDUTOIT SJ, 1993, AM J PATHOL, V143, P1072; HAN XL, 1995, P NATL ACAD SCI USA, V92, P9747, DOI 10.1073/pnas.92.21.9747; HASEGAWA Y, 1995, J MOL MED-JMM, V73, P107, DOI 10.1007/BF00198237; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; HURFORD RK, 1995, NAT GENET, V10, P430, DOI 10.1038/ng0895-430; Knowles Daniel M., 1993, Current Opinion in Oncology, V5, P845, DOI 10.1097/00001622-199309000-00012; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; OSHIRO EM, 1995, CANCER GENE THER, V2, P87; REA D, 1994, ANN ONCOL, V5, pS113, DOI 10.1093/annonc/5.suppl_1.S113; ROONEY CM, 1992, J VIROL, V66, P496, DOI 10.1128/JVI.66.1.496-504.1992; SHEWACH DS, 1994, CANCER GENE THER, V1, P107; VILE RG, 1993, CANCER RES, V53, P962; WANG F, 1991, J VIROL, V65, P4101, DOI 10.1128/JVI.65.8.4101-4106.1991; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	24	39	41	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1996	2	12					1379	1382		10.1038/nm1296-1379	http://dx.doi.org/10.1038/nm1296-1379			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946840				2022-12-25	WOS:A1996VW51500047
J	Garkavtsev, I; Kazarov, A; Gudkov, A; Riabowol, K				Garkavtsev, I; Kazarov, A; Gudkov, A; Riabowol, K			Suppression of the novel growth inhibitor p33(ING1) promotes neoplastic transformation	NATURE GENETICS			English	Article							CLONING; EXPRESSION; GENE; CELLS	Using a new strategy for tumour suppressor gene isolation based on subtractive hybridization and the subsequent selection of transforming 'genetic suppressor elements', we have cloned a novel gene called ING1 encoding a 33-kD protein (p33(ING1)) that displays characteristics of a tumour suppressor. Acute expression of transfected constructs encoding this gene inhibited cell growth while chronic expression of ING1 antisense constructs promoted cell transformation. Limited analyses of tumour cell lines show that mutation of the ING1 gene occurs in neuroblastoma cells and reduced expression was seen in some breast cancer cell lines. These results demonstrate that ING1 can act as a potent growth regulator in normal and in established cells and provide evidence for a role as a candidate tumour suppressor gene whose inactivation may contribute to the development of cancers.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,SO ALBERTA CANC RES,CALGARY,AB T2N 4N1,CANADA; UNIV ILLINOIS,DEPT GENET,CHICAGO,IL 60607	University of Calgary; University of Calgary; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R01CA060730, R21CA062045] Funding Source: NIH RePORTER; NCI NIH HHS [CA60730, CA62045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OSSOVSKAYA V, IN PRESS P NATL ACAD; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Sambrook J., 2002, MOL CLONING LAB MANU; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YASWEN P, 1990, P NATL ACAD SCI USA, V87, P7360, DOI 10.1073/pnas.87.19.7360	16	278	348	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					415	420		10.1038/ng1296-415	http://dx.doi.org/10.1038/ng1296-415			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944021				2022-12-25	WOS:A1996VV73000017
J	Oh, J; Bailin, T; Fukai, K; Feng, GH; Ho, LL; Mao, JI; Frenk, E; Tamura, N; Spritz, RA				Oh, J; Bailin, T; Fukai, K; Feng, GH; Ho, LL; Mao, JI; Frenk, E; Tamura, N; Spritz, RA			Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles	NATURE GENETICS			English	Article							EXON AMPLIFICATION; PLATELETS; CHROMOSOME-19; POPULATION; SEQUENCES; STRATEGY; REGION; MAPS	Hermansky-Pudlak syndrome (HPS) is an often-fatal autosomal recessive disease in which albinism, bleeding, and lysosomal storage result from defects of diverse cytoplasmic organelles: melanosomes, platelet dense bodies, and lysosomes. HPS is the most common single-gene disorder in Puerto Rico, with an incidence of 1 in 1,800. We have identified the HPS gene by positional cloning, and found homozygous frameshifts in this gene in Puerto Rican, Swiss, Irish and Japanese HPS patients. The HPS polypeptide is a novel transmembrane protein that is likely to be a component of multiple cytoplasmic organelles and that is apparently crucial for their normal development and function. The different clinical phenotypes associated with the different HPS frameshifts we observed suggests that differentially truncated HPS polypeptides may have somewhat different consequences for subcellular function.	UNIV WISCONSIN, DEPT MED GENET, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA; GENOME THERAPEUT CORP, COLLABORAT RES DIV, WALTHAM, MA 02154 USA; CHU VAUDOIS, SERV DERMATOVENEREOL, LAUSANNE, SWITZERLAND; JUNTENDO UNIV, SCH MED, DEPT RESP MED, TOKYO 113, JAPAN	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Juntendo University			Fukai, Kazuyoshi/AAI-7365-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Dracopoli NC, 1994, CURRENT PROTOCOLS HU; FRENK E, 1982, J INVEST DERMATOL, V78, P141, DOI 10.1111/1523-1747.ep12506274; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKAI K, 1995, HUM MOL GENET, V4, P1665, DOI 10.1093/hmg/4.9.1665; HARDISTY RM, 1972, BRIT J HAEMATOL, V23, P679, DOI 10.1111/j.1365-2141.1972.tb03483.x; HARMON KR, 1994, J LAB CLIN MED, V123, P617; HERMANSKY F, 1959, BLOOD, V14, P162, DOI 10.1182/blood.V14.2.162.162; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOLMSEN H, 1979, ANNU REV MED, V30, P119, DOI 10.1146/annurev.me.30.020179.001003; HOLMSEN H, 1972, BLOOD-J HEMATOL, V39, P197, DOI 10.1182/blood.V39.2.197.197; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; LATTION F, 1983, HELV PAEDIATR ACTA, V38, P495; Lee ST, 1995, MOL CELLS, V5, P668; Lyon M., 1989, GENETIC VARIANTS STR; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; OBRIEN EP, 1994, MAMM GENOME, V5, P356, DOI 10.1007/BF00356554; POIRIER C, 1994, MAMM GENOME, V5, pS266; SCHALLREUTER KU, 1993, DERMATOLOGY, V187, P248, DOI 10.1159/000247258; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WHITE JG, 1973, AM J PATHOL, V70, P329; WHITE JG, 1971, AM J PATHOL, V63, P319; WILDENBERG SC, 1995, AM J HUM GENET, V57, P755; Witkop C J, 1990, Bol Asoc Med P R, V82, P333; [No title captured]; [No title captured]; [No title captured]	32	242	245	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					300	306		10.1038/ng1196-300	http://dx.doi.org/10.1038/ng1196-300			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896559				2022-12-25	WOS:A1996VQ14600024
J	Sango, K; McDonald, MP; Crawley, JN; Mack, ML; Tifft, CJ; Skop, E; Starr, CM; Hoffmann, A; Sandhoff, K; Suzuki, K; Proia, RL				Sango, K; McDonald, MP; Crawley, JN; Mack, ML; Tifft, CJ; Skop, E; Starr, CM; Hoffmann, A; Sandhoff, K; Suzuki, K; Proia, RL			Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis	NATURE GENETICS			English	Article							TAY-SACHS-DISEASE; TARGETED DISRUPTION; HEXA GENE; MODEL		NIDDKD, SECT BIOCHEM GENET, GENET & BIOCHEM BRANCH, NIH, BETHESDA, MD 20892 USA; NIMH, SECT BEHAV NEUROPHARMACOL, EXPT THERAPEUT BRANCH, NIH, BETHESDA, MD 20892 USA; CHILDRENS NATL MED CTR, DEPT MED GENET, WASHINGTON, DC 20010 USA; GLYKO INC, NOVATO, CA 94949 USA; UNIV BONN, INST ORGAN CHEM & BIOCHEM, D-53121 BONN, GERMANY; UNIV N CAROLINA, DEPT PATHOL & LAB MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, UNC NEUOSCI CTR, CHAPEL HILL, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Children's National Health System; BioMarin Pharmaceutical Inc.; Glyko Biomedical; University of Bonn; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270; McDonald, Michael P./0000-0002-9642-964X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024453] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-03110] Funding Source: Medline; NINDS NIH HHS [NS-24453] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APPLEGARTH DA, 1972, CLIN CHIM ACTA, V39, P258, DOI 10.1016/0009-8981(72)90327-0; CANTZ M, 1974, EUR J BIOCHEM, V47, P581, DOI 10.1111/j.1432-1033.1974.tb03729.x; FRATANTONI JC, 1968, P NATL ACAD SCI USA, V60, P699, DOI 10.1073/pnas.60.2.699; Gravel R. A., 1995, METABOLIC MOL BASIS, P2839; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; SINGH J, 1975, ENZYME, V19, P15, DOI 10.1159/000458968; Starr CM, 1996, J CHROMATOGR A, V720, P295, DOI 10.1016/0021-9673(95)00749-0; TANIIKE M, 1995, ACTA NEUROPATHOL, V89, P296; VOGLER C, 1990, AM J PATHOL, V136, P207; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975	12	163	166	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1996	14	3					348	352		10.1038/ng1196-348	http://dx.doi.org/10.1038/ng1196-348			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896570				2022-12-25	WOS:A1996VQ14600035
J	Helmlinger, G; Netti, PA; Lichtenbeld, HC; Melder, RJ; Jain, RK				Helmlinger, G; Netti, PA; Lichtenbeld, HC; Melder, RJ; Jain, RK			Solid stress inhibits the growth of multicellular tumor spheroids	NATURE BIOTECHNOLOGY			English	Article						tumor growth; apoptosis; proliferation	RESIDUAL STRAINS; BLOOD-FLOW; CELL; RAT; RESISTANCE; RADIATION; TISSUE; DRUG; APOPTOSIS; DORMANCY	In normal tissues, the processes of growth, remodeling, and morphogenesis are tightly regulated by the stress field; conversely, stress may be generated by these processes. We demonstrate that solid stress inhibits tumor growth iii vitro, regardless of host species, tissue of origin, or differentiation state. The inhibiting stress for multicellular tumor spheroid growth in agarose matrices was 45 to 120 mm Hg. This stress, which greatly exceeds blood pressure in tumor vessels, is sufficient to induce the collapse of vascular or lymphatic vessels in tumors in vivo and can explain impaired blood flow, poor lymphatic drainage, and suboptimal drug delivery previously reported in solid tumors. The stress-induced growth inhibition of plateau-phase spheroids was accompanied, at the cellular level, by decreased apoptosis with no significant changes in proliferation. A concomitant increase In the cellular packing density was observed, which may prevent cells from undergoing apoptosis via a cell-volume or cell-shape transduction mechanism. These results suggest that solid stress controls tumor growth at both the macroscopic and cellular levels, and thus influences tumor progression and delivery of therapeutic agents.	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital			Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548; NETTI, PAOLO/0000-0002-2435-7181	NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-56591] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BOUCHER Y, 1990, CANCER RES, V50, P4478; BOUCHER Y, 1992, CANCER RES, V52, P5110; Boucher Y, 1996, CANCER RES, V56, P4264; EAVES G, 1973, J PATHOL, V109, P233, DOI 10.1002/path.1711090308; FALK P, 1980, EUR J CANCER, V16, P203, DOI 10.1016/0014-2964(80)90152-8; FALK P, 1978, EUR J CANCER, V14, P237, DOI 10.1016/0014-2964(78)90187-1; FREYER JP, 1994, ADV EXP MED BIOL, V345, P335; FREYER JP, 1988, CANCER RES, V48, P2432; FREYER JP, 1989, J CELL PHYSIOL, V138, P384, DOI 10.1002/jcp.1041380222; Fung Y.C., 1990, BIOMECHANICS MOTION, P499; FUNG YC, 1989, CIRC RES, V65, P1340, DOI 10.1161/01.RES.65.5.1340; FUNG YC, 1991, ANN BIOMED ENG, V19, P237, DOI 10.1007/BF02584301; GARTNER MFRM, 1992, BRIT J CANCER, V65, P487, DOI 10.1038/bjc.1992.101; Gompertz B, 1825, PHILOS T ROY SOC LON, V31, P513, DOI [10.1098/rstl.1825.0026, DOI 10.1098/RSTL.1825.0026]; GYLLENBERG M, 1989, GROWTH DEVELOP AGING, V53, P25; HAN HC, 1991, J BIOMECH, V24, P307, DOI 10.1016/0021-9290(91)90349-R; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IOZZO RV, 1995, LAB INVEST, V73, P157; ISCOVE NN, 1979, IMMUNOLOGICAL METHOD, P379; JAIN RK, 1988, CANCER RES, V48, P2641; Johnson EM, 1996, BIOPHYS J, V70, P1017, DOI 10.1016/S0006-3495(96)79645-5; KERBEL RS, 1994, COLD SPRING HARB SYM, V59, P661, DOI 10.1101/SQB.1994.059.01.076; Knight M. M., 1996, Cellular Engineering, V1, P97; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; MACPHEE PJ, 1995, J PHYSL, V1484, P183; Netti PA, 1996, MICROVASC RES, V52, P27, DOI 10.1006/mvre.1996.0041; NICOLSON GL, 1988, CANCER RES, V48, P399; OLIVE PL, 1994, CANCER METAST REV, V13, P121, DOI 10.1007/BF00689632; OMENS JH, 1990, CIRC RES, V66, P37, DOI 10.1161/01.RES.66.1.37; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAK JW, 1993, IN VITRO CELL DEV-AN, V29A, P742; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TANIGAWA N, 1981, LYMPHOLOGY, V14, P149; TOZER GM, 1990, BRIT J CANCER, V61, P250, DOI 10.1038/bjc.1990.46; VAAGE J, 1992, INT J CANCER, V51, P325, DOI 10.1002/ijc.2910510225; Wolff J, 1870, VIRCHOWS ARCH PATHOL, V50, P389, DOI [10.1007/BF01944490, DOI 10.1007/BF01944490]; YOUNG JS, 1959, J PATHOL BACTERIOL, V77, P321, DOI 10.1002/path.1700770203	42	581	591	4	88	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					778	783		10.1038/nbt0897-778	http://dx.doi.org/10.1038/nbt0897-778			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255794				2022-12-25	WOS:A1997XM70700031
J	Jeffs, B; Clark, JS; Anderson, NH; Gratton, J; Brosnan, MJ; Gauguier, D; Reid, JL; Macrae, IM; Dominiczak, AF				Jeffs, B; Clark, JS; Anderson, NH; Gratton, J; Brosnan, MJ; Gauguier, D; Reid, JL; Macrae, IM; Dominiczak, AF			Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus	NATURE GENETICS			English	Article							QUANTITATIVE TRAIT LOCI; HYPERTENSIVE-RATS; ARTERY OCCLUSION; PRONE	Ischaemic stroke is a complex disorder caused by a combination of genetic and environmental factors. clinical and epidemiological studies have provided strong evidence for genetic influences in the development of human stroke(1-3) and several mendelian traits featuring stroke have been described(4,5). The genetic analysis of the non-mendelian, common ischaemic stroke in humans is hindered by the late onset of the disease and the mode of inheritance, which is complex, polygenic and multifactorial. An important approach to the study of such polygenic diseases is the use of appropriate animal models in which individual contributing factors can be recognized and analysed(6,7). The spontaneously hypertensive stroke-prone rat (SHRSP) is an experimental model of stroke characterized by a high frequency of spontaneous strokes(8) as well as an increased sensitivity to experimentally induced focal cerebral ischaemia(9,10). Rubattu et al.(11) performed a genome-wide screen in an F-2 cross obtained by mating SHRSP and SHR, in which latency to stroke on Japanese rat diet was used as a phenotype. This study identified three major quantitative trait loci (QTLs), STR-1-3. Of these, STR-2 and 3 conferred a protective effect against stroke in the presence of SHRSP alleles and STR-2 co-localized with the genes encoding for atrial natriuretic tic and brain natriuretic factors(11). Our investigation was designed to identify the genetic component responsible for large infarct volumes in the SHRSP in response to a focal ischaemic insult by performance of a genome scan in an F-2 cross derived from the SHRSP and the normotensive reference strain, WKY rat. We identified a highly significant QTL on rat chromosome 5 with a lod score trf 16.6 which accounts for 67% of the total variance, co-localizes with the genes encoding atrial and brain natriuretic factor and is blood pressure independent.	UNIV GLASGOW, WESTERN INFIRM,DEPT MED & THERAPEUT, GLASGOW G11 6NT, LANARK, SCOTLAND; UNIV GLASGOW, WELLCOME SURG INST, GLASGOW G61 1QH, LANARK, SCOTLAND; WELLCOME TRUST CTR HUMAN GENET, OXFORD OX3 7LD, ENGLAND	University of Glasgow; University of Glasgow; University of Oxford; Wellcome Centre for Human Genetics			Dominiczak, Anna F/P-9390-2017; Gauguier, Dominique/G-2190-2016; Dominiczak, Anna F/D-2262-2009	Dominiczak, Anna F/0000-0003-4913-3608; Gauguier, Dominique/0000-0001-6156-9530; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERTS MJ, 1991, STROKE, V22, P276, DOI 10.1161/01.STR.22.2.276; Arribas SM, 1996, STROKE, V27, P1118, DOI 10.1161/01.STR.27.6.1118; BRASS LM, 1992, STROKE, V23, P221, DOI 10.1161/01.STR.23.2.221; Clark JS, 1996, HYPERTENSION, V28, P898, DOI 10.1161/01.HYP.28.5.898; COYLE P, 1983, STROKE, V14, P605, DOI 10.1161/01.STR.14.4.605; COYLE P, 1991, BLOOD VESSELS, V28, P183; COYLE P, 1984, STROKE, V15, P711, DOI 10.1161/01.STR.15.4.711; DAVIDSON AO, 1995, HYPERTENSION, V26, P452, DOI 10.1161/01.HYP.26.3.452; DOMINICZAK AF, 1994, NEWS PHYSIOL SCI, V9, P246; DOMINICZAK AF, 1993, AM J HYPERTENS, V6, P1003, DOI 10.1093/ajh/6.12.1003; ESTRADA V, 1994, AM J HYPERTENS, V7, P1085, DOI 10.1093/ajh/7.12.1085; Gunel M, 1996, NAT GENET, V13, P384, DOI 10.1038/ng0896-384; JACEWICZ M, 1992, HYPERTENSION, V19, P47, DOI 10.1161/01.HYP.19.1.47; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KIELY DK, 1993, STROKE, V24, P1366, DOI 10.1161/01.STR.24.9.1366; Konig JFR, 1963, RAT BRAIN STEREOTAXI; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; OKAMOTO K, 1974, CIRC RES, V34, pI143; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; QUIRION R, 1986, P NATL ACAD SCI USA, V83, P174, DOI 10.1073/pnas.83.1.174; Rawlings O., 1998, APPL REGRESSION ANAL, VSecond, P372, DOI DOI 10.1007/B98890; Rubattu S, 1996, NAT GENET, V13, P429, DOI 10.1038/ng0896-429; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; Volpe M, 1996, J CLIN INVEST, V98, P256, DOI 10.1172/JCI118787	27	144	147	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1997	16	4					364	367		10.1038/ng0897-364	http://dx.doi.org/10.1038/ng0897-364			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241273				2022-12-25	WOS:A1997XM90900018
J	Lavie, A; Schlichting, I; Vetter, IR; Konrad, M; Reinstein, J; Goody, RS				Lavie, A; Schlichting, I; Vetter, IR; Konrad, M; Reinstein, J; Goody, RS			The bottleneck in AZT activation	NATURE MEDICINE			English	Article							REVERSE-TRANSCRIPTASE; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; DNA-POLYMERASES; CELLS; 5'-TRIPHOSPHATE; TRIPHOSPHATE; INHIBITION; EXPRESSION	Nucleoside-based inhibitors of reverse transcriptase were the first drugs to be used in the chemotherapy of AIDS. After entering the cell, these substances are activated to their triphosphate form by cellular kinases, after which they are potent chain terminators for the growing viral DNA (ref. 1). The two main factors limiting their efficacy are probably interrelated. These are the insufficient degree of reduction of viral load at the commencement of treatment and the emergence of resistant variants of the virus. The reason for the relatively poor suppression of viral replication appears to be inefficient metabolic activation. Thus, for the most extensively used drug, 3'-azido-3'-deoxythymidine (AZT), whereas phosphorylation to the monophosphate is facile, the product is a very poor substrate for the next kinase in the cascade, thymidylate kinase(2,3). Because of this, although high concentrations of the monophosphate can be reached in the cell, the achievable concentration of the active triphosphate is several orders of magnitude lower. Determination of the structure of thymidylate kinase as a complex with AZT monophosphate (AZTMP) together with studies on the kinetics of its phosphorylation have now led to a detailed understanding of the reasons for and consequences of the poor substrate properties.	MAX PLANCK INST MOL PHYSIOL,DEPT STRUCT PHYSIOL,D-44139 DORTMUND,GERMANY; MAX PLANCK INST BIOPHYS CHEM,DEPT MOL GENET,D-37018 GOTTINGEN,GERMANY	Max Planck Society; Max Planck Society	Lavie, A (corresponding author), MAX PLANCK INST MOL PHYSIOL,DEPT PHYS BIOCHEM,RHEINLANDDAMM 201,D-44139 DORTMUND,GERMANY.		Schlichting, Ilme/I-1339-2013; Goody, Roger S/J-8845-2014; Lavie, Arnon/H-4927-2012	Goody, Roger S/0000-0002-0772-0444; Lavie, Arnon/0000-0001-5591-8722				BERGHAUSER J, 1975, BIOCHIM BIOPHYS ACTA, V397, P370, DOI 10.1016/0005-2744(75)90126-6; BRIDGES EG, 1993, BIOCHEM PHARMACOL, V45, P1571, DOI 10.1016/0006-2952(93)90296-9; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; FRICK LW, 1988, BIOCHEM BIOPH RES CO, V154, P124, DOI 10.1016/0006-291X(88)90659-6; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; HARRINGTON JA, 1993, ANTIMICROB AGENTS CH, V37, P918, DOI 10.1128/AAC.37.4.918; HUANG P, 1990, J BIOL CHEM, V265, P11914; LAVIE A, IN PRESS NATRUE STRU; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; NICKEL W, 1992, J BIOL CHEM, V267, P848; QIAN MX, 1994, BIOCHEM PHARMACOL, V48, P383, DOI 10.1016/0006-2952(94)90111-2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TORNEVIK Y, 1995, BIOCHEM PHARMACOL, V49, P829, DOI 10.1016/0006-2952(94)00453-S; YAN JP, 1995, J BIOL CHEM, V270, P22836, DOI 10.1074/jbc.270.39.22836	16	122	128	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					922	924		10.1038/nm0897-922	http://dx.doi.org/10.1038/nm0897-922			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256287				2022-12-25	WOS:A1997XP01400038
J	Sonnewald, U; Hajirezaei, MR; Kossmann, J; Heyer, A; Trethewey, RN; Willmitzer, L				Sonnewald, U; Hajirezaei, MR; Kossmann, J; Heyer, A; Trethewey, RN; Willmitzer, L			Increased potato tuber size resulting from apoplastic expression of a yeast invertase	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; Solanum tuberosum; sink strength; metabolic engineering	TRANSGENIC TOBACCO PLANTS; SACCHAROMYCES-CEREVISIAE; SOLANUM-TUBEROSUM; SINK STRENGTH; METABOLISM; SUCROSE; GROWTH; MAIZE; CELLS; GENE	The role of sucrose cleavage in determining sink strength in potato was investigated by generating transgenic potato plants that expressed a yeast invertase in either the cytosol or apoplast of tubers. Cytosolic localization gave rise to a reduction in tuber size and an increase in tuber number per plant whereas apoplastic targeting led to an increase in tuber size and a decrease in tuber number per plant. Sink organ size can be manipulated through modification of sucrose metabolism.	INST GENBIOL FORSCH BERLIN GMBH, D-14195 BERLIN, GERMANY; INST PFLANZENGENET & KULTURPFLANZEUFORSCH, D-06466 GATERSLEBEN, GERMANY; MAX PLANCK INST MOLEK PFLANZENPHYSIOL, D-14475 GOLM, GERMANY	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Max Planck Society			Heyer, Arnd G./O-9828-2015; Willmitzer, Lothar/F-7377-2011; Sonnewald, Uwe/J-7875-2012	Heyer, Arnd G./0000-0003-2074-3234; Sonnewald, Uwe/0000-0003-1835-5339; Kossmann, Jens/0000-0001-8895-894X				Abel GJW, 1996, PLANT J, V10, P981, DOI 10.1046/j.1365-313X.1996.10060981.x; Bussis D, 1997, PLANTA, V202, P126, DOI 10.1007/s004250050111; CHOUREY PS, 1976, BIOCHEM GENET, V14, P1041, DOI 10.1007/BF00485135; Dietze J., 1995, P24; GIAQUINTA RT, 1983, ANNU REV PLANT PHYS, V34, P347, DOI 10.1146/annurev.pp.34.060183.002023; GILLIES RJ, 1981, P NATL ACAD SCI-BIOL, V78, P2125, DOI 10.1073/pnas.78.4.2125; GRANOT D, 1993, YEAST, V9, P465, DOI 10.1002/yea.320090503; GRANOT D, 1991, P NATL ACAD SCI USA, V88, P5724, DOI 10.1073/pnas.88.13.5724; HO LC, 1988, ANNU REV PLANT PHYS, V39, P355, DOI 10.1146/annurev.arplant.39.1.355; KEIL M, 1986, NUCLEIC ACIDS RES, V14, P5641, DOI 10.1093/nar/14.14.5641; Klann EM, 1996, PLANT PHYSIOL, V112, P1321, DOI 10.1104/pp.112.3.1321; Koch KE, 1996, ANNU REV PLANT PHYS, V47, P509, DOI 10.1146/annurev.arplant.47.1.509; MILLER ME, 1992, PLANT CELL, V4, P297, DOI 10.1105/tpc.4.3.297; MUNCH ERNST, 1927, BE R DEUTSCH BOI GES, V45, P340; OPARKA KJ, 1992, ENV PLANT B, P91; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; SONNEWALD U, 1991, PLANT J, V1, P95, DOI 10.1111/j.1365-313X.1991.00095.x; THORPE MR, 1996, PHOTOASSIMILATE DIST; TOMOS AD, 1992, ENV PLANT B, P71; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; VONSCHAEWEN A, 1990, EMBO J, V9, P3033, DOI 10.1002/j.1460-2075.1990.tb07499.x; Weber H, 1996, PLANT J, V10, P823, DOI 10.1046/j.1365-313X.1996.10050823.x; ZRENNER R, 1995, PLANT J, V7, P97, DOI 10.1046/j.1365-313X.1995.07010097.x; [No title captured], DOI DOI 10.1007/BF03044296	25	171	187	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					794	797		10.1038/nbt0897-794	http://dx.doi.org/10.1038/nbt0897-794			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255797				2022-12-25	WOS:A1997XM70700034
J	GarciaCampayo, V; Sato, A; Hirsch, B; Sugahara, T; Muyan, M; Hsueh, AJW; Boime, I				GarciaCampayo, V; Sato, A; Hirsch, B; Sugahara, T; Muyan, M; Hsueh, AJW; Boime, I			Design of stable biologically active recombinant lutropin analogs	NATURE BIOTECHNOLOGY			English	Article						lutropin; single chain gonadotropin; structure-function	HUMAN CHORIONIC-GONADOTROPIN; LUTEINIZING-HORMONE; BETA-SUBUNITS; ESCHERICHIA-COLI; GRANULOSA-CELLS; CHAIN; STABILITY; PROTEIN; EXPRESSION; SECRETION	Glycoprotein hormones are noncovalent heterodimers comprised of a common alpha subunit and a hormone-specific beta subunit, Secretion and biologic action of these hormones are dependent on the formation of the heterodimer. The human LH beta subunit is unique among the other beta subunits in that it assembles inefficiently with the alpha subunit. To bypass this rate-limiting step, we constructed the LH single chains where the carboxy terminus of beta was fused to the amino terminus of alpha subunit through a linker. Compared to the human LH heterodimer, the extent of secretion was greater for the tethers although the rate was dependent on the nature of the linker. The LH single chains were biologically active even though there was loss of recognition by a LH-specific monoclonal antibody. This suggests that receptor binding of the single chains is not impaired by changes in the heterodimeric configuration resulting from tethering the subunits. In addition, single chains exhibited a remarkably greater in vitro stability than the heterodimer, implying that these analogs will be useful as diagnostic reagents and that their purification will be facilitated.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; STANFORD UNIV,MED CTR,DIV REPROD BIOL,DEPT OBSTET GYNECOL,STANFORD,CA 94305	Washington University (WUSTL); Stanford University			Muyan, Mesut/AAZ-4888-2020; Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Muyan, Mesut/0000-0003-3058-6228; Garcia-Campayo, Javier/0000-0002-3797-4218; Garcia-Campayo, Vicenta/0000-0002-5737-9897	NICHD NIH HHS [N01-HD 92922] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092922] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; ARORA N, 1994, J BIOL CHEM, V269, P26165; Catt KJ, 1986, REPRODUCTIVE ENDOCRI, P75; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DEMEDEIROS SF, 1991, OBSTET GYNECOL, V77, P53; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; KEENE JL, 1989, J BIOL CHEM, V264, P4769; KESNER JS, 1995, REPROD TOXICOL, V9, P239, DOI 10.1016/0890-6238(95)00005-U; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIVESEY JH, 1980, CLIN BIOCHEM, V13, P151, DOI 10.1016/S0009-9120(80)91040-1; LIVESEY JH, 1983, J ENDOCRINOL, V98, P381, DOI 10.1677/joe.0.0980381; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P1173; Muyan M, 1996, MOL ENDOCRINOL, V10, P1678, DOI 10.1210/me.10.12.1678; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; SAKETOS M, 1994, CLIN CHEM, V40, P749; SANO T, 1992, P NATL ACAD SCI USA, V89, P1534, DOI 10.1073/pnas.89.5.1534; SCHIMMEL P, 1992, PROTEIN SCI, V1, P1387, DOI 10.1002/pro.5560011018; SOMOZA JR, 1993, J MOL BIOL, V234, P390, DOI 10.1006/jmbi.1993.1594; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; Sugahara T, 1996, MOL CELL ENDOCRINOL, V125, P71, DOI 10.1016/S0303-7207(96)03944-5; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TOTH MJ, 1986, J BIOL CHEM, V261, P6643; WHITLOW M, 1991, Methods (Orlando), V2, P97, DOI 10.1016/S1046-2023(05)80209-9; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YEH P, 1992, P NATL ACAD SCI USA, V89, P1904, DOI 10.1073/pnas.89.5.1904	39	35	39	2	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					663	667		10.1038/nbt0797-663	http://dx.doi.org/10.1038/nbt0797-663			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219270				2022-12-25	WOS:A1997XH58300031
J	Jackson, RS; Creemers, JWM; Ohagi, S; RaffinSanson, ML; Sanders, L; Montague, CT; Hutton, JC; ORahilly, S				Jackson, RS; Creemers, JWM; Ohagi, S; RaffinSanson, ML; Sanders, L; Montague, CT; Hutton, JC; ORahilly, S			Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene	NATURE GENETICS			English	Article							CLEAVAGE; FURIN		UNIV CAMBRIDGE, DEPT MED, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CAMBRIDGE, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QQ, ENGLAND; ADDENBROOKES HOSP, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV LOUVAIN, MOL ONCOL LAB, CTR HUMAN GENET, B-3000 LOUVAIN, BELGIUM; FLANDERS INTERUNIV INST BIOTECHNOL, B-3000 LOUVAIN, BELGIUM; WAKAYAMA UNIV MED SCI, DEPT MED 1, WAKAYAMA 640, JAPAN; UNIV PARIS 05, INST COCHIN GENET MOL, INSERM CJF9208, GRP ETUD PHYSIOPATHOL ENDOCRINENNE, PARIS, FRANCE; UNIV COLORADO, HLTH SCI CTR, BARBARA DAVIS CTR CHILDHOOD DIABET, DENVER, CO 80262 USA	University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wakayama Medical University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Montague, Carl/0000-0001-5411-9291	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KRAWCZAK M, 1992, HUM GENET, V90, P41; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Ohagi S, 1996, DIABETES, V45, P897, DOI 10.2337/diabetes.45.7.897; ORAHILLY S, 1995, NEW ENGL J MED, V333, P1386, DOI 10.1056/NEJM199511233332104; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SCRIVER CR, 1995, METABOLIC MOL BASIS, P269; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Taylor NA, 1997, BIOCHEM J, V321, P367, DOI 10.1042/bj3210367; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; YI Z, 1993, J BIOL CHEM, V268, P5615; Zaidi FK, 1997, DIABETIC MED, V14, P228, DOI 10.1002/(SICI)1096-9136(199703)14:3<228::AID-DIA330>3.0.CO;2-N	22	781	802	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1997	16	3					303	306		10.1038/ng0797-303	http://dx.doi.org/10.1038/ng0797-303			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207799				2022-12-25	WOS:A1997XG60900029
J	Li, LH; Krantz, ID; Deng, Y; Genin, A; Banta, AB; Collins, CC; Qi, M; Trask, BJ; Kuo, WL; Cochran, J; Costa, T; Pierpont, MEM; Rand, EB; Piccoli, DA; Hood, L; Spinner, NB				Li, LH; Krantz, ID; Deng, Y; Genin, A; Banta, AB; Collins, CC; Qi, M; Trask, BJ; Kuo, WL; Cochran, J; Costa, T; Pierpont, MEM; Rand, EB; Piccoli, DA; Hood, L; Spinner, NB			Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1	NATURE GENETICS			English	Article							INTERLOBULAR BILE-DUCTS; DROSOPHILA-NOTCH; CELL-FATE; ARTERIOHEPATIC DYSPLASIA; PHYSICAL MAP; HOMOLOG; EXPRESSION; GENE; DELETION; PAUCITY	Alagille syndrome is an autosomal dominant disorder characterized by abnormal development of liver, heart, skeleton, eye, face and, less frequently, kidney. Analyses of many patients with cytogenetic deletions or rearrangements have mapped the gene to chromosome 20p12, although deletions are found in a relatively small proportion of patients (< 7%). We have mapped the human Jagged1 gene (JAG1), encoding a ligand for the developmentally important Notch transmembrane receptor, to the Alagille syndrome critical region within 20p12. The Notch intercellular signalling pathway has been shown to mediate cell fate decisions during development in invertebrates and vertebrates. We demonstrate four distinct coding mutations in JAG1 from four Alagille syndrome families, providing evidence that it is the causal gene for Alagille syndrome. All four mutations lie within conserved regions of the gene and cause translational frameshifts, resulting in gross alterations of the protein product. Patients with cytogenetically detectable deletions including JAG1 have Alagille syndrome, supporting the hypothesis that haploinsufficiency for this gene is one of the mechanisms causing the Alagille syndrome phenotype.	UNIV PENN,CHILDRENS HOSP,SCH MED,DIV HUMAN GENET,PHILADELPHIA,PA 19104; UNIV PENN,CHILDRENS HOSP,SCH MED,DIV GASTROENTEROL & NUTR,PHILADELPHIA,PA 19104; UNIV WASHINGTON,STOWERS INST MED RES,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MOL BIOTECHNOL,SEATTLE,WA 98195; FUDAN UNIV,INST GENET,SHANGHAI 200433,PEOPLES R CHINA; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; UNIV CALIF SAN FRANCISCO,CTR CANC,CANC GENET PROGRAM,SAN FRANCISCO,CA 94141; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Stowers Institute for Medical Research; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fudan University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Banta, Amy/0000-0002-1843-5059; Li, Linheng/0000-0001-9963-430X	NICHD NIH HHS [5 P30 HD288215] Funding Source: Medline; NIDDK NIH HHS [1R01DK53104-01, DK02338-03] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053104, K08DK002338] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAGILLE D, 1987, J PEDIATR-US, V110, P195, DOI 10.1016/S0022-3476(87)80153-1; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bao ZZ, 1997, J NEUROSCI, V17, P1425; CONLON RA, 1995, DEVELOPMENT, V121, P1533; DANKS DM, 1977, ARCH DIS CHILD, V52, P360, DOI 10.1136/adc.52.5.360; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DELAMO FF, 1992, DEVELOPMENT, V115, P737; Deleuze Jean-Francois, 1994, European Journal of Human Genetics, V2, P185; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DHORNEPOLLET S, 1994, J MED GENET, V31, P453, DOI 10.1136/jmg.31.6.453; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KAHN E, 1986, HEPATOLOGY, V6, P890, DOI 10.1002/hep.1840060514; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; Krantz ID, 1997, J MED GENET, V34, P152, DOI 10.1136/jmg.34.2.152; Krantz ID, 1997, AM J MED GENET, V70, P80, DOI 10.1002/(SICI)1096-8628(19970502)70:1<80::AID-AJMG15>3.3.CO;2-H; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LI L, IN PRESS IMMUNITY; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; NICKERSON E, 1995, AM J HUM GENET, V56, P1156; NOVOTNY NM, 1981, AM J GASTROENTEROL, V75, P449; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PICCOLI DA, 1991, DIAGNOSIS MANAGEMENT, P1124; POLLET N, 1995, GENOMICS, V27, P467, DOI 10.1006/geno.1995.1078; RAND EB, 1995, AM J HUM GENET, V57, P1068; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; SCHNITTGER S, 1989, HUM GENET, V83, P239, DOI 10.1007/BF00285164; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; SPINNER NB, 1994, AM J HUM GENET, V55, P238; SPINNER NB, 1997, IN PRESS CYTOGENETIC; STOKKE T, 1995, GENOMICS, V26, P134, DOI 10.1016/0888-7543(95)80092-Z; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WATSON GH, 1973, ARCH DIS CHILD, V48, P459, DOI 10.1136/adc.48.6.459; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	54	870	927	2	31	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					243	251		10.1038/ng0797-243	http://dx.doi.org/10.1038/ng0797-243			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207788				2022-12-25	WOS:A1997XG60900018
J	Liu, XZ; Walsh, J; Mburu, P; KendrickJones, J; Cope, MJTV; Steel, KP; Brown, SDM				Liu, XZ; Walsh, J; Mburu, P; KendrickJones, J; Cope, MJTV; Steel, KP; Brown, SDM			Mutations in the myosin VIIA gene cause non-syndromic recessive deafness	NATURE GENETICS			English	Article								Genetic hearing impairment affects around 1 in every 2,000 births(1). The bulk (approximately 70%) of genetic deafness is non-syndromic, in which hearing impairment is not associated with any other abnormalities. Over 25 loci involved in nonsyndromic deafness have been mapped and mutations in connexin 26 have been identified as a cause of non-sydromic deafness(2). One locus for non-syndromic recessive deafness, DFNB2 (ref. 4), has been localized to the same chromosomal region, 11q14, as one of the loci, USH1B, underlying the recessive deaf-blind syndrome, Usher syndrome type 1b, which is characterized by profound congenital sensorineural deafness, constant vestibular dysfunction and prepubertal onset of retinitis pigmentosa. Recently, it has been shown that a gene encoding an unconventional myosin, myosin VIIA, underlies the mouse recessive deafness mutation, shaker-1 (ref. 5) as well as Usher syndrome type 1b(6). Mice with shaker-1 demonstrate typical neuroepithelial defects manifested by hearing loss and vestibular dysfunction but no retinal pathology. Differences in retinal patterns of expression may account for the variance in phenotype between shaker-1 mice and Usher type 1 syndrome(7). Nevertheless, the expression of MYO7A in the neuroepithelium suggests that it should be considered a candidate for non-syndromic deafness in the human population. By screening families with non-syndromic deafness from China. we have identified two families carrying MYO7A mutations.	MRC, MOUSE GENOME CTR, HARWELL OX11 0RD, BERKS, ENGLAND; MRC, MAMMALIAN GENET UNIT, HARWELL OX11 0RD, BERKS, ENGLAND; MRC, MOL BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND; UNIV CALIF BERKELEY, DEPT CELL & MOL BIOL, BERKELEY, CA 94720 USA; MRC, INST HEARING RES, NOTTINGHAM NG7 2RD, ENGLAND	MRC Laboratory Molecular Biology; University of California System; University of California Berkeley				Cope, Jamie/0000-0002-6960-8271				Anderson H, 1968, Acta Otolaryngol, V65, P535; Chen ZY, 1996, GENOMICS, V36, P440, DOI 10.1006/geno.1996.0489; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; Fraser G. R, 1976, BIG 4 CAUSES POVERTY; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Levy G, 1997, HUM MOL GENET, V6, P111, DOI 10.1093/hmg/6.1.111; LIU XZ, 1994, AM J MED GENET, V53, P192, DOI 10.1002/ajmg.1320530214; LIU XZ, 1994, ANN OTO RHINOL LARYN, V103, P428, DOI 10.1177/000348949410300602; LIU XZ, IN PRESS HUM MUTAT; MEREDITH R, 1992, J AUDIOL MED, V1, P11; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Solc CK, 1994, AUDIT NEUROSCI, V1, P63; Steel KP, 1996, CURR OPIN NEUROBIOL, V6, P520, DOI 10.1016/S0959-4388(96)80059-6; STEPHENS D, 1996, GENETICS HEARING IMP, P100; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Weston MD, 1996, AM J HUM GENET, V59, P1074	19	350	368	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1997	16	2					188	190		10.1038/ng0697-188	http://dx.doi.org/10.1038/ng0697-188			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171832				2022-12-25	WOS:A1997XB54300021
J	Campbell, RK; Bergert, ER; Wang, YH; Morris, JC; Moyle, WR				Campbell, RK; Bergert, ER; Wang, YH; Morris, JC; Moyle, WR			Chimeric proteins can exceed the sum of their parts: Implications for evolution and protein design	NATURE BIOTECHNOLOGY			English	Article						protein-protein interactions; human chorionic gonadotropin; thyrotropin; chimeric proteins; evolution	HUMAN CHORIONIC-GONADOTROPIN; FOLLICLE-STIMULATING-HORMONE; HUMAN THYROTROPIN RECEPTOR; FRTL-5 THYROID-CELLS; BETA-SUBUNIT; GLYCOPROTEIN HORMONES; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; BINDING	Chimeric analogs derived from pairs of homologous proteins routinely exhibit activities found in one or both parents, We describe chimeras of two glycoprotein hormones, human chorionic gonadotropin (hCG) and human follitropin (hFSH), that exhibit activity unique to a third family member, human thyrotropin (hTSH). The results show that biological activity can be separated from hormone-specific amino acid residues. This is consistent with a model for the evolution of homologous ligand-receptor pairs involving gene duplication and the creation of inhibitory determinants that restrict binding. Disruption of these determinants can unmask activities characteristic of other members of a protein family. Combining portions of two ligands to create analogs with properties of a third family member can facilitate identifying key determinants of protein-protein interaction and may be a useful strategy for creating novel therapeutics, In the case of the glycoprotein hormones, this showed that two different hormone regions (i.e., the seat-belt and the intersubunit groove) appear to limit inappropriate contacts with receptors for other members of this family, These observations also have important caveats for chimera-based protein design because an unexpected gain of function may limit the therapeutic usefulness of some chimeras.	RUTGERS STATE UNIV,ROBERT WOOD JOHNSON MED SCH,DEPT OBGYN,PISCATAWAY,NJ 08854; MAYO CLIN & MAYO GRAD SCH MED,DEPT ENDOCRINOL & INTERNAL MED,ROCHESTER,MN 55905	Rutgers State University New Brunswick; Rutgers State University Medical Center; Mayo Clinic			Campbell, Robert/G-4112-2012		NICHD NIH HHS [HD15454, HD14907] Funding Source: Medline; NIDDK NIH HHS [DK42008] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD015454, R01HD014907, R37HD014907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042008] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CARAYON P, 1981, ENDOCRINOLOGY, V108, P1891, DOI 10.1210/endo-108-5-1891; CHENG KW, 1973, J BIOL CHEM, V248, P7930; COLE ES, 1993, BIOTECHNOLOGY, V11, P1015; COMBARNOUS Y, 1981, J BIOL CHEM, V256, P9567; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DIAS JA, 1994, J BIOL CHEM, V269, P25289; ELDEIRY S, 1991, MOL CELL ENDOCRINOL, V76, P105, DOI 10.1016/0303-7207(91)90265-T; GLINOER D, 1993, J ENDOCRINOL INVEST, V16, P881, DOI 10.1007/BF03348950; Han Y, 1996, MOL CELL ENDOCRINOL, V124, P151, DOI 10.1016/S0303-7207(96)03936-6; HOERMANN R, 1991, ENDOCRINOLOGY, V128, P1129; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LEWIS EB, 1951, COLD SPRING HARB SYM, V16, P159, DOI 10.1101/SQB.1951.016.01.014; MARENGERE LEM, 1994, NATURE, V369, P50; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MERZ WE, 1985, BIOCHIM BIOPHYS ACTA, V844, P62, DOI 10.1016/0167-4889(85)90234-4; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P456, DOI 10.1210/endo-123-1-456; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; OHNO S, 1970, EVOLUTION GENE DUPLI, P59; PAVLAKIS GN, 1987, GENE TRANSFER VECTOR, P29; PEKARY AE, 1993, J CLIN ENDOCR METAB, V76, P70, DOI 10.1210/jc.76.1.70; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SOUZA SC, 1995, P NATL ACAD SCI USA, V92, P959, DOI 10.1073/pnas.92.4.959; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STRICKLAND TW, 1981, ENDOCRINOLOGY, V109, P1933, DOI 10.1210/endo-109-6-1933; Tian Y, 1996, J BIOL CHEM, V271, P20250, DOI 10.1074/jbc.271.34.20250; TOMER Y, 1992, J CLIN ENDOCR METAB, V74, P1477, DOI 10.1210/jc.74.6.1477; TSURUTA E, 1995, J CLIN ENDOCR METAB, V80, P350, DOI 10.1210/jc.80.2.350; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VITTI P, 1983, J CLIN ENDOCR METAB, V57, P782, DOI 10.1210/jcem-57-4-782; VITTI P, 1993, J CLIN ENDOCR METAB, V76, P499, DOI 10.1210/jc.76.2.499; WANG Y, 1994, INT CONGR SER, V1046, P191; Ward D.N., 1979, ANIMAL MODELS RES FE, P151; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YAMAZAKI K, 1995, J CLIN ENDOCR METAB, V80, P473, DOI 10.1210/jc.80.2.473; YCAS M, 1974, J THEOR BIOL, V44, P145, DOI 10.1016/S0022-5193(74)80035-4; YOSHIKAWA N, 1990, ENDOCRINOL JAPON, V37, P639; YOSHIMURA M, 1991, ACTA ENDOCRINOL-COP, V124, P173, DOI 10.1530/acta.0.1240173; YOSHIMURA M, 1994, EUR J ENDOCRINOL, V130, P92, DOI 10.1530/eje.0.1300092	49	37	42	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					439	443		10.1038/nbt0597-439	http://dx.doi.org/10.1038/nbt0597-439			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131622				2022-12-25	WOS:A1997WX23700027
J	Bonyadi, M; Rusholme, SAB; Cousins, FM; Su, HC; Biron, CA; Farrall, M; Akhurst, RJ				Bonyadi, M; Rusholme, SAB; Cousins, FM; Su, HC; Biron, CA; Farrall, M; Akhurst, RJ			Mapping of a major genetic modifier of embryonic lethality in TGF beta 1 knockout mice	NATURE GENETICS			English	Article							TGF-BETA; TARGETED DISRUPTION; COMPLEX TRAITS; MESSENGER-RNA; NEURAL-TUBE; MOUSE; RECEPTOR; LINKAGE; LOCALIZATION; DISSECTION	The transforming growth factor beta 1 (TGF beta 1) signalling pathway(1,2) is important in embryogenesis(3) and has been implicated in hereditary haemorrhagic telangiectasia (HHT)(4,5) atherosclerosis(6,7), tumorigenesis(8,9) and immunomodulation(10,11) ll. Therefore, identification of factors which modulate TGF beta 1 bioactivity in vivo is important. On a mixed genetic background, similar to 50% Tgfb1(-/-) conceptuses die midgestation from defective yolk sac vasculogenesis(3). The other half are developmentally normal but die three weeks postpartum(3,10,11). Intriguingly, the vascular defects of Tgfb1(-/-) mice share histological similarities to lesions seen in HHT patients(3-5) It has been suggested that dichotomy in Tgfb1(-/-) lethal phenotypes is due to maternal TGF beta 1 rescue of some, but not all, Tgfb1(-/-) embryos(12). Here we show that the Tgfb1(-/-) phenotype depends on the genetic background of the conceptus. In NIH/Ola, C57BL/6J/Ola and F1 conceptuses, Tgfb1(-/-) lethality can be categorized into three developmental classes. A major codominant modifier gene of embryo lethality was mapped to proximal mouse chromosome 5, using a genome scan for non-mendelian distribution of alleles in Tgfb1(-/-) neonatal animals which survive prenatal lethality. This gene accounts for around three quarters of the genetic effect between mouse strains and can, in part, explain the distribution of the three lethal phenotypes. This approach, using neonatal DNA samples, is generally applicable to identification of loci that influence the effect of early embryonic lethal mutations, thus furthering knowledge of genetic interactions that occur during early mammalian development in vivo.	BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912; UNIV OXFORD,NUFFIELD DEPT MED,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND; UNIV GLASGOW,DUNCAN GUTHRIE INST,DEPT MED GENET,GLASGOW G3 8SJ,LANARK,SCOTLAND	Brown University; University of Oxford; Wellcome Centre for Human Genetics; University of Glasgow			Su, Helen C/H-9541-2015	Su, Helen C/0000-0002-5582-9110; Bonyadi, Mortaza/0000-0003-3216-2947; AKHURST, ROSEMARY/0000-0002-4474-9668				AVRAHAM KB, 1994, GENOMICS, V21, P656, DOI 10.1006/geno.1994.1330; Bonyadi M, 1996, GENOMICS, V33, P328, DOI 10.1006/geno.1996.0204; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; CUI W, 1996, GROWTH FACTORS CYTOK, P357; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; GAUTAM SC, 1993, ONCOL RES, V5, P423; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MARKOWITZ S, 1995, SCIENCE, V268, P1276; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MOCK BA, 1989, J IMMUNOL, V142, P1372; NEUMANN PE, 1994, NAT GENET, V6, P357, DOI 10.1038/ng0494-357; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; QURESHI ST, 1995, GENOMICS, V26, P165, DOI 10.1016/0888-7543(95)80099-8; RISCH N, 1993, AM J HUM GENET, V53, P702; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; SAUNDERS K B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P157; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084	32	136	141	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	FEB	1997	15	2					207	211		10.1038/ng0297-207	http://dx.doi.org/10.1038/ng0297-207			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020852				2022-12-25	WOS:A1997WF08700026
J	Reinhart, TA; Rogan, MJ; Viglianti, GA; Rausch, DM; Eiden, LE; Haase, AT				Reinhart, TA; Rogan, MJ; Viglianti, GA; Rausch, DM; Eiden, LE; Haase, AT			A new approach to investigating the relationship between productive infection and cytopathicity in vivo	NATURE MEDICINE			English	Article							FOLLICULAR DENDRITIC CELLS; IMMUNODEFICIENCY SYNDROME AIDS; LYMPH-NODE; RHESUS-MONKEYS; VIRUS TYPE-1; HIV-1; MACROPHAGES; PROGRESSION; EXPRESSION; PARTICLES	We describe a novel experimental approach to analyzing virus-host relationships and potential mechanisms of cytopathicity in vivo in simian immunodeficiency virus (SIV) infections. Progressive destruction of lymphoid tissue in the course of infection by SIV or human immunodeficiency virus (HIV) accompanies the loss of CD4(+) T lymphocytes and sets the stage for AIDS(1,2). Because one of the important early events in this pathological process is lysis of follicular dendritic cells(3) (FDCs), we investigated the controversial role of productive SIV infection in the destruction of FDCs. To differentiate productive infections from the known association of virus with FDCs as immune complexes trapped on cell surfaces(4-6), we used detection of spliced viral mRNAs in cells as evidence of productive infection. We found that spliced and unspliced viral RNAs could be detected by in situ hybridization (ISH) with specific antisense oligonucleotide probes in lymphocytes and macrophages with sensitivities of fewer than ten copies of spliced viral RNA per cell. We detected only unspliced RNA in germinal centers where FDCs reside. Thus, no productive infection of these cells can be detected in vivo by this assay, and their destruction likely occurs by indirect mechanisms that have yet to be determined.	UNIV MINNESOTA,SCH MED,DEPT MICROBIOL,MINNEAPOLIS,MN 55455; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; NIMH,CELL BIOL LAB,BETHESDA,MD	University of Minnesota System; University of Minnesota Twin Cities; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)				Eiden, Lee/0000-0001-7524-944X; Viglianti, Gregory/0000-0002-0244-8293				ARMSTRONG JA, 1984, LANCET, V2, P370; CAMERON PU, 1987, CLIN EXP IMMUNOL, V68, P465; CHAKRABARTI L, 1994, J VIROL, V68, P6634, DOI 10.1128/JVI.68.10.6634-6643.1994; DIEBOLD J, 1985, PATHOL RES PRACT, V180, P590, DOI 10.1016/S0344-0338(85)80037-6; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; MURRAY EA, 1992, SCIENCE, V255, P1246, DOI 10.1126/science.1546323; PARMENTIER HK, 1990, AM J PATHOL, V137, P247; PENG HR, 1995, VIROLOGY, V206, P16, DOI 10.1016/S0042-6822(95)80015-8; RAUSCH DM, 1994, J NEUROPATH EXP NEUR, V53, P165, DOI 10.1097/00005072-199403000-00008; Reinhart TA, 1996, VIROLOGY, V224, P338, DOI 10.1006/viro.1996.0539; SCHMITZ J, 1994, J IMMUNOL, V153, P1352; SCHUURMAN HJ, 1985, J PATHOL, V147, P269, DOI 10.1002/path.1711470405; SPIEGEL H, 1992, AM J PATHOL, V140, P15; SPRENGER R, 1995, MED MICROBIOL IMMUN, V184, P129, DOI 10.1007/BF00224349; STAHMER I, 1991, EUR J IMMUNOL, V21, P1873, DOI 10.1002/eji.1830210814; STAHMER J, 1996, J ACQUIR IMMUN DEFIC, V11, P1; TENNERRACZ K, 1994, RES VIROLOGY, V145, P177, DOI 10.1016/S0923-2516(07)80020-3; Tsunoda R, 1996, AIDS, V10, P595, DOI 10.1097/00002030-199606000-00004; VIGLIANTI GA, 1990, J VIROL, V64, P4207, DOI 10.1128/JVI.64.9.4207-4216.1990	26	33	33	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					218	221		10.1038/nm0297-218	http://dx.doi.org/10.1038/nm0297-218			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018242				2022-12-25	WOS:A1997WF08800042
J	Wu, LJC; Wang, ZW; Tsan, JT; Spillman, MA; Phung, A; Xu, XL; Yang, MCW; Hwang, LY; Bowcock, AM; Baer, R				Wu, LJC; Wang, ZW; Tsan, JT; Spillman, MA; Phung, A; Xu, XL; Yang, MCW; Hwang, LY; Bowcock, AM; Baer, R			Identification of a RING protein that can interact in vivo with the BRCA1 gene product	NATURE GENETICS			English	Article							GLUTATHIONE-S-TRANSFERASE; OVARIAN-CANCER; ESCHERICHIA-COLI; FAMILIAL BREAST; LEUCINE ZIPPER; DNA-BINDING; MUTATIONS; PURIFICATION; EXPRESSION; POLYPEPTIDES	The hereditary breast and ovarian cancer gene, BRCA1, encodes a large polypeptide that contains the cysteine-rich RING motif, a zinc-binding domain found in a variety of regulatory proteins. Here we describe a novel protein that interacts in vivo with the N-terminal region of BRCA1. This BRCA1-associated RING domain (BARD1) protein contains an N-terminal RING motif, three tandem ankyrin repeats, and a C-terminal sequence with significant homology to the phylogenetically conserved BRCT domains that lie near the C terminus of BRCA1. The BARD1/BRCA1 interaction is disrupted by BRCA1 missense mutations that segregate with breast cancer susceptibility, indicating that BARD1 may be involved in mediating tumour suppression by BRCA1.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR HUMAN GROWTH & DEV,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MOL IMMUNOL CTR,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Bowcock, Anne/0000-0001-8691-9090	NATIONAL CANCER INSTITUTE [R01CA060650] Funding Source: NIH RePORTER; NCI NIH HHS [CA60650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EASTON DF, 1993, AM J HUM GENET, V52, P678; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARPER JW, 1993, CELL, V75, P805; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sambrook J., 2002, MOL CLONING LAB MANU; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TSAN JT, IN PRESS YEAST 2 HYB	30	591	610	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					430	440		10.1038/ng1296-430	http://dx.doi.org/10.1038/ng1296-430			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944023				2022-12-25	WOS:A1996VV73000019
J	Salomon, R; Attie, T; Pelet, A; Bidaud, C; Eng, C; Amiel, J; Sarnacki, S; Goulet, O; Ricour, C; NihoulFekete, C; Munnich, A; Lyonnet, S				Salomon, R; Attie, T; Pelet, A; Bidaud, C; Eng, C; Amiel, J; Sarnacki, S; Goulet, O; Ricour, C; NihoulFekete, C; Munnich, A; Lyonnet, S			Germline mutations of the RET ligand GDNF are not sufficient to cause hirschsprung disease	NATURE GENETICS			English	Article							TYROSINE KINASE; NEUROTROPHIC FACTOR; GENE; CHROMOSOME-10; PROTOONCOGENE; NEURONS; MAPS		HOP ENFANTS MALAD,INST NECKER,FEDERAT GENET,CLIN CHIRURG INFANTILE,INSERM,U393,F-75743 PARIS 15,FRANCE; HOP ENFANTS MALAD,INST NECKER,SERV NUTR & GASTROENTEROL PEDIAT,F-75743 PARIS 15,FRANCE; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV CANC EPIDEMIOL & CONTROL,BOSTON,MA 02115	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Lyonnet, Stanislas/H-5483-2017; ATTIE-BITACH, Tania/K-1453-2017; Sarnacki, Sabine/I-2692-2017; amiel, jeanne/AGX-1124-2022; amiel, jeanne/H-3501-2017	Lyonnet, Stanislas/0000-0001-5426-9417; ATTIE-BITACH, Tania/0000-0002-1155-3626; Sarnacki, Sabine/0000-0003-4304-5578; amiel, jeanne/0000-0001-5973-4728; PELET, Anastella/0000-0002-8353-1725; Eng, Charis/0000-0002-3693-5145				Amiel J, 1996, HUM MOL GENET, V5, P355, DOI 10.1093/hmg/5.3.355; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; ATTIE T, 1995, HUM MOL GENET, V4, P2407, DOI 10.1093/hmg/4.12.2407; BADNER JA, 1990, AM J MED GENET, V35, P100, DOI 10.1002/ajmg.1320350119; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; EMANUEL B, 1965, J PEDIATR-US, V66, P437, DOI 10.1016/S0022-3476(65)80201-3; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MOORE M, 1996, NATURE, V381, P785; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PASSARGE E, 1967, NEW ENGL J MED, V276, P138, DOI 10.1056/NEJM196701192760303; PASSARGE E, 1993, NAT GENET, V4, P325, DOI 10.1038/ng0893-325; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; RESCORLA FJ, 1992, ARCH SURG-CHICAGO, V127, P934; RICHARD I, 1995, NAT GENET, V10, P259, DOI 10.1038/ng0795-259; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHINDELHAUER D, 1995, GENOMICS, V28, P605, DOI 10.1006/geno.1995.1202; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; YIN L, 1994, EUR J HUM GENET, V4, P821	29	157	158	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1996	14	3					345	347		10.1038/ng1196-345	http://dx.doi.org/10.1038/ng1196-345			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VQ146	8896569				2022-12-25	WOS:A1996VQ14600034
J	Neurath, MF; Pettersson, S; zumBuschenfelde, KHM; Strober, W				Neurath, MF; Pettersson, S; zumBuschenfelde, KHM; Strober, W			Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice	NATURE MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; RECEPTOR MUTANT MICE; CELL-PROLIFERATION; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; ULCERATIVE-COLITIS; GENE INHIBITION; EXPRESSION; ALPHA; DNA	Chronic intestinal inflammation induced by 2,4,6,-trinitrobenzene sulfonic acid (TNBS) is characterized by a transmural granulomatous colitis that mimics some characteristics of human Crohn's disease. Here, we show that the transcription factor NF-kappa S p65 was strongly activated in TNBS-induced colitis and in colitis of interleukin-10-deficient mice. Local administration of p65 antisense phosphorothioate oligonucleotides abrogated clinical and histological signs of colitis and was more effective in treating TNBS-induced colitis than single or daily administration of glucocorticoids. The data provide direct evidence for the central importance of p65 in chronic intestinal inflammation and suggest a potential therapeutic utility of p65 antisense oligonucleotides as a novel molecular approach for the treatment of patients with Crohn's disease.	KAROLINSKA INST, CTR BIOTECHNOL, S-14157 HUDDINGE, SWEDEN; NIAID, CLIN INVEST LAB, MUCOSAL IMMUN SECT, BETHESDA, MD 20892 USA	Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Neurath, MF (corresponding author), UNIV MAINZ, MED CLIN 1, IMMUNOL LAB, LANGENBECKSTR 1, D-55101 MAINZ, GERMANY.		Pettersson, Sven/F-9511-2015					AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BULL DM, 1977, J CLIN INVEST, V59, P966, DOI 10.1172/JCI108719; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; Duchmann R, 1996, EUR J IMMUNOL, V26, P934, DOI 10.1002/eji.1830260432; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GURA T, 1995, SCIENCE, V270, P575, DOI 10.1126/science.270.5236.575; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOLLANDER GA, 1995, IMMUNITY, V3, P27, DOI 10.1016/1074-7613(95)90156-6; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HOLT JT, 1995, NAT MED, V1, P407, DOI 10.1038/nm0595-407; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; NESTEROVA M, 1995, NAT MED, V1, P528, DOI 10.1038/nm0695-528; NEURATH MF, 1995, P NATL ACAD SCI USA, V92, P5336, DOI 10.1073/pnas.92.12.5336; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SARTOR RB, 1990, CAN J GASTROENTEROL, V4, P271; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; STROBER W, 1993, CELL, V75, P203, DOI 10.1016/0092-8674(93)80062-J; STROBER W, 1995, CLIN IMMUNOLOGY, P1401; Stuber E, 1996, J EXP MED, V183, P693, DOI 10.1084/jem.183.2.693; VALTIERI M, 1991, BLOOD, V77, P1181; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	47	720	750	1	33	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1996	2	9					998	1004		10.1038/nm0996-998	http://dx.doi.org/10.1038/nm0996-998			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782457				2022-12-25	WOS:A1996VF49700034
J	Sawada, S; Florell, S; Purandare, SM; Ota, M; Stephens, K; Viskochil, D				Sawada, S; Florell, S; Purandare, SM; Ota, M; Stephens, K; Viskochil, D			Identification of NF1 mutations in both alleles of a dermal neurofibroma	NATURE GENETICS			English	Letter							TYPE-1 NEUROFIBROMATOSIS; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; GENE-PRODUCT; DELETIONS; TUMORS; HETEROZYGOSITY; CHROMOSOME-17; PROTEINS; DOMAIN; ORIGIN		UNIV UTAH,DEPT PEDIAT,DIV MED GENET,SALT LAKE CITY,UT 84112; JIKEI UNIV,SCH MED,DEPT DERMATOL,MINATO KU,TOKYO 105,JAPAN; UNIV UTAH,DEPT PATHOL,SALT LAKE CITY,UT 84112; UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195	Utah System of Higher Education; University of Utah; Jikei University; Utah System of Higher Education; University of Utah; University of Washington; University of Washington Seattle								ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; COLMAN SD, 1995, NAT GENET, V11, P90, DOI 10.1038/ng0995-90; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; ENZINGER F, 1988, SOFT TISSUE TUMORS, P821; FIALKOW PJ, 1971, NEW ENGL J MED, V284, P298, DOI 10.1056/NEJM197102112840604; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; KAYES LM, 1994, AM J HUM GENET, V54, P424; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Leppig KA, 1996, CYTOGENET CELL GENET, V72, P95, DOI 10.1159/000134171; LI Y, 1995, GENOMICS, V25, P9, DOI 10.1016/0888-7543(95)80104-T; LOTHE RA, 1995, J NEUROPATH EXP NEUR, V54, P65, DOI 10.1097/00005072-199501000-00008; MARCHUK DA, 1992, GENOMICS, V13, P672, DOI 10.1016/0888-7543(92)90140-N; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; REYNOLDS JE, 1992, HUM GENET, V90, P450; Sambrook J., 2002, MOL CLONING LAB MANU; SARNOWITZ W, 1995, GASTROENTEROLOGY, V109, P1765; SAWADA S, 1995, JAP J DERMATOL, V105, P1187; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SHIMIZU E, 1993, CANCER, V71, P725, DOI 10.1002/1097-0142(19930201)71:3<725::AID-CNCR2820710312>3.0.CO;2-F; SKUSE GR, 1991, AM J HUM GENET, V49, P600; SKUSE GR, 1989, GENE CHROMOSOME CANC, V1, P36, DOI 10.1002/gcc.2870010107; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	29	123	125	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	SEP	1996	14	1					110	112		10.1038/ng0996-110	http://dx.doi.org/10.1038/ng0996-110			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782831				2022-12-25	WOS:A1996VF61100032
J	Cantwell, M; Hua, T; Pappas, J; Kipps, TJ				Cantwell, M; Hua, T; Pappas, J; Kipps, TJ			Acquired CD40-ligand deficiency in chronic lymphocytic leukemia	NATURE MEDICINE			English	Article							ACTIVATED T-CELLS; X-LINKED IMMUNODEFICIENCY; HYPER-IGM SYNDROME; CD40 LIGAND; B-CELLS; DEFECTIVE EXPRESSION; ANTIGEN; ENDOCYTOSIS; MICE; RESPONSIVENESS	Patients with B-cell chronic lymphocytic leukemia (CLL) acquire an immunodeficiency with many characteristics similar to those of persons with inherited defects in the gene encoding the CD40-ligand (CD154). We found that the blood and splenic CD4(+) T cells of patients with CLL failed to express surface CD154 after CD3 ligation. However, using an enzyme-linked immunosorbent assay (ELISA)-based quantitative competitive polymerase chain reaction (PCR), we noted that CD3 ligation could induce such T cells to express CD154 messenger RNA at levels similar to that of CD3-activated T cells from normal donors. Moreover, addition of Increasing numbers of CLL B cells to activated normal donor T cells rapidly resulted in progressively greater down-modulation of CD154. Such down-modulation of CD154 could be blocked by addition of CD40 monoclonal antibody to cultures in vitro. We propose that leukemia cell-mediated down-modulation of CD154 on activated T cells accounts for some of the acquired immune defects of patients with CLL.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R37CA049870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041897] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA49870R01] Funding Source: Medline; NIAMS NIH HHS [P01-AR41897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; AYANLARBATUMAN O, 1986, BLOOD, V67, P279; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BENAISSA H, 1988, ANTICANCER RES, V8, P443; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; BOWEN F, 1995, EUR J IMMUNOL, V25, P2830, DOI 10.1002/eji.1830251018; CALLERY RT, 1980, CLIN IMMUNOL IMMUNOP, V17, P451, DOI 10.1016/0090-1229(80)90116-6; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; CASTLE BE, 1993, J IMMUNOL, V151, P1777; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FERNANDEZ LA, 1977, CANCER, V39, P1168, DOI 10.1002/1097-0142(197703)39:3<1168::AID-CNCR2820390323>3.0.CO;2-G; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; HAMBLIN TJ, 1986, J CLIN PATHOL, V39, P713, DOI 10.1136/jcp.39.7.713; HAN SH, 1995, J IMMUNOL, V155, P556; HAN T, 1982, BLOOD, V60, P1075; HERRMANN P, 1993, EUR J IMMUNOL, V23, P961; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; KAY NE, 1984, BRIT J HAEMATOL, V57, P105, DOI 10.1111/j.1365-2141.1984.tb08504.x; KAY NE, 1986, BLOOD, V67, P578; KIPPS TJ, 1995, WILLIAMS HEMATOLOGY, P1017; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LOTZ M, 1994, J EXP MED, V179, P999, DOI 10.1084/jem.179.3.999; LUCIVERO G, 1983, J CLIN IMMUNOL, V3, P111, DOI 10.1007/BF00915481; MATUTES E, 1981, BRIT J HAEMATOL, V49, P635, DOI 10.1111/j.1365-2141.1981.tb07274.x; MIZOGUCHI H, 1992, SCIENCE, V258, P1795, DOI 10.1126/science.1465616; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; Pammer J, 1996, AM J PATHOL, V148, P1387; Patel HR, 1996, J IMMUNOL, V156, P1781; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; PLATSOUCAS CD, 1980, J IMMUNOL, V125, P1216; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; Rossi E, 1996, LEUKEMIA, V10, P494; ROY M, 1993, J IMMUNOL, V151, P2497; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; SEMENZATO G, 1981, CANCER-AM CANCER SOC, V48, P2191, DOI 10.1002/1097-0142(19811115)48:10<2191::AID-CNCR2820481013>3.0.CO;2-9; STORRIE B, 1977, CELL, V11, P707, DOI 10.1016/0092-8674(77)90087-3; Stuber E, 1996, J EXP MED, V183, P693, DOI 10.1084/jem.183.2.693; TOTTERMAN TH, 1989, BLOOD, V74, P786; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; VANKOOTEN C, 1994, EUR J IMMUNOL, V24, P787, DOI 10.1002/eji.1830240402; WESTBROOK CA, 1984, SEMIN ONCOL, V11, P514; YELLIN MJ, 1994, J IMMUNOL, V152, P598	46	149	153	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					984	989		10.1038/nm0997-984	http://dx.doi.org/10.1038/nm0997-984			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288724				2022-12-25	WOS:A1997XT84200030
J	Koutnikova, H; Campuzano, V; Foury, F; Dolle, P; Cazzalini, O; Koenig, M				Koutnikova, H; Campuzano, V; Foury, F; Dolle, P; Cazzalini, O; Koenig, M			Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin	NATURE GENETICS			English	Article							FRIEDREICHS ATAXIA; GENE; MUTATIONS; PROTEIN; DISEASE; CELLS	Friedreich's ataxia is due to loss of function mutations in the gene encoding frataxin (FRDA). Frataxin is a protein of unknown function. In situ hybridization analyses revealed that mouse frataxin expression correlates well with the main site of neurodegeneration, but the expression pattern is broader than expected from the pathology of the disease. Frataxin mRNA is predominantly expressed in tissues with a high metabolic rate, including liver, kidney, brown fat and heart. We found that mouse and yeast frataxin homologues contain a potential mitochondrial targeting sequence in their N-terminal domains and that disruption of the yeast gene results in mitochondrial dysfunction. Finally, tagging experiments demonstrate that human frataxin co-localizes with a mitochondrial protein. Friedreich's ataxia is therefore a mitochondrial disease caused by a mutation in the nuclear genome.	UNIV STRASBOURG 1, INST GENET & BIOL MOL & CELLULAIRE, INSERM, CNRS, F-67404 ILLKIRCH STRASBOU, FRANCE; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite Catholique Louvain			Koutnikova, Hana/I-7758-2017; Campuzano, Victoria/ABG-7429-2020; Dolle, Pascal/A-8037-2010; CAMPUZANO, VICTORIA/K-7883-2019; Campuzano, V/G-1826-2014	Campuzano, Victoria/0000-0001-8128-2641; Dolle, Pascal/0000-0002-9294-9090; Campuzano, V/0000-0001-8128-2641				Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Gibson TJ, 1996, TRENDS NEUROSCI, V19, P465, DOI 10.1016/S0166-2236(96)20054-2; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GORMAN CM, 1984, PHILOS T ROY SOC B, V307, P343, DOI 10.1098/rstb.1984.0137; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OPPENHEIMER DR, 1992, GREENFIELDS NEUROPAT, P1015; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; ROMEO G, 1983, AM J HUM GENET, V35, P523; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONNING LAB MAN; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHREIBER V, 1994, GENE, V150, P411, DOI 10.1016/0378-1119(94)90466-9; SKRE H, 1975, CLIN GENET, V7, P287; Stryer L., 1988, BIOCHEMISTRY-US; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7	27	389	401	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1997	16	4					345	351		10.1038/ng0897-345	http://dx.doi.org/10.1038/ng0897-345			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XM909	9241270				2022-12-25	WOS:A1997XM90900015
J	Dieterich, W; Ehnis, T; Bauer, M; Donner, P; Volta, U; Riecken, EO; Schuppan, D				Dieterich, W; Ehnis, T; Bauer, M; Donner, P; Volta, U; Riecken, EO; Schuppan, D			Identification of tissue transglutaminase as the autoantigen of celiac disease	NATURE MEDICINE			English	Article							CROSS-LINKING; CELLULAR TRANSGLUTAMINASE; ANTIBODIES; COMPLEXES; SUBSTRATE; ANTIGLIADIN; FIBRONECTIN; DIAGNOSIS; COLLAGEN; GLIADIN	Celiac disease is characterized by small intestinal damage with loss of absorptive villi and hyperplasia of the crypts, typically leading to malabsorption(1). In addition to nutrient deficiencies, prolonged celiac disease is associated with an increased risk for malignancy, especially intestinal T-cell lymphoma(1-3). Celiac disease is precipitated by ingestion of the protein gliadin, a component of wheat gluten, and usually resolves on its withdrawal. Gliadin initiates mucosal damage which involves an immunological process in individuals with a genetic predisposition. However, the mechanism responsible for the small intestinal damage characteristic of celiac disease is still under debate(4-6). Small intestinal biopsy with the demonstration of a flat mucosa which is reversed on a gluten-free diet is considered the main approach for diagnosis of classical celiac disease(7). In addition, IgA antibodies against gliadin and endomysium, a structure of the smooth muscle connective tissue, are valuable tools for the detection of patients with celiac disease and for therapy control(7-9). Incidence rates of childhood celiac disease range from 1:300 in Western Ireland to 1:4700 in other European countries(10-12), and subclinical cases detected by serological screening revealed prevalences of 3.3 and 4 per 1000 in Italy and the USA, respectively IgA antibodies to endomysium are particularly specific indicators of celiac disease(9,15), suggesting that this structure contains one or more target autoantigens that play a role in the pathogenesis of the disease(16,17). However, the identification of the endomysial autoantigen(s) has remained elusive. We identified tissue transglutaminase as the unknown endomysial autoantigen. Interestingly, gliadin is a preferred substrate for this enzyme, giving rise to novel antigenic epitopes.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, DEPT GASTROENTEROL, D-12200 BERLIN, GERMANY; SCHERING AG, RES LABS, D-13342 BERLIN, GERMANY; POLICLIN S ORSOLA, IST CLIN MED GEN & TERAPIA MED, I-40138 BOLOGNA, ITALY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG; IRCCS Azienda Ospedaliero-Universitaria di Bologna				Volta, Umberto/0000-0003-3405-3808				AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; BRUCE SE, 1985, CLIN SCI, V68, P573, DOI 10.1042/cs0680573; BURGINWOLFF A, 1991, ARCH DIS CHILD, V66, P941, DOI 10.1136/adc.66.8.941; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; FERGUSON A, 1995, MALIGNANCY CHRONIC I, P51; GENTILE V, 1991, J BIOL CHEM, V266, P478; Greco L., 1992, COMMON FOOD INTOLERA, P25; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; KLEMAN JP, 1995, BIOCHEMISTRY-US, V34, P13768, DOI 10.1021/bi00042a007; KNIGHT CRL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P312, DOI 10.1016/0925-4439(91)90067-J; LADINSER B, 1994, GUT, V35, P776, DOI 10.1136/gut.35.6.776; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lankisch PG, 1996, Z GASTROENTEROL, V34, P473; LERNER A, 1994, CLIN EXP IMMUNOL, V95, P78; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; Maki M, 1996, LANCET, V348, P1046, DOI 10.1016/S0140-6736(05)64411-X; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MYLOTTE M, 1973, BMJ-BRIT MED J, V1, P703, DOI 10.1136/bmj.1.5855.703; Not T, 1996, GASTROENTEROLOGY, V110, pA351; Piacentini M, 1995, Curr Top Microbiol Immunol, V200, P163; Picarelli A, 1996, LANCET, V348, P1065, DOI 10.1016/S0140-6736(96)03060-7; SANDFORTH F, 1991, Z GASTROENTEROL, V29, P327; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOSROSENO W, 1995, J ROY SOC MED, V88, P14; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; SZABOLCS M, 1987, Acta Paediatrica Hungarica, V28, P215; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; VOLTA U, 1991, DIGEST DIS SCI, V36, P752, DOI 10.1007/BF01311232; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909	37	1518	1579	3	170	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					797	801		10.1038/nm0797-797	http://dx.doi.org/10.1038/nm0797-797			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212111				2022-12-25	WOS:A1997XG76700044
J	Lefebvre, S; Burlet, P; Liu, Q; Bertrandy, S; Clermont, O; Munnich, A; Dreyfuss, G; Melki, J				Lefebvre, S; Burlet, P; Liu, Q; Bertrandy, S; Clermont, O; Munnich, A; Dreyfuss, G; Melki, J			Correlation between severity and SMN protein level in spinal muscular atrophy	NATURE GENETICS			English	Article							MOTOR-NEURON GENE; DELETIONS; INDIVIDUALS; 5Q13		HOP NECKER ENFANTS MALAD,INST NECKER,IFREM,INSERM U393,UNITE RECH HANDICAPS GENET LENFANT,F-75743 PARIS,FRANCE; UNIV PENN,HOWARD HUGHES MED INST,SCH MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOCHEM & BIOPHYS,SCH MED,PHILADELPHIA,PA 19104	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			Lefebvre, Suzie/D-5092-2017; Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Burglen L, 1997, AM J HUM GENET, V60, P72; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; CHANG JG, 1995, AM J HUM GENET, V57, P1503; COBBEN JM, 1995, AM J HUM GENET, V57, P805; DUBOWITZ V, 1964, BRAIN, V87, P707, DOI 10.1093/brain/87.4.707; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Munsat TL., 1991, NEUROMUSCUL DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; POWERS MM, 1955, STAIN TECHNOL, V30, P83, DOI 10.3109/10520295509113749; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERSTEEGE G, 1995, LANCET, V345, P985, DOI 10.1016/S0140-6736(95)90732-7	17	828	853	0	43	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					265	269		10.1038/ng0797-265	http://dx.doi.org/10.1038/ng0797-265			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207792				2022-12-25	WOS:A1997XG60900022
J	Heise, C; SampsonJohannes, A; Williams, A; McCormick, F; VonHoff, DD; Kirn, DH				Heise, C; SampsonJohannes, A; Williams, A; McCormick, F; VonHoff, DD; Kirn, DH			ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents	NATURE MEDICINE			English	Article							CARCINOMA CELL-LINES; P53 GENE; IN-VIVO; CANCER-CELLS; SOLID TUMORS; G(1) ARREST; THERAPY; EXPRESSION; APOPTOSIS; TRANSFECTION	The 55-kilodalton (kDa) protein from the E1B-region of adenovirus binds to and inactivates the p53 gene, which is mutated in half of human cancers. We have previously shown that the replication and cytopathogenicity of an E1B, 55-kDa gene-attenuated adenovirus, ONYX-015, is blocked by functional p53 in RKO and U2OS carcinoma lines. We now report that normal human cells were highly resistant to ONYX-015-mediated, replication-dependent cytolysis. In contrast, a wide range of human tumor cells, including numerous carcinoma lines with either mutant or normal p53 gene sequences (exons 5-9), were efficiently destroyed. Antitumoral efficacy was documented following intratumoral or intravenous administration of ONYX-015 to nude mouse-human tumor xenografts; efficacy with ONYX-015 plus chemotherapy (cisplatin, 5-fluorouracil) was significantly greater than with either agent alone.	ONYX PHARMACEUT,RICHMOND,CA 94806; CANC THERAPY & RES CTR S TEXAS,SAN ANTONIO,TX 78245	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio								BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; CLAYMAN GL, 1995, CANCER RES, V55, P1; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DVORAK HF, 1988, AM J PATHOL, V133, P95; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FEARON ER, 1988, CANCER RES, V48, P2975; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FUJIWARA T, 1994, CANCER RES, V54, P2287; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG HS, 1994, INFECT AGENT DIS, V3, P1; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Kirn DH, 1996, EXPERT OPINION INVES, V5, P753; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LI CY, 1995, ONCOGENE, V11, P1885; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MacCallum DE, 1996, ONCOGENE, V13, P2575; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Roth J, 1996, P NATL ACAD SCI USA, V93, P4781, DOI 10.1073/pnas.93.10.4781; RUGGERI B, 1992, ONCOGENE, V7, P1503; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; VAN MEIR EG, 1994, CANCER RES, V54, P649; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG NP, 1993, ONCOGENE, V8, P279; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; WILSON JM, 1994, HUM GENE THER, V5, P501, DOI 10.1089/hum.1994.5.4-501; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	38	767	839	2	33	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					639	645		10.1038/nm0697-639	http://dx.doi.org/10.1038/nm0697-639			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176490				2022-12-25	WOS:A1997XB97400033
J	Crowe, MJ; Bresnahan, JC; Shuman, SL; Masters, JN; Beattie, MS				Crowe, MJ; Bresnahan, JC; Shuman, SL; Masters, JN; Beattie, MS			Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; MACACA-MULATTA; METHYLPREDNISOLONE; NECROSIS; SURVIVAL	Apoptosis is a morphologically defined form of programmed cell death seen in a variety of circumstances, including immune cell selection, carcinogenesis and development(1,2). Apoptosis has very recently been seen after ischemic or traumatic injury to the central nervous system (CNS)(3-5), suggesting that active cell death as well as passive necrosis may mediate damage after CNS injury. After spinal cord injury (SCI) in the rat, typical post-traumatic necrosis occurred, but in addition, apoptotic cells were found from 6 hours to 3 weeks after injury, especially in the spinal white matter. Apoptotic cells were positive for oligodendrocyte markers. After SCI in monkeys, apoptotic cells were found within remote degenerating fiber tracts. Both secondary degeneration at the site of SCI and the chronic demyelination of tracts away from the injury appear to be due in part to apoptosis. As cytokines have been shown to mediate oligodendrocyte death in vitro(6), it seems likely that chronic demyelination after CNS injury shares features with chronic degenerative disorders like multiple sclerosis.	OHIO STATE UNIV,COLL MED,DEPT ANAT CELL BIOL & NEUROBIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DIV NEUROSURG,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,NEUROSCI PROGRAM,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,NEUROBIOTECHNOL CTR,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Beattie, Michael S/A-8953-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS010165, R01NS032000, R01NS031193] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10165, NS 31193, NS 32000] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARRES BA, 1993, CURR BIOL, V3, P489, DOI 10.1016/0960-9822(93)90039-Q; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BHAT RV, GLIA, V17, P169; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BRESNAHAN JC, 1976, J NEUROL SCI, V28, P521, DOI 10.1016/0022-510X(76)90122-2; Bunge RP, 1994, NEUROBIOLOGY CENTRAL, P329; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Crowe M. J., 1995, Society for Neuroscience Abstracts, V21, P232; DSOUZA S, 1995, J NEUROSCI, V15, P7293; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HALL ED, 1992, J NEUROTRAUM, V9, pS425; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MAJNO G, 1995, AM J PATHOL, V146, P3; POPOVICH PG, IN PRESS J COMP NEUR; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RINK A, 1995, AM J PATHOL, V147, P1575; VARTANIAN T, 1995, MOL MED, V1, P732, DOI 10.1007/BF03401888; WOOD PL, 1995, NEUROL RES, V17, P242, DOI 10.1080/01616412.1995.11740321	25	930	976	0	54	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					73	76		10.1038/nm0197-73	http://dx.doi.org/10.1038/nm0197-73			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986744				2022-12-25	WOS:A1997WA73300040
J	Koehler, KE; Boulton, CL; Collins, HE; French, RL; Herman, KC; Lacefield, SM; Madden, LD; Schuetz, CD; Hawley, RS				Koehler, KE; Boulton, CL; Collins, HE; French, RL; Herman, KC; Lacefield, SM; Madden, LD; Schuetz, CD; Hawley, RS			Spontaneous X chromosome MI and MII nondisjunction events in Drosophila melanogaster oocytes have different recombinational histories	NATURE GENETICS			English	Article							KINESIN-LIKE PROTEIN; GENETIC-ANALYSIS; DISTRIBUTIVE SEGREGATION; MEIOTIC MUTANTS; NOD; MECHANISMS; MUTATION; FEMALES; MEIOSIS; LOCALIZATION	Recent studies of human oocytes have demonstrated an enrichment for distal exchanges among meiosis I (MI) nondisjunction events and for proximal exchanges among meiosis II (MII) events. Our characterization of 103 cases of spontaneous X chromosome nondisjunction in Drosophila oocytes strongly parallels these observations. The recombinational histories of MI (97/103) and MII (6/103) nondisjunctional ova were strikingly different. MI nondisjunction occurred primarily in oocytes with non-exchange X chromosomes; of the few nondisjoining exchange bivalents, most carried distal crossovers. Thus, spontaneous MI nondisjunction reflects the failure of the achiasmate segregation systems. MII nondisjunction occurred only in oocytes with proximal exchanges. We propose several models to explain how very proximal exchanges might impair proper segregation.	UNIV CALIF DAVIS,DEPT GENET,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616	University of California System; University of California Davis			French, Rachael/AAI-2427-2020	French, Rachael/0000-0001-9974-4293; Hawley, R. Scott/0000-0002-6478-0494				ABRUZZO MA, 1995, ENVIRON MOL MUTAGEN, V25, P38, DOI 10.1002/em.2850250608; AFSHAR K, 1995, J CELL BIOL, V131, P833, DOI 10.1083/jcb.131.4.833; AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; ANGELL RR, 1994, CYTOGENET CELL GENET, V65, P194, DOI 10.1159/000133631; ANGELL RR, 1995, CYTOGENET CELL GENET, V69, P266, DOI 10.1159/000133977; BAKER BS, 1972, GENETICS, V71, P255; Bickel SE, 1996, EMBO J, V15, P1451, DOI 10.1002/j.1460-2075.1996.tb00487.x; Bridges CB, 1916, GENETICS, V1, P1; CARPENTER AT, 1973, GENETICS, V73, P393; CARPENTER ATC, 1982, GENETICS, V101, P81; Darlington CD, 1939, J GENET, V37, P341, DOI 10.1007/BF02982733; DERNBURG AF, 1996, CELL, V85, P135; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GREEN MM, 1959, P NATL ACAD SCI USA, V45, P16, DOI 10.1073/pnas.45.1.16; Hartwell LW, 1982, RECENT ADV YEAST MOL, V1, P28; HASSOLD T, 1995, AM J HUM GENET, V57, P867; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HAWLEY RS, 1993, ANNU REV GENET, V27, P281; HAWLEY RS, 1994, HUM MOL GENET, V3, P1521, DOI 10.1093/hmg/3.9.1521; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HAWLEY RS, 1993, DEV GENET, V13, P440; HUNT P, 1995, HUM MOL GENET, V4, P2007, DOI 10.1093/hmg/4.11.2007; JANG JK, 1995, SCIENCE, V268, P1917, DOI 10.1126/science.7604267; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KNOWLES BA, 1991, P NATL ACAD SCI USA, V88, P7165, DOI 10.1073/pnas.88.16.7165; Koehler KE, 1996, HUM MOL GENET, V5, P1495, DOI 10.1093/hmg/5.Supplement_1.1495; Lamb NE, 1996, NAT GENET, V14, P400, DOI 10.1038/ng1296-400; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACDONALD M, 1994, HUM MOL GENET, V3, P1365, DOI 10.1093/hmg/3.8.1365; MATTHIES HJG, IN PRESS J CELL BIOL; MCKIM KS, 1995, SCIENCE, V270, P1595, DOI 10.1126/science.270.5242.1595; MERRIAM JR, 1964, GENETICS, V49, P109; MIYAZAKI WY, 1992, GENETICS, V132, P1047; NELSON CR, 1992, CELL MOTIL CYTOSKEL, V23, P34, DOI 10.1002/cm.970230105; NICKLAS RB, 1977, PHILOS T ROY SOC B, V277, P267, DOI 10.1098/rstb.1977.0017; NICKLAS RB, 1974, GENETICS, V78, P205; NOVITSKI E, 1955, J CELL COMPAR PHYSL, V45, P151, DOI 10.1002/jcp.1030450509; OTOUSA J, 1982, GENETICS, V102, P503; PETERSEN MB, 1992, AM J HUM GENET, V51, P516; RASOOLY RS, 1991, GENETICS, V129, P409; Ross LO, 1996, P NATL ACAD SCI USA, V93, P4979, DOI 10.1073/pnas.93.10.4979; SANDLER L, 1968, GENETICS, V60, P525; SEARS ER, 1952, CHROMOSOMA, V4, P535, DOI 10.1007/BF00325789; SHERMAN SL, 1994, HUM MOL GENET, V3, P1529, DOI 10.1093/hmg/3.9.1529; STEWART RJ, 1990, P NATL ACAD SCI USA, V90, P5209; Sturtevant AH, 1936, GENETICS, V21, P554; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x; Weinstein A, 1936, GENETICS, V21, P155; WHITECOOPER H, 1993, J CELL SCI, V106, P1035; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115; ZITRON AE, 1989, GENETICS, V122, P801	55	115	118	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					406	414		10.1038/ng1296-406	http://dx.doi.org/10.1038/ng1296-406			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944020				2022-12-25	WOS:A1996VV73000016
J	Nigro, V; Moreira, ED; Piluso, G; Vainzof, M; Belsito, A; Politano, L; Puca, AA; PassosBueno, MR; Zatz, M				Nigro, V; Moreira, ED; Piluso, G; Vainzof, M; Belsito, A; Politano, L; Puca, AA; PassosBueno, MR; Zatz, M			Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene	NATURE GENETICS			English	Letter							BETA-SARCOGLYCAN; LINKAGE; ADHALIN; PROTEINS; COMPLEX; MAPS		UNIV SAO PAULO,IBUSP,DEPT BIOL,BR-05508900 SAO PAULO,BRAZIL; UNIV NAPLES 2,FAC MED,IST PATOL GEN & ONCOL,I-80138 NAPLES,ITALY; UNIV NAPLES,DIPARTIMENTO INTERNIST CLIN & SPERIMENTALE,NAPLES,ITALY; TELETHON INST GENET & MED,MILAN,ITALY	Universidade de Sao Paulo; Universita della Campania Vanvitelli; University of Naples Federico II; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM)			POLITANO, LUISA/AAK-6885-2020; Nigro, Vincenzo/AAB-2274-2022; Piluso, Giulio/AAA-3661-2019; Vainzof, Mariz/Q-4787-2019; Passos-Bueno, Maria Rita/I-6796-2016; Zatz, Mayana/M-5338-2015; Vainzof, Mariz/J-7150-2012; Moreira, Eloisa/K-9155-2014; PILUSO, Giulio/AAA-3400-2019; Puca, Annibale Alessandro/K-2099-2018	Vainzof, Mariz/0000-0002-2797-0782; Passos-Bueno, Maria Rita/0000-0002-9248-3008; Zatz, Mayana/0000-0003-3970-8025; Vainzof, Mariz/0000-0002-2797-0782; PILUSO, Giulio/0000-0001-9418-125X; Nigro, Vincenzo/0000-0002-3378-5006	Telethon [899] Funding Source: Medline	Telethon(Fondazione Telethon)		Argov Z, 1988, DISORDERS VOLUNTARY, Vfifth, P981, DOI [10.1093/med/9780199698073.001.0001/med-9780199698073-chapter-33, DOI 10.1093/MED/9780199698073.001.0001/MED-9780199698073-CHAPTER-33]; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P337, DOI 10.1016/0960-8966(95)00005-8; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; NIGRO V, 1992, HUM MOL GENET, V1, P517, DOI 10.1093/hmg/1.7.517; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OTHMANE KB, 1992, NAT GENET, V2, P316; OWRTON R, 1995, SCIENCE, V270, P755; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PassosBueno MR, 1996, HUM MOL GENET, V5, P815, DOI 10.1093/hmg/5.6.815; PassosBueno MR, 1996, J MED GENET, V33, P97, DOI 10.1136/jmg.33.2.97; PASSOSBUENO MR, 1995, HUM MOL GENET, V4, P1163; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; SPEER MC, 1992, AM J HUM GENET, V50, P1211; VAINZOF M, 1991, J NEUROL SCI, V101, P141, DOI 10.1016/0022-510X(91)90038-9; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x	24	350	360	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					195	198		10.1038/ng1096-195	http://dx.doi.org/10.1038/ng1096-195			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841194				2022-12-25	WOS:A1996VL44600028
J	Dessart, G				Dessart, G			The American Cancer Society versus tobacco - The first 40 years or the last?	NATURE MEDICINE			English	Editorial Material											Dessart, G (corresponding author), AMER CANC SOC,1599 CLIFTON RD NE,ATLANTA,GA 30329, USA.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					712	713		10.1038/nm0797-712	http://dx.doi.org/10.1038/nm0797-712			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212089				2022-12-25	WOS:A1997XG76700022
J	Graham, BH; Waymire, KG; Cottrell, B; Trounce, IA; MacGregor, GR; Wallace, DC				Graham, BH; Waymire, KG; Cottrell, B; Trounce, IA; MacGregor, GR; Wallace, DC			A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator	NATURE GENETICS			English	Article							MUSCLE ADP/ATP TRANSLOCATOR; EMBRYONIC STEM-CELLS; ADP ATP TRANSLOCASE; MUSCULAR-DYSTROPHY LOCUS; SYNTHASE BETA-SUBUNIT; SKELETAL-MUSCLE; MOLECULAR-CLONING; NUCLEAR GENES; DNA DISEASE; CARRIER	In an attempt to create an animal model of tissue-specific mitochondrial disease, we generated 'knockout' mice deficient in the heart/muscle isoform of the adenine nucleotide translocator (Ant1). Histological and ultrastructural examination of skeletal muscle from Anti null mutants revealed ragged-red muscle fibers and a dramatic proliferation of mitochondria, while examination of the heart revealed cardiac hypertrophy with mitochondrial proliferation. Mitochondria isolated from mutant skeletal muscle exhibited a severe defect in coupled respiration. Ant1 mutant adults also had a resting serum lactate level fourfold higher than that of controls, indicative of metabolic acidosis. Significantly, mutant adults manifested severe exercise intolerance. Therefore, Anti mutant mice have the biochemical, histological, metabolic and physiological characteristics of mitochondrial myopathy and cardiomyopathy.	EMORY UNIV, SCH MED, CTR MOL MED, ATLANTA, GA 30322 USA	Emory University			Graham, Brett/R-8685-2018; Trounce, Ian A/F-8338-2010	Graham, Brett/0000-0001-8451-8154; Trounce, Ian A/0000-0002-1070-8892	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013154] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKKER HD, 1993, J INHERIT METAB DIS, V16, P548, DOI 10.1007/BF00711678; BAKKER HD, 1993, PEDIATR RES, V33, P412; BARTH E, 1992, J MOL CELL CARDIOL, V24, P669, DOI 10.1016/0022-2828(92)93381-S; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BLAU DM, 1995, VIROLOGY, V210, P91, DOI 10.1006/viro.1995.1320; BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099; CHEN ST, 1990, SOMAT CELL MOLEC GEN, V16, P143, DOI 10.1007/BF01233044; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; Ellison JW, 1996, MAMM GENOME, V7, P25, DOI 10.1007/s003359900007; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; HARAGUCHI Y, 1994, J BIOL CHEM, V269, P9330; HARAGUCHI Y, 1993, GENOMICS, V16, P479, DOI 10.1006/geno.1993.1214; HATCHELL PL, 1973, GENETICS, V75, P191; KLINGENBERG M, 1992, BIOCHEM SOC T, V20, P547, DOI 10.1042/bst0200547; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KU DH, 1990, J BIOL CHEM, V265, P16060; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACGREGOR GR, 1995, DEVELOPMENT, V121, P1487; Mills KA, 1996, MAMM GENOME, V7, P707, DOI 10.1007/s003359900296; Munnich A, 1996, EUR J PEDIATR, V155, P262; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; OMALLEY K, 1982, J BIOL CHEM, V257, P2097; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; PFANNER N, 1987, J BIOL CHEM, V262, P7528; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RASMUSSEN UB, 1986, BIOCHEM BIOPH RES CO, V138, P850, DOI 10.1016/S0006-291X(86)80574-5; RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAMBRA UB, 1992, ATLAS PRENATAL MOUSE, V1; Servidei S, 1994, Adv Pediatr, V41, P1; SHANSKE S, 1994, CURR TOP BIOENERG, V17, P21; Sheehan D.C., 1980, THEORY PRACTICE HIST; SHINOHARA Y, 1993, BIOCHIM BIOPHYS ACTA, V1152, P192, DOI 10.1016/0005-2736(93)90248-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEELE BF, 1950, ARCH BIOCHEM, V25, P124; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; STEWART CL, 1993, METHOD ENZYMOL, V225, P823; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U; WALLACE DC, 1995, AM J HUM GENET, V57, P201; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WASSERMAN K, 1987, PRINCIPLES EXERCISE, P1; WIJMENGA C, 1993, HUM GENET, V92, P198; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376	53	405	419	0	23	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1997	16	3					226	234		10.1038/ng0797-226	http://dx.doi.org/10.1038/ng0797-226			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207786				2022-12-25	WOS:A1997XG60900016
J	Holliger, P; Wing, M; Pound, JD; Bohlen, H; Winter, G				Holliger, P; Wing, M; Pound, JD; Bohlen, H; Winter, G			Retargeting serum immunoglobulin with bispecific diabodies	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; diabody; immunotherapy	PHAGOCYTE RESPIRATORY BURST; AFFINITY HUMAN-ANTIBODIES; FC-GAMMA-RI; MONOCLONAL-ANTIBODIES; CELLS; PHAGE; REPERTOIRE; FRAGMENTS; THERAPY; CHAINS	Monospecific antibody fragments produced in bacteria lack the Fc portion of antibodies, and are therefore unable to recruit natural effector functions. We describe the use of a bispecific antibody fragment (diabody) to recruit the whole spectrum of antibody effector functions by retargeting serum immunoglobulin (Ig). One arm of the diabody was directed against the target antigen, and the other against the serum Ig. The bispecific diabodies were able to recruit complement, induce mononuclear phagocyte respiratory burst and phagocytosis, and promote synergistic cytotoxicity towards colon carcinoma cells in conjunction with CD8(+) T-cells, Further, by virtue of binding to serum Ig their half-life (beta-phase) was increased fivefold compared to a control diabody of the same molecular weight. Such bispecific diabodies may provide an attractive alternative to monoclonal antibodies for serotherapy.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,NEUROL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV COLOGNE,INNERE MED KLIN 1,D-50931 COLOGNE,GERMANY; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham; University of Cologne; MRC Laboratory Molecular Biology	Holliger, P (corresponding author), MRC,CTR PROT ENGN,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BOHLEN H, 1994, J IMMUNOL METHODS, V173, P55, DOI 10.1016/0022-1759(94)90283-6; BRUGGEMANN M, 1989, J EXP MED, V170, P2153, DOI 10.1084/jem.170.6.2153; CHESTER KA, 1994, LANCET, V343, P455, DOI 10.1016/S0140-6736(94)92695-6; CLARKSON T, 1991, NATURE, V352, P624; CUMBER AJ, 1992, J IMMUNOL, V149, P120; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; Holliger P, 1996, PROTEIN ENG, V9, P299, DOI 10.1093/protein/9.3.299; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Holliger Philipp, 1993, Current Opinion in Biotechnology, V4, P446, DOI 10.1016/0958-1669(93)90010-T; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KING DJ, 1994, CANCER RES, V54, P6176; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; McGuinness BT, 1996, NAT BIOTECHNOL, V14, P1149, DOI 10.1038/nbt0996-1149; MCINTIRE K R, 1970, Federation Proceedings, V29, P704; Neri D, 1996, BIOTECHNIQUES, V20, P708; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; NEUBERGER MS, 1984, NATURE, V312, P604, DOI 10.1038/312604a0; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; PERELSON AS, 1989, IMMUNOL REV, V110, P5, DOI 10.1111/j.1600-065X.1989.tb00025.x; PERESICS O, 1994, STRUCTURE, V2, P1218; POUND JD, 1993, MOL IMMUNOL, V30, P233, DOI 10.1016/0161-5890(93)90052-D; POUND JD, 1993, MOL IMMUNOL, V30, P469, DOI 10.1016/0161-5890(93)90115-R; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; SMITHGILL SJ, 1984, J IMMUNOL, V132, P963; TOMLINSON S, 1993, CURR OPIN IMMUNOL, V5, P83, DOI 10.1016/0952-7915(93)90085-7; TUTT A, 1991, J IMMUNOL, V147, P60; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; WALKER MR, 1989, BIOCHEM J, V259, P347, DOI 10.1042/bj2590347; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YOKOTA T, 1992, CANCER RES, V52, P3402	34	69	86	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					632	636		10.1038/nbt0797-632	http://dx.doi.org/10.1038/nbt0797-632			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219264				2022-12-25	WOS:A1997XH58300025
J	Snyder, RO; Miao, CH; Patijn, GA; Spratt, SK; Danos, O; Nagy, D; Gown, AM; Winther, B; Meuse, L; Cohen, LK; Thompson, AR; Kay, MA				Snyder, RO; Miao, CH; Patijn, GA; Spratt, SK; Danos, O; Nagy, D; Gown, AM; Winther, B; Meuse, L; Cohen, LK; Thompson, AR; Kay, MA			Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors	NATURE GENETICS			English	Article							ADENOASSOCIATED VIRUS VECTORS; IN-VIVO; HEMOPHILIA-B; HUMAN ALPHA-1-ANTITRYPSIN; EXPRESSION; TRANSDUCTION; CELLS; DOGS; HEPATOCYTES; DISORDERS		UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; SOMATIX THERAPY CORP,ALAMEDA,CA 94501; UNIV WASHINGTON,PUGET SOUND BLOOD CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Puget Sound Blood Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Kay, Mark/0000-0002-2799-2615	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047754] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53682] Funding Source: Medline; NIDDK NIH HHS [DK47754] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afione SA, 1996, J VIROL, V70, P3235, DOI 10.1128/JVI.70.5.3235-3241.1996; ALEXANDER IE, 1994, J VIROL, V68, P8282, DOI 10.1128/JVI.68.12.8282-8287.1994; BARR D, 1995, GENE THER, V2, P151; Baskar JF, 1996, J VIROL, V70, P3207, DOI 10.1128/JVI.70.5.3207-3214.1996; BRAY GL, 1986, J LAB CLIN MED, V107, P269; CARTER BJ, 1990, HDB PARVOVIRUSES, V1, P155; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guo ZS, 1996, GENE THER, V3, P802; Kaplitt MG, 1996, ANN THORAC SURG, V62, P1669, DOI 10.1016/S0003-4975(96)00946-0; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; KAY MA, 1994, TRENDS GENET, V10, P253, DOI 10.1016/0168-9525(94)90173-2; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; KAY MA, 1994, P NATL ACAD SCI USA, V91, P2353, DOI 10.1073/pnas.91.6.2353; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Lalwani AK, 1996, GENE THER, V3, P588; LI JP, IN PRESS J VIROL; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; Peeters MJTFDV, 1996, BIOTECHNIQUES, V20, P278; REINER AP, 1995, METABOLIC MOL BASES, V3, P3181; Schowalter DB, 1997, GENE THER, V4, P351, DOI 10.1038/sj.gt.3300398; SNYDER RO, 1996, CURRENT PROTOCOLS HU, V1, P1; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; Su H, 1996, HUM GENE THER, V7, P463, DOI 10.1089/hum.1996.7.4-463; THOMPSON AR, 1976, J LAB CLIN MED, V88, P922; THOMPSON AR, 1983, BLOOD, V62, P1027; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	36	488	534	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUL	1997	16	3					270	276		10.1038/ng0797-270	http://dx.doi.org/10.1038/ng0797-270			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XG609	9207793				2022-12-25	WOS:A1997XG60900023
J	Taylor, RM; Wolfe, JH				Taylor, RM; Wolfe, JH			Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase	NATURE MEDICINE			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; CENTRAL-NERVOUS-SYSTEM; MEDIATED GENE-TRANSFER; DEFICIENCY; EXPRESSION; MICE; CELLS	A deficiency of beta-glucuronidase (GUSB) causes the multisystem progressive degenerative syndrome, mucopolysaccharidosis (MPS) type VII (Sly disease)(1), which includes mental retardation(2). Animal homologues of MPS VII (ref. 3, 4) are models for testing somatic gene transfer approaches to treat the central nervous system in this and other lysosomal storage disorders(5). Previous attempts to correct murine MPS VII by gene therapy have successfully treated lesions in some organs but not in the brain(6-8). Other experimental modalities have forestalled some disease progression in the brain, but only if done at birth(9,10), before the onset of severe lesions, when the animals are phenotypically normal. We tested whether therapeutic amounts of GUSB could be delivered to the diseased adult brain by transplanting cells engineered to super-secrete the normal enzyme for export to surrounding neural tissues. Lysosomal distention was cleared from neurons and glial cells in the vicinity of the grafts, showing that the secreted enzyme could reach the diseased cells and reverse lesions in the severely diseased brain. The ability to correct established lesions will be important for the treatment of many lysosomal storage diseases affecting the brain, because most patients are not diagnosed until lesions are advanced enough to affect phenotype or developmental milestones in early childhood, and some forms of the diseases do not become apparent until later in life(11).	UNIV PENN,DEPT PATHOBIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH VET MED,CTR COMPARAT MED GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NIDDK NIH HHS [DK 42707, DK 47757] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047757, R01DK042707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; FISHER LJ, 1993, PHYSIOL REV, V73, P583, DOI 10.1152/physrev.1993.73.3.583; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450-198418100-00014; KYLE JW, 1990, P NATL ACAD SCI USA, V87, P3914, DOI 10.1073/pnas.87.10.3914; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; SCRIVER CR, 1995, METABOLIC MOL BASES, P2427; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; TAYLOR RM, 1994, EXP CELL RES, V214, P606, DOI 10.1006/excr.1994.1298; Taylor RM, 1997, J NEUROCHEM, V68, P2079; Wolfe J, 1996, PROTOCOLS GENE TRANS, P263; WOLFE JH, 1995, GENE THER, V2, P70; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFE JH, 1992, NATURE, V360, P749, DOI 10.1038/360749a0; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	19	136	147	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					771	774		10.1038/nm0797-771	http://dx.doi.org/10.1038/nm0797-771			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212105				2022-12-25	WOS:A1997XG76700038
J	Ye, BH; Cattoretti, G; Shen, QO; Zhang, JD; Hawe, N; deWaard, R; Leung, C; NouriShirazi, M; Orazi, A; Chaganti, RSK; Rothman, P; Stall, AM; Pandolfi, PP; DallaFavera, R				Ye, BH; Cattoretti, G; Shen, QO; Zhang, JD; Hawe, N; deWaard, R; Leung, C; NouriShirazi, M; Orazi, A; Chaganti, RSK; Rothman, P; Stall, AM; Pandolfi, PP; DallaFavera, R			The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation	NATURE GENETICS			English	Article							NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; CENTER B-CELLS; INTERACTION MOTIF; IMMUNE-RESPONSES; BTB/POZ DOMAIN; DEFICIENT MICE; ZINC FINGERS; EXPRESSION; RECEPTOR	Structural alterations of the promoter region of the BCL-6 proto-oncogene represent the most frequent genetic alteration associated with non-Hodgkin lymphoma, a malignancy often deriving from germinal-centre B cells. The BCL-6 gene encodes a zinc-finger transcriptional repressor normally expressed in both B cells and CD4(+) T cells within germinal centres, but its precise function is unknown. We show that mice deficient in BCL-6 displayed normal B-cell, T-cell and lymphoid-organ development but have a selective defect in T-cell-dependent antibody responses. This defect included a complete lack of affinity maturation and was due to the inability of follicular B cells to proliferate and form germinal centres. In addition, BCL-6-deficient mice developed an inflammatory response in multiple organs characterized by infiltrations of eosinophils and IgE-bearing B lymphocytes typical of a Th2-mediated hyperimmune response. Thus, BCL-6 functions as a transcriptional switch that controls germinal centre formation and may also modulate specific T-cell-mediated responses. Altered expression of BCL-6 in lymphoma represents a deregulation of the pathway normally leading to B cell proliferation and germinal centre formation.	COLUMBIA UNIV,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT MICROBIOL,NEW YORK,NY 10032; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT BIOL MOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021; INDIANA UNIV,SCH MED,DEPT PATHOL & LAB MED,INDIANAPOLIS,IN 46202	Columbia University; Columbia University; Columbia University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Indiana University System; Indiana University-Purdue University Indianapolis			Nouri-Shirazi, Mahyar/AAG-5663-2020; Cattoretti, Giorgio/H-2340-2011	orazi, attilio/0000-0002-1660-7013; O'Connor, Nicola/0000-0003-1981-3055; Cattoretti, Giorgio/0000-0003-3799-3221				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CRABBE PA, 1970, LAB INVEST, V22, P448; Dalla-Favera Riccardo, 1996, P139; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; DIBELLO PR, 1991, GENETICS, V129, P385; Flenghi L, 1996, AM J PATHOL, V148, P1543; GAIDANO G, IN PRESS BLOOD; Hardy RR, 1995, ANN NY ACAD SCI, V764, P19; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HONG R, 1987, NELSON TXB PEDIATRIC, P461; ISHIZAKA A, 1990, IMMUNOLOGY, V70, P414; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOIKE M, 1994, INT ARCH ALLERGY IMM, V104, P1, DOI 10.1159/000236702; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LAM KP, 1994, J EXP MED, V180, P507, DOI 10.1084/jem.180.2.507; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; LUNA LG, 1960, MANUAL HISTOLOGIC ST; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Mombaerts P, 1995, Int Rev Immunol, V13, P43, DOI 10.3109/08830189509061737; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURRAY AB, 1990, VET PATHOL, V27, P274, DOI 10.1177/030098589002700409; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Orazi A, 1996, LAB INVEST, V75, P33; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Seyfert VL, 1996, ONCOGENE, V12, P2331; SNAPPER CM, 1988, IMMUNOL REV, V102, P51, DOI 10.1111/j.1600-065X.1988.tb00741.x; STALL AM, 1997, HDB EXPT IMMUNOLOGY, V2, pCH63; STEIN H, 1992, NEOPLASTIC HEMATOPAT, P675; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WELLS SM, 1994, J IMMUNOL, V153, P5503; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732	63	639	665	3	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					161	170		10.1038/ng0697-161	http://dx.doi.org/10.1038/ng0697-161			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171827	Bronze			2022-12-25	WOS:A1997XB54300016
J	Licinio, J; Mantzoros, C; Negrao, AB; Cizza, G; Wong, ML; Bongiorno, PB; Chrousos, GP; Karp, B; Allen, C; Flier, JS; Gold, PW				Licinio, J; Mantzoros, C; Negrao, AB; Cizza, G; Wong, ML; Bongiorno, PB; Chrousos, GP; Karp, B; Allen, C; Flier, JS; Gold, PW			Human leptin levels are pulsatile and inversely related to pituitary-adrenal function	NATURE MEDICINE			English	Article							MESSENGER-RIBONUCLEIC-ACID; HORMONE; VASOPRESSIN; RECEPTORS; RATS	Leptin communicates nutritional status to regulatory centers in the brain(1,2). Because peripheral leptin influences the activity of the highly pulsatile adrenal and gonadal axes(3,4), we sought to determine whether leptin levels in the blood are pulsatile. We measured circulating leptin levels every 7 minutes for 24 hours, in six healthy men, and found that total circulating leptin levels exhibited a pattern indicative of pulsatile release, with 32.0 +/- 1.5 pulses every 24 hours and a pulse duration of 32.8 +/- 1.6 minutes. We also show an inverse relation between rapid fluctuations in plasma levels of leptin and those of adrenocorticotropic hormone (ACTH) and cortisol that could not be accounted for on the basis of glucocorticoid suppression of leptin. As leptin levels are pulsatile, we propose that a key function of the CNS is regulated by a peripheral pulsatile signal. In a separate pilot study we compared leptin pulsatility in 414 plasma samples collected every 7 minutes for 24 hours from one obese woman and one normal-weight woman. We found that high leptin levels in the obese subject were due solely to increased leptin pulse height; all concentration-independent pulsatility parameters were almost identical in the two women. Leptin pulsatility therefore can be preserved in the obese.	HARVARD UNIV,BETH ISRAEL DEACONESS MED CTR,SCH MED,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215; NICHHD,DEV ENDOCRINOL BRANCH,NIH,BETHESDA,MD 20892; NIH,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA	Licinio, J (corresponding author), NIMH,CLIN NEUROENDOCRINOL BRANCH,NIH,BLDG 10,ROOM 2D46,10 CTR DR,BETHESDA,MD 20892, USA.		Mantzoros, Christos/Y-2902-2019; Wong, Ma-Li/D-7903-2011; Wong, Ma-Li/ABD-5525-2020; Flier, jeffrey/AAG-6223-2019; Licinio, Julio/L-4244-2013; NegrÃo, AndrÃ© Brooking/C-9526-2014	Wong, Ma-Li/0000-0003-1512-3073; Licinio, Julio/0000-0001-6905-5884; NegrÃo, AndrÃ© Brooking/0000-0002-8133-6723				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; AULITZKY W, 1989, INT J ANDROL, V12, P265, DOI 10.1111/j.1365-2605.1989.tb01313.x; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004; FEHMWOLFSDORF G, 1988, PSYCHOPHARMACOLOGY, V94, P496, DOI 10.1007/BF00212844; Glaum SR, 1996, MOL PHARMACOL, V50, P230; GOLD PW, 1983, NEW ENGL J MED, V308, P1117, DOI 10.1056/NEJM198305123081902; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; HAISENLEDER DJ, 1991, ENDOCRINOLOGY, V128, P509, DOI 10.1210/endo-128-1-509; HAISENLEDER DJ, 1993, ENDOCRINOLOGY, V132, P1292, DOI 10.1210/en.132.3.1292; HOMBURG R, 1989, BRIT MED J, V298, P809, DOI 10.1136/bmj.298.6676.809; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; Jenkins G., 1968, SPECTRAL ANAL ITS AP; LICINIO J, 1993, ENDOCRINE, V1, P120; LopezFernandez J, 1996, ENDOCRINOLOGY, V137, P4384, DOI 10.1210/en.137.10.4384; MAITER D, 1988, ENDOCRINOLOGY, V123, P1053, DOI 10.1210/endo-123-2-1053; MICHELSON D, 1994, J CLIN ENDOCR METAB, V79, P848, DOI 10.1210/jc.79.3.848; OERTER KE, 1986, COMPUT BIOMED RES, V19, P170, DOI 10.1016/0010-4809(86)90014-5; SCHWARTZ MW, 1996, AM J PHYSIOL, V98, P1101; Sinha MK, 1996, J CLIN INVEST, V97, P1344, DOI 10.1172/JCI118551; Sinha MK, 1996, BIOCHEM BIOPH RES CO, V228, P733, DOI 10.1006/bbrc.1996.1724; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SUTTON RE, 1982, NATURE, V297, P331, DOI 10.1038/297331a0; TURZILLO AM, 1995, BIOL REPROD, V53, P418, DOI 10.1095/biolreprod53.2.418; VELDHUIS JD, 1986, AM J PHYSIOL, V250, pE486, DOI 10.1152/ajpendo.1986.250.4.E486; VELDHUIS JD, 1990, CLIN OBSTET GYNECOL, V33, P538, DOI 10.1097/00003081-199009000-00021; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZINAMAN MJ, 1995, J CLIN ENDOCR METAB, V80, P2088, DOI 10.1210/jc.80.7.2088	29	520	535	0	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					575	579		10.1038/nm0597-575	http://dx.doi.org/10.1038/nm0597-575			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142131				2022-12-25	WOS:A1997WX54300042
J	Persidis, A				Persidis, A			The carbohydrate-based drug industry - Whether used as a target or a tool, carbohydrates face manufacturing challenges before they can realize their true value.	NATURE BIOTECHNOLOGY			English	Editorial Material											Persidis, A (corresponding author), ARGONEX INC,2044 INDIA RD,CHARLOTTESVILLE,VA 22901, USA.							BEDNARSKI M, 1991, ACS SERIES, V446; *BIOV IND REV CO D, 1997, CARB THER; Boons GJ, 1996, DRUG DISCOV TODAY, V1, P331, DOI 10.1016/1359-6446(96)10031-3; BORMAN S, 1994, CHEM ENG NEWS, V72, P37; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; FRECHET JM, 1971, J AM CHEM SOC, V93, P492; PERSIDIS A, 1995, BIO-TECHNOL, V13, P1172, DOI 10.1038/nbt1195-1172; Persidis A, 1997, NAT BIOTECHNOL, V15, P391, DOI 10.1038/nbt0497-391; Rouhi M, 1996, CHEM ENG NEWS, V74, P4	9	15	16	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					479	480		10.1038/nbt0597-479	http://dx.doi.org/10.1038/nbt0597-479			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131631				2022-12-25	WOS:A1997WX23700036
J	Takada, T; Iida, K; Awaji, T; Itoh, K; Takahashi, R; Shibui, A; Yoshida, K; Sugano, S; Tsujimoto, G				Takada, T; Iida, K; Awaji, T; Itoh, K; Takahashi, R; Shibui, A; Yoshida, K; Sugano, S; Tsujimoto, G			Selective production of transgenic mice using green fluorescent protein as a marker	NATURE BIOTECHNOLOGY			English	Article						transgenic mice; gene integration; embryo selection; green fluorescent protein	ELONGATION FACTOR-1-ALPHA; EMBRYOS; GENE; PROMOTER; INVITRO	The low efficiency of transgenic animal production by microinjection has been a serious problem especially for the production of transgenic livestock. We developed a method to selectively produce transgenic mice using green fluorescent protein (GFP) as a marker. Using this method, we obtained eight fetuses and four live-born mice derived from 55 GFP-positive blastocysts. PCR analysis showed II out of 12 mice (fetuses and newborn mice) were transgenic. Southern blot analysis showed that 8 out of 12 were transgenic. GFP expression was also observed in bovine blastocysts, suggesting that this method should contribute to the efficient production of transgenic livestock.	YS NEW TECHNOL INST INC,ISHIBASHI,TOCHIGI 32905,JAPAN; UNIV TOKYO,INST MED SCI,DEPT VIROL,TOKYO 108,JAPAN	University of Tokyo	Takada, T (corresponding author), NATL CHILDRENS MED RES CTR,TOKYO 154,JAPAN.			Shibui, Akiko/0000-0002-0428-5336				BRACKETT BG, 1975, BIOL REPROD, V12, P260, DOI 10.1095/biolreprod12.2.260; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0; HANAOKA K, 1991, DIFFERENTIATION, V48, P183, DOI 10.1111/j.1432-0436.1991.tb00256.x; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOGAN B, 1994, MANIPULATING MOUSE E, P232; IKAWA M, 1995, FEBS LETT, V375, P125, DOI 10.1016/0014-5793(95)01162-8; IKAWA M, 1995, DEV GROWTH DIFFER, V37, P455, DOI 10.1046/j.1440-169X.1995.t01-2-00012.x; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KING D, 1988, Molecular Reproduction and Development, V1, P57, DOI 10.1002/mrd.1080010109; NINOMIYA T, 1989, Molecular Reproduction and Development, V1, P242, DOI 10.1002/mrd.1080010404; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OSHIMA M, 1995, CANCER RES, V55, P2719; TAKAHASHI Y, 1992, THERIOGENOLOGY, V37, P963, DOI 10.1016/0093-691X(92)90096-A; THOMPSON EM, 1995, P NATL ACAD SCI USA, V92, P1317, DOI 10.1073/pnas.92.5.1317; UETSUKI T, 1989, J BIOL CHEM, V264, P5791	18	110	122	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					458	461		10.1038/nbt0597-458	http://dx.doi.org/10.1038/nbt0597-458			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131626				2022-12-25	WOS:A1997WX23700031
J	Itzhaki, JE; Gilbert, CS; Porter, ACG				Itzhaki, JE; Gilbert, CS; Porter, ACG			Construction by gene targeting in human cells of a 'conditional' CDC2 mutant that rereplicates its DNA	NATURE GENETICS			English	Article							COLI LAC REPRESSOR; INTERFERON-INDUCIBLE GENE; HAMSTER OVARY CELLS; MAMMALIAN-CELLS; PROTEIN-KINASE; FISSION YEAST; S-PHASE; EUKARYOTIC CELLS; CYCLE REGULATION; ANIMAL-CELLS	We describe a novel gene targeting strategy for the genetic analysis of essential genes in mammalian cells and its use to study the role of the cell cycle control gene CDC2 in human cells. A cell line (HT2-19) was generated in which endogenous CDC2 gene expression and cell viability depend on the presence of an inducer in the growth medium. In the absence of inducer, HT2-19 cells undergo extensive DNA rereplication and apoptosis. Rereplication is indicative of a role for human CDC2 in a control mechanism, previously undetected in mammalian cells, that prevents premature entry into S-phase.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, MRC, CTR CLIN SCI, LONDON W12 0NN, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Imperial College London; Cancer Research UK					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BORDES JC, 1995, CELL, V83, P1001; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BRUNO S, 1992, CANCER RES, V52, P470; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DURSO G, 1995, CURR OPIN GENET DEV, V5, P12, DOI 10.1016/S0959-437X(95)90047-0; FIECK A, 1992, NUCLEIC ACIDS RES, V20, P1785, DOI 10.1093/nar/20.7.1785; FIGGE J, 1988, CELL, V52, P713, DOI 10.1016/0092-8674(88)90409-6; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayashi S, 1996, DEVELOPMENT, V122, P1051; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HERZINGER T, 1995, ONCOGENE, V11, P2151; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ITZHAKI JE, 1992, NAT GENET, V2, P283, DOI 10.1038/ng1292-283; ITZHAKI JE, 1991, NUCLEIC ACIDS RES, V19, P3835, DOI 10.1093/nar/19.14.3835; KELLY JM, 1986, EMBO J, V5, P1601, DOI 10.1002/j.1460-2075.1986.tb04402.x; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1992, CANCER RES, V52, P1817; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NUSSE M, 1990, CYTOMETRY, V11, P813, DOI 10.1002/cyto.990110707; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; ONGKEKO W, 1995, J CELL SCI, V108, P2897; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Porter A. C. G., 1989, Technique, A Journal of Methods in Cell and Molecular Biology, V1, P53; PORTER ACG, 1993, EUR J BIOCHEM, V218, P273, DOI 10.1111/j.1432-1033.1993.tb18375.x; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANG FJK, 1989, J HISTOCHEM CYTOCHEM, V37, P697, DOI 10.1177/37.5.2703705; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TRAGANOS F, 1994, J CELL PHYSIOL, V158, P535, DOI 10.1002/jcp.1041580320; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAO YP, 1992, CANCER RES, V52, P1823; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WYBORSKI DL, 1991, NUCLEIC ACIDS RES, V19, P4647, DOI 10.1093/nar/19.17.4647; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Zhang Y, 1996, J BIOL CHEM, V271, P4266	68	141	148	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					258	265		10.1038/ng0397-258	http://dx.doi.org/10.1038/ng0397-258			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054937				2022-12-25	WOS:A1997WK38600014
J	Goulder, PJR; Phillips, RE; Colbert, RA; McAdam, S; Ogg, G; Nowak, MA; Giangrande, P; Luzzi, G; Morgan, B; Edwards, A; McMichael, AJ; RowlandJones, S				Goulder, PJR; Phillips, RE; Colbert, RA; McAdam, S; Ogg, G; Nowak, MA; Giangrande, P; Luzzi, G; Morgan, B; Edwards, A; McMichael, AJ; RowlandJones, S			Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS	NATURE MEDICINE			English	Article							HIV-1 INFECTION; PEPTIDE BINDING; VIRUS; CELLS; RECOGNITION; DISEASE; IDENTIFICATION; VARIANTS; AFFINITY; VIREMIA	The precise role played by HIV-specific cytotoxic T lymphocytes (CTL) in HIV infection remains controversial. Despite strong CTL responses being generated during the asymptomatic phase, the virus persists and AIDS ultimately develops. It has been argued that the virus is so variable, and the virus turnover so great that escape from CTL recognition would occur continually, but so far there is limited evidence for CTL escape. The opposing argument is that evidence for CTL escape is present but hard to find because multiple anti-HIV immune responses are acting simultaneously during the asymptomatic phase of infection. We describe six donors who make a strong CTL response to an immunodominant HLA-B27-restricted epitope. In the two donors who progressed to AIDS, CTL escape to fixation by the same mutation was observed, but only after 9-12 years of epitope stability. CTL escape may play an important role in the pathogenesis of HIV infection.	UNIV OXFORD,INST MOL MED,OXFORD OX3 9DU,ENGLAND; CHILDRENS HOSP,MED CTR,WILLIAM S ROWE DIV RHEUMATOL,CINCINNATI,OH 45229; UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND; CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LJ,ENGLAND; WYCOMBE GEN HOSP,S BUCKINGHAMSHIRE NHS TRUST,HIGH WYCOMBE HP11 2TT,BUCKS,ENGLAND; RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND	University of Oxford; Cincinnati Children's Hospital Medical Center; University of Oxford; University of Oxford; Radcliffe Infirmary	Goulder, PJR (corresponding author), UNIV OXFORD,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.		Nowak, Martin A/A-6977-2008	Ogg, Graham/0000-0002-3097-045X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEVAN MJ, 1995, P NATL ACAD SCI USA, V92, P5765, DOI 10.1073/pnas.92.13.5765; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLBERT RA, 1994, IMMUNITY, V1, P121, DOI 10.1016/1074-7613(94)90105-8; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; GOTCH F, 1987, THESIS U OXFORD; GOULDER PJR, IN PRESS AIDS; Harrer T, 1996, J IMMUNOL, V156, P2616; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; McNeil AJ, 1996, QJM-INT J MED, V89, P177; MEYERHANS A, 1991, EUR J IMMUNOL, V21, P2637, DOI 10.1002/eji.1830211051; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; MYERS G, 1995, HUMAN RETROVIRUSES A; NIETFELD W, 1995, J IMMUNOL, V154, P2188; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NIXON DF, 1990, THESIS U OXFORD; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; ROTZSCHKE O, 1994, IMMUNOGENETICS, V39, P74; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	34	998	1023	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					212	217		10.1038/nm0297-212	http://dx.doi.org/10.1038/nm0297-212			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018241				2022-12-25	WOS:A1997WF08800041
J	McInnes, IB; Leung, BP; Sturrock, RD; Field, M; Liew, FY				McInnes, IB; Leung, BP; Sturrock, RD; Field, M; Liew, FY			Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis	NATURE MEDICINE			English	Article							IL-2 RECEPTOR; INFLAMMATORY ARTHRITIS; GROWTH-FACTOR; KILLER-CELLS; BETA-CHAIN; EXPRESSION; LYMPHOCYTES; SYNOVITIS; INDUCTION; CYTOKINE	Tumor necrosis factor-alpha occupies a central role in rheumatoid arthritis (RA) pathogenesis. We now report that interleukin-15 (IL-15) can induce TNF-alpha production in RA through activation of synovial T cells. Peripheral blood (PB) T cells activated by IL-15 induced significant TNF-alpha production by macrophages via a cell-contact-dependent mechanism. Freshly isolated RA synovial T cells possessed similar capability, and in vitro, IL-15 was necessary to maintain this activity. IL-15 also induced direct TNF-alpha production by synovial T cells. In contrast, IL-2 induced significantly lower TNF-alpha production in either cell-contact-dependent or direct culture, and IL-8 and MIP-1 alpha were ineffective. Antibodies against CD69, LFA-1 or ICAM-1 significantly inhibited the ability of T cells to activate macrophages by cell contact.	UNIV GLASGOW,DEPT IMMUNOL,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,CTR RHEUMAT DIS,DEPT MED,GLASGOW G11 6NT,LANARK,SCOTLAND	University of Glasgow; University of Glasgow			Leung, Bernard/O-2409-2013	Leung, Bernard/0000-0002-1119-4934; McInnes, Iain/0000-0002-6462-4280				Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; AlMughales J, 1996, CLIN EXP IMMUNOL, V106, P230, DOI 10.1046/j.1365-2249.1996.d01-836.x; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BURMESTER GR, 1987, J CLIN INVEST, V80, P595, DOI 10.1172/JCI113111; BURMESTER GR, 1983, RHEUMATOL INT, V3, P173, DOI 10.1007/BF00541597; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; ELLIOTT MJ, 1995, LANCET, V344, P1105; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FERNANDEZGUTIERREZ B, 1995, J RHEUMATOL, V22, P413; FIRESTEIN GS, 1988, J EXP MED, V168, P1573, DOI 10.1084/jem.168.5.1573; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HARRISON WB, 1992, 2 LINE AGENTS TREATM; IANNONE F, 1994, EUR J IMMUNOL, V24, P2706, DOI 10.1002/eji.1830241120; ISLER P, 1993, EUR CYTOKINE NETW, V4, P15; Kanegane H, 1996, BLOOD, V88, P230; Kohem CL, 1996, ARTHRITIS RHEUM, V39, P844, DOI 10.1002/art.1780390518; LACRAZ S, 1994, J BIOL CHEM, V269, P22027; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; McInnes IB, 1996, NAT MED, V2, P175, DOI 10.1038/nm0296-175; Miossec P, 1996, IMMUNOL TODAY, V17, P170, DOI 10.1016/0167-5699(96)80615-3; MONZON CG, 1990, GASTROENTEROLOGY, V98, P1029; Nieto M, 1996, EUR J IMMUNOL, V26, P1302, DOI 10.1002/eji.1830260619; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; PERRELLA O, 1993, EUR NEUROL, V33, P152, DOI 10.1159/000116923; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; STAINES NA, 1994, BRIT J RHEUMATOL, V33, P798; STRUYK L, 1995, ARTHRITIS RHEUM-US, V38, P577, DOI 10.1002/art.1780380502; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; ULFGREN AK, 1995, ANN RHEUM DIS, V54, P654, DOI 10.1136/ard.54.8.654; WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255	40	409	440	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					189	195		10.1038/nm0297-189	http://dx.doi.org/10.1038/nm0297-189			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018238				2022-12-25	WOS:A1997WF08800038
J	Bao, LR; Loda, M; Janmey, PA; Stewart, R; AnandApte, B; Zetter, BR				Bao, LR; Loda, M; Janmey, PA; Stewart, R; AnandApte, B; Zetter, BR			Thymosin beta 15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer	NATURE MEDICINE			English	Article							F-ACTIN; ANTIGEN; ADENOCARCINOMA; POLYMERIZATION; DICTYOSTELIUM; EXPRESSION; PREDICTION; GELSOLIN; MODEL; RNA	The Dunning rat prostatic carcinoma is a model system where cell motility closely correlates with the metastatic phenotype. We have identified a novel gene, upregulated in the highly motile and metastatic Dunning cancer cell lines, that represents a new member of the thymosin-beta family, thymosin beta 15. Transfection of antisense thymosin beta 15 constructs into rat prostatic carcinoma cells demonstrates that this molecule positively regulates cell motility, a critical component of the metastatic pathway. Thymosin beta 15 levels are elevated in human prostate cancer and correlate positively with the Gleason tumor grade. Thymosin beta 15 may represent a potential new biochemical marker for human prostate cancer progression.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG & CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,DEACONESS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV EXPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASPINALL JO, 1995, J UROLOGY, V154, P622, DOI 10.1016/S0022-5347(01)67123-4; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BUBB MR, 1995, BIOCHEMISTRY-US, V34, P3921, DOI 10.1021/bi00012a008; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P157; COOKSON MS, 1995, J UROLOGY, V154, P1070, DOI 10.1016/S0022-5347(01)66979-9; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FREEMAN MR, 1994, J CELL PHYSIOL, V158, P325, DOI 10.1002/jcp.1041580215; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; HAEMMERLI G, 1981, INT J CANCER, V27, P603, DOI 10.1002/ijc.2910270506; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HOSAKA S, 1978, GANN, V69, P273; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liotta L A, 1988, Cancer Treat Res, V40, P223; MIHELIC M, 1994, AMINO ACIDS, V6, P1, DOI 10.1007/BF00808118; MOHLER JL, 1988, CANCER RES, V48, P4312; MOHLER JL, 1993, CANCER METAST REV, V12, P53, DOI 10.1007/BF00689790; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254, DOI 10.1073/pnas.86.4.1254; PIENTA KJ, 1993, CANCER SURV, V11, P255; SAFER D, 1991, J BIOL CHEM, V266, P4029; SOGANI PC, 1985, UROLOGY, V25, P223, DOI 10.1016/0090-4295(85)90316-4; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; YU FX, 1993, J BIOL CHEM, V268, P502; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; ZHOU BS, 1992, CANCER RES, V52, P4280	36	134	144	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1322	1328		10.1038/nm1296-1322	http://dx.doi.org/10.1038/nm1296-1322			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946830				2022-12-25	WOS:A1996VW51500037
J	Fijneman, RJA; deVries, SS; Jansen, RC; Demant, P				Fijneman, RJA; deVries, SS; Jansen, RC; Demant, P			Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse	NATURE GENETICS			English	Article							RECOMBINANT CONGENIC STRAINS; TUMOR SUSCEPTIBILITY; LENGTH POLYMORPHISMS; GENETIC-MAP; MICE; RESOLUTION	Many complex traits, including susceptibility to lung cancer, are controlled by multiple genes - quantitative trait loci (QTLs). We facilitated the mapping of QTLs by making use of recombinant congenic strains (RCS)(1), a system of mouse inbred strains in which the genetic complexity is reduced, and by applying MQM-mapping(2-4) (multiple-QTL models or marker-QTL-marker), a multilocus method with an increased power of detecting of individual QTLs and interacting QTLs (epistasis). The mouse strain O20 develops significantly larger N-ethyl-N-nitrosourea induced lung tumours than mice of the RC strain OcB-9 (ref. 5); the latter share approximately 87.5% of their genes with strain O20 and 12.5% with strain B10.O20 (refs 6,7). QTL analysis of 222 (OcB-9 x O20) F2 mice revealed four new loci that influence susceptibility to lung cancer (Slue genes). They are involved in two significant, partly counteracting interactions which mask their individual main effects: Sluc1 (on chromosome 19) interacts with Sluc2 (chromosome 2), and Sluc3 (chromosome 6) interacts with Sluc4 (chromosome 11). Together with the data of van Wezel et al. in the accompanying report(8), our results indicate that I interactions between tumour susceptibility genes are a common phenomenon which complicates their mapping.	NETHERLANDS CANC INST,DIV MOL GENET,NL-1066 CX AMSTERDAM,NETHERLANDS; DLO,CTR PLANT BREEDING & REPROD RES,DEPT POPULAT BIOL,NL-6700 AA WAGENINGEN,NETHERLANDS	Netherlands Cancer Institute			Fijneman, Remond/X-4199-2019; Jansen, Ritsert C/C-1160-2013	Fijneman, Remond/0000-0003-2076-5521; Jansen, Ritsert C/0000-0003-2977-9110				DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FIJNEMAN RJA, 1994, ONCOGENE, V9, P1417; FIJNEMAN RJA, 1995, IMMUNOGENETICS, V41, P106, DOI 10.1007/BF00182320; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; JANSEN RC, 1994, GENETICS, V138, P871; JANSEN RC, 1994, GENETICS, V136, P1447; Jansen RC, 1996, TRENDS PLANT SCI, V1, P89, DOI 10.1016/S1360-1385(96)80040-9; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; OOMEN LCJM, 1983, INT J CANCER, V31, P447, DOI 10.1002/ijc.2910310409; OOMEN LCJM, 1991, EXP LUNG RES, V17, P283, DOI 10.3109/01902149109064419; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; RYAN J, 1987, J NATL CANCER I, V79, P1351; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468	20	200	201	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					465	467		10.1038/ng1296-465	http://dx.doi.org/10.1038/ng1296-465			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944028				2022-12-25	WOS:A1996VV73000024
J	Reifsnyder, C; Lowell, J; Clarke, A; Pillus, L				Reifsnyder, C; Lowell, J; Clarke, A; Pillus, L			Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases	NATURE GENETICS			English	Article							ATAXIA-TELANGIECTASIA GENE; MATING-TYPE LOCI; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REPRESSION; HISTONE ACETYLATION; N-ACETYLTRANSFERASE; DNA; CHROMOSOME; PROTEIN; IDENTIFICATION	Silencing is an epigenetic form of transcriptional regulation whereby genes are heritably, but not necessarily permanently, inactivated. We have identified the Saccharomyces cerevisiae genes SAS2 and SAS3 through a screen for enhancers of sir1 epigenetic silencing defects. SAS2, SAS3 and a Schizosaccharomyces pombe homologue are closely related to several human genes, including one associated with acute myeloid leukaemia arising from the recurrent translocation t(8;16)(p11;p13) and one implicated in HIV-1 Tat interactions. All of these genes encode proteins with an atypical zinc finger and well-conserved similarities to acetyltransferases. Sequence similarities and yeast mutant phenotypes suggest that SAS-like genes function in transcriptional regulation and cell-cycle exit and reveal novel connections between transcriptional silencing and human disease.	UNIV COLORADO, DEPT MOL CELLULAR & DEV BIOL, BOULDER, CO 80309 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA AR, 1987, EMBO J, V6, P3065, DOI 10.1002/j.1460-2075.1987.tb02613.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; BALDARELLI RM, 1988, DEV BIOL, V125, P85, DOI 10.1016/0012-1606(88)90061-9; BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, MOL CELL BIOL, V16, P593; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DILLIN A, 1995, TRENDS BIOCHEM SCI, V20, P231, DOI 10.1016/S0968-0004(00)89023-4; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HANSLIP JJ, 1992, LEUKEMIA LYMPHOMA, V6, P479, DOI 10.3109/10428199209053586; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KULKARNI MS, 1994, J BIOL CHEM, V269, P13141; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LINK AJ, 1991, GENETICS, V127, P681; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LYON MF, 1993, CURR BIOL, V3, P242, DOI 10.1016/0960-9822(93)90345-O; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; ORR WT, 1988, MOL CELL BIOL, V8, P5292; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; PILLUS L, 1995, CHROMATIN STRUCTURE; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RILES L, 1993, GENETICS, V134, P81; RINE J, 1987, GENETICS, V116, P9; Rivier DH, 1992, CURR OPIN GENET DEV, V2, P286, DOI 10.1016/S0959-437X(05)80286-2; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; SHERMAN F, 1993, TRANSLATIONAL REGULA, V2; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SPENCER F, 1990, GENETICS, V124, P237; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; SUSSEL L, 1993, MOL CELL BIOL, V13, P3919, DOI 10.1128/MCB.13.7.3919; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713	67	242	247	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1996	14	1					42	49		10.1038/ng0996-42	http://dx.doi.org/10.1038/ng0996-42			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VF611	8782818				2022-12-25	WOS:A1996VF61100019
J	Baes, M; Gressens, P; Baumgart, E; Carmeliet, P; Casteels, M; Fransen, M; Evrard, P; Fahimi, D; Declercq, PE; Collen, D; vanVeldhoven, PP; Mannaerts, GP				Baes, M; Gressens, P; Baumgart, E; Carmeliet, P; Casteels, M; Fransen, M; Evrard, P; Fahimi, D; Declercq, PE; Collen, D; vanVeldhoven, PP; Mannaerts, GP			A mouse model for Zellweger syndrome	NATURE GENETICS			English	Article							PEROXISOME BIOGENESIS DISORDERS; HEPATO-RENAL SYNDROME; PROTEIN IMPORT; MEMBRANE-PROTEINS; RAT-LIVER; RECEPTOR; GROWTH; MICE; ACID; IDENTIFICATION	The cerebro-hepato-renal syndrome of Zellweger is a fatal inherited disease caused by deficient import of peroxisomal matrix proteins. The pathogenic mechanisms leading to extreme hypotonia, severe mental retardation and early death are unknown. We generated a Zellweger animal model through inactivation of the murine Pxr1 gene (formally known as Pex5) that encodes the import receptor for most peroxisomal matrix proteins. Pxr1(-/-) mice lacked morphologically identifiable peroxisomes and exhibited the typical biochemical abnormalities of Zellweger patients. They displayed intrauterine growth retardation, were severely hypotonic at birth and died within 72 hours. Analysis of the neocortex revealed impaired neuronal migration and maturation and extensive apoptotic death of neurons.	HOP ROBERT DEBRE, SERV NEUROL PEDIAT, F-75019 PARIS, FRANCE; HOP ROBERT DEBRE, LAB NEUROL DEV, F-75019 PARIS, FRANCE; UNIV HEIDELBERG, INST ANAT & ZELLBIOL 2, D-6900 HEIDELBERG, GERMANY; VLAAMS INST BIOTECHNOL, CTR TRANSGENE TECHNOL & GENE THERAPY, LOUVAIN, BELGIUM; KATHOLIEKE UNIV LEUVEN, PHARMACOL LAB, B-3001 LOUVAIN, BELGIUM	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Ruprecht Karls University Heidelberg; Flanders Institute for Biotechnology (VIB); KU Leuven	Baes, M (corresponding author), KATHOLIEKE UNIV LEUVEN, CLIN CHEM LAB, B-3001 LOUVAIN, BELGIUM.		Carmeliet, Peter/AAQ-5140-2020; gressens, pierre/M-7557-2017; Fransen, Marc/ADL-0723-2022; Baumgart-Vogt, Eveline/I-5945-2013; , Van Veldhoven Paul/U-6359-2019; Fransen, Marc/C-6262-2008	Carmeliet, Peter/0000-0001-7961-1821; gressens, pierre/0000-0002-0909-4221; Baumgart-Vogt, Eveline/0000-0002-8265-3763; , Van Veldhoven Paul/0000-0002-4478-2564; Fransen, Marc/0000-0001-9284-1197; Baes, Myriam/0000-0002-2525-2269				AGAMANOLIS DP, 1976, J NEUROPATH EXP NEUR, V35, P226, DOI 10.1097/00005072-197605000-00002; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BAUMGART E, 1989, J CELL BIOL, V108, P2221, DOI 10.1083/jcb.108.6.2221; BAUMGART E, 1994, PEROXISOMES, P37; BLANK ML, 1975, BIOCHIM BIOPHYS ACTA, V380, P208, DOI 10.1016/0005-2760(75)90007-7; BRAVERMAN N, 1995, HUM MOL GENET, V4, P1791, DOI 10.1093/hmg/4.suppl_1.1791; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Carlberg M, 1996, J BIOL CHEM, V271, P17453, DOI 10.1074/jbc.271.29.17453; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; ESPEEL M, 1995, EUR J CELL BIOL, V67, P319; EVRARD P, 1978, ACTA NEUROPATHOL, V41, P109, DOI 10.1007/BF00689761; FAHIMI HD, 1969, J CELL BIOL, V43, P275, DOI 10.1083/jcb.43.2.275; FAHIMI HD, 1996, ELECT MICROSCOPIC CY, P491; Fransen M, 1996, ANAL BIOCHEM, V242, P26, DOI 10.1006/abio.1996.0423; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRESSENS P, 1992, J NEUROPATH EXP NEUR, V51, P206, DOI 10.1097/00005072-199203000-00010; HEYMANS HSA, 1983, NATURE, V306, P69, DOI 10.1038/306069a0; JOHNSON AB, 1976, J HISTOCHEM CYTOCHEM, V24, P725, DOI 10.1177/24.6.59773; JONES KM, 1994, CLIN CHEM, V40, P946; KALUZNY MA, 1985, J LIPID RES, V26, P135; Krisans SK, 1996, ANN NY ACAD SCI, V804, P142, DOI 10.1111/j.1749-6632.1996.tb18614.x; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; Mannaerts G. P., 1993, PEROXISOMES BIOL IMP, P19; Moser HW, 1991, TECHNIQUES DIAGNOSTI, P177; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; POWERS JM, 1995, J NEUROPATH EXP NEUR, V54, P710, DOI 10.1097/00005072-199509000-00014; POWERS JM, 1989, J NEUROPATH EXP NEUR, V48, P270, DOI 10.1097/00005072-198905000-00005; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; ROELS F, 1995, FUNCTIONS BIOGENESIS, P271; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; Subramani S, 1996, J BIOL CHEM, V271, P32483, DOI 10.1074/jbc.271.51.32483; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; VanVeldhoven PP, 1995, J INHERIT METAB DIS, V18, P125, DOI 10.1007/BF00711435; WANDERS RJA, 1993, PEROXISOMES BIOL IMP, P63; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407	47	217	219	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1997	17	1					49	57		10.1038/ng0997-49	http://dx.doi.org/10.1038/ng0997-49			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XU724	9288097				2022-12-25	WOS:A1997XU72400017
J	Carbone, M; Rizzo, P; Grimley, PM; Procopio, A; Mew, DJY; Shridhar, V; DeBartolomeis, A; Esposito, V; Giuliano, MT; Steinberg, SM; Levine, AS; Giordano, A; Pass, HI				Carbone, M; Rizzo, P; Grimley, PM; Procopio, A; Mew, DJY; Shridhar, V; DeBartolomeis, A; Esposito, V; Giuliano, MT; Steinberg, SM; Levine, AS; Giordano, A; Pass, HI			Simian virus-40 large-T antigen binds p53 in human mesotheliomas	NATURE MEDICINE			English	Article							LUNG-CARCINOMA; RAS MUTATIONS; MONKEY CELLS; ASBESTOS; GENE; DNA; TRANSFORMATION; INDUCTION; LINES	We found that simian virus 40 (SV40) induces mesotheliomas in hamsters(1) and that 60% of human mesotheliomas contain and express SV40 sequences', results now confirmed by others [ref. 3-5, and presentations by D. Griffiths & R. Weiss, F. Galateau-SallE, and H.I.P. at ''Simian virus 40: A possible human polyoma virus,'' NIH workshop, 27-28 January 1997, Bethesda, MD (transcript available through SAG Corp., Washington, DC 20008)]. Mesothelioma(6-8), an aggressive malignancy resistant to therapy, originates from the serosal lining of the pleural, pericardial and peritoneal cavities. The incidence of mesothelioma continues to increase worldwide because of exposure to crocidolite asbestos. However, at least 20% of mesotheliomas in the United States are not associated with asbestos exposure, and only a minority of people exposed to high concentrations of asbestos develop mesothelioma(6-8). Thus, other carcinogens may induce mesothelioma in individuals not exposed to asbestos, and/or may render particular individuals more susceptible to the carcinogenic effect of asbestos. We investigated whether the expression of the 5V40 large T-antigen (Tag) interferes with the normal expression of the tumor suppressor gene p53 in human mesotheliomas. We found that SV40 Tag retains its ability to bind and to inactivate p53, a cellular protein that when normally expressed plays an important role in suppressing tumor growth and in inducing sensitivity to therapy. Our findings do not establish a cause-and-effect relation, but indicate that the possibility that SV40 contributes to the development of human mesotheliomas should be carefully investigated.	UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20889; UNIV CHIETI,LAB FISIOPATOL MOL,I-66013 CHIETI,ITALY; KARMANOS CANC INST,AERODIGEST PROGRAM,DETROIT,MI 48201; NIMH,EXPT THERAPEUT BRANCH,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,SBARRO INST CANC RES,PHILADELPHIA,PA 19107; NCI,BIOSTAT & DATA MANAGEMENT SECT,BETHESDA,MD 20892; NICHHD,SECT DNA REPLICAT REPAIR & MUTAGENESIS,BETHESDA,MD 20892	Uniformed Services University of the Health Sciences - USA; G d'Annunzio University of Chieti-Pescara; Barbara Ann Karmanos Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Carbone, M (corresponding author), LOYOLA UNIV,DEPT PATHOL,CANC IMMUNOL PROGRAM,CARDINAL BERNARDIN CANC CTR,ROOM 205,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.		Giordano, Antonio/F-1927-2010; Procopio, Antonio Domenico/AAB-2451-2021	Giordano, Antonio/0000-0002-5959-016X; Procopio, Antonio Domenico/0000-0001-6897-8724; Pass, Harvey/0000-0003-3222-3471; Esposito, Vincenzo/0000-0003-4696-2363; Giuliano, Mariateresa/0000-0002-7338-9200; de Bartolomeis, Andrea/0000-0002-3188-5652; rizzo, paola/0000-0001-7174-9674	NCI NIH HHS [CA 60999-01A1, CA 77220-01A1] Funding Source: Medline; NINDS NIH HHS [NS 36466-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077220, R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON M, 1995, INT J CANCER, V63, P330, DOI 10.1002/ijc.2910630304; APPEL JD, 1988, P NATL ACAD SCI USA, V85, P7670, DOI 10.1073/pnas.85.20.7670; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; CARBONE M, IN PRESS ONCOGENE; CICALA C, 1994, J VIROL, V68, P3138, DOI 10.1128/JVI.68.5.3138-3144.1994; CICALA C, 1993, AM J PATHOL, V142, P1524; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DEBARTOLOMEIS A, 1994, BRAIN RES MOL BRAIN, V21, P312; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DUBES GR, 1993, JP AM ASS CANC RES, V34, P185; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HEINTZ NH, 1993, P NATL ACAD SCI USA, V90, P3299, DOI 10.1073/pnas.90.8.3299; JENSEN F, 1964, J NATL CANCER I, V32, P917; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEDNICKY JA, IN PRESS INT J CANC; LEHMAN TA, 1991, CANCER RES, V51, P4090; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARSELLA JM, IN PRESS ENV HLTH PE; MARSHALL J, 1991, ONCOGENE, V6, P1673; Martini F, 1996, CANCER RES, V56, P4820; MAYALL FG, 1993, HISTOPATHOLOGY, V22, P383, DOI 10.1111/j.1365-2559.1993.tb00140.x; METCALF RA, 1992, CANCER RES, V52, P2610; METHA CR, 1984, BIOMETRICS, V40, P819; MICHIELI P, 1994, CANCER RES, V54, P3391; Moorwood K, 1996, EXP CELL RES, V223, P308, DOI 10.1006/excr.1996.0086; MOSSMAN BT, 1996, CANC INVEST, V14, P464; Pepper C, 1996, THORAX, V51, P1074, DOI 10.1136/thx.51.11.1074; PETO J, 1995, LANCET, V345, P535, DOI 10.1016/S0140-6736(95)90462-X; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; Ruley H. Earl, 1996, P37; SIMMONS DT, 1995, DNA TUMOR VIRUSES ON, P27; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995	42	224	225	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					908	912		10.1038/nm0897-908	http://dx.doi.org/10.1038/nm0897-908			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256284				2022-12-25	WOS:A1997XP01400035
J	Sultan, P; Schechner, JS; McNiff, JM; Hochman, PS; Hughes, CCW; Lorber, MI; Askenase, PW; Pober, JS				Sultan, P; Schechner, JS; McNiff, JM; Hochman, PS; Hughes, CCW; Lorber, MI; Askenase, PW; Pober, JS			Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras	NATURE BIOTECHNOLOGY			English	Article						animal model; transplantation; T lymphocytes; costimulatory molecules	T-CELL RESPONSES; HUMAN CD2; ANTIGENS; ADHESION; MOUSE	A human skin allograft injury model in immunodeficient mice, engrafted with human peripheral blood mononuclear cells from a different donor, has been used to test whether reagents that block human T cell CD2 interactions with its principal ligand, LFA-3 (CD58), can inhibit immune reactions in vivo. In this model, human skin grafts show a reproducible pattern of progressive human T-cell infiltration and human graft microvascular injury that resembles human first-set skin graft rejection. Murine Mab to human LFA-3 or human LFA-3-IgG1 fusion protein, but not isotype-matched control antibodies, each markedly protected skin grafts from leukocyte infiltration and injury. These data provide the first evidence that LFA-3 functions in vivo and establish the ability of this new model to test human-specific immune modulators.	YALE UNIV, SCH MED, MOL CARDIOBIOL PROGRAM, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT MED, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT SURG, NEW HAVEN, CT 06536 USA; BIOGEN INC, CAMBRIDGE, MA 02142 USA; UNIV CALIF IRVINE, DEPT MOL BIOL & BIOCHEM, IRVINE, CA 92697 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Biogen; University of California System; University of California Irvine			Hughes, Christopher/F-7510-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043364, R01HL051014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51014, HL-43364] Funding Source: Medline; NIAMS NIH HHS [2T32-AR07016-23] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Chisholm P L, 1994, Ther Immunol, V1, P205; COLLINS T, 1984, J IMMUNOL, V133, P1878; Kaplon RJ, 1996, TRANSPLANTATION, V61, P356, DOI 10.1097/00007890-199602150-00004; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; MAJEAU GR, 1994, J IMMUNOL, V152, P2753; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; MURRAY AG, 1994, P NATL ACAD SCI USA, V91, P9146, DOI 10.1073/pnas.91.19.9146; MURRAY AG, 1994, IMMUNITY, V1, P57, DOI 10.1016/1074-7613(94)90009-4; Pober JS, 1996, TRANSPLANTATION, V61, P343, DOI 10.1097/00007890-199602150-00001; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0	12	55	58	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					759	762		10.1038/nbt0897-759	http://dx.doi.org/10.1038/nbt0897-759			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255790				2022-12-25	WOS:A1997XM70700027
J	Agadjanyan, M; Luo, P; Westerink, MAJ; Carey, LA; Hutchins, W; Steplewski, Z; Weiner, DB; KieberEmmons, T				Agadjanyan, M; Luo, P; Westerink, MAJ; Carey, LA; Hutchins, W; Steplewski, Z; Weiner, DB; KieberEmmons, T			Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus	NATURE BIOTECHNOLOGY			English	Article						applied immunology; peptide mimetic; carbohydrate; polysaccharide; HIV-1; Lewis Y	ALPHA-AMYLASE INHIBITOR; NEUTRALIZING ANTIBODIES; SPECIFICITY ANALYSIS; MONOCLONAL-ANTIBODY; TYPE-1 HIV-1; IDENTIFICATION; INFECTION; ANTIGENS; LIBRARY; GP120	Cancer-related, mucin-type carbohydrate epitopes, principally mannose and sialo-syl residues, are expressed on the envelope protein gp160 of the human immunodeficiency virus (HIV), Anticarbohydrate antibodies directed toward these and other carbohydrate epitopes are known to neutralize HIV-1 infection by cell-free virus, Carbohydrates, however, being T cell-independent antigens, typically elicit diminished immune responses. To overcome this potential draw back, we have examined the ability of peptides that mimic such epitopes to elicit immune responses that cross-react with carbohydrate structures, We report that mouse polyclonal antisera generated against peptides that mimic mucin-related carbohydrate epitopes have anti-HIV-1 activity. Generation of antibodies was not Ir-gene restricted, as at least two different strains of mice, Balb/c (H-2(d)) and C57BI/6 (H-2(b)), responded equally to the peptides, The antipeptide sera displayed neutralizing activity against HIV-I/MN and HIV-I/3B viral strains, This neutralization was as good as human anti-HIV sera. These results indicate that peptide mimics of carbohydrates provide a novel strategy for the further development of reagents that elicit immune responses to carbohydrate epitopes associated with many infectious organisms and tumor cells.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; THOMAS JEFFERSON UNIV,DEPT MED,PHILADELPHIA,PA 19107; MED COLL OHIO,DEPT MED,TOLEDO,OH 43699	University of Pennsylvania; Jefferson University			Weiner, David B/H-8579-2014					ADLURI S, 1995, CANCER IMMUNOL IMMUN, V41, P185, DOI 10.1007/BF01521345; AGADJANYAN MG, 1994, J VIROL, V68, P485, DOI 10.1128/JVI.68.1.485-493.1994; BOLMSTEDT A, 1992, J GEN VIROL, V73, P3039; DIAKUN KR, 1989, J IMMUNOL, V142, P2037; EARL PL, 1994, J VIROL, V68, P3015, DOI 10.1128/JVI.68.5.3015-3026.1994; FURUKAWA K, 1993, P NATL ACAD SCI USA, V90, P1972, DOI 10.1073/pnas.90.5.1972; GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27; GRAM GJ, 1994, ARCH VIROL, V139, P253, DOI 10.1007/BF01310789; HANSEN JES, 1991, J VIROL, V65, P6461, DOI 10.1128/JVI.65.12.6461-6467.1991; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; Hutchins WA, 1996, MOL IMMUNOL, V33, P503, DOI 10.1016/0161-5890(96)00012-0; IMBERTY A, 1994, GLYCOBIOLOGY, V4, P351, DOI 10.1093/glycob/4.3.351; KITAMURA K, 1994, P NATL ACAD SCI USA, V91, P12957, DOI 10.1073/pnas.91.26.12957; MIRKOV TE, 1995, GLYCOBIOLOGY, V5, P45, DOI 10.1093/glycob/5.1.45; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231, DOI 10.1128/JCM.26.2.231-235.1988; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; MULLER WEG, 1991, J ACQ IMMUN DEF SYND, V4, P694; MURAI H, 1985, J BIOCHEM-TOKYO, V97, P1129, DOI 10.1093/oxfordjournals.jbchem.a135157; NARA PL, 1988, NATURE, V332, P469, DOI 10.1038/332469a0; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; PRAMMER KV, 1994, RECEPTOR, V4, P93; ROBINSON WE, 1987, AIDS RES HUM RETROV, V3, P265, DOI 10.1089/aid.1987.3.265; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375; STEPLEWSKI Z, 1990, HYBRIDOMA, V9, P201, DOI 10.1089/hyb.1990.9.201; SUGIYAMA T, 1991, J IMMUNOL, V146, P3097; THURINBLASZCZYK M, 1996, PROTEIN ENG, V9, P101; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Tsuyuoka K, 1996, J IMMUNOL, V157, P661; UGEN KE, 1993, MODERN APPROACHES NE, P215; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; Willey RL, 1996, J VIROL, V70, P6431, DOI 10.1128/JVI.70.9.6431-6436.1996	33	80	85	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					547	551		10.1038/nbt0697-547	http://dx.doi.org/10.1038/nbt0697-547			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181577	Bronze			2022-12-25	WOS:A1997XC77200030
J	Cannizzo, SJ; Frey, BM; Raffi, S; Moore, MAS; Eaton, D; Suzuki, M; Singh, R; Mack, CA; Crystal, RG				Cannizzo, SJ; Frey, BM; Raffi, S; Moore, MAS; Eaton, D; Suzuki, M; Singh, R; Mack, CA; Crystal, RG			Augmentation of blood platelet levels by intratracheal administration of an adenovirus vector encoding human thrombopoietin cDNA	NATURE BIOTECHNOLOGY			English	Article						gene therapy; adenovirus; thrombopoietin; lung epithelium	MEDIATED GENE-TRANSFER; HEMATOPOIETIC GROWTH-FACTORS; C-MPL LIGAND; ERYTHROPOIETIN GENE; AIRWAY EPITHELIUM; CYSTIC-FIBROSIS; CFTR CDNA; LUNG; REGULATOR; THERAPY	This study was designed to evaluate the hypothesis that administration of a replication-deficient, recombinant adenovirus vector to the epithelial surface of the respiratory tract can be used to deliver a recombinant protein to the systemic circulation in sufficient quantities to evoke a systemic response appropriate to the recombinant protein. We administered AdCMV.TPO-an adenovirus vector containing an expression cassette coding for the human thrombopoietin (TPO) cDNA-to the respiratory epithelium of immunocompetent Balb/c mice. Over the following week, serum human TPO levels were elevated, platelet levels increased more than sixfold, and megakaryocytosis was evident in bone marrow. This strategy may be a useful approach to the nonparenteral administration of a variety of therapeutic recombinant proteins, such as those relevant to clotting, endocrine function, and bone-marrow function.	NEW YORK HOSP,CORNELL MED CTR,DIV PULM & CRIT CARE MED,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,JAMES EWING LAB DEV HEMATOPOIESIS,NEW YORK,NY 10021; NEW YORK HOSP,CORNELL MED CTR,DIV HEMATOL ONCOL,NEW YORK,NY 10021; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Cornell University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center; Cornell University; NewYork-Presbyterian Hospital; Roche Holding; Genentech			Singh, Ravi/B-1221-2010; Singh, Ravi N/A-5740-2011	Singh, Ravi N/0000-0003-0750-1804	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051746, K08HL002926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042693] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08-HL-02926, P01 HL51746-03] Funding Source: Medline; NIDDK NIH HHS [R01-DK-42693] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELBAUM FR, 1995, STEM CELLS, V13, P344, DOI 10.1002/stem.5530130404; BOUT A, 1994, HUM GENE THER, V5, P3, DOI 10.1089/hum.1994.5.1-3; BROUDY VC, 1995, J LEUKOCYTE BIOL, V57, P719, DOI 10.1002/jlb.57.5.719; CHANDRA T, 1992, ANN BIOMED ENG, V20, P481, DOI 10.1007/BF02368138; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CRYSTAL RG, 1994, 9409085 RAC; CRYSTAL RG, 1992, 9212034 RAC; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DESCAMPS V, 1994, HUM GENE THER, V5, P979, DOI 10.1089/hum.1994.5.8-979; EFFROS RM, 1997, LUNG SCI FDN, P1567; ENGELHARDT JF, 1993, HUM GENE THER, V4, P759, DOI 10.1089/hum.1993.4.6-759; Frey B. M., 1996, Experimental Hematology (Charlottesville), V24, P1056; HERSH J, 1995, GENE THER, V2, P124; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KAUSHANSKY K, 1993, BLOOD, V82, P3229; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; NEIDHART JA, 1993, CANCER, V72, P3381, DOI 10.1002/1097-0142(19931201)72:11+<3381::AID-CNCR2820721604>3.0.CO;2-0; Ohwada A, 1996, BLOOD, V88, P778; PARKER JC, 1986, MICROVASC RES, V31, P1, DOI 10.1016/0026-2862(86)90002-6; RIPPE B, 1991, LUNG, P349; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SETOGUCHI Y, 1994, BLOOD, V84, P2946; SIEGFRIED W, 1995, AM J RESP CELL MOL, V12, P379, DOI 10.1165/ajrcmb.12.4.7695917; TRIPATHY SK, 1994, P NATL ACAD SCI USA, V91, P11557, DOI 10.1073/pnas.91.24.11557; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Whetton AD, 1993, CURR OPIN CELL BIOL, V5, P1044, DOI 10.1016/0955-0674(93)90090-D; Xing Z, 1996, J LEUKOCYTE BIOL, V59, P481, DOI 10.1002/jlb.59.4.481; Xing Z, 1996, J CLIN INVEST, V97, P1102, DOI 10.1172/JCI118503; YEI SP, 1994, HUM GENE THER, V5, P731, DOI 10.1089/hum.1994.5.6-731; ZABNER J, 1994, NAT GENET, V6, P75, DOI 10.1038/ng0194-75	31	18	20	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					570	573		10.1038/nbt0697-570	http://dx.doi.org/10.1038/nbt0697-570			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181581				2022-12-25	WOS:A1997XC77200034
J	Mansfield, TA; Simon, DB; Farfel, Z; Bia, M; Tucci, JR; Lebel, M; Gutkin, M; Vialettes, B; Christofilis, MA; KauppinenMakelin, R; Mayan, H; Risch, N; Lifton, RP				Mansfield, TA; Simon, DB; Farfel, Z; Bia, M; Tucci, JR; Lebel, M; Gutkin, M; Vialettes, B; Christofilis, MA; KauppinenMakelin, R; Mayan, H; Risch, N; Lifton, RP			Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21	NATURE GENETICS			English	Article							HYPERKALEMIA; SODIUM; STRATEGIES; GENE	Essential hypertension is a common multifactorial trait. The molecular basis of a number of rare diseases that alter blood pressure in humans has been established, identifying pathways that may be involved in more common forms of hypertension(1). Pseudohypoaldosteronism type II (PHAII, also known as familial hyperkalaemia and hypertension or Gordon's syndrome; OMIM #145260), is characterized by hyperkalaemia despite normal renal glomerular filtration, hypertension and correction of physiologic abnormalities by thiazide diuretics(2,3). Mild hyperchloremia, metabolic acidosis and suppressed plasma renin activity are variable associated findings. The pathogenesis of PHAII is unknown, although clinical studies indicate an abnormality in renal ion transport(4). As thiazide diuretics are among the most efficacious agents in the treatment of essential hypertension, understanding the pathogenesis of PHAII may be of relevance to more common forms of hypertension. Analysis of linkage in eight PHAII families showing autosomal dominant transmission demonstrates locus heterogeneity of this trait, with a multilocus lod score of 8.1 for linkage of PHAII to chromosomes 1q31-q42 and 17p11-q21. Interestingly, the chromosome-17 locus overlaps a syntenic interval in rat that contains a blood pressure quantitative trait locus (QTL). Our findings provide a first step toward identification of the molecular basis of PHAII.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,NEW HAVEN,CT 06510; TEL AVIV UNIV,SCH MED,CHAIM SHEBA MED CTR,DEPT MED E,IL-52621 TEL HASHOMER,ISRAEL; BROWN UNIV,SCH MED,DIV ENDOCRINOL & METAB,PROVIDENCE,RI 02908; HOP HOTEL DIEU,RES CTR,DEPT NEPHROL,QUEBEC CITY,PQ,CANADA; HYPERTENS & RENAL GRP,LIVINGSTON,NJ 07039; CHRU MARSEILLE,DIV ENDOCRINOL,MARSEILLE,FRANCE; UNIV HELSINKI,DEPT MED 3,HELSINKI,FINLAND; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Chaim Sheba Medical Center; Tel Aviv University; Brown University; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Helsinki; Stanford University								BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; FARFEL Z, 1978, ARCH INTERN MED, V138, P1837, DOI 10.1001/archinte.138.12.1837; FARFEL Z, 1978, ARCH INTERN MED, V138, P1828, DOI 10.1001/archinte.138.12.1828; GORDON RD, 1970, AUST ANN MED, V4, P287; Gordon Richard D., 1995, P2111; GUPTA SK, 1995, COMPUT BIOMED RES, V28, P116, DOI 10.1006/cbmr.1995.1009; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; ISENRING P, 1992, HYPERTENSION, V19, P371, DOI 10.1161/01.HYP.19.4.371; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; MUHAMMAD S, 1994, J ENDOCRINOL INVEST, V17, P453, DOI 10.1007/BF03347738; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OTT J, 1985, ANAL HUMAN GENETIC L; PAVER W K, 1964, Med J Aust, V2, P305; SANJAD SA, 1982, PEDIATRICS, V69, P317; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SCHAMBELAN M, 1981, KIDNEY INT, V19, P716, DOI 10.1038/ki.1981.72; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Strautnieks SS, 1996, HUM MOL GENET, V5, P293, DOI 10.1093/hmg/5.2.293; THROCKMORTON DC, 1991, YALE J BIOL MED, V64, P247; VALIMAKI M, 1989, ACTA ENDOCRINOL-COP, V120, P331, DOI 10.1530/acta.0.1200331; [No title captured]	24	175	180	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	JUN	1997	16	2					202	205		10.1038/ng0697-202	http://dx.doi.org/10.1038/ng0697-202			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XB543	9171836				2022-12-25	WOS:A1997XB54300025
J	Good, DJ; Porter, FD; Mahon, KA; Parlow, AF; Westphal, H; Kirsch, IR				Good, DJ; Porter, FD; Mahon, KA; Parlow, AF; Westphal, H; Kirsch, IR			Hypogonadism and obesity in mice with a targeted deletion of the Nhlh2 gene	NATURE GENETICS			English	Article							HORMONE-RELEASING HORMONE; DEVELOPING NERVOUS-SYSTEM; MESSENGER-RNA; NEUROPEPTIDE-Y; MOUSE; EXPRESSION; PITUITARY; DEFICIENCY; LETHALITY; NSCL-2	The family of basic helix-loop-helix (bHLH) genes comprises transcription factors involved in many aspects of growth and development. We have previously described two bHLH transcription factors, Nhlh1 and Nhlh2 (originally named NSCL1 and NSCL2)(1-3). The nucleotide and predicted protein sequences of Nhlh1 and Nhlh2 are homologous within their bHLH domain where there are only three conservative amino acid differences(2,3). During murine embryogenesis, Nhlh1 and Nhlh2 share an overlapping but distinct pattern of expression in the developing nervous system(1,2). To improve our understanding of the role of these genes during neurogenesis, we have generated mice containing targeted deletions of both genes and here describe our results for Nhlh2. Loss of Nhlh2 results in a disruption of the hypothalamic-pituitary axis in mice. Male Nhlh2-/- mice are microphallic, hypogonadal and infertile with alterations in circulating gonadotropins, a defect spermatogenesis and a loss of instinctual male sexual behaviour. Female Nhlh2-/- mice reared alone are hypogonadal, but when reared in the presence of males, their ovaries and uteri develop normally and they are fertile. Both male and female homozygotes exhibit progressive adult-onset obesity. Nhlh2 is expressed in the ventral-medial and lateral hypothalamus, Rathke's pouch and in the anterior lobe of the adult pituitary. Our results support a role for Nhlh2 in the onset of puberty and the regulation of body weight metabolism.	NCI, ACQUIRED GENE REARRANGEMENT SECT, NIH, BETHESDA, MD 20889 USA; NICHHD, LAB MAMMALIAN GENES & DEV, NIH, BETHESDA, MD 20889 USA; UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR, PITUITARY HORMONES & ANTISERA CTR, TORRANCE, CA 90509 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								BEGLEY CG, 1992, P NATL ACAD SCI USA, V89, P38, DOI 10.1073/pnas.89.1.38; BRAY GA, 1989, VITAM HORM, V45, P1; Bronson F.H., 1983, P175; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; CHARLTON HM, 1992, PROG BRAIN RES, V93, P321; CONLON RA, 1992, DEVELOPMENT, V116, P357; CROWLEY WF, 1991, RECENT PROG HORM RES, V47, P27; CULLER MD, 1986, ENDOCRINOLOGY, V118, P609, DOI 10.1210/endo-118-2-609; DEYEBENES EG, 1995, BRAIN RES, V674, P112, DOI 10.1016/0006-8993(94)01429-L; GOBEL V, 1992, CELL GROWTH DIFFER, V3, P143; HALPIN DMG, 1986, J REPROD FERTIL, V78, P119, DOI 10.1530/jrf.0.0780119; Hogan B, 1994, MANIPULATING MOUSE E; IKEDA M, 1995, BIOCHEM BIOPH RES CO, V207, P800, DOI 10.1006/bbrc.1995.1257; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; KOVACIC N, 1972, ENDOCRINOLOGY, V91, P910, DOI 10.1210/endo-91-4-910; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIPKOWITZ S, 1992, J BIOL CHEM, V267, P21065; LOPEZ FJ, 1991, P NATL ACAD SCI USA, V88, P4508, DOI 10.1073/pnas.88.10.4508; LOVE PE, 1992, P NATL ACAD SCI USA, V89, P9929, DOI 10.1073/pnas.89.20.9929; MATOCHIK JA, 1994, BEHAV BRAIN RES, V60, P141, DOI 10.1016/0166-4328(94)90141-4; McGILL THOMAS E., 1962, BEHAVIOUR, V19, P341, DOI 10.1163/156853962X00087; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; OATES E, 1984, J BIOL CHEM, V259, P7421; PARKINSON WL, 1990, AM J PHYSIOL, V259, pR829, DOI 10.1152/ajpregu.1990.259.4.R829; REHBEIN M, 1986, BIOL CHEM H-S, V367, P695, DOI 10.1515/bchm3.1986.367.2.695; RUGH R, 1990, MOUSE ITS REPROD DEV, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TAKEUCHI T, 1986, J CLIN INVEST, V77, P1038, DOI 10.1172/JCI112357; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WRAY S, 1988, PEPTIDES, V9, P1151, DOI 10.1016/0196-9781(88)90103-9; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	36	94	97	0	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1997	15	4					397	401		10.1038/ng0497-397	http://dx.doi.org/10.1038/ng0497-397			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WQ389	9090387				2022-12-25	WOS:A1997WQ38900020
J	Wang, T; Lacik, I; Brissova, M; Anilkumar, AV; Prokop, A; Hunkeler, D; Green, R; Shahrokhi, K; Powers, AC				Wang, T; Lacik, I; Brissova, M; Anilkumar, AV; Prokop, A; Hunkeler, D; Green, R; Shahrokhi, K; Powers, AC			An encapsulation system for the immunoisolation of pancreatic islets	NATURE BIOTECHNOLOGY			English	Article						transplantation; encapsulation; diabetes; capsules; xenograft	BIOARTIFICIAL PANCREAS; RAT ISLETS; MICROENCAPSULATION; CELLS; XENOTRANSPLANTATION; IMMUNOSUPPRESSION; PORCINE; TRANSPLANTATION; XENOGRAFTS; SURVIVAL	Over a thousand combinations of polyanions and polycations were tested to search for new polymer candidates that would be suitable for encapsulation of living cells. The combination of sodium alginate, cellulose sulfate, poly (methylene-co-guanidine) hydrochloride, calcium chloride, and sodium chloride was most promising. In parallel, a novel multiloop chamber reactor was developed to control the time of complex formation and to negate gravitational effects such as pancreatic islet sedimentation and droplet deformation during the encapsulation process. Encapsulated rat islets demonstrated glucose-stimulated insulin secretion in vitro, and reversed diabetes in mice. This new capsule formulation and encapsulation system allows independent adjustments of capsule size, wall thickness, mechanical strength, and permeability, which may offer distinct advantages for immunoisolating cells.	VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CHEM ENGN,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,DIV ENDOCRINOL,NASHVILLE,TN 37232; DEPT VET AFFAIRS MED CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wang, T (corresponding author), VANDERBILT UNIV,SCH ENGN,CTR MICROGRAV RES,221 KIRKLAND HALL,NASHVILLE,TN 37235, USA.			Lacik, Igor/0000-0001-6037-3747	NIDDK NIH HHS [DK 20593] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brissova M, 1996, ANAL BIOCHEM, V242, P104, DOI 10.1006/abio.1996.0435; Calafiore R, 1996, TRANSPLANT P, V28, P812; Chang T M, 1992, ASAIO J, V38, P128, DOI 10.1097/00002480-199204000-00013; COLTON CK, 1991, J BIOMECH ENG-T ASME, V113, P152, DOI 10.1115/1.2891229; CROOKS CA, 1990, J BIOMED MATER RES, V24, P1241, DOI 10.1002/jbm.820240908; DEVOS P, 1993, INT J ARTIF ORGANS, V16, P205, DOI 10.1177/039139889301600407; GOOSEN MFA, 1985, BIOTECHNOL BIOENG, V27, P146, DOI 10.1002/bit.260270207; GOOSEN MFA, 1994, IMMUNOISOLATION PANC, P21; KENDALL JM, 1986, PHYS FLUIDS, V29, P2086, DOI 10.1063/1.865595; KENDALL JM, 1982, J VAC SCI TECHNOL, V20, P1091, DOI 10.1116/1.571574; KENDALL JM, 1988, AM I PHYSICS P, V197, P487; LACY PE, 1995, SCI AM, V273, P50, DOI 10.1038/scientificamerican0795-50; LANZA RP, 1994, TRANSPLANTATION, V57, P1371, DOI 10.1097/00007890-199405150-00015; LANZA RP, 1991, P NATL ACAD SCI USA, V88, P11100, DOI 10.1073/pnas.88.24.11100; LANZA RP, 1992, DIABETES, V41, P1503, DOI 10.2337/diabetes.41.12.1503; LANZA RP, 1995, TRANSPLANTATION, V59, P1377, DOI 10.1097/00007890-199505270-00003; Lardner TJ., 1980, MECH TODAY, V5, P161; LEE CP, 1988, J FLUID MECH, V188, P411, DOI 10.1017/S0022112088000783; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; LIN KC, 1992, AIAA; LUM ZP, 1991, DIABETES, V40, P1511, DOI 10.2337/diabetes.40.11.1511; MAKI T, 1995, CLIN PHARMACOKINET, V28, P471, DOI 10.2165/00003088-199528060-00005; NAVE R, 1993, J CHROMATOGR A, V654, P229, DOI 10.1016/0021-9673(93)83366-Z; OSHEA GM, 1986, DIABETES, V35, P943, DOI 10.2337/diabetes.35.8.943; REACH G, 1994, TRANSPLANT P, V26, P397; Ricordi C., 1992, PANCREATIC ISLET CEL, P137; SCHARP DW, 1994, DIABETES, V43, P1167, DOI 10.2337/diabetes.43.9.1167; SOONSHIONG P, 1993, P NATL ACAD SCI USA, V90, P5843, DOI 10.1073/pnas.90.12.5843; SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1; SUN YL, 1993, ARTIF ORGANS, V17, P727; WEBER C, 1991, TRANSPLANT P, V23, P764	31	266	282	0	79	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					358	362		10.1038/nbt0497-358	http://dx.doi.org/10.1038/nbt0497-358			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094138				2022-12-25	WOS:A1997WQ55400037
J	Silva, AJ; Frankland, PW; Marowitz, Z; Friedman, E; Lazlo, G; Cioffi, D; Jacks, T; Bourtchuladze, R				Silva, AJ; Frankland, PW; Marowitz, Z; Friedman, E; Lazlo, G; Cioffi, D; Jacks, T; Bourtchuladze, R			A mouse model for the learning and memory deficits associated with neurofibromatosis type I	NATURE GENETICS			English	Article							LONG-TERM POTENTIATION; TARGETED MUTATION; MICE; BEHAVIOR; HIPPOCAMPAL; EXPRESSION; NEURONS; BRAIN; FEAR; NF1	Neurofibromatosis type I (NF1) is one of the most commonly inherited neurological disorders in humans, affecting approximately one in 4,000 individuals(1-3). NF1 results in a complex cluster of developmental and tumour syndromes that include benign neurofibromas, hyperpigmentation of melanocytes and hamartomas of the iris. Some NF1 patients may also show neurologic lesions, such as optic pathway gliomas, dural ectasia and aqueduct stenosis(1-3). Importantly, learning disabilities occur in 30% to 45% of patients with NF1, even in the absence of any apparent neural pathology. The learning disabilities may include a depression in mean IQ scores, visuoperceptual problems and impairments in spatial cognitive abilities(4-9). Spatial learning has been assessed with a variety of cognitive tasks and the most consistent spatial learning deficits have been observed with the Judgement of Line Orientation test(4,7,10,11). It is important to note that some of these deficits could be secondary to developmental abnormalities(1) and other neurological problems, such as poor motor coordination and attentional deficits(9). Previous studies have suggested a role for neurofibromin in brain function. First, the expression of the Nf1 gene is largely restricted to neuronal tissues in the adult(12-14). Second, this GTPase activating protein may act as a negative regulator of neurotrophin-mediated signalling(15). Third, immunohistochemical studies suggest that activation of astrocytes may be common in the brain of NF1 patients(13). Here, we show that the Nf1(+/-) mutation also affects learning and memory in mice. As in humans, the learning and memory deficits of the Nf1(+/-) mice are restricted to specific types of learning, they are not fully penetrant, they can be compensated for with extended training, and they do not involve deficits in simple associative learning.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Silva, AJ (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.		Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; CRAWLEY JN, 1985, NEUROSCI BIOBEHAV R, V9, P37, DOI 10.1016/0149-7634(85)90030-2; DATSON MM, 1992, NEURON, V8, P415; EASTON DF, 1993, AM J HUM GENET, V53, P305; ELDRIDGE R, 1989, AM J DIS CHILD, V143, P833, DOI 10.1001/archpedi.1989.02150190083027; Eliason M J, 1988, Neurofibromatosis, V1, P17; ELIASON MJ, 1986, J DEV BEHAV PEDIATR, V7, P175; GUTMANN DH, 1992, ANN NEUROL, V31, P555, DOI 10.1002/ana.410310515; HOFMAN KJ, 1994, J PEDIATR-US, V124, pS1, DOI 10.1016/S0022-3476(05)83163-4; HUSON SM, 1994, NEUROFIBROMATOSES PA, P204; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOY P, 1995, DEV MED CHILD NEUROL, V37, P906; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NORDLUND M, 1993, J NEUROSCI, V13, P1588; NORDLUND ML, 1995, J NEUROPATH EXP NEUR, V54, P588, DOI 10.1097/00005072-199507000-00013; NORTH K, 1993, J CHILD NEUROL, V8, P395, DOI 10.1177/088307389300800421; NORTH K, 1995, DEV MED CHILD NEUROL, V37, P427, DOI 10.1111/j.1469-8749.1995.tb12026.x; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; RICCARDI VM, 1992, NEUROFIBROMATOSIS PH, P195; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; VARNHAGEN CK, 1988, J DEV BEHAV PEDIATR, V9, P257; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	30	254	260	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					281	284		10.1038/ng0397-281	http://dx.doi.org/10.1038/ng0397-281			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054942				2022-12-25	WOS:A1997WK38600019
J	Vafiadis, P; Bennett, ST; Todd, JA; Nadeau, J; Grabs, R; Goodyer, CG; Wickramasinghe, S; Colle, E; Polychronakos, C				Vafiadis, P; Bennett, ST; Todd, JA; Nadeau, J; Grabs, R; Goodyer, CG; Wickramasinghe, S; Colle, E; Polychronakos, C			Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus	NATURE GENETICS			English	Article							DIABETES SUSCEPTIBILITY LOCUS; GENE; PROINSULIN; TOLERANCE; SELECTION; REGION; RISK; AUTOANTIBODIES; MINISATELLITE; TRANSCRIPTION	Type 1 diabetes or insulin-dependent diabetes mellitus (IDDM) is due to autoimmune destruction of pancreatic beta-cells. Genetic susceptibility to IDDM is encoded by several loci, one of which (IDDM2) maps to a variable number of tandem repeats (VNTR) minisatellite, upstream of the insulin gene (INS)(1-5). The short class 1 VNTR alleles (26-63 repeats) predispose to IDDM, while class III alleles (140-210 repeats) have a dominant protective effect(1-6). We have reported that, in human adult(4,6) and fetal(7) pancreas in vivo, class III alleles are associated with marginally lower INS mRNA levels than class I, suggesting transcriptional effects of the VNTR. These may be related to type 1 diabetes pathogenesis, as insulin is the only known beta-cell specific IDDM autoantigen. In search of a more plausible mechanism for the dominant effect of class III alleles, we analysed expression of insulin in human fetal thymus, a critical site for tolerance induction to self proteins. Insulin was detected in all thymus tissues examined and class III VNTR alleles were associated with 2- to 3-fold higher INS mRNA levels than class I. We therefore propose higher levels of thymic INS expression, facilitating immune tolerance induction, as a mechanism for the dominant protective effect of class III alleles.	MCGILL UNIV, MONTREAL CHILDRENS HOSP, RES INST, MONTREAL, PQ H3H 1P3, CANADA; MCGILL UNIV, DEPT PEDIAT, DIV ENDOCRINOL, MONTREAL, PQ H3H 1P3, CANADA; UNIV OXFORD, NUFFIELD DEPT SURG, WELLCOME TRUST CTR HUMAN GENET, OXFORD OX3 7BN, ENGLAND; MCGILL UNIV, DEPT HUMAN GENET, MONTREAL, PQ H3G 1A4, CANADA; MONTREAL GEN HOSP, MONTREAL, PQ H3G 1A4, CANADA	McGill University; McGill University; University of Oxford; Wellcome Centre for Human Genetics; McGill University; McGill University			Polychronakos, Constantin/B-8151-2008; Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148; Polychronakos, Constantin/0000-0002-7624-6635	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTONIA SJ, 1995, INT IMMUNOL, V7, P715, DOI 10.1093/intimm/7.5.715; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; ATKINSON MA, 1990, DIABETES, V39, P933, DOI 10.2337/diabetes.39.8.933; BATANERO E, 1992, BRAIN BEHAV IMMUN, V6, P249, DOI 10.1016/0889-1591(92)90047-R; Bennett ST, 1996, J AUTOIMMUN, V9, P415, DOI 10.1006/jaut.1996.0057; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BERG H, 1993, J IMMUNOL METHODS, V164, P221, DOI 10.1016/0022-1759(93)90315-X; Bui MM, 1996, J AUTOIMMUN, V9, P97, DOI 10.1006/jaut.1996.0012; DENNY P, IN PRESS DIABETES; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GRIFFIN AC, 1995, AM J PATHOL, V147, P845; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; JOLICOEUR C, 1994, P NATL ACAD SCI USA, V91, P6707, DOI 10.1073/pnas.91.14.6707; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; KEILACKER H, 1995, HORM METAB RES, V27, P90, DOI 10.1055/s-2007-979915; KELLER RJ, 1993, LANCET, V341, P927, DOI 10.1016/0140-6736(93)91215-8; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; MCGINNIS RE, 1995, DIABETES, V44, P1296, DOI 10.2337/diabetes.44.11.1296; MILLER JFAP, 1989, COLD SPRING HARB SYM, V54, P807; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; Owerbach D, 1996, DIABETES, V45, P544, DOI 10.2337/diabetes.45.5.544; POLYCHRONAKOS C, 1995, DIABETOLOGIA, V38, P715, DOI 10.1007/s001250050343; POSSELT AM, 1992, SCIENCE, V256, P1321, DOI 10.1126/science.1598576; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; PUGLIESE A, 1994, J AUTOIMMUN, V7, P687, DOI 10.1006/jaut.1994.1053; RUDY G, 1995, MOL MED, V1, P625, DOI 10.1007/BF03401603; Saoudi A, 1996, IMMUNOL REV, V149, P195, DOI 10.1111/j.1600-065X.1996.tb00905.x; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; UNDLIEN DE, 1995, DIABETES, V44, P620, DOI 10.2337/diabetes.44.6.620; Vafiadis P, 1996, J AUTOIMMUN, V9, P397, DOI 10.1006/jaut.1996.0054; VONHERRATH MG, 1994, J EXP MED, V180, P1901, DOI 10.1084/jem.180.5.1901; WEGMANN DR, 1994, EUR J IMMUNOL, V24, P1853, DOI 10.1002/eji.1830240820; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542	37	628	649	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1997	15	3					289	292		10.1038/ng0397-289	http://dx.doi.org/10.1038/ng0397-289			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WK386	9054944				2022-12-25	WOS:A1997WK38600021
J	Neyroud, N; Tesson, F; Denjoy, I; Leibovici, M; Donger, C; Barhanin, J; Faure, S; Gary, F; Coumel, P; Petit, C; Schwartz, K; Guicheney, P				Neyroud, N; Tesson, F; Denjoy, I; Leibovici, M; Donger, C; Barhanin, J; Faure, S; Gary, F; Coumel, P; Petit, C; Schwartz, K; Guicheney, P			A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome	NATURE GENETICS			English	Article							LONG QT SYNDROME; STRIA VASCULARIS; CARDIAC-ARRHYTHMIA; K+ CHANNEL; PROTEIN; LOCALIZATION; VOLTAGE; EXPRESSION; CLONING; CELLS	The Jervell and Lange-Nielsen (JLN) syndrome (MIM 220400) is an inherited autosomal recessive disease characterized by a congenital bilateral deafness associated with a QT prolongation on the electrocardiogram, syncopal attacks due to ventricular arrhythmias and a high risk of sudden death(1). JLN syndrome is a rare disease, which seems to affect less than one percent of all deaf children(2-4) Linkage to chromosome 11p15.5 markers was found by analysing four consanguinous families. Recombinants allowed us to map the JLN gene between D11S922 and D11S4146, to a 6-cM interval where KVLQT1, a potassium channel gene causing Romano-Ward (RW) syndrome, the dominant form of long QT syndrome, has been previously localized(5), An homozygous deletion-insertion event (1244, -7 +8) in the C-terminal domain of this gene was detected in three affected children of two families. We found that KVLQT1 is expressed in the stria vascularis of mouse inner ear by in situ hybridization. Taken together, our data indicate that KVLQT1 is responsible for both JLN and RW syndromes and has a key role not only in the ventricular repolarization but also in normal hearing, probably via the control of endolymph homeostasis.	GRP HOSP PITIE SALPETRIERE, INST MYOL, INSERM UR153, F-75013 PARIS, FRANCE; HOP LARIBOISIERE, SERV CARDIOL, F-75010 PARIS, FRANCE; CHATEAU COTES, F-78350 LES LOGES EN JOSAS, FRANCE; INST PASTEUR, CNRS URA 1968, MOL GENET UNIT, F-75015 PARIS, FRANCE; CNRS, INST PHARMACOL MOL & CELLULAIRE, F-06560 VALBONNE, FRANCE; GENETHON CNRS URA 1922, F-91002 EVRY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS)			Leibovici, Michel/ABB-6745-2020; Tesson, Frederique/A-3218-2013; Neyroud, Nathalie/D-1013-2017; Guicheney, Pascale/D-1034-2017	Neyroud, Nathalie/0000-0003-3382-7680; Guicheney, Pascale/0000-0002-7663-2050; Petit, Christine/0000-0002-9069-002X				ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; DAUSSE E, 1995, CR ACAD SCI III-VIE, V318, P879; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRASER GR, 1964, ANN HUM GENET, V28, P133, DOI 10.1111/j.1469-1809.1964.tb00469.x; FRASER GR, 1964, Q J MED, V33, P361; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HOFFMAN EP, 1995, CELL, V80, P681, DOI 10.1016/0092-8674(95)90345-3; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HOVNANIAN A, 1992, J CLIN INVEST, V90, P1032, DOI 10.1172/JCI115916; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; JEFFERY S, 1992, LANCET, V339, P255, DOI 10.1016/0140-6736(92)90071-A; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; MORI N, 1993, EUR ARCH OTO-RHINO-L, V250, P186; PERNOT C, 1972, ARCH MAL COEUR VAISS, V65, P261; PERNOT C, 1974, COEUR MED INTERNE, V13, P429; SAKAGAMI M, 1991, HEARING RES, V56, P168, DOI 10.1016/0378-5955(91)90166-7; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHOTT JJ, 1995, AM J HUM GENET, V57, P1114; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tesson F, 1996, J MOL CELL CARDIOL, V28, P2051, DOI 10.1006/jmcc.1996.0198; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WANGEMANN P, 1995, HEARING RES, V84, P19, DOI 10.1016/0378-5955(95)00009-S; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153	31	679	701	1	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1997	15	2					186	189		10.1038/ng0297-186	http://dx.doi.org/10.1038/ng0297-186			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	WF087	9020846				2022-12-25	WOS:A1997WF08700020
J	Hacia, JG; Brody, LC; Chee, MS; Fodor, SPA; Collins, FS				Hacia, JG; Brody, LC; Chee, MS; Fodor, SPA; Collins, FS			Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis	NATURE GENETICS			English	Article							OVARIAN-CANCER FAMILIES; BREAST-CANCER; SUSCEPTIBILITY GENE; GERMLINE MUTATIONS; 185DELAG; LINKAGE	The ability to scan a large gene rapidly and accurately for all possible heterozygous mutations in large numbers of patient samples will be critical for the future of medicine. We have designed high-density arrays consisting of over 96,600 oligonucleotides 20-nucleotides (nt) in length to screen for a wide range of heterozygous mutations in the 3.45-kilobases (kb) exon 11 of the hereditary breast and ovarian cancer gene BRCA1. Reference and test samples were co-hybridized to these arrays and differences in hybridization patterns quantitated by two-colour analysis. Fourteen of fifteen patient samples with known mutations were accurately diagnosed, and no false positive mutations were identified in 20 control samples. Eight single nucleotide polymorphisms were also readily detected. DNA chip-based assays may provide a valuable new technology for high-throughput cost-efficient detection of genetic alterations.	NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; AFFYMETRIX,SANTA CLARA,CA 95051	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Affymetrix								CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cronin MT, 1996, HUM MUTAT, V7, P244, DOI 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.0.CO;2-A; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gayther SA, 1996, AM J HUM GENET, V58, P451; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; HOULDSWORTH J, 1994, AM J PATHOL, V145, P1253; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LIPSHUTZ RJ, 1995, BIOTECHNIQUES, V19, P442; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; ROWELL S, 1994, AM J HUM GENET, V55, P861; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; TONIN P, 1995, AM J HUM GENET, V57, P189; Yershov G, 1996, P NATL ACAD SCI USA, V93, P4913, DOI 10.1073/pnas.93.10.4913	29	443	597	1	50	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1996	14	4					441	447		10.1038/ng1296-441	http://dx.doi.org/10.1038/ng1296-441			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VV730	8944024				2022-12-25	WOS:A1996VV73000020
J	Marquet, S; Abel, L; Hillaire, D; Dessein, H; Kalil, J; Feingold, J; Weissenbach, J; Dessein, AJ				Marquet, S; Abel, L; Hillaire, D; Dessein, H; Kalil, J; Feingold, J; Weissenbach, J; Dessein, AJ			Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33	NATURE GENETICS			English	Letter							MULTILOCUS LINKAGE ANALYSIS; HUMAN RESISTANCE; MAJOR GENE; IMMUNE-RESPONSES; IGE LEVELS; REINFECTION; ASSOCIATION; SUSCEPTIBILITY; INTERLEUKIN-4; HAEMATOBIUM		FAC MED MARSEILLE,LAB PARASITOL MYCOL,INSERM,U399,F-13385 MARSEILLE 5,FRANCE; HOSP PITIE SALPETRIERE,INSERM,U436,PARIS,FRANCE; UNIV SAO PAULO,INST HEART,IMMUNOL LAB,BR-05508 SAO PAULO,BRAZIL; INSERM,U155,PARIS,FRANCE; GENETHON,EVRY,FRANCE; CNRS,URA 1922,EVRY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universidade de Sao Paulo; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)			Abel, Laurent/H-8888-2017; MARQUET, Sandrine/B-2843-2008; MARQUET, Sandrine/I-6566-2016; KALIL, JORGE/C-8029-2012	Abel, Laurent/0000-0001-7016-6493; MARQUET, Sandrine/0000-0001-7011-6496; KALIL, JORGE/0000-0001-8415-4274				ABEL L, 1991, AM J HUM GENET, V48, P959; BONNEY GE, 1984, AM J MED GENET, V18, P731, DOI 10.1002/ajmg.1320180420; BUTTERWORTH AE, 1985, T ROY SOC TROP MED H, V79, P393, DOI 10.1016/0035-9203(85)90391-8; CHANDRASEKHARAPPA SC, 1990, GENOMICS, V6, P94, DOI 10.1016/0888-7543(90)90452-Z; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; COULSSINIERPARI.P, 1995, EUR J IMMUNOL, V25, P2295; DEMENAIS F, 1994, GENET EPIDEMIOL, V11, P291; DEMEURE CE, 1993, J INFECT DIS, V168, P1000, DOI 10.1093/infdis/168.4.1000; DESSEIN AJ, 1992, IMMUNOL INVEST, V21, P423, DOI 10.3109/08820139209069383; DESSEIN AJ, 1988, J IMMUNOL, V140, P2727; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HAGAN P, 1987, T ROY SOC TROP MED H, V81, P938, DOI 10.1016/0035-9203(87)90359-2; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MOUT R, 1991, NUCLEIC ACIDS RES, V19, P3763, DOI 10.1093/nar/19.13.3763; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106; ROBERTS M, 1993, INFECT IMMUN, V61, P4984, DOI 10.1128/IAI.61.12.4984-4993.1993; SALTMAN DL, 1993, GENOMICS, V16, P726, DOI 10.1006/geno.1993.1254; STANLEY ER, 1994, CYTOKINE HDB, P387; *UNDP WORLD BANK W, 1990, TROP DIS PROGR RES, P41; VANLIESHOUT L, 1995, J INFECT DIS, V172, P1336, DOI 10.1093/infdis/172.5.1336; VIGNAL A, 1993, METHODS MOL GENETICS, V1, P211; WILKINS HA, 1987, T ROY SOC TROP MED H, V81, P29, DOI 10.1016/0035-9203(87)90273-2	30	292	300	0	28	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1996	14	2					181	184		10.1038/ng1096-181	http://dx.doi.org/10.1038/ng1096-181			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	VL446	8841190				2022-12-25	WOS:A1996VL44600024
J	Rivera, VM; Clackson, T; Natesan, S; Pollock, R; Amara, JF; Keenan, T; Magari, SR; Phillips, T; Courage, NL; Cerasoli, F; Holt, DA; Gilman, M				Rivera, VM; Clackson, T; Natesan, S; Pollock, R; Amara, JF; Keenan, T; Magari, SR; Phillips, T; Courage, NL; Cerasoli, F; Holt, DA; Gilman, M			A humanized system for pharmacologic control of gene expression	NATURE MEDICINE			English	Article							HUMAN GROWTH-HORMONE; SIGNAL-TRANSDUCTION; MAMMALIAN PROTEIN; RAPAMYCIN; COMPLEX; CELLS; YEAST; CLONING; FKBP12; DESIGN	Gene therapy was originally conceived as a medical intervention to replace or correct defective genes in patients with inherited disorders. However, it may have much broader potential as an alternative delivery platform for protein therapeutics, such as cytokines, hormones, antibodies and novel engineered proteins. One key technical barrier to the widespread implementation of this form of therapy is the need for precise control over the level of protein production. A suitable system for pharmacologic control of therapeutic gene expression would permit precise titration of gene product dosage, intermittent or pulsatile treatment, and ready termination of therapy by withdrawal of the activating drug. We set out to design such a system with the following properties: (1) low baseline expression and high induction ratio; (2) positive control by an orally bioavailable small-molecule drug; (3) reduced potential for immune recognition through the exclusive use of human proteins; and (4) modularity to allow the independent optimization of each component using the tools of protein engineering. We report here the properties of this system and demonstrate its use to control circulating levels of human growth hormone in mice implanted with engineered human cells.	ARIAD PHARMACEUT INC,GENE THERAPEUT,CAMBRIDGE,MA 02139	Takeda Pharmaceutical Company Ltd; Takeda Oncology			Wilson, Matthew H/K-3193-2013	Rivera, Victor/0000-0002-7258-3001				ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; Austin D J, 1994, Chem Biol, V1, P131, DOI 10.1016/1074-5521(94)90002-7; BELSHAW PJ, 1995, ANGEW CHEM INT EDIT, V34, P2129, DOI 10.1002/anie.199521291; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; HEARTLEIN MW, 1994, P NATL ACAD SCI USA, V91, P10967, DOI 10.1073/pnas.91.23.10967; HO SN, IN PRESS NATURE; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KAHAN BD, 1991, TRANSPLANTATION, V52, P185, DOI 10.1097/00007890-199108000-00001; KAY JE, 1991, IMMUNOLOGY, V72, P544; LUENGO JI, 1995, CHEM BIOL, V2, P471, DOI 10.1016/1074-5521(95)90264-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Pruschy M N, 1994, Chem Biol, V1, P163, DOI 10.1016/1074-5521(94)90006-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; Spencer DM, 1996, TRENDS GENET, V12, P181, DOI 10.1016/0168-9525(96)10013-5; STAN R, 1994, J BIOL CHEM, V269, P32037; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEPKOWSKI SM, 1991, TRANSPLANTATION, V51, P22, DOI 10.1097/00007890-199101000-00002; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5	39	433	550	0	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1028	1032		10.1038/nm0996-1028	http://dx.doi.org/10.1038/nm0996-1028			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782462				2022-12-25	WOS:A1996VF49700039
